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treatment of pain by  interventional pain  and other pain  specialists. The  evidence  is 
accumulating, and the etiologies of painful conditions are also better understood. 
Policy makers need to include input from physicians recognized in interventional pain 
training  and  experience,  as well  as  other  practicing  physicians,  in  order  to  avoid 
excluding data  from studies regarding one camp of pain practitioners which may be 






material  contained within  this book has been  assembled more  for quality  rather  than 
completeness. One may wish to have other and different areas covered, but there is only 
so much  that  can be accomplished  in a  limited amount of  time and  space. There  is  a 
significant amount covered in the various parts on opioids which must be looked at, as 
treatment of pain in many parts of the world is heavily opioid dependent.  
It  is  interesting  to  note  that  in  the United  States  over  the  last  couple  of  years,  the 
mortality  rate  from prescribed opioids has  exceeded  that  for motor vehicle‐induced 
mortality. When opioids are used, the nature of the medication is such that it is subject 
to diversion and abuse. Disciplining patients  should not be  the  responsibility of  the 
physician, but verifying  the use  interestingly helps  to maintain  the appropriate use. 
For  example,  urine  tests  two  to  six  times  per  year,  qualitative  and  quantitative  is 
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which branch of medicine they practice. 
The purpose of this project is to bring the best minds together from around the world 
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Intrathecal Studies on Animal Pain Models 
Jen-Kun Cheng 
Mackay Memorial Hospital/Mackay Medical College 
Taiwan 
1. Introduction  
Spinal and epidural anesthesia have been widely used in clinical settings for the 
management of peri-operative, neuropathic and cancer pain (Dureja et al., 2010; Hong, 2010; 
Mercadante, 1999). They provide another route for the analgesic administration in addition 
to oral or systemic absorption. Since the pain pathway initiate with primary and secondary 
neurons located in dorsal root ganglion and spinal cord, respectively, the intrathecal 
(spinal) route may provide an effective alternative for less drug dosage and fewer side 
effects, compared with systemic administration.  
In recent decades, many animal pain models have been developed to explore the possible 
mechanisms involved in the pathogenesis of clinically relevant pain statuses, such as 
postoperative (Brennan et al., 1996), neuropathic (Kim & Chung, 1992), inflammatory 
(Wheeler-Aceto et al., 1990) and cancer pain (Clohisy & Mantyh, 2003). These studies not only 
help to extent our understanding on pain mechanisms but also provide novel promising 
agents or targets for the management of different pain situations (Mogil et al., 2010). In this 
chapter, we present various animal pain models, emphasizing on intrathecal studies, and 
potential therapeutic molecular targets and analgesics found in latest years. In addition, the 
related neurotoxicity studies and morphine-induced tolerance will be mentioned.  
2. Intrathecal animal pain studies 
The first mentioned intrathecal study using rat animal model was reported by Yaksh, 
beginning with the study of intrathecal morphine (Yaksh et al., 1977). For intrathecal drug 
administration, a polyethylene catheter is inserted intrathecally in rats during inhalation 
anesthesia (LoPachin et al., 1981). The catheter is passed caudally from the cisterna magnum 
to the level of lumbar enlargement. Since the development of intrathecal catheterization, lots 
of studies explored the pharmacology and pain pathways using intrathecal space as a route 
of drug administration, either in basic researches or clinical studies. The intrathecal studies 
on various pain models provide a lot of promising analgesics for the management of 
different pain statuses.  
2.1 Postoperative pain model  
The postoperative or incisional pain model was proposed by Brennan in 1996 (Brennan et 
al., 1996). A 1-cm longitudinal incision is made through skin, fascia and muscle of the 
plantar aspect of the hindpaw in anesthetized rats. The lesion produced reliable and 
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quantifiable mechanical allodynia and thermal hyperalgesia around the wound and 
spontaneous nociceptive behaviors for about one week, which mimics the clinical course of 
postoperative pain. Selective denervations of the rat hindpaw prior to foot incision reveal 
both the sural and tibial nerves are responsible for the nociception transmission from the 
incision. This model helps to better understand mechanisms of sensitization caused by 
surgery and provide promising therapeutics for postoperative pain management (Kang & 
Brennan, 2009). 
2.2 Inflammatory formalin pain model  
The formalin test involves subcutaneous injection of 5% formaldehyde (50 l) at the plantar 
surface of the rat hindpaw, using a 27-gauge needle. After injection, the rat displays 
characteristic nociceptive behaviors, flinching, shaking, biting and licking of the injected 
paw. Two phases of nociceptive behaviors are observed after formalin injection as described 
previously (Abbott et al., 1995). Phase 1 is initiated within seconds after injection and it lasts 
for about 5–10min. After several minutes quiescent, a second phase of flinching occurs and 
peaks at 25–35 min after injection.  
The formalin-induced nociceptive response in rats is believed to be an inflammatory pain 
and involves central sensitization in the spinal cord (Abbott et al., 1995). The hindpaw 
injection of formalin induces tissue injury leading to acute (phase 1) and facilitated (phase 2) 
states of pain. The phase 2 response is believed to be a persistent input-induced nociceptive 
behavior mediated through central sensitization (Coderre & Melzack, 1992). LTP of C-fiber-
evoked field potentials in the spinal superficial dorsal horn has been reported in the 
formalin-injected rats (Sandkuhler & Liu, 1998). Intrathecal injection of T-type Ca2+ channel 
blockers (mibefradil and Ni2+) has been reported to attenuate formalin-induced pain 
behaviours, either phase 1 or 2, indicating the important role of T-type Ca2+ channel in the 
spinal central sensitization (Cheng et al., 2007). Other chemical irritants, such as complete 
Freund's adjuvant (CFA), carrageenan or capsaicin, could also be used to be injected 
subcutaneously into the plantar surface of rat hindpaw to induce pain behaviors (Duarte et 
al., 2011; Thorpe et al., 2011; Yu et al., 2011).  
2.3 Nerve injury-induced neuropathic pain model 
Nerve injuries due to trauma, chemotherapy, diabetic mellitus or tumor invasion may 
induce neuropathic pain, which is usually refractory to conventional analgesic agents, 
including opioids and non-steroid anti-inflammatory agents. For the past decades, several 
animal models have been developed to mimic the clinical conditions and explore the 
possible mechanisms underlying neuropathic pain. Among these neuropathic pain models, 
nerve injury-induced neuropathic pain (NINP) models, such as spinal nerve ligation, spared 
nerve injury and chronic constriction injury, are most often studied (Ji & Strichartz, 2004 ).  
Several targets have been proposed to be involved in the pathogenesis of NINP, such as 
NMDA receptors (Szekely et al., 2002) and ion channels (Rogers et al., 2006). Recently, new 
molecules have been emerging as promising targets for the treatment of NINP, such as 
purinergic receptors (Donnelly-Roberts et al., 2008), cannabinoid receptors (Lynch & 
Campbell, 2011), transient receptor potential V1 (TRPV1) receptor (Facer et al., 2007), 
chemokine receptors (White et al., 2007), acid-sensing ion channel (Mazzuca et al., 2007; 
Poirot et al., 2006), annexin 2 light chain p11 (Foulkes et al., 2006) and matrix 
metalloproteinase (Kawasaki et al., 2008a). 
 
Intrathecal Studies on Animal Pain Models 
 
5 
The L5/6 spinal nerve ligation neuropathic pain model was reported by Kim and Chung in 
1992 (Kim & Chung, 1992). This model involves a tight ligation of L5 and L6 spinal nerves of 
animals under anesthesia. The nociceptive behavioral assessments also consist of von Frey 
hair test (Chaplan et al., 1994) and radiant heat test (Hargreaves et al., 1988) for the 
quantification of mechanical allodynia and thermal hyperalgesia, respectively, on the 
affected hindpaw. Compared with postoperative pain model and formalin inflammatory 
pain model, this model induced chronic nociceptive behaviors lasting for several weeks. 
This chronic pain model helps to reveal the possible mechanisms involved in the 
development and maintenance of nerve injury-induced pain, either the neuronal 
components or glial components. 
Spared nerve injury pain model was developed by Decosterd and Woolf in 2000 (Decosterd 
& Woolf, 2000). An adaptation of spared nerve injury surgery was later developed in the 
mouse (Bourquin et al., 2006). This model involves a lesion of two of the three terminal 
branches of the sciatic nerve (tibial and common peroneal nerves) leaving the remaining 
sural nerve intact. The spared nerve injury model differs from the L5/6 spinal ligation pain 
model in that the co-mingling of distal intact axons with degenerating axons is restricted, 
and it permits behavioral testing of the non-injured skin territories adjacent to the 
denervated areas. The mechanical (von Frey and pinprick) sensitivity and thermal (hot and 
cold) responsiveness is increased in the ipsilateral sural territory. 
2.4 Cancer pain model 
Cancer pain significantly affects the diagnosis, quality of life and survival of patients with 
cancer. Tumor growth may produce inflammation in tumor bearing tissues, which will 
release inflammatory mediators to stimulate nociceptors. Tumor growth may also compress 
the peripheral nerves in tumor bearing tissues, inducing nerve injury. Therefore, cancer pain 
is likely to share mechanisms of inflammatory pain and neuropathic pain, although this 
pain may have distinct mechanisms (Ghilardi et al., 2010). Whether inflammation or nerve 
injury dominates during tumor growth may depend on the interactions between tumor cells 
and surrounding tissues (Cain et al., 2001).  
In recent years, several laboratories have developed cancer pain models by inoculation of 
tumor cells into a hindpaw of mouse (Constantin et al., 2008). Animals inoculated with 
melanoma cells into the plantar of the hindpaw show marked pain hypersensitivity and 
peripheral nerve degeneration (Gao et al., 2009a). We have used this melanoma cancer pain 
model to test the anti-tumor growth and analgesic effects of JNK inhibitor (Gao et al., 2009a). 
Other cancer pain models include breast, prostate and bone cancer pain models (Bloom et 
al., 2011; Ghilardi et al., 2010; Jimenez-Andrade et al., 2010). These cancer pain models may 
possess different pathophysiologies for pain induction. For example, intramedullary 
injection of breast cancer cells could induce periosteal sprouting of CGRP(+) sensory fibers 
and pain, both of which could be blocked by anti-nerve growth factor (NGF) (Bloom et al., 
2011). Inhibitor of NGF receptor TrkA has been shown to attenuate bone cancer pain and 
tumor-induced sprouting of sensory nerve fibers (Ghilardi et al., 2010). Similarly, NGF also 
plays an important role in the induction of prostate cancer-induced sensory fiber sprouting 
and bone pain (Jimenez-Andrade et al., 2010). 
3. Potential therapeutic molecular targets for pain management   
Voltage-gated ion channels and glial cells have all been found to be promising therapeutic 
targets for pain management. Voltage-gated ion channels are a class of transmembrane ion 
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The L5/6 spinal nerve ligation neuropathic pain model was reported by Kim and Chung in 
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melanoma cells into the plantar of the hindpaw show marked pain hypersensitivity and 
peripheral nerve degeneration (Gao et al., 2009a). We have used this melanoma cancer pain 
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injection of breast cancer cells could induce periosteal sprouting of CGRP(+) sensory fibers 
and pain, both of which could be blocked by anti-nerve growth factor (NGF) (Bloom et al., 
2011). Inhibitor of NGF receptor TrkA has been shown to attenuate bone cancer pain and 
tumor-induced sprouting of sensory nerve fibers (Ghilardi et al., 2010). Similarly, NGF also 
plays an important role in the induction of prostate cancer-induced sensory fiber sprouting 
and bone pain (Jimenez-Andrade et al., 2010). 
3. Potential therapeutic molecular targets for pain management   
Voltage-gated ion channels and glial cells have all been found to be promising therapeutic 
targets for pain management. Voltage-gated ion channels are a class of transmembrane ion 
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channels that are activated by changes in membrane potential; these types of ion channels 
are especially critical in excitable cells, including neuronal, cardiac and skeletal cells (Szu-Yu 
Ho & Rasband, 2011), or even cancer cell migration (Cuddapah & Sontheimer, 2011). Since 
voltage-gated ion channels are important for neuronal excitability, conduction and 
transmission, they have long been the targets of interest in the field of pain research. 
3.1 Voltage-gated Na+ channels  
Voltage-gated Na+ channels are essential for the initiation of action potentials which are 
crucial for nerve conduction. Their activation and inactivation are strongly gated by the 
membrane potential of neuronal cells, but their properties can also be modulated by G-
proteins or protein kinases (Kakimura et al., 2010). Voltage-gated Na+ channels are 
constituted by the pore-forming α−subunit and auxiliary β-subunits. Up to now, nine 
α−subunits (Nav1.1-1.9) and four β-subunits (β1-4) have been identified (Catterall et al., 
2005). The Na+ channels can be either sensitive (Nav1.1, Nav1.2, Nav1.3, Nav1.6) or resistant 
(Nav1.4, Nav1.5, Nav1.7, Nav1.8, Nav1.9) to tetrodotoxin (TTX), a toxin found in the liver of 
puffer fish. Neuronal cells contain most of the Na+ channel subtypes but Nav1.4 and Nav1.5, 
respectively, are mainly in skeletal and cardiac muscles (Jarecki et al., 2010). Nav1.1, Nav1.3, 
Nav1.6, Nav1.7, Nav1.8 and Nav1.9 have been found in adult dorsal root ganglion (DRG) 
sensory neurons and these isoforms can be important for the firing properties of sensory 
neurons (Hunanyan et al., 2011). After spared nerve injury in rats, altered neuronal 
electrogenesis in DRG neurons, such as accelerated re-priming of TTX-sensitive Na+ 
currents, was observed and may be due to a complex regulation of voltage-gated Na+ 
channels (Berta et al., 2008; Wang et al., 2011).  
Several lines of evidence indicate that Nav1.7, and Nav1.8 are involved in pain regulation, 
especially NINP (Lampert et al., 2010). Nav1.7 and Nav1.8 channels have been shown to 
accumulate in neuroma endings in humans with neuropathic pain (Kretschmer et al., 2002). 
This accumulation may be due to a loss of myelin inhibition or target determined transfer of 
Na+ channels (Aurilio et al., 2008). Loss of Nav1.7 function may lead to complete 
insensitivity to pain in humans (Cox et al., 2010). Compounds possessing Nav1.7 blocking 
effects have been reported to reverse nerve injury-induced mechanical allodynia 
(Tyagarajan et al., 2010). Nav1.8 is increased in sciatic nerve after nerve injury and intrathecal 
antisense oligoneucleotide directed against Nav1.8 is effective in neuropathic pain models 
(Joshi et al., 2006). A μΩ-conotoxin MrVIB was found to be a preferential Nav1.8 blocker and 
could reverse partial sciatic nerve ligation-induced mechanical allodynia and thermal 
hyperalgesia, when given intrathecally (Ekberg et al., 2006). Intraperitoneal administration of 
A-803467, a selective Nav1.8 blocker, has been reported to attenuate nerve injury-induced 
mechanical allodynia (Jarvis et al., 2007). Nonetheless, Nassar et al. found that mice lacking 
Nav1.7 and Nav1.8 still develop neuropathic pain after spinal nerve ligation (Nassar et al., 
2005). Recent studies also revealed a role of Nav1.3 (Mo et al., 2011) and Nav1.9 (Leo et al., 
2010) in the development of neuropathic pain. For normal nerve conduction, Nav1.1 family 
is involved (Catterall et al., 2010). Therefore, the selective Nav1.3, Nav1.7, Nav1.8 and 
Nav1.9 channel blockers will have clinical potential in the treatment of neuropathic pain 
since they do not affect normal neuronal conduction.  
Besides the pore-forming α-subunit, β2 subunit was reported to be up-regulated in injured 
and non-injured sensory neurons after peripheral nerve injuries (Pertin et al., 2005) and the 
development of spared nerve injury-induced mechanical allodynia is attenuated in β2-null 
mice (Lopez-Santiago et al., 2006), suggesting the important role of β2 subunit in NINP. The 
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involvement of Na+ channel β2 subunit in neuropathic and inflammatory pain has been 
extensively reviewed (Brackenbury & Isom, 2008). 
In addition to changes in protein expression, phosphorylation-induce change of 
conductance or gating property of Na+ channels may also lead to enhanced neuronal 
excitability and NINP (Aurilio et al., 2008). The activation of presynaptic delta-opioid 
receptor by enkephalin has been reported to prevent the increase in neuronal NaV1.7 in DRG 
through inhibition of PKC and p38 (Chattopadhyay et al., 2008). Tumor necrosis factor-α 
(TNF-α), a pro-inflammatory cytokine involved in NINP formation (Schafers et al., 2003), 
was found to enhance TTX-resistant Na+ currents in isolated DRG neurons via a TNF 
receptor 1- and p38-dependent mechanism (Jin & Gereau, 2006). The Na+ currents of 
isolated sensory neurons can be enhanced by protein kinase A and protein kinase C (Gold et 
al., 1998; Mo et al., 2011), both of which are involved in NINP (Gao et al., 2005; Song et al., 
2006). Phosphorylation of TTX-S and TTX-R sodium channels involving both 
serine/threonine and tyrosine sites has been reported to contribute to painful diabetic 
neuropathy (Hong et al., 2004). Further studies are required to reveal the exact role of Na+ 
channel phosphorylation in the pathogenesis of NINP.  
3.2 Voltage-gated Ca2+ channels  
Voltage-gated Ca2+ channels are involved in neuron excitability, neurotransmitter release, 
synaptic transmission and gene expression (Dolmetsch et al., 2001). Ca2+ channels are 
constituted by the pore-forming α-subunit and auxiliary subunits, β- and α2δ�subunits. 
They are classified into Cav1, Cav2 and Cav3 families based on their structure homology, 
but are categorized as L- (Cav1.1, Cav1.2 and Cav1.3), P/Q- (Cav2.1), N- (Cav2.2), R- 
(Cav2.3), and T- (Cav3.1, Cav3.2 and Cav3.3) type based on their sensitivity to specific 
blockers, activation/inactivation characteristics and current conductance (Catterall et al., 
2002). Various Ca2+ channel blockers have been tested in the postoperative, inflammatory 
and neuropathic pain models (Cheng et al., 2007). The potential use of Ca2+ channel blockers 
for neuropathic pain treatment and roles of Ca2+ channels in ascending pain pathway have 
been well reviewed (Yaksh, 2006; Zamponi et al., 2009). 
3.2.1 N-type Ca2+ channels  
N-type Ca2+ channels are distributed in the dorsal root ganglia and spinal dorsal horn. It is 
generally believed that N-type Ca2+ channels are involved in the neurotransmitter release of 
spinal dorsal horn (Smith et al., 2002). Substance P, one of the neurotransmitter of primary 
sensory neurons, has been found to be mostly co-localized with N-type Ca2+ channels in the 
spinal dorsal horn (Westenbroek et al., 1998). 
Several lines of evidence indicate that N-type Ca2+ channels play an important role in NINP. 
Mice lacking N-type Ca2+ channels exhibit reduced signs of neuropathic pain after spinal 
nerve ligation (Saegusa et al., 2001). Intrathecal small interference RNA knockdown of N-
type Ca2+ channels reversed sciatic nerve constriction-induced tactile allodynia and thermal 
hyperalgesia (Altier et al., 2007). 
New non-peptide compounds with N-type Ca2+ channel blocking property have been 
recently developed in pharmaceutical companies for the treatment of neuropathic pain 
(Knutsen et al., 2007). A highly reversible ω-conotoxin FVIA, a potent N-type Ca2+ channel 
blocker with fewer side effects, was found to possess analgesic effect in the formalin test and 
neuropathic pain models (Lee et al., 2010). Recent findings suggest that diminished Ca2+ 
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channels that are activated by changes in membrane potential; these types of ion channels 
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influx through N-type Ca2+ channels may contribute to sensory neuron dysfunction and 
pain after nerve injury (McCallum et al., 2011). 
3.2.2 T-type Ca2+ channels 
T-type Ca2+ channels are low-voltage activated Ca2+ channels. It can serve as an initiator to 
trigger the opening of high-voltage activated ion channels. In spinal dorsal horn, it may be 
involved in spontaneous neurotransmitter release and long term potentiation (LTP) (Ikeda 
et al., 2003). LTP, a form of synaptic plasticity, in the spinal dorsal horn is believed to 
contribute to the central sensitization of pain transmission (Ji et al., 2003), a wiring 
phenomenon usually observed in neuropathic pain (Romanelli & Esposito, 2004). 
Among three subtypes of T-type Ca2+ channels, CaV3.1, CaV3.2 and CaV3.3, CaV3.2 mRNAs 
are mostly abundant in the spinal dorsal horn and are limited to the superficial layers 
(Talley et al., 1999). Intrathecal injection of the antisense oligonucleotide targeted to the α1-
subunit of CaV3.2, but not CaV3.3 or CaV3.1, produced analgesic effect in both acute and 
neuropathic pain states (Bourinet et al., 2005), suggesting that CaV3.2 is much more involved 
in spinal nociceptive pathway than CaV3.1 and CaV3.3.  
Subtype-specific blockers of T-type Ca2+ channels are not commercially available. However, 
mibefradil, a non-selective T-type Ca2+ channel blocker, when given systemically or 
intraplantarly, can reverse mechanical allodynia and thermal hyperalgesia induced by L5/6 
spinal nerve ligation (Dogrul et al., 2003). Our recent work on intrathecal T-type Ca2+ channel 
blockers (mibefradil or Ni2+) revealed their effectiveness in the second phase of formalin test 
(Cheng et al., 2007). In these years, small molecules with potent blocking effect on T-type 
Ca2+ channels, such as KYS05090, have been developed (Doddareddy et al., 2007; Seo et al., 
2007). Recent studies revealed spinal T-type Ca2+ (Cav3.2 and Cav3.3 but not Cav3.1) 
channels may play an important role in the pathogenesis of chronic compression of DRG-
induced neuropathic pain (Wen et al., 2010). In addition, Cav3.2-dependent activation of 
extracellular signal-regulated kinase in the anterior nucleus of paraventricular thalamus was 
found to contribute to the development of acid-induced chronic mechanical hyperalgesia 
(Chen et al., 2010). 
3.2.3 P/Q- and R-type Ca2+ channels  
Compared with N-type Ca2+ channel, it seems P/Q type is much less important in NINP. 
Only one study using transgenic mice revealed its involvement in chronic constriction 
injury-induced mechanical allodynia (Luvisetto et al., 2006). The hypoalgesic behaviors of 
P/Q-type Ca2+ channel mutant mouse suggest P/Q-type Ca2+ channel has a pro-nociceptive 
role (Fukumoto et al., 2009). As for R-type Ca2+ channel, its blocker SNX-482 could inhibit C-
fiber and Aδ-fiber-mediated neuronal responses after L5/6 spinal nerve ligation, when 
administered intrathecally (Matthews et al., 2007). Moreover, the responses to innocuous 
mechanical and thermal stimuli were more sensitive to SNX-482 in nerve-ligated rats than 
control animals (Matthews et al., 2007). These findings suggest spinal R-type Ca2+ channel 
could be a potential therapeutic target for NINP. Blocking the R-type Ca2+ channel has been 
reported to enhance morphine analgesia and reduce morphine-induced tolerance 
(Yokoyama et al., 2004). 
3.2.4 2 subunit of Ca2+ channels 
α2δsubunit is one of the modulatory subunits of Ca2+ channels, which could modulate the 
membrane targeting and conductance of α1 subunit of Ca2+ channel (Felix, 1999). Four 
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isoforms (α2δ-1~4) were identified (Qin et al., 2002). The α2δ-1 subunit is up-regulated in 
dorsal root ganglion and dorsal spinal cord after peripheral nerve injury (Li et al., 2004). 
Intrathecal injection of α2δ-1 antisense oligonucleotide could block this up-regulation in 
spinal dorsal horn and diminish injury-induced tactile allodynia (Li et al., 2004). Over 
expression of α2δ-1 in spinal dorsal horn neurons could enhance Ca2+ currents, exaggerate 
dorsal horn neuronal responses to external stimuli and increase the nociceptive responses in 
neuropathic pain models (Li et al., 2006). 
α2δ subunit is the specific binding site in the central nervous system of gabapentin and its 
analogue pregabalin (Klugbauer et al., 2003), both of which have been shown to be effective 
in preclinical and clinical studies of neuropathic pain (Cheng & Chiou, 2006). Gabapentin 
was first designed as a chemical analogue of γ-aminobutyric acid, an inhibitory 
neurotransmitter, to treat spasticity and was later found to have anticonvulsant and 
antinociceptive activities in various seizure and pain models. A point mutation of the 
arginine 217 of α2δ-1 subunit, which is critical for gabapentin binding (Wang et al., 1999), 
was found to cause a loss of gabapentin-induced analgesia (Field et al., 2006). Recently, 
chronic intrathecal infusion of gabapentin was found to prevent nerve ligation-induced 
mechanical allodynia and thermal hyperalgesia without causing obvious neuropathological 
changes in spinal cord and cauda equine (Chu et al., 2011).  
Gabapentin has been found to attenuate morphine-induced tolerance (Lin et al., 2005) and 
this finding may encourage the combined use of gabapentin with morphine in the treatment 
of neuropathic pain. It is interesting to note that α2δ-1 subunit was identied to be a 
receptor involved in excitatory synapse formation and gabapentin may act by blocking new 
synapse formation (Eroglu et al., 2009).     
3.3 Voltage-gated K+ channels  
The opening of K+ channel may lead to cell repolarization and make the neuron less 
excitable and down-regulation of K+ channel in nociceptive neurons may decrease pain 
threshold. There are 12 different families of voltage-gated K+ channels (Kv1 to Kv12) and all 
Kv channels are tetramers of α subunits (Ocana et al., 2004). A-type K+ channel (A-channels) 
is a group of Kv channels that are activated transiently and inactivated rapidly. Five A-
channels Kv1.4, Kv3.4, Kv4.1, Kv4.2, and Kv4.3 were found in mammals (Chien et al., 2007; 
Mienville et al., 1999; Serodio et al., 1996). Except for Kv3.4 with high-voltage activation, the 
other four are activated at low voltages (Coetzee et al., 1999). Kv1.4 proteins in the somata of 
DRG neurons are greatly reduced in the L5/6 spinal nerve ligation pain model (Rasband et 
al., 2001). The expression of Kv1.4 is also reduced in the small-/medium sized (A-/C-) 
trigeminal ganglion neurons after temporomandibular joint inflammation (Takeda et al., 
2008). Gene expressions of Kv1.2, Kv1.4, and Kv4.2 are down-regulated in the DRG 
following sciatic nerve transection (Park et al., 2003). Recent study also revealed the Kv1.2 
expression is decreased in DRG neurons from rats with irritable bowel syndrome, a visceral 
pain model (Luo et al., 2011). The expression of Kv3.4 and Kv4.3 in DRG neurons were 
found to be also decreased after spinal nerve ligation and intrathecal injections of antisense 
oligodeoxynucleotides against Kv3.4 or Kv4.3 in naïve rats could induce mechanical 
hypersensitivity (Chien et al., 2007). New compounds with A-type K+ channel opening 
activity, such as KW-7158 (Sculptoreanu et al., 2004), may prove to be effective for the 
treatment of NINP. 
The Kv7 channel (also known as KCNQ) opener retigabine has been reported to be effective 
in sciatic chronic constrict injury (Blackburn-Munro & Jensen, 2003) and L5 spinal nerve 
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influx through N-type Ca2+ channels may contribute to sensory neuron dysfunction and 
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isoforms (α2δ-1~4) were identified (Qin et al., 2002). The α2δ-1 subunit is up-regulated in 
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activity, such as KW-7158 (Sculptoreanu et al., 2004), may prove to be effective for the 
treatment of NINP. 
The Kv7 channel (also known as KCNQ) opener retigabine has been reported to be effective 
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ligation (Dost et al., 2004) pain models. It is important to note that the antiallodynic effect of 
retigabine could be inhibited by linopirdine, a selective KCNQ channel blocker, indicating 
the involvement of KCNQ channel opening in the effect of retigabine (Dost et al., 2004). 
When directly applied to the spinal cord, retigabine inhibited the A and C fiber-mediated 
response of dorsal horn neurons to noxious stimuli (Passmore et al., 2003). Recently, the 
selective cyclooxygenase-2 (COX-2) inhibitor celecoxib was found to enhance Kv7.2-7.4, 
Kv7.2/7.3 and Kv7.3/7.5 currents expressed in HEK 293 cells, providing a novel mechanism 
for its antinociceptive effect (Du et al., 2011b). Based on these reports, further efforts may be 
needed to develop subtype-specific K+ channel openers and to test their effects in NINP 
models.  
Just as voltage-gated Na+ channels, K+ channels could also be modulated by 
phosphorylation (Sergeant et al., 2005). The Kv4.2 current of spinal dorsal horn neurons 
could be inhibited by extracellular signal-regulated kinase (ERK)-induced phosphorylation 
(Hu et al., 2003). Genetic elimination of Kv4.2 increases excitability of dorsal horn neurons 
and sensitivity to tactile and thermal stimuli (Hu et al., 2006). This modulation of Kv4.2 by 
ERK may underlie the induction of central sensitization, a cellular mechanism of NINP (Ji et 
al., 2003). The role of Kv channels in different trigeminal neuropathic and inflammatory 
pain models was recently reviewed (Takeda et al., 2011). 
3.4 Other K+ channels  
In addition to Kv channels, there are other K+ channels that are important for pain 
modulation, such as G-protein coupled inwardly rectifying (GIRK or Kir3), ATP-sensitive 
(KATP or Kir6), Ca2+-activated (KCa) and two-pore (K2P) K+ channels (Gutman et al., 2003). 
Activation of KATP channels was recently found to antagonize nociceptive behavior and 
hyper-excitability of DRG neurons from rats (Du et al., 2011a). Following partial sciatic 
nerve ligation, elevated tyrosine phosphorylation (pY12) of Kir3.1 was observed in the 
spinal superficial dorsal horn of wild type, but not Kir3.1 knock-out, mice (Ippolito et al., 
2005). This phosphorylation may suppress channel conductance and accelerate channel 
deactivation (Ippolito et al., 2002), leading to enhanced neuronal excitability and could 
possibly contribute to the genesis of NINP. It is interesting to note that induced expression 
of Kir2.1 in chronically compressed DRG neurons can effectively suppress the neuronal 
excitability and, if induced at the beginning of the chronic compression, prevent the 
development of compression-induced hyperalgesia (Ma et al., 2010). 
The TREK-1 channel is a member of mechano-gated K2P family, one of the targets of 
inhalation anesthetics (Patel et al., 1999). TREK-1 is highly expressed in small sensory 
neurons and extensively co-localized with TRPV1 (Alloui et al., 2006). Mice with a disrupted 
TREK-1 gene are more sensitive to painful heat and low threshold mechanical stimuli and 
display an increased thermal and mechanical hyperalgesia in conditions of inflammation 
(Alloui et al., 2006). On the other hand, the TREK-1 null mice showed decreased sensitivity 
to acetone (less cold allodynia) after sciatic nerve ligation (Alloui et al., 2006). The 
chemotherapy drug oxaliplatin, which induces cold hypersensitivity, could lower the 
expression of TREK-1 (Descoeur et al., 2011). Future studies are needed to elucidate the role 
of TREK-1 channels in NINP. Similar as TREK-1, TREK-2 is also a member of the K2P family. 
TREK-2 provide the major background K+ conductance in cell body of small to medium-
sized DRG neurons (Mathie, 2007), which are the major component of nociceptors. Based on 
these findings, it is also intriguing to investigate the role of TREK-2 in NINP (Huang & Yu, 
2008). 
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Changes in the expression and function of voltage-gated ion channels in the pain pathway 
may contribute to the development and maintenance of NINP. Manipulations aiming at 
voltage-gated ion channels may provide novel strategies for the treatment of NINP. In 
addition to ion channel modulators, recent studies also reveal the promising roles of glial 
inhibitors, such as minocycline, and morphine in the management of NINP. 
3.5 Microglia and astrocyte activation in nerve injury-induced neuropathic pain  
During the last decade, the neuroimmune system, such as spinal glial cells, has been found 
to be critical for the development and maintenance of nerve injury-induced neuropathic 
pain (Watkins et al., 2007). Nerve injury not only induces morphological changes of 
microglia but also biochemical changes to induce pain. Nerve injury results in a up-
regulation of P2X4 receptor (Tsuda et al., 2003) and CX3CR1 receptor in spinal cord 
microglia (Verge et al., 2004; Zhuang et al., 2007). Intrathecal blockade of P2X4 and CX3CR1 
signaling attenuates NINP (Tsuda et al., 2003; Zhuang et al., 2007). The chemokine receptor 
CCR2 and the Toll-like recepotor-4 (TLR4) are also important for the formation of 
neuropathic pain via microglial activation (Abbadie et al., 2003; Tanga et al., 2005). 
Phosphorylation of p38 in microglia via activation of P2X4 receptor could increase the 
synthesis and release of the neurotrophin BDNF and pro-inflammatory cytokines (IL-1, IL-
6, and TNF-, all of which could enhance nociceptive transmission in the spinal cord (Coull 
et al., 2005; Ji & Suter, 2007; Kawasaki et al., 2008b; Wang et al., 2010) 
Our study using continuous intrathecal infusion of minocycline, a microglia inhibitor, 
revealed its effectiveness in attenuating the development of nerve injury-induced pain 
and no obvious spinal neurotoxicity was observed after the infusion (Lin et al., 2007). 
Other glial modulators, such as AV-411 (Ledeboer et al., 2006) and pentoxifylline (Mika et 
al., 2007), also possessed analgesic effect in NINP models. In addition to glial activation, 
compliment activation was recently found to participate in spinal nerve ligation-induced 
pain (Levin et al., 2008). Similar with gabapentin, minocycline could also attenuate 
morphine-induced tolerance (Cui et al., 2008) and this made itself a promising drug to be 
co-administered with morphine in the treatment of neuropathic pain. It is worthwhile to 
note that the attenuation effect of minocycline on morphine-induced tolerance is 
associated with inhibition of p38 activation in spinal microglia caused by chronic 
morphine (Cui et al., 2008). 
In contrast to microglia, which is important for the development phase of NINP (Ji & Suter, 
2007), astrocytes activation was critical for the maintenance phase of NINP (Zhuang et al., 
2006). JNK-induced MCP-1 production and JAK-STAT3 pathway in spinal cord astrocytes 
was found to contribute to the maintenance of NINP (Gao et al., 2009b; Tsuda et al., 2011). 
The role of astrocyte activation and kinases involved in glial activation after nerve injury 
have been well reviewed (Gao & Ji, 2010; Ji et al., 2009).  
4. Morphine in nerve injury-induced neuropathic pain 
Morphine is the main drug used in pain clinics, especially in cancer pain. Recent animal 
studies also revealed the effectiveness of morphine in NINP models (Mika et al., 2007; 
Zhang et al., 2005). However, acute and chronic use of morphine can induce hyperalgesia 
and analgesia tolerance (Mao et al., 1994), which often lead to increased drug consumption 
and unwanted side-effects. 
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4.1 Glial non-opioid/p38 pathway in morphine-induced analgesia and tolerance 
Using the tail flick test, Tseng’s group has shown that morphine could induce anti-analgesia, 
which could be prevented by levo-, dextronaloxone (a non-opioid ligand) and p38 inhibitor 
via a glial non-opioid mechanism (Wu et al., 2006a; Wu et al., 2006b; Wu et al., 2005). From 
the works of Tseng’s group, it could be summarized that 1) both dextro- and levo-morphine 
and lipopolysaccharide (LPS), a toll-like receptor (TLR)-4 agonist, could induce anti-
analgesia, which could be prevented by dextro-, levo-naloxone and p38 inhibitor; 2) the anti-
analgesia-inducing potency is: dextro-morphine > levo-morphine, and the reversal potency is: 
levo-naloxone > dextro-naloxone, which may imply the different binding affinities of 
dextro/levo- morphine and naloxone to the putative non-opioid receptor or TLR-4 
(Hutchinson et al., 2007). 
Inspired by the studies of Hong’s group showing naloxone could attenuate LPS-induced 
microglial activation and neuronal damage (Liu et al., 2000), Watkin’s group further tested 
the possible involvement of the putative nonopioid/TLR-4 pathway in NINP. They found 
dextro-naloxone, levo-naltrexone, and LPS-antagonist possess analgesic effects in chronic 
constriction neuropathic pain model (Hutchinson et al., 2007). Taken together with the role 
of glial p38 activation in NINP (Jin et al., 2003) and morphine-induced tolerance (Cui et al., 
2006), it is possible that the putative glia non-opioid/TLR-4 pathway is important for the 
development of NINP and morphine-induced tolerance (Cui et al., 2006). 
4.2 Intrathecal studies on morphine tolerance  
Morphine has long been used intrathecally in the management of cancer and non-cancer 
chronic pain (Plummer et al., 1991; Roberts et al., 2001). However, the long-term use of 
morphine is associated with severe side-effects and tolerance (Osenbach & Harvey, 2001). 
Recently, many studies have revealed that intrathecal morphine could induce glial activation 
and neuro-inflammation in the spinal cord (Muscoli et al., 2010; Zhang et al., 2011). Several 
therapeutic targets have been found, including cytokine receptors, kappa-opioid receptors, 
N-methyl-D-aspartate receptors, and Toll-like receptors (Hameed et al., 2010; Lewis et al., 
2010). Recently, tumor necrosis factor (TNF)-α antagonist etanercept was found to reverse 
morphine-induced tolerance and block morphine-induced neuroinflammation in the 
microglia (Shen et al., 2011). Intrathecal gabapentin and minocycline could also enhance the 
antinociceptive effects of morphine and attenuate morphine-induced tolerance (Habibi-Asl 
et al., 2009; Hutchinson et al., 2008; Lin et al., 2005). These promising agents may be co-
administered with intrathecal morphine to improve the pain management for cancer patients 
(Christo & Mazloomdoost, 2008; Mercadante et al., 2004). 
5. Intrathecal neurotoxicity studies 
For a drug to be tested intrathecally in clinical trials, it is imperative to examine its neurotoxic 
effects rst in animals (Bennett et al., 2000; Smith et al., 2008). For instance, intrathecal 
lidocaine has been found to induce neuropathological changes in the spinal cord and cauda 
equina (Kirihara et al., 2003). Other analgesics, such as adenosine, sufentanil, alfentanil and 
morphine have all been tested intrathecally in animal studies to examine their potential 
neurotoxicity (Chiari et al., 1999; Sabbe et al., 1994; Westin et al., 2010). Recently, chronic 
intrathecal infusion of minocycline or gabapentin has been reported to cause no grossly 
neurotoxicity in animal studies (Chu et al., 2011; Lin et al., 2007), supporting the intrathecal 
use of these agents for pain management.      
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6. Conclusion  
Intrathecal space has been a route for spinal anesthesia and analgesics. This space also 
provides us a way to explore the possible mechanisms involved in pain transmission. Since 
pain is a major world-wide issue in clinical settings, more and more intrathecal animal 
studies have been undertaken to explore the possible mechanisms involved in the formation 
of different pain statuses and help to develop promising analgesics to alleviate the suffering 
of pain patients. These efforts will eventually help to provide better pain managements in 
clinical settings. 
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4.1 Glial non-opioid/p38 pathway in morphine-induced analgesia and tolerance 
Using the tail flick test, Tseng’s group has shown that morphine could induce anti-analgesia, 
which could be prevented by levo-, dextronaloxone (a non-opioid ligand) and p38 inhibitor 
via a glial non-opioid mechanism (Wu et al., 2006a; Wu et al., 2006b; Wu et al., 2005). From 
the works of Tseng’s group, it could be summarized that 1) both dextro- and levo-morphine 
and lipopolysaccharide (LPS), a toll-like receptor (TLR)-4 agonist, could induce anti-
analgesia, which could be prevented by dextro-, levo-naloxone and p38 inhibitor; 2) the anti-
analgesia-inducing potency is: dextro-morphine > levo-morphine, and the reversal potency is: 
levo-naloxone > dextro-naloxone, which may imply the different binding affinities of 
dextro/levo- morphine and naloxone to the putative non-opioid receptor or TLR-4 
(Hutchinson et al., 2007). 
Inspired by the studies of Hong’s group showing naloxone could attenuate LPS-induced 
microglial activation and neuronal damage (Liu et al., 2000), Watkin’s group further tested 
the possible involvement of the putative nonopioid/TLR-4 pathway in NINP. They found 
dextro-naloxone, levo-naltrexone, and LPS-antagonist possess analgesic effects in chronic 
constriction neuropathic pain model (Hutchinson et al., 2007). Taken together with the role 
of glial p38 activation in NINP (Jin et al., 2003) and morphine-induced tolerance (Cui et al., 
2006), it is possible that the putative glia non-opioid/TLR-4 pathway is important for the 
development of NINP and morphine-induced tolerance (Cui et al., 2006). 
4.2 Intrathecal studies on morphine tolerance  
Morphine has long been used intrathecally in the management of cancer and non-cancer 
chronic pain (Plummer et al., 1991; Roberts et al., 2001). However, the long-term use of 
morphine is associated with severe side-effects and tolerance (Osenbach & Harvey, 2001). 
Recently, many studies have revealed that intrathecal morphine could induce glial activation 
and neuro-inflammation in the spinal cord (Muscoli et al., 2010; Zhang et al., 2011). Several 
therapeutic targets have been found, including cytokine receptors, kappa-opioid receptors, 
N-methyl-D-aspartate receptors, and Toll-like receptors (Hameed et al., 2010; Lewis et al., 
2010). Recently, tumor necrosis factor (TNF)-α antagonist etanercept was found to reverse 
morphine-induced tolerance and block morphine-induced neuroinflammation in the 
microglia (Shen et al., 2011). Intrathecal gabapentin and minocycline could also enhance the 
antinociceptive effects of morphine and attenuate morphine-induced tolerance (Habibi-Asl 
et al., 2009; Hutchinson et al., 2008; Lin et al., 2005). These promising agents may be co-
administered with intrathecal morphine to improve the pain management for cancer patients 
(Christo & Mazloomdoost, 2008; Mercadante et al., 2004). 
5. Intrathecal neurotoxicity studies 
For a drug to be tested intrathecally in clinical trials, it is imperative to examine its neurotoxic 
effects rst in animals (Bennett et al., 2000; Smith et al., 2008). For instance, intrathecal 
lidocaine has been found to induce neuropathological changes in the spinal cord and cauda 
equina (Kirihara et al., 2003). Other analgesics, such as adenosine, sufentanil, alfentanil and 
morphine have all been tested intrathecally in animal studies to examine their potential 
neurotoxicity (Chiari et al., 1999; Sabbe et al., 1994; Westin et al., 2010). Recently, chronic 
intrathecal infusion of minocycline or gabapentin has been reported to cause no grossly 
neurotoxicity in animal studies (Chu et al., 2011; Lin et al., 2007), supporting the intrathecal 
use of these agents for pain management.      
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6. Conclusion  
Intrathecal space has been a route for spinal anesthesia and analgesics. This space also 
provides us a way to explore the possible mechanisms involved in pain transmission. Since 
pain is a major world-wide issue in clinical settings, more and more intrathecal animal 
studies have been undertaken to explore the possible mechanisms involved in the formation 
of different pain statuses and help to develop promising analgesics to alleviate the suffering 
of pain patients. These efforts will eventually help to provide better pain managements in 
clinical settings. 
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1. Introduction 
Since chronic pain manifests functional limitation, it is the leading cause of longer term 
disability [1, 2]. In the US alone, an estimated 75 million people suffer from chronic pain [3]. 
In addition to chronic pain, proper management of postoperative acute pain impacts the 
clinical outcome of patients undergoing surgery [4]. Opioid family of analgesics and non-
steroidal anti-inflammatory drugs (NSAIDs) are the main stays of current pharmacological 
agents available for the management of chronic pain [5, 6]. However, current therapies for 
pain management show modest efficacy and are associated with significant side effects. The 
major adverse effects of oral NSAIDs are gastrointestinal bleeding, gastric ulcer, renal 
failure and cardiovascular risks (in particular with selective COX-2 inhibitors) [7, 8]. The 
side effects of opioid family therapies include constipation, nausea, cognitive impairment 
and most importantly addiction [9, 10]. Thus, development of safer and effective treatment 
of chronic pain is an important goal of current pharmaceutical research. 
In recent years numerous efforts have been made to develop long-acting opioid analgesics 
and NSAIDs to modulate their pharmacokinetic profiles. Some of these include sustained 
release formulations and topical gels [11, 12]. Biological agents such as antibody against 
nerve growth factor (NGF) have also been evaluated as therapies for chronic pain. The anti-
NGF antibody acts by sequestering NGF and thus inhibits its interaction with the NGF-
receptor on the sensory neurons [13].  
Polymeric approach offers an attractive route to develop novel therapeutic agents for effective 
management of chronic pain. Interesting physical and chemical characteristics of synthetic and 
natural polymers enable them as promising materials for biomedical applications such as 
therapeutic agents, drug delivery carriers, and medical devices [14, 15]. A number of polymer 
derived therapies have been commercialized in the marketplace [16, 17]. The present article 
reviews the current state of research and development efforts to discover and develop 
biomedical polymer as therapeutic agents for the treatment of chronic pain. While use of 
polymer-derived agents for the treatment of different kinds of pains will be highlighted, the 
primary focus of the present article pertains to management of pain arising from osteoarthritis. 
Furthermore, role of polymers as intrinsically pain relieving agents either alone or as chemical 
conjugates of low molecular weight pain modulating agents are described in this article. The 
research and development efforts to develop control release formulations of low molecular 
weight pain therapies are outside the scope of this article. There are in fact a number of 
interesting articles that describe this aspect of pain management therapies [18, 19].  
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2. Osteoarthritis pain 
Osteoarthritis (OA) is one of the most prevalent musculo-skeletal degenerative diseases [20]. 
Although OA affects joints of the knee, hip, hand, and spine, knee is the most affected joint 
[21]. As a result of pain and reduced mobility, OA leads to significant loss of quality of life. 
Since OA is generally considered to be a result of mechanical “wear and tear” of joints, it 
typically affects people over the age of 60. However, its onset can be expedited at younger 
age due to other factors including obesity, genetic factors, and joint injury [22, 23]. 
Approximately 10% of the world’s adult population over the age of 60 has been affected by 
OA [24]. Therefore, the economic burden of this disease, which includes healthcare costs 
and loss of productivity, is significant. These expenditures are likely to escalate with aging 
population. At present approximately 27 million people in the US suffer from OA and it has 
been estimated that by the year 2030 25% of the US adult population (a third of which of 
working age) will be affected by OA [25]. 
Although OA manifests a broad clinical syndrome, its primary cause has been attributed to 
the progressive breakdown of articular cartilage and chondrocytes within the synovial 
joints. This degeneration leads to narrowing of the joint space, suchondral sclerosis, and 
synovial inflammation. Breakdown of the cartilage results in alternation in joint mechanics, 
which further exacerbates the disease [26, 27]. In OA, concentrations of a number of 
mediators of inflammation such as cytokines, chemokines, and proteolytic enzymes like 
matrix metalloproteinases (MMPs) as well as free radicals are elevated in the synovial fluid 
that catalyze further degradation of cartilage [28, 29]. This process results in a self-sustaining 
degenerative circle that hinders the natural process of cartilage repair. 
In spite of years of intensive research in tissue engineering, there has been no breakthrough 
to regenerate physiologically viable articular cartilage [30]. Also, no therapeutic agent has 
been developed that demonstrates structure modifying efficacy in OA patients [31]. The 
current therapies for OA are largely symptomatic in alleviating the chronic pain. These 
agents largely include anti-inflammatory agents, NSAIDs, and opioid family of analgesics. 
The relative efficacies of these therapies to relieve OA associated chronic pain have been 
modest at best [32, 33]. As mentioned earlier, long term use of these pharmacological agents 
results in major side effects (see above). In order to minimize systemic side effects associated 
with oral NSAIDs, topical agents containing the active agents have been developed. These 
delivery systems are expected to deliver the drugs in high concentrations locally and would 
reduce systemic side effects [34]. However, efficacy of these topical therapies is modest. In 
recent years, other novel therapeutic approaches for the management of OA pain has been 
pursued that include antibodies targeting NGF and antagonist of Transient Receptor 
Potential Vanilloid (TRPV) family of ion channels [35, 36]. One of the attractive therapeutic 
options for treating OA associated pain are polymer based viscosupplements. The following 
section describes the state of viscosupplement based treatments for OA pain.  
3. Hyaluronic acid derived viscosupplements 
3.1 Hyaluronic acid and its biology 
Hyaluronic acid or hyaluronan (HA) is a polysaccharide that belongs to the 
glycosaminoglycan class of biological macromolecules. This highly viscous anionic 
biopolymer is composed of -1, 3-D-glucuronic acid and -1, 4-N-acetyl-D-glucosamine 
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arranged in an alternate fashion along the polymer backbone (Fig. 1). HA is ubiquitous in 
nature and is produced by every tissue of higher organisms and some bacteria. The 
biopolymer is found in the extracellular matrices (particularly in soft connective tissues), 
synovial fluid, and cartilage. HA is endogenously synthesized by chondrocytes and 
synoviocytes [37-39]. After being released into the synovial space, HA accumulates on the 
surfaces of cartilage and ligament. Endogenously synthesized HA is generally of very 
high molecular weight (in the range of 3 -5 million Dalton) and its fully hydrated form 
assumes a globular shape [40]. Unique viscoelastic properties of HA enables it to maintain 
rheological homeostasis of the synovial fluid in the joints and plays a critical role in 
providing lubrication, elasticity, and shock absorption to joint tissues. Furthermore, by 
providing a coat on the surface of articular cartilage, HA protects the cartilage and blocks 
the loss of proteoglycan from the cartilage matrix into the synovial space [41]. In healthy 
joint of human knee, the normal concentration of HA in the synovial fluid is in the range 
of 2.5 - 4.0 mg/mL. However, under pathological conditions such as osteoarthritis, the 
concentration of HA is significantly reduced (estimated to be ~ 1 - 2 mg/mL) [42]. 
Furthermore, the biopolymer undergoes degradation under diseased conditions with 
substantial reduction in molecular weight. A combination of lowering in concentration 
and molecular weights leads to lowering in viscosity and elasticity of synovial fluid and 
consequently adverse impact on joint function. Thus, catabolic degradation of HA directly 
correlates with the onset OA. 
 
 
Fig. 1. Chemical structure of hyaluronic acid. 
3.2 HA derivatives for the treatment of osteoarthritis 
In addition to acting as a lubricant for the joint, HA has been reported to impart anti-
inflammatory, anabolic, and chondroprotective effects [43, 44]. Since OA onset is attributed 
to degradation of high molecular weight HA and its concentration in the synovial fluid, 
increase in HA concentration either by increasing the rate of the proteoglycan biosynthesis 
or by incorporating HA exogenously to the joint space would improve joint function and 
relieve OA associated chronic pain. Therefore, the effect of intraarticular administration of 
exogenous HA to restore rheological properties of the synovial fluid have been extensively 
studied [45]. 
In order to maintain desired viscoelastic property of synovial fluid, the exogenous HA 
needs to have high molecular weight. It has been observed that the frequency and the 
amount of exogenous HA injected can be lowered by increasing the molecular weight of HA 
based exogenous viscosupplement. Towards that end, a variety of synthetic approaches 
have been undertaken to engineer high molecular weight HA derivatives [46]. In general, 
the desired rheological properties of HA based viscosupplements are achieved by 
crosslinking of naturally occurring linear HA to produce higher molecular weight 
compounds. 
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have been undertaken to engineer high molecular weight HA derivatives [46]. In general, 
the desired rheological properties of HA based viscosupplements are achieved by 
crosslinking of naturally occurring linear HA to produce higher molecular weight 
compounds. 
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Functional group richness of HA has rendered it to be an important precursor material for 
the design and synthesis of numerous biomaterials with tuned physicochemical and 
biological properties that have found broad applications in biomedicine and biosurgery [47, 
48]. HA offers three kinds of functional groups that can be used for chemical modification: 
carboxylic acid, primary and secondary hydroxyl, and N-acetyl (after removal of acetyl 
group to generate primary amine). While carboxyl groups can be modified to introduce 
amide and ester bonds, the hydroxyl groups can be subjected to reaction with various 
electrophiles such as epoxides, alkyl halides, alkyl tosylates, vinyl sulfones, etc. However, 
since HA is unstable at low pH, the chemical reactions employed for its modification must 
be selected very carefully so that they are mild and compatible to HA. This is necessary to 
avoid undesired degradation of HA to lower molecular weight. Furthermore, the 
byproducts of these reactions must be benign for both short- and long-term uses. Over the 
years, a great deal of research efforts have been put forth to synthesize chemically modified 
HA [49]. 
In order to synthesize HA derived viscosupplements, linear HA has been subjected to 
crosslinking reactions with a number of bifunctional reagents such as diepoxides, divinyl 
sulfone, epichlorohydrin etc [50, 51]. Some representative examples of crosslinking 
chemistries that were carried out to prepare HA based hydrogels are shown in Figure 2.  
 
 
Fig. 2. Representative examples of crosslinking chemistries used to prepare HA hydrogels. 
Several factors need to be taken into consideration while optimizing HA derived 
viscosupplementation products. For example, the rheological properties need to be tuned 
so that they match with those of native synovial fluid. The hydrogels must be free from 
any reagents that could trigger an inflammatory response associated with an exogenous 
material. The molecular weight of the hydrogel is critical to obtain desired clinical benefits 
since HA is prone to degradation and this process is accelerated in a diseased joint. A 
variety of HA derived crosslinked viscosupplements have been approved for human use. 
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The precursor HA for these preparations are obtained either from avian sources or by 
biofermentation in bacteria. Table 1 summarizes some important features of 
representative HA based viscosupplements that are marketed for intraarticular injection 
in the knee to relieve OA pain [52]. Particularly, these products differ by their molecular 




Brand name Generic name HA source Modification type 
Molecular 
weight (kDa) 
Artz/Supartz Sodium hyaluronate Avian N/A 600 – 1,200 
Euflexxa Sodium hyaluronate Biofermentation N/A 2,400 – 3,600 
Hyalgan Sodium hyaluronate Avian N/A 500 - 730 
Intragel Sodium hyaluronate Biofermentation N/A 800 – 1, 200 
Orthovisc High mol. Wt. hyaluronan Biofermentation 
Chemical 
Modification 1,100 – 2,900 
Synvisc Hylan G-F 20 Avian Cross-linked 6,000 
Table 1. Representative examples of clinically approved hyaluronic acid (HA) based 
viscosupplementation products (reference 45). 
One of the most effective viscosupplement that has been approved for clinical use is 
Synvisc (Hylan G-F 20) and its single injection formulation, Synvisc-One [53]. The 
main components of Synvisc are HA lightly crosslinked with formaldehyde (Hylan A) 
and divinyl sulfone crosslinked hylan A (Hylan B). Synvisc contains 90% (v/v) of Hylan 
A and 10% (v/v) of hylan B and its chemical structure is shown in Figure 3. Synvisc has 
been approved for the treatment of pain associated with mild to moderate OA. In 
subsequent clinical studies it has been observed that intraarticular injection of Synvisc 
resulted in significant pain relief in the carpometacapal joint, temporomandibular joint 
and the hip [54]. These findings suggest that pain relief from the intraarticular injections 
of HA-derived viscosupplements is not limited to knee. Since, OA of the hip is the second 
most common form of arthritis after OA of the knee, additional clinical investigation of 
the role of viscosupplements in relieving chronic pain arising from hip arthritis is 
warranted. 
The biological mechanisms underlying the pharmacological action of HA derived 
viscosupplements to relieve OA pain are not completely understood. It was initially 
thought that since there is a reduced level of HA in OA joints, intraarticular injection of 
exogenous HA restores the rheological properties of synovial fluid to the level present in 
healthy joints. However, while the half-life of exogenous HA in the synovial fluid is only 
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HA [49]. 
In order to synthesize HA derived viscosupplements, linear HA has been subjected to 
crosslinking reactions with a number of bifunctional reagents such as diepoxides, divinyl 
sulfone, epichlorohydrin etc [50, 51]. Some representative examples of crosslinking 
chemistries that were carried out to prepare HA based hydrogels are shown in Figure 2.  
 
 
Fig. 2. Representative examples of crosslinking chemistries used to prepare HA hydrogels. 
Several factors need to be taken into consideration while optimizing HA derived 
viscosupplementation products. For example, the rheological properties need to be tuned 
so that they match with those of native synovial fluid. The hydrogels must be free from 
any reagents that could trigger an inflammatory response associated with an exogenous 
material. The molecular weight of the hydrogel is critical to obtain desired clinical benefits 
since HA is prone to degradation and this process is accelerated in a diseased joint. A 
variety of HA derived crosslinked viscosupplements have been approved for human use. 
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The precursor HA for these preparations are obtained either from avian sources or by 
biofermentation in bacteria. Table 1 summarizes some important features of 
representative HA based viscosupplements that are marketed for intraarticular injection 
in the knee to relieve OA pain [52]. Particularly, these products differ by their molecular 




Brand name Generic name HA source Modification type 
Molecular 
weight (kDa) 
Artz/Supartz Sodium hyaluronate Avian N/A 600 – 1,200 
Euflexxa Sodium hyaluronate Biofermentation N/A 2,400 – 3,600 
Hyalgan Sodium hyaluronate Avian N/A 500 - 730 
Intragel Sodium hyaluronate Biofermentation N/A 800 – 1, 200 
Orthovisc High mol. Wt. hyaluronan Biofermentation 
Chemical 
Modification 1,100 – 2,900 
Synvisc Hylan G-F 20 Avian Cross-linked 6,000 
Table 1. Representative examples of clinically approved hyaluronic acid (HA) based 
viscosupplementation products (reference 45). 
One of the most effective viscosupplement that has been approved for clinical use is 
Synvisc (Hylan G-F 20) and its single injection formulation, Synvisc-One [53]. The 
main components of Synvisc are HA lightly crosslinked with formaldehyde (Hylan A) 
and divinyl sulfone crosslinked hylan A (Hylan B). Synvisc contains 90% (v/v) of Hylan 
A and 10% (v/v) of hylan B and its chemical structure is shown in Figure 3. Synvisc has 
been approved for the treatment of pain associated with mild to moderate OA. In 
subsequent clinical studies it has been observed that intraarticular injection of Synvisc 
resulted in significant pain relief in the carpometacapal joint, temporomandibular joint 
and the hip [54]. These findings suggest that pain relief from the intraarticular injections 
of HA-derived viscosupplements is not limited to knee. Since, OA of the hip is the second 
most common form of arthritis after OA of the knee, additional clinical investigation of 
the role of viscosupplements in relieving chronic pain arising from hip arthritis is 
warranted. 
The biological mechanisms underlying the pharmacological action of HA derived 
viscosupplements to relieve OA pain are not completely understood. It was initially 
thought that since there is a reduced level of HA in OA joints, intraarticular injection of 
exogenous HA restores the rheological properties of synovial fluid to the level present in 
healthy joints. However, while the half-life of exogenous HA in the synovial fluid is only 
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few days, its clinical effect in reducing OA pain has been found to be maintained for 
several months [55]. This indicates that mechanism of action of HA derived 
viscosupplements is of multifactorial nature and is a combination of physical and 
biological effects. A number of in vitro studies have been carried out to investigate the 
biological activities of HA [56]. The results of these studies suggest that HA exhibits 
chondroprotective and anti-inflammatory effects in the synoviocytes by preventing 
invasion of inflammatory cells to the joint space. Biological activity of HA has also been 
attributed to down regulation of the gene expression of various inflammatory cytokines 
and catabolic enzymes like aggrecanase. Furthermore, being a natural ligand of the cell 
surface receptor CD44, HA has been thought to impart its effect by modulating CD44-
mediated metabolism. In another in vitro study, when synovial fibroblasts were cultured 
with high molecular weight HA, newly synthesized HA molecules were found. These 
biological effects of exogenous HA may result in overall cartilage protection [57, 58]. 
Thus, well controlled clinical studies would shed further light on the chondro-protection 
properties of exogenous HA like Synvisc and lead to the discovery of novel therapies with 




Fig. 3. Structure of Hylan B component of Synvisc. 
3.3 HA-steroid combinations for the treatment of chronic pain 
One of the shortcomings of HA derived viscosupplements is their slower onset of action 
to reduce OA pain relative to low molecular weight drugs such as NSAIDs and steroids. 
Therefore, the viscosupplements are generally administered weekly over a course of three 
to five weeks. As described earlier, unlike traditional pain killers, pain relief from 
viscosupplements lasts much longer (up to several months). Although intraarticular 
injection of corticosteroids achieves maximum benefit within few days of injection, 
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repeated injection of these catabolic agents can have adverse effect [59]. In order to 
achieve fast and longer lasting pain relief while minimizing the side effects of steroids, 
combination therapy of HA and corticosteroids have been envisioned. Non-covalently 
bound admixtures of HA gel with steroids, where the steroid is dispersed within the HA 
hydrogel matrix have been investigated as combination therapy to treat OA pain. This 
approach allows sustained local delivery of the steroid at OA site and would overcome 
the side effects associated with steroid overdose. Figure 4 shows the structures of 





Fig. 4. Corticosteroids used to prepare HA-steroid composite hydrogel  
viscosupplements. 
Preparation stable formulation of crosslinked HA hydrogel, Synvisc with triamcinolone 
hexaacetonide (TAH) (Figure 4, 1) was investigated by dispersing Tween-80 stabilized TAH 
colloidal suspension within a swollen gel of Syvisc [60]. By optimizing the ratio of 
Synvisc to TAH in the formulation mixture, a stable composite was obtained. The 
rheological properties of Synvisc were not adversely affected by the presence of the 
hydrophobic corticosteroid and the composition was found to be stable in an accelerated 
shelf life test.  
Another steroid-viscosupplement composite was prepared by crosslinking linear HA in the 
presence of triamcinolone acetonide (Figure 4, 2). In this study, divinyl sulfone was allowed 
to react partially with HA to generate a linear HA structure with pendant vinyl sulfone 
group. To a solution of this vinyl sulfone functionalized HA was added a suspension of 2 
and resulting reaction mixture was treated with ,-dithio polyethylene glycol (PEG)  
as the crosslinking agent. A crosslinked HA gel with relatively homogeneously distributed 
steroid particles within the gel matrix was obtained. The synthetic strategy adopted for  
the preparation of this dual-acting viscosupplement is shown in Figure 5 [61]. In a 
preliminary clinical study, this steroid-HA composite (Hydros-TA) showed faster pain relief 
compared to the corresponding native viscosupplement alone. Long term clinical  
study involving larger patient population needs to be carried out to demonstrate the clinical 
efficacy of such steroid-viscosupplement composites to treat OA associated chronic  
pain.  
 
Pain Management – Current Issues and Opinions 
 
32
few days, its clinical effect in reducing OA pain has been found to be maintained for 
several months [55]. This indicates that mechanism of action of HA derived 
viscosupplements is of multifactorial nature and is a combination of physical and 
biological effects. A number of in vitro studies have been carried out to investigate the 
biological activities of HA [56]. The results of these studies suggest that HA exhibits 
chondroprotective and anti-inflammatory effects in the synoviocytes by preventing 
invasion of inflammatory cells to the joint space. Biological activity of HA has also been 
attributed to down regulation of the gene expression of various inflammatory cytokines 
and catabolic enzymes like aggrecanase. Furthermore, being a natural ligand of the cell 
surface receptor CD44, HA has been thought to impart its effect by modulating CD44-
mediated metabolism. In another in vitro study, when synovial fibroblasts were cultured 
with high molecular weight HA, newly synthesized HA molecules were found. These 
biological effects of exogenous HA may result in overall cartilage protection [57, 58]. 
Thus, well controlled clinical studies would shed further light on the chondro-protection 
properties of exogenous HA like Synvisc and lead to the discovery of novel therapies with 




Fig. 3. Structure of Hylan B component of Synvisc. 
3.3 HA-steroid combinations for the treatment of chronic pain 
One of the shortcomings of HA derived viscosupplements is their slower onset of action 
to reduce OA pain relative to low molecular weight drugs such as NSAIDs and steroids. 
Therefore, the viscosupplements are generally administered weekly over a course of three 
to five weeks. As described earlier, unlike traditional pain killers, pain relief from 
viscosupplements lasts much longer (up to several months). Although intraarticular 
injection of corticosteroids achieves maximum benefit within few days of injection, 
 
Polymer Based Therapies for the Treatment of Chronic Pain 
 
33 
repeated injection of these catabolic agents can have adverse effect [59]. In order to 
achieve fast and longer lasting pain relief while minimizing the side effects of steroids, 
combination therapy of HA and corticosteroids have been envisioned. Non-covalently 
bound admixtures of HA gel with steroids, where the steroid is dispersed within the HA 
hydrogel matrix have been investigated as combination therapy to treat OA pain. This 
approach allows sustained local delivery of the steroid at OA site and would overcome 
the side effects associated with steroid overdose. Figure 4 shows the structures of 





Fig. 4. Corticosteroids used to prepare HA-steroid composite hydrogel  
viscosupplements. 
Preparation stable formulation of crosslinked HA hydrogel, Synvisc with triamcinolone 
hexaacetonide (TAH) (Figure 4, 1) was investigated by dispersing Tween-80 stabilized TAH 
colloidal suspension within a swollen gel of Syvisc [60]. By optimizing the ratio of 
Synvisc to TAH in the formulation mixture, a stable composite was obtained. The 
rheological properties of Synvisc were not adversely affected by the presence of the 
hydrophobic corticosteroid and the composition was found to be stable in an accelerated 
shelf life test.  
Another steroid-viscosupplement composite was prepared by crosslinking linear HA in the 
presence of triamcinolone acetonide (Figure 4, 2). In this study, divinyl sulfone was allowed 
to react partially with HA to generate a linear HA structure with pendant vinyl sulfone 
group. To a solution of this vinyl sulfone functionalized HA was added a suspension of 2 
and resulting reaction mixture was treated with ,-dithio polyethylene glycol (PEG)  
as the crosslinking agent. A crosslinked HA gel with relatively homogeneously distributed 
steroid particles within the gel matrix was obtained. The synthetic strategy adopted for  
the preparation of this dual-acting viscosupplement is shown in Figure 5 [61]. In a 
preliminary clinical study, this steroid-HA composite (Hydros-TA) showed faster pain relief 
compared to the corresponding native viscosupplement alone. Long term clinical  
study involving larger patient population needs to be carried out to demonstrate the clinical 
efficacy of such steroid-viscosupplement composites to treat OA associated chronic  
pain.  
 




Fig. 5. Crosslinking of HA in the presence of a dispersion of triamcinolone acetonide to 
prepare viscosupplment-steroid composite hydrogel 
3.4 Covalent conjugates of HA and low molecular pain killers 
Intrinsic biocompatibility and its versatility for chemical modification make HA  
an attractive biomaterial to synthesize conjugated drug delivery systems. Chemical 
modification of HA has allowed the preparation of an array HA-drug conjugates and  
HA-protein conjugates as sustained-release carriers for drugs and biotherapeutics [62, 63]. 
Covalent conjugates of HA containing hydrogels with pain relieving agents have  
been explored as dual acting agents to treat chronic pain. This approach would offer a 
number of potential clinical benefits, that include: i) retaining viscosupplementation 
property of soluble HA, ii) minimizing the systemic exposure of NSAIDs and opioid 
family pain killers by localizing administration to the target site, iii) modulating the 
duration of action of these pain killers by incorporating appropriate conjugation 
chemistry to control the rate of cleavage of the drug from the HA gel, and iv) minimizing 
the frequency of administration of viscosupplement and the pain killer in the clinic. These 
features of the HA-drug conjugates could lead to better patient compliance and improved 
quality of life. 
A series of HA derived functional hydrogels conjugated with local analgesics (e.g. 
bupivacaine) and opioid drugs (e.g. morphine) were synthesized in our laboratories as 
long acting treatments for chronic pain [64, 65]. Divinyl sulfone crosslinked HA hydrogel 
(Hylan B) was used as the polymer matrix for the synthesis of these drug conjugates. 
Appropriate linker arms were designed to tether these pain relieving agents to the HA 
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matrix. Bupivacaine was conjugated to HA through a hydrolysable imide bond (Figure 
6A). On the other hand, opioid drugs such as morphine, naloxone analogs were 
conjugated via a hydrolysable ester bonds (Figure 6B). A number of conjugates were 
synthesized by varying the nature of the linker arm, spacer length, and the amount of the 
drug loading. A systematic evaluation of the release kinetics of the drugs from the HA gel 
was carried out under in vitro conditions to identify an optimum composition. The 
optimum drug-HA conjugate from each class was evaluated in vivo for its biological 
activity. These drug-conjugated HA hydrogels exhibited therapeutic benefits by 
prolonging pain relief and were more effective than the individual agents and their 
admixtures. These preclinical research findings suggest that development of HA based 
viscosupplements conjugated with traditional pain relieving agents might lead to a 





Fig. 6. HA conjugated local analgesics (A) and opioids. 
In related work, conjugates of HA with methotrexate (MTX) were synthesized to achieve 
viscosupplementation and anti-inflammatory effect concurrently intraarticularly [66]. 
Increased levels of TNF- have been found in the synovium of OA affected joints that can be 
mitigated by oral administration of MTX [67]. However, systemic administration of MTX is 
associated with certain side effects such as pneumonitis and myelosuppression [68]. 
Therefore, by localizing MTX to target joint by delivering it as a polymer conjugate, the 
systemic side effect could be minimized. After a careful structure-activity study by 
screening various linker arms and enzyme target groups, an optimized HA conjugate of 
MTX was identified (Figure 7). A peptiditic linker was chosen as target for cathepsin 
enzymes, which are over-expressed in OA joints. The polyethyleneglycol (PEG) linker was 
chosen to enable the peptide target to be accessible to the cathepsin enzyme in the joint 
environment. In vitro and in vivo studies revealed that the HA-MTX conjugate is capable of 
reducing joint pain and swelling of the knee. On the other hand, admixture of HA and MTX 
showed marginal efficacy. 
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Fig. 7. HA conjugate of methotrexate as an intraarticular combination therapy for the 
treatment of OA pain. 
4. Polymer-opioid conjugates and polymeric opioid derivatives 
Besides being a first-line analgesic therapy for acute pain, opioids have been found to be 
useful in treating chronic pain. However, the adverse effects associated with their long term 
use limit the therapeutic benefits of opioid analgesics, thus leading to discontinuation of the 
therapy. Constipation (opioid-induced bowel dysfunction (OBD)) is one of the significant 
side effects associated with opioid therapies. OBD affects up to 80% of the patients 
undergoing opioid therapy. While other side effects associated with chronic use of opioids 
resolve with time, constipation continues to persist [69]. 
Efforts have been made to utilize polymeric approach to design and develop new generation 
of opioid analogs as pain killers. These polymeric compounds enable the patients to 
overcome OBD without losing the benefits of opioid therapy by limiting drugs’ systemic 
absorption. Pegylation chemistry was utilized to synthesize these macromolecular opioids. 
The technology of pegylation has been successfully utilized to improve pharmacokinetic 
properties of a number of (bio)pharmaceutical agents [70]. Two representative polymer 
conjugated opioid derivatives are shown in Figure 8. These compounds consist of naloxol 
analogs linked to PEG chains through hydrolytically stable ether linkage [71, 72]. In 
preclinical studies, these pegylated opioid derivatives were found to maintain their centrally 
mediated analgesia, while antagonizing peripherally mediated constipation. One of the key 
conjugates, NKTR-118 (Figure 8A, n = 7) has proceeded to advanced clinical trial. In the 
phase II clinical trial, patients receiving NKTR-118 exhibited significant increase in bowel 
movement compared to patients receiving native naloxol, without compromising the 
analgesic property of the opioid [73]. NKTR-118 is currently undergoing phase III clinical 
trial. 
 




Fig. 8. Polymer modified naloxol derivatives to prevent opioid induced constipation. 
Another interesting approach to develop polymeric pain relievers has been reported that 
utilizes a polymerization chemistry to synthesize poly(anhydride-esters), where the 
bioactive drug becomes part of the polymer backbone [74]. The general structure of this 
class of polymeric pain relievers is shown in Figure 9. Following this strategy, they were 
able to incorporate significant amounts (~ 62%) of the deliverable drug to the polymer chain. 
Hydrolytic degradation of these poly(anhydride-ester) polymers under physiological pH 
conditions releases the drug in a controlled manner. As a result, the side effects associated 
with the native drug (if released immediately) can be minimized. Some of the polymeric 
pain relievers reported are poly(anhydride-esters) containing the anti-inflammatory agent, 
salicylic acid and the opioid drug, morphine (Figure 10). Although syntheses of polymeric 
pain relievers based on these poly(anhydride-ester) scaffolds have been studied extensively, 
there is limited information about the biological activities of these polymers as treatments 
for chronic pain [75, 76]. Nevertheless, these polymeric opioids and anti-inflammatory 
agents offer a new perspective to develop novel treatments for chronic pain. 
 
 




Fig. 10. Structure of morphine-based poly(ester-anhydride). 
 













































Fig. 7. HA conjugate of methotrexate as an intraarticular combination therapy for the 
treatment of OA pain. 
4. Polymer-opioid conjugates and polymeric opioid derivatives 
Besides being a first-line analgesic therapy for acute pain, opioids have been found to be 
useful in treating chronic pain. However, the adverse effects associated with their long term 
use limit the therapeutic benefits of opioid analgesics, thus leading to discontinuation of the 
therapy. Constipation (opioid-induced bowel dysfunction (OBD)) is one of the significant 
side effects associated with opioid therapies. OBD affects up to 80% of the patients 
undergoing opioid therapy. While other side effects associated with chronic use of opioids 
resolve with time, constipation continues to persist [69]. 
Efforts have been made to utilize polymeric approach to design and develop new generation 
of opioid analogs as pain killers. These polymeric compounds enable the patients to 
overcome OBD without losing the benefits of opioid therapy by limiting drugs’ systemic 
absorption. Pegylation chemistry was utilized to synthesize these macromolecular opioids. 
The technology of pegylation has been successfully utilized to improve pharmacokinetic 
properties of a number of (bio)pharmaceutical agents [70]. Two representative polymer 
conjugated opioid derivatives are shown in Figure 8. These compounds consist of naloxol 
analogs linked to PEG chains through hydrolytically stable ether linkage [71, 72]. In 
preclinical studies, these pegylated opioid derivatives were found to maintain their centrally 
mediated analgesia, while antagonizing peripherally mediated constipation. One of the key 
conjugates, NKTR-118 (Figure 8A, n = 7) has proceeded to advanced clinical trial. In the 
phase II clinical trial, patients receiving NKTR-118 exhibited significant increase in bowel 
movement compared to patients receiving native naloxol, without compromising the 
analgesic property of the opioid [73]. NKTR-118 is currently undergoing phase III clinical 
trial. 
 




Fig. 8. Polymer modified naloxol derivatives to prevent opioid induced constipation. 
Another interesting approach to develop polymeric pain relievers has been reported that 
utilizes a polymerization chemistry to synthesize poly(anhydride-esters), where the 
bioactive drug becomes part of the polymer backbone [74]. The general structure of this 
class of polymeric pain relievers is shown in Figure 9. Following this strategy, they were 
able to incorporate significant amounts (~ 62%) of the deliverable drug to the polymer chain. 
Hydrolytic degradation of these poly(anhydride-ester) polymers under physiological pH 
conditions releases the drug in a controlled manner. As a result, the side effects associated 
with the native drug (if released immediately) can be minimized. Some of the polymeric 
pain relievers reported are poly(anhydride-esters) containing the anti-inflammatory agent, 
salicylic acid and the opioid drug, morphine (Figure 10). Although syntheses of polymeric 
pain relievers based on these poly(anhydride-ester) scaffolds have been studied extensively, 
there is limited information about the biological activities of these polymers as treatments 
for chronic pain [75, 76]. Nevertheless, these polymeric opioids and anti-inflammatory 
agents offer a new perspective to develop novel treatments for chronic pain. 
 
 




Fig. 10. Structure of morphine-based poly(ester-anhydride). 
 




Because of its clinical relevance, development of novel pharmacologic agents for effective 
management of chronic pain continues to be an important goal of pharmaceutical research. 
Although numerous therapeutic agents with different modes of action have been developed 
to treat chronic pain, no single agent exhibits the most desired profile. For example, while 
opioids and NSAIDs remain the main stay of therapeutic options, concerns over their 
associated side effects have begun to limit their use. Polymeric approach offers a variety of 
options to develop a new generation of pain relievers, which include intrinsically bioactive 
polymers to different delivery systems for traditional pain killers. HA derived 
viscosupplements offer an attracting option to treat chronic pain due to excellent 
biocompatibility and various biological functions of HA. The ability to trigger various 
biological functions makes HA based viscosupplements as promising agents to not only 
relieve symptomatic effects of chronic OA pain, but also to bring about potentially disease 
modifying effects. Therapies comprising of polymers in combination with traditional pain 
killers (either as conjugates or as stable non-covalent formulations) have been found to 
minimize the side effects of the latter. By targeting the disease via different mechanisms of 
actions, these combination agents could become superior therapeutic options to treat 
chronic pain. With increasing understanding of the pathobiology of chronic pain and intense 
research in biomedical polymers, it will be possible to develop novel polymer based 
therapies in the near future that are safe and could act as structure modifying treatments for 
chronic pain.  
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Because of its clinical relevance, development of novel pharmacologic agents for effective 
management of chronic pain continues to be an important goal of pharmaceutical research. 
Although numerous therapeutic agents with different modes of action have been developed 
to treat chronic pain, no single agent exhibits the most desired profile. For example, while 
opioids and NSAIDs remain the main stay of therapeutic options, concerns over their 
associated side effects have begun to limit their use. Polymeric approach offers a variety of 
options to develop a new generation of pain relievers, which include intrinsically bioactive 
polymers to different delivery systems for traditional pain killers. HA derived 
viscosupplements offer an attracting option to treat chronic pain due to excellent 
biocompatibility and various biological functions of HA. The ability to trigger various 
biological functions makes HA based viscosupplements as promising agents to not only 
relieve symptomatic effects of chronic OA pain, but also to bring about potentially disease 
modifying effects. Therapies comprising of polymers in combination with traditional pain 
killers (either as conjugates or as stable non-covalent formulations) have been found to 
minimize the side effects of the latter. By targeting the disease via different mechanisms of 
actions, these combination agents could become superior therapeutic options to treat 
chronic pain. With increasing understanding of the pathobiology of chronic pain and intense 
research in biomedical polymers, it will be possible to develop novel polymer based 
therapies in the near future that are safe and could act as structure modifying treatments for 
chronic pain.  
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1. Introduction 
The unpleasant sensation of pain is experienced by all human beings at a given point in life. 
When pain gets severe and/or chronic it requires medical treatment. For over a thousand 
years, opioid agonists have been employed therapeutically to treat pain, with the first 
reports of such use involving the alkaloid morphine dated to the second century 
B.C.(Waldhoer, Bartlett et al. 2004)  The term opioid refers to any substance with opium-like 
activity. Opium is extracted from the juice of the poppy plant Papaver somniferum. Opium 
contains in excess of 20 different alkaloids, and for centuries its crude form was used for 
pain management and for its psychological effects. In 1806 the German pharmacist Sertürner 
isolated a pure substance from opium, which he called morphine after the Greek god of 
dreams, Morpheus. Thereafter other alkaloids such as codeine (1832) and papaverine (1848) 
were isolated.(Reisine and Pasternak 1996) These discoveries paved the way for the use of 
pure alkaloids as opposed to crude opium in the medical profession. It became apparent 
that these alkaloids had a high potential for abuse and addiction. However, it was not until 
1973 that the first descriptions of the pharmacological properties of morphine, along with 
other agonists and antagonists, at the level of the receptor were reported.(Pert, Pasternak et 
al. 1973) 
Opioid receptors are of therapeutic relevance because they constitute the primary targets in 
the clinical treatment of both acute and chronic pain. They are members of the superfamily 
of seven helix transmembrane (TM) proteins known as G-protein coupled receptors 
(GPCRs); so-called because they are coupled in the cytoplasmic side to a group of Gi/Go 
hetero-trimeric proteins called G-proteins: Gα, Gβ and Gγ.(Eguchi M 2004) Currently four 
types of opioid receptors have been identified:  (mu for morphine),  (kappa for 
ketocyclazocine),  (delta for deferens given that it was originally discovered in the vas 
deferens of mice)(Waldhoer, Bartlett et al. 2004) and orphan opioid receptor-like 1. They are 
in turn sub-divided into additional subtypes on the basis of their ligand binding and 
pharmacological profiles: 1-2, 1-3, and 1-2.(Pasternak 1993; Blakeney, Reid et al. 2007) 
The ,  and  main types are the most studied, each playing a different role in pain 
sedation: the -receptor generates the most profound analgesia, but is also associated with 
constipation, respiratory depression, euphoria, tolerance, dependence and 
addition;(Schmauss and Yaksh 1984; Cowan, Zhu et al. 1988)  the -receptor is involved in 
pain relief from thermal sources,(Mansour, Khachaturian et al. 1988) but like the μ-receptor, 
it is also associated with respiratory depression and addiction;(Abdelhamid, Sultana et al. 
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1991; Maldonado, Negus et al. 1992) the -receptor mediates pain originating from chemical 
stimuli,(Leighton, Johnson et al. 1987; Wollemann, Benyhe et al. 1993) but it promotes 
dysphoria, diuresis and sedation.(von Voigtlander, Lahti et al. 1983; Lahti, Mickelson et al. 
1985) There is also evidence that opioid receptors exist as homo- or hetero-oligomeric 
complexes and that their pharmacological responses may be cross-modulated.(Zhu, King et 
al. 1999; Rutherford, Wang et al. 2008) For instance, Waldhoer M et al. used 6’-GNTI to 
demonstrate the existence of a δ-κ hetero-dimer in vivo.(Waldhoer, Fong et al. 2005) 
Furthermore, δ-opioid antagonists suppress some of the side effects of -opioid agonists 
such as dependence and tolerance while retaining their analgesic properties.(Ananthan 
2006) The realization of this potential for cross-modulation generated interests in developing 
so-called bivalent ligands of opioid receptors.(Dietis, Guerrini et al. 2009; Balboni, Salvadori 
et al. 2011) One therapeutic relevance of opioid receptors worth mentioning is that opioid 
receptors antagonists such as naloxone are utilized clinically in the treatment of morphine 
and heroin addiction and overdose.(Blakeney, Reid et al. 2007) In this chapter, we 
summarize structural aspects of opioid receptors and opioid receptor ligands, with special 
emphasis on the -opioid receptor. The importance of the combined use of experimental 
information and computational models is highlighted. 
 
 
Fig. 1. (A) The three domains of the μ-opioid receptor. Intracellular serine, threonine and 
tyrosine residues are shown in red. (B) Extracellular perspective: the seven transmembrane 
helices are arranged sequentially in a counterclockwise direction. The modeled active and 
inactive structures are shown in cyan and tan, respectively. A substantial structural 
difference between the two states can be seen at TM6. (C) Hypothesized outcome of degree 
of ligand-induced receptor endocytosis. Homology models from Pogozheva, I. D., A. L. 
Lomize, et al. (1998), Fowler, C. B. et al. (2004). 
2. Biochemical and biophysical characterization of the μ-opioid receptor 
2.1 Structural studies of the -opioid receptor 
The notion of preferential stabilization of distinct conformational states by agonists and 
non-agonists has been established experimentally and also demonstrated computationally 
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(see Figure1). The experimental studies include: Li et al. (Li, Han et al. 2007) employing 
agonists and inverse-agonists of the muscarinic acetylcholine GPCR; Xu et al. (Xu, Sanz et 
al. 2008) identified inter-residue interaction differences between the active and inactive 
states for the -opioid receptor. From the computational side, molecular dynamics 
simulations studies suggest that -opioid receptor agonists and antagonists bind to the 
receptor with a set of interactions that are specific to each class.(Kolinski and Filipek 2008) 
In addition, MD simulations have been utilized to elucidate an increase in solvent 
exposure of the intracellular domains between helices 3 and 6, and different interactions 
between the arginine of the E/DRY motif for active and inactive GPCRs.(Fanelli and De 
Benedetti 2006) 
2.2 Mechanism of activation of opioid receptors 
To describe the mechanism of activation and action of opioid receptors it suffices to describe 
the cellular assembly of these receptors. Opioid receptors comprise three domains: an 
extracellular N-terminus, seven transmembrane -helices and an intracellular C-terminus, 
Figure 1. The 7TM helices are arranged sequentially in a counter-clockwise manner when 
viewed from the extracellular side, and are linked by loops called EL1, EL2, EL3, IL1, IL2 
and IL3. EL and IL denote extracellular loop and intracellular loop, respectively. Across the 
receptors the intracellular loops share the highest sequence homology (90%), followed by 
TM domains (70%), while the extracellular loops, the N- and C-termini show the greatest 
diversity.(Knapp, Malatynska et al. 1995) Coupling between the receptors and G-proteins 
occurs via the pertussis toxin sensitive Gα unit. 
Activation and signaling from opioid receptors by different classes of ligands are regulated 
by a highly conserved mechanism.(Finn and Whistler 2001; Eguchi 2004) They are activated 
naturally by endogenous peptides, but also by exogenous opiates. Agonist-dependent 
opioid receptor activation induces conformational changes in the receptor, which promote 
exchange of Gα-bound GDP for unbound GTP, followed by dissociation of the G-proteins 
from the receptor. The Gα unit further dissociates from the Gβγ units. Signal transduction 
occurs via GTP-bound Gα inhibiting adenylate cyclase, responsible for producing cyclic 
adenosine monophosphate (cAMP). Down-regulation of cAMP results in the reduction of 
voltage-dependent current and neurotransmitter release.(Eguchi 2004) Moreover, the 
threshold of voltage-dependent ion channels becomes more negative, decreasing inward 
flow of current responsible for spontaneous neuronal activity resulting in a drop in cellular 
excitability. cAMP reduction also leads to a decrease in neurotransmitter release by cAMP-
dependent protein kinase. The Gβ and Gγ subunits also play key roles in decreasing cell 
excitability by inhibiting voltage-gated Ca2+ channels, hyperpolarizing the membrane and 
up-regulating the conduction of potassium.(Eguchi 2004) These combined decreases in 
neurotransmitter release and excitability are manifested as analgesia. Finally, the inactive 
state is re-constituted when Gα-bound GTP is hydrolyzed to GDP, re-association with Gβγ 
and recoupling with the receptor. 
Numerous experimental approaches have been utilized to investigate GPCR structure and 
activation including: solution and solid-state NMR, fluorescence, IR and UV spectroscopy, 
spin-labeling, site-directed mutagenesis, substituted cysteine accessibility, disulphide cross-
linking, engineering metal-binding sites, and identification of constitutively active 
mutants.(Gether 2000; Meng and Bourne 2001; Parnot, Miserey-Lenkei et al. 2002; Decaillot, 
Befort et al. 2003; Hubbell, Altenbach et al. 2003; Struts, Salgado et al. 2011) Experimentally 
and computationally, the importance of the lipid membrane should be recognized. It is well 
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al. 2008) identified inter-residue interaction differences between the active and inactive 
states for the -opioid receptor. From the computational side, molecular dynamics 
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dependent protein kinase. The Gβ and Gγ subunits also play key roles in decreasing cell 
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up-regulating the conduction of potassium.(Eguchi 2004) These combined decreases in 
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spin-labeling, site-directed mutagenesis, substituted cysteine accessibility, disulphide cross-
linking, engineering metal-binding sites, and identification of constitutively active 
mutants.(Gether 2000; Meng and Bourne 2001; Parnot, Miserey-Lenkei et al. 2002; Decaillot, 
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documented that membrane composition affects receptor function.(Botelho, Gibson et al. 
2002; Botelho, Huber et al. 2006) From the computational side, molecular dynamics 
simulations showed that the modification of the original positioning of the lipids in the 
membrane influences the dynamics of the protein.(Lau, Grossfield et al. 2007) In addition, 
water flux though the transmembrane helices, has been proposed to affect rhodopsin 
activation. (Grossfield, Pitman et al. 2008)  Lastly, the time scale involved in the activation of 
GPCRs is a challenging task. However, the combined use of computer power and 
experimental information allows for the generation of detailed structural information. For 
instance, 2000 ns molecular dynamics simulations and solid-state 2H-NMR data were 
combined to elucidate the protonation state of key residues directly involved in rhodopsin 
activation.(Martinez-Mayorga, Pitman et al. 2006)  This exemplifies how computational 
models can provide detailed structural information not available otherwise.  
Advances in crystallography and molecular engineering have provided the three-dimensional 
structures of a few GPCR’s: rhodopsin,(Palczewski, Kumasaka et al. 2000; Ridge and 
Palczewski 2007; Choe, Kim et al. 2011) -adrenergic receptor,(Kobilka and Schertler 2008) and 
adenosine receptor.(Jaakola, Griffith et al. 2008)  In the absence of experimental structures of 
opioid receptors, the 2.6-Å resolution crystal structure of bovine rhodopsin(Palczewski, 
Kumasaka et al. 2000) has served as a template for generating homology models of these 
receptors,(Pogozheva, Lomize et al. 1998; Fowler, Pogozheva et al. 2004; Fowler, Pogozheva et 
al. 2004; Pogozheva, Przydzial et al. 2005)  Like rhodopsin, opioid receptors belong to class A 
of the GPCR superfamily. The crystallographic structure of the active state of rhodopsin is now 
available (Choe, Kim et al. 2011) and can be contrasted with the large body of literature that 
suggests a common active conformation among the class-A GPCRs. (Karnik, Gogonea et al. 
2003) In the activated state TM6 undergoes outward rigid-body translation toward TM5, but 
away from TM3 and TM7. As a result, a cavity opens up in the intracellular domain in contact 
with G-proteins. Similar movements have been also suggested for TM1-3 and TM7.(Lin and 
Sakmar 1996; Gether, Lin et al. 1997; Altenbach, Cai et al. 2001) A better understanding of these 
activation mechanisms at the molecular level could lead to new drugs geared towards the 
therapeutic regulation of their functions. 
Decaillot FM et al. applied mutagenesis to study the mechanism of activation of the human 
-opioid receptor.(Decaillot, Befort et al. 2003) By analyzing 30 constitutively active mutants 
of this receptor, mutations hypothesized to produce distinct active conformations were 
grouped into four abutting areas of the receptor from the extracellular (group I) to the 
intracellular (group IV) domain. Details about the residues that form each group can be 
found in Decaillot FM. A sequential binding mechanism was proposed to activate the 
receptor.(Decaillot, Befort et al. 2003) Sequential binding in GPCRs is not uncommon. A 
similar mechanism has been postulated for the β2-adrenergic receptors.(Swaminath, Xiang 
et al. 2004) In the case of the -opioid receptor agonists bind to residues in group I 
comprising a hydrophobic region in EL3, weakening interactions with TM6 and TM7 in the 
extracellular domain thus initiating a signal. Next, the ligand enters the binding pocket 
disrupting interactions in groups II and III. Group II residues form a molecular switch that 
controls movements of TM3. Group III residues are closest to the binding site, consist of 
patches of hydrophilic and hydrophobic residues and form a network of interactions 
between residues derived from TM3, 6 and 7. The disruption of these interactions results in 
a receptor state that is susceptible to activation and helps propagate signals to the 
intracellular side. It was hypothesized that the amphiphilic nature of opiates and opioid 
ligands makes them complementary to residues in group III, i.e., the hydrophilic portion of 
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the ligands disrupt the hydrogen-bonding network, while the hydrophobic portion compete 
with the hydrophobic residues. Finally, disrupting the interactions in group 4 residues 
results in the separation of TM6 and TM7 in the intracellular side and possibly destabilizing 
interactions with Gα and exposure to other secondary protein effectors. 
Insights about the conformation of the activated state of the -opioid receptor are based on 
modeling experimental distance constraints derived from site-directed mutagenesis, inter-
helix H-bonds, disulphide bonds, and engineered Zn2+ binding sites between the -opioid 
receptor and analogues of the receptor-bound conformation of a cyclic tetra-peptidomimetic, 
JOM6.(Fowler, Pogozheva et al. 2004) Structural data for the active state were also derived 
from disulphide bonds between TM5 and TM6 in the ACM3 muscarinic receptor,(Ward SD, 
JBC 2002) intrinsic allosteric Zn2+ binding sites  in TM5 and TM6 of the β2-adrenergic 
receptor,(Swaminath, Lee et al. 2003) engineered activating metal-coordination center akin to 
those between TM3 and TM7 in the β2-adrenergic(Elling, Thirstrup et al. 1999) and 
tachykinin(Holst, Elling et al. 2000) receptors, between TM2 and TM3 of the MC4 melanocortin 
receptor. Finally one hydrogen bond constraint from the δ-opioid receptor(Decaillot, Befort et 
al. 2003) was introduced. A comparison between the modeled structures of the active and 
inactive states of the -opioid receptor is shown in Figure 1. A noticeable difference is seen in 
TM6 highlighting the rigid-body movement described for the -opioid receptor. 
2.3 Internalization of opioid receptors and changes in downstream signaling  
Signal transduction by the -opioid receptor is determined by properties of the ligand such 
as affinity, potency, efficacy, bio-availability and half-life, collectively defined as ‘relative 
activity’ or RA.(Martini and Whistler 2007) In addition, the length of time the receptor-
ligand complex remains coupled to the G-protein, is controlled by receptor desensitization, 
endocytosis and to an extent the pharmacokinetic properties of the ligand. It has been noted 
that ligand activity and endocytosis do not have a linear relationship.(Martini and Whistler 
2007) Hence, an interplay of relative activity versus endocytosis (RAVE) for each ligand 
determines the magnitude of the signal transduced. Thus each ligand-receptor complex has 
an associated RAVE value. As highlighted by Martini L et al.(Martini and Whistler 2007) 
endogenous peptides have good RA values at the μ-opioid receptor, and also induce 
significant desensitization and endocytosis. Based on this reasoning, the good balance 
between their RA and VE values explain why they do not induce tolerance. Another 
example is methadone. Methadone has comparable potency with encephalin and is also an 
equally good receptor internalizer.(Whistler, Chuang et al. 1999) Nonetheless, it has a longer 
half-life compared to other opioids, and consequently a larger RA value giving rise to a 
moderately higher RAVE value. The extension of the RAVE analysis to morphine is more 
complicated and invokes secondary protein effectors and region-selective differences in 
receptor endocytosis.(Martini and Whistler 2007) In general, agonists such as morphine with 
high RAVE values are more likely to induce tolerance. It has been demonstrated that the 
development of -opioid tolerance is inversely related to the ability of an agonist to promote 
receptor endocytosis or internalization.(Whistler, Chuang et al. 1999; Finn and Whistler 
2001) This theory distinguishes two types of agonists based on their ability to stabilize 
different receptor conformational states, resulting in phosphorylation by different kinases. 
Depending on the type of kinase the receptor can be rapidly endocytosed, resensitized and 
recycled to the cell surface, preventing the development of tolerance.  
The formation of an opioid ligand-receptor complex results in structural changes at the 
extracellular and transmembrane domains, which are propagated to the intracellular 
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documented that membrane composition affects receptor function.(Botelho, Gibson et al. 
2002; Botelho, Huber et al. 2006) From the computational side, molecular dynamics 
simulations showed that the modification of the original positioning of the lipids in the 
membrane influences the dynamics of the protein.(Lau, Grossfield et al. 2007) In addition, 
water flux though the transmembrane helices, has been proposed to affect rhodopsin 
activation. (Grossfield, Pitman et al. 2008)  Lastly, the time scale involved in the activation of 
GPCRs is a challenging task. However, the combined use of computer power and 
experimental information allows for the generation of detailed structural information. For 
instance, 2000 ns molecular dynamics simulations and solid-state 2H-NMR data were 
combined to elucidate the protonation state of key residues directly involved in rhodopsin 
activation.(Martinez-Mayorga, Pitman et al. 2006)  This exemplifies how computational 
models can provide detailed structural information not available otherwise.  
Advances in crystallography and molecular engineering have provided the three-dimensional 
structures of a few GPCR’s: rhodopsin,(Palczewski, Kumasaka et al. 2000; Ridge and 
Palczewski 2007; Choe, Kim et al. 2011) -adrenergic receptor,(Kobilka and Schertler 2008) and 
adenosine receptor.(Jaakola, Griffith et al. 2008)  In the absence of experimental structures of 
opioid receptors, the 2.6-Å resolution crystal structure of bovine rhodopsin(Palczewski, 
Kumasaka et al. 2000) has served as a template for generating homology models of these 
receptors,(Pogozheva, Lomize et al. 1998; Fowler, Pogozheva et al. 2004; Fowler, Pogozheva et 
al. 2004; Pogozheva, Przydzial et al. 2005)  Like rhodopsin, opioid receptors belong to class A 
of the GPCR superfamily. The crystallographic structure of the active state of rhodopsin is now 
available (Choe, Kim et al. 2011) and can be contrasted with the large body of literature that 
suggests a common active conformation among the class-A GPCRs. (Karnik, Gogonea et al. 
2003) In the activated state TM6 undergoes outward rigid-body translation toward TM5, but 
away from TM3 and TM7. As a result, a cavity opens up in the intracellular domain in contact 
with G-proteins. Similar movements have been also suggested for TM1-3 and TM7.(Lin and 
Sakmar 1996; Gether, Lin et al. 1997; Altenbach, Cai et al. 2001) A better understanding of these 
activation mechanisms at the molecular level could lead to new drugs geared towards the 
therapeutic regulation of their functions. 
Decaillot FM et al. applied mutagenesis to study the mechanism of activation of the human 
-opioid receptor.(Decaillot, Befort et al. 2003) By analyzing 30 constitutively active mutants 
of this receptor, mutations hypothesized to produce distinct active conformations were 
grouped into four abutting areas of the receptor from the extracellular (group I) to the 
intracellular (group IV) domain. Details about the residues that form each group can be 
found in Decaillot FM. A sequential binding mechanism was proposed to activate the 
receptor.(Decaillot, Befort et al. 2003) Sequential binding in GPCRs is not uncommon. A 
similar mechanism has been postulated for the β2-adrenergic receptors.(Swaminath, Xiang 
et al. 2004) In the case of the -opioid receptor agonists bind to residues in group I 
comprising a hydrophobic region in EL3, weakening interactions with TM6 and TM7 in the 
extracellular domain thus initiating a signal. Next, the ligand enters the binding pocket 
disrupting interactions in groups II and III. Group II residues form a molecular switch that 
controls movements of TM3. Group III residues are closest to the binding site, consist of 
patches of hydrophilic and hydrophobic residues and form a network of interactions 
between residues derived from TM3, 6 and 7. The disruption of these interactions results in 
a receptor state that is susceptible to activation and helps propagate signals to the 
intracellular side. It was hypothesized that the amphiphilic nature of opiates and opioid 
ligands makes them complementary to residues in group III, i.e., the hydrophilic portion of 
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the ligands disrupt the hydrogen-bonding network, while the hydrophobic portion compete 
with the hydrophobic residues. Finally, disrupting the interactions in group 4 residues 
results in the separation of TM6 and TM7 in the intracellular side and possibly destabilizing 
interactions with Gα and exposure to other secondary protein effectors. 
Insights about the conformation of the activated state of the -opioid receptor are based on 
modeling experimental distance constraints derived from site-directed mutagenesis, inter-
helix H-bonds, disulphide bonds, and engineered Zn2+ binding sites between the -opioid 
receptor and analogues of the receptor-bound conformation of a cyclic tetra-peptidomimetic, 
JOM6.(Fowler, Pogozheva et al. 2004) Structural data for the active state were also derived 
from disulphide bonds between TM5 and TM6 in the ACM3 muscarinic receptor,(Ward SD, 
JBC 2002) intrinsic allosteric Zn2+ binding sites  in TM5 and TM6 of the β2-adrenergic 
receptor,(Swaminath, Lee et al. 2003) engineered activating metal-coordination center akin to 
those between TM3 and TM7 in the β2-adrenergic(Elling, Thirstrup et al. 1999) and 
tachykinin(Holst, Elling et al. 2000) receptors, between TM2 and TM3 of the MC4 melanocortin 
receptor. Finally one hydrogen bond constraint from the δ-opioid receptor(Decaillot, Befort et 
al. 2003) was introduced. A comparison between the modeled structures of the active and 
inactive states of the -opioid receptor is shown in Figure 1. A noticeable difference is seen in 
TM6 highlighting the rigid-body movement described for the -opioid receptor. 
2.3 Internalization of opioid receptors and changes in downstream signaling  
Signal transduction by the -opioid receptor is determined by properties of the ligand such 
as affinity, potency, efficacy, bio-availability and half-life, collectively defined as ‘relative 
activity’ or RA.(Martini and Whistler 2007) In addition, the length of time the receptor-
ligand complex remains coupled to the G-protein, is controlled by receptor desensitization, 
endocytosis and to an extent the pharmacokinetic properties of the ligand. It has been noted 
that ligand activity and endocytosis do not have a linear relationship.(Martini and Whistler 
2007) Hence, an interplay of relative activity versus endocytosis (RAVE) for each ligand 
determines the magnitude of the signal transduced. Thus each ligand-receptor complex has 
an associated RAVE value. As highlighted by Martini L et al.(Martini and Whistler 2007) 
endogenous peptides have good RA values at the μ-opioid receptor, and also induce 
significant desensitization and endocytosis. Based on this reasoning, the good balance 
between their RA and VE values explain why they do not induce tolerance. Another 
example is methadone. Methadone has comparable potency with encephalin and is also an 
equally good receptor internalizer.(Whistler, Chuang et al. 1999) Nonetheless, it has a longer 
half-life compared to other opioids, and consequently a larger RA value giving rise to a 
moderately higher RAVE value. The extension of the RAVE analysis to morphine is more 
complicated and invokes secondary protein effectors and region-selective differences in 
receptor endocytosis.(Martini and Whistler 2007) In general, agonists such as morphine with 
high RAVE values are more likely to induce tolerance. It has been demonstrated that the 
development of -opioid tolerance is inversely related to the ability of an agonist to promote 
receptor endocytosis or internalization.(Whistler, Chuang et al. 1999; Finn and Whistler 
2001) This theory distinguishes two types of agonists based on their ability to stabilize 
different receptor conformational states, resulting in phosphorylation by different kinases. 
Depending on the type of kinase the receptor can be rapidly endocytosed, resensitized and 
recycled to the cell surface, preventing the development of tolerance.  
The formation of an opioid ligand-receptor complex results in structural changes at the 
extracellular and transmembrane domains, which are propagated to the intracellular 
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domain followed by the dissociation of G-proteins; phosphorylation by G-protein coupled 
receptor kinases (GRK), protein kinase A (PKA) and C (PKC); and binding by other proteins 
such as β-arrestins.(Eguchi 2004) The phosphorylated receptor is endocytosed, whereby it is 
re-sensitized and recycled to the cell surface or it is marked for degradation. Unlike PKA 
and PKC, specific GRK-phosphorylation triggers the recruitment of β-arrestins, receptor 
internalization, resensitization and recycling to the cell surface. This dynamic recycling 
process has been suggested as crucial to circumvent development to drug tolerance. 
Tolerance-causing agonists impede receptor endocytosis and/or resensitization, while non-
tolerance-inducing drugs promote rapid receptor desensitization-internalization-
resensitization and recycling.(Martini and Whistler 2007)  
The exact cause of development of tolerance is still a subject of debate. Nonetheless, it is 
generally accepted that chronic administration of opiates for analgesia gives rise to 
tolerance. The cellular mechanism of tolerance may involve downstream compensatory 
changes in neuronal circuits.(Eguchi 2004) The continual and sustained inhibition of 
adenylate cyclase activity triggers a positive feedback to compensate for the low 
intracellular levels of cAMP, resulting in the reversible superactivation of adenylate cyclase. 
This up-regulation of enzyme activity restores the cellular concentration of cAMP, resulting 
in cells being tolerant to the opiate and also dependent on it given that withdrawing the 
drug or introducing an antagonist gives rise to abnormally high levels of cAMP and also a 
restoration of the normal activity level of adenylate cyclase.(Sharma, Klee et al. 1975) The 
change is delayed but relatively stable and is known to be responsible for opiate tolerance 
and dependence.(Sharma, Klee et al. 1975) The combined inhibition and up-regulation of 
adenylyl cyclase provide a means of activating and deactivating neuronal circuits and may 
play a role in a memory process. It was later shown that the adenylate cyclase V and Gβγ 
played a role in this activation.(AvidorReiss, Nevo et al. 1996) 
2.4 Point-mutation studies to identify key residue targets for phosphorylation 
Mutation studies have been successful in identifying key cytosolic domains and residues of 
ligand-activated -opioid receptors, which are liable to phosphorylation, and potentially 
directly involved in agonist-dependent receptor internalization. (Celver, Lowe et al. 2001; El 
Kouhen, Burd et al. 2001; Celver, Xu et al. 2004) Truncation of the -opioid receptor at Ser363 
produced a mutant that was not phosphorylated, and was endocytosed and recycled more 
slowly than the wild-type,(Qiu, Law et al. 2003) suggesting that phosphorylating residues in 
this segment may be important for internalization. Cleaving off the entire C-terminal resulted 
in increased agonist-independent internalization and recycling,(Waldhoer, Bartlett et al. 2004) 
indicating a greater exposure of some residues critical for the dynamic recycling machinery. 
Utilizing a single agonist, [D-Ala2,MePhe4,Gly5-ol]enkephalin (DAMGO), the mutation of 
Thr180 to alanine in the second intracellular loop prevented receptor desensitization, while 
alanine scanning of serine or threonine in the third cytoplasmic loop did not inhibit receptor 
desensitization.(Celver, Lowe et al. 2001) In a DAMGO-induced receptor activation study, 
mutations of C-terminal serine/threonine residues identified three phosphorylation sites: 
Ser363, Thr370 and Ser375. The S375A mutant decreased the rate of receptor internalization, 
while the S363A and T370A double mutant accelerated the rate of internalization,(El Kouhen, 
Burd et al. 2001) which may suggest that the combined phosphorylation of Ser363 and Thr370 
attenuates receptor internalization. Other studies employing etorphine and multiple mutations 
have also identified Ser356 and Ser363,(Burd, El-Kouhen et al. 1998)  and Thr394 (using 
DAMGO)(Pak, Odowd et al. 1997; Wolf, Koch et al. 1999) as sites for phosphorylation that 
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result in down-regulation of the -opioid receptor. Mutation of Ser356 and Ser363 
simultaneously did not alter receptor phosphorylation, but the mutations prevented down-
regulation of the receptor suggesting that the absence of down-regulation was not due to the 
removal of phosphorylation sites. Down-regulation may be occurring through a 
phosphorylation-independent mechanism or these two sites are not phosphorylated. This is 
contrary to later studies that demonstrated that Ser363 is phosphorylated.(El Kouhen, Burd et 
al. 2001) The T394A mutant is more rapidly internalized and resensitized relative to the wild-
type -opioid receptor. These mutation studies show that multiple phosphorylation motifs 
may be needed for internalization and that not every phosphorylation site is phosphorylated. 
3. Discovery and development of opioid receptor ligands 
3.1 Endogenous opioid ligands 
Extensive structural and pharmacological studies have been performed to understand the 
mechanisms of action of opioids as well as for the design of new and more efficient opioid-
based painkillers. The opioid agonists propagate their analgesic effects by interacting with 
opioid receptors. They are both endogenously expressed peptides and exogenous opiates. 
The term opiate is reserved for foreign substances introduced into the body to target opioid 
receptors. The endogenous peptides enkephalins, dynorphins, β-endorphins and 
nociceptins are excised from their precursors pro-enkephalin, pro-dynorphin, pro-
opiomelanocortin and pro-nociceptin/orphanin FQ, respectively. The majority of these 
peptides comprise a conserved N-terminal YGGF motif,(Gentilucci, Squassabia et al. 2007) 
except the uncharacteristically short peptides endomorphin-1 (YPWF-NH2) and 
endomorphin-2 (YPFF-NH2) that are considered analogues of the YGGF motif.  A list of 
endogenous peptides, their precursors and receptor selectivity is presented in Table 1. 
 
Peptide Sequences Precursor Selectivity 
Endomorphin-1 YPWF-NH2 NDa μ Endomorphin-2 YPFF-NH2 
β-endorphin YGGFMTSEKSQTPLVTLFK         NAIIKNAYKKGE Pro-opiomelanocortin μ=δ 
[Leu5]enkephalin YGGFL 
Pro-enkephalin δ [Met5]enkephalin YGGFM 
Metorphinamide YGGFMRRV-NH2 
Deltorphin A YmFHLMD-NH2 
NDa δ Deltorphin I YaFDVVG-NH2 
Deltorphin II YaFEVVG-NH2 
Dynorphin A YGGFLRRIRPKLKWDNQ 
Pro-dynorphin κ 
Dynorphin A(1-8)  YGGFLRRI 
Dynorphin B YGGFLRRQFKVVT 
α-neoendorphin YGGFLRKYPK 
β-neoendorphin YGGFLRKYP 
Nociceptin FGGFTGARKSARKLANQ Pro-nociceptin / Orphanin FQ ORL-1b 
a Not yet determined. The conserved YGGF sequence is shown in bold 
b Orphan opioid receptor-like 1 
Table 1. Endogenous opioid peptides, the precursor and receptor selectivity. 
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domain followed by the dissociation of G-proteins; phosphorylation by G-protein coupled 
receptor kinases (GRK), protein kinase A (PKA) and C (PKC); and binding by other proteins 
such as β-arrestins.(Eguchi 2004) The phosphorylated receptor is endocytosed, whereby it is 
re-sensitized and recycled to the cell surface or it is marked for degradation. Unlike PKA 
and PKC, specific GRK-phosphorylation triggers the recruitment of β-arrestins, receptor 
internalization, resensitization and recycling to the cell surface. This dynamic recycling 
process has been suggested as crucial to circumvent development to drug tolerance. 
Tolerance-causing agonists impede receptor endocytosis and/or resensitization, while non-
tolerance-inducing drugs promote rapid receptor desensitization-internalization-
resensitization and recycling.(Martini and Whistler 2007)  
The exact cause of development of tolerance is still a subject of debate. Nonetheless, it is 
generally accepted that chronic administration of opiates for analgesia gives rise to 
tolerance. The cellular mechanism of tolerance may involve downstream compensatory 
changes in neuronal circuits.(Eguchi 2004) The continual and sustained inhibition of 
adenylate cyclase activity triggers a positive feedback to compensate for the low 
intracellular levels of cAMP, resulting in the reversible superactivation of adenylate cyclase. 
This up-regulation of enzyme activity restores the cellular concentration of cAMP, resulting 
in cells being tolerant to the opiate and also dependent on it given that withdrawing the 
drug or introducing an antagonist gives rise to abnormally high levels of cAMP and also a 
restoration of the normal activity level of adenylate cyclase.(Sharma, Klee et al. 1975) The 
change is delayed but relatively stable and is known to be responsible for opiate tolerance 
and dependence.(Sharma, Klee et al. 1975) The combined inhibition and up-regulation of 
adenylyl cyclase provide a means of activating and deactivating neuronal circuits and may 
play a role in a memory process. It was later shown that the adenylate cyclase V and Gβγ 
played a role in this activation.(AvidorReiss, Nevo et al. 1996) 
2.4 Point-mutation studies to identify key residue targets for phosphorylation 
Mutation studies have been successful in identifying key cytosolic domains and residues of 
ligand-activated -opioid receptors, which are liable to phosphorylation, and potentially 
directly involved in agonist-dependent receptor internalization. (Celver, Lowe et al. 2001; El 
Kouhen, Burd et al. 2001; Celver, Xu et al. 2004) Truncation of the -opioid receptor at Ser363 
produced a mutant that was not phosphorylated, and was endocytosed and recycled more 
slowly than the wild-type,(Qiu, Law et al. 2003) suggesting that phosphorylating residues in 
this segment may be important for internalization. Cleaving off the entire C-terminal resulted 
in increased agonist-independent internalization and recycling,(Waldhoer, Bartlett et al. 2004) 
indicating a greater exposure of some residues critical for the dynamic recycling machinery. 
Utilizing a single agonist, [D-Ala2,MePhe4,Gly5-ol]enkephalin (DAMGO), the mutation of 
Thr180 to alanine in the second intracellular loop prevented receptor desensitization, while 
alanine scanning of serine or threonine in the third cytoplasmic loop did not inhibit receptor 
desensitization.(Celver, Lowe et al. 2001) In a DAMGO-induced receptor activation study, 
mutations of C-terminal serine/threonine residues identified three phosphorylation sites: 
Ser363, Thr370 and Ser375. The S375A mutant decreased the rate of receptor internalization, 
while the S363A and T370A double mutant accelerated the rate of internalization,(El Kouhen, 
Burd et al. 2001) which may suggest that the combined phosphorylation of Ser363 and Thr370 
attenuates receptor internalization. Other studies employing etorphine and multiple mutations 
have also identified Ser356 and Ser363,(Burd, El-Kouhen et al. 1998)  and Thr394 (using 
DAMGO)(Pak, Odowd et al. 1997; Wolf, Koch et al. 1999) as sites for phosphorylation that 
 
Molecular Aspects of Opioid Receptors and Opioid Receptor Painkillers 49 
result in down-regulation of the -opioid receptor. Mutation of Ser356 and Ser363 
simultaneously did not alter receptor phosphorylation, but the mutations prevented down-
regulation of the receptor suggesting that the absence of down-regulation was not due to the 
removal of phosphorylation sites. Down-regulation may be occurring through a 
phosphorylation-independent mechanism or these two sites are not phosphorylated. This is 
contrary to later studies that demonstrated that Ser363 is phosphorylated.(El Kouhen, Burd et 
al. 2001) The T394A mutant is more rapidly internalized and resensitized relative to the wild-
type -opioid receptor. These mutation studies show that multiple phosphorylation motifs 
may be needed for internalization and that not every phosphorylation site is phosphorylated. 
3. Discovery and development of opioid receptor ligands 
3.1 Endogenous opioid ligands 
Extensive structural and pharmacological studies have been performed to understand the 
mechanisms of action of opioids as well as for the design of new and more efficient opioid-
based painkillers. The opioid agonists propagate their analgesic effects by interacting with 
opioid receptors. They are both endogenously expressed peptides and exogenous opiates. 
The term opiate is reserved for foreign substances introduced into the body to target opioid 
receptors. The endogenous peptides enkephalins, dynorphins, β-endorphins and 
nociceptins are excised from their precursors pro-enkephalin, pro-dynorphin, pro-
opiomelanocortin and pro-nociceptin/orphanin FQ, respectively. The majority of these 
peptides comprise a conserved N-terminal YGGF motif,(Gentilucci, Squassabia et al. 2007) 
except the uncharacteristically short peptides endomorphin-1 (YPWF-NH2) and 
endomorphin-2 (YPFF-NH2) that are considered analogues of the YGGF motif.  A list of 
endogenous peptides, their precursors and receptor selectivity is presented in Table 1. 
 
Peptide Sequences Precursor Selectivity 
Endomorphin-1 YPWF-NH2 NDa μ Endomorphin-2 YPFF-NH2 
β-endorphin YGGFMTSEKSQTPLVTLFK         NAIIKNAYKKGE Pro-opiomelanocortin μ=δ 
[Leu5]enkephalin YGGFL 
Pro-enkephalin δ [Met5]enkephalin YGGFM 
Metorphinamide YGGFMRRV-NH2 
Deltorphin A YmFHLMD-NH2 
NDa δ Deltorphin I YaFDVVG-NH2 
Deltorphin II YaFEVVG-NH2 
Dynorphin A YGGFLRRIRPKLKWDNQ 
Pro-dynorphin κ 
Dynorphin A(1-8)  YGGFLRRI 
Dynorphin B YGGFLRRQFKVVT 
α-neoendorphin YGGFLRKYPK 
β-neoendorphin YGGFLRKYP 
Nociceptin FGGFTGARKSARKLANQ Pro-nociceptin / Orphanin FQ ORL-1b 
a Not yet determined. The conserved YGGF sequence is shown in bold 
b Orphan opioid receptor-like 1 
Table 1. Endogenous opioid peptides, the precursor and receptor selectivity. 
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Endomorphin-1 and endomorphin-2 are highly potent, selective μ-opioid receptor 
endogenous peptides isolated from mammals, and elicit responses similar to that of 
morphine.(Zadina, Hackler et al. 1997; Horvath 2000) The endogenous peptides are 
advantageous in that they do not display any of the side effects of opiates (see below); 
however, they are not effective in clinical settings because of in vivo degradation by 
peptidases.(Witt, Gillespie et al. 2001) Notwithstanding their degradation, these peptides 
and their analogues have been utilized extensively as tools to probe receptor categorization 
and structure-activity relationships.(Hruby and Agnes 1999; Gentilucci, Squassabia et al. 
2007) The exogenous opiates on the other hand are more effective in pain management, but 
present numerous undesirable side effects, some of which are highlighted below. As such, 
several efforts are being undertaken to identify beneficial analgesics with minimal to no side 
effects. 
3.2 Potent opioid-based analgesics 
Interests in identifying more effective analgesics have led to the reporting of a large number 
potent opioid peptide and non-peptide compounds that are generally classified as agonists 
or antagonists.(Pan 1998; Stevens, Jones et al. 2000; Eguchi 2004; Waldhoer, Bartlett et al. 
2004; Gentilucci, Squassabia et al. 2007; Prisinzano and Rothman 2008; Volpe, Tobin et al. 
2011) In spite of the multitude of known opioid compounds, only a relatively small number 
has been approved for clinical use. The majority of these prescribed analgesics are relatively 
selective for the μ-opioid receptor,(Volpe, Tobin et al. 2011) though at sufficiently higher 
doses interactions with the other opioid receptors will occur. While some of these 
compounds are selective for either the μ (morphine), κ (salvinorin A), or δ (naltrindole) 
opioid receptors, some are non-selective and display mixed agonist/antagonist responses, 
for example buprenorphine, pentazocine and butorphanol. Buprenorphine is a partial μ-
agonist and partial κ-antagonist that is administered clinically for opioid detoxification and 
maintenance.(Blakeney, Reid et al. 2007)  
 
Compound Receptor Functiona Compound Receptor Functiona 
Morphine* Μ A Cyclazocine* μ/κ A/AN 
Fentanyl* “ “ Pentazocine* “ “ 
Hydrocodone* “ “ Nalbuphine* “ “ 
Levorphanol* “ “ SIOM Δ A 
Meperidine* “ “ SCN-80 “ “ 
Sufentanyl* “ “ TAN-67 “ “ 
Methadone* “ “ Ketocyclazocine Κ A 
Oxycodone* “ “ Ethyl Ketocyclazocine “ “ 
Oxymorphone* “ “ U-50,488 “ “ 
Codeine* “ “ Salvinorin A “ “ 
Naloxone* “ AN 6’-GNTIa “ “ 
Buprenorphine* μ/κ A/AN 5’-GNTIa “ AN 
Butorphanol* “ “ Bremazocine μ/δ/κ A/AN 
A = agonist; AN = antagonist 
*Currently in clinical use. a GNTI: guanidino-naltrindole   
Table 2. Opioid receptor ligands. 
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Fig. 2. The chemical structures of some exogenous opiates. The classical “message” tyramine 
moiety is colored in red in the structure of morphine. 
The classification of some opioid compounds is given in Table 2. The chemical structures of 
selected compounds are shown in Figure 2. Several factors affect the potency of an analgesic, 
including route of administration, whether they act as full or partial agonists, ability to cross 
the blood-brain barrier (physico-chemical properties) and their effects on other major 
physiological systems.(Volpe, Tobin et al. 2011) Some potency comparisons with morphine 
worth mentioning include the following: fentanyl when administered intramuscularly is 
about 100 fold more potent; hydromorphone is 6-8 fold more potent;(Inturrisi 2002) and oral 
oxycodone is about 1.8 times more potent.(Curtis, Johnson et al. 1999) Though a partial 
agonist buprenorphine is reported to be 25-40 times more potent than morphine.(Blakeney, 
Reid et al. 2007) 
3.3 Pharmacophoric features of opioid ligands 
Numerous structure-activity relations (SAR) studies have been carried out on opioid 
receptor ligands to determine features that drive affinity or efficacy with the goal of 
generating more effective therapeutic compounds,(Eguchi 2004; Metcalf and Coop 2005; 
Prisinzano and Rothman 2008; Yongye, Appel et al. 2009, amongst others). SAR studies 
employing site-directed substitutions and constraints of endogenous peptides, as well as 
modifications of morphine have provided valuable insights about the pharmacophoric 
features, ligand selectivity and biological roles of opioid receptors.(Blakeney, Reid et al. 
2007) For example it has been determined that a positively charged amine group, an 
aromatic moiety and a hydrophobic group result in tight binding of morphine. A salt-
bridge is formed between the protonated amine and an aspartate residue in TM3, π-π 
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Endomorphin-1 and endomorphin-2 are highly potent, selective μ-opioid receptor 
endogenous peptides isolated from mammals, and elicit responses similar to that of 
morphine.(Zadina, Hackler et al. 1997; Horvath 2000) The endogenous peptides are 
advantageous in that they do not display any of the side effects of opiates (see below); 
however, they are not effective in clinical settings because of in vivo degradation by 
peptidases.(Witt, Gillespie et al. 2001) Notwithstanding their degradation, these peptides 
and their analogues have been utilized extensively as tools to probe receptor categorization 
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several efforts are being undertaken to identify beneficial analgesics with minimal to no side 
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Compound Receptor Functiona Compound Receptor Functiona 
Morphine* Μ A Cyclazocine* μ/κ A/AN 
Fentanyl* “ “ Pentazocine* “ “ 
Hydrocodone* “ “ Nalbuphine* “ “ 
Levorphanol* “ “ SIOM Δ A 
Meperidine* “ “ SCN-80 “ “ 
Sufentanyl* “ “ TAN-67 “ “ 
Methadone* “ “ Ketocyclazocine Κ A 
Oxycodone* “ “ Ethyl Ketocyclazocine “ “ 
Oxymorphone* “ “ U-50,488 “ “ 
Codeine* “ “ Salvinorin A “ “ 
Naloxone* “ AN 6’-GNTIa “ “ 
Buprenorphine* μ/κ A/AN 5’-GNTIa “ AN 
Butorphanol* “ “ Bremazocine μ/δ/κ A/AN 
A = agonist; AN = antagonist 
*Currently in clinical use. a GNTI: guanidino-naltrindole   
Table 2. Opioid receptor ligands. 
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Fig. 2. The chemical structures of some exogenous opiates. The classical “message” tyramine 
moiety is colored in red in the structure of morphine. 
The classification of some opioid compounds is given in Table 2. The chemical structures of 
selected compounds are shown in Figure 2. Several factors affect the potency of an analgesic, 
including route of administration, whether they act as full or partial agonists, ability to cross 
the blood-brain barrier (physico-chemical properties) and their effects on other major 
physiological systems.(Volpe, Tobin et al. 2011) Some potency comparisons with morphine 
worth mentioning include the following: fentanyl when administered intramuscularly is 
about 100 fold more potent; hydromorphone is 6-8 fold more potent;(Inturrisi 2002) and oral 
oxycodone is about 1.8 times more potent.(Curtis, Johnson et al. 1999) Though a partial 
agonist buprenorphine is reported to be 25-40 times more potent than morphine.(Blakeney, 
Reid et al. 2007) 
3.3 Pharmacophoric features of opioid ligands 
Numerous structure-activity relations (SAR) studies have been carried out on opioid 
receptor ligands to determine features that drive affinity or efficacy with the goal of 
generating more effective therapeutic compounds,(Eguchi 2004; Metcalf and Coop 2005; 
Prisinzano and Rothman 2008; Yongye, Appel et al. 2009, amongst others). SAR studies 
employing site-directed substitutions and constraints of endogenous peptides, as well as 
modifications of morphine have provided valuable insights about the pharmacophoric 
features, ligand selectivity and biological roles of opioid receptors.(Blakeney, Reid et al. 
2007) For example it has been determined that a positively charged amine group, an 
aromatic moiety and a hydrophobic group result in tight binding of morphine. A salt-
bridge is formed between the protonated amine and an aspartate residue in TM3, π-π 
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stacking interactions between the aromatic group and residues in the binding pocket and 
hydrophobic-hydrophobic interactions. In endogenous peptides the N-terminal tyrosine 
contains a protonated amine and aromatic group, akin to the aromatic ring (A) and basic 
nitrogen (N) in morphine, Figure 3. This moiety termed tyramine is common to a majority 
of opioids, though there are some notable potent and selective opiates that lack this 
classical pharmacophore: Salvinorin A was the first highly potent, non-nitrogen opiate 
agonist selective towards the -opioid receptor;(Roth, Baner et al. 2002) one of its 
analogues, herkinorin became the first non-nitrogenous agonist selective towards the -
opioid receptor.(Harding, Tidgewell et al. 2005) Furthermore, the phenylalanine side 
chain in endogenous peptides mimics the hydrophobic feature (B) of morphine (ring C). It 
should be pointed out that due to size differences between the peptides and morphine, 
the interactions between their respective hydrophobic features (B) and the receptor are 
different.  
The observation of the occurrence of a common structural feature amongst opioid ligands 
gave rise to the “message-address” concept of ligand-receptor interactions, i.e., the same 
message (signal transduction) is delivered to different addresses (receptors). For the 
endogenous peptides the message comprises the conserved YGGF motif, with the 
exceptions cited in Table 1, while for the opiates the tyramine moiety represents the 




Fig. 3. Chemical structures of morphine and the truncated “message” motif of an 
endogenous peptide. The YGGF represents amino acids: Y, tyrosine; G, glycine and F, 
phenylalanine. 
Generating pharmacophore models for opioid receptors have followed two traditional 
approaches: ligand-based or docking-based. Ligand-based methods involve identifying and 
superimposing common substructures of low energy conformers from which features that 
drive biological activity are determined. However, because of the inherent difficulties of 
superimposing structurally different scaffolds these efforts have typically revolved around 
congeneric series. See Shim J et al.(Shim, Coop et al. 2011) and references therein. In ligand-
based virtual screenings via multi-conformer ensembles, the quality and coverage of the 
conformational ensemble are important. The production of the conformers can be 
computationally intensive, especially for compounds with a large number of rotatable 
bonds. Thus, reducing the size of multi-conformer databases and the number of query 
conformers, while simultaneously reproducing the bioactive conformer with good accuracy, 
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is of crucial interest. A recent protocol that takes into account these aspects has been 
proposed.(Yongye, Bender et al. 2010) This protocol and other important aspects of 
conformational coverage in ligand-based virtual screening methods have been recently 
revised.(Musafia and Senderowitz 2010) On the other hand, docking-based approaches are 
most valuable when experimental structures of receptors are available. The absence of 
experimental opioid receptor structures means docking-based methods must rely on 
homology models. Moreover, for docking-based virtual screening, one has to contend with 
no induced fit and the possibility of different binding modes.  
The identification of enkephalins and -opioid receptors fueled interests in developing 
ligands that target this receptor. The observation that co-administration of -opioid receptor 
antagonists with -opioid receptor agonists produced analgesia without the side effect of -
only agonists further served as motivation to identify -selective opioids. Hence, 
considerable efforts have been devoted to studying the SAR of -opioid receptor ligands 
using both pharmacophore and quantitative structure-activity relationship modeling. See 
Bernard D et al.(Bernard, Coop et al. 2007) and references therein. Employing the 
conformationally sampled pharmacophore (CSP) approach Bernard D et al. were able to 
differentiate between -opioid receptor agonists and antagonists.(Bernard, Coop et al. 2003; 
Bernard, Coop et al. 2005) An advantage of the CSP method is the inclusion of high energy 
conformers in describing pharmacophores, the justification stemming from the fact that 
ligands may bind in higher energy conformers stabilized by intermolecular interactions with 
receptors. The CSP methodology was later applied to peptide and nonpeptide agonists to 
derive pharmacophore models of -opioid receptor ligands.(Bernard, Coop et al. 2007) Three 
pharmacophore points were considered: aromatic (A), basic nitrogen (N) and hydrophobic 
group (B). 
Utilizing efficacy as the activity index, CSP was extended to five peptides and twenty 
nonpeptides comprising -opioid receptor ligands, to derive an aggregate pharmacophore. 
By analyzing a diverse group of agonists, partial agonists and antagonists the following 
conclusions were derived: interactions with the B or hydrophobic site of oripavines 
(etorphine, buprenorphine and diprenorphine) modulated the degree of agonism; agonists 
with bulky B groups adopt a pose in which interactions occur with both the basic amine and 
the B site; agonists with large N-substituents are oriented such that the substituents occupy 
the position of the traditional B site. The resultant pharmacophore is an aromatic group (A), 
a basic amine (N), a hydrophobic group (B) and N-substituents (S). The investigators claim 
that such an approach would facilitate efforts to develop compounds that possess both μ-
agonistic and δ-antagonistic properties even though the cell lines only expressed the μ-
opioid receptor.(Shim, Coop et al. 2011) Furthermore, depending on the structural class of 
the ligand, N-subsituents can enhance agonism or antagonism. For example, N-allyl and N-
cyclopropylmethyl substituents in etorphines give rise to better agonists compared to 
morphine,(Gorin and Marshall 1977) while they induce antagonism in 4,5-
epoxymorphinans.(Shim, Coop et al. 2011) 
The currently known -opioid receptor agonists have been classified into eight structural 
classes(Yamaotsu and Hirono 2011): peptides (dynorphins), benzomorphans (pentazocine), 
morphinans (butorphanol), arylacetamines (U-69593), diazabicyclononanones (HZ2), 
bicyclic guanidines (TPI-614-1), benzodiazepines (±tifluadom) and neocleorodane 
diterpenes (salvinorin A). A comprehensive review of these classes and the history of the 
development of -opioid receptor ligand pharmacophores was published recently by 
Yamaotsu N et al.(Yamaotsu and Hirono 2011) Evidently, the structural diversity of these 
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stacking interactions between the aromatic group and residues in the binding pocket and 
hydrophobic-hydrophobic interactions. In endogenous peptides the N-terminal tyrosine 
contains a protonated amine and aromatic group, akin to the aromatic ring (A) and basic 
nitrogen (N) in morphine, Figure 3. This moiety termed tyramine is common to a majority 
of opioids, though there are some notable potent and selective opiates that lack this 
classical pharmacophore: Salvinorin A was the first highly potent, non-nitrogen opiate 
agonist selective towards the -opioid receptor;(Roth, Baner et al. 2002) one of its 
analogues, herkinorin became the first non-nitrogenous agonist selective towards the -
opioid receptor.(Harding, Tidgewell et al. 2005) Furthermore, the phenylalanine side 
chain in endogenous peptides mimics the hydrophobic feature (B) of morphine (ring C). It 
should be pointed out that due to size differences between the peptides and morphine, 
the interactions between their respective hydrophobic features (B) and the receptor are 
different.  
The observation of the occurrence of a common structural feature amongst opioid ligands 
gave rise to the “message-address” concept of ligand-receptor interactions, i.e., the same 
message (signal transduction) is delivered to different addresses (receptors). For the 
endogenous peptides the message comprises the conserved YGGF motif, with the 
exceptions cited in Table 1, while for the opiates the tyramine moiety represents the 




Fig. 3. Chemical structures of morphine and the truncated “message” motif of an 
endogenous peptide. The YGGF represents amino acids: Y, tyrosine; G, glycine and F, 
phenylalanine. 
Generating pharmacophore models for opioid receptors have followed two traditional 
approaches: ligand-based or docking-based. Ligand-based methods involve identifying and 
superimposing common substructures of low energy conformers from which features that 
drive biological activity are determined. However, because of the inherent difficulties of 
superimposing structurally different scaffolds these efforts have typically revolved around 
congeneric series. See Shim J et al.(Shim, Coop et al. 2011) and references therein. In ligand-
based virtual screenings via multi-conformer ensembles, the quality and coverage of the 
conformational ensemble are important. The production of the conformers can be 
computationally intensive, especially for compounds with a large number of rotatable 
bonds. Thus, reducing the size of multi-conformer databases and the number of query 
conformers, while simultaneously reproducing the bioactive conformer with good accuracy, 
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is of crucial interest. A recent protocol that takes into account these aspects has been 
proposed.(Yongye, Bender et al. 2010) This protocol and other important aspects of 
conformational coverage in ligand-based virtual screening methods have been recently 
revised.(Musafia and Senderowitz 2010) On the other hand, docking-based approaches are 
most valuable when experimental structures of receptors are available. The absence of 
experimental opioid receptor structures means docking-based methods must rely on 
homology models. Moreover, for docking-based virtual screening, one has to contend with 
no induced fit and the possibility of different binding modes.  
The identification of enkephalins and -opioid receptors fueled interests in developing 
ligands that target this receptor. The observation that co-administration of -opioid receptor 
antagonists with -opioid receptor agonists produced analgesia without the side effect of -
only agonists further served as motivation to identify -selective opioids. Hence, 
considerable efforts have been devoted to studying the SAR of -opioid receptor ligands 
using both pharmacophore and quantitative structure-activity relationship modeling. See 
Bernard D et al.(Bernard, Coop et al. 2007) and references therein. Employing the 
conformationally sampled pharmacophore (CSP) approach Bernard D et al. were able to 
differentiate between -opioid receptor agonists and antagonists.(Bernard, Coop et al. 2003; 
Bernard, Coop et al. 2005) An advantage of the CSP method is the inclusion of high energy 
conformers in describing pharmacophores, the justification stemming from the fact that 
ligands may bind in higher energy conformers stabilized by intermolecular interactions with 
receptors. The CSP methodology was later applied to peptide and nonpeptide agonists to 
derive pharmacophore models of -opioid receptor ligands.(Bernard, Coop et al. 2007) Three 
pharmacophore points were considered: aromatic (A), basic nitrogen (N) and hydrophobic 
group (B). 
Utilizing efficacy as the activity index, CSP was extended to five peptides and twenty 
nonpeptides comprising -opioid receptor ligands, to derive an aggregate pharmacophore. 
By analyzing a diverse group of agonists, partial agonists and antagonists the following 
conclusions were derived: interactions with the B or hydrophobic site of oripavines 
(etorphine, buprenorphine and diprenorphine) modulated the degree of agonism; agonists 
with bulky B groups adopt a pose in which interactions occur with both the basic amine and 
the B site; agonists with large N-substituents are oriented such that the substituents occupy 
the position of the traditional B site. The resultant pharmacophore is an aromatic group (A), 
a basic amine (N), a hydrophobic group (B) and N-substituents (S). The investigators claim 
that such an approach would facilitate efforts to develop compounds that possess both μ-
agonistic and δ-antagonistic properties even though the cell lines only expressed the μ-
opioid receptor.(Shim, Coop et al. 2011) Furthermore, depending on the structural class of 
the ligand, N-subsituents can enhance agonism or antagonism. For example, N-allyl and N-
cyclopropylmethyl substituents in etorphines give rise to better agonists compared to 
morphine,(Gorin and Marshall 1977) while they induce antagonism in 4,5-
epoxymorphinans.(Shim, Coop et al. 2011) 
The currently known -opioid receptor agonists have been classified into eight structural 
classes(Yamaotsu and Hirono 2011): peptides (dynorphins), benzomorphans (pentazocine), 
morphinans (butorphanol), arylacetamines (U-69593), diazabicyclononanones (HZ2), 
bicyclic guanidines (TPI-614-1), benzodiazepines (±tifluadom) and neocleorodane 
diterpenes (salvinorin A). A comprehensive review of these classes and the history of the 
development of -opioid receptor ligand pharmacophores was published recently by 
Yamaotsu N et al.(Yamaotsu and Hirono 2011) Evidently, the structural diversity of these 
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classes making it difficult to construct a consensus pharmacophore model. Previous SAR 
and pharmacophore analyses of -opioid receptor ligands are typically confined to 
structural analogues. Yamaotsu N et al. proposed a consensus pharmacophore 
encompassing all eight classes using seven compounds in both the training and test sets. 
Superposition was based on the physico-chemical properties of groups of atoms. The 
consensus pharmacophore comprised three hydrophobic groups, a hydrogen bond donor 
and three hydrogen bond acceptors. These pharmacophoric features were employed to 
describe four binding orientations of the different classes of ligands for the -opioid 
receptor. It remains to be determined how this consensus pharmacophore will perform in 
virtual screening: for example screening a database, requiring that a given number of 
features match, followed by biological evaluation of the top scoring compounds. 
Additionally, in the search of opioid receptor ligands, structure similarity(Martinez-
Mayorga, Medina-Franco et al. 2008; Yongye, Appel et al. 2009) and chemoinformatic 
analyses(Medina-Franco, Martínez-Mayorga et al. 2009) have been employed to develop 
SAR and to characterize highly dense combinatorial libraries. 
3.4 Identification of opioid receptor ligands 
A large and growing body of literature has reported the identification of opioid receptor 
ligands. In particular, improvements in high-throughput chemical synthesis have made 
possible the rapid and efficient generation of molecules, giving rise to thousands or millions 
of compounds in combinatorial libraries. Advances in molecular biology have also enabled 
the evaluation of millions of individual compounds against a number of different biological 
targets via high-throughput screening (HTS). However, some high content assays, such as in 
vivo studies, are not amenable to the high-throughput miniaturization required to screen 
millions of individual compounds.  In such cases, screening libraries using a mixture-based 
format(Houghten, Pinilla et al. 1999; Pinilla, Appel et al. 2003; Houghten, Dooley et al. 2006) 
(also known as positional scanning-synthetic combinatorial libraries or PS-SCL) enables the 
evaluation of thousands to millions of molecules in approximately a hundred to a few 
hundred samples. PS-SCL have been used to successfully identify active molecules for a 
variety of biological targets. (Houghten, Pinilla et al. 1999; Pinilla, Appel et al. 2003; 
Houghten, Pinilla et al. 2008) In the case of opioid receptors highly active peptides (Dooley, 
Chung et al. 1994; Houghten, Dooley et al. 2006) and peptidomimetics have been identified. 
(Houghten, Dooley et al. 2006)  This technique has recently found new applications in the 
search of conotoxins (Armishaw, Singh et al.) and in-vivo screening (Reilley, Giulianotti et 
al.). A step forward in the development of peptides with therapeutic relevance corresponds 
to the formation of cyclic structures. Cyclic peptides are therapeutically attractive due to 
their high bioavailability, potential selectivity, and scaffold novelty. In addition, the 
presence of D-residues induces conformational preferences not followed by peptides 
consisting of only naturally abundant L-residues.  Therefore, the development of synthetic 
schemes and comprehending how amino acids induce turns in peptides is significant in 
peptide design. For example, a successful method for the synthesis of cyclic peptides by the 
intramolecular aminolysis of peptide thioesters, has been recently reported,(Li, Yongye et al. 
2009) and the corresponding explicit solvent molecular dynamics simulations were 
produced and analyzed.(Yongye, Li et al. 2009) The cyclic tetra-peptidomimetic, JOM6, 
(Fowler, Pogozheva et al. 2004) is an example of a conformationally constrained peptide that 
retains activity against the -opioid receptor. It is anticipated that research will continue in 
this direction.  
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The search of opioid receptor ligands using experimental screening of combinatorial 
libraries has been complemented using computational methods. In silico methods can be 
incorporated at different stages of the drug discovery process, from library design to lead 
optimization. (Brooijmans and Kuntz 2003) Computational methods are largely applied to 
corporate chemical collections (Bajorath 2002) as well as combinatorial chemical libraries. 
(Houghten, Pinilla et al. 2008) However, limited efforts have been reported so far to 
explicitly integrate information from mixture-based combinatorial libraries and 
computational techniques (López-Vallejo, Caulfield et al. 2011; Yongye, Pinilla et al. 2011). 
The structural analogy contained in combinatorial libraries in general and in mixture-based 
libraries in particular deserves particular considerations. Virtual screening may assist in 
downsizing large compound libraries and the selection of a smaller set of promising hits, 
whereas mixture-based screening may screen out some of the false positives of virtual 
screening. The integration of mixture-based combinatorial library screening data and virtual 
screening information has been undertaken. In the particular case of opioid receptors, the 
predicted activity obtained from the experimental mixture-based screening of a large library 
of bicyclic guanidines was combined with structural similarity methods. This approach 
allowed categorizing the molecules as actives, activity cliffs, diverse compounds and missed 
hits.(Yongye, Pinilla et al. 2011) 
4. Conclusions 
Ever since the discovery of opioid receptors as the principal mediators of analgesia and the 
identification of endogenous peptides as well as opiates that elicit analgesic responses, 
considerable efforts have been devoted to finding compounds that target these receptors 
with the aim of alleviating the sensation of pain. While the endogenous peptides do not 
display any side effects, their use in clinical settings is hampered because of in vivo 
degradation by protein-digesting enzymes. Opiates are more effective, but adverse side 
effects such as tolerance, dependence and addiction limit their prolonged usage; thus the 
continual search for more efficient analgesics. Several compounds have been reported as 
opioid receptor ligands, however, only a relatively few are currently prescribed in clinical 
settings with morphine being the prototypical -opioid agonist. A high proportion of 
opioid-based drugs is selective toward the μ-opioid receptor, and still retains untoward side 
effects prompting extensive studies about the molecular origins of these undesirable 
properties.  
This review focuses on structural aspects of opioid receptors and opioid receptor ligands, 
with special emphasis on the -opioid receptor. The information presented here can be 
summarized as follows: 
1. Considerable evidence now point to the existence of opioid receptors as homo- or 
hetero-oligomeric complexes and that their pharmacological responses may be cross-
modulated. For example the co-administration of a -opioid agonist with a δ-opioid 
antagonist suppressed side effects such as dependence and tolerance while retaining -
agonist induced analgesia. The realization of this potential for cross-modulation has 
generated interests in the development of bivalent ligands. The ligands may be 
individual compounds that possess mixed agonist/antagonist properties or a separate 
agonist and antagonist tethered through a linker. Future directions of research in 
analgesia will continue to point towards agonists with acceptable side effects, designing 
bivalent ligands, or ligands with mixed receptor specificities and functions. 
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2. While the exact mechanisms of development of tolerance are still under debate, the 
current models suggest a combination of ligand-induced conformational changes and 
receptor desensitization, as well as down-stream compensatory changes of secondary 
effectors. 
3. Promising computational methods such as consensus pharmacophore models using 
different structural scaffold might serve a role in identifying ligands with mixed 
secondary functional profiles. Understanding the cross-talk between the different 
signaling pathways of the opioid receptors will also be significant. 
4. Production and analysis of a large number of compounds with potential affinity to 
opioid receptors are possible. However, considerably more work will need to be done 
to understand and design compounds with high analgesic effect and lower side effects. 
To that end, a more detailed understanding of the signaling process upon opioid 
receptor activation is needed.  
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1. Introduction  
Pain is a widely spread symptom and one of the most common causes making people seek 
medical attention. Though at present, different methods of pain control such as general 
narcosis, acupuncture, hypnosis, electroanaesthesia, homeopathy, etc., are known, nothing 
is better for safety and reliability than local anaesthesia. More often it is an effective 
alternative to general narcosis and promotes decreasing and even eliminating the use of 
narcotic analgesics in surgery. Dentists, dermatologists and other medical professionals 
apply it in their work. Unfortunately, an "ideal" local anesthetic has not been created yet, 
and all current medicines of the given pharmacological group have some drawbacks. The 
most serious disadvantages are high neuro- and cardiotoxicity, as well as tendency to cause 
allergy. Thus, the search for new, more effective and safe local anesthetics is ongoing and 
scientists all over the world continue to work on this problem. 
Quinolines are the interesting compounds for research in this area. Numerous derivatives of 
this azaheterocycle are widely distributed in nature. Some of them are well-known to man and 
used for curative purposes from ancient times. For example, alkaloids cinchonine (1a, R = Н) 
and quinine (1b, R = ОМе, Figure 1) with antimalarial properties are isolated from Cinchona L. 
The utility of the majority of other natural quinolines prospects are to be determined. However, 
recently there has been a noticeable progress toward a solution of this problem. Natural 
compounds themselves more often attract the attention of scientists working in different fields 
of science and engineering. The stimulating motive for their research is the widely spread 
conviction that the living nature does nothing without purpose and everything it synthesizes is 
important at all events for life and, therefore, for man (Bochkov & Smith, 1987). This conviction 
finds the experimental confirmation constantly, as a result, at present the spectrum of biological 
















Fig. 1. Natural antimalarial drugs and the first synthetic local anesthetic of the quinoline group 
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Hence the increased interest in quinolines by synthetic chemists becomes clear. Their 
belonging to natural metabolites, as well as practically unlimited possibilities for chemical 
transformations make this molecular system, especially its hydroxyanalogues, rather 
convenient matrices for fixing various structural elements-pharmacophores on them. It allows 
making systematic changes into the structure of the finished products and thus to purposefully 
change their physical and chemical, as well as biological properties. Finally one can succeed in 
obtaining new substances corresponding to high requirements for medicines. So, in particular, 
the first local anesthetic of the quinoline group – Cinchocaine (2, Figure 1) was synthesized; 
though it was created 85 ago (Kleemann & Engel, 2001), it has been applied successfully in 
medical practice nowadays (Tomoda et al., 2009; Kang & Shin, 2010; Douglas et al., 2011). 
2. 1-R-4-Hydroxy-2-oxo-1,2-dihydroquinoline-3-carboxamides as a source of 
new privileged structures with the local anesthetics activity  
When systematically studying the biological properties of 1-R-4-hydroxy-2-oxo-1,2-dihydro-
quinoline-3-carboxamides we repeatedly noted the opportunity of creating new potential 
medicines with various effects on a living organism on their basis, including local 
anesthetics (Ukrainets, 1992; Ukrainets et al., 1994). After the experimental study of 
anaesthetic properties of a large group of compounds of this chemical range, our attention 
was paid to the most active of them. Hydrochlorides of (2-diethylaminoethyl)amides of 1-
ethyl- (3a, R = Et) and, especially, 1-propyl- (3b, R = Pr) substituted 4-hydroxy-2-oxo-1,2-
dihydroquinoline-3-carboxylic acids (Figure 2), were superior the known local anesthetic 
Lidocaine by the specific activity possessing at the same time the lower toxicity. 
Later (Gorokhova, 1993) in the same range one more compound – hydrochloride of 1-ethyl-4-
hydroxy-2-oxo-1,2-dihydroquinoline-3-carboxylic acid (2-morpholin-4-ylethyl)amide (4) was 
found. By the level of infiltration anaesthesia this amide had some more activity than its 1-N-
ethyl analogue 3a, but it was noticeably inferior to 1-N-propyl derivative 3b. However, after 
the primary screening it was also included into the list of candidates for profound research as 
it possessed another important for future medicine property – a relatively low toxicity. By this 


















































Fig. 2. Biologically active 4-hydroxy-2-oxo-1,2-dihydroquinoline-3-carboxamides 
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And recently (Davidenko, 2011) a new pharmacological property – the ability to block opioid 
receptors – has been revealed in 4-hydroxy-2-oxo-1,2-dihydroquinoline-3-carboxamides. It 
has also been found that substances closely related in structure can reveal quite opposite 
biological effects. Hydrochloride of 1-allyl-4-hydroxy-6,7-dimethoxy-2-oxo-1,2-dihydro-
quinoline-3-carboxylic acid (3-morpholin-4-ylpropyl)amide (5) in the dose of 1 mg/kg 
completely eliminates the analgesic effect of Tramadol and its homologue – (2-morpholin-4-
yl-ethyl)amide 6 – prolongs the analgesic effect significantly. This fact requires further 
research and is doubtless of interest for researchers engaged in searching not only new 
opioid receptors antagonists, but highly effective pain-killers as well. 
3. Chemical modification of Сhinoxicaine by its transformation into pro-drugs 
All compounds that passed the stage of primary pharmacological screening were subjected 
to more profound and thorough analysis in pre-clinical trials. To evaluate the local 
anaesthetic properties a greater number of parameters were taken into account; these 
parameters characterized the main specific manifestations of the biological effect: potency of 
local anaesthesia, the rate of its onset and duration. Additionally at this stage some 
experimental models, such as repeated infiltration and additional conduction anaesthesia, 
epidural and surface anaesthesia, were involved. The local irritant properties of the 
compounds,  as well as their acute and chronic toxicity were studied.  
From the experiments, only one compound emerged – hydrochloride of 4-hydroxy-2-oxo-1-
propyl-1,2-dihydroquinoline-3-carboxylic acid (2-diethylaminoethyl)amide (3b), which 
further was studied as a privileged structure under the name of Chinoxicaine and was 
transferred to the next level of investigations. This amide causes a rapid, deep and long local 
anaesthesia on all models studied and has a low toxicity. It has been found that prolonged 
introduction of Chinoxicaine to the experimental animals does not produce any statistically 
significant changes in the activity of central nervous  and cardio-vascular systems and does 
not cause negative reactions of the liver and gastrointestinal tract. The medicine does not 
produce nephrotoxic action and, thus, it can be used safely by the patients with renal 
pathology. While using Chinoxicaine, there were no cases of blood pressure decrease, which 
is its beneficial advantage over many known anesthetics. Additional advantages of 
Chinoxicaine are that together with the high specific activity it shows clear antiarrhythmic, 
antimicrobial, antioxidant, and fungicidal effects.  
Simultaneously with the pharmacological studies, diversified synthetic research to find the 
most available method for obtaining Chinoxicaine substance was carried out. As the result, 
principally different synthetic schemes providing a high quality of the final product have 
been suggested (Ukrainets et al., 1998; Ukrayinecz & Bezuhliy, 2002; Romanov & Ukrainets, 
2006). 
Unfortunately, the "Chinoxicaine" project faced some problems. For example, possessing a 
unique set of pharmacological properties Chinoxicaine appeared to be surprisingly poorly 
soluble in water. Its solubility is only 13.85 g in 100 ml of water at 20°С, and this caused 
great difficulty when preparing a stable medicinal form for injections. We solved this 
problem rather rapidly, though water had to be replaced by the combined solvent.  
At the later stages of introduction of a new local anesthetic into medical practice, namely at 
the stage of clinical trials, one more serious drawback was revealed. In some patients, 
Chinoxicaine solution in the site of injection caused a transient feeling of burning. Though 
this undesirable effect lasted less than one minute, further work with the medicine 
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Fig. 2. Biologically active 4-hydroxy-2-oxo-1,2-dihydroquinoline-3-carboxamides 
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And recently (Davidenko, 2011) a new pharmacological property – the ability to block opioid 
receptors – has been revealed in 4-hydroxy-2-oxo-1,2-dihydroquinoline-3-carboxamides. It 
has also been found that substances closely related in structure can reveal quite opposite 
biological effects. Hydrochloride of 1-allyl-4-hydroxy-6,7-dimethoxy-2-oxo-1,2-dihydro-
quinoline-3-carboxylic acid (3-morpholin-4-ylpropyl)amide (5) in the dose of 1 mg/kg 
completely eliminates the analgesic effect of Tramadol and its homologue – (2-morpholin-4-
yl-ethyl)amide 6 – prolongs the analgesic effect significantly. This fact requires further 
research and is doubtless of interest for researchers engaged in searching not only new 
opioid receptors antagonists, but highly effective pain-killers as well. 
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to more profound and thorough analysis in pre-clinical trials. To evaluate the local 
anaesthetic properties a greater number of parameters were taken into account; these 
parameters characterized the main specific manifestations of the biological effect: potency of 
local anaesthesia, the rate of its onset and duration. Additionally at this stage some 
experimental models, such as repeated infiltration and additional conduction anaesthesia, 
epidural and surface anaesthesia, were involved. The local irritant properties of the 
compounds,  as well as their acute and chronic toxicity were studied.  
From the experiments, only one compound emerged – hydrochloride of 4-hydroxy-2-oxo-1-
propyl-1,2-dihydroquinoline-3-carboxylic acid (2-diethylaminoethyl)amide (3b), which 
further was studied as a privileged structure under the name of Chinoxicaine and was 
transferred to the next level of investigations. This amide causes a rapid, deep and long local 
anaesthesia on all models studied and has a low toxicity. It has been found that prolonged 
introduction of Chinoxicaine to the experimental animals does not produce any statistically 
significant changes in the activity of central nervous  and cardio-vascular systems and does 
not cause negative reactions of the liver and gastrointestinal tract. The medicine does not 
produce nephrotoxic action and, thus, it can be used safely by the patients with renal 
pathology. While using Chinoxicaine, there were no cases of blood pressure decrease, which 
is its beneficial advantage over many known anesthetics. Additional advantages of 
Chinoxicaine are that together with the high specific activity it shows clear antiarrhythmic, 
antimicrobial, antioxidant, and fungicidal effects.  
Simultaneously with the pharmacological studies, diversified synthetic research to find the 
most available method for obtaining Chinoxicaine substance was carried out. As the result, 
principally different synthetic schemes providing a high quality of the final product have 
been suggested (Ukrainets et al., 1998; Ukrayinecz & Bezuhliy, 2002; Romanov & Ukrainets, 
2006). 
Unfortunately, the "Chinoxicaine" project faced some problems. For example, possessing a 
unique set of pharmacological properties Chinoxicaine appeared to be surprisingly poorly 
soluble in water. Its solubility is only 13.85 g in 100 ml of water at 20°С, and this caused 
great difficulty when preparing a stable medicinal form for injections. We solved this 
problem rather rapidly, though water had to be replaced by the combined solvent.  
At the later stages of introduction of a new local anesthetic into medical practice, namely at 
the stage of clinical trials, one more serious drawback was revealed. In some patients, 
Chinoxicaine solution in the site of injection caused a transient feeling of burning. Though 
this undesirable effect lasted less than one minute, further work with the medicine 
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practically lost any progress without its removal. Theoretically a  rather simple and effective 
solution of the problem has been found. The irritant action of Chinoxicaine is completely 
eliminated by addition such substances as adrenaline in insignificant concentrations in its 
solution.  
However, we tried to solve the problem by structure modification well known in the art to 
modern researchers (Kubinyi, 2006).  
For example, on the basis of structural biological regularities previously revealed a quite 
new analogue of Chinoxicaine with the improved properties can be synthesized. But is 
should be taken into account that in such case all complex of biological and pharmaceutical 
trials have to be carried out in a full volume. Besides to achieve the aim is quite unreal as a 
result of synthesis of only one new substance. Most likely, to solve the task successfully is 
possible only after the study of the series of new compounds. 
Taking this into account we began to improve pharmaceutical properties of Chinoxicaine 
from the most rational variant – creation of pro-drugs on its basis. Biologically active source 
in this approach remains the same, that is why both the terms of development and costs for 
its implementation are greatly reduced.  
However, the practical realization of the method is linked with certain difficulties. In 
particular, to increase the water solubility, as a rule, it is necessary to introduce additional 
ionizing groups into the structure of the modified compounds, while to eliminate the irritant 
action the same ionizing groups in the molecule should be masked (Kuznetsov et al., 1991). 
In other words, theoretically possible methods of elimination of the revealed drawbacks of 
Chinoxicaine mutually exclude each other. 
Most likely the irritant action of Chinoxicaine is related to the presence of 4-ОН-group in its 
structure, which accounts for the marked acid properties in 1-R-4-hydroxy-2-oxo-1,2-
dihydroquinoline-3-carboxamides (Ukrainets, 1988). However, it has been noted 
(Gorokhova, 1993) that the potency of the given side effect to a great extent depends on the 
structure of the amide fragment as well. For example, hydrochloride of 4-hydroxy-2-oxo-1-
propyl-1,2-dihydroquinoline-3-carboxylic acid (2-morpholin-4-ylethyl)amide (7, Figure 3) 
and its 1-N-ethyl analogue 4 mentioned above do not yield to Chinoxicaine in the specific 
activity, but they do not practically render the irritant action. This fact was the foundation 
for performing bioreversible chemical modification of Chinoxicaine by the tertiary amino 
group (Ukrainets et al., 2009). 
One of the obvious solutions of the target trasformation of the Chinoxicaine molecule is 
trasformation into quaternary ammonium salts, which is simple in its performance. It 
should be noted here that common alkyl halides are not suitable for such transformation 
since they form with the medicine – tertiary amine – the stable compounds, which are 
almost not subjected to metabolism and are excreted from the organism unchanged 
(Kuznetsov et al., 1991). Carboxylic acid haloalkyl esters are more interesting. They allow to 
transform tertiary amines in quaternary ammonium salts with labile grouping N+−C−O, 
which is capable of relatively easily to be splitted by hydrolysis and release the initial 
medicine in the form of the corresponding hydrohalide (Kuznetsov et al., 1991; Vinogradova 
et al., 1980). One of this reagents is commercially available bromomethylacetate, by its 
interaction with (2-diethylaminoethyl)amide of 4-hydroxy-2-oxo-1-propyl-1,2-dihydro-
quinoline-3-carboxylic acid (8) in the anhydrous acetonitrile medium the target bromo-
acetoxymethylate 9 was obtained (Figure 3). 
The biological screening has demonstrated that quaternization conducted eliminated the 
irritant action of Chinoxicaine almost completely, unlike it bromoacetoxy-methylate 9 in the 
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form of 2% aqueous solution which causes only insignificant hyperemia of conjunctiva of 
the rabbit’s eye. At the same time in spite of expectations, dissolution in water decreased 
significantly (up to 8.86 g per 100 ml), but usually it increases sharply in pro-drugs of this 
type in 1-2 thresholds comparing to hydrohalides (Vinogradova et al., 1980). Significantly 
there is almost a threefold shortening of the duration of the surface anesthesia by the 
bromoacetoxymethylate 9 and this is evidently due to the low rate of liberation of the 
















































































Fig. 3. Modification of  Chinoxicaine into pro-drugs 
The attempt to optimize the value by substitution of 2-bromomethyl acetate with 2-bromo-
ethyl failed. Under the action of amide 8 the reagent is dehydrobrominated, as a result, 
instead of bromoacetoxyethylate hydrobromide 10 was isolated, it could be also obtained by 
neutralization of the tertiary amino group of amide 8 by hydrobromic acid. Though salt 
formation is not accompanied with the change of number, character and location of covalent 
bonds, it is widely used as an individual type of chemical modification of medicinal 
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substances in medical chemistry. Hence, hydrobromide 10 can be considered as an original 
pro-drug of Chinoxicaine. However, there was no positive results due to transfer of 
hydrochloride to hydrobromide. Absolutely all the parameters worsened: solubility 
decreased to 3.40 g in 100 ml of water, the irritant action increased considerably, and the 
local anaesthetic activity decreased. 
The substitution of hydrogen chloride as a salt-forming reagent of methanesulfonic acid, 
which forms methanesulfonate 11 practically with the quantitative yield reacting with 
amide 8 in the anhydrous diethyl ester medium, was more successful.  
According to the X-ray structural data, in the symmetrically independent part of the unit cell 
of the methanesulfonate 11 there is a molecule of the 4-hydroxy-2-oxo-1-propyl-1,2-
dihydroquinoline-3-carboxylic acid (2-diethylaminoethyl)amide protonated at atom N(19) 
and the methanesulfonic acid anion (see Figure 4).  
The dihydroquinolone fragment is planar within 0.02 Å. The deviations of atoms C(11) and 
C(15) from the mean square plane of the dihydropyridine ring are 0.067 and 0.022 Å 
respectively. A marked deviation of atom C(11) from the ring plane is explained by the 
presence of a shortened intramolecular contact H(9)H(11B) of 1.986 Å. The amide fragment 
is virtually coplanar with the dihydroquinolone (torsional angle C(4)–C(3)–C(15)–O(15) = 4º). 
Such an orientation is stabilized by two intramolecular hydrogen bonds: O(4)–H(4)O(15) 
(HO 1.74 Å, O–HO 155º) and N(16)–H(16)O(2) (HN 1.91 Å, NH–O 140º). 
The O(4)–C(4) 1.319(3), N(16)–C(15) 1.313(3), and C(2)–C(3) 1.451(3) Å bonds in the compound 
studied are shortened (mean values 1.331, 1.334, and 1.464 Å respectively) but the O(15)–C(15) 




Fig. 4. The structure of the methanesulfonate 11 molecule with atomic numbering. The 
dotted lines indicate the intra-  and intermolecular hydrogen bonds 
Atom N(1) has a planar trigonal configuration. The substituents at atoms N(1) and N(16) have 
an anti-periplanar conformation (torsional angles N(1)–C(11)–C(12)–C(13) and N(16)–C(17)–C(18)–
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N(19) 176.2 and 176.3º respectively). The plane of the carbon atoms of the propyl group on the 
N(1) atom is virtually perpendicular to the mean-square plane of the dihydropyridine ring, 
the angle between them being 89.1º. 
In the crystal the molecules of the methanesulfonate 11 form dimers via stacking interactions 
between the dihydroquinolone fragments, the benzene rings being situated over the 
dihydropyridines. The distance between the ring centroids is 3.54 Å and the mean-square 
planes of the dihydropyridine and benzene fragments form a dihedral angle of 2.2º. 
The cation and anion are mutually bonded by an intermolecular hydrogen bond N(19)–
H(19)O(11) (HO 1.88 Å, N–HO 176º). 
The biological screening has shown that methanesulfonate 11 demonstrates a significant 
improvement of all pharmaceutical properties comparing to the initial hydrochloride 3b 
(Chinoxicaine). In particular, the local irritant action was successfully decreased to the level 
of bromoacetoxymethylate 9. Dissolution in water increased in more than six times – up to 
85.72 g per 100 ml, and it has eliminated the problem of choosing a solvent for preparation 
of a stable medicinal form for injections. Finally, there are also some positive aspects of 
revealing the specific activity: the rate of anaesthesia onset remains the same, but the total 
duration of the surface anaesthesia and the deep anaesthetization phase increased. 
4. Synthesis of conformation stable forms of quinolones as an attempt to 
improve pharmaceutical properties of Сhinoxicaine 
In modern medical chemistry several standard methods are successfully applied for 
improving the privileged structures chosen according to the results of preliminary 
pharmacological trials. Recently with accumulation of information about the spatial 
structure of active binding sites for many types of receptors a greater attention has been 
paid to methodology of conformation restrictions (Chen et al., 2010; Watanabe et al., 2010; 
Nirogia et al., 2011). In general, this method of the structural transformation of a molecule 
suggests the preservation of all functional groups contacting with a biological target in their 
original form and at the same time it is directed to fixing of some of them in ”active” 
conformation. 
One of the most wide-spread ways of practical realization of the method is cyclization, 
which allows transformation of the open side chains of the initial molecule in endo- or exo-
cyclic fragments, making possible the change of the pharmaceutical and (or) 
pharmacokinetic properties. Taking into account the given data it is quite logical to study N-
R-amides of 1-hydroxy-3-oxo-5,6-dihydro-3H-pyrrolo- (12a-m) and 1-hydroxy-3-oxo-6,7-
dihydro-3H,5H-pyrido- (13a-m) [3,2,1-ij]quinoline-2-carboxylic acids as potential local 
anesthetics (Figure 5). 
The interest of these compounds is caused by the fact that they are very similar to 
Chinoxicaine (3b) and its 1-N-ethyl analogue 3a by their structure. At the same time 
amides 12-13a-m have a principally important structural difference: though their 1-N-
alkyl substituents contain the same two-three carbon atoms, they are situated not in the 
open alkyl chains, but are included in the composition of pyrrole or tetrahydropyridine 
cycles annelation with the quinolone nucleus. Such modification is known to lead to the 
essential spatial trasformation of the molecule. In particular, in 1-propylsubstituted 4-
hydroxy-quinolones-2 the ethyl fragment is placed perpendicular the plane of the 
quinolone nucleus, as a result the terminal methyl group is far from the bicycle more than 
3 Å (Ukrainets et al., 2009). And on the contrary, the tricyclic pyrido[3,2,1-ij]quinoline 
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system is much compact – in spite of the sofa conformation of the tetrahydropyridine ring, 
С(6) atom deviates from its relative plane only in 0.56 Å (Ukrainets et al., 2008). Unlike 1-
N-ethylsubstituted 4-hydroxyquinolones-2, in which the methyl group of ethyl 
substituent is never located in the quinolone cycle plane (Baumer et al., 2004; Ukrainets et 
al., 2007), tricyclic pyrrolo[3,2,1-ij]- quinoline system is practically flat (Ukrainets et al., 
2006a). It is clear that transfer from 1-N-ethyl- and 1-N-propylsubtituted 3a,b to 
conformation limited pyrrolo- and pyridoquinolines 12-13 should be obligatory reflected 
to the biological properties. The answer to the question about this influence has been 













12-13:   a R =  2-aminoethyl;   b  R  = 3-aminopropyl;  c  R =  4-aminobutyl;  d  R =  6-aminohexyl;
             e R = 2-ethylaminoethyl; f R =  2-(2-hydroxyethylamino)ethyl; g R =  2-dimetylaminoethyl;
             h R = 2-diethylaminoethyl;  i  R =  3-dimethylaminopropyl;   j  R =   3-diethylaminopropyl;
             k R = 2-piperazin-1-ylethyl;  l  R = 2-morpholin-4-ylethyl;  m  R = 3-morpholin-4-ylpropyl
                  
Fig. 5. Tricyclic analogues of Chinoxicaine 
Testing of the samples synthesized has been carried out on the infiltration anaesthesia 
model by Buelbring-Yueid method (Table 1).  
Analysis of the experimental data obtained demonstrates that compounds with the primary 
amino groups, i.e. amides 12-13а-d, do not practically show the anesthetic properties. The 
weak activity (the anaesthesia lasts for not more 5 min, and the phase of complete sensitivity 
loss has not come) has appeared in monoalkylaminoalkylamides 12-13е,f. And only when 
the second alkyl residue is introduced into the terminal amino group (amides 12-13g-m), the 
local anaesthetic action increases noticeably, but though in this case its duration remains 
rather short. For example, for the most active diethylaminoethyl derivative 13h this index is 
approximately 40 min, though the infiltration anaesthesia index reaches the maximum 
possible value. As compared, Chinoxicaine in the similar conditions causes total anaesthesia 
lasting for approximately 75 min (with the general duration of anaesthesia of 4 hours), and 
its 1-N-ethyl analogue 3a – approximately 60 min (with the general duration of anaesthesia 
of 2 hours). 
It is interesting to note that the irritant action of 2% aqueous solutions of tricyclic amides 
12-13, determined by the rabbit’s eye cornea according to the simplified modification of 
Setnikar method, is absent in most examples at all or decreases significantly comparing to 
its bicyclic prototypes 3a,b. And it is in spite of the fact that acidity of enolic ОН-groups 
in 1-hydroxy-3-oxo-5,6-dihydro-3H-pyrrolo[3,2,1-ij]quinoline-2-carboxylic acid and its  
1-N-ethyl analogue is practically the same, and in 1-hydroxy-3-oxo-6,7-dihydro-3H,5H-
pyrido[3,2,1-ij]-quinoline-2-carboxylic acid is similar with its 1-N-propyl analogue  
(pKaOH = 13,44-13,48). 
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In general, based on the biological trials conducted, it can be stated that the structural 
transformation of the molecule, which accompanies the transfer from 1-alkylsubstitued 4-
hydroxyquinolin-2-ones to conformation limited tricyclic pyrrolo- or tetrahydropyrido-
quinolones, allows to decrease the irritant action of compounds of this class, but at the same 
time it has a strong negative effect on the local anesthetic properties and that is why it can 







The start of 
anaesthesia, 
min 
Index Duration of  total  anaesthesia, min 
12а 4.32 ± 0.28 1.1 Undetermined 0 
12b 3.81 ± 0.21 2.7 Undetermined 0 
12c 4.60 ± 0.33 2.0 Undetermined 0 
12d 4.93 ± 0.39 1.2 Undetermined 0 
12e 3.27 ± 0.30 5.1 Undetermined 0 
12f 3.66 ± 0.27 3.5 Undetermined 0 
12g 2.82 ± 0.31 12.2 10.64 ± 1.20 2 
12h 2.05 ± 0.17 36.0 39.82 ± 2.37 1 
12i 3.09 ± 0.28 9.8 9.27 ± 1.33 2 
12j 2.91 ± 0.32 14.2 15.92 ± 1.24 1 
12k 3.87 ± 0.45 6.4 5.30 ± 1.45 1 
12l 2.24 ± 0.26 27.0 25.56 ± 1.62 0 
12m 3.04 ± 0.34 16.2 14.75 ± 1.18 0 
13а 5.26 ± 0.44 2.8 Undetermined 0 
13b 4.32 ± 0.35 3.9 Undetermined 0 
13c 4.63 ± 0.41 4.2 Undetermined 0 
13d 5.65 ± 0.48 2.3 Undetermined 0 
13e 3.72 ± 0.33 7.6 Undetermined 0 
13f 4.08 ± 0.29 5.4 Undetermined 0 
13g 3.26 ± 0.30 16.7 13.51 ± 1.81 1 
13h 2.23 ± 0.23 36.0 40.24 ± 3.06 1 
13i 3.92 ± 0.22 14.1 8.83 ± 1.26 1 
13j 3.10 ± 0.25 17.3 11.48 ± 2.55 1 
13k 4.05 ± 0.36 9.7 6.63 ± 1.14 0 
13l 2.64 ± 0.23 21.4 28.96 ± 3.73 0 
13m 3.22 ± 0.31 15.8 15.37 ± 2.02 0 
3a 1.84 ± 0.10 36.0 58.92 ± 4.11 2 
Сhinoxicaine 1.61 ± 0.13 36.0 74.79 ± 4.71 2 
Table 1. Biological properties of tricyclic compounds 12-13 
5. Application of the bioisosteric replacements methodology for optimization 
of the Сhinoxicaine molecule 
The term „isosters“ was introduced by Irwing Langmuir at the beginning of the 20th 
century. By his definition, isosters are molecules or ions containing the same number of 
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system is much compact – in spite of the sofa conformation of the tetrahydropyridine ring, 
С(6) atom deviates from its relative plane only in 0.56 Å (Ukrainets et al., 2008). Unlike 1-
N-ethylsubstituted 4-hydroxyquinolones-2, in which the methyl group of ethyl 
substituent is never located in the quinolone cycle plane (Baumer et al., 2004; Ukrainets et 
al., 2007), tricyclic pyrrolo[3,2,1-ij]- quinoline system is practically flat (Ukrainets et al., 
2006a). It is clear that transfer from 1-N-ethyl- and 1-N-propylsubtituted 3a,b to 
conformation limited pyrrolo- and pyridoquinolines 12-13 should be obligatory reflected 
to the biological properties. The answer to the question about this influence has been 













12-13:   a R =  2-aminoethyl;   b  R  = 3-aminopropyl;  c  R =  4-aminobutyl;  d  R =  6-aminohexyl;
             e R = 2-ethylaminoethyl; f R =  2-(2-hydroxyethylamino)ethyl; g R =  2-dimetylaminoethyl;
             h R = 2-diethylaminoethyl;  i  R =  3-dimethylaminopropyl;   j  R =   3-diethylaminopropyl;
             k R = 2-piperazin-1-ylethyl;  l  R = 2-morpholin-4-ylethyl;  m  R = 3-morpholin-4-ylpropyl
                  
Fig. 5. Tricyclic analogues of Chinoxicaine 
Testing of the samples synthesized has been carried out on the infiltration anaesthesia 
model by Buelbring-Yueid method (Table 1).  
Analysis of the experimental data obtained demonstrates that compounds with the primary 
amino groups, i.e. amides 12-13а-d, do not practically show the anesthetic properties. The 
weak activity (the anaesthesia lasts for not more 5 min, and the phase of complete sensitivity 
loss has not come) has appeared in monoalkylaminoalkylamides 12-13е,f. And only when 
the second alkyl residue is introduced into the terminal amino group (amides 12-13g-m), the 
local anaesthetic action increases noticeably, but though in this case its duration remains 
rather short. For example, for the most active diethylaminoethyl derivative 13h this index is 
approximately 40 min, though the infiltration anaesthesia index reaches the maximum 
possible value. As compared, Chinoxicaine in the similar conditions causes total anaesthesia 
lasting for approximately 75 min (with the general duration of anaesthesia of 4 hours), and 
its 1-N-ethyl analogue 3a – approximately 60 min (with the general duration of anaesthesia 
of 2 hours). 
It is interesting to note that the irritant action of 2% aqueous solutions of tricyclic amides 
12-13, determined by the rabbit’s eye cornea according to the simplified modification of 
Setnikar method, is absent in most examples at all or decreases significantly comparing to 
its bicyclic prototypes 3a,b. And it is in spite of the fact that acidity of enolic ОН-groups 
in 1-hydroxy-3-oxo-5,6-dihydro-3H-pyrrolo[3,2,1-ij]quinoline-2-carboxylic acid and its  
1-N-ethyl analogue is practically the same, and in 1-hydroxy-3-oxo-6,7-dihydro-3H,5H-
pyrido[3,2,1-ij]-quinoline-2-carboxylic acid is similar with its 1-N-propyl analogue  
(pKaOH = 13,44-13,48). 
 
Creation of New Local Anesthetics Based on Quinoline Derivatives and Related Heterocycles 
 
71 
In general, based on the biological trials conducted, it can be stated that the structural 
transformation of the molecule, which accompanies the transfer from 1-alkylsubstitued 4-
hydroxyquinolin-2-ones to conformation limited tricyclic pyrrolo- or tetrahydropyrido-
quinolones, allows to decrease the irritant action of compounds of this class, but at the same 
time it has a strong negative effect on the local anesthetic properties and that is why it can 







The start of 
anaesthesia, 
min 
Index Duration of  total  anaesthesia, min 
12а 4.32 ± 0.28 1.1 Undetermined 0 
12b 3.81 ± 0.21 2.7 Undetermined 0 
12c 4.60 ± 0.33 2.0 Undetermined 0 
12d 4.93 ± 0.39 1.2 Undetermined 0 
12e 3.27 ± 0.30 5.1 Undetermined 0 
12f 3.66 ± 0.27 3.5 Undetermined 0 
12g 2.82 ± 0.31 12.2 10.64 ± 1.20 2 
12h 2.05 ± 0.17 36.0 39.82 ± 2.37 1 
12i 3.09 ± 0.28 9.8 9.27 ± 1.33 2 
12j 2.91 ± 0.32 14.2 15.92 ± 1.24 1 
12k 3.87 ± 0.45 6.4 5.30 ± 1.45 1 
12l 2.24 ± 0.26 27.0 25.56 ± 1.62 0 
12m 3.04 ± 0.34 16.2 14.75 ± 1.18 0 
13а 5.26 ± 0.44 2.8 Undetermined 0 
13b 4.32 ± 0.35 3.9 Undetermined 0 
13c 4.63 ± 0.41 4.2 Undetermined 0 
13d 5.65 ± 0.48 2.3 Undetermined 0 
13e 3.72 ± 0.33 7.6 Undetermined 0 
13f 4.08 ± 0.29 5.4 Undetermined 0 
13g 3.26 ± 0.30 16.7 13.51 ± 1.81 1 
13h 2.23 ± 0.23 36.0 40.24 ± 3.06 1 
13i 3.92 ± 0.22 14.1 8.83 ± 1.26 1 
13j 3.10 ± 0.25 17.3 11.48 ± 2.55 1 
13k 4.05 ± 0.36 9.7 6.63 ± 1.14 0 
13l 2.64 ± 0.23 21.4 28.96 ± 3.73 0 
13m 3.22 ± 0.31 15.8 15.37 ± 2.02 0 
3a 1.84 ± 0.10 36.0 58.92 ± 4.11 2 
Сhinoxicaine 1.61 ± 0.13 36.0 74.79 ± 4.71 2 
Table 1. Biological properties of tricyclic compounds 12-13 
5. Application of the bioisosteric replacements methodology for optimization 
of the Сhinoxicaine molecule 
The term „isosters“ was introduced by Irwing Langmuir at the beginning of the 20th 
century. By his definition, isosters are molecules or ions containing the same number of 
 
Pain Management – Current Issues and Opinions 
 
72
atoms, as well as the same number and arrangement of electrons. Therefore, “isosteric 
replacements” in the created drugs are replacement of an atom or the group to the similar 
one by size or valency. If the physiological activity remains at the same time, then such 
replacement is called “bioisosteric“. After a while the term “bioisoster“ has been referred to 
compounds obtained by replacement of quite “unsimilar” groupings, but with preserving 
their biological properties (King, 2002). As a result, the concept of bioisosteric replacements 
at present has become one of the most powerful means for creating effective and safe 
medicines (Devereux & Popelier, 2010; Wassermann & Bajorath, 2011; Large et al., 2011). Its 
application allows not only to optimise the known biologically active substances, but to 
reveal new structures with the similar or related properties and, thus, to increase the patent 
protection of a future medicine. 
5.1 Hydrochlorides of 4-hydroxy-2-oxo-1,2,5,6,7,8-hexahydroquinoline-3-carboxylic 
acids N-R-amides 
The first attempt to optimize the Chinoxicaine molecule by the method of bioisosteric 
replacements was replacement of its 1,2-dihydroquinoline nucleus by 1,2,5,6,7,8-hexahydro-
quinoline. We did it expecting that such transformation may appear to be bioisosteric. With 
this aim a large group of hydrochlorides of 4-hydroxy-2-oxo-1,2,5,6,7,8-hexahydro-
quinoline-3-carboxylic acids N-R-amides 14a-y has been synthesized by the method 










14:     R' = H: a R =  2-aminoethyl;   b  R  = 3-aminopropyl;  c  R =  4-aminobutyl;  d  R =  6-aminohexyl;
                       e R = 2-ethylaminoethyl; f R =  2-(2-hydroxyethylamino)ethyl; g R =  2-dimetylaminoethyl;
                       h R = 2-diethylaminoethyl;  i  R =  3-dimethylaminopropyl;   j  R =   3-diethylaminopropyl;
                       k R = 1-ethylpyrrolidin-2-ylmethyl;  l  R = 2-morpholin-4-ylethyl;  m  R = 3-morpholin-4-
                       ylpropyl;  o R = 3-piperidin-1-ylpropyl;  p R = 3-(4-methylpiperazin-1-yl)propyl; 
                       q R = 4-diethylamino-1-methylbutyl
        R' = Pr:   r R = 2-diethylaminoethyl; s R = 3-diethylaminopropyl
 R' = cyclo-Pr: t R = 2-ethylaminoethyl; u R = 2-(2-hydroxyethylamino)ethyl;  v R =  2-dimetylaminoethyl;




Fig. 6. Hydrogenated analogues of Chinoxicaine 
The biological screening conducted allow to state that reduction of the benzene part of the 
quinolone ring, unfortunately, leads to practically complete loss of local anaesthetic 
properties and that is why such modification should be considered unsuccessful. In other 
words, there is no reason to declare 4-hydroxy-2-oxo-1,2-dihydroquinoline and 4-hydroxy-
2-oxo-1,2,5,6,7,8-hexahydroquinoline molecular systems to be bioisosteric (at least, in 
relation to local anaesthesia). 
5.2 1-R-3-(2-Diethylaminoethyl)-1H-quinazoline-2,4-diones hydrochlorides 
All ways of modification of Chinoxicaine molecule considered by us previously could not 
remove the local irritant action completely, therefore, it can be assumed that this drawback 
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had been stipulated mainly by the presence of 4-ОН-group. Thus, the next step of 
potentially bioisosteric transformation of Chinoxicaine was the synthesis of compounds 
known to be without groupings with acid properties. One of the examples of such 
substances were 1-R-3-(2-diethylaminoethyl)-1H-quinazoline-2,4-diones hydrochlorides 15a-f 
(Figure 7). We considered various variants of obtaining compounds of this class allowing to 
choose the most suitable of them depending on the structure of the target product 










15: a R = H;  b R = Me; c R = Et; d R = Pr; e R = Bu; f R = i-Bu  
Fig. 7. Derivatives of 1H-quinazoline-2,4-dione 
The study of the local irritant action of 1-R-3-(2-diethylaminoethyl)-1H-quinazoline-2,4-
diones hydrochlorides 15 conducted in rabbits by the method of Lebo and Camage, has 
shown that the substances under research in the form of aqueous solutions with 2% 
concentration do not cause any reactive changes on the surface of the skin of the 
experimental animals. It should be worth mentioning that in similar conditions 
Chinoxicaine also does not reveal the irritating effect. That is why other, more sensitive, 
models should be involved in further research. 
The ability of 2% aqueous solutions of the compounds synthesized to cause infiltration 
anaesthesia of the skin and subcutaneous cellulose has been studied in guinea pigs 
(Buelbring-Yueid method). Simultaneously several parameters characterizing the basic 
specific manifestations of the pharmacological effect such as the rate of anaesthesia onset, its 
depth (potency) and duration were taken into account. The data given in Table 2 shows that 
all 1-R-3-(2-diethylaminoethyl)-1H-quinazoline-2,4-diones hydrochlorides 15, without 
exception, possess the local anaesthetic properties in some degree. In most cases anaesthesia 
occurs rather quickly and in some minutes after injection, the phase of deep anaesthesia 
begins. However, in spite of high values of the infiltration anaesthesia index, sometimes 
reaching the duration of the total anaesthesia caused by quinazolones 15 remains 
comparatively short and they yield to Chinoxicaine and Lidocaine greatly by this parameter.  
However, unlike the reference drugs the most active of the compounds synthesized – 
hydrochlorides 15a,e,f – reveal a number of new properties, which can be considered as 
useful in the complex of the short, but powerful local anaesthetic action. They are sedation 
as well as movement disorder or motor block on the site of introduction of the substance 
examined. The motor block was estimated on the "peak" of the local anesthesia by 5 point 
scale: 0 points - the tail root tone preserved, movements preserved in full; 1 point - 
weakening of the tail root tone; 2 points - the weak tail root tone, sluggish movement, the 
animal sitting more; 3 points - lowering of the tail root tone and possible slight movement of 
the animal during stimulation of the skin section not occurring in the anesthetized zone, 
slight inhibition of the animal; 4 points - general atonia of the tail root, appearance of some 
inhibition of movement in response to stimulation, overall inhibition of the animal; 5 points 
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- the state of general atonia of the tail root without movement upon pain or electrical 













Duration of  
total  anaesthesia, 
min 
15a 1.14 ± 0.16 36.0 32.35 ± 1.38 4 1 
15b 1.53 ± 0.19 35.8 30.19 ± 0.75 0 0 
15c 4.46 ± 0.29 18.5 15.74 ± 1.05 0 1 
15d 2.97 ± 0.32 35.7 29.82 ± 0.59 0 0 
15e 2.82 ± 0.43 36.0 36.46 ± 2.53 5 1 
15f 1.59 ± 0.25 34.2 29.20 ± 1.43 5 3 
Chinoxicaine 1.50 ± 0.04 36.0 75.61 ± 4.54 0 0 
Lidocaine 2.12 ± 0.19 36.0 52.80 ± 3.76 0 0 
Table 2. Biological properties of the quinazoline-2,4-diones hydrochlorides  15 
The sedative effect was estimated in the following way: 0 points - absent, the animal moving 
independently in cage; 1 point - the animal calm, sitting more, moving around the cage only 
when disturbed by the researcher; 2 points - the animal slowed down, sitting in the corner of 
the cage, anxiety with the researcher significantly set aside and again sitting, often closing 
eyelids, sleep onset; 3 points - the animal sleeping, lying on side, not responsive to 
stimulation by the researcher or to needle stick. 
In general, the combination of analgesic, sedative and immobile extremities effects 
rendering by hydrochlorides 15a,e,f can be used in creating medicines on their basis that are 
available for practical application in tiny surgical interventions, for example, in veterinary 
medicine. Thus, it can be stated confidently that 1-R-quinazoline-2,4-dionic cycle is 
bioisoster of 4-hydroxy-2-oxo-1,2-dihydroquinoline nucleus. 
5.3 The irreversible chemical modification of Сhinoxicaine at position 4 of the 
quinolone nucleus 
The complex research described by us above has shown convincingly that 4-ОН-group is 
the main cause of the local irritant properties of Сhinoxicaine. Therefore, after its blocking 
one can expect the elimination of the undesired side effect. Meanwhile, we have not even 
considered alkylation or acylation of 4-ОН-group as the most obvious variant of another 
bioreversible modification of Сhinoxicaine. The reason is quite simple. Within a rather 
limited choice of pharmacologically available protective groups, neither 4-О-alkyl, nor 4-О-
acyl derivatives of 4-hydroxyquinolin-2-ones have a high chemical stability. It is the 
tendency to hydrolysis that is a serious obstacle when synthesizing such compounds, as 
well as when further preparing sterile solutions for injections on their basis. 
Taking it into account we tried to modify 4-ОН-group of Сhinoxicaine not by means of 
forming pro-drugs, but by using the same method of bioisosteric replacements, i.e. by its 
irreversible replacement with the groupings similar not by sizes or volume, but having the 
same physical and chemical properties and that is why inducing the similar 
pharmacological effect (King, 2002).  
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The first example of such transformation was 4-chloro-2-oxo-1-propyl-1,2-dihydroquinoline-
3-carboxylic acid (2-diethylaminoethyl)amide hydrochloride 16 (Figure 8). 
A high reactivity of the chlorine atom in 1-R-4-chloro-3-ethoxycarbonyl-2-oxo-1,2-dihydro-
quinolines in relation to nucleophilic reagents allows to transform them easily into 4-
methyl-2-oxo-1,2-dihydroquinoline-3-carboxylic acids, one being the basis for synthesis of 
one more bioisoster of Сhinoxicaine – 4-methyl substituted analogue 17. 
N-R-Amides of 2-oxo-1,2-dihydroquinoline-3-carboxylic acid with a primary amino group 
in position 4 of the quinolone ring exist in the 2-hydroxy-4-imino form rapidly hydrolyzed 
by mineral acids to 4-hydroxy-2-quinolones (Ukrainets et al., 2006b). Proceeding from it as 
the next object for pharmacological screening we deliberately obtained hydrochloride of 4-
diethylamino-2-oxo-1-propyl-1,2-dihydroquinoline-3-carboxylic acid (2-diethylaminoethyl)-
amide 18 as chemically more stable product. Amides 19a-d containing no substituents at 
position 4 are of particular interest, in spite of the fact that due to the absence of these 
substituents they cannot be considered to be classical bioisosters of Сhinoxicaine.  
The study of local irritant action of the compounds synthesized, the ability to cause 
infiltration anaesthesia of the skin and subcutaneous cellulose, as well as the evaluation of 
the motor block and the sedative effect were carried out by standard methods previously 
described in detail by us (Ukrainets et al., 2010). It has been determined that all substances 
tested in the form of aqueous solutions with 2% concentration do not cause any reactive 
changes on the skin surface of the experimental animals. 
From the data presented in Table 3 it follows that bioisosteric replacement of 4-ОН-group to 
the chlorine atom – amide 16 – leads to significant decrease of all pharmacological indexes 




























16  R = Cl
17  R = Me
18  R = N(Et)2
. HCl





Fig. 8. Modification of  4-ОН-group of Сhinoxicaine 
More interesting was the replacement of the hydroxyl group to the methyl one. From all 
substances of the last series 4-methyl-substituted amide 17 possesses the most rapid 
development of the biological effect (less than 2 min after injection). The infiltration 
anaesthesia index reaches the maximum possible value, and the total anaesthesia or the time 
of absence of pain and all types of sensitivity (tactile, temperature, etc.), during which the 
surgical intervention can be made (the section of tissues, wound suture, etc.), last 
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The first example of such transformation was 4-chloro-2-oxo-1-propyl-1,2-dihydroquinoline-
3-carboxylic acid (2-diethylaminoethyl)amide hydrochloride 16 (Figure 8). 
A high reactivity of the chlorine atom in 1-R-4-chloro-3-ethoxycarbonyl-2-oxo-1,2-dihydro-
quinolines in relation to nucleophilic reagents allows to transform them easily into 4-
methyl-2-oxo-1,2-dihydroquinoline-3-carboxylic acids, one being the basis for synthesis of 
one more bioisoster of Сhinoxicaine – 4-methyl substituted analogue 17. 
N-R-Amides of 2-oxo-1,2-dihydroquinoline-3-carboxylic acid with a primary amino group 
in position 4 of the quinolone ring exist in the 2-hydroxy-4-imino form rapidly hydrolyzed 
by mineral acids to 4-hydroxy-2-quinolones (Ukrainets et al., 2006b). Proceeding from it as 
the next object for pharmacological screening we deliberately obtained hydrochloride of 4-
diethylamino-2-oxo-1-propyl-1,2-dihydroquinoline-3-carboxylic acid (2-diethylaminoethyl)-
amide 18 as chemically more stable product. Amides 19a-d containing no substituents at 
position 4 are of particular interest, in spite of the fact that due to the absence of these 
substituents they cannot be considered to be classical bioisosters of Сhinoxicaine.  
The study of local irritant action of the compounds synthesized, the ability to cause 
infiltration anaesthesia of the skin and subcutaneous cellulose, as well as the evaluation of 
the motor block and the sedative effect were carried out by standard methods previously 
described in detail by us (Ukrainets et al., 2010). It has been determined that all substances 
tested in the form of aqueous solutions with 2% concentration do not cause any reactive 
changes on the skin surface of the experimental animals. 
From the data presented in Table 3 it follows that bioisosteric replacement of 4-ОН-group to 
the chlorine atom – amide 16 – leads to significant decrease of all pharmacological indexes 
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Fig. 8. Modification of  4-ОН-group of Сhinoxicaine 
More interesting was the replacement of the hydroxyl group to the methyl one. From all 
substances of the last series 4-methyl-substituted amide 17 possesses the most rapid 
development of the biological effect (less than 2 min after injection). The infiltration 
anaesthesia index reaches the maximum possible value, and the total anaesthesia or the time 
of absence of pain and all types of sensitivity (tactile, temperature, etc.), during which the 
surgical intervention can be made (the section of tissues, wound suture, etc.), last 
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approximately 55 min. These data prove the sufficient high activity of amide 17, which are 
comparable to the reference drugs - Chinoxicaine and Lidocaine. However, amide 17 yields 
them significantly in the total duration of anaesthesia, i.e. time when the sensitivity 


















duration of  
anaesthesia, 
min 
16 3.96 ± 0.42 26.3 14.25 ± 1.11 24.72 ± 2.18 0 0 
17 1.94 ± 0.21 36.0 55.33 ± 2.74 68.38 ± 2.68 0 0 
18 2.28 ± 0.31 36.0 37.51 ± 2.83 67.85 ± 2.37 0 0 
19a 4.52 ± 0.32 19.3 13.20 ± 1.00 21.01 ± 1.67 0 0 
19b 4.50 ± 0.36 35.5 27.89 ± 1.89 32.34 ± 2.92 0 0 
19c 3.03 ± 0.28 36.0 39.04 ± 2.12 58.26 ± 2.81 5 2 
19d 2.71 ± 0.37 36.0 53.77 ± 1.93 83.28 ± 2.05 5 3 
20 2.82 ± 0.44 35.6 47.56 ± 1.74 85.48 ± 2.33 5 3 
Chinoxicaine 1.62 ± 0.13 36.0 74.74 ± 4.71 236.89 ± 9.34 0 0 
Lidocaine 2.34 ± 0.20 36.0 51.26 ± 3.45 140.27 ± 6.20 0 0 
Table 3. Biological properties of 4-ОН-modified derivatives of Chinoxicaine  
A special attention should be paid to 4-diethylamine derivative 18, not only for its high 
anaesthetic properties, but for the perspective to perform further modifications of such type 
easily and practically in unlimited quantity as well and to reach the result required. 
From the series of non-substituted amides 19 at position 4 it is worth mentioning only 
compounds with butyl and iso-butyl substituents at the cyclic nitrogen atom (amides 19c 
and 19d respectively). Both are characterized by a rather rapid onset of action and high 
values of infiltration anaesthesia indexes. The distinctive feature of the first one is the signs 
of drowsiness, inertia in animals in 10-15 min after the injection and complete sleepiness can 
occur at 15-20 min. The motor block with the strength of 5 points lasts for approximately 20 
min on the site of introduction of the substance examined. In the case of amide 19d already 
by 7-10 min after injection the animals had the state of deep sleep: they slept on their side 
without the reaction to the active stimulation by the needle (tactile, pain and temperature 
sensitivity is absent). In 15-20 min the animals awoke, but they were drowsy and motionless 
for approximately 20 min and then began to move their paws. Therefore, one can speak 
about the deep and prolonged motor block and the marked sedative effect, which can be 
very useful properties of local anesthetic while conducting a number of short-termed 
surgical interventions, especially when rendering aid to patients with the increased 
excitability and possible fear before any surgical manipulations. 
The study of hydrochloride of 2-isobutoxyquinoline-3-carboxylic acid (2-diethylamino-
ethyl)amide 20 is of particular interest. This compound has been specially synthesized by us 
as an aromatic analogue of the most active of 1,2-dihydro derivatives, i.e. amide 19d. A 
comparative analysis of biological properties of these isomers demonstrates that with 
transfer to the aromatic structure some parameters decrease, and others, vice versa, 
intensify. For example, amide 20 differs with the later start of anaesthesia, decrease of the 
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index and reduction of duration of the deep anaesthesia phase. At the same time the general 
duration of anaesthesia increases a little, as well as duration of the sedative effect. 
Unfortunately, transfer of the isobutyl substituent from the nitrogen atom to the oxygen 
atom is accompanied by appearance of undesirable properties – unlike amide 19d its 
aromatic isomer 20 has been found to have the irritant action, though a transient one.  
6. Conclusion 
The research carried out by us gives reason to suppose that 4-hydroxy-2-oxo-1,2-dihydro-
quinoline-3-carboxylic acids are of great interest as a base in creating new effective 
medicines to eliminate pain. Such medicines can be not only local anesthetics possessing the 
unique complex of pharmacological properties, but, as it has been found quite recently, non-
narcotic analgesics with high activity and low toxicity as well. The rich arsenal of  structural 
and biological regularities accumulated, as well as practically unlimited synthetic potential 
of 4-hydroxyquinolin-2-ones allow to change the character of impact of such compounds on 
a living organism easily and in the required direction, and thus, to provide their direct 
practical value and a great perspective. 
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1. Introduction 
Pain, as a sub modality of somatic sensation, has been defined as a complex constellation of 
unpleasant sensory, emotional and cognitive experiences provoked by real or perceived 
tissue damage and manifested by certain autonomic, psychological, and behavioral 
reactions. The benefit of these unpleasant sensations, however, is underscored by extreme 
cases: patients lacking the ability to perceive pain due to hereditary neuropathies often 
maintain unrealized infections; self mutilate, and have curtailed life spans. Normally, 
nociception and the perception of pain are evoked only at pressures and temperatures 
extreme enough to potentially injured tissues and by toxic molecules and inflammatory 
mediators. As opposed to the relatively more objective nature of other senses, pain is highly 
individual and subjective and the translation of nociception into pain perception can be 
curtailed by stress or exacerbated by anticipation (Woolf). 
Chronic pain is estimated to affect millions of people worldwide and is one of the most 
common reasons for physician visits (Scascighini et al. 2008). Inflammation may cause direct 
painful stimuli as well as sensitize nociceptors to stimulation (McMahon et al. 2005). Thus, 
there are multiple points along the pain pathway that represent opportunities for 
therapeutic intervention. Despite this, there are only a limited number of mechanisms 
through which current pain medications work. Major classes of analgesics include opioids, 
non-steroidal anti-inflammatory drugs, antidepressants, and anticonvulsants. Although 
these treatments provide relief, the effects are often incomplete and complicated by serious 
side effects and/or tolerance. Thus, therapeutics with novel mechanisms of actions are 
desperately needed (Finnerup et al. 2005).  
What exactly, from a neurobiological perspective, is pain? Pain is actually three quite 
different things, although it is difficult to make the distinction; nociceptive pain, 
inflammatory pain and neuropathic pain. Nociceptive pain is not a clinical problem, except 
in the specific context of surgery and other clinical procedures that necessarily involve 
noxious stimuli, where it must be suppressed by local and general anesthetics or high-dose 
opioids (Woolf). 
Nociception involves multiple steps from the peripheral receptor, the afferent nerve 
transmitting the impulse to the spinal cord, the signal processing in the dorsal horn, with 
inhibitory and facilitatory elements and finally transmission to higher cerebral centers 
where the peripheral nociceptive stimulus is perceived as pain (Arendt-Nielsen and 
Sumikura 2002).   
The second kind of pain is also adaptive and protective. By heightening sensory sensitivity 
after unavoidable tissue damage, this pain assists in the healing of the injured body part by 
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creating a situation that discourages physical contact and movement. Pain hypersensitivity, 
or tenderness, reduces further risk of damage and promotes recovery, as after a surgical 
wound or in an inflamed joint, where normally innocuous stimuli now elicit pain. This pain 
is caused by activation of the immune system by tissue injury or infection, and is therefore 
called inflammatory pain. 
Finally, there is the pain that is not protective, but maladaptive, resulting from abnormal 
functioning of the nervous system. This pathological pain, which is not a symptom of some 
disorder but rather a disease state of the nervous system, can occur after damage to the 
nervous system (neuropathic pain), but also in conditions in which there is no such damage 
or inflammation (dysfunctional pain) (Woolf).  
The incidence of pain rises as people get older and women are more likely to be in pain than 
men. Pain management strategies include pain relieving medications, physical or 
occupational therapy and complementary therapies (such as acupuncture and massage). 
Pharmacologic therapies are the foundation of chronic pain management. These therapies 
include nonopioids, opioids, and adjuvant analgesics, physical techniques physical 
measures, such as physical activity, physical and occupational therapy, orthotics, and 
assistive devices can serve as adjuncts to analgesics in the management of chronic pain 
(Paice and Ferrell).   
On the other hand in recent years, we and others have focused on the relationship between 
neuroprotection and pain mechanism and management. Thus in this chapter we will review 
recent progress related to neuronal mechanism for using neuroprotective agents alone or in 
combination with antinociceptive drugs to reduce the pain. In addition we will focus on the 
effect of neuroprotective agents on prevention of tolerance to the analgesic effect of opiates. 
2. Neuroprotection 
Neuroprotection is the mechanism and strategies used to protect against neural injury or 
degeneration in the central nervous system (CNS). There is a wide range of neuroprotective 
products available or under investigation. Some products with neuroprotective effects are 
grouped into the following categories: 
 Free radical scavengers  
 Anti excitotoxic agents 
 Anti apoptotic agents 
 Anti inflammatory agents 
 Neurotrophic factors 
To better understand, we first discuss the mechanism by which neurotoxins induce toxicity. 
3. Glutamate 
Glutamate is a neurotransmitter with roles such as long-term potentiation and synaptic 
plasticity of the brain (Harris et al. 1984) and is also a exitotoxin whose neurotoxicity has 
been associated with numerous neurodegenerative diseases, such as Alzheimer disease 
(AD), (Kihara et al. 2002) vascular dementia, (Martinez et al. 1993) Parkinson disease 
(Greenamyre 2001) and amyotrophic lateral sclerosis (Cid et al. 2003).  
Glutamatergic synapses are the key excitatory synapses within the brain, and mechanisms 
of both hyperglutamatergic and hypoglutamatergic functioning have been implicated in the 
pathophysiology of CNS disorders (Olney et al. 1999). 
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Glutamatergic receptors include both iontropic and metabotropic receptor subtypes. The 
iontropic receptors include N-Methyl-D-Aspartat (NMDA), α-amino-3-hydroxy-5-methyl-4-
isoxazole propionic acid (AMPA), and kainate receptors. Binding of glutamate to these 
receptors causes Ca2+ and Na+ entry into neurons, resulting in excitatory postsynaptic 
potentials and membrane depolarization. In addition, increased intracellular Ca2+ levels 
activate a number of signaling cascades (Berridge 1998). The NMDA receptor forms a 
channel allowing for ion influx, whereas the AMPA and kainate receptors open voltage-
sensitive ion channels on the cell membrane. The NMDA receptor is voltage-gated and is 
blocked by magnesium and modulated by two coagonists, glycine and d-serine, as well as 
by several intracellular and extracellular mediators (Millan 2005)). It has been proposed that 
NMDA receptor hypofunction may lead to excessive stimulation of other iontropic 
receptors, causing a cascade of excitotoxic events including oxidative stress and apoptosis 
(Deutsch et al. 2001). Dysregulation of glutamateric functioning has been observed across 
many components of the glutamate neurotransmission system.  
The mechanism of glutamate-induced neuronal death has been extensively studied: 
glutamate induces neuronal death via stimulation of NMDA receptor through which Ca2+ 
enters the cell and activates Ca2+-dependent nitric oxide (NO) synthase, resulting in 
excessive nitric oxide formation, production of radicals, mitochondrial dysfunction and 
cell death (Kaneko et al. 1997). It has been shown that glutamate induces neuronal death 
associated with necrosis and apoptosis. Necrosis is caused by catastrophic cell damage 
and is characterized by cell swelling, injury to cytoplasmic organelles and rapid collapse 
of internal homeostasis, leading to the lysis of membranes and the release of cellular 
contents, resulting in inflammation. On the other hand, apoptosis is a process 
characterized by cell shrinkage, membrane blebbing, nuclear pyknosis, chromatin 
condensation and genomic fragmentation (Kerr et al. 1972; Schulte-Hermann et al. 1992; 
Takada-Takatori et al. 2009).  
In rodents, blocking of NMDA receptors is associated with increased release of glutamate 
within the cerebral cortex (Moghaddam et al. 1997), (Adams and Moghaddam 1998) and 
nucleus accumbens (Razoux et al. 2007). However, elevations in glutamate within the 
prefrontal cortex of rodents occurs during short-term administration of NMDA antagonists, 
whereas long-term administration over 7 consecutive days actually results in a trend for 
lower basal levels and lower dialysate levels of glutamate upon challenge (Zuo et al. 2006). 
Thus, excitotoxic events associated with NMDA antagonists may be reflected by initial 
increases in glutamatergic neurotransmission that are followed subsequently and 
chronically by lower levels.  
4. Apoptosis and N-Methyl-D-Aspartate antagonist-induced 
neurodegeneration 
As noted before glutamate can induce apoptosis via NMDA receptor activation. Apoptosis 
or programmed cell death is a process normally associated with the elimination of 
redundant neurons during neurodevelopment (Johnson et al. 1995). Apoptosis involves the 
regulation of a complex molecular cascade controlling the activation of a family of cysteine 
proteases known as caspase proteins (Glantz et al. 2006). Caspases are responsible for 
breaking down important structural and functional proteins, leading to cellular degradation 
and eventually death. Apoptosis results from a cascade of gene activation and involves 
genes that both promote (i.e., Bax) (Schlesinger et al. 1997), (Gross et al. 1998) and oppose 
 
Pain Management – Current Issues and Opinions 
 
82
creating a situation that discourages physical contact and movement. Pain hypersensitivity, 
or tenderness, reduces further risk of damage and promotes recovery, as after a surgical 
wound or in an inflamed joint, where normally innocuous stimuli now elicit pain. This pain 
is caused by activation of the immune system by tissue injury or infection, and is therefore 
called inflammatory pain. 
Finally, there is the pain that is not protective, but maladaptive, resulting from abnormal 
functioning of the nervous system. This pathological pain, which is not a symptom of some 
disorder but rather a disease state of the nervous system, can occur after damage to the 
nervous system (neuropathic pain), but also in conditions in which there is no such damage 
or inflammation (dysfunctional pain) (Woolf).  
The incidence of pain rises as people get older and women are more likely to be in pain than 
men. Pain management strategies include pain relieving medications, physical or 
occupational therapy and complementary therapies (such as acupuncture and massage). 
Pharmacologic therapies are the foundation of chronic pain management. These therapies 
include nonopioids, opioids, and adjuvant analgesics, physical techniques physical 
measures, such as physical activity, physical and occupational therapy, orthotics, and 
assistive devices can serve as adjuncts to analgesics in the management of chronic pain 
(Paice and Ferrell).   
On the other hand in recent years, we and others have focused on the relationship between 
neuroprotection and pain mechanism and management. Thus in this chapter we will review 
recent progress related to neuronal mechanism for using neuroprotective agents alone or in 
combination with antinociceptive drugs to reduce the pain. In addition we will focus on the 
effect of neuroprotective agents on prevention of tolerance to the analgesic effect of opiates. 
2. Neuroprotection 
Neuroprotection is the mechanism and strategies used to protect against neural injury or 
degeneration in the central nervous system (CNS). There is a wide range of neuroprotective 
products available or under investigation. Some products with neuroprotective effects are 
grouped into the following categories: 
 Free radical scavengers  
 Anti excitotoxic agents 
 Anti apoptotic agents 
 Anti inflammatory agents 
 Neurotrophic factors 
To better understand, we first discuss the mechanism by which neurotoxins induce toxicity. 
3. Glutamate 
Glutamate is a neurotransmitter with roles such as long-term potentiation and synaptic 
plasticity of the brain (Harris et al. 1984) and is also a exitotoxin whose neurotoxicity has 
been associated with numerous neurodegenerative diseases, such as Alzheimer disease 
(AD), (Kihara et al. 2002) vascular dementia, (Martinez et al. 1993) Parkinson disease 
(Greenamyre 2001) and amyotrophic lateral sclerosis (Cid et al. 2003).  
Glutamatergic synapses are the key excitatory synapses within the brain, and mechanisms 
of both hyperglutamatergic and hypoglutamatergic functioning have been implicated in the 
pathophysiology of CNS disorders (Olney et al. 1999). 
 
Neuroprotection and Pain Management 
 
83 
Glutamatergic receptors include both iontropic and metabotropic receptor subtypes. The 
iontropic receptors include N-Methyl-D-Aspartat (NMDA), α-amino-3-hydroxy-5-methyl-4-
isoxazole propionic acid (AMPA), and kainate receptors. Binding of glutamate to these 
receptors causes Ca2+ and Na+ entry into neurons, resulting in excitatory postsynaptic 
potentials and membrane depolarization. In addition, increased intracellular Ca2+ levels 
activate a number of signaling cascades (Berridge 1998). The NMDA receptor forms a 
channel allowing for ion influx, whereas the AMPA and kainate receptors open voltage-
sensitive ion channels on the cell membrane. The NMDA receptor is voltage-gated and is 
blocked by magnesium and modulated by two coagonists, glycine and d-serine, as well as 
by several intracellular and extracellular mediators (Millan 2005)). It has been proposed that 
NMDA receptor hypofunction may lead to excessive stimulation of other iontropic 
receptors, causing a cascade of excitotoxic events including oxidative stress and apoptosis 
(Deutsch et al. 2001). Dysregulation of glutamateric functioning has been observed across 
many components of the glutamate neurotransmission system.  
The mechanism of glutamate-induced neuronal death has been extensively studied: 
glutamate induces neuronal death via stimulation of NMDA receptor through which Ca2+ 
enters the cell and activates Ca2+-dependent nitric oxide (NO) synthase, resulting in 
excessive nitric oxide formation, production of radicals, mitochondrial dysfunction and 
cell death (Kaneko et al. 1997). It has been shown that glutamate induces neuronal death 
associated with necrosis and apoptosis. Necrosis is caused by catastrophic cell damage 
and is characterized by cell swelling, injury to cytoplasmic organelles and rapid collapse 
of internal homeostasis, leading to the lysis of membranes and the release of cellular 
contents, resulting in inflammation. On the other hand, apoptosis is a process 
characterized by cell shrinkage, membrane blebbing, nuclear pyknosis, chromatin 
condensation and genomic fragmentation (Kerr et al. 1972; Schulte-Hermann et al. 1992; 
Takada-Takatori et al. 2009).  
In rodents, blocking of NMDA receptors is associated with increased release of glutamate 
within the cerebral cortex (Moghaddam et al. 1997), (Adams and Moghaddam 1998) and 
nucleus accumbens (Razoux et al. 2007). However, elevations in glutamate within the 
prefrontal cortex of rodents occurs during short-term administration of NMDA antagonists, 
whereas long-term administration over 7 consecutive days actually results in a trend for 
lower basal levels and lower dialysate levels of glutamate upon challenge (Zuo et al. 2006). 
Thus, excitotoxic events associated with NMDA antagonists may be reflected by initial 
increases in glutamatergic neurotransmission that are followed subsequently and 
chronically by lower levels.  
4. Apoptosis and N-Methyl-D-Aspartate antagonist-induced 
neurodegeneration 
As noted before glutamate can induce apoptosis via NMDA receptor activation. Apoptosis 
or programmed cell death is a process normally associated with the elimination of 
redundant neurons during neurodevelopment (Johnson et al. 1995). Apoptosis involves the 
regulation of a complex molecular cascade controlling the activation of a family of cysteine 
proteases known as caspase proteins (Glantz et al. 2006). Caspases are responsible for 
breaking down important structural and functional proteins, leading to cellular degradation 
and eventually death. Apoptosis results from a cascade of gene activation and involves 
genes that both promote (i.e., Bax) (Schlesinger et al. 1997), (Gross et al. 1998) and oppose 
 
Pain Management – Current Issues and Opinions 
 
84
the process (i.e., Bcl-2) (Craig 1995), (Schlesinger et al. 1997), (Adams and Cory 1998). In a 
study we showed that there is a relation between glutamate increase and apoptosis 
promotion and increase in proapoptotic agent activity in both cerebral cortex and lumbar 
spinal cord of rat (Hassanzadeh et al.).  
A vast array of stimuli can activate apoptosis in neurons (Sastry and Rao 2000). Many of 
these stimuli have been implicated in the pathophysiology of opioid–induced tolerance 
including glutamate excitotoxicity, increased calcium flux and mitochondria dysfunction 
and these mechanisms are discussed in detail later in this chapter.    
5. Neuroactive steroids are neuroprotective 
Neuroactive steroids are endogenous neuromodulators synthesized either within the brain 
(neurosteroids) or in the periphery by the adrenal glands and gonads. In addition to the 
classic effect of steroids on gene transcription via binding to intracellular steroid receptors, 
neuroactive steroids can alter neuronal excitability via nongenomic effects by acting at 
inhibitory Gama Amino Butiric Acid A (GABAA) receptors and/or excitatory NMDA 
receptors, among others (Shulman and Tibbo 2005), (Marx et al. 2006). There is also evidence 
for a potential role of these neurosteroids in controlling GABA and glutamate release. 
Neuroactive steroids have also been implicated in neuroprotection, myelination, and 
modulation of the stress response. A number of neuroactive steroids are present in human 
postmortem brain at physiologically relevant nanomolar concentrations and serve as 
allosteric modulators of the GABAA receptor (Marx et al. 2006). Neuroactive steroids that are 
effective modulators of GABAA and/or T-type Ca2+ channels are promising tools for 
studying the role of these channels in peripheral pain perception. They appear to be very 
effective in alleviating peripheral Nociception in rat models of acute and chronic pain 
(Jevtovic-Todorovic et al. 2009).  
6. Acetyl Choline Receptors (AChRs) and neuroprotection 
Agonists and antagonist selective for AChR subtypes have been used in experimental and 
clinical research. Some of those compounds are potential candidates for the treatment of 
neurodegenerative disease such as Alzheimer's disease, Parkinson's disease and others. A 
growing list of in vivo and in vitro research suggest that AChRs modulators are gaining 
importance as clinically relevant neuroprotective drugs (Mudo et al. 2007). 
The inhibition of α7 AChRs decreases the GABAergic tone causing increased ACh release 
into the synaptic cleft (Giorgetti et al. 2000), which then activates the α4β2 AChRs located 
post-synaptically. The selective α7 inhibitor methyllycaconitine (Ivy Carroll et al. 2007) 
mimics, at least in part, the neuroprotective effect of 4R (Ferchmin et al. 2003). Other in vivo 
and in vitro studies confirm that α7 inhibition can be neuroprotective (de Fiebre and de 
Fiebre 2005), (Laudenbach et al. 2002), (Martin et al. 2004).  
Protection of neurons from neuronal damage and cell death in neurodegenerative disease is 
a major challenge in neuroscience research. Donepezil, galantamine and tacrine are 
acetylcholinesterase inhibitors used for the treatment of Alzheimer’s disease, and were 
believed to be symptomatic drugs whose therapeutic effects are achieved by slowing the 
hydrolysis of acetylcholine at synaptic termini. However, recent accumulated evidence 
strongly suggests that these acetylcholinesterase inhibitors also possess neuroprotective 
properties whose mechanism is independent of acetylcholinesterase inhibition. It has been 
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shown that acetylcholinesterase inhibitors protect neurons from glutamate-induced 
neurotoxicity in the primary culture of rat cortical neurons.  
The long-standing belief was that acetylcholinesterase inhibitors are symptomatic agents 
that ameliorate cholinergic deficits by slowing the hydrolysis of acetylcholinesterase at 
synaptic nerve termini; however, recent studies have shown that acetylcholinesterase 
inhibitors have other pharmacological properties, for example, neuroprotection against toxic 
insults, such as glutamate and up-regulation of nicotinic receptors (Akaike 2006), (Takada-
Takatori et al. 2009). 
Several reports have indicated that activation of cholinergic neurons in the central nervous 
system produces antinociception and analgesia in a variety of animals, including humans 
(Harte et al. 2004) provide evidence supporting the involvement of the intralaminar 
thalamus in muscarinic induced antinociception. Pharmacological experiments have shown 
that the microinjection of acetylcholine or carbachol into specific brainstem nuclei can 
produce antinociception and can be reversed by muscarinic receptor antagonists (Brodie 
and Proudfit 1984), (Yaksh et al. 1985). Meanwhile some other types of receptors or drugs 
produce analgesia by mediation of ACh. Sumatriptan (5- HT1agonist) is able to induce 
antinociception by increasing cholinergic neurotransmission (Ghelardini et al. 1997). D2 
antagonist prochlorperazine exerts an antinocicptive effect mediated by a central cholinergic 
mechanism (Ghelardini et al. 2004), (Yang et al. 2008). In addition, more recently we showed 
that an acethylcolinesterase inhibitor, donepezil, could prevent tolerance to the analgesic 
effect of morphine (unpublished data).  
7. Cannabinoids, pain and neuroprotection  
Pain severely impairs quality of life. Currently available treatments, generally opioids and 
anti-inflammatory drugs, are not always effective for certain painful conditions. The 
discovery of the cannabinoid receptors in the 1990s led to the characterization of the 
endogenous cannabinoid system in terms of its components and numerous basic 
physiologic functions. Cannabinoid1 (CB1) receptors are present in nervous system areas 
involved in modulating nociception and evidence supports a role of the endocannabinoids 
in pain modulation. Cannabinoids have antinociceptive mechanisms different from that of 
other drugs currently in use, which thus opens a new line of promising treatment to 
mitigate pain that fails to respond to the pharmacologic treatments available, especially for 
neuropathic and inflammatory pains (Manzanares et al. 2006).  
Cannabis extracts and synthetic cannabinoids are still widely considered illegal substances. 
The Cannabis sativa plant has been exploited for medicinal, agricultural and spiritual 
purposes in diverse cultures over thousands of years. Cannabis has been used recreationally 
for its psychotropic properties, while effects such as stimulation of appetite, analgesia and 
anti-emesis have lead to the medicinal application of cannabis. Indeed, reports of medicinal 
efficacy of cannabis can been traced back as far as 2700 BC, and even at that time reports 
also suggested a neuroprotective effect of the cultivar (Scotter et al.).  
Preclinical and clinical studies have suggested that they may result useful to treat diverse 
diseases, including those related with acute or chronic pain. The discovery of cannabinoid 
receptors, their endogenous ligands, and the machinery for the synthesis, transport, and 
degradation of these retrograde messengers, has equipped us with neurochemical tools for 
novel drug design. Agonist-activated cannabinoid receptors, modulate nociceptive 
thresholds, inhibit release of pro-inflammatory molecules, and display synergistic effects 
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the process (i.e., Bcl-2) (Craig 1995), (Schlesinger et al. 1997), (Adams and Cory 1998). In a 
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6. Acetyl Choline Receptors (AChRs) and neuroprotection 
Agonists and antagonist selective for AChR subtypes have been used in experimental and 
clinical research. Some of those compounds are potential candidates for the treatment of 
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The inhibition of α7 AChRs decreases the GABAergic tone causing increased ACh release 
into the synaptic cleft (Giorgetti et al. 2000), which then activates the α4β2 AChRs located 
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shown that acetylcholinesterase inhibitors protect neurons from glutamate-induced 
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in pain modulation. Cannabinoids have antinociceptive mechanisms different from that of 
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mitigate pain that fails to respond to the pharmacologic treatments available, especially for 
neuropathic and inflammatory pains (Manzanares et al. 2006).  
Cannabis extracts and synthetic cannabinoids are still widely considered illegal substances. 
The Cannabis sativa plant has been exploited for medicinal, agricultural and spiritual 
purposes in diverse cultures over thousands of years. Cannabis has been used recreationally 
for its psychotropic properties, while effects such as stimulation of appetite, analgesia and 
anti-emesis have lead to the medicinal application of cannabis. Indeed, reports of medicinal 
efficacy of cannabis can been traced back as far as 2700 BC, and even at that time reports 
also suggested a neuroprotective effect of the cultivar (Scotter et al.).  
Preclinical and clinical studies have suggested that they may result useful to treat diverse 
diseases, including those related with acute or chronic pain. The discovery of cannabinoid 
receptors, their endogenous ligands, and the machinery for the synthesis, transport, and 
degradation of these retrograde messengers, has equipped us with neurochemical tools for 
novel drug design. Agonist-activated cannabinoid receptors, modulate nociceptive 
thresholds, inhibit release of pro-inflammatory molecules, and display synergistic effects 
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with other systems that influence analgesia, especially the endogenous opioid system. 
Cannabinoid receptor agonists have shown therapeutic value against inflammatory and 
neuropathic pains, conditions that are often refractory to therapy. Although the 
psychoactive effects of these substances have limited clinical progress to study cannabinoid 
actions in pain mechanisms, preclinical research is progressing rapidly.  
There has been anecdotal and preliminary scientific evidence of cannabis affording 
symptomatic relief in diverse neurodegenerative disorders. These include multiple sclerosis, 
Huntington’s, Parkinson’s and Alzheimer’s diseases, and amyotrophic lateral sclerosis. This 
evidence implied that hypofunction or dysregulation of the endocannabinoid system may 
be responsible for some of the symptomatology of these diseases.  
In Huntington’s disease, Alzheimer’s disease, as well as in ALS, pathologic changes in 
endocannabinoid levels and CB2 expression are induced by the inflammatory environment. 
CB1 activation has been shown to be effective in limiting cell death following excitotoxic 
lesions, while CB2 is involved in dampening inflammatory immune cell response to disease. 
These two targets may therefore work together to provide both neuroprotection to acute 
injury and immune suppression during more chronic responses (Scotter et al.).  
During the last two decades, a large number of research papers have demonstrated the 
efficacy of cannabinoids and modulators of the endocannabinoid system in suppressing 
neuropathic pain in animal models. Cannabinoids suppress hyperalgesia and allodynia (i.e. 
mechanical allodynia, mechanical hyperalgesia, thermal hyperalgesia and, where evaluated, 
cold allodynia), induced by diverse neuropathic pain states through CB1 and CB2-specific 
mechanisms (Rahn and Hohmann 2009). 
On the other hand, responses to cannabinoid (CB) receptor activation include opening of 
potassium channels, inhibition of calcium currents, and stimulation of various protein 
kinases (Deadwyler et al. 1995; Gomez del Pulgar et al. 2000; Galve-Roperh et al. 2002; 
Karanian et al. 2005b; Molina-Holgado et al. 2005; Karanian et al. 2007). Some of the many 
such signaling elements activated by endocannabinoids play important roles in neuronal 
maintenance (Bahr et al. 2006; Galve-Roperh et al. 2008). CB receptor transmission elicits 
modulatory effects on calcium channels, resulting in reduced neurotransmitter (e.g., GABA, 
glutamate) release (Hajos et al. 2000; Kreitzer and Regehr 2001; Wilson et al. 2001). One 
particular mitogen-activated protein kinase, extracellular signal-regulated kinase (ERK), is 
involved in cannabinergic signaling, as are focal adhesion kinase (FAK) and 
phosphatidylinositol 3′-kinase (PI3K). These signaling elements appear to play key roles in 
the neuroprotective nature of the endocannabinoid system, and the associated signaling 
pathways are disrupted by blocking CB receptor activation (Hwang et al.; Wallace et al. 
2003; Khaspekov et al. 2004; Karanian et al. 2005a; Karanian et al. 2005b).  
Together, these studies indicate that the neuroprotectant cannabinoids have antinociceptive 
properties.  
8. Neuroprotection and tolerance to the analgesic effect 
8.1 Opioid tolerance 
Many types of neuronal cells and brain nuclei have the property of changing, acutely or 
chronically, their regular behavior by the action of pharmacological agents, such as 
psychoactive drugs. Acute changes, those that cease in a short time, would not be important 
to the chronic altered behavior if the cell recovered its original drug-free state, but it is 
observed that some adaptation occurs that impairs such a recovery. In fact, the disturbed 
 
Neuroprotection and Pain Management 
 
87 
cell under the influence of a drug tries to compensate for its acute effects by promoting 
changes in the opposite direction, transiently restoring its homeostasis. However, when the 
acute action of the drug is finished, the cell is imbalanced by its own reactive 
response(Sharma SK et al. 1975). As a consequence, the phenomenon of tolerance develops, 
that is, the need for an increased dose of the drug to produce the same effect (McQuay 1999). 
After tolerance is established, the withdrawal of the drug may produce physical or 
psychological symptoms opposed to the acute pharmacological actions of the drug itself. 
Opioid drugs are used clinically as unsurpassed analgesic agents but are also illegally 
abused on the street to induce a sense of well-being and euphoria. Tolerance to opioids, 
defined as a loss of effect following repeated treatments such that a higher dose is required 
for equivalent effect, limits the analgesic efficacy of these drugs  and contributes to the social 
problems surrounding recreational opioid abuse.  
In order to safely use morphine in clinic, we need to know how morphine tolerance and 
dependence are developed and what kinds of medicines could inhibit or prevent such 
mechanisms. In line with this, various approaches have been attempted to clarify the 
mechanisms underlying morphine tolerance and dependence. Here we summarize various 
proposed hypotheses and introduce our new approaches in this area. 
8.2 Mechanisms for acute morphine tolerance 
Prolonged and repeated exposures to opioid agonists reduce the responsiveness of G 
protein coupled opioid receptors. This reduction in receptor function is hypothesized to 
contribute to opioid tolerance, dependence, and addiction in humans (Nestler 1992). 
Substantial experimental evidence has divided this reduced function into separate but 
correlated receptor traffickings, 1) desensitization, 2) internalization, 3) 
sequestration/recycling, 4) down regulation (Law et al. 2000). The molecular events 
underlying opioid tolerance are currently discussed in relation to all these receptor 
trafficking mechanisms. According to current understanding, opioid receptors are 
desensitized on the cell surface through a phosphorylation process in the C-terminal (Afify 
et al. 1998) and/or third intracellular loop. On the other hand, receptor internalization or 
receptor disappearance from the cell surface, is now believed to contribute to resensitization 
through dephosphorylation during endosomal stages (Krueger et al. 1997; Zhang et al. 
1997). Down-regulation is a loss of receptor protein in cells through increased degradation 
or decreased synthesis of the receptor. Little is known, however, regarding the regulation of 
this mechanism and involvement in opioid tolerance. Thus, much research has been done on 
the molecular basis of events in receptor phosphorylation in the membranes and 
internalization. Recent studies revealed that cAMP-dependent protein kinase A (PKA) 
(Harada et al. 1990), protein kinase C (PKC) (Ueda et al. 1995), Ca2 +/calmodulin-dependent 
protein kinases (Koch et al. 1997), G protein-coupled receptor kinases (GRKs) (Zhang et al. 
1998), and mitogen-activated protein kinase (Polakiewicz et al. 1998) have roles in opioid 
receptor phosphorylation. PKC and GRK mechanisms are likely candidates for opioid 
desensitization and internalization (Ueda et al. 1995; Zhang et al. 1998).  
8.3 PKC hypothesis 
A number of reports have demonstrated that PKC is involved in the opioid tolerance or 
desensitization. Most of recent reports have demonstrated that PKC activators or inhibitors 
modulate opioid signaling in cells expressing opioid receptors. A series of reports have 
demonstrated the involvement of PKC in opioid tolerance by correlating both in vitro and in 
vivo studies.  
 
Pain Management – Current Issues and Opinions 
 
86
with other systems that influence analgesia, especially the endogenous opioid system. 
Cannabinoid receptor agonists have shown therapeutic value against inflammatory and 
neuropathic pains, conditions that are often refractory to therapy. Although the 
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modulatory effects on calcium channels, resulting in reduced neurotransmitter (e.g., GABA, 
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particular mitogen-activated protein kinase, extracellular signal-regulated kinase (ERK), is 
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cell under the influence of a drug tries to compensate for its acute effects by promoting 
changes in the opposite direction, transiently restoring its homeostasis. However, when the 
acute action of the drug is finished, the cell is imbalanced by its own reactive 
response(Sharma SK et al. 1975). As a consequence, the phenomenon of tolerance develops, 
that is, the need for an increased dose of the drug to produce the same effect (McQuay 1999). 
After tolerance is established, the withdrawal of the drug may produce physical or 
psychological symptoms opposed to the acute pharmacological actions of the drug itself. 
Opioid drugs are used clinically as unsurpassed analgesic agents but are also illegally 
abused on the street to induce a sense of well-being and euphoria. Tolerance to opioids, 
defined as a loss of effect following repeated treatments such that a higher dose is required 
for equivalent effect, limits the analgesic efficacy of these drugs  and contributes to the social 
problems surrounding recreational opioid abuse.  
In order to safely use morphine in clinic, we need to know how morphine tolerance and 
dependence are developed and what kinds of medicines could inhibit or prevent such 
mechanisms. In line with this, various approaches have been attempted to clarify the 
mechanisms underlying morphine tolerance and dependence. Here we summarize various 
proposed hypotheses and introduce our new approaches in this area. 
8.2 Mechanisms for acute morphine tolerance 
Prolonged and repeated exposures to opioid agonists reduce the responsiveness of G 
protein coupled opioid receptors. This reduction in receptor function is hypothesized to 
contribute to opioid tolerance, dependence, and addiction in humans (Nestler 1992). 
Substantial experimental evidence has divided this reduced function into separate but 
correlated receptor traffickings, 1) desensitization, 2) internalization, 3) 
sequestration/recycling, 4) down regulation (Law et al. 2000). The molecular events 
underlying opioid tolerance are currently discussed in relation to all these receptor 
trafficking mechanisms. According to current understanding, opioid receptors are 
desensitized on the cell surface through a phosphorylation process in the C-terminal (Afify 
et al. 1998) and/or third intracellular loop. On the other hand, receptor internalization or 
receptor disappearance from the cell surface, is now believed to contribute to resensitization 
through dephosphorylation during endosomal stages (Krueger et al. 1997; Zhang et al. 
1997). Down-regulation is a loss of receptor protein in cells through increased degradation 
or decreased synthesis of the receptor. Little is known, however, regarding the regulation of 
this mechanism and involvement in opioid tolerance. Thus, much research has been done on 
the molecular basis of events in receptor phosphorylation in the membranes and 
internalization. Recent studies revealed that cAMP-dependent protein kinase A (PKA) 
(Harada et al. 1990), protein kinase C (PKC) (Ueda et al. 1995), Ca2 +/calmodulin-dependent 
protein kinases (Koch et al. 1997), G protein-coupled receptor kinases (GRKs) (Zhang et al. 
1998), and mitogen-activated protein kinase (Polakiewicz et al. 1998) have roles in opioid 
receptor phosphorylation. PKC and GRK mechanisms are likely candidates for opioid 
desensitization and internalization (Ueda et al. 1995; Zhang et al. 1998).  
8.3 PKC hypothesis 
A number of reports have demonstrated that PKC is involved in the opioid tolerance or 
desensitization. Most of recent reports have demonstrated that PKC activators or inhibitors 
modulate opioid signaling in cells expressing opioid receptors. A series of reports have 
demonstrated the involvement of PKC in opioid tolerance by correlating both in vitro and in 
vivo studies.  
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8.4 Mechanisms for chronic morphine tolerance and dependence 
Clear difference between acute morphine tolerance and chronic one has not been 
demonstrated for a long time. In algogenic-induced nociceptive flexion (ANF) test in mice 
the peripheral morphine analgesia developed the acute tolerance by 4 h pretreatment with 
morphine (Ueda et al. 2001). However, the peripheral analgesia had no change in mice that 
were given morphine for 5 days, a treatment which caused a marked chronic tolerance to 
systemic morphine analgesia (Ueda and Inoue 1999). Thus, it is evident that acute morphine 
tolerance mediates distinct mechanisms from the chronic one, and chronic tolerance is likely 
mediated through a complicated neuronal network present in the central nervous system. 
8.5 cAMP hypothesis 
Since the report by Sharma et al. (1975), it has been accepted that cAMP may play a key role 
in the morphine tolerance and dependence. According to this so-called cAMP hypothesis, a 
morphine-induced decrease in cAMP production is getting disappeared during long-period 
exposure to morphine (Sharma SK et al. 1975). As the naloxone application causes an abrupt 
increase in cAMP production, some unidentified mechanisms are supposed to mediate an 
increase in cAMP production through specific gene expressions during chronic morphine 
treatment. A candidate could be a cAMP-responsive element binding protein (CREB), which 
is involved in the gene expression of adenylyl cyclase. In vivo study using knockout mice 
demonstrates that CREB plays roles in the development of morphine dependence 
(Maldonado et al. 1996). Although several compounds possessing the antagonistic activity 
are reported to inhibit morphine tolerance and dependence, they have serious side effects at 
the same time (Trujillo and Akil 1991; Mao et al. 1992; Trujillo 1995; Mao 1999; Habibi-Asl 
and Hassanzadeh 2004; Habibi-Asl 2005; Asl et al. 2008). 
8.6 Anti-opioid hypothesis 
In addition to mechanisms at the single cellular level, the plasticity through neuronal 
networks would be involved in the development of morphine tolerance and dependence, as 
above-mentioned. One of approaches to cut in the mechanisms is based on the view that 
enhanced anti-opioid neuronal activity during chronic morphine treatments might suppress 
the acute morphine actions. The candidates include cholecystokinin (Mitchell et al. 2000 ), 
neuropeptide FF (Lake et al. 1992), nociceptin (Ueda et al. 2000) and glutamate, as an 
NMDA receptor ligand (Ueda et al. 2000; Mao and Mayer 2001). Among them the nociceptin 
(N/OFQ) system has been extensively characterized to be involved in the development of 
morphine tolerance and dependence. NMDA receptor has been long supposed to play 
important roles in the development of morphine tolerance and dependence (Trujillo and 
Akil 1991). Although several compounds possessing the antagonistic activity are reported to 
inhibit morphine tolerance and dependence, they have serious side effects at the same time 
(Trujillo and Akil 1991; Mao et al. 1992; Trujillo 1995; Mao 1999; Habibi-Asl and 
Hassanzadeh 2004; Habibi-Asl 2005; Asl et al. 2008).  
8.7 Apoptosis hypothesis 
Apoptosis, or programmed cell death, is an active process of normal cell death during 
development and also occurs as a consequence of the cytotoxic effect of various neurotoxins 
(e.g., MPTP/MPP+, MDMA, ethanol and cocaine) (Sastry and Rao 2000). Among the drugs of 
abuse, cocaine has been shown to cause a direct cytotoxic effect on the foetal rat heart, and to 
induce apoptosis in foetal rat myocardial cells in a dose-dependent manner (Xiao et al. 2000). 
 
Neuroprotection and Pain Management 
 
89 
The induction of apoptosis in neurons has been demonstrated to share the same basic 
mechanisms with all other cell types (Sastry and Rao 2000). In vitro studies also indicate that 
exposure to μ- and/or κ-opioid receptor agonists of neuronal cultures from embryonic chick 
brain (Goswami et al. 1998) and specific cell lines (Dawson et al. 1997; Singhal et al. 1998; 
Singhal et al. 1999) increases their vulnerability to death by apoptotic mechanisms. The 
molecular mechanisms of apoptosis (i.e., the detailed cascade of events from the cell surface to 
final changes in the nucleus) have not been established yet, but various key proteins are 
involved in the regulation of programmed cell death (Sastry and Rao 2000). Some members of 
the Bcl-2 family of proteins, such as Bcl-2 and Bcl-xL, suppresses apoptosis, while the 
expression of other, such as the homologues Bax and Bak, are pro-apoptotic (Adams and Cory 
1998). Specifically, the Bcl-2 oncoprotein, localized mainly to the mitochondrial membranes, 
has been shown to play an important role in protecting neurons from apoptotic cell death 
(Hockenbery et al. 1990), probably by preventing the release of cytochrome c (induced by Bax) 
and the subsequent activation of specific proteases termed caspases, the proteolytic enzymes 
which are crucial for the execution of nuclear fragmentation and apoptosis (Adams and Cory 
1998; Sastry and Rao 2000). In fact, Bax mRNA and Bax protein are increased in the substantia 
nigra of MPTP-treated mice (degeneration of dopamine neurons by apoptosis) (Hassouna et al. 
1996), and the release of cytochrome c from the mitochondria and the subsequent activation of 
caspases-3/9 was shown to play a key role in cocaine-induced apoptosis in foetal rat 
myocardial cells (Xiao et al. 2000). The results of our studies demonstrated that chronic 
morphine administration in rat, induced apoptosis; decrease in Bcl-2 and increase in caspase3 
activity in both cerebral cortex and lumbar spinal cord in rat (Hassanzadeh et al.). Another key 
element involved in the regulation of apoptosis is the Fas glycoprotein (also known as CD95 or 
Apo1), a cell surface receptor that belongs to the tumor necrosis factor receptor family (death 
receptors) and that is expressed abundantly in various tissues (Nagata 1999). In contrast to Bcl-
2 mitochondrial protein, the Fas receptor triggers cell apoptosis when it binds to its ligand, Fas, 
and Fas-mediated death bypasses the usual long sequence of signaling enzymes and 
immediately activates a pre-existing caspase cascade (Nagata 1999). In the context of the 
induction of aberrant apoptosis in opioid addiction, it was of great interest the in vitro study 
demonstrating the ability of morphine to increase, through a naloxone-sensitive mechanism, 
the expression (mRNA) of the pro-apoptotic receptor Fas in mouse splenocytes and in human 
blood lymphocytes (Yin et al. 1999). A relevant consequence of the morphine-induced 
potentiation of apoptosis in lymphocytes (Singhal et al. 1999; Yin et al. 1999) is the reduction of 
the immune response (and the increase in recurrent infections) observed in heroin addicts 
(Govitrapong et al. 1998). 
On the other hand, over a decade, the NMDA receptor (NMDAR), a subgroup of glutamate 
receptors, has been implicated in the development of opioid tolerance (Trujillo and Akil 1991; 
Mao et al. 1994). Activation of NMDARs can lead to neurotoxicity under many circumstances 
(Rothman and Olney 1986; Moncada et al. 1992; Catania et al. 1993) For instance, peripheral 
nerve injury has been shown to activate spinal cord NMDARs, which results in not only 
intractable neuropathic pain but also neuronal cell death by means of apoptosis (Mao et al. 
1997; Whiteside and Munglani 2001). Furthermore, cross talk between the cellular mechanisms 
of opioid tolerance and neuropathic pain has been proposed, suggesting that a common 
cellular mechanism may be involved in both neuropathic pain and opioid tolerance (Mayer et 
al. 1999). Thus, it is possible that the cellular process leading to the development of opioid 
tolerance may also cause neurotoxic changes in response to prolonged opioid administration. 
More recently, we examined the hypothesis that neurotoxicity in the form of apoptotic cell 
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The induction of apoptosis in neurons has been demonstrated to share the same basic 
mechanisms with all other cell types (Sastry and Rao 2000). In vitro studies also indicate that 
exposure to μ- and/or κ-opioid receptor agonists of neuronal cultures from embryonic chick 
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Singhal et al. 1999) increases their vulnerability to death by apoptotic mechanisms. The 
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tolerance may also cause neurotoxic changes in response to prolonged opioid administration. 
More recently, we examined the hypothesis that neurotoxicity in the form of apoptotic cell 
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death would be induced in association with the development of morphine tolerance. In 
confirmation of Mao et al. findings, we demonstrated that chronic opioid injection leads to 
apoptosis in the CNS which was in association with the development of tolerance to the 
analgesic effect (Habibi-Asl et al. 2009a).  Figure1 shows the possible mechanisms of opioid-
induced neuronal apoptosis and its association with opioid tolerance. 
 
 
Fig. 1. Schematic diagram illustrating the possible mechanisms of opioid-induced neuronal 
apoptosis and tolerance. The results of before studies suggest that chronic opioid 
administration may induce NMDAR, microglia, FAAD/P53,… activation resulting in 
intracellular positive apoptosis regulators induction. The resultant apoptosis contributes to 
the cellular mechanism of opioid tolerance. NMDA: N-Methyl-D-Aspartate, NO: Nitric 
Oxide, AIF: Apoptosis-Inducing Factor, FADD: Fas-Associated Death Domain,  
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Opioid tolerance manifests as a loss of agonist potency and as a shift of the dose-response 
curve to the right. During the past decades, many studies have focused on excitatory amino 
acid receptors to investigate the role which they play in the development of tolerance to the 
antinociceptive action of opiates. This idea was suggested by Trujillo and Akil who reported 
that the NMDA receptor antagonist, MK801 (dizocilpine), inhibited the development of 
tolerance to the antinociceptive effect of morphine and morphine physical dependence 
(Trujillo and Akil 1991). 
Using behavioral studies, we and others have shown that a variety of NMDA receptor 
antagonists have the ability to inhibit the development of opiate tolerance and dependence 
(Trujillo and Akil 1991; Trujillo 1995; Habibi-Asl and Hassanzadeh 2004; Asl et al. 2008; 
Habibi-Asl et al. 2009b). There are also several lines of evidence which suggest that 
activation of NMDARs leads to removing the magnesium blockade (Begon et al. 2001) in the 
calcium channel and toxic calcium influx, which activates numerous enzymes, including 
neuronal nitric oxide (NO) synthase (NOS). In our unpublished data we observed that nitric 
oxide donors such as nitroglycerin or nicorandil increased the tolerance to the analgesic 
effect of morphine. On the other hand the nitric oxide synthase inhibitor, N-Nitro-L-
Arginine Methyl Ester (LNAME) could prevent the tolerance.  It has been demonstrated that 
Magnesium (Mg)-deficient rats develop a mechanical hyperalgesia which is reversed by a 
N-Methyl-D-Aspartate (NMDA) receptor antagonist (Begon et al. 2001). Our study in 
agreement with those studies showed that systemic administration of magnesium sulfate 
could attenuate morphine tolerance to the analgesic effect (Habibi-Asl 2005; Habibi-Asl et al. 
2009b). Also we showed that selenium with similar mechanism appeared to have a weaker 
effect than magnesium (Charkhpour M et al. 2009).   
Our recently published finding, indicated that riluzole (2- amino-6-[trifluoromethoxy] 
benzothiazole), an antiglutamatergic agent, decreases the development of tolerance, shifting 
the first day of established tolerance from the 8th day in the control group to the 13th day 
(Habibi-Asl et al. 2009a). Riluzole interferes with responses mediated by excitatory amino 
acids, even though it does not interact with any known binding sites on the NMDA, kainate 
or AMPA glutamate receptors (Debono et al. 1993). The neuroprotective effect of riluzole, 
which has been shown both in vivo and in vitro, is believed to be beneficial in various 
neurodegenerative diseases and amelioration of trauma and stroke (Doble 1999; Albo et al. 
2004).  
The results indicated that there was a significant shift to the right in the dose-response curve 
as well as an increase in the antinociceptive 50% effective dose (ED50) of morphine for 
animals who received morphine also compared with those that received morphine and 
riluzole. On the other hand, co-administration of riluzole delayed the onset of morphine-
induced apoptosis and significantly decreased the average number of TUNEL-positive cells 
(p < 0.01). This finding is in line with our recent results concerning the lumbar region of the 
spinal cord (Hassanzadeh et al.). In addition, we found that the group that received 
morphine and riluzole for 13 days had developed tolerance; they showed an increase in the 
number of apoptotic cells, as under control conditions. This result indicates that after the 
completion of tolerance in both the control and the treated groups, apoptosis had already 
developed. Previous studies have indicated that certain addictive drugs, such as morphine, 
could induce apoptosis in cultured neuronal cell lines  as well as human cells (Singhal et al. 
1998; Singhal et al. 1999). More recently, it has been shown that in vivo neuronal apoptosis 
occurs in the rat’s spinal cord dorsal horn after chronic morphine treatment that was 
associated with the expression of activated caspase- 3 and the involvement of mitogen-
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activated protein kinase (MAPK) (Mao et al. 2002), suggesting that chronic morphine may 
lead to changes within the central nervous system. 
Our more recent studies demonstrated that prolonged morphine administration induces up-
regulation of proapoptotic elements such as caspase-3 and down regulation of the anti-
apoptotic factors Bcl-2 and HSP70 in the rat cerebral cortex and spinal cord (Hassanzadeh et 
al.; Hassanzadeh et al.; Tikka and Koistinaho 2001; Gabra et al. 2005; Hassanzadeh K et al. 
2011). Importantly, up-regulation of caspase-3 and Bax was inhibited when morphine was 
co-administered with the noncompetitive NMDAR antagonist MK-801, thereby supporting 
a link between NMDAR activation and intracellular changes in caspase-3 and Bax in 
response to prolonged morphine administration (Jordan et al. 2007). 
Interestingly, our results demonstrated that neuroprotective agents such as serotonin1A 
receptor agonist, minocycline (Habibi-Asl 2009; Habibi-Asl et al. 2009a), selegiline,… could 
prevent morphine induced tolerance and apoptosis. The stimulation of serotonin1A (5HT1A) 
receptors induces a variable level of neuroprotection in different animal models of central 
nervous system injury such as ischemia, (Prehn et al. 1993; Semkova et al. 1998; Schaper et 
al. 2000; Kukley et al. 2001; Torup et al. 2000) N-methyl-D-aspartate (NMDA) excitotoxicity, 
(Oosterink et al. 1998; Oosterink et al. 2003) acute subdural hematoma, (Alessandri et al. 
1999) and traumatic brain injury (Kline et al. 2001). Furthermore, in vitro evidence indicates 
that 5HT1A agonists are able to protect neurons from apoptosis induced by staurosporine 
(Suchanek et al. 1998), glutamate (Semkova et al. 1998), or serum deprivation (Ahlemeyer 
and Krieglstein 1997; Ahlemeyer et al. 1999). There are different hypotheses on the 
mechanisms involved in 5HT1A-mediated neuroprotection, including neuronal membrane 
hyperpolarization that reduces excitability,(Ahlemeyer and Krieglstein 1997; Krüger et al. 
1999), reduced glutamate release, (Mauler et al. 2001) and blockade of voltage-sensitive Na 
channels (Melena et al. 2000). 
Other neuroprotective mechanisms have also been proposed for 5HT1A agonists such as 
stimulation of the anti-apoptotic proto-oncogene B-cell lymphoma protein 2 (BCL-2) 
expression through the mitogen-activated protein kinase (MAPK/ERK) signaling pathway 
(Kukley et al. 2001) and suppression of the proapoptotic protein caspase-3 in a MAPK- and 
protein kinase C alfa-dependent manner (Adayev et al. 2003). 
More recently we examined the effect of 8-OH-DPAT, a specific 5-HT1A receptor agonist, on 
morphine induced tolerance to an analgesic effect in rat. We found that Intra-dorsal raphe 
nucleus (DRN) administration of the 5-HT1A receptor agonist, 8-OH-DPAT, prevented 
morphine-induced apoptosis after tolerance to the analgesic effect. On the other hand, the 
total analgesic effect of morphine significantly increased in animals treated with morphine 
and 8-OH-DPAT in comparison with the control group. In addition, the results indicated 
that administration of both 5HT1 agonist (8-OH-DPAT) and antagonist (NAN-190) together 
with morphine prevent the antiapoptotic activity of the 5HT1A agonist. This means that 
after antagonizing the 5HT1A receptor, the apoptosis process has already developed. 
Another mechanism contributes to the morphine tolerance is microglial activation. Studies 
showed that NMDA-induced neuronal death involved proliferation and activation of 
microglial cells and that neuroprotective agents such as minocycline completely prevented 
NMDA toxicity and the preceding activation and proliferation of microglial cells. These 
results support the notion that microglial activation contributes to excitotoxic neuronal 
death, which can be inhibited by anti- inflammatory compounds, such as minocycline 
(Tikka and Koistinaho 2001). The mechanism underlying the role of glial cells in the effects 
of morphine on naive mice is unclear. It is possible that morphine acts directly on microglia, 
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triggering alterations in their morphology, metabolism, and function (Watkins et al. 2005). 
Mika et al. concluded that the effect of minocycline on morphine tolerance is related to 
microglia. Their results provide evidence that systemic administration of minocycline in 
mice influences morphine’s effectiveness and delays the development of morphine tolerance 
by attenuating microglial activation and its markers (Mika et al. 2009). 
In summary, we believe that adding the neuroprotective agents to analgesic drugs specially 
opioids, increase the analgesic effect and prevents the hyperalgesia and tolerance to their 
analgesic effects. 
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In both preclinical and clinical studies, agents that activate cannabinoid receptors type 1 
(CB1) and 2 (CB2) have shown promise in the treatment of pain (Wade et al., 2004; Romero-
Sandoval and Eisenach, 2007). Cannabinoids are licensed for the clinical treatment of cancer 
chemotherapy-associated nausea and vomiting (USA and Canada), immunodeficiency 
syndrome-associated loss of appetite and weight loss (USA and Canada), multiple sclerosis-
associated spasticity (United Kingdom and Canada) and neuropathic pain (Canada). 
However, clinical use of cannabinoid compounds is limited both by undesirable 
neurological side effects and by induction of tolerance. In animal models, neurological side 
effects have been shown to be dependent on CB1 receptor but not CB2 receptor activation 
(Romero-Sandoval and Eisenach, 2007). Furthermore, sustained spinal or subcutaneous 
administration of the CB1 receptor agonist, WIN 55,212-2 has been shown to induce 
hypersensitivity and antinociceptive tolerance in naive mice and rats. In contrast, we 
(Romero-Sandoval and Eisenach, 2007; Romero-Sandoval et al., 2008a) and others (Yao et al., 
2009) have shown that spinal CB2 receptor agonists (such as JWH015) relieve postoperative 
and neuropathic pain in rodent models without inducing neurological side effects or 
antinociceptive tolerance. Despite advancements in the molecular mechanisms involved in 
cannabinoid tolerance (Martini et al., 2010), a better understanding of the respective roles of 
CB1 and CB2 receptors is required to design effective therapies that do not induce tolerance. 
Further advances in this area may also guide clinical treatment of patients who have already 
developed tolerance through prior exposure to non-selective cannabinoid agonists for 
recreational or medical purposes. 
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In both preclinical and clinical studies, agents that activate cannabinoid receptors type 1 
(CB1) and 2 (CB2) have shown promise in the treatment of pain (Wade et al., 2004; Romero-
Sandoval and Eisenach, 2007). Cannabinoids are licensed for the clinical treatment of cancer 
chemotherapy-associated nausea and vomiting (USA and Canada), immunodeficiency 
syndrome-associated loss of appetite and weight loss (USA and Canada), multiple sclerosis-
associated spasticity (United Kingdom and Canada) and neuropathic pain (Canada). 
However, clinical use of cannabinoid compounds is limited both by undesirable 
neurological side effects and by induction of tolerance. In animal models, neurological side 
effects have been shown to be dependent on CB1 receptor but not CB2 receptor activation 
(Romero-Sandoval and Eisenach, 2007). Furthermore, sustained spinal or subcutaneous 
administration of the CB1 receptor agonist, WIN 55,212-2 has been shown to induce 
hypersensitivity and antinociceptive tolerance in naive mice and rats. In contrast, we 
(Romero-Sandoval and Eisenach, 2007; Romero-Sandoval et al., 2008a) and others (Yao et al., 
2009) have shown that spinal CB2 receptor agonists (such as JWH015) relieve postoperative 
and neuropathic pain in rodent models without inducing neurological side effects or 
antinociceptive tolerance. Despite advancements in the molecular mechanisms involved in 
cannabinoid tolerance (Martini et al., 2010), a better understanding of the respective roles of 
CB1 and CB2 receptors is required to design effective therapies that do not induce tolerance. 
Further advances in this area may also guide clinical treatment of patients who have already 
developed tolerance through prior exposure to non-selective cannabinoid agonists for 
recreational or medical purposes. 
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Using the L5 nerve transection (L5NT) rodent model of chronic neuropathic pain, this 
study was designed to test: 1) whether a non-selective cannabinoid agonist (CP55940) 
induces tolerance following repeated intrathecal (i.t.) administration in a model of 
neuropathic pain; 2) whether this antinociceptive tolerance could be reversed by the 
cessation of drug exposure; and 3) whether sustained spinal administration of the non-
selective cannabinoid CP55940 affects antinociception induced by a CB2 receptor agonist 
(JWH015). To determine the site of action of these agonists we additionally examined 
expression levels and cellular localization of CB1 and CB2 receptors in the spinal cord of 
rats receiving either L5NT or sham surgery. 
2. Materials and methods 
2.1 Animals and surgical procedures 
These studies were performed in accordance with the Guidelines for Animal 
Experimentation of the International Association for the Study of Pain (IASP) and after 
approval by the Institutional Animal Care and Use Committee at Dartmouth College 
(Dartmouth Medical School, Hanover, New Hampshire). Male Sprague-Dawley rats 
weighing 200–250 g (Harlan, Indianapolis, IN) at the start of surgery underwent L5NT 
surgery as previous described (Tanga et al., 2005). Briefly, rats were anesthetized with 2% 
isoflurane in oxygen and a small incision to the skin overlying L5–S1 was made followed by 
retraction of the paravertebral musculature from the vertebral transverse processes. The L6 
transverse process was then partially removed to expose the L4 and L5 spinal nerves. The L5 
spinal nerve was identified, lifted slightly, and transected. The wound was irrigated with 
saline and sutured in two layers. Sham surgeries were performed in other group of rats 
following the same procedure but without manipulating or injuring the nerves. The 
surgeries and anesthesia exposure lasted 15 – 20 minutes. Animals were housed 
individually and maintained in a 12:12 hr light/dark cycle with ad libitum access to food and 
water. Efforts were made to limit animal distress and to use the minimum number of 
animals necessary to achieve statistical significance. 
2.2 Tissue preparation, immunohistochemistry, imaging and image analysis 
After being anesthetized with 2-4% isoflurane in oxygen, rats were perfused transcardially 
with phosphate buffered saline (0.01 M, 150 ml) followed by 4% formaldehyde (350 ml) at 
room temperature. The L5 spinal cord section was collected and placed in 30% sucrose for 
48–72 hr at 4 °C. The tissue was then frozen in O.C.T. Compound (Sakura Finetek, Torrance, 
CA) and stored at -80 °C. To determine the expression of spinal CB2 receptor 
immunohistochemistry was performed on transverse 20-µm L5 spinal cord free-floating 
sections by using the Vector ELITE ABC (Vector Labs, Burlingame, CA), avidin-biotin 
complex technique and a goat polyclonal antibody against the C-terminus of CB2 receptor 
(1:150, Santa Cruz biotechnology, Santa Cruz, CA, sc10076) as we have previously described 
(Romero-Sandoval et al., 2008a). Immunofluorescence was performed to determine the 
spinal CB1 receptor expression level using a rabbit polyclonal antibody (1:200, Cayman, 
Ann Arbor, MI) and a Alexa-Fluor™ 488 Goat anti-Rabbit IgG1 secondary antibody 
(Molecular Probes, Eugene, Oregon). For CB1 receptor and CB2 receptor expression 
quantification, the sections were examined with an Olympus microscope, and images were 
captured with a Q-Fire cooled camera (Olympus, Melville, NY). We quantified the CB1 
receptor or CB2 receptor expression, blinded to experimental conditions, as the number of 
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pixels above a preset intensity threshold using SigmaScan Pro 5 as previously described 
(Romero-Sandoval and Eisenach, 2007; Romero-Sandoval et al., 2008b). For both CB1 
receptor and CB2 receptor expression, the staining intensity was examined in a standardized 
area of superficial laminae (I-II) and deep laminae (III-V) of the L5 dorsal horn in 3–4 slices 
examined per animal. 
Immunofluorescence was also used for dual labeling with specific cell markers and CB1 
receptor or CB2 receptor. All sections were blocked in 5% Normal Goat Serum (NGS) and 
0.01% Triton-X-100 for 1 hour at 4 °C. Sections were incubated in the appropriate primary 
antibody or antibodies diluted in a buffer composed of 1% NGS and 1% Triton-X-100 in PBS 
overnight at 4 °C. To determine the cellular localization of CB1 receptor or CB2 receptor we 
co-labeled antibodies for CB1 receptor and CB2 receptor with the following cellular markers 
(antibodies): rabbit polyclonal anti-Iba-1 for microglia (1:1000, Wako Pure Chemical 
Industries, Richmond, VA), mouse polyclonal anti-GFAP for astrocytes (1:400, Sigma, Saint 
Louis, Missouri), mouse polyclonal antibody anti- ED2/CD163 for perivascular cells (1:150, 
Serotec, Raleigh, NC), mouse polyclonal anti-Neuronal Nuclei, NeuN for neurons (1:10,000, 
Chemicon, Billerica, Massachusetts). 
The following secondary antibodies were used as indicated in table 1: Alexa-Fluor™ 488 
Goat anti-Rabbit IgG1 (Molecular Probes, Eugene, Oregon), Alexa-Fluor™ 488 Goat anti-
Mouse IgG1 (Molecular Probes, Eugene, Oregon), Alexa-Fluor™ 555 Goat anti-Mouse IgG 
(Molecular Probes, Eugene, Oregon) and Alexa-Fluor™ 555 Donkey anti-Goat IgG 
(Molecular Probes, Eugene, Oregon). 
To avoid cross-reactivity between the secondary antibodies in the CB2 receptor co-
localization experiments, sections were first incubated in Alexa-Fluor™ 555 Donkey anti-
Goat IgG (Molecular Probes, Eugene, Oregon) as described above, washed 2 times in PBS 
and then incubated in the appropriate Alexa-Fluor™ 488 secondary antibody as described 
above. This protocol modification prevented binding of the Alexa-Fluor™ 555 Donkey 
anti-Goat IgG to the goat-derived Alexa-Fluor™ 488. The specificity of each antibody was 
tested by omitting the primary antibody on 1-3 additional sections. To avoid cross-
reactivity when co-staining with primary antibodies against Iba-1 and CB1 receptors that 
are both rabbit-derived, a TSA Signal Amplification Kit was used following the 
manufacturer instructions (PerkinElmer LifeSciences Inc, Boston, MA). On the first day, 
normal immunofluorescence protocol was followed except that sections were incubated 
only in anti-CB1 receptor antibody at a concentration of 1:10,000. On the second day 
sections were washed 2 times for 5 minutes in PBS then incubated in a biotinylated Goat α 
Rabbit secondary antibody for 1 hour at 4 °C. Sections were then subjected to another 
wash, incubated in SA-HRP (1:100) for 1 hour at 4 °C, washed again and incubated in the 
TSA fluorophore (1:250) for 10 minutes at 4 °C. Sections were then washed again and 
incubated overnight in the Iba-1 primary antibody (1:1000). The next day sections were 
subjected to normal day 2 immunofluorescence protocol to visualize Iba-1 (described 
above). One control was included with only the anti-CB1 receptor primary antibody 
(1:10,000) and the Alexa 555 Goat α Rabbit secondary antibody to control for any cross-
reactivity that might cause CB1 receptor expression to appear in red. A second control 
included only the anti-CB1 receptor primary antibody and the TSA kit in order to 
visualize the staining achieved in the absence of the co-stain. Finally, a third control 
included the TSA kit, Iba-1 primary and the Alexa 555 Goat α Rabbit secondary antibody 
but excluded the anti-CB1 receptor primary antibody. This third control provided 
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visualization of the non-specific background staining produced by the kit alone. All 
controls confirmed the specificity of the co-stain. 
 
Antigen  
(Co-stain) Primary Secondary 
Fluorophore optimal 
excitation (nm) 
CB1 Rabbit Goat α Rabbit 488 
Iba1 (CB1) Rabbit (Rabbit) Goat α Rabbit  (TSA Signal Amplification Kit) 488 (555) 
GFAP (CB1) Mouse (Rabbit) Goat α Mouse  (Goat α Rabbit) 488 (555) 
ED2 (CB1) Mouse (Rabbit) Goat α Mouse  (Goat α Rabbit) 488 (555) 
Iba1 (CB2) Rabbit (Goat) Goat α Rabbit  (Donkey α Goat) 488 (555) 
GFAP (CB2) Rabbit (Goat) Goat α Rabbit  (Donkey α Goat) 488 (555) 
ED2 (CB2) Mouse (Goat) Goat α Mouse  (Donkey α Goat) 488 (555) 
NeuN (CB2) Mouse (Goat) Goat α Mouse  (Donkey α Goat) 488 (555) 
Table 1. Details of antibody selections for all immunofluorescense experiments,  
CB1: Cannabinoid receptor type 1, CB2: Cannabinoid receptor type 2, ED2: Perivascular cell 
marker, GFAP: Glial Fibrillary Acidic Protein, Iba-1: Ionized Calcium–Binding Adapter 
Molecule 1, NeuN: Neuronal Nuclei. 
Stained sections were examined with an Olympus fluorescence microscope, and images 
were captured with a Q-Fire cooled camera (Olympus, Melville, NY). Confocal microscopy 
was also performed using a Zeiss LSM 510 Meta confocal microscope (Carl Zeiss AG, 
Oberkochen, Germany; Englert Cell Analysis Laboratory, Dartmouth). Merged color images 
were processed using Adobe Photoshop 7.0 (Adobe Systems, San Jose, CA). 
2.3 Behavioral testing 
Mechanical allodynia was evaluated by measuring the 50% withdrawal threshold using an 
up–down statistical method (Chaplan et al., 1994) and calibrated von Frey filaments (1 – 60 
g, Stoelting, Wood Dale, IL). At each time point, two measurements were made on the paw 
ipsilateral to surgery in 5-10 min intervals, and the average of these values was used for data 
analyses. As an internal control, withdrawal thresholds were also measured in the paw 
contralateral to surgery (uninjured side). The withdrawal threshold was determined for 
each animal before surgery, 4 days after surgery (immediately before any pharmacological 
treatment), and after drug administration (different time points for different paradigms, see 
below). The investigator was blinded to drug treatment in all behavioral tests. 
2.4 Drugs and treatments 
Drugs were administered by intrathecal (i.t.) injection by means of lumbar puncture under 
brief inhalational anesthesia (2-4% isoflurane in oxygen) using a Hamilton syringe and a 28-
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gauge 5/8-inch hypodermic needle. The needle was inserted intrathecally, on the midline 
between the fourth and fifth lumbar vertebrae. The correct injection site was confirmed with 
the stimulation of nerves in the cauda equina when the lumbar needle penetrated the dura and 
produced a brief but obvious movement of the tail and/or the hind paws. The animals 
regained consciousness 2–3 min after the discontinuation of anesthesia. Drugs were diluted in 
dimethylsulfoxide and saline in a ratio of 1:1 and administered in a volume of 15 µl as 
previously described (Romero-Sandoval et al., 2008a). The drugs used were: the dual (CB1 
receptor and CB2 receptor) cannabinoid receptor agonist CP55940 (5-(1,1-Dimethylheptyl)-2-
[5-hydroxy-2-(3-hydroxypropyl) cyclohexyl]phenol; Sigma Chemical Co., St. Louis, MO); the 
CB2 receptor agonist JWH015 ((2-Methyl-1-propyl-1H-indol-3-yl)-1-naphthalenylmethanone), 
the CB1 receptor antagonist AM281 (1-(2,4-Dichlorophenyl)-5-(4-iodophenyl)-4-methyl-N-4-
morpholinyl-1H-pyrazole-3-carboxamide) and the CB2 receptor antagonist AM630 (6-Iodo-2-
methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl)methanone), purchased 
from Tocris, Ellisville, MI.  
2.5 Repeated CP55940 administration and monitoring of behavioral effects 
Beginning four days after surgery, CP55940 (100 µg/injection, n=18) or vehicle (n=17) was 
administered in single daily injections (8:00-9:00 AM) for five days. This dose and i.t. 
administration method were chosen based on our previous study using CP55940 in the same 
model of neuropathic pain (Romero-Sandoval and Eisenach, 2007), and on a previous study 
that demonstrated induction of antinociceptive tolerance with another non-selective 
cannabinoid agonist WIN 55,212-2 (Gardell et al., 2002) at a dose of 100 µg twice daily. 
Drugs and vehicle were administered i.t. based on previous evidence that spinal cord 
mechanisms drive induction of cannabinoid tolerance (Gardell et al., 2002). Two hours after 
each injection, mechanical withdrawal thresholds in both ipsilateral and contralateral hind-
paws were evaluated as described above. 
2.6 Evaluation of response to acute CP55940 dose escalation in tolerant and  
non-tolerant animals 
CP55940 was acutely administered i.t. in 30-min interval escalating doses: 0.4, 2, 10 and 50 
µg in L5NT animals 24 hr before and 24 hr after the repeated (5 day) treatment with 
CP55940 (n=5) or vehicle (n=6). As a control, vehicle was administered i.t. using the same 
dose escalation paradigm in animals that had previously received L5NT followed by 
repeated (5 days) treatment with CP55940 (n=8). The antinociceptive effect of escalating 
doses of CP55940 was evaluated 15 min after every injection. The effectiveness and potency 
of CP55940 were calculated using these dose responses and were compared in both repeated 
CP55940 and repeated vehicle treatment groups. To determine whether cannabinoid-
mediated tolerance was reversed following the discontinuation of sustained CP55940 
administration, the antinociceptive response to escalating doses of CP55940 were also 
measured two weeks after the last day of repeated CP55940 treatment (washout period). In 
summary, responses to acute CP55940 dose escalation (or vehicle) was evaluated in the 
following cases: 1) prior to any additional treatment, 2) 24 hours after repeated (5-day) 
treatment with CP55940, 3) 24 hours after repeated (5-day) treatment with vehicle, and 4) 2 
weeks (washout period) after repeated (5-day) treatment with CP55940. To confirm that 
CP55940 induced its effects via CB1 receptor and CB2 receptor as we have previously 
demonstrated (Romero-Sandoval and Eisenach, 2007; Romero-Sandoval et al., 2008a), we 
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administered in single daily injections (8:00-9:00 AM) for five days. This dose and i.t. 
administration method were chosen based on our previous study using CP55940 in the same 
model of neuropathic pain (Romero-Sandoval and Eisenach, 2007), and on a previous study 
that demonstrated induction of antinociceptive tolerance with another non-selective 
cannabinoid agonist WIN 55,212-2 (Gardell et al., 2002) at a dose of 100 µg twice daily. 
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2.6 Evaluation of response to acute CP55940 dose escalation in tolerant and  
non-tolerant animals 
CP55940 was acutely administered i.t. in 30-min interval escalating doses: 0.4, 2, 10 and 50 
µg in L5NT animals 24 hr before and 24 hr after the repeated (5 day) treatment with 
CP55940 (n=5) or vehicle (n=6). As a control, vehicle was administered i.t. using the same 
dose escalation paradigm in animals that had previously received L5NT followed by 
repeated (5 days) treatment with CP55940 (n=8). The antinociceptive effect of escalating 
doses of CP55940 was evaluated 15 min after every injection. The effectiveness and potency 
of CP55940 were calculated using these dose responses and were compared in both repeated 
CP55940 and repeated vehicle treatment groups. To determine whether cannabinoid-
mediated tolerance was reversed following the discontinuation of sustained CP55940 
administration, the antinociceptive response to escalating doses of CP55940 were also 
measured two weeks after the last day of repeated CP55940 treatment (washout period). In 
summary, responses to acute CP55940 dose escalation (or vehicle) was evaluated in the 
following cases: 1) prior to any additional treatment, 2) 24 hours after repeated (5-day) 
treatment with CP55940, 3) 24 hours after repeated (5-day) treatment with vehicle, and 4) 2 
weeks (washout period) after repeated (5-day) treatment with CP55940. To confirm that 
CP55940 induced its effects via CB1 receptor and CB2 receptor as we have previously 
demonstrated (Romero-Sandoval and Eisenach, 2007; Romero-Sandoval et al., 2008a), we 
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administered CP55940 at a dose of 50 µg in combination with vehicle, the CB1 receptor 
antagonist AM281 at a dose of 50 µg or the CB2 receptor antagonist AM630 at a dose of 50 
µg in a separate group of rats. Mechanical withdrawal threshold was determined 2 hr after 
treatments. 
2.7 Evaluation of response to acute JWH015 dose escalation in tolerant and  
non-tolerant animals 
JWH015, a CB2 receptor agonist, was acutely administered i.t. in 30-min interval 
escalating doses: 0.4, 2, 10 and 50 µg in L5NT animals that had previously received 
repeated (5 days) treatment with CP55940 (n=8) or vehicle (n=8). Vehicle was acutely 
administered i.t. using the same dose escalation paradigm in animals that had previously 
received L5NT followed by repeated (5 days) treatment with CP55940 (n=8). The 
antinociceptive effect of escalating doses of JWH015 was evaluated 15 min after every 
injection and its efficacy and potency were quantified. The first set of experiments was 
performed 24 hr after the last day of repeated CP55940 administration to test whether the 
cannabinoid-mediated tolerance influenced the antinociceptive effects of a CB2 receptor 
agonist administered acutely. The second set of experiments was performed two weeks 
after the last day of repeated CP55940 treatment (washout period) to test whether the 
potency and/or efficacy of the CB2 receptor agonist, JWH015 improves following the 
discontinuation of sustained CP55940 treatment. In summary, responses to acute JWH015 
dose escalation (or vehicle) were evaluated in the following cases: 1) 24 hours after 
repeated (5-day) treatment with CP55940 or vehicle and 2) 2 weeks (washout period) after 
repeated (5-day) treatment with CP55940 or vehicle. 
To confirm that JWH015 induced its effects via CB2 receptors as we have previously 
demonstrated (Romero-Sandoval and Eisenach, 2007; Romero-Sandoval et al., 2008a), we 
administered JWH015 at a dose of 50 µg in combination with the CB2 receptor antagonist 
AM630 at a dose of 50 µg or vehicle in a separate group of animals. Mechanical withdrawal 
threshold was determined 2 hr after treatments. 
2.8 Evaluation of response to repeated JWH015 administration in tolerant and  
non-tolerant animals 
Following the washout period (two weeks after repeated administration of CP55940 or 
vehicle), JWH015 (50 µg/injection, n=9) or vehicle (n=8) was administered in single daily 
injections (8:00-9:00 AM) for four days. Behavioral testing were performed before and 2 hr 
after each injection. Antinociceptive tolerance was evaluated by testing mechanical 
withdrawal thresholds in the paw ipsilateral or contralateral to surgery. 
2.9 Assessment of neurological side effects 
Based on our previous studies (Romero-Sandoval and Eisenach, 2007; Romero-Sandoval et 
al., 2008a) righting and placing-stepping tests were used to evaluate motor reflexes; the bar 
test was used to evaluate catalepsy; vocalization was used as a sign of irritability or 
discomfort to manipulation and exploratory activity was used as a measure of awareness. 
These parameters were evaluated before, 20 minutes and 2.5 hr after each injection 
(following behavioral mechanical hypersensitivity testing). The placing-stepping reflex was 
tested by placing the rostral aspect of the hind paws on the edge of a table and was 
quantified as the seconds in which the animals put the paws up and forward into a position 
to walk. A cut-off of 60 s was used. The bar test consists of placing the forelimbs on a bar of 
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~1 cm of diameter and 10 cm above and parallel to a table, leaving the hind paws resting on 
the table. A cataleptic animal will stay in that position longer than a normal animal. The 
time in which the animal puts its forelimb on the table was recorded, using a cut off time of 
60 s. The righting test consists of placing the animal supine and recording the ability to right 
itself. Righting was scored on a scale of 0-3, 0 indicating normal righting reflex (an 
immediate and coordinated twisting of the body to an upright position), 1 indicating mild 
impairment (ability to completely right, but slowly), 2 indicating moderate impairment 
(ability to right the forelimbs slowly followed by the hind limbs with more difficulty) and 3 
indicating severe impairment (inability to right in 20 sec). Vocalization was rated on a scale 
of 0-3, 0 indicating absent vocalization, 1 indicating some vocalization when manipulated, 2 
indicating consistent vocalization when manipulated and 3 indicating vocalization even 
light touch. Exploratory activity was rated on a scale of 0-3 with 0 indicating normal activity, 
1 indicating only head movements without vertical and/or horizontal exploration, 2 
indicating no spontaneous movements and 3 indicating splayed posture with no 
spontaneous movements. All behavioral measures were performed twice and the average 
used for analyses. 
2.10 Statistical analyses 
The effects of L5NT surgery and drug injections on bar test, placing-stepping test and 
withdrawal thresholds were examined using the repetitive measurements one-way 
analysis of variance. If significant effects were found, Tukey’s multiple comparison or 
Dunnett’s test was conducted. Differences between groups were examined using two-way 
analysis of variance. If differences were found, the Bonferroni post test was used. In the 
acute antinociceptive effect studies, acute i.t. JWH015 50% of maximum efficacy (ED50) 
and its 95% confidence limits were calculated and compared between repeated CP55940 
and repeated vehicle groups using Student’s t test. ED50s were calculated using the 
baseline and after-surgery withdrawal thresholds as maximum and minimum effect 
values respectively. Vocalization, righting test and exploratory activity data following 
treatment were compared using the Friedman Repeated Measures Analysis of Variance on 
Rank test. If significant effects were found, non-parametric Wilcoxon signed ranks tests 
were conducted comparing each time point to the baseline value (before surgery). 
Between group differences were compared at each time period using the Kruskal-Wallis 
test. Significant effects were further evaluated using the Mann-Whitney U test comparing 
only the novel treatment to control or agonist group. The effects of CP55940 in acute 
antinociception vs. CP55940 in the presence of CB1 receptor or CB2 receptor antagonist 
was evaluated by one-way ANOVA followed by Dunnett’s post-test. The effects of 
JWH015 in acute antinociception in the presence of the CB2 receptor antagonist was 
evaluated by unpaired Student’s t-test. Data are presented as mean ± SEM. In all cases a P 
value less than 0.05 was considered significant. SigmaStat and GraphPad inStat software 
were used for statistical analyses. 
3. Results 
3.1 Spinal cord CB1 and CB2 receptor expression and cellular localization 
Compared to rats receiving sham surgery, rats receiving L5NT surgery demonstrated 
significantly higher CB1 receptor expression in the L5 dorsal horn on postoperative days  
4 and 7 (Figure 1). The changes in CB1 receptor expression were primarily apparent in  
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quantified as the seconds in which the animals put the paws up and forward into a position 
to walk. A cut-off of 60 s was used. The bar test consists of placing the forelimbs on a bar of 
Reduced Antinociceptive Effect of Repeated Treatment with a Cannabinoid  
Receptor Type 2 Agonist in Cannabinoid-Tolerant Rats Following Spinal Nerve Transection 
 
107 
~1 cm of diameter and 10 cm above and parallel to a table, leaving the hind paws resting on 
the table. A cataleptic animal will stay in that position longer than a normal animal. The 
time in which the animal puts its forelimb on the table was recorded, using a cut off time of 
60 s. The righting test consists of placing the animal supine and recording the ability to right 
itself. Righting was scored on a scale of 0-3, 0 indicating normal righting reflex (an 
immediate and coordinated twisting of the body to an upright position), 1 indicating mild 
impairment (ability to completely right, but slowly), 2 indicating moderate impairment 
(ability to right the forelimbs slowly followed by the hind limbs with more difficulty) and 3 
indicating severe impairment (inability to right in 20 sec). Vocalization was rated on a scale 
of 0-3, 0 indicating absent vocalization, 1 indicating some vocalization when manipulated, 2 
indicating consistent vocalization when manipulated and 3 indicating vocalization even 
light touch. Exploratory activity was rated on a scale of 0-3 with 0 indicating normal activity, 
1 indicating only head movements without vertical and/or horizontal exploration, 2 
indicating no spontaneous movements and 3 indicating splayed posture with no 
spontaneous movements. All behavioral measures were performed twice and the average 
used for analyses. 
2.10 Statistical analyses 
The effects of L5NT surgery and drug injections on bar test, placing-stepping test and 
withdrawal thresholds were examined using the repetitive measurements one-way 
analysis of variance. If significant effects were found, Tukey’s multiple comparison or 
Dunnett’s test was conducted. Differences between groups were examined using two-way 
analysis of variance. If differences were found, the Bonferroni post test was used. In the 
acute antinociceptive effect studies, acute i.t. JWH015 50% of maximum efficacy (ED50) 
and its 95% confidence limits were calculated and compared between repeated CP55940 
and repeated vehicle groups using Student’s t test. ED50s were calculated using the 
baseline and after-surgery withdrawal thresholds as maximum and minimum effect 
values respectively. Vocalization, righting test and exploratory activity data following 
treatment were compared using the Friedman Repeated Measures Analysis of Variance on 
Rank test. If significant effects were found, non-parametric Wilcoxon signed ranks tests 
were conducted comparing each time point to the baseline value (before surgery). 
Between group differences were compared at each time period using the Kruskal-Wallis 
test. Significant effects were further evaluated using the Mann-Whitney U test comparing 
only the novel treatment to control or agonist group. The effects of CP55940 in acute 
antinociception vs. CP55940 in the presence of CB1 receptor or CB2 receptor antagonist 
was evaluated by one-way ANOVA followed by Dunnett’s post-test. The effects of 
JWH015 in acute antinociception in the presence of the CB2 receptor antagonist was 
evaluated by unpaired Student’s t-test. Data are presented as mean ± SEM. In all cases a P 
value less than 0.05 was considered significant. SigmaStat and GraphPad inStat software 
were used for statistical analyses. 
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the deeper laminae (III-V) of the dorsal horn in rats that had received L5NT surgery.  




Fig. 1. CB1 receptor expression is increased on days 4 and 7 after L5 nerve transection. 
Representative images (A-D) show CB1 receptor expression at postoperative days 4 (D4) 
and 7 (D7) in the L5 dorsal horn of rats receiving sham surgery or L5 nerve transection. 
Details of the deep laminae (III-IV) of the dorsal horn of these spinal cord tissues are shown 
next to each original image (Aa-Dd). CB1 expression was quantified in the ipsilateral whole 
dorsal horn (E), laminae I-II (F) and laminae III-IV (G) of rats receiving sham surgery or L5 
nerve transection at postoperative days 1, 4 and 7. Receptor expression was quantified as the 
number of pixels above a set threshold per total pixels in the selected area and normalized 
to percent of each control, sham group. *p<0.05 vs. respective sham group by t test. N=3 for 
all groups. 
Compared to the sham surgery group, rats receiving L5NT also demonstrated significantly 
higher spinal CB2 receptor expression on postoperative day 4 (Figure 2). This increased CB2 
receptor expression was mainly observed in the superficial laminae (I-II) of the dorsal horn 
in animals with L5NT surgery. No significant changes in CB2 receptor expression were 
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Fig. 2. CB2 receptor expression is increased on day 4 following L5 nerve transection. 
Representative images (A-B) show CB2 receptor expression at postoperative day 4 (D4) in 
the L5 dorsal horn of rats receiving sham surgery or L5 nerve transection. Details of the 
superficial laminae (II-III) of the dorsal horn of these spinal cord tissues are shown next to 
each original image (Aa and Bb). CB2 expression was quantified in the ipsilateral whole 
dorsal horn (C), laminae I-II (D) and laminae III-IV (E) of rats receiving sham surgery or L5 
nerve transection at postoperative days 1, 4 and 7. Receptor expression was quantified as the 
number of pixels above a set threshold per total pixels in the selected area and normalized 
to percent of each control, sham group. *p<0.05 vs. respective sham group by t test. N=3 for 
all groups. 
Using confocal microscopy, we observed that spinal CB1 receptors were primarily expressed 
on NeuN-positive neurons in the dorsal horns of animals receiving L5NT surgery (Figure 3). 
Occasionally, CB1 receptors expression co-localized with the astrocyte marker GFAP (Figure 
3). CB1 receptor expression did not co-localize with Iba-1-positive microglia or ED2/CD163-
positive perivascular cells at any observed time point following L5NT (Figure 3). However, 
cells expressing CB1 receptor were in close proximity to Iba-1-positive microglia and 
perivascular cells. 
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Fig. 3. CB1 receptor is expressed primarily in neurons. Representative confocal images show 
CB1 receptor cell localization in the ipsilateral L5 dorsal horn of rats at days 1, 4 and 7 after 
L5 nerve transection. CB1 receptor staining appears in red. NeuN (marker for neurons),  
Iba-1 (marker for microglia) and ED2/CD163 (ED2, marker for perivascular microglia) 
appear in green, and GFAP (marker for astrocytes) appears in grey. In the images of CB1 
receptors and Iba-1, Iba-1 (originally in red) was changed to green, and CB1 receptor 
(originally in green) was changed to red to consistently show CB1 receptors in red in all 
images. GFAP color (originally in green) was changed to  grey to obtain a better 
visualization of occasional expression of CB1 receptors on GFAP-positive cells.  
The colocalization of CB1 receptors with NeuN appears in yellow. 
Microglia (Iba-1 positive cells) and perivascular cells (ED2/CD163 positive cells) displayed 
localized areas of CB2 receptor expression (Figure 4). Diffuse, punctate CB2 receptor 
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expression was occasionally observed on NeuN-positive neuronal somata (Figure 4). Even 
though GFAP-positive spinal cord astrocytes did not demonstrate CB2 receptor expression, 
these cells were in close proximity to cells that expressed CB2 receptor (Figure 4). 
 
 
Fig. 4. CB2 receptors are mainly expressed in microglial cells. Representative confocal 
images show CB2 receptor cell localization in the ipsilateral L5 dorsal horn of rats at days 1, 
4 and 7 after L5 nerve transection. CB2 receptor appears in red. NeuN (marker for neurons), 
Iba-1 (marker for microglia) and ED2/CD163 (ED2, marker for perivascular microglia) 
appear in green, and GFAP (marker for astrocytes) appears in grey. GFAP color (originally 
in green) was changed to grey to obtain a better visualization of this specific marker and any 
potential expression of CB2 receptors. The colocalization of CB2 receptors with the other 
cellular markers is visualized in yellow. 
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3.2 CP55940 antinociceptive tolerance 
Mechanical withdrawal thresholds on the uninjured side (paw contralateral to L5NT) 
were not affected by surgery (26.7±1.4 g vs. 23.1±1.1 g, before and after surgery 
respectively), nor were they significantly different at any observed time point during the 
five subsequent days of intrathecal vehicle or CP55940 administration (Figure 5). In the 
paw ipsilateral to L5NT surgery, withdrawal thresholds were significantly reduced after 
surgery (26.6±1.3 g vs. 5.4±0.5 g, before and after surgery respectively, p<0.05).  
 
 
Fig. 5. Antinociceptive effects of repeated i.t. administration of CP55940. Paw withdrawal 
thresholds indicate responses to von Frey stimulation ipsilateral to L5NT or contralateral to 
surgery (uninjured side) before surgery (base line = BL), four days after surgery (S), and 2 hr 
after i.t. injections of vehicle (n=17) or CP55940 (n=18) on days 1, 3 and 5. Withdrawal 
thresholds on day 1 (D1), day 3 (D3) and day 5 (D5) vs. after surgery data significantly differ 
by repeated measures one way ANOVA; *p<0.05 vs. after surgery, +p<0.05 vs.  
D1 L5NT-CP55940, # p<0.05 vs. D3 L5NT-CP55940 by repeated measures one way  
ANOVA followed by Tukey's multiple comparison test. Groups significantly differ by  
two way ANOVA; p<0.05 compared to vehicle and both contralateral groups by two way 
ANOVA followed by Bonferroni post tests. 
Administration of vehicle (i.t.) on each of the subsequent 5 days did not significantly alter 
this L5NT-induced hypersensitivity at any time point observed (Figure 5). In contrast, 
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administration of the non-selective cannabinoid agonist CP55940 (100 µg, i.t.) resulted in 
significantly higher withdrawal thresholds (measured 2 hours following injection) 
compared to vehicle-treated controls on each day observations were made (Figure 1). 
However, ipsilateral withdrawal thresholds in animals treated with CP55940 were 
significantly lower at 2 hr after injection on days 3 - 5 compared to day 1 values (Figure 1). 
Additionally, the anti-allodynic effect of CP55940 was significantly lower at 2 hr after 
injection on day 5 compared to day 3 (Figure 5). 
In order to test the efficacy and potency of CP55940 before and after its repeated 
administration, we performed an acute dose escalation with i.t. CP55940. CP55940 reduced 
L5NT-induced hypersensitivity in a significant and dose-dependent manner before and 24 
hr after the 5-day course of daily CP55940 administration (Figure 6). Compared to acute i.t. 
vehicle treatment, the minimum effective dose of CP55940 was 10 µg, and its maximum 
effective dose (dose that induced a return to base line values) was 50 µg (the maximum dose 
tested) before and after its repeated administration. However, CP55940 displayed an 
approximately 2-fold higher efficacy (p<0.05, Table 2) and an approximately 7-fold higher 
potency (p<0.05, Table 2) in untreated animals (Figure 6A) than in animals previously 
treated with CP55940 for five days (repeated CP55940 group, Figure 6B). The higher efficacy 
and potency of CP55940 observed in untreated animals were similar to the ones observed in 
animals previously treated for five days with vehicle (repeated vehicle group, Figure 6C, 
Table 2). We then evaluated the effects of acute CP55940 two weeks after repeated treatment 
with CP55940 was discontinued (washout period). Even though acute CP55940 was still 
effective (at 10 and 50 µg doses vs. vehicle) following 2 weeks of washout period, its efficacy 
and potency were significantly lower than in animals that had not received repeated 
CP55940 treatment (Figure 6D, Table 2). The acute antinociception induced by CP55940 50 
µg (plus vehicle, 32.9  2.1 g, n=6) in the L5NT group was blocked by either the CB1 receptor 
antagonist AM281 50 µg (14.5  4.3 g, n=4, P<0.05) or the CB2 receptor antagonist AM630 50 
µg (15.2  4.3 g, n=4, P<0.05), confirming that the activity of this compound depends on 
activation of both CB1 and CB2 receptors. 
 
 50% w.t. for the 50 µg dose (efficacy in g) 
ED50 
(95% confidence limits) 
 CP55940 JWH015 CP55940 JWH015 
L5NT no previous 
treatment 32.9±1.94  
14.7 (10.91-19.9)  
24 hr after 
repeated vehicle 29.7±2.85 17.0±2.7 11.9 (7.6-18.6) 26.4 (13.8-50.5) 
24 hr after 
repeated CP55940 14.9±1.12 * 16.3±3.9 112.6 (21.2-596.6) * 37.4 (26.7-52.5) 
2 weeks after 
repeated CP55940 15.7±4.8 * 14.2±2.5 162.6 (5.7-4567) * 32.5 (1.2-872) 
Table 2. Effect of the highest dose (50 µg) and ED50 (95% confidence limits) of acute i.t. 
administration of CP55940 and JWH015 in L5NT, *P<0.05 vs. L5NT no previous treatment 
and 24 hr after repeated vehicle groups. Withdrawal threshold = w.t. 
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3.2 CP55940 antinociceptive tolerance 
Mechanical withdrawal thresholds on the uninjured side (paw contralateral to L5NT) 
were not affected by surgery (26.7±1.4 g vs. 23.1±1.1 g, before and after surgery 
respectively), nor were they significantly different at any observed time point during the 
five subsequent days of intrathecal vehicle or CP55940 administration (Figure 5). In the 
paw ipsilateral to L5NT surgery, withdrawal thresholds were significantly reduced after 
surgery (26.6±1.3 g vs. 5.4±0.5 g, before and after surgery respectively, p<0.05).  
 
 
Fig. 5. Antinociceptive effects of repeated i.t. administration of CP55940. Paw withdrawal 
thresholds indicate responses to von Frey stimulation ipsilateral to L5NT or contralateral to 
surgery (uninjured side) before surgery (base line = BL), four days after surgery (S), and 2 hr 
after i.t. injections of vehicle (n=17) or CP55940 (n=18) on days 1, 3 and 5. Withdrawal 
thresholds on day 1 (D1), day 3 (D3) and day 5 (D5) vs. after surgery data significantly differ 
by repeated measures one way ANOVA; *p<0.05 vs. after surgery, +p<0.05 vs.  
D1 L5NT-CP55940, # p<0.05 vs. D3 L5NT-CP55940 by repeated measures one way  
ANOVA followed by Tukey's multiple comparison test. Groups significantly differ by  
two way ANOVA; p<0.05 compared to vehicle and both contralateral groups by two way 
ANOVA followed by Bonferroni post tests. 
Administration of vehicle (i.t.) on each of the subsequent 5 days did not significantly alter 
this L5NT-induced hypersensitivity at any time point observed (Figure 5). In contrast, 
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administration of the non-selective cannabinoid agonist CP55940 (100 µg, i.t.) resulted in 
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Table 2). We then evaluated the effects of acute CP55940 two weeks after repeated treatment 
with CP55940 was discontinued (washout period). Even though acute CP55940 was still 
effective (at 10 and 50 µg doses vs. vehicle) following 2 weeks of washout period, its efficacy 
and potency were significantly lower than in animals that had not received repeated 
CP55940 treatment (Figure 6D, Table 2). The acute antinociception induced by CP55940 50 
µg (plus vehicle, 32.9  2.1 g, n=6) in the L5NT group was blocked by either the CB1 receptor 
antagonist AM281 50 µg (14.5  4.3 g, n=4, P<0.05) or the CB2 receptor antagonist AM630 50 
µg (15.2  4.3 g, n=4, P<0.05), confirming that the activity of this compound depends on 
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Fig. 6. Antinociceptive effects of acute i.t. administration of CP55940. Withdrawal thresholds 
(95% confidence limits, doted lines) indicate responses to von Frey stimulation ipsilateral to 
L5NT surgery 15 min after escalating doses (0.4, 2, 10 and 50 µg) of i.t. CP55940 in animals 
receiving no additional treatment (A, n=5), 24 hr after the discontinuation of repeated 
treatment (5 days) with CP55940 i.t., 100 µg (B, n=6) or vehicle (C, n=6) and 2 weeks 
(washout period) after the discontinuation of repeated treatment (5 days) with CP55940  
100 µg (D, n=5). Withdrawal thresholds in response to dose escalation of CP55940 
significantly differ from after-surgery values by repeated measures one way ANOVA, 
*p<0.05 vs. after surgery by repeated measures one way ANOVA followed by Tukey's multiple 
comparison test. Groups significantly differ by two way ANOVA; p<0.05 L5NT or L5NT 24 hr 
after repeated vehicle groups vs. L5NT 24 hr after repeated CP55940 or L5NT 2 weeks after 
repeated CP55940 groups for 50 µg by two way ANOVA followed by Bonferroni post tests. 
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3.3 CP55940 neurological side effects 
In order to investigate the neurological side effects of CP55940 administration, we evaluated 
the place-stepping reflex, vocalization, exploratory activity and the bar test. Repeated 
vehicle injection did not significantly affect any of these behaviors at any time point 
observed. CP55940 significantly impaired the placing-stepping reflex (Figure 7A), induced 
vocalization (Figure 7B) and reduced exploratory activity (Figure 7C) on days 1, 2 and 3 
compared to vehicle group, and induced catalepsy (Figure 7D) on days 1, 2, 3 and 4  
 
 
Fig. 7. Neurological side effects in response to repeated treatment with CP55940. Placing-
stepping (A), vocalization (B), exploratory activity (C) and bar test (C) scores are shown 
from before the first injection (base line = BL), and 0.5, 2 and 24 hr after each i.t. injection 
(days 1 - 5) of vehicle (n=8) or CP55940 (n=13) during five consecutive days. Withdrawal 
thresholds on days 1, 3 and 5 in placing-stepping and bar test vs. base line data significantly 
differ by repeated measures one way ANOVA, *p<0.05 vs. base line, #p<0.05 vs. 0.5 hr, 
^p<0.05 vs. 2 hr by repeated measures one way ANOVA followed by Tukey's multiple 
comparison test. Groups differ in placing-stepping and bar test by repetitive measurements 
two-way ANOVA, +p<0.05 vs. CP55940 group by two way ANOVA followed by Bonferroni 
post tests. Days 1, 3 and 5 values in vocalization and exploratory activity vs. base line 
significantly differ by Friedman test, *p<0.05 vs. base line, #p<0.05 vs. 0.5 hr, ^p<0.05 vs.  
2 hr by Friedman test followed by Wilcoxon test. Groups in vocalization and exploratory 
activity significantly differ by Kruskal-Wallis test; +p<0.05 vs. CP55940 by Kruskal-Wallis 
test followed by Mann-Whitney U test. 
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*p<0.05 vs. after surgery by repeated measures one way ANOVA followed by Tukey's multiple 
comparison test. Groups significantly differ by two way ANOVA; p<0.05 L5NT or L5NT 24 hr 
after repeated vehicle groups vs. L5NT 24 hr after repeated CP55940 or L5NT 2 weeks after 
repeated CP55940 groups for 50 µg by two way ANOVA followed by Bonferroni post tests. 
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two-way ANOVA, +p<0.05 vs. CP55940 group by two way ANOVA followed by Bonferroni 
post tests. Days 1, 3 and 5 values in vocalization and exploratory activity vs. base line 
significantly differ by Friedman test, *p<0.05 vs. base line, #p<0.05 vs. 0.5 hr, ^p<0.05 vs.  
2 hr by Friedman test followed by Wilcoxon test. Groups in vocalization and exploratory 
activity significantly differ by Kruskal-Wallis test; +p<0.05 vs. CP55940 by Kruskal-Wallis 
test followed by Mann-Whitney U test. 
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compared to vehicle group. The magnitude of these neurological side effects decreased 
over the 5-day course of daily CP55940 injections until they were not significantly 
different compared to vehicle group on days 4 and 5 (except for catalepsy, 2 hr after 
CP55940 injection on day 4 vs. vehicle group, p<0.05). The righting reflex was 
significantly impaired by CP55940 compared to base line on days 1 and 3 (30 min and 2 hr 
after injections, data not shown). The effects of CP55940 on placing-stepping reflex, 
vocalization and bar test on day 1 were significantly higher compared to its effects on 
days 4 and 5. The effects of CP55940 on exploratory activity on day 1 were significantly 
higher compared to its effects on days 3, 4 and 5. For clarity, only the data obtained on 
days 1, 3 and 5 of treatment are shown. 
3.4 Acute antinociceptive effect of JWH015 in CP55940-tolerant animals 
JWH015, a selective CB2 receptor agonist, reduced mechanical hypersensitivity ipsilateral to 
surgery in a dose-dependent fashion when administered i.t. in cumulative, escalating doses 




Fig. 8. Antinociceptive effects of acute i.t. administration of JWH015 in CP55940-mediated 
tolerant animals. Withdrawal thresholds (95% confidence limits, doted lines) indicate 
responses to von Frey stimulation ipsilateral to L5NT surgery 15 min after escalating doses 
(0.4, 2, 10 and 50 µg) of i.t. JWH015 administered 24 hr (A) or two weeks (washout period, B) 
after the discontinuation of repeated treatment with CP55940 100 µg (Repeated CP55940) or 
vehicle (Repeated Vehicle). Groups did not differ by two-way ANOVA. Withdrawal 
thresholds after each dose vs. after surgery values significantly differ by repeated measures 
one way ANOVA, *p<0.05 vs. after surgery by repeated measures one way ANOVA 
followed by Tukey's multiple comparison test. Twenty-four hr after repeated treatment 
cessation: Repeated CP55940 n=8, Repeated Vehicle n=8, Repeated CP55940-washout period 
n=6 and Repeated Vehicle-washout period n=5. 
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maximum effective doses of JWH015 in the repeated CP55940 group were 10 and 50 µg 
respectively (50 µg was the highest dose used).  JWH015 was equally effective in both 
repeated CP55940 and vehicle groups since no significant difference in withdrawal 
thresholds was observed between groups in any dose tested. As a result, the ED50 value 
[95% confidence limits] of JWH015 was not significantly different in animals previously 
treated with repeated CP55940 compared to animals previously treated with vehicle (Table 1 
and Figure 8A). Vehicle (same paradigm as cumulative JWH015) did not modify the 
withdrawal thresholds ipsilateral to surgery (3.5±0.6 vs. 5.3±1.4 g before and 15 min after the 
last injection respectively, n=6) 24 hr after repeated treatment with vehicle. 
JWH015 was also effective in reversing the L5NT-induced hypersensitivity when it was 
administered in a cumulative manner two weeks after the cessation of CP5940 treatment 
(washout period). In this case, the minimum and maximum effective dose of JWH015 were 2 
and 50 µg respectively in animals previously exposed to CP55940 (repeated CP55940 group), 
and 10 and 50 µg respectively in animals previously treated with vehicle (repeated vehicle 
group). Similar efficacy and potency of JWH015 were observed in both repeated CP55940 
and vehicle groups (Table 2). No significant difference in withdrawal thresholds was 
observed between groups in any dose tested (Figure 8B). Vehicle (same paradigm as 
cumulative JWH015) did not modify the withdrawal thresholds ipsilateral to surgery in the 
repeated vehicle group after the two-week washout period (3.5±0.6 vs. 3.6±0.7 g before and 
15 min after the last injection respectively, n=6). The acute antinociception induced by 
JWH015 50 µg (plus vehicle, 17  2.7 g, n=8) in the L5NT group was completely blocked by 
the CB2 receptor antagonist AM630 50 µg (2.4  0.4 g, n=4, P<0.05). 
3.5 Antinociceptive effect of a CB2 receptor agonist administered repeatedly in 
CP55940 tolerant animals studies 
JWH015 injected i.t. for four consecutive days induced similar antinociceptive effects on all 
days tested in animals previously exposed to repeated i.t. vehicle treatment (for 5 days) and 
a washout period of two weeks. However, JWH015 injected i.t. for four consecutive days 
induced antinociception only on days 1 and 4 in animals previously exposed to sustained 
spinal CP55940 administration (for 5 days) and a washout period of two weeks. Repeated i.t. 
JWH015 was significantly less effective on the last three days of treatment in animals 
previously exposed to repeated CP55940 when compared to those previously exposed to 
repeated vehicle (Figure 9A). The JWH015 repeated treatment did not modify the 
mechanical withdrawal threshold in the contralateral paw in the repeated vehicle or 
CP55940 group, and the effects of repeated JWH015 did not differ between groups, except 
on day 3 when the withdrawal threshold was significantly higher in the repeated vehicle 
group than the CP55940 one (Figure 9B). Vehicle (same paradigm as repeated JWH015) did 
not modify the withdrawal thresholds ipsilateral (n=6) or contralateral (n=6) to surgery in 
the repeated CP55940 group after the two-week washout period (data not shown). 
4. Discussion 
The main findings of our study are: 1) the repeated administration of a non-selective 
cannabinoid agonist (CP55940) induces antinociceptive tolerance and tolerance to 
cannabinoid-induced neurological side effects in a rat model of neuropathic pain; 2) 
CP55940 tolerance persists two weeks after the discontinuation of cannabinoid 
administration; 3) prior induction of CP55940 tolerance reduced the antinociceptive effect of 
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compared to vehicle group. The magnitude of these neurological side effects decreased 
over the 5-day course of daily CP55940 injections until they were not significantly 
different compared to vehicle group on days 4 and 5 (except for catalepsy, 2 hr after 
CP55940 injection on day 4 vs. vehicle group, p<0.05). The righting reflex was 
significantly impaired by CP55940 compared to base line on days 1 and 3 (30 min and 2 hr 
after injections, data not shown). The effects of CP55940 on placing-stepping reflex, 
vocalization and bar test on day 1 were significantly higher compared to its effects on 
days 4 and 5. The effects of CP55940 on exploratory activity on day 1 were significantly 
higher compared to its effects on days 3, 4 and 5. For clarity, only the data obtained on 
days 1, 3 and 5 of treatment are shown. 
3.4 Acute antinociceptive effect of JWH015 in CP55940-tolerant animals 
JWH015, a selective CB2 receptor agonist, reduced mechanical hypersensitivity ipsilateral to 
surgery in a dose-dependent fashion when administered i.t. in cumulative, escalating doses 




Fig. 8. Antinociceptive effects of acute i.t. administration of JWH015 in CP55940-mediated 
tolerant animals. Withdrawal thresholds (95% confidence limits, doted lines) indicate 
responses to von Frey stimulation ipsilateral to L5NT surgery 15 min after escalating doses 
(0.4, 2, 10 and 50 µg) of i.t. JWH015 administered 24 hr (A) or two weeks (washout period, B) 
after the discontinuation of repeated treatment with CP55940 100 µg (Repeated CP55940) or 
vehicle (Repeated Vehicle). Groups did not differ by two-way ANOVA. Withdrawal 
thresholds after each dose vs. after surgery values significantly differ by repeated measures 
one way ANOVA, *p<0.05 vs. after surgery by repeated measures one way ANOVA 
followed by Tukey's multiple comparison test. Twenty-four hr after repeated treatment 
cessation: Repeated CP55940 n=8, Repeated Vehicle n=8, Repeated CP55940-washout period 
n=6 and Repeated Vehicle-washout period n=5. 
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maximum effective doses of JWH015 in the repeated CP55940 group were 10 and 50 µg 
respectively (50 µg was the highest dose used).  JWH015 was equally effective in both 
repeated CP55940 and vehicle groups since no significant difference in withdrawal 
thresholds was observed between groups in any dose tested. As a result, the ED50 value 
[95% confidence limits] of JWH015 was not significantly different in animals previously 
treated with repeated CP55940 compared to animals previously treated with vehicle (Table 1 
and Figure 8A). Vehicle (same paradigm as cumulative JWH015) did not modify the 
withdrawal thresholds ipsilateral to surgery (3.5±0.6 vs. 5.3±1.4 g before and 15 min after the 
last injection respectively, n=6) 24 hr after repeated treatment with vehicle. 
JWH015 was also effective in reversing the L5NT-induced hypersensitivity when it was 
administered in a cumulative manner two weeks after the cessation of CP5940 treatment 
(washout period). In this case, the minimum and maximum effective dose of JWH015 were 2 
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group). Similar efficacy and potency of JWH015 were observed in both repeated CP55940 
and vehicle groups (Table 2). No significant difference in withdrawal thresholds was 
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spinal CP55940 administration (for 5 days) and a washout period of two weeks. Repeated i.t. 
JWH015 was significantly less effective on the last three days of treatment in animals 
previously exposed to repeated CP55940 when compared to those previously exposed to 
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mechanical withdrawal threshold in the contralateral paw in the repeated vehicle or 
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not modify the withdrawal thresholds ipsilateral (n=6) or contralateral (n=6) to surgery in 
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4. Discussion 
The main findings of our study are: 1) the repeated administration of a non-selective 
cannabinoid agonist (CP55940) induces antinociceptive tolerance and tolerance to 
cannabinoid-induced neurological side effects in a rat model of neuropathic pain; 2) 
CP55940 tolerance persists two weeks after the discontinuation of cannabinoid 
administration; 3) prior induction of CP55940 tolerance reduced the antinociceptive effect of 
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repeated administration of a CB2 receptor agonist (JWH015), but did not alter the 
antinociceptive response to acute JWH015 dose escalation. 
 
 
Fig. 9. Antinociceptive effects of repeated i.t. administration of JWH015 in CP55940-
mediated tolerant animals. Paw withdrawal thresholds indicate responses to von Frey 
stimulation ipsilateral to L5NT (A) or contralateral to surgery (uninjured side, B) two weeks 
after the cessation of repeated CP55940 or vehicle administration (After washout period), 
and 2 hr after each i.t. injection of JWH015 during four consecutive days. Withdrawal 
thresholds on days 1-4 vs. after washout period data significantly differ by repeated 
measures one way ANOVA, *p<0.05 after washout period by repeated measures one way 
ANOVA followed by Tukey's multiple comparison test. Groups significantly differ by two 
way ANOVA; +p<0.05 compared to vehicle group by two way ANOVA followed by 
Bonferroni post tests. 
We demonstrate that a non-selective cannabinoid agonist administered repeatedly at a 
concentration that induces neurological side effects (such as the effects that regular cannabis 
users seek for recreational purposes) is sufficient to produce a long lasting antinociceptive 
tolerance that persists weeks after the cessation of drug exposure. In agreement with these 
findings, diminished psychotropic effects (D'Souza et al., 2008) and analgesic tolerance to 
delta-9-tetrahydrocannabinol (Clark et al., 1981) have been demonstrated in frequent users 
of cannabis. This hypothesis has been further supported by a double-blind, placebo-
controlled study demonstrating evidence of dronabinol tolerance in regular marijuana users 
(Bedi et al., 2010). It has also been shown that repeated administration of CB1 receptor 
agonists results in antinociceptive tolerance in naïve mice and rats (Gardell et al., 2002; 
Hama and Sagen, 2009), and that this tolerance  is dependent on spinal cord mechanisms 
(Gardell et al., 2002). In contrast, we have previously shown that i.t. administration of the 
CB2 receptor agonist JWH015 effectively reverses L5 nerve transection-induced behavioral 
hypersensitivity without antinociceptive tolerance through at least five days of treatment 
(Romero-Sandoval and Eisenach, 2007). Similar findings have been described with another 
CB2 receptor agonist, A-836339 (Yao et al., 2009). Taken together, these previous findings 
suggest that CB1 rather than CB2 receptor agonism is responsible for the antinociceptive 
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tolerance observed in response to CP55940 administration in the current study. Repeated 
administration of CP55940 also induced tolerance to a range of neurological side effects. We 
have previously observed that CP55940-induced neurological side effects are dependent on 
CB1 receptor activation, but not on CB2 receptor activation in rat postoperative and 
neuropathic pain models (Romero-Sandoval and Eisenach, 2007; Romero-Sandoval et al., 
2008a). While these findings support the potential role of CB1 receptors in cannabinoid 
induced tolerance in our neuropathic pain model, CB1 receptor agonism does not induce 
antinociceptive tolerance in a spinal cord injury model (Hama and Sagen, 2009). Therefore, 
agonism of both CB1 and CB2 receptors may be required to induce antinociceptive tolerance 
to cannabinoid therapies in animals or patients with peripheral or central nerve injury. 
CB1 receptor-dependent cross-tolerance among cannabinoids has recently been described 
between delta-tetrahydrocannabinol (the active ingredient of cannabis) and anandamide 
(one of the major endocannabinoids) (Falenski et al., 2010), and between 2-
arachidonylglycerol (another major endocannabinoid) and the CB1 receptor agonist 
WIN55,212-2 (Schlosburg et al., 2010). This cross-tolerance is thought to be CB1-dependent 
(Falenski et al., 2010). However, we demonstrate in our current study that repeated 
administration of JWH015 exhibited reduced efficacy in rats with peripheral nerve injury 
that have been previously exposed to a non-selective cannabinoid agonist. This finding 
directly contrasts with our previous observation that repeated JWH015 reduces L5NT-
induced hypersensitivity without signs of tolerance in the same rat model of neuropathic 
pain (Romero-Sandoval et al., 2008a). Taken together, these findings indicate that 
cannabinoid antinociceptive tolerance to non-selective cannabinoid agonists affects 
subsequent responsiveness of both CB1 and CB2 receptors. We also observed that CB1 
receptors are predominantly expressed in neurons and that CB2 receptors are 
predominantly expressed in microglia in the spinal cord of both sham surgery and L5NT 
groups. Therefore, neuronal and glial interactions may contribute to the effects of CP55940-
induced tolerance on JWH015’s antinociceptive effectiveness. 
Cannabinoid tolerance depends on CB receptor availability (Tappe-Theodor et al., 2007; 
Martini et al., 2010) and/or sensitivity (Jin et al., 1999; Selley et al., 2004). These receptor 
properties may change following peripheral insults such as paw incision (Alkaitis et al., 
2010), peripheral nerve injury (Lim et al., 2003) or sustained activation by endogenous 
(Falenski et al., 2010; Schlosburg et al., 2010) or exogenous cannabinoids (Gardell et al., 2002; 
Hama and Sagen, 2009). In accordance with our findings, others have shown that a single 
intracerebroventricular dose of CB1 receptor agonists (WIN55,212-2 or ACEA) induces 
antinociceptive tolerance that lasts for more than 14 days through actions on the pertussis 
toxin-insensitive G proteins, Gz (Garzon et al., 2009). The mechanisms involved in long 
lasting CB1 receptor-mediated tolerance may also include the persistent cellular 
internalization or degradation of CB1 receptor (Sim-Selley et al., 2006). These data suggest 
that cannabinoid responsiveness and tolerance are shaped by a number of factors including 
type of pain or injury, exposure to endogenous or exogenous cannabinoids and receptor 
expression and sensitivity. 
5. Conclusion 
We demonstrate that a non-selective cannabinoid drug induces tolerance under neuropathic 
pain conditions, that this tolerance persists several weeks after the suspension of the 
treatment and that this tolerance affects the antinociceptive effects of repeated 
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repeated administration of a CB2 receptor agonist (JWH015), but did not alter the 
antinociceptive response to acute JWH015 dose escalation. 
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tolerance observed in response to CP55940 administration in the current study. Repeated 
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that cannabinoid responsiveness and tolerance are shaped by a number of factors including 
type of pain or injury, exposure to endogenous or exogenous cannabinoids and receptor 
expression and sensitivity. 
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We demonstrate that a non-selective cannabinoid drug induces tolerance under neuropathic 
pain conditions, that this tolerance persists several weeks after the suspension of the 
treatment and that this tolerance affects the antinociceptive effects of repeated 
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administration of a CB2 receptor agonist. These findings suggest that potential future 
analgesic drugs based on selective actions on CB2 receptor may not be a good alternative for 
long-term treatment in patients previously exposed to chronic cannabinoids. These results 
build on previous published data demonstrating that central CB1 receptor-mediated 
tolerance enhances tolerance to opioids (Trang et al., 2007; Garzon et al., 2009) and non-
steroidal anti-inflammatory agents (Anikwue et al., 2002). Further research is needed to 
determine the mechanisms for this broad cross-tolerance among distinct drug classes. 
Additional studies are also warranted to determine whether patients with histories of 
cannabis or cannabinoid-based drug use for recreational or medical purposes demonstrate 
tolerance to common analgesic therapies. 
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1. Introduction 
Accompanied by the work from innovative physician researchers and biomedical engineers 
who introduced new techniques and devices to expand armamentariums in interventional 
pain medicine in the 1990s and 2000s, the first decade of the 21st century resulted in a 
significant rise in the number of interventional procedures performed for pain management. 
For example, data from the Centers for Medicare and Medicaid Services shows a 518% 
increase from 1997 through 2006 in the Medicare population receiving spinal cord 
stimulation therapy (Manchikanti et al., 2009). Other examples include the efforts to design 
radiofrequency probes to target the sacroiliac joint and subsequently denervate this 
relatively complex but biomechanically unique structure with as little local tissue trauma as 
possible (Wininger, 2010); or the application of novel neuromodulation techniques to treat 
challenging cases of headache (Deshpande & Wininger, 2011). 
The use of ionizing radiation for image construction (x-ray imaging) continues to be the 
standard in image guidance at many interventional pain medicine centers. Hence, the 
competent use of x-radiation not only benefits patients as well as physicians and ancillary 
staff in close proximity to the patient at the time of treatment—but from a health physics 
point of view also yields benefits for the general population given that recent evidence 
points to an overall increase in the use of radiation in medicine (Fazel et al., 2009; U.S. 
National Academy of Sciences, 2006). As of 2007, for example, medical sources of radiation 
represented the primary source of radiation exposure in the United States. Comparatively 
speaking, natural sources accounted for 3.0 mSv of the total dose, whereas medical sources 
accounted for 3.2 mSv (which was 5.9 times higher when compared to benchmark figures 
from 1980). The increase was primarily due to increased use of computed tomography (CT) 
and nuclear medicine studies. Note that medical sources were delineated as follows: 1.5 mSv 
from CT, 0.7 mSv from nuclear medicine, 0.6 mSv from radiography, and 0.4 mSv from 
interventional radiology (Johnston et al., 2011). 
This chapter is intended to serve as a reference to help guide interventional pain physicians 
in their decision-making process concerning radiation risk management. In this context, the 
subject matter goes beyond the traditional emphasis placed solely on the cardinal rules of 
radiation safety (i.e., time, distance, and shielding) to render a systematic review of the 
different interventional imaging modalities used in the treatment of pain, namely 
fluoroscopy, CT, and ultrasound. Notably, we will center our discussion on the so-called 
 
Pain Management – Current Issues and Opinions 
 
122 
Tappe-Theodor, A., Agarwal, N., Katona, I., Rubino, T., Martini, L., Swiercz, J., Mackie, K., 
Monyer, H., Parolaro, D., Whistler, J., Kuner, T., & Kuner, R. (2007). A molecular 
basis of analgesic tolerance to cannabinoids. J Neurosci, Vol. 27, No. 15, pp. 4165-
4177 
Trang, T., Sutak, M., & Jhamandas, K. (2007). Involvement of cannabinoid (CB1)-receptors in 
the development and maintenance of opioid tolerance. Neuroscience, Vol. 146, No. 3, 
pp. 1275-1288 
Wade, DT., Makela, P., Robson, P., House, H., & Bateman, C. (2004). Do cannabis-based 
medicinal extracts have general or specific effects on symptoms in multiple 
sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. 
Mult Scler, Vol. 10, No. 4, pp. 434-441 
Yao, BB., Hsieh, G., Daza, AV., Fan, Y., Grayson, GK., Garrison, TR., El Kouhen, O., Hooker, 
BA., Pai, M., Wensink, EJ., Salyers, AK., Chandran, P., Zhu, CZ., Zhong, C., Ryther, 
K., Gallagher, ME., Chin, CL., Tovcimak, AE., Hradil, VP., Fox, GB., Dart, MJ., 
Honore, P., & Meyer MD. (2009). Characterization of a cannabinoid CB2 receptor-
selective agonist, A-836339 [2,2,3,3-tetramethyl-cyclopropanecarboxylic acid [3-(2-
methoxy-ethyl)-4,5-dimethyl-3H-thiazol-(2Z)-ylidene]-amide], using in vitro 
pharmacological assays, in vivo pain models, and pharmacological magnetic 
resonance imaging. J Pharmacol Exp Ther, Vol. 328, No. 1, pp. 141-151 
7 
Applied Radiologic Science in the Treatment  
of Pain: Interventional Pain Medicine 
Kevin L. Wininger1,2 
1Orthopaedic & Spine Center, Columbus, Ohio  
2Otterbein University, Westerville, Ohio 
USA 
1. Introduction 
Accompanied by the work from innovative physician researchers and biomedical engineers 
who introduced new techniques and devices to expand armamentariums in interventional 
pain medicine in the 1990s and 2000s, the first decade of the 21st century resulted in a 
significant rise in the number of interventional procedures performed for pain management. 
For example, data from the Centers for Medicare and Medicaid Services shows a 518% 
increase from 1997 through 2006 in the Medicare population receiving spinal cord 
stimulation therapy (Manchikanti et al., 2009). Other examples include the efforts to design 
radiofrequency probes to target the sacroiliac joint and subsequently denervate this 
relatively complex but biomechanically unique structure with as little local tissue trauma as 
possible (Wininger, 2010); or the application of novel neuromodulation techniques to treat 
challenging cases of headache (Deshpande & Wininger, 2011). 
The use of ionizing radiation for image construction (x-ray imaging) continues to be the 
standard in image guidance at many interventional pain medicine centers. Hence, the 
competent use of x-radiation not only benefits patients as well as physicians and ancillary 
staff in close proximity to the patient at the time of treatment—but from a health physics 
point of view also yields benefits for the general population given that recent evidence 
points to an overall increase in the use of radiation in medicine (Fazel et al., 2009; U.S. 
National Academy of Sciences, 2006). As of 2007, for example, medical sources of radiation 
represented the primary source of radiation exposure in the United States. Comparatively 
speaking, natural sources accounted for 3.0 mSv of the total dose, whereas medical sources 
accounted for 3.2 mSv (which was 5.9 times higher when compared to benchmark figures 
from 1980). The increase was primarily due to increased use of computed tomography (CT) 
and nuclear medicine studies. Note that medical sources were delineated as follows: 1.5 mSv 
from CT, 0.7 mSv from nuclear medicine, 0.6 mSv from radiography, and 0.4 mSv from 
interventional radiology (Johnston et al., 2011). 
This chapter is intended to serve as a reference to help guide interventional pain physicians 
in their decision-making process concerning radiation risk management. In this context, the 
subject matter goes beyond the traditional emphasis placed solely on the cardinal rules of 
radiation safety (i.e., time, distance, and shielding) to render a systematic review of the 
different interventional imaging modalities used in the treatment of pain, namely 
fluoroscopy, CT, and ultrasound. Notably, we will center our discussion on the so-called 
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“imaging (or ‘viewing’) chain” of each modality, and thus the issues surrounding image 
quality and signal processing relative to radiation exposure (or the lack thereof in the case of 
ultrasound imaging). Moreover, to develop a fundamental understanding of signal 
processing, key physical and mathematical concepts will be explored. 
While this chapter is well-motivated allowing each section to stand alone, the subject matter 
is presented in such a way to promote continuity from one section to the next. We begin by 
focusing on fluoroscopic guidance; here analysis has been included to help establish 
benchmark radiation exposure for spinal cord stimulation procedures as first reported by 
Wininger et al. (2010). We then look closely at interventional approaches in pain medicine 
that utilize CT. Throughout these sections, ways to mitigate radiation dose will be 
considered, including recent steps to improve the shielding afforded by radiation protection 
apparel. Next, we provide an overview on ultrasound-guided pain medicine; here the 
tradeoff between spatial resolution and achievable depth of imaging is highlighted. Finally, 
future directions in image guidance for pain management will be surveyed, including non-
ionizing radiation emitting modalities such as ultrasound imaging beyond regional 
anesthesia and interventional magnetic resonance imaging. 
2. Fluoroscopy and interventional pain medicine 
2.1 The fluoroscopic imaging chain 
Overall radiographic quality is based on two principal properties, photographic quality (i.e., 
visibility of detail) and geometric quality (i.e., sharpness of detail) (Carlton & Adler, 2006; 
Bushong, 2004). Photographic quality is determined by density and contrast, whereas 
geometric quality is governed by recorded detail (i.e., resolution) and image distortion. In 
fluoroscopic image acquisition, the term “density” (a term derived from static film-based 
radiography) is replaced by the term “brightness” to be congruent with the language used to 
describe the visibility of images on a display monitor. The notion of an imaging chain makes 
reference to highly integrated instrumentation (together with the patient), regardless of the 
modality of interest. The fluoroscopic imaging chain denotes the x-ray generator, x-ray tube, 
collimator and filtration, table and patient, grid, image intensifier, optical coupler, and the 
image viewing system (Schueler, 2000). To this end, while each link in the chain is of equal 
importance, an understanding of fluoroscopic image quality relative to the image intensifier 
will be emphasized. The image intensifier functions as a “pass-through” device by converting 
x-rays to light (fluorescence) and then to electrons by way of its input phosphor-screen with 
adjoined photocathode backing (see Figure 1). This design effectively and efficiently reduces 
overall radiation exposure (Wang & Blackburn, 2000), and at the same time, allows physicians 
to dynamically view anatomy with a relatively high degree of resolution due to the total 
brightness gain. It is the ability to view dynamically with excellent image resolution—that 
underpins the role of fluoroscopy in many of the modern disciplines of medicine. 
The potential for x-rays to penetrate an object (i.e., soft tissue or bone) and create an image is 
related to the quality of the x-ray beam as a result of the operating kilovoltage (kV) at the x-
ray tube, and may simply be referred to as the “x-ray tube intensity,” “tube intensity,” or 
“tube potential.” The amount of x-rays produced is related to tube current (in milliamperage 
(mA)) and time (in seconds (s)). Whereas the operator presets these factors in static film-
based radiography, producing kilovoltage peak (kVp) and milliamperage seconds (mAs) 
upon exposure, this is not commonplace in fluoroscopic imaging due to automatic 
brightness control and real-time intended-use. Automatic brightness control is a type of 
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automated “negative feedback” commonly set by most operators to ensure a proper amount 
of x-rays in order to image patients with thin to average body types. Because of its real-time 
imaging capability, extended exposure times are possible when operating fluoroscopy 
systems, and thus, the amount of tube current is substantially less compared to that used in 
static film-based radiography, 1 to 5 mA versus 100 to 500 mA, respectively (Carlton & 
Adler, 2006; Bushong, 2004). However, the physician has likely encountered degradation of 
recorded detail while using fluoroscopy due to a blotchy or grainy appearance that is 
directly related to an insufficient amount of radiation to create a uniform image (a 
phenomenon common to all electromagnetic imaging modalities) (Carlton & Adler, 2006). 
This is referred to as quantum noise or quantum mottle, as “quantum” means counted or 
measured. According to Carlton and Adler (2006): 
With fluoroscopy, the time factor is controlled by the length of time the eye can integrate, 
or accumulate, light photons from the fluoro imaging chain. Because this period is 0.2 
seconds, fluoroscopy must provide sufficient photons, through mA, to avoid mottle. 
Quantum mottle is also a large part of video noise and is a special problem during 
fluoroscopy because the units operate with the minimum number of photons possible to 
activate the fluoro screen. The factors that influence mottle are those that affect the total 
number of photons arriving at the retina of the eye. This includes radiation output, beam 
attenuation by the subject, the conversion efficiency of the input screen, minification gain, 
flux gain, total brightness gain, viewing system, and the distance of the eye from the 
viewing system. Increasing the efficiency of any of these factors can assist in reducing 
quantum mottle, but the most common solution is to increase the fluoro tube mA. 
 
 
Fig. 1. Inside the image intensifier tube, x-rays photons are converted to light photons at the 
input screen and then to electrons at the photocathode. Flowing through the image 
intensifier tube the electron stream is repelled by the negatively charged electrostatic lenses 
and is attracted to the positively charged anode. Electrons are converted back to light at the 
output screen in order to proceed to the image viewing system. The output quantity of light 
photons is significantly greater than the input quantity of x-ray photons due to total 
brightness gain. 
Image degradation from quantum mottle not only presents patient safety concerns due to 
challenges surrounding needle placement, particularly in patients with hypersthenic body 
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“imaging (or ‘viewing’) chain” of each modality, and thus the issues surrounding image 
quality and signal processing relative to radiation exposure (or the lack thereof in the case of 
ultrasound imaging). Moreover, to develop a fundamental understanding of signal 
processing, key physical and mathematical concepts will be explored. 
While this chapter is well-motivated allowing each section to stand alone, the subject matter 
is presented in such a way to promote continuity from one section to the next. We begin by 
focusing on fluoroscopic guidance; here analysis has been included to help establish 
benchmark radiation exposure for spinal cord stimulation procedures as first reported by 
Wininger et al. (2010). We then look closely at interventional approaches in pain medicine 
that utilize CT. Throughout these sections, ways to mitigate radiation dose will be 
considered, including recent steps to improve the shielding afforded by radiation protection 
apparel. Next, we provide an overview on ultrasound-guided pain medicine; here the 
tradeoff between spatial resolution and achievable depth of imaging is highlighted. Finally, 
future directions in image guidance for pain management will be surveyed, including non-
ionizing radiation emitting modalities such as ultrasound imaging beyond regional 
anesthesia and interventional magnetic resonance imaging. 
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fluoroscopic image acquisition, the term “density” (a term derived from static film-based 
radiography) is replaced by the term “brightness” to be congruent with the language used to 
describe the visibility of images on a display monitor. The notion of an imaging chain makes 
reference to highly integrated instrumentation (together with the patient), regardless of the 
modality of interest. The fluoroscopic imaging chain denotes the x-ray generator, x-ray tube, 
collimator and filtration, table and patient, grid, image intensifier, optical coupler, and the 
image viewing system (Schueler, 2000). To this end, while each link in the chain is of equal 
importance, an understanding of fluoroscopic image quality relative to the image intensifier 
will be emphasized. The image intensifier functions as a “pass-through” device by converting 
x-rays to light (fluorescence) and then to electrons by way of its input phosphor-screen with 
adjoined photocathode backing (see Figure 1). This design effectively and efficiently reduces 
overall radiation exposure (Wang & Blackburn, 2000), and at the same time, allows physicians 
to dynamically view anatomy with a relatively high degree of resolution due to the total 
brightness gain. It is the ability to view dynamically with excellent image resolution—that 
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(mA)) and time (in seconds (s)). Whereas the operator presets these factors in static film-
based radiography, producing kilovoltage peak (kVp) and milliamperage seconds (mAs) 
upon exposure, this is not commonplace in fluoroscopic imaging due to automatic 
brightness control and real-time intended-use. Automatic brightness control is a type of 
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automated “negative feedback” commonly set by most operators to ensure a proper amount 
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systems, and thus, the amount of tube current is substantially less compared to that used in 
static film-based radiography, 1 to 5 mA versus 100 to 500 mA, respectively (Carlton & 
Adler, 2006; Bushong, 2004). However, the physician has likely encountered degradation of 
recorded detail while using fluoroscopy due to a blotchy or grainy appearance that is 
directly related to an insufficient amount of radiation to create a uniform image (a 
phenomenon common to all electromagnetic imaging modalities) (Carlton & Adler, 2006). 
This is referred to as quantum noise or quantum mottle, as “quantum” means counted or 
measured. According to Carlton and Adler (2006): 
With fluoroscopy, the time factor is controlled by the length of time the eye can integrate, 
or accumulate, light photons from the fluoro imaging chain. Because this period is 0.2 
seconds, fluoroscopy must provide sufficient photons, through mA, to avoid mottle. 
Quantum mottle is also a large part of video noise and is a special problem during 
fluoroscopy because the units operate with the minimum number of photons possible to 
activate the fluoro screen. The factors that influence mottle are those that affect the total 
number of photons arriving at the retina of the eye. This includes radiation output, beam 
attenuation by the subject, the conversion efficiency of the input screen, minification gain, 
flux gain, total brightness gain, viewing system, and the distance of the eye from the 
viewing system. Increasing the efficiency of any of these factors can assist in reducing 
quantum mottle, but the most common solution is to increase the fluoro tube mA. 
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habitus, but can also be a concern to the interventional pain physician and staff members 
inside the fluoroscopy suite, especially when team members are standing near the patient. 
We turn to x-ray attenuation physics to help us better understand this (McKetty, 1998). We 
see that in most fluoroscopically-guided pain procedures, the primary beam is directed at 
bony structures (i.e., material with a large content of calcium atoms, atomic number-20, 
which efficiently attenuates the beam) as opposed to soft tissues (i.e., material containing 
more atoms of carbon, oxygen, and hydrogen, producing an effective atomic number-7.4 
and thus allowing more of the beam to transmit to the image intensifier). Moreover, Table 1 
lists differences in the atomic numbers and densities of matter found in the makeup of the 
human body. It follows that in order to compensate for the attenuated beam within the 
field-of-view for bony imaging compared to soft tissue imaging, radiation output ramps up 
either as a result of adjustments to technique factors via automatic brightness control or by 
means of manual technique adjustments or activation of high-fluoro/boost mode by the 
operator. It is also important to note that most manufacturers incorporate an increase in mA 
during pulsed fluoroscopy to maintain equivalent image perception (Mahesh, 2001). With 
this in mind, a study on perceptual comparison between pulsed and continuous fluoroscopy 
concluded that the average absolute differences in the equivalent-perception dose is 
approximately 3% (Aufrichtig et al., 1994), where the equivalent-perception dose is defined 
as the dose of radiation in pulsed mode needed to give the visual equivalence in continuous 
mode. Thus, we find, importantly, an average radiation dose savings of 22%, 38%, and 49% 
for pulsed-15 frames per second, pulsed-10 frames per second, and pulsed-7.5 frames per 
second, respectively (Aufrichtig et al., 1994). 
 
Matter Effective Atomic Number 
Density 
(kg/m3) 
Air 7.78 1.29 
Fat 6.46 916. 
Soft Tissue 7.40 n/a 
*Water 7.51 1000. 
Muscle 7.64 1040. 
Spongy Bone 12.31 1650. 
Compact Bone 13.80 1850. 
Calcium 20.00 n/a 
Adapted from Johns & Cunningham, 1983, and Dowd & Tilson, 1999. 
*Note: x-ray output relative to the density of water serves as a baseline measure of x-ray output in the 
original design and calibration of x-ray producing systems as well as many radiation dose models, and 
may still be used to check system standards during annual physics acceptance testing. To this point, CT 
systems assign the number zero to water when calculating voxel/pixel brightness values (see Figure 6, 
CT Numbers and Hounsfield Units). 
Table 1. Differences between matter in the makeup of the human body. 
2.2 The physics of fluoroscopy 
2.2.1 Primary radiation 
When the x-ray tube is activated, electrons are “boiled off” from the wire element (i.e., a thin 
filament of tungsten) to form an electron cloud (see Figure 2). The wire element is 
strategically located opposite from the spinning target anode as part of a built-in concavity 
(of which the rim is slightly more negatively charged to concentrate the electrons in the 
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cloud) on the cathode. The number of electrons boiled off is directly related to the tube 
current. Occurring nearly simultaneously with tube activation, the electrons in the electron 
cloud are forcefully attracted to the target anode due to the potential difference between the 
cathode and anode. The rate of speed and the efficiency of attraction are dependent on the 
potential difference across the tube. When high-speed (incident) electrons strike the target, 
the change in kinetic energy produces only less than 1% of x-rays, with most of the change 
occurring in the form of heat production (99% or greater) (Dowd & Tilson, 1999). More 
specifically, x-rays are generated by two processes. The first process involves the interaction 
of electrons with the nucleus of an atom of tungsten in which the incident electron slows 
down to change direction (called bremsstrahlung, or “braking radiation”). Bremsstrahlung 
radiation is emitted from zero to the maximum energy (operating kV). The second process is 
a collision of the incident electron and an outer shell electron of the tungsten atom. The 
collision knocks the outer shell electron out of orbit (producing characteristic radiation). 
Characteristic radiation is the term used to reference the fact that the x-ray energy produced 
is related to the binding energy between the outer shell electron and the nucleus of the 
target atom, and is always the same for a specific target atom (again, tungsten in the case of 
x-ray production in fluoroscopy) (Dowd & Tilson, 1999). 
 
 
Fig. 2. A closer look inside the x-ray tube. When tube current is applied the filament heats 
up to boil off electrons into a cloud. X-rays are produced as the tube potential forces the 
incident (free) electrons to strike the target on the anode at a high-speed. 
2.2.2 Secondary radiation—the patient as the point source 
When x-ray photons in the primary beam pass through matter, they either pass unaltered 
(transmission) or undergo attenuation. Moreover, attenuated x-ray photons are either 
absorbed (all energy lost and the photon “dies”) or scattered (some energy lost and the photon 
changes direction). The x-ray photons which are absorbed are primarily responsible for patient 
radiation exposure (via the photoelectric effect) and those photons which scatter are 
responsible for occupational radiation exposure (via Compton scattering). Note: when tube 
potential increases the photoelectric effect decreases greatly and the percentage of Compton 
interactions decreases slightly. (Dowd & Tilson, 1999). We will further elucidate the 
significance of the patient as the point source when discussing radiation risk management in 
fluoroscopy (or otherwise briefly stated, the occupational exposure due to secondary radiation 
emanating from the patient due to the interactions between the primary beam and the patient). 
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cloud) on the cathode. The number of electrons boiled off is directly related to the tube 
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potential difference across the tube. When high-speed (incident) electrons strike the target, 
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occurring in the form of heat production (99% or greater) (Dowd & Tilson, 1999). More 
specifically, x-rays are generated by two processes. The first process involves the interaction 
of electrons with the nucleus of an atom of tungsten in which the incident electron slows 
down to change direction (called bremsstrahlung, or “braking radiation”). Bremsstrahlung 
radiation is emitted from zero to the maximum energy (operating kV). The second process is 
a collision of the incident electron and an outer shell electron of the tungsten atom. The 
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Characteristic radiation is the term used to reference the fact that the x-ray energy produced 
is related to the binding energy between the outer shell electron and the nucleus of the 
target atom, and is always the same for a specific target atom (again, tungsten in the case of 
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2.3 Fluoroscopically-guided pain medicine procedures 
Nearly all interventional pain treatments and techniques evolved using fluoroscopic 
guidance. This was, in part, due to the capability of fluoroscopy systems to render high 
resolution images of bony anatomy (and adjacent tissues) to target pain generators. Today, 
with the versatility afforded by mobile C-arms (Tuohy et al., 1997), together with continued 
fidelity of the images rendered, the fluoroscope remains the principal modality for pain 
medicine image guidance. As a resulting consequence of this history, the literature not only 
contains several articles on the pros and cons of imaging techniques (for example, see 
Kapural and Goyle, 2007), but also contains multiple and diverse reports on radiation 
exposure associated with interventional pain procedures. 
Notably, data collected on fluoroscopy time (the traditional metric used for clinical radiation 
management) serves to benchmark performance (Balter, 2006). While this parameter 
(fluoroscopy time) plays an essential role in the development of suitable registries to catalog 
radiation exposure levels according to the different pain procedures being performed, it 
may also be said that it is simply an awareness of this parameter by the physician that is 
inherent to optimization strategies in health physics (Shahabi, 1999). Table 2 presents the 
fluoroscopy times reported for the more common interventional pain medicine procedures 
using mobile multi-directional fluoroscopy systems (i.e., the conventional mobile C-arm). 
Other data noteworthy to collect includes: dose settings employed (operator chosen) and 
patient body mass. It is this additional information along with fluoroscopy time which may 
be used to calculate patient radiation dose received (i.e., entrance skin exposure). Table 3 
shows fluoroscopy time as well as radiation dose using mobile multi-directional systems or 
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TFESI – Cervical 
TFESI – Lumbar 
— — — 12.7 — — Medial Branch Block 
57.2 — 146.8 — — — Discography 
— 133.4 — — — — Spinal Cord Stimulation 
*Wininger et al. also reported calculations on entrance skin exposure. 
Table 2. Fluoroscopy time (in seconds) using mobile multi-directional systems. 
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**without or ***with 3D navigation in vertebroplasty or kyphoplasty procedures. 
Fluoroscopy time (in seconds); patient entrance skin exposure (ESE) and dose area product (DAP, a 
calculation of stochastic risk for the patient [Vano et al., 2001]) (in centiGray); physician total and hand 
exposure (in microSieverts/minute). 
Table 3. Radiation exposure associated with biplanar systems or multi-directional systems.  
Inter-procedural variance compared to fluoroscopy times observed in Tables 2 and 3 may be 
attributed to differences in procedural techniques, level of experience, and/or physician 
preferences in imaging assistance, as well as attenuation physics relative to image quality. 
To illustrate this last point, we consider spinal imaging. During spinal imaging, two 
common challenges associated with image quality exist: 1) highly radiolucent vertebral 
bodies, particularly against the imaged lung field, creating excess image brightness in the 
region of interest, and 2) large body habitus with resultant poor image quality. In the 
former, tight collimation with the paired leaves shutters drawn close to the spine and 
continuous-mode imaging may help compensate for poor contrast resolution due to the 
vertebral bodies lacking enough cortical bone density to effectively attenuate the beam (i.e., 
low beam attenuation) (Johns & Cunningham, 1983). Subsequently, overriding automatic 
brightness control by manually ramping down tube current (mA) during tightly collimated 
bony imaging can help improve image resolution, especially for extremely radiolucent 
vertebral bodies. Alternatively, a manual adjustment to monitor/display window contrast 
may effectively improve image quality. To compensate for poor image quality secondary to 
large body habitus (i.e., a highly attenuated beam with resultant image granularity), it too 
may be necessary to operate the fluoroscope in continuous mode to increase the overall 
radiation at the image intensifier rather than disengaging the low dose feature. This strategy 
may improve image contrast while limiting patient exposure if a “manual beam on/off” 
operator technique is used, e.g., while panning or moving the C-arm between 
anteroposterior/oblique positioning to keep region of interest in the field of view. 
2.4 Radiation risk management/safety 
In recent years the assessment of radiation dose has received increased scrutiny; notably, the 
evaluation of deterministic effects, for which the severity of effects will vary according to the 
dose received and for which dose thresholds usually exist (e.g., radiation induced skin 
injuries) (Balter, 2006 & 2008). Moreover, dose assessment has seemingly evolved from an 
academic enterprise to a clinical endeavour. Direct influence on clinical practice is 
appreciated by The Joint Commission’s recent decision to add unexpectedly prolonged 
fluoroscopic exposure to its list of reviewable sentinel events, as well as their suggestion to 
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In recent years the assessment of radiation dose has received increased scrutiny; notably, the 
evaluation of deterministic effects, for which the severity of effects will vary according to the 
dose received and for which dose thresholds usually exist (e.g., radiation induced skin 
injuries) (Balter, 2006 & 2008). Moreover, dose assessment has seemingly evolved from an 
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fluoroscopic exposure to its list of reviewable sentinel events, as well as their suggestion to 
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follow-up qualifying events with a period of over six-months to one-year to monitor 
cumulative skin dose (The Joint Commission, n.d.). While fluoroscopy time alone provides 
inadequate skin dose estimates (Balter, 2006; Balter, 2008), the evaluation of incident air 
kerma (x-ray exposure to the skin, previously referred to as entrance skin exposure) is 
possible by simplistic modeling (Balter, 2008; American Association of Physicists in 
Medicine (AAPM), 2001; Bushong, 2004). 
In part with its approach to minimally invasive treatments and therapeutic procedures, 
interventional medicine is the one branch of medicine which, in its practice, is riddled with 
concepts that stem from physics. It may be further stated that physicians, even 
interventionally-trained physicians, may feel as though they are not able to translate 
applicable literature into everyday practice without possessing a doctorate in the physical 
sciences. For example, radiation dose models can be complicated as there exists many 
nuances when talking about dose, and the units of measure are not intuitive. However, both 
radiation safety and radiation protection are fundamental considerations for the 
interventional pain physician, and are equally paramount responsibilities in the 
interventional pain practice. In the view of the author, physicians who utilize fluoroscopic 
guidance will find that keeping radiation exposure, and therefore radiation dose, as low as 
reasonably achievable (given the acronym ALARA) is a challenge that is not 
insurmountable. This goal is achieved by exploitation of the principles unique to image 
acquisition in fluoroscopy, together with radiologic physics and applied radiobiology 
(Dowd & Tilson, 1999), and a suitable quality assurance program. Thus, by first laying out 
the conversion between the basic units of measure in radiation physics, 
 
this section will strive to provide the interventional pain physician with information on 
radiation risk management which may be readily acted on and implemented. 
Entrance skin exposure is the radiation exposure to the skin measured in Roentgen (R) or 
milliRoentgen (mR) at the point of skin entrance for the nominal patient (i.e., 30 cm from the 
image intensifier). The measurement is made without the contributions from scatter radiation. 
In compliance with physics acceptance testing, the fluoroscopic tube potentials (kVp) under 
automatic brightness control should operate at/or between 70 and 90 kVp with 3.8 cm of 
aluminum (~15 cm of water or acrylic plastic) attenuation material. This produces measured 
fluoroscopic exposure rates in the range of 1.0 to 4.0 R/minute for all magnification modes 
(fields of view) for continuous mode in the normal dose setting (AAPM, 2001; Bushong, 2004). 
The lower portion of the exposure range accounts for the largest field of view (least 
magnification), and the upper portion of the exposure range accounts for the smallest field of 
view (most magnification). The name of the quantity which corresponds to entrance skin 
exposure and which is recognized by the International Commission on Radiation Units and 
Measurements is incident air kerma (Balter, 2008), and the unit of measurement is milligray 
(mGy). (Note: 1 R = 1 Roentgen = 2.58 × 10-4 coulombs/kg-m of air at standard temperature 
and pressure, and 1 R = 8.76 mGy [milligray].) 
The dedicated use of the low dose setting (which provides 40% or more dose reduction 
compared to the normal dose setting, Smiddy et al., 1996; Davies et al., 2006), when paired 
with pulsed fluoroscopy (which provides 50% dose reduction at 7.5 frames per second, 
Aufrichtig et al., 1994) promotes optimal radiation risk management. This impact is best 
observed by a closer inspection of the work by Wininger et al. (2010) on radiation exposure 
in spinal cord stimulation [trialing] procedures. The authors point out that although pulsed 
 
Applied Radiologic Science in the Treatment of Pain: Interventional Pain Medicine 131 
fluoroscopy was utilized differently during cases #3 and #43, the fluoroscopy time for each 
case was recorded as 198.9 seconds. Analysis between actual settings used and hypothetical 
use variances for the low dose setting and the pulsed mode feature, based on simplistic 
modeling, illustrated how fluoroscopy time alone may lead to inadequate skin dose 
assessments. In other words, analysis of incident air kerma derived from the actual settings 
revealed that case #43 incurred 39.4% more skin exposure than case #3. Hypothetically, if 
neither the low dose feature nor pulsed fluoroscopy had been utilized, the resultant incident 
air kerma (i.e., 38.7 mGy) would have approximated the actual estimates derived for 
fluoroscopy times greater than 300 seconds (i.e., approximately double) for this procedure 
(i.e., 25.7–43.7 mGy). However, because the earliest deterministic threshold is 2.0 Gy, the 
level associated with transient erythema (Geleijns & Wondergem, 2005), research indicates 
that induction of deterministic insults (such as skin injuries) is highly unlikely during 
interventional pain medicine procedures. Rather, in interventional pain medicine, the prime 
objective is to safeguard to the degree possible (i.e., ALARA) against low doses of x-radiation (U.S. 
National Academy of Sciences, 2006; Little et al., 2009). 
With respect to quality assurance programs for fluoroscopy systems, it is important to 
address mechanical and electrical safety in addition to radiation safety and image quality. 
Moreover, such programs are particularly important for mobile systems due to the various 
uses and locations in which these units are intended to perform. Given that mobile units are 
often the more commonly utilized systems in pain management applications, a quality 
assurance protocol is essential. However, due to differences between mobile systems from 
the various manufacturers, as well the different regulations overseeing radiologic licensure 
in the various jurisdictions the reader finds him- or herself in, an outline of such program is 
beyond the scope of this chapter. The reader is, therefore, referred to Tuohy et al. (1997) who 
tackled these issues and made several key recommendations. 
Reports on occupational incurred dose from scatter radiation are typically based on 
radiation exposure to standardized phantoms, thus representing the symmetrical ideal 
“small lumbar” spine. This methodology, however, may potentially underestimate the 
amount of occupational radiation exposure since body habitus does not always lend itself to 
symmetry and body size varies from patient to patient. Hence, Whitworth (n.d.) performed 
scatter radiation vector analysis on the lumbar spines of five cadavers to better parallel the 
general experience of the interventional pain physician and those team members inside the 
fluoroscopy suite. The study employed an OEC 9800 mobile C-arm with automatic 
brightness control engaged. Radiation exposure was recorded using Geiger Mueller 
techniques (measurements are shown in Table 4). 
 
OEC 9800 mrem/hour kV  mA 
High Level/Boost Fluoro 204 71 3.9 
Normal Dose 111 70 2.2 
Low Dose 56 72 0.76 
Low Dose + Collimation 15 74 0.82 
Pulsed-8 frames per second 7 76 0.86 
Meter set at 17 inches above the floor and 12 inches lateral to the image intensifier. 
Table 4. Scatter radiation measurements: imaging the lumbar spine of a cadaver with 21.5 
body mass index. 
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fluoroscopy was utilized differently during cases #3 and #43, the fluoroscopy time for each 
case was recorded as 198.9 seconds. Analysis between actual settings used and hypothetical 
use variances for the low dose setting and the pulsed mode feature, based on simplistic 
modeling, illustrated how fluoroscopy time alone may lead to inadequate skin dose 
assessments. In other words, analysis of incident air kerma derived from the actual settings 
revealed that case #43 incurred 39.4% more skin exposure than case #3. Hypothetically, if 
neither the low dose feature nor pulsed fluoroscopy had been utilized, the resultant incident 
air kerma (i.e., 38.7 mGy) would have approximated the actual estimates derived for 
fluoroscopy times greater than 300 seconds (i.e., approximately double) for this procedure 
(i.e., 25.7–43.7 mGy). However, because the earliest deterministic threshold is 2.0 Gy, the 
level associated with transient erythema (Geleijns & Wondergem, 2005), research indicates 
that induction of deterministic insults (such as skin injuries) is highly unlikely during 
interventional pain medicine procedures. Rather, in interventional pain medicine, the prime 
objective is to safeguard to the degree possible (i.e., ALARA) against low doses of x-radiation (U.S. 
National Academy of Sciences, 2006; Little et al., 2009). 
With respect to quality assurance programs for fluoroscopy systems, it is important to 
address mechanical and electrical safety in addition to radiation safety and image quality. 
Moreover, such programs are particularly important for mobile systems due to the various 
uses and locations in which these units are intended to perform. Given that mobile units are 
often the more commonly utilized systems in pain management applications, a quality 
assurance protocol is essential. However, due to differences between mobile systems from 
the various manufacturers, as well the different regulations overseeing radiologic licensure 
in the various jurisdictions the reader finds him- or herself in, an outline of such program is 
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tackled these issues and made several key recommendations. 
Reports on occupational incurred dose from scatter radiation are typically based on 
radiation exposure to standardized phantoms, thus representing the symmetrical ideal 
“small lumbar” spine. This methodology, however, may potentially underestimate the 
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symmetry and body size varies from patient to patient. Hence, Whitworth (n.d.) performed 
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Four important concepts were drawn from the resulting data set, as follows: 
 Scatter radiation is exponential with increasing kilovoltage (kV) and linear with 
increasing mA; 
 Collimation reduces scatter radiation by 50% or more; 
 Use of low dose reduces scatter radiation by 50-75%; use of pulsed mode reduces scatter 
radiation by 65-90%; and 
 Scatter radiation drops 50% every 6 inches away from the image intensifier. 
It is interesting to pair the data set obtained by Whitworth with a law in radiophysics which 
aptly describes the phenomenon of scatter radiation in a meaningful way: as kilovoltage 
increases the photoelectric effect decreases greatly and the percentage of Compton 
interactions decreases slightly. Thus, Whitworth actually observed the following. As tube 
potential (kVp) increases, fewer x-rays interact with tissue, and therefore less scatter is 
created. However, the scatter that is created has higher energy and is more likely to reach 
the image intensifier [or nearby dosimeter(s)] than to interact with the patient’s body. This 
makes increased kVp a radiation protection tool that must be counterbalanced with image 





(The Patient as the Point Source) 
Total Number of 
Interactions in 1mm 
Tissue 
Total Number of 
Photoelectric 
Effects 





50 500 (50%) 500 (50%) 1000 
90 165 (33%) 335 (67%) 500 
Adapted from Dowd & Tilson, 1999. 
Table 5. Effects of x-ray tube potential (kilovoltage) on secondary radiation generated. 
In many interventional pain suites, “lead aprons” are the principal shield for radiation 
protection of personnel. In addition, it should be noted that a table skirt substantially 
decreases occupational radiation levels—since the majority of scatter radiation is produced 
under the fluoroscopy table (for fluoroscopes/C-arms with under-table x-ray tubes) in the 
form of backscatter. Thus, significant reduction to scatter radiation is gained from the 
combined pair, as each scattering incidence results in x-radiation energy levels of only 
1/1000 of that prior to the episode (Dowd & Tilson, 1999). Moreover, largely as a 
consequence of complaints of back pain over time from the wearers of lead aprons 
(Christodoulou et al., 2003), lead equivalent aprons became the apron-of-choice among 
interventionalists, and recently, “lead free” aprons have emerged in the marketplace. Such 
alternative materials include tin, iodine, barium, and antimony, or any combination thereof. 
Such “lead free” alternatives offer significant weight reduction, compared to primarily-
leaded aprons, and equivalent radiation protection (Finnerty, 2005) (see Table 6). As part of 
an occupation radiation safety program, it is suggested that the reader ensure annual 
inspections of aprons are performed and rejection criteria established. Practical rejection 
criteria have been offered by Stam and Pillay (2008). 
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It is know that the dominant hand of the interventionalist receives the highest dose of 
radiation. It is interesting to note that a new type of sterilizable, radiation protection glove 
(primarily composed of tungsten) was recently tested among surgeons during a variety of 
cases, including micro-discectomy (Back et al., 2004). In terms of radiation protection, results 
revealed that the glove was superior to all other gloves in the marketplace, attenuating 90% 
of x-rays (see Table 6), and radiation dose to the dominant hand was reduced to less than 
the dose received by the non-dominant hand. 
 
Aprons (0.25 mm) Aprons (0.50 mm) 
 Pure lead 
Lead 
equivalent Pure lead Lead equivalent “Lead-free” 
Attenuation at 70 kVp 





Transmission at 70 kVp  





Attenuation at 100 kVp  







Transmission at 100 kVp  


















90% 65% 57% 32% 25% 
Adapted from Back et al., 2005; Christodoulou et al., 2003; and Clasper & Pinks, 1995. 
Table 6. Radiation protection apparel. 
Risks of cataract development due to radiation exposure to the eyes have been investigated 
in interventionalists, with no conclusive evidence to date. However, the use of lead-based 
glasses is advocated, especially when the risk of “rescatter” (radiation which emanates from 
within the interventionalist’s head, or so-called tertiary exposure) is considered (Cousin et 
al. 1987). As pointed out in a review on exposure risks of interventional pain physicians, 
studies demonstrate a decrease in transmission rates of 70-90% with appropriate eyewear 
(“lead” glasses) ( Fish et al., 2011). Moreover, because it is the patient that is the point source 
of occupational radiation risk coupled with the proximity of the interventional pain 
physician to the patient, positioning the monitor to require the interventionalist to look 90° 
(from the patient) with eyewear with side shields could further help reduce eye exposure. 
As stated by Fish et al. (2011), “…It is extremely vital for the interventionalist to be 
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cognizant of his/her surroundings. This reiterates the importance of increasing the distance 
between the physician and the source of the radiation, it also emphasizes decreasing the 
amount of exposure time, which can both drastically reduce unnecessary radiation via 
scatter.” 
2.5 Special report: Radiation exposure during spinal cord stimulation mapping: A new 
data set 
Summary of Background Data: The increase in exposure to low-dose radiation from the 
growing use of medical imaging has raised concerns about cumulative dose among the 
general population (Fazel et al., 2009; U.S. National Academy of Sciences, 2006; Little et 
al., 2009), and accordingly, dose assessment has received increased scrutiny (Balter, 2008). 
Conversely, unique among implantable devices, some spinal cord stimulation systems 
utilize integrated technology to perform “electronic fluoroscopy” to assess device 
orientation (i.e., the leads) without irradiation (Kosek et al., 2006). Recently, however, a 
first look at radiation exposure from spinal cord stimulation [trialing] procedures was 
published to help benchmark radiation exposure reference levels for this procedure 
(Wininger et al., 2010). Although estimated exposure was negligible, data on patient size 
was unavailable and the source-to-skin distance (SSD) was not taken into account due to 
simplistic modeling. 
Objective: To address the aforementioned limitations, radiation exposure was reexamined 
by the author for a new patient population. 
Methods: 106 dual parallel lead spinal cord stimulation trialing procedures [using either 
multiple-independent current-controlled systems or constant-voltage systems] in the non-
university, outpatient setting, from October 2008 to October 2009, were studied 
prospectively. Body mass index (BMI) measurements were retrieved. The *fluoroscopy 
system automatically tabulated total fluoro-time (in seconds) per case, and partitioned the 
absolute time- and the percentage of time allocated to- pulsed and continuous-mode 
imaging. High dose fluoroscopy, or “boost” mode, was not used. A study specific ‡personal 
dosimeter was worn by the physician. For the dose model, radiation output was measured 
with a §dosimeter/ion chamber located 30 cm from the image intensifier, along the central 
axis of an anteroposterior projected beam, and calculated based on the following equation. 





� 	 • 	 ���� 
Where ESEpat and ESEpha are skin exposure to the patient and †phantom; Opha and Opat are 
radiation output for phantom and patient exposure (in Röentgens); SSDpat and SSDpha are the 
distances from the x-ray source to the skin for the patient and phantom; and tflu is fluoro-
time (converted to minutes). Note: incident air kerma is measured in milligray (mGy) and is 
converted from ESEpat by applying a factor of 8.76 mGy to 1 Röentgen. Incident air kerma 
estimates were stratified according to SSD and low dose mode engaged/disengaged. 
Results: 
Total fluoroscopy time: 
 Mean: 71.7 seconds 
 (standard deviation: 34.9 seconds) 
 Range: 19.5 seconds to 166.6 seconds 
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Percentage pulsed imaging: 
 Mean: 33.4% 
 Range: 1.80% to 75.2% 
 Mode: 55.4% (compiled % most frequent) 
Source-to-skin distance: 
 Mean: not reported 
 Range: 43 cm to 50 cm 
Body mass index: 
 n = 54 females 
 Mean: 31.54 kg/m2 
 Range: 18.46-53.32 kg/m2 
 n = 52 males 
 Mean: 29.65 kg/m2 
 Range: 17.03-42.45 kg/m2  
Incident air kerma: 
 Mean: 8.33 mGy  
 Range: 1.53 mGy to 32.0 mGy  
Physician dosimeter: 
Whole body cumulative dose: 73 mrem 
Discussion: 
1. Figure 3 shows the descriptive statistical summary for fluoroscopy time. Seven outliers 
were identified in each data set. Notably, less variance around the median value 
occurred with the new data (i.e., the interquartile range was reduced by 47.4%). 
2. Accounting for outliers, total fluoroscopy time was normally distributed. 
 Figure 4 compares the grouped subsets—based on one minute intervals. 
3. Mean total fluoroscopy time was 46.3% less (71.7 seconds compared to 133.4 seconds). 
However, it is noted that outliers from the previous data set had not been removed in 
the reporting of that data, and thus mean total fluoroscopy time for the previous data 
set was artificially inflated. 
4. Percentage pulsed imaging was equivalent. 
5. Patient radiation exposure was reduced: 1.53—32.0 mGy compared to 1.8—43.7 mGy. 
6. Patient size ranged from mildly underweight to morbidly obese according to BMI (as 
defined by the World Health Organization, n.d.). The mean BMI, by gender, bordered 
pre-obese and obese. 
 Note: trending increase in body weight among the U.S. population paired with 
concern about cumulative dose trends (Yanch et al., 2009; Fazel et al., 2009) 
underscore the need to obtain accurate reference levels on radiation exposure, as 
such exposure will, in general, be higher for patients with greater body mass. 
7. Estimates for incident air kerma were stratified according to various SSDs, see Figure 5. 
Conclusions:  
Radiation exposure from spinal cord stimulation trialing procedures remains negligible 
despite the likelihood, as suggested here, for this therapy to be used in a patient population 
with a greater risk for increased irradiation based on BMI valuations. 
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Percentage pulsed imaging: 
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the reporting of that data, and thus mean total fluoroscopy time for the previous data 
set was artificially inflated. 
4. Percentage pulsed imaging was equivalent. 
5. Patient radiation exposure was reduced: 1.53—32.0 mGy compared to 1.8—43.7 mGy. 
6. Patient size ranged from mildly underweight to morbidly obese according to BMI (as 
defined by the World Health Organization, n.d.). The mean BMI, by gender, bordered 
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concern about cumulative dose trends (Yanch et al., 2009; Fazel et al., 2009) 
underscore the need to obtain accurate reference levels on radiation exposure, as 
such exposure will, in general, be higher for patients with greater body mass. 
7. Estimates for incident air kerma were stratified according to various SSDs, see Figure 5. 
Conclusions:  
Radiation exposure from spinal cord stimulation trialing procedures remains negligible 
despite the likelihood, as suggested here, for this therapy to be used in a patient population 
with a greater risk for increased irradiation based on BMI valuations. 
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Footnotes: 
*OEC 9800 Super-C, GE Healthcare, Salt Lake City, UT, USA. 
†Phantom: 3.8 cm of aluminum. 
‡Badge report, study specific: Luxel, optically stimulated luminescence dosimetry, 
 LANDAUER, Glenwood, IL, USA. 
§Radiation meter – Model 1515 with converter model 1050U and ion chamber model 10X6-




 Previous data set (n=110) 
Current data set 
(n=106) 
Interquartile Range 98.9 52.0 
Lower Fence -76.6 -30.8 
Upper Fence 319.1 177.2 
   
Outliers 321.1 208.9 
 329.3 217.7 
 336.2 236.3 
 343.8 239.4 
 373.1 294.0 
 387.2 299.7 
 387.4 304.0 
Fig. 3. Box plots comparing previous and current fluoroscopy time data sets for spinal cord 
stimulation mapping procedures. Note: Because all data (both sets) were obtained from the 
same interventional spine team, inter- and intra- procedural variability was minimized. 
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Fig. 4. Bar chart comparing the prior and new data sets with respect to fluoroscopy time 
during percutaneous spinal cord stimulation mapping procedures. 
 
 
Fig. 5. ESEpat to anterior chest: 50 kg. adult patient accounting for one dose reduction feature, 
i.e., the low dose mode, either “on” or “off” for stratified SSDs (either 43 cm or 50 cm) in 
percutaneous spinal cord stimulation mapping. (Note: valuations represent continuous-
mode imaging, no beam collimation.) 
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3. Computed Tomography (CT) and interventional pain medicine 
3.1 The CT imaging chain 
Although the underlying physical concepts are, for the most part, the same (such as x-ray 
production), the CT imaging chain offers a higher level of sophistication compared to the 
imaging chain of fluoroscopy. This is exemplified by the application of mathematical filters 
selected for a desired level of image reconstruction to control signal/quantum noise to 
optimize image quality (Sprawls, 1992), and most commonly applied using high-pass filters 
to control edge artifacts. According to Barnes (1992), while the CT scanner is capable of 
dividing its measurement of tissue attenuation into a range of 4,096 CT numbers, the eye is 
not capable of distinguishing this much detail in an image. The image display of a CT 
scanner represents only 256 levels of gray, which must therefore be mapped onto the 
portion of the Hounsfield scale that is to be displayed. Adjustments called “window level” 
and “window width” are used to define this mapping. Selection of the window level (i.e., 
brightness) specifies the CT number for centering the gray scale, and choice of the window 
width (i.e., contrast) defines the range of CT numbers over which the gray scale is to extend. 
These adjustments can be thought of as defining the “slope” of the gray scale. When the 
gray scale is placed at a window level of 100 and the window width is set at 500, the gray 
scale permits display of CT numbers from -150 to +350. All CT numbers below the lower 
limit of the window width are displayed as black, and all those above the upper limit are 
displayed as white on the image (see Figure 6). 
 
 
Fig. 6. CT Numbers = Hounsfield Units. 
3.2 The mathematics of CT physics 
The language of mathematics not only permeates all scientific study, but the very 
application of mathematics itself allows exploration to occur at the limits-of-discovery to 
find answers to questions that vex human nature. To this end, it is through a mathematical 
framework that physicists talk about dosimetry—with various selected examples on 
dosimetric methods in CT given in Table 7. Moreover, computational models for CT 
scanning enable testing of quality control algorithms to ultimately help reduce overexposure 
errors (Ferreira et al., 2010). This section will serve as a mathematical primer to highlight the 
physics behind image acquisition/signal processing of CT scanning to allow interventional 
pain physicians to gain deeper insight into this modality, and through this appreciation, 
demystify the process of CT imaging. 
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First Author Title of Article Citation: Journal  Year;Volume:Page 
Balter Why (Continue to) Study Physics? Radiographics 1992;12:609 
Rothenberg Radiation Dose in CT Radiographics 1992;12:1225 
McNitt-Gray Topics in CT: Radiation Dose in CT? Radiographics 2002;22:1541 
Bauhs CT Dosimetry: Comparison of Measurement Techniques and Devices Radiographics 2008;28:245 
Huda Converting Dose-Length Products to Effective Dose at CT Radiology 2008;248:995 
Table 7. Select references on the physics of CT appearing in the journals of the Radiological 
Society of North America. 
Although the subject matter on this topic is diverse, no truly rigorous mathematical 
justification of a tomographic algorithm exists (Shepp & Kruskal, 1978).  For this reason a 
generalized derivation (that of inverting the Radon transform, as this is the widely accepted 
technique to describe how we recapture the information lost to attenuated x-ray photons) will 
be described in plain mathematical language. In addition, where noted, Wolfram 
Mathematica—the online computational engine, Wolfram|Alpha™—was used to plot the 
traditional representative line equations of the x-ray photons. It is also important to note that 
in order to simplify the derivation the following three constraints will be made. First, we will 
ignore the playoff between Cartesian and polar coordinate representations, i.e., the 2-
dimensional xy-plane versus spherical or circular symmetry. Second, we will not account for 
adjustments in the derivation for cone beam and/or fan-beam CT constructs due to their 
mathematical complexities (Note: the fan-beam third generation CT scanner, see Figure 7, is 
the most commonly utilized type of scanner.) Finally, discrete numerical analysis will not be  
 
 
Fig. 7. Third generation “fan-beam“ CT scanner. 
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addressed. To this end, the steps necessary to invert the Radon transform with respect to the 
parallel beam model (and thus most enthusiastically applicable to first and second 
generation CT scanners will constitute the balance of this section. It is the hope that such 
insight will complement the physician’s knowledge-base when carrying out CT-guided pain 
procedures. 
The set up 
The underlying theme in this mathematical application is a signal processing challenge, and 
the set up for the analysis is straightforward. We have a 2-dimensional slice of a region of 
variable density (the patient), and the goal as applied to CT scanning is to reconstruct the 
resulting x-ray signal (the image) after repeatedly passing x-rays through the region at 
different angles of initial projection (the CT gantry). More concisely stated, we are 
measuring the resultant signal at different trajectory lines by accumulating (integrating) the 
signal after projecting x-ray photons through the region. Hence, the approach reconstructs 
the densities of the materials interacting with the x-ray photons (Johns & Cunningham, 
1983), to ultimately assign density values according to the Hounsfield unit scale of CT 
numbers for data acquisition/image processing (Jackson & Thomas, 2004). Such modeling 
serves as an engineering template for trouble-shooting in the event of errors, such as 
equipment failure or computer algorithm failures, which may lead to radiation overdose of 
the patient. 
Given that the approach resolves signal processing by means of calculating line integrals to 
recover the intensity of the x-ray signal (i.e., capture the data lost to attenuated or scattered 
x-rays), a comparison may be made to the inverse square law which estimates beam 
intensity from known initial conditions, the intensity of- and distance from- the beam 
(Carlton & Adler, 2006). However, the comparison is rudimentary at best because the central 
and interesting feature of the model applicable here, i.e., the Radon transform and its 
inverse, lies in the fact that we are strictly calculating the intensity of the exit/secondary 
beam based solely on a known intensity of the primary beam. 
It is important to understand that the Radon transform refers to a special case of the Fourier 
transform; and the Fourier transform is a limiting case of the Fourier series (Boyce & 
DiPrima, 2005; Bracewell, 1986). This means whereas a Fourier series is the mathematical 
instrument used when evaluating periodic phenomena (Boyce & DiPrima, 2005), a Fourier 
transform is reserved for the study of phenomena that is nonperiodic (Bracewell, 1986). 
Thus, the choice of the application of a “transform” is an intuitively simple decision, given 
that x-ray photons in the exit beam strike the image receptor in burst-like impulses that are 
mostly nonperiodic rather than periodic in fashion. In mathematical terms, burst-like 
physical phenomena that are almost periodic are known as line impulses. The concept of the 
line impulse will be a key point expanded upon below. 
The derivation of the mathematical model can be relatively easy to follow since the steps 
involved are pragmatic to imaging tasks carried out in the CT suite. We begin by a detailed 
inspection of representative x-ray trajectories relative to the CT gantry (i.e., the family of 
parallel lines), and then compare the suitability of two different proposed coordinate 
systems for the model. 
Lines/family of lines 
Refer to Figure 8 for a depiction of the CT gantry with the x-ray beam drawn as a family of 
parallel lines though the region. Each representative x-ray trajectory (i.e., the parallel lines) 
can be written in the slope-intercept form of a line. 
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In this form, the coordinates of the lines in the xy-plane are the points (m,b), “m” the slope 
of the line and “b” the y-intercept. However, this coordinate system breaks down as “m” 
and “b” vary because the formula is not valid for vertical lines, such that a vertical slope is 
not defined (Larson et al., 2007). Therefore, a more suitable coordinate system is required to 
parameterize a line (and all families of parallel lines), and therefore, it is interesting to look 
at what a family of parallel lines may have in common (see Figure 9). 
 
 
Fig. 8. (Top left) Gantry of CT scanner showing trajectories of x-rays [long arrows] emitted 
as lines/family of parallel lines. (Top right) Illustrated clockwise rotation of the x-ray tube 
inside the gantry. (Bottom left/right) Representative, corresponding line equations written 
in the slope-intercept form y=mx+b in the xy-plane. The (m,b) coordinates are given by the 
line equations. 
Referring to Figure 9, one such identified commonality is that each line has the same angle 
to the horizontal axis, the x1-axis. Thus, we will call this angle, the angle φ (phi). Specifically, 
it is the normal vectors of these lines that have the same angle to the x1-axis. However, to 
better identify locations of lines, we need more than just the angle to the x1-axis. To single-
out a line we look at its distance ρ (rho) from the line passing through the origin (see Figure 
9). Thus, with these parameters, the distance ρ (rho) and the angle φ (phi), we have 
successfully established an unambiguous coordinate system that is not flawed by the non-
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existence issue of a vertical slope. The Cartesian equation of the line for the model, is now 
specified by a given coordinate pair (ρ,φ) in the form: 
 
where both x and n are vectors, each defined in the following way, x=‹x1,x2› and 
n=‹cos(φ),sin(φ)›, and the line equation is derived by vector multiplication, in this case by 




Fig. 9. A better-suited coordinate system (ρ,φ) for the model. (Top panel) Arrow 
demonstrating the unit normal vector associated with the line passing through the origin, 
and oriented with an angle phi (φ) to the x1-axis in the x1-x2 plane. (Bottom panel) A 
family of 3-parallel lines and their unit normal vectors [arbitrarily placed on the lines] 
showing signed distances rho (ρ) from the origin [double ended arrows]. By convention, 
distances are positive [i.e., positive rho (ρ)] when measured in the direction of the normal 
vector from the line passing through the origin to associated parallel lines. In a similar fashion, 
distances are negative [i.e., negative rho (-ρ)] when measured from the line passing through 
the origin to parallel lines spatially existing opposite to the direction established for the normal 
vector. Rho (ρ) is zero at the line passing through the origin. (Note: the unit normal vectors 
are not drawn to scale, and when compared to Figure 8, the xy-plane has been renamed 
the x1-x2 plane.) 
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Line impulse 
Accordingly, it is necessary to account for the nonperiodic nature of the signal concentrated 
along each trajectory taken by the x-ray photons, and this is accomplished by considering 
the line impulse (Bracewell, 1986). The line impulse describes the physical phenomena of x-
ray photons striking the image receptor in the CT gantry. To define the line impulse 
mathematically, we first need to set the Cartesian equation of the line for the model to zero as 
shown. 
 
The resultant equation, specifically the left hand side of the new equation above, then 
becomes a function of delta, denoted by δ, on the right hand side (Bracewell, 1986). 
 
The delta function δ, is the classical way to approach the line impulse, and has 
advantageous implications for dimensionality and integration of a line (Figure 10) 
(Bracewell, 1986). Such line integrals have a domain of infinity on the line and zero off the 




Fig. 10. Expansion of the line integral to an integral of a plane (2-dimensional space) 
containing the line impulse. The above notations of the integrals, L and R2, are understood 
to have domains or “boundaries” from negative infinity (-∞) to infinity (∞). 
The Radon transform 
Equipped with a suitable coordinate system and having addressed the line integral with 
respect to the line impulse, we are ready to introduce the computational steps central to the 
mathematical model, inverting the Radon transform. As we do this, it is important to first 
point out what is varying as we work through the computations, i.e., to identify the 
variables associated with the integrand (those terms being integrated). 
As shown below in Figure 11, superimposition of the useful/suitable coordinate system (as 
described earlier) onto a representative cross-sectional image (the region of interest) will 
help identify the variable. 
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family of 3-parallel lines and their unit normal vectors [arbitrarily placed on the lines] 
showing signed distances rho (ρ) from the origin [double ended arrows]. By convention, 
distances are positive [i.e., positive rho (ρ)] when measured in the direction of the normal 
vector from the line passing through the origin to associated parallel lines. In a similar fashion, 
distances are negative [i.e., negative rho (-ρ)] when measured from the line passing through 
the origin to parallel lines spatially existing opposite to the direction established for the normal 
vector. Rho (ρ) is zero at the line passing through the origin. (Note: the unit normal vectors 
are not drawn to scale, and when compared to Figure 8, the xy-plane has been renamed 
the x1-x2 plane.) 
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Line impulse 
Accordingly, it is necessary to account for the nonperiodic nature of the signal concentrated 
along each trajectory taken by the x-ray photons, and this is accomplished by considering 
the line impulse (Bracewell, 1986). The line impulse describes the physical phenomena of x-
ray photons striking the image receptor in the CT gantry. To define the line impulse 
mathematically, we first need to set the Cartesian equation of the line for the model to zero as 
shown. 
 
The resultant equation, specifically the left hand side of the new equation above, then 
becomes a function of delta, denoted by δ, on the right hand side (Bracewell, 1986). 
 
The delta function δ, is the classical way to approach the line impulse, and has 
advantageous implications for dimensionality and integration of a line (Figure 10) 
(Bracewell, 1986). Such line integrals have a domain of infinity on the line and zero off the 




Fig. 10. Expansion of the line integral to an integral of a plane (2-dimensional space) 
containing the line impulse. The above notations of the integrals, L and R2, are understood 
to have domains or “boundaries” from negative infinity (-∞) to infinity (∞). 
The Radon transform 
Equipped with a suitable coordinate system and having addressed the line integral with 
respect to the line impulse, we are ready to introduce the computational steps central to the 
mathematical model, inverting the Radon transform. As we do this, it is important to first 
point out what is varying as we work through the computations, i.e., to identify the 
variables associated with the integrand (those terms being integrated). 
As shown below in Figure 11, superimposition of the useful/suitable coordinate system (as 
described earlier) onto a representative cross-sectional image (the region of interest) will 
help identify the variable. 
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Fig. 11. Notice what this family of parallel lines has in common, each line has the same angle 
φ (phi) to the x1-axis. Thus, the variable to use with respect to integrating the constituent 
integrals of the Radon transform (and those integrals contributing to the Fourier transform) 
is the distance ρ (rho) of a line from the line passing through the origin. 
Looking at Figure 11, think in terms of what it means to fix φ (phi) and let ρ (rho) vary. This 
means the family of parallel lines will be defined by the angle made with the x1-axis, and 
only the distance of a line from the line going through the origin will be of concern. In other 
words, the angle is fixed, it does not change, allowing ρ (rho) to be the variable as we 
accumulate (integrate) data. Thus, the Radon transform R can now be introduced by 
rewriting the equation from Figure 10 in greater detail (Bracewell, 1986), in relation to the 
signal/function μ (mu), where μ (mu) is a function of ρ (rho) and φ (phi), as shown below. 
Note: in this and the remaining sections, the x-ray signal will be written as the function μ 
(mu). 
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Accordingly, both the line integral L and the double integral above are more concisely 
expressed here than that seen in Figure 10. With respect to the line integral, it is now written 
as a function of ρ (rho) and φ (phi), and the limits of integration (-∞ to ∞) are explicitly 
stated for the double integral. 
As discussed earlier the Radon transform is a special case of the Fourier transform, thus it 
is accurate to write the Fourier transform F with respect to ρ (rho) (denoted by the 
subscript ρ) as a function of the Radon transform R, as seen in the following notation 
(Bracewell, 1986). 
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The significance of this step is that we are now accounting for the spatial domain, denoted 
by the letter “r” in the complex exponential, ������� (Boyce & DiPrima, 2005). In reality, 
the derivation for this mathematical application (as we strive to understand it in the context 
of CT) is concerned with two domains, the spatial domain and the frequency domain, and 
moreover, both are present/available in the complex exponential, 	�������.	 
 
 
Fig. 12. Illustrative drawing to explain the way in which the dimensionality of the model is 
handled as the mathematical derivation unfolds. 
Refer to Figure 12 which shows the critical steps on how dimensionality is dealt with in the 
model. The 1-dimensional component is evaluated first, as described in Figure 12, and is 
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We see that the integral equates to the complex exponential, ��������� ������� �����,	 
which is rewritten after distributing the “r”. 
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To finish simplifying the complex exponential, we introduce the concept of dual variables, 
in that (x1 is paired with ξ1) and (x2 is paired with ξ2), where ξ1 and ξ2 are each constants 
defined in the following way: 
�� � � �����  and    �� � � ���� 
Although it is noted that each of these equalities above suggest implementation of polar 
coordinates (the coordinate system employed for spherical/circular symmetry), they are not 
intended to do so in this derivation. The equalities merely serve as a means to express the 
complex exponential more simply with dual variables, as follows: 
� ���������������� 
It is now important to emphasize what has been derived thus far, and what computational 
steps remain. The above result is the answer to the evaluation of the 1-dimensional integral 
described in Figure 12 (that integral involving the line impulse, which has now been 
computed). The remaining computational steps involve the actual processes to recover the 
values of the densities μ (mu), i.e., to reconstruct the densities from the region, by inverting 
the Radon transform as a function of the Fourier transform over 2-dimensional region. 
Inverting the Radon transform 
To invert the Radon transform, we first plug the result of the 1-dimensional integral  
(as derived above and in bold type face below) back into the original Fourier transform 
which we set up earlier. This is shown below. We now have the 2-dimensional Fourier 
transform of μ (mu), i.e., the double integral, set up to integrate first with respect to ��� and 
then with respect to ���. 





� ������������������������ ��� 
Hence, to best convey the details of the final computation step, it is of certain benefit to 
pause in order to recapitulate the entire mathematical derivation up to this point. 
1. A suitable coordinate system (ρ,φ) was found. 
2. φ (phi) was fixed to let ρ (rho) vary, where φ (phi) is the angle that each line in the 
family of parallel lines makes with the x1-axis, and ρ (rho) represents the values of 
distances of these lines from the line passing through the origin. 
3. The 1-dimensional Fourier transform of the corresponding Radon transform was found 
with respect to ρ (rho), resulting in the 2-dimensional Fourier transform of μ (mu). 
a. In principle the problem is solved. We have measured the Radon transform, i.e., the 
line integral of μ (mu) along the family of parallel lines. 
b. Because we know the 1-dimensional transform expression and the values which 
emerge, those associated with�����2����1�1��2�2��� we can now compute the 
Fourier transform with respect to ρ (rho) (Bracewell, 1986). 
By computing the Fourier transform with respect to ρ (rho), we get the 2-dimensional 
Fourier transform with respect to μ (mu). This means that we can find μ (mu) by taking the 
inverse of the 2-dimensional Fourier transform of what was found: 
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where ����� ���		equals (	����������������), the known values of the 1-dimensional 
Fourier transform. By taking the inverse of the signal/function μ (mu) (we recover the lost 
data contained in the trajectory lines of the x-ray photons passing through the region of 
interest), and we are able to reconstruct the densities of the region (Bracewell, 1986). That is 
to say, we now have μ (mu). In turn, this enables the CT scanner to assign density values 
according to the Hounsfield unit scale of CT numbers for data acquisition/image processing (Jackson 
& Thomas, 2004). 
In summary, the goal of this section was to familiarize interventional pain physicians with 
the equations that ultimately underscore quality control algorithms for CT scanners and 
provide a footprint to build quality assurance protocols for CT scanning to help reduce risks 
of radiation overexposure. Accordingly, the derivation presented here represents the 
mathematical framework employing the parallel beam model. Ideally, to make the model 
practical, and to implement it numerically, discrete versions need to be rooted in the steps 
above, and certain computation issues, such as the playoff between Cartesian and polar 
coordinate representations, need to be dealt with. 
Acknowledgements: The author thanks Stanford University Engineering for open access to 
EE261 The Fourier Transform and Its Applications as taught by Brad Osgood, PhD, as well 
as acknowledges John Labowsky for his technical critique of this section. 
3.3 Triplanar imaging in pain medicine procedures: Conventional-CT guidance and 
CT-fluoroscopy 
In the 1990s conventional-CT guidance began to be used by interventionally-trained pain 
physicians for chronic benign spinal pain (Aguirre et al., 2005; Gangi et al., 1998). During 
this period, algorithms were also developed to establish CT-fluoroscopy, which 
introduced a real-time feature to this modality (Daly & Templeton, 1999). Accordingly, 
CT-fluoroscopy has become a powerful imaging tool (Meleka, 2005). To this point, 
interventional pain techniques have been proposed and studied under this imaging 
technique, such as treatment of coccydynia by targeting the ganglion impar (Datir et al., 
2010) or the efficacy of lumbar sympathetic blocks (Schmid, 2006). Interestingly, the 
literature remains sparse for pain procedure-specific dosimetry reports relative to CT, 
although Table 8 highlights the work in this area by Wagner (2004a, 2004b). In this light, 
the interested reader performing CT-guided pain procedures (or interested in being 
trained for such procedures) may wish to initiate dosimetry studies, since all radiologic 
based procedures should be evaluated specifically and the knowledge gained 
disseminated to help follow ALARA principles for patients and personnel radiation 
exposure (and hence, optimize health physics strategies). 
3.4 Radiation risk management/safety 
While CT-fluoroscopy may decrease patient absorbed dose by 94% compared to 
conventional CT (Meleka et al., 2005), others argue that the radiation exposure may not be 
justified, especially when other modalities can be used which eliminate the need for such 
exposure altogether, such as CT-guided (Thoumas et al., 1999) versus ultrasound-guided 
(Gruber & Bodner, 2004) pudendal nerve blocks. In cases were CT guidance has shown to be 
clearly beneficial, the lower doses associated with CT-fluoroscopy have been attributed to 
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intermittent exposure techniques and/or exposure parameters, such as lower tube current 
(Meleka et al., 2005). Moreover, strategies have also emerged to help reduce occupational 
radiation dose. For example, the use of lead shields, or as previously discussed, the use of 
lead aprons. In addition, the use of needle holders, when feasible during the procedure, 




















 Lumbar Selective Nerve Root Block 
CT-Fluoroscopy Time 
o Patient Effective Dose 













 Lumbar Epidural 
CT-Fluoroscopy Time 
o Effective Dose (Physician/Procedure) 







 Effective Dose (given in microSieverts per second ) 
o Physician Hand 
Key: CT-Fluoroscopy time (in seconds); effective dose (in microSieverts). 
Table 8. CT-Fluoroscopy exposure metrics. 
4. Ultrasound and interventional pain medicine 
4.1 The ultrasound imaging chain 
Continued research in the area of medical imaging has led to the development of compact 
and durable ultrasound scanners with improved imaging capabilities. Nevertheless, the 
basic instrumentation and underlying principles of this modality remain the same. The 
ultrasound imaging chain is considered a “closed” loop made up of the following links: a 
transmitter, a transducer, a receiver, and the image viewing system (Aldrich, 2007). Note 
that the physical phenomenon behind image creation is the piezoelectric effect, or stated 
more explicitly it is the effect on and induced by deformations of piezoelectric crystals 
embedded within materials housed inside the transducer which enables mechanical energy 
to be transformed into ultrasonic impulses—and vice versa for signal processing. 
Upon interaction with tissue, ultrasonic waveforms may be 1) transmitted through the tissue, 
2) undergo reflection (echo) or refraction (bending) at tissue boundaries, or 3) the acoustic 
energy may be attenuated. Surfaces that reflect these sound waves are classified as either 
specular reflectors or scattering reflectors. An example of the former is the needle, whereas an 
example of the latter is the interface between neural and adjacent tissues. Thus, it is the 
reflected sound waves (i.e., the available energy contained in the echoes collected at the 
transducer) which contribute to a meaningful image. Refracted sound waves are those which 
change direction due to slight differences at the boundary (i.e., edge) between two tissue types. 
We note that such waves may not contribute to successful imaging if a significant amount of 
the propagated waveform is lost. Finally, with similarities which evoke comparisons to the 
attenuated x-ray beam, the attenuation of sound beams conveys a loss of energy as the 
ultrasonic waveforms are absorbed by the tissue. According to Sites et al. (2007): 
While attenuation can have a profound negative impact on image quality, there are two 
important adjustments that can be made on the ultrasound machine that help to overcome 
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some of the effects of attenuation. First, most machines allow the operator to artificially 
increase (or decrease) the signal intensity of the return echoes from all points in the 
displayed field. This is accomplished by adjusting the gain control higher to increase the 
overall brightness. Second, most machines offer the operator the ability to control gain 
independently at specified depth intervals. This is known as time gain compensation. The 
time gain compensation should be progressively increased as the depth of penetration 
increases in order to compensate for the corresponding loss of signal intensity. 
It is also interesting to note that attenuation is inversely related to waveform frequency, and that 
this relationship is nontrivial with respect to image resolution (i.e., recorded detail or the 
ability to distinguish between objects) and ultrasound physics. In the following subsection, 
which highlights the physics behind ultrasound imaging, we will further explore this 
relation to better understand the clinical impact of sound wave attenuation. 
4.2 Waveform propagation in tissue: The physics of ultrasound 
Based on waveform physics, that is, frequency, amplitude, and wavelength, the principles of 
ultrasound are unified by the foregoing description. A pulse of sound is emitted from a 
source (i.e., the transducer) and travels outward through a medium. If an object reflects the 
wave, then acoustic energy travels back to the source and is detected as an echo at the 
source. Thus, at a known speed (the speed of sound of the surrounding medium), the 
waveform travels a distance equal to twice the distance from the source to the reflected 
object (Kane, 2009). The basic equation follows: 
� � � ��� � � �� 2⁄  
where L is twice the distance from the source to the object, VS is the speed of sound of the 
surrounding medium, and T is time. Note: the average value of VS in soft tissue is 1540 m/s. 
The ultrasound scanner records the time required for each pulse to return, and then uses the 
speed of sound to calculate the distance of the object. See Figure 13. Echo intensity is indicated 
by plotting a variety of intensities on the monitor subsequent to a gray-scale (white to gray to 
black). Thus, brightness is a consequence of a mapping of echo intensity versus position; hence 
this viewing algorithm/mode is named B-scan, where “B” means brightness. 
 
 
Fig. 13. Panel-A shows a target nerve (or scattering reflector) and direction of travel of 
incident sound waves (white) and echoes (blue). Panel-B shows a zoomed-in view of the 
same nerve to more closely exhibit the reflection of sound waves from near and far tissue 
borders (with respect to the transducer). 
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(Meleka et al., 2005). Moreover, strategies have also emerged to help reduce occupational 
radiation dose. For example, the use of lead shields, or as previously discussed, the use of 
lead aprons. In addition, the use of needle holders, when feasible during the procedure, 
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increase (or decrease) the signal intensity of the return echoes from all points in the 
displayed field. This is accomplished by adjusting the gain control higher to increase the 
overall brightness. Second, most machines offer the operator the ability to control gain 
independently at specified depth intervals. This is known as time gain compensation. The 
time gain compensation should be progressively increased as the depth of penetration 
increases in order to compensate for the corresponding loss of signal intensity. 
It is also interesting to note that attenuation is inversely related to waveform frequency, and that 
this relationship is nontrivial with respect to image resolution (i.e., recorded detail or the 
ability to distinguish between objects) and ultrasound physics. In the following subsection, 
which highlights the physics behind ultrasound imaging, we will further explore this 
relation to better understand the clinical impact of sound wave attenuation. 
4.2 Waveform propagation in tissue: The physics of ultrasound 
Based on waveform physics, that is, frequency, amplitude, and wavelength, the principles of 
ultrasound are unified by the foregoing description. A pulse of sound is emitted from a 
source (i.e., the transducer) and travels outward through a medium. If an object reflects the 
wave, then acoustic energy travels back to the source and is detected as an echo at the 
source. Thus, at a known speed (the speed of sound of the surrounding medium), the 
waveform travels a distance equal to twice the distance from the source to the reflected 
object (Kane, 2009). The basic equation follows: 
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where L is twice the distance from the source to the object, VS is the speed of sound of the 
surrounding medium, and T is time. Note: the average value of VS in soft tissue is 1540 m/s. 
The ultrasound scanner records the time required for each pulse to return, and then uses the 
speed of sound to calculate the distance of the object. See Figure 13. Echo intensity is indicated 
by plotting a variety of intensities on the monitor subsequent to a gray-scale (white to gray to 
black). Thus, brightness is a consequence of a mapping of echo intensity versus position; hence 
this viewing algorithm/mode is named B-scan, where “B” means brightness. 
 
 
Fig. 13. Panel-A shows a target nerve (or scattering reflector) and direction of travel of 
incident sound waves (white) and echoes (blue). Panel-B shows a zoomed-in view of the 
same nerve to more closely exhibit the reflection of sound waves from near and far tissue 
borders (with respect to the transducer). 
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As emphasized in the above subsection, a nontrivial inverse relationship exists between 
attenuation and waveform frequency. We will now look more closely at this relation. 
The most important aspects of ultrasound image resolution are those which govern axial, 
lateral, and temporal resolution—in which all three together comprise spatial resolution. Axial 
resolution is the ability to distinguish two structures at different depths, parallel to the 
direction of the ultrasound beam. Furthermore, it is approximately equal to one half of the 
ultrasound pulse length. In other words, if the distance between two objects is greater than one 
half of the pulse length, then the objects will appear as two distinct structures. It follows that 
higher waveform frequencies (short pulse lengths) produce the best axial resolution. However, 
because of the existing inverse relationship, higher frequency waveforms are more readily 
attenuated, and thus, tissue penetration is sacrificed. Lateral resolution is the ability to 
distinguish two structures at the same depth, perpendicular to the direction of the ultrasound 
beam. High frequency and focused ultrasound beams produce the narrowest beams, thus 
maximizing lateral resolution, but once again tissue penetration is sacrificed. Finally, temporal 
resolution relates to frame rate, and therefore, the ability to distinguish between real-time 
imaging and motion artifacts. During nerve blocks in regional anesthesia for example, motion 
artifacts occur with movement of the probe/transducer, or during needle insertion, or with 
injection of the anesthetic agent. Ultimately, temporal resolution is limited by the sweep speed 
(activation of the piezoelectric crystals) of the ultrasound beam, which in turn is limited by the 
speed of sound in tissue. Attempts to control temporal resolution consist of 1) increasing the 
sweep speed or 2) decreasing the scanning angle (applicable to phased array probes only). The 
first option decreases the lateral resolution, and the second option decreases the field of view. 
Thus, not only do we see an interconnected relationship with respect to image resolution, but 
at present, adjustments available to try to improve resolution are restrained by the laws of 
waveform physics. That is to say, despite the progress made in ultrasound equipment and 
technology (which we will highlight in the accompanying discussion on regional anesthesia), 
ultrasound imaging is, in reality, a tradeoff between spatial resolution and achievable depth of 
imaging (Sites et al., 2007). 
4.3 Ultrasound guidance in pain medicine: Regional anesthesia 
The use of ultrasound for image guidance in regional anesthesia has several practical 
benefits (Sites et al., 2009), the foremost being that ionizing radiation is not necessary for 
image production enabling ultrasound machines to be highly portable. Case series and 
small-scaled outcomes studies with respect to nerve blocks have purported shortened 
procedure times and faster block onset; increased patient satisfaction; and fewer block-
related complications (Marhofer & Chan, 2007). As far as limitations, there are two primary 
considerations: 1) resolution and image quality vary inversely with depth of penetration, as 
previously discussed; and 2) needle tracking for in-plane needle entry is a challenge in part 
because the needle is not visible on the monitor (Marhofer & Chan, 2007). However, with 
respect to in-plane needle tracking, one company (SonoSite, Inc.) has developed an 
ultrasound system to remedy this problem. By sending out a “secondary beam” at a 45° 
angle from the transducer for perpendicular beam-to-needle alignment established outside 
the region of interest, needle visualization is optimized. This enables the physician to see the 
needle’s approach to the target nerve within the field of view. In addition, to help improve 
therapeutic accuracy of ultrasound-guided pain medicine, the ultrasound characteristics of 
needles have been described (Maecken et al., 2007), “echo-friendly” needle designs have 
been developed (Deam, 2007), and the benefits of three-dimensional (3D) ultrasound 
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imaging has been investigated (Feinglass et al., 2007; Foxall, et al., 2007). Moreover, cutting 
edge ultrasonic technological advances have introduced image-enhanced tissue staining to 
remotely palpate the target nerve of interest using acoustic radiation force imaging to both 
improve accuracy and limit variability in regional anesthesia (Palmeri et al., 2008; 
Nightingale et al., 2001). 
4.4 Risk management: Ultrasound safety 
While there are no known absolute contraindications in ultrasound imaging, the position of 
The U.S. Food and Drug Administration (FDA) (n.d.) concerning ultrasound safety follows. 
Ultrasound imaging has been used for over 20 years and has an excellent safety record. 
It is non-ionizing radiation, so it does not have the same risks as x-rays or other types of 
ionizing radiation. Even though there are no known risks of ultrasound imaging, it can 
produce effects on the body. When ultrasound enters the body, it heats the tissues 
slightly. In some cases, it can also produce small pockets of gas in body fluids or tissues 
(cavitation). The long-term effects of tissue heating and cavitation are not known. 
For a more in-depth discussion on tissue sensitivity relative to interpreting risk from 
exposure to ultrasound imaging, the reader is encouraged to study the report on this topic 
issued by members of the World Federation for Ultrasound in Medicine and Biology Safety 
Committee (Barnett et al., 1997). 
5. Future directions in interventional pain medicine 
5.1 *The promise of real-time three-dimensional (3D) fluoroscopy 
While CT-fluoroscopy offers unique viewing perspectives with overall imaging capabilities 
(as discussed in the earlier section, “Triplanar Imaging in Pain Medicine Procedures: 
Conventional-CT Guidance and CT-Fluoroscopy”), interestingly, real-time 3D imaging has 
not been reported. Conversely, although real-time 3D ultrasound has been show to be 
beneficial in regional anesthesia (as cited in the above section, “Ultrasound guidance in Pain 
Medicine: Regional Anesthesia”), ultrasound imaging does not offer the allure that 
fluoroscopy enjoys with respect to image resolution, particularly of bony anatomy. 
Technology is currently available to fit mobile C-arm fluoroscopy systems with 3D imaging 
capabilities (Stübig et al., 2009; Izadpanah et al., 2009; Villavicencio et al., 2005). (Note: 
current fluoroscopy systems creating 3D imagery are limited to 150°—360° with mechanical 
orientation or manipulation or post-processing.) Notably, the limiting factor in the utility of 
these systems under most interventional pain protocols is image construction time. 
However, one company, Imaging3 Inc., claims to have developed signal processing 
algorithms to produce 3D high-resolution fluoroscopic images in real-time via its 
“Dominion” platform. (Note: at the time of this publication, this device has not received 
FDA clearance.) The design is built around a dedicated O-arm—a gantry similar to that used 
in CT—to allow continuous 360° rotation of the x-ray tube and scintillation detector with on-
demand imaging of the patient under continuous or pulsed fluoroscopy. (See the earlier 
discussion on radiation risk management in fluoroscopy to review the advantages of pulsed 
fluoroscopy.) This approach is expected to allow imaging of the patient from any frame of 
reference or angulation. Intended use is anticipated by the company to be procedures in 
which multiple frames of reference are required. From a pain medicine perspective, real-
time 3D fluoroscopic guidance may be possible for discography, vertebral augmentation, 
percutaneous lumbar decompression, facet rhizotomy, or intradiscal electrothermal therapy. 
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imaging has been investigated (Feinglass et al., 2007; Foxall, et al., 2007). Moreover, cutting 
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produce effects on the body. When ultrasound enters the body, it heats the tissues 
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For a more in-depth discussion on tissue sensitivity relative to interpreting risk from 
exposure to ultrasound imaging, the reader is encouraged to study the report on this topic 
issued by members of the World Federation for Ultrasound in Medicine and Biology Safety 
Committee (Barnett et al., 1997). 
5. Future directions in interventional pain medicine 
5.1 *The promise of real-time three-dimensional (3D) fluoroscopy 
While CT-fluoroscopy offers unique viewing perspectives with overall imaging capabilities 
(as discussed in the earlier section, “Triplanar Imaging in Pain Medicine Procedures: 
Conventional-CT Guidance and CT-Fluoroscopy”), interestingly, real-time 3D imaging has 
not been reported. Conversely, although real-time 3D ultrasound has been show to be 
beneficial in regional anesthesia (as cited in the above section, “Ultrasound guidance in Pain 
Medicine: Regional Anesthesia”), ultrasound imaging does not offer the allure that 
fluoroscopy enjoys with respect to image resolution, particularly of bony anatomy. 
Technology is currently available to fit mobile C-arm fluoroscopy systems with 3D imaging 
capabilities (Stübig et al., 2009; Izadpanah et al., 2009; Villavicencio et al., 2005). (Note: 
current fluoroscopy systems creating 3D imagery are limited to 150°—360° with mechanical 
orientation or manipulation or post-processing.) Notably, the limiting factor in the utility of 
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However, one company, Imaging3 Inc., claims to have developed signal processing 
algorithms to produce 3D high-resolution fluoroscopic images in real-time via its 
“Dominion” platform. (Note: at the time of this publication, this device has not received 
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In addition, it is projected that the Dominion will offer a multi-modal feature to give 
physicians the ability to view cross-sectional anatomy by emulating CT, using a cone-beam 
CT model. 
*Note: neither the author nor anyone known to the author has any relationship with any of 
the companies mentioned in this subsection. This includes but is not limited to financial, 
consulting, and business relationships. All information was obtained through company 
filings and/or press releases and/or marketing literature. 
5.2 *Interventional magnetic resonance imaging (MRI) 
This section presents a brief discussion on the concept of MRI-guided procedures. Whereas 
the use of MRI for this purpose is in its infancy, the intent of MRI-guided/interventional 
scanning is to assist physicians during intra-operative, and diagnostic and therapeutic 
procedures using magnetic-compatible instrumentation. The Fonar 360™ MRI unit 
represents the cutting edge in technology for this vision. The Fonar 360™ is a specialized 
MRI design with the field and gradient magnets encapsulated in the ceiling and floor of a 
dedicated, monolithic room. In this capacity, the enlarged room-sized magnet and the 360° 
access to the patient permits full-fledged medical teams to walk into the room (i.e., “inside 
the magnet”) to interact with the patient. The first unit was installed at the Nuffield 
Orthopaedic Centre in Oxford, United Kingdom. 
Another developer, MRI Interventions Inc., a medical device maker focusing on 
interventional MRI applications, has obtained FDA clearance on their ClearPoint® system 
which is designed to enable minimally invasive procedures in the brain—namely to 
facilitate image guidance for the introduction of deep brain stimulation leads—utilizing a 
hospital’s existing MRI suite. On this note, although to date the use of deep brain 
stimulation for pain is limited due to lackluster outcomes (Levy et al., 1987; Coffey, 2001; 
Hamani et al., 2006), research is ongoing to find appropriate surgical candidates and areas in 
the brain conducive to long-term efficacy for conditions with a central pain aspect. Such 
targeted brain centers currently under investigation are the ventral capsule/ventral striatum 
in thalamic pain syndrome (U.S. National Institutes of Health [NIH], NCT 01072656). On 
another note, the introduction of deep brain stimulation systems with “steerable” field 
currents (the VANTAGE trial) (NIH, NCT 01221948) may ultimately prove clinically 
advantageous in such approaches to pain management. 
Finally, our discussion on interventional MRI would be incomplete without reference made 
to patient care and concerns about biologic effects relative to exposure to MRI. Hence, we 
refer the reader to the collection of work by Frank Shellock. On this point, we encourage the 
reader to begin with Shellock and Cruse (2004) to gain an overview on tissue sensitivity 
associated with gradient magnetic fields, acoustic noise, and radiofrequency 
fields/radiation in MRI. 
*Note: neither the author nor anyone known to the author has any relationship with any of 
the companies mentioned in this subsection. This includes but is not limited to financial, 
consulting, and business relationships. All information was obtained through company 
filings and/or press releases and/or marketing literature. 
5.3 Ultrasound imaging: Beyond regional anesthesia 
With ultrasound guidance for nerve blocks in regional anesthesia established, intriguing 
applications of this modality in pain medicine are beginning to surface. For example, 
ultrasound guidance for trigger point injection therapy has been shown to be comparable to 
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electromyographic guidance (Botwin et al., 2008). One advantage of this technique is that in 
the cervicothoracic area, the physician can see the lungs in order to guard against 
inadvertent procedure-induced pneumothorax. In other applications, the use of ultrasound 
was also recently documented as the modality of choice to facilitate placement of 
percutaneous leads in two peripheral nerve stimulation trialing procedures to treat 
ilioinguinal neuralgia (Carayannopoulos et al., 2009). This marked a new era in ultrasound-
guided pain medicine, as well as technical improvement and refinement of a surgical 
technique. Likewise, image guidance with ultrasound in pain procedures traditionally 
reserved for x-ray producing modalities (fluoroscopy) have been reported. The evidence for 
this is gleaned from reports on real-time ultrasound-guided epidural injections (Karmakar, 
2009), and even the introduction of current procedural terminology codes for transforaminal 
epidural injections and paravertebral/facet injections. 
However, more compelling evidence for the versatility of ultrasound in pain medicine is 
found in its utility in pain-related physical rehabilitation (a role for this modality which is in 
its infancy) (Peolsson & Brodin, 2009; Primack, 2010; Wininger, 2010). It is well recognized 
that when musculoskeletal injuries/syndromes induce pain, use of the involved body part 
(such as the shoulder for example) becomes limited, which may in turn cause more pain and 
more limited use and a vicious cycle is started, possibly leading to physical limitation that 
negatively influences the quality of life of the patient. Alternatively, qualitative and 
quantitative description of musculoskeletal tissue dynamics and coordination during real-
time procedures is possible through ultrasound imaging via tissue velocity imaging. This 
technique may be used to scrutinize both intra-muscular and inter-muscular coordination 
patterns (Peolsson & Brodin, 2009). Dynamic imaging using ultrasound to assess shoulder 
impingement syndromes is another example of pain-related physical rehabilitation 
ultrasound use (Bureau et al., 2006). To this point, it is noteworthy to mention that 
researchers have looked into how the overall utility of musculoskeletal ultrasound imaging 
impacts MRI. It was discovered that selective substitution of musculoskeletal ultrasound for 
MRI can result in significant cost savings to the health care system, but issues related to 
accuracy, variability, education and competence need to be further addressed (Jacobson, 
2009). 
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Local Anesthetic Agents in Arthroscopy 
Joseph Baker 
Cappagh National Orthopaedic Hospital 
Ireland 
1. Introduction 
Arthroscopy is performed with increasing frequency on a number of joints. In the lower 
limb the role of knee arthroscopy is well established with procedures enabling more 
accurate diagnosis and treatment of a myriad of conditions including but not being limited 
to meniscal injury and articular surface defects. Hip and ankle arthroscopy are less widely 
performed. However, despite this their use can be expected to increase as indications are 
better developed and techniques honed. 
While surgical technique often determines outcome in the long-term, analgesic control can 
significantly affect the patient’s satisfaction following a procedure as well as the overall 
acceptability of a procedure. Arthroscopic procedures in particular have enabled many 
procedures to be performed on a day case basis where as more traditional surgical 
interventions may have required at least an overnight hospital stay. This trend toward day 
case surgery also emphasizes the importance of optimum analgesic control. 
Traditionally intra-articular analgesic agents have been used following arthroscopic 
procedures as an augment to post-operative pain control. Classically these include the 
typical local anesthetic agents but also alternatives such as morphine. Recently however, the 
potential for deleterious effects of the intra-articular analgesics on the articular cartilage has 
been reported in a number of experimental studies, which has caused concern among 
practicing arthroscopic surgeons. The purpose of this chapter is to review the potential 
intra-articular analgesic agents used for pain control following lower limb arthroscopy and 
to also provide an up-to-date review of the evidence for the potential chondrotoxic effect of 
these agents. 
2. Analgesic agents 
Classical local anesthetic agents can be classified into the esters and amides. Amides 
including lignocaine and bupivacaine among others have commonly been used in 
arthroscopy. Local anesthetics block action potential initiation and propagation along 
sensory pathways by blocking the sodium channel transmembrane pores. Their activity is 
increased in alkaline conditions and this enables them to penetrate the nerve sheath and 
axonal membrane. 
Other agents to have been trialed as intra-articular agents include opiates or opiate related 
substances (e.g. morphine, tramadol), non-steroidal anti-inflammatory medications, 
benzodiazepines and NMDA-receptor antagonists (e.g. magnesium sulfate) among others. 
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2.1 Hip and ankle arthroscopy 
Numerous studies have assessed the ability of local anesthetic agents to provide pain 
control following arthroscopic procedures in the lower limb. A vast majority of these have 
focused on the knee and only a few have reported the use of local anaesthetic following hip 
and ankle arthroscopy(Middleton et al., 2006, Baker et al., 2011c).  
Of these two studies both found that intra-articular local anaesthetic was superior to either 
placebo or local anesthetic infiltrated around the arthroscopic portals (Table 1). The paucity 
of data here reflects the relative infancy of hip and ankle arthroscopy compared to knee 
arthroscopy and highlights the need for further work – hip arthroscopy in particular 
requires significant force to overcome the intra-articular negative pressures and can result in 
significant post-operative pain(Baker et al., 2011a). 
 
Author Setting Number Key findings 
(Baker et al., 
2011c) RCT 73 
Intra-articular bupivacaine superior to peri-portal bupivacaine at 
controlling pain following HIP arthroscopy 
(Middleton 
et al., 2006) RCT 35 
Intra-articular bupivacaine was superior to saline placebo in 
reducing post-operative VAS pain scores and need for 
supplemental analgesia following ANKLE arthroscopy 
Table 1. Studies assessing the benefit of intra-articular analgesic agents following hip and 
ankle arthroscopy 
2.2 Knee arthroscopy 
Numerous studies have attempted to establish the ideal intra-articular analgesic for pain 
control following knee arthroscopy (for a summary of these studies see Table2). The studies 
selected for inclusion here predominantly include those that use an intra-articular analgesic 
following surgery in a bolus dose fashion. Some studies that use it prior to surgery are also 
included for comparison sake particularly where comparison is later made with a bolus 
given following surgery. This section focuses on intra-articular analgesia given as an 
augment following surgery performed under general anesthesia or spinal anesthesia.   
Although many studies have found that classical local anesthetic agents are of benefit 
following knee arthroscopy a randomized controlled trial reported by Townsend et al noted 
that intra-articular bupivacaine was no more effective that bupivacaine infiltrated around 
the portal sites(Townshend et al., 2009). This equivalence takes on even more importance 
with the reported potential for the toxic effect on articular cartilage of bupivacaine and other 
similar agents.  
In general local anesthetics have been shown to be effective compared to placebo although 
this is not necessarily the case if the surgery is performed under spinal anesthetic when it 
appears the additional use of an intra-articular agent is negated by the spinal 
block(Santanen et al., 2001).  
Non-steroidal anti-inflammatory medications have been trialed as intra-articular agents but 
are not in wide spread use. A single study has found that tenoxicam was superior to 
bupivacaine following surgery but this was only with regards analgesic consumption – the 
reported pain scores were still similar(Cook et al., 1997). It was similarly found that 
lornoxicam resulted in lower pain scores than did bupivacaine in a randomized controlled 
trial of 40 patients(Fagan et al., 2003). The use of an anti-inflammatory into the joint cavity 
may play a role in pain control particularly when a significant inflammatory component to 
the intra-articular pathology is found(Izdes et al., 2003). 
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When compared to opiate type analgesics ropivacaine was shown in one study to provide 
quicker onset of analgesia but was not significantly better at 24 hours after 
surgery(Franceschi et al., 2001). The benefit of morphine as an intra-articular analgesic is 
questionable however as noted later and this perhaps reflects poorly on ropivacaine.  
Combinations of amide local anesthetics with other agents have been tried and this may 
represent the optimum way to control pain although at this point in time it is unknown. A 
combination of magnesium sulfate and bupivacaine was shown to be superior to either 
agent in isolation, which were again superior to placebo with regard pain scores following 
knee arthroscopy(Elsharnouby et al., 2008). These findings are supported by another study 
that also included morphine in the intra-articular cocktail but again found that a 
combination of agents was superior to any of the agents given in isolation(Farouk and Aly, 
2009). A combination of bupivacaine with fentanyl was shown to be superior to bupivacaine 
in isolation following knee arthroscopy in a randomized trial including 33 patients(Jawish et 
al., 1996). Despite these promising reports in combinations of an amide local anesthetic and 
an opiate type agent others have failed to find this multimodal approach any better than 
placebo alone(Aasbo et al., 1996). While pain intensity or pain scale score is a frequent 
measure in these studies, the actual need for additional analgesia is a limiting factor with 
regard the ability to perform a procedure as a day case or not and may reflect a more 
practical end-point for further research. 
Despite a small number of studies suggesting that morphine provides adequate analgesic 
control following knee a recent review of these studies has suggested that of the higher 
quality studies, most had a negative finding not in favor of its use as an intra-articular 
analgesic agent(Rosseland, 2005, Drosos et al., 2002). The key point of this review was that 
post-operative pain intensity was no less in the morphine treated groups than the placebo 
treated groups in the well-designed studies. This review is supported by a study by the 
same author group that found only those with intense pain after arthroscopy had any 
benefit from intra-articular morphine(Rosseland et al., 1999).  
Other agents have been studied in with some success including midazolam (increased the 
time to first analgesia after surgery compared to placebo), clonidine (additive effect with 
bupivacaine compared to bupivacaine alone) and neostigmine (more effective when 
compared to morphine)(Batra et al., 2008, Tamosiunas et al., 2005, Yang et al., 1998). 
Unfortunately these agents have been studies in a very limited capacity and a clear 
conclusion in unable to be drawn as their effectiveness.  
 
Author Setting Number Key findings 
(Aasbo et al., 
1996) RCT 107 
Patients randomised to receive either: bupivacaine (20ml of 
2.5mg/ml) + morphine (3mg); bupivacaine (20ml of 2.5mg/ml)  
alone; morphine (3mg) alone; or isotonic saline – no differences 
between the groups with regard analgesic requirement post-surgery 
(Al-Metwalli 
et al., 2008) RCT 60 
Intra-articular dexmedetomidine (-2-adrenergic agonist) given 
via the intra-articular route resulted in less post-operative pain 
and analgesic requirement than  either dexmedetomidine given 
intravenously or intra-articulat and intravenous placebo (saline) 
(Alagol et al., 
2004) RCT 210 
Intra-articular tramadol at doses 50-100mg provided good post-
operative analgesia with the higher doe more effectuve. The intra-
articular route was more effective than the intravenous route. 
(Batra et al., 
2008) RCT 60 
Intra-articular midazolam (50 or 75g/kg) provided superior, albeit 
briefly, analgesic control compared to saline placebo. Time to first 
analgesic requirement was 4.7 and 4.6 hours compared to 0.7. 
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Author Setting Number Key findings 
(Buerkle et 
al., 2000) RCT 60 
Patients given morphine (1mg) and clonidine (150g)  intra-
articularly in combination had lower VAS pain scores at 2 hours 
post-surgery and lower need for rescue analgesia compared to 
groups given either agent in isolation or saline placebo 
(Calmet et 
al., 2004) RCT 80 
Following arthroscopic meniscectomy, patients receiving intra-
articular ketorolac (60mg) had better post-operative pain control and 
less need for rescue analgesia compared to those receiving 10ml of 
0.25% bupivacaine, 1mg of morphine or normal saline placebo. 
(Cepeda et 
al., 1997) RCT 112 
Intra-articular and subcuticular morphine (10mg) and 
intraarticuular bupivacaine (20ml 0.5%) were compared with 
noraml saline placebo. Single dose morphine by either route 
provided superior pain conrol with lower pain scores at 6- and 3-
hours post-surgery. 
(Colbert et 
al., 1999) RCT 88 
Patients receiving intra-articular tenoxicam had lower pain scores at 
30-180 minutes post-surgery and required less analgesia later than 
thos receiving the same drug intravenously. 
(Convery et 
al., 1998) RCT 60 
Patients given 5mg ketorolac with 20ml of 0.25% bupivacaine into 
the joint after surgery provided similar analgesic control to 10mg 
ketorolac given intravenously with 20ml of 0.25% bupivacaine given 
into the joint. 
(Cook et al., 
1997) RCT 63 
Patients received either 40ml solution containing only normal saline, 
0.25% bupivacaine or 20mg tenoxicam at the end of knee 
arthroscopy. Less analgesia was needed by the tenoxicam group but 
subjective pain reporting was similar in all groups. 
(Dalsgaard et 
al., 1993) RCT 52 
Patients receiving 1mg of morphine intrarticularly at the end of 
surgery had lower pain scores at 8- and 24-hours after surgery and 
used less paracetamol compared to those receiving saline placebo. 
(Drosos et 
al., 2002) RCT 30 
No significant difference seen in VAS pain scores between patients 
receiving intra-articular saline, 5mg morphine or 15mg morphine 
following diagnostic arthroscopy or arthroscopic meniscectomy. 
(Elhakim et 
al., 1999) RCT 60 
Patients randomised to receive either saline placebo; 2% lidocaine 
and 10mg pethidine, or; 2% lidocaine, 10mg pethidine and 20mg 
tenoxicam. Combination of all three agents resulted in lower VAS 
pain scores for longer and less need for analgesic use. 
(Elsharnouby 
et al., 2008) RCT 108 
Patients receiving 1g magnesium sulfate and 0.25% bupivacaine 
(20ml total) had significantly lower VAS pain scores and longer time 
to first analgesic use than thos receiving either agent in isolation or 
placebo. 
(Eren et al., 
2008) RCT 90 
Patients receving either 8mg lornoxicam or 50mg bupivacaine had 
less analgesic consumption after surgery than those receiving plcebo. 
Pain rating were lower for those receinving the lornoxicam than thos 
receiving the bupivacaine. 
(Fagan et al., 
2003) RCT 40 
Patients receiving pre-emptive injection of bupivacaine with 
adrenaline showed a trend toward needing less analgesia in the 
recovery room than those receiving the injection at completion of 
surgery. 
(Farouk and 
Aly, 2009) RCT 80 
A combination of magnesium (150mg) and morphine (2mg) with 20 
ml of 0.25% bupivacaine provided superior analgesic control (lower 
VAS scores and longer time to first analgesic) than either agent alone 
with bupivacaine or bupivacaine alone. 
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Author Setting Number Key findings 
(Franceschi 
et al., 2001) RCT 90 
Ropivacaine (75mg in 20ml saline) had quicker onset of effective 
analgesia post-opeatively than morphine (2mg in 20ml saline) with 
lower VAS pain scores in the first 4 hours and equivalent control in 







Bupivacaine with epinephrine and morphine or bupivacaine with 
epinephrine alone given either pre- or post-operatively resulted in 
lower pain scores and narcotic onsumption than with epinephrine 
alone. There was a trend toward superior control in those receiving 




RCT  Combinations of bupivacaine, morphine and epinephrine given pre- or post-surgery resulted in similar pain control. 
(Grabowska-
Gawel et al., 
2003) 
 56 
Patients received either 10ml 0.5% bupivacaine or 5mg morphine in 
normal saline. Mean time to rescue analgesia was shorter in the 
bupivacaine group but there was no difference in reported VAS pain 
scores. 
(Graham et 
al., 2000) RCT 36 
Intra-articular analgesia given at completion of arthroscopy was 
equivalent to pre-operative intravenous regional analgesia with 
respect to post-opertive pain control 
(Gupta et al., 
1999) RCT 100 
Knee arthroscopy performed under LA (prilocaine (5mg/ml). 
Morphine (3mg), ketorolac (30mg) or a combination of the two was 
given at completion of surgery.  A combination of morphine and 
ketorolac provided significantly superior analgesia than morphine 




RCT 59 Morphine (1mg) given either intra-articularly or intravenously at the end of arthroscopy had equivalent analgesic benefit. 
(Izdes et al., 
2003) RCT 90 
Patients receiving intra-articular piroxicam (20mg) and 25ml of 
0.25% bupivacaine had longer analgesic duration in cases where 
synovial inflammation was confirmed present than when not 
present.  
(Jacobson et 
al., 2006) RCT 120 
Levobupivacaine (5mg/ml) significantly reduced the need for 
analgesia in the first 24 hours post-surgery compared to 
levobupivacaine (2.5mg/ml) and lidocaine (10mg/ml) with 
adrenaline. 
(Jaureguito 
et al., 1995) RCT  
Knee arthroscopy [performed under LA. Patients receiving intra-
articular morphine (4mg) had lower VAS pain scores than those 
receiving 0.25% bupivacaine or saline placebo. Less supplemental 
pain medication was needed by the morphine group. 
(Jawish et al., 
1996) RCT 33 
Patients receiving a combination of 0.25% bupivacaine with 50g of 
fentanyl had reduced post-operative pain for at least 9 hours post-
surgery when compared to patients receiving 0.25% bupivacaine 
alone or saline placebo. 
(Joshi et al., 
1992) RCT 20 
Patients receiving intra-articular morphine (5mg) following knee 
arthroscopy had lower VAS pain scores and needed less rescue 
analgesia than those recevinign saline placebo. Low serum morphine 
metabolites suggested that the morphine was acting locally. 
(Joshi et al., 
1993) RCT 40 
Intra-articular morphine (5mg) either in isolation or incombination 
with 25ml of 0.25% bupivacaine resulted in significantly lower pain 
scores and need for supplementary analgesia than bupivacaine in 
isolation or saline placebo. 
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(Buerkle et 
al., 2000) RCT 60 
Patients given morphine (1mg) and clonidine (150g)  intra-
articularly in combination had lower VAS pain scores at 2 hours 
post-surgery and lower need for rescue analgesia compared to 
groups given either agent in isolation or saline placebo 
(Calmet et 
al., 2004) RCT 80 
Following arthroscopic meniscectomy, patients receiving intra-
articular ketorolac (60mg) had better post-operative pain control and 
less need for rescue analgesia compared to those receiving 10ml of 
0.25% bupivacaine, 1mg of morphine or normal saline placebo. 
(Cepeda et 
al., 1997) RCT 112 
Intra-articular and subcuticular morphine (10mg) and 
intraarticuular bupivacaine (20ml 0.5%) were compared with 
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(Jaureguito 
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pain medication was needed by the morphine group. 
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Patients receiving a combination of 0.25% bupivacaine with 50g of 
fentanyl had reduced post-operative pain for at least 9 hours post-
surgery when compared to patients receiving 0.25% bupivacaine 
alone or saline placebo. 
(Joshi et al., 
1992) RCT 20 
Patients receiving intra-articular morphine (5mg) following knee 
arthroscopy had lower VAS pain scores and needed less rescue 
analgesia than those recevinign saline placebo. Low serum morphine 
metabolites suggested that the morphine was acting locally. 
(Joshi et al., 
1993) RCT 40 
Intra-articular morphine (5mg) either in isolation or incombination 
with 25ml of 0.25% bupivacaine resulted in significantly lower pain 
scores and need for supplementary analgesia than bupivacaine in 
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(Juelsgaard 
et al., 1993) RCT 47 
There was no difference in reposrted VAS pain scores or 
acetaminophen use in the 48 hours after knee arthroscopy in patients 
receiving either 2 or 4mg of intra-articular morphine after surgery 
(Kanbak et 
al., 1997) RCT  
Patients receiving 5mg morphine intra-articularly after arthroscopy 
had superior pain control in the 24 hours after surgery compared to 
those receiving 1mg morphine or saline placebo. 
(Karaman et 
al., 2009) RCT 40 
No significant difference was found in control of post-operative pain 
and analgesic requirement between patients receiving 20ml of 0.5% 
levobupivacaine and 20ml of 0.5% bupivacaine. 
(Kligman et 
al., 2002) RCT 60 
Infiltration of morphine (1mg) into the synovial tissue or outer third 
of meniscal tissue resulted in better pain control (lower VAS pain 
scores and less analgesic use) post-arthroscopy than if morphine 
(1mg) was given by the intra-articular route. 
(Lundin et 
al., 1998) RCT 50 
Intra-articular bupivacaine 0.25% (40ml) with the addition of 
morphine 1mg compared to bupivacaine alone. Lower VAS pain 
scores noted with the addition of morphine in the 24 hours after 
surgery but no difference in supplementary analgesic use. 
(Niemi et al., 
1994) RCT 80 
Patients underwent knee arthroscopy under either spinal or LA  (1% 
lidocaine with adrenaline) blockade. Intra-articular morphine (1mg) 
given at the end of the procedure resulted in  reduced rescue 
analgesia requirement in the group that had LA block. 
(Pooni et al., 
1999) RCT 107 
Patients randomized to receive either intra-articular bupivacaine or 
fantanyl after knee arthroscopy reported similar pain scores except 
at 2-hours post-surgery when bupivacaine was superior 
(Raj et al., 
2004) RCT 40 
Patients receinving 10mg morphine intra-articularly repoted lower 
pain scores between 4- and 24-hours post-surgery and consumed 
less analgesia than patients receiving 10mg morphine via the 
intramuscular route. 
(Rasmussen 
et al., 2002) RCT 60 
Patients randomized to receive either saline placebo; 150mg 
bupivacaine and 4mg morphine, or; 150mg bupivacaine, 4mg 
morphine and 40mg methylprednisolone intra-articulalry at the end 
of surgery.Bupivacaine with mprhine was effective at reducing pain 
and duration of immobilization, the addition of methylprednisolone 
futher reduce dpain and use of analgesics. 
(Rautoma et 
al., 2000) RCT 200 
Pre-operative per oral diclofenac reduced post-operative pain scores 
compared to the intra-articular ropivacaine given at the time of 
surgery. Arthoscopy performed under spinal anaesthesia. 
(Richardson 
et al., 1997) RCT  
Intra-articular morphine (1mg) was superior to bupivacaine (100mg) 
at reducing pain scores and need for supplementary anlgesia at 6- 
and 24-hours post-surgery. 
An intra-articular dose of 5mg morphine was more effective thatn 
1mg intra-articular or 5mg intravenous at reducing VAS pain scores. 
(Rosseland et 
al., 2004) RCT 60 
Intra-articular saline (1 or 10ml) was given following surgery via an 
intra-articular catheter in patients with at least moderate pain. 
Within 1 hour VAS pain scores reduced from 50 to 27 on a 100mm 
scale with both volumes. 
(Rosseland et 
al., 2003) RCT 40 
Intra-articular saline (10ml) or morphine (2mg in 10ml saline) was 
given following surgery via an intra-articular catheter in patients 
with at least moderate pain. Equivalent improvements in pain 
intesnity were found in both groups. 
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(Rosseland et 
al., 1999) RCT 90 
Only patients with more intense pain after arthroscopy had beneift 
from intra-articular morphine (2mg) with regard reduced pain 
intensity and analgesia requirement. In most patients morphine (1 or 
2mg) was equivalent to saline placebo. 
(Samoladas 
et al., 2006) RCT 60 
Patientes received either 10 or 20ml of 7.5mg/ml ropivacaine. Both 
provided excellent pain control for two hours, however after that the 
lower dose group reported increased pain and need for 
supplementary analgesia. 
(Santanen et 
al., 2001) RCT 100 
Knee arthroscopy performed under spinal anaesthesia. 20ml of 0.5% 
ropivacaine failed to reduce VAS pain scores or need for rescue 
analgesia when compared to saline control. 
(Solheim et 
al., 2006) RCT 40 
Patients received intra-articular morphine (5mg) or saline placebo 
via intra-articular catheter 1 hour post-surgery if they developed at 
least moderate pain. Morphine was of no greater benefit than saline. 
Timing of catheter removal did not influence the outcome. 
(Souza et al., 
2002) RCT 60 
Patients receiving either saline placebo, 10ml 0.25% bupivacaine, 
2mg morphine or 100g fentanyl intra-articularly at the end of 
arthroscopy did not differ significantly in reported pain intensity. 
(Tamosiunas 
et al., 2005) RCT 48 
Patients receiving 20ml of 0.5% bupivacaine with the addition of 
1g/kg of clonidine controlled post-operative pain more effectivley 
than bupivacaine in isolation or placebo. 
(Townshend 
et al., 2009) RCT 137 
Patients receiving 20ml of 0.5% bupivacaine either intra-articulalry 






Patients receiving intra-artticular morphine (2mg) reported 
significantly less pain and lower analgesic requirements in the 24-
hours after surgery than those receiving 30ml of 0.25% bupivacaine 
with epinephrine.. 
(Varrassi et 
al., 1999) RCT 48 
Intra-articular buprenorphine (100g) and intra-articular 
bupivacaine (50mg) resulted in lower VAS pain scores in the 6-hours 
after surgery than intra-articular saline or intra-muscular 
buprenorphine. Analgesic use was less in thoe treated with intra-
articular buprenorphine or bupivacaine. 
(Vranken et 
al., 2001) RCT 60 
Sufentanil (5 or 10g) given intra-articulalry resulted in lower VAS 
pain scores than in control (intravenous sufentanil). Post-operative 
analgesic use was also lower in the treatment group. 
(White et al., 
1990) RCT  
Patients treated with prilocaine with adenaline reported prolonged 
time to first dose of oral analgesia but overall there was no difference 
in pain scores. 
(Yang et al., 
1998) RCT 60 
Patients receiving intra-articular neostigmine (500g) had lower 
VAS pain scores 1-hour after surgery and had longer lasting 
duration of analgesia compared to those receiving intra-articular 
morphine (2mg) or saline placebo. No significant effects were seen 
with neostigmine 125 or 250g. 
(Zeidan et 
al., 2008) RCT 90 
Intra-articular administration of tramadol (100mg) and 0.25% 
bupivacaine to 20ml vloume had lower VAS scores, longer time to 
rescue analgesia and less analgesic use in the first 24-hours 
compared to when either agent was given in isolation. 
Table 2. Studies assessing the benefit of intra-articular analgesic agents following knee 
arthroscopy. Treatments are in bold. 
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and duration of immobilization, the addition of methylprednisolone 
futher reduce dpain and use of analgesics. 
(Rautoma et 
al., 2000) RCT 200 
Pre-operative per oral diclofenac reduced post-operative pain scores 
compared to the intra-articular ropivacaine given at the time of 
surgery. Arthoscopy performed under spinal anaesthesia. 
(Richardson 
et al., 1997) RCT  
Intra-articular morphine (1mg) was superior to bupivacaine (100mg) 
at reducing pain scores and need for supplementary anlgesia at 6- 
and 24-hours post-surgery. 
An intra-articular dose of 5mg morphine was more effective thatn 
1mg intra-articular or 5mg intravenous at reducing VAS pain scores. 
(Rosseland et 
al., 2004) RCT 60 
Intra-articular saline (1 or 10ml) was given following surgery via an 
intra-articular catheter in patients with at least moderate pain. 
Within 1 hour VAS pain scores reduced from 50 to 27 on a 100mm 
scale with both volumes. 
(Rosseland et 
al., 2003) RCT 40 
Intra-articular saline (10ml) or morphine (2mg in 10ml saline) was 
given following surgery via an intra-articular catheter in patients 
with at least moderate pain. Equivalent improvements in pain 
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(Rosseland et 
al., 1999) RCT 90 
Only patients with more intense pain after arthroscopy had beneift 
from intra-articular morphine (2mg) with regard reduced pain 
intensity and analgesia requirement. In most patients morphine (1 or 
2mg) was equivalent to saline placebo. 
(Samoladas 
et al., 2006) RCT 60 
Patientes received either 10 or 20ml of 7.5mg/ml ropivacaine. Both 
provided excellent pain control for two hours, however after that the 
lower dose group reported increased pain and need for 
supplementary analgesia. 
(Santanen et 
al., 2001) RCT 100 
Knee arthroscopy performed under spinal anaesthesia. 20ml of 0.5% 
ropivacaine failed to reduce VAS pain scores or need for rescue 
analgesia when compared to saline control. 
(Solheim et 
al., 2006) RCT 40 
Patients received intra-articular morphine (5mg) or saline placebo 
via intra-articular catheter 1 hour post-surgery if they developed at 
least moderate pain. Morphine was of no greater benefit than saline. 
Timing of catheter removal did not influence the outcome. 
(Souza et al., 
2002) RCT 60 
Patients receiving either saline placebo, 10ml 0.25% bupivacaine, 
2mg morphine or 100g fentanyl intra-articularly at the end of 
arthroscopy did not differ significantly in reported pain intensity. 
(Tamosiunas 
et al., 2005) RCT 48 
Patients receiving 20ml of 0.5% bupivacaine with the addition of 
1g/kg of clonidine controlled post-operative pain more effectivley 
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(Townshend 
et al., 2009) RCT 137 
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Patients receiving intra-artticular morphine (2mg) reported 
significantly less pain and lower analgesic requirements in the 24-
hours after surgery than those receiving 30ml of 0.25% bupivacaine 
with epinephrine.. 
(Varrassi et 
al., 1999) RCT 48 
Intra-articular buprenorphine (100g) and intra-articular 
bupivacaine (50mg) resulted in lower VAS pain scores in the 6-hours 
after surgery than intra-articular saline or intra-muscular 
buprenorphine. Analgesic use was less in thoe treated with intra-
articular buprenorphine or bupivacaine. 
(Vranken et 
al., 2001) RCT 60 
Sufentanil (5 or 10g) given intra-articulalry resulted in lower VAS 
pain scores than in control (intravenous sufentanil). Post-operative 
analgesic use was also lower in the treatment group. 
(White et al., 
1990) RCT  
Patients treated with prilocaine with adenaline reported prolonged 
time to first dose of oral analgesia but overall there was no difference 
in pain scores. 
(Yang et al., 
1998) RCT 60 
Patients receiving intra-articular neostigmine (500g) had lower 
VAS pain scores 1-hour after surgery and had longer lasting 
duration of analgesia compared to those receiving intra-articular 
morphine (2mg) or saline placebo. No significant effects were seen 
with neostigmine 125 or 250g. 
(Zeidan et 
al., 2008) RCT 90 
Intra-articular administration of tramadol (100mg) and 0.25% 
bupivacaine to 20ml vloume had lower VAS scores, longer time to 
rescue analgesia and less analgesic use in the first 24-hours 
compared to when either agent was given in isolation. 
Table 2. Studies assessing the benefit of intra-articular analgesic agents following knee 
arthroscopy. Treatments are in bold. 
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In summary a myriad of agents have been studied for their potential use in attenuating post-
operative pain following knee arthroscopy. While the amide local anesthetic agents are the 
most widely studied their continuing benefit and use is questionable as portal infiltration 
has been shown to be as effective at providing pain control for a procedure that is generally 
very well tolerated. Knee arthroscopy performed under local anesthetic is a different entity 
although far less frequent. 
Hip and ankle arthroscopy are far less studied and the ideal intra-articular agent is 
uncertain in these joints. A multi-model intra-articular analgesic bolus may be the best 
approach in these joints that require significant traction and subsequent injury to the capsule 
that can cause greater discomfort after surgery. 
2.3 The potential for articular chondrocyte toxicity 
The potential for deleterious effects of local anesthetic agents on articular chondrocytes was 
increasingly noted with the use of arthroscopic pain pumps following glenohumeral 
arthroscopy(Busfield and Romero, 2009, Hansen et al., 2007, Solomon et al., 2009). Increasingly 
however studies are alerting the practicing clinician to the potential for toxic effects secondary 
to amide local anesthetics given as a single bolus injection. Most of these are laboratory-based 
studies. Although some have questioned the relevance given the long use of intra-articular 
local anesthetic without seemingly any complication the serve as a caution. 
The aim of this section is to provide an over view of the basic science evidence on the 
potential for local anesthetic agents to cause articular chondrocyte toxicity. 
2.3.1 In vitro reports 
A number of different laboratory modesl utilizing cell lines from a variety of animal species 
have been used in the study of local anaesthetic toxicity. A toxic effect in canine 
chondrocytes exposed to bupivacaine 0.5% using a proven in vitro model by Anz et al. They 
reported an almost 100% reduction in cell viability after two days exposure to bupivacaine. 
Bupivacaine conferred an anti-inflammatory effect in their study, evidenced by reduced 
nitric oxide and PGE rise in the presence of interleukin-1, but their conclusion maintained 
that continuous exposure to bupivacine resulted in a clear toxic effect toward the canine 
chondrocytes(Anz et al., 2009). Again using a canine osteochondral model the toxic effect of 
bupivacaine was again confirmed, with or without the addition of methylparaben(Hennig et 
al., 2010). Exposure to the local anaesthetic alone for 5 or 30 minutes caused significant cell 
death, although this was only significant statistically at the 30 minute exposure.  
Miyazaki et al demonstrated a concentration dependent reduction in bovine chondrocyte 
viability after treatment with lidocaine (0.125, 0.25, 0.5 or 1%) (Miyazaki et al., 2011).  
Glycosaminoglycan (GAG)content of the cells was also noted to be reduced as the 
concentration of the local anaesthetic was increased. GAG and lactate production were 
higher in the cells treated with 0.5 and 1% lidocaine. The authors felt that this finding 
conferred a reparative response by the cells.  
Using bovine articular chondrocytes in alginate bead cultures Karpie et al exposed these to 1 
or 2% lidocaine for 15 to 60 minutes(Karpie and Chu, 2007). A dose and time dependent 
increase in cell toxicity was reported. An intact surface on the osteochondral core or variation 
in the pH of the treatments (pH 7.4, 7.0, 5.0) failed to confer any protective effect (this is in 
contrast to other studies – see below). Others have also reported time and concentration 
dependent reductions in cell viability using a bovine disc model(Lo et al., 2009). In this case 
osteochondral cores were harvested from the radiocarpal joint of cows and these were treated 
with either lidocaine (1%), bupivacaine (0.25%) or ropivacaine (0.5%).  
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The toxic effects of bupivacine (0.125, 0.25 and 0.5%) on the the articular chondrocyte from a 
bovine cell line were well demonstrated (Chu et al., 2008). Cells were cultured in a 3-
dimensional alginate-bead culture. Specimens were exposed for 15, 30 or 60 minutes and 
analysis was performed at 1 and 24 hours and at 1 week. A clear time and concentration 
dependent respose to the local anaetshetic treatments was observed. Treatment with 0.125% 
bupivacaine for 15 minutes was not significantly different to the saline control. Almost 
complete loss of cell viability was noted with 0.5% bupivacaine. Analysis of osteochondral 
cores with an intact superficial cell layer suggested that an the superficial layer of the 
articular cartilage provided some protective benefit when intact. This may be significant in 
deciding during surgery whether or not intra-articular analgesic agents are safe to 
administer. 
To test the respective toxic effects on chondrocytes of lidocaine, mepivacaine and 
bupivacaine Park et al used an equine model (Park et al., 2011). Bupivacaine (0.5%) was the 
most toxic of the agents used with cell viability reduced to 29 +/- 8% after 30 minutes. Cell 
viability after treatment with saline was 96%. Lidocaine and mepivacaine were both less 
toxic with mepivacine exerting the least toxic effect of the three. 
A number of studies have used human cell lines which is arguably more useful for the 
extrapolation of results into clinical pratice. Dragoo et al used a custom made bioreactor to 
mimic the metabolism of synovial fluid to simulate the use of a pain pump following 
arthroscopic surgery(Dragoo et al., 2008). They found that both lignocaine (1%) and 
bupivacaine (0.25 or 0.5%) resulted in reduced cell viability but that the  rates of necrosis 
were noted with the presence of epinephrine.  Cell viability was similar at 24 and 48 hours 
in the bupivaine group, but there was a greater toxic effect seen at 72 hours. Further work 
using the same bioreactor model demonstrated that epineprhine, at levels of 1:100000-
200000, conferred no significant increase in cell death compared to acidic media with a pH 
of 4.5-5.0 and local anaesthetics in combination with epinephrine (Dragoo et al., 2010). The 
authors suggest that local anaesthetic agents containing epinephrine should be used with 
caution as these are often titrated to a low pH. 
Syed et al reported significant toxic effects of bupivacaine either alone or in combination 
with triamcinolone in a monlayer culture model using human articular chondrocytes (Syed 
et al., 2011). When the treatments were administered to the osteochondral plug with an 
intact surface however, the toxic effect of bupivacaine in isolation was no more than that of 
the control – again suggesting there is a benefit to an intact articular surface with regard 
exposure to potentially toxic agents.  
Using chondrocytes harvested from osteoarthritic human knees it was demonstrated that 
exposure to lidocaine, bupivacaine or ropivacaine for 24 or 120 hours resulted in significant 
levels of cell death(Grishko et al., 2010). In the lignocaine 2% group massive necrosis was 
seen at 24 hours. After 120 hours exposure there were significant dereases in cell viability in 
all treatments groups with the exception of those cells treated with 0.2% ropivacaine. As 
viability decreased a concomitant rise in cell apoptosis was noted. 
Jacobs et al harvested human articular chondrocytes from the knees of human tissue donors 
or patients undergoing total knee arthroplasty(Jacobs et al., 2011). They treated the articular 
chondrcytes with either 1% or 2% lidocaine with or without epinephrine and used saline as 
a control. Cell death between 91-99% was seen for each of the three treatments. A prolonged 
exposure time was also associated with higher rates of cell death. 
Ropivacaine 0.5% was found to be significantly less toxic to human chondrocytes than 
bupivacaine 0.5% (Piper and Kim, 2008). Normal human articular cartilage was harvested 
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In summary a myriad of agents have been studied for their potential use in attenuating post-
operative pain following knee arthroscopy. While the amide local anesthetic agents are the 
most widely studied their continuing benefit and use is questionable as portal infiltration 
has been shown to be as effective at providing pain control for a procedure that is generally 
very well tolerated. Knee arthroscopy performed under local anesthetic is a different entity 
although far less frequent. 
Hip and ankle arthroscopy are far less studied and the ideal intra-articular agent is 
uncertain in these joints. A multi-model intra-articular analgesic bolus may be the best 
approach in these joints that require significant traction and subsequent injury to the capsule 
that can cause greater discomfort after surgery. 
2.3 The potential for articular chondrocyte toxicity 
The potential for deleterious effects of local anesthetic agents on articular chondrocytes was 
increasingly noted with the use of arthroscopic pain pumps following glenohumeral 
arthroscopy(Busfield and Romero, 2009, Hansen et al., 2007, Solomon et al., 2009). Increasingly 
however studies are alerting the practicing clinician to the potential for toxic effects secondary 
to amide local anesthetics given as a single bolus injection. Most of these are laboratory-based 
studies. Although some have questioned the relevance given the long use of intra-articular 
local anesthetic without seemingly any complication the serve as a caution. 
The aim of this section is to provide an over view of the basic science evidence on the 
potential for local anesthetic agents to cause articular chondrocyte toxicity. 
2.3.1 In vitro reports 
A number of different laboratory modesl utilizing cell lines from a variety of animal species 
have been used in the study of local anaesthetic toxicity. A toxic effect in canine 
chondrocytes exposed to bupivacaine 0.5% using a proven in vitro model by Anz et al. They 
reported an almost 100% reduction in cell viability after two days exposure to bupivacaine. 
Bupivacaine conferred an anti-inflammatory effect in their study, evidenced by reduced 
nitric oxide and PGE rise in the presence of interleukin-1, but their conclusion maintained 
that continuous exposure to bupivacine resulted in a clear toxic effect toward the canine 
chondrocytes(Anz et al., 2009). Again using a canine osteochondral model the toxic effect of 
bupivacaine was again confirmed, with or without the addition of methylparaben(Hennig et 
al., 2010). Exposure to the local anaesthetic alone for 5 or 30 minutes caused significant cell 
death, although this was only significant statistically at the 30 minute exposure.  
Miyazaki et al demonstrated a concentration dependent reduction in bovine chondrocyte 
viability after treatment with lidocaine (0.125, 0.25, 0.5 or 1%) (Miyazaki et al., 2011).  
Glycosaminoglycan (GAG)content of the cells was also noted to be reduced as the 
concentration of the local anaesthetic was increased. GAG and lactate production were 
higher in the cells treated with 0.5 and 1% lidocaine. The authors felt that this finding 
conferred a reparative response by the cells.  
Using bovine articular chondrocytes in alginate bead cultures Karpie et al exposed these to 1 
or 2% lidocaine for 15 to 60 minutes(Karpie and Chu, 2007). A dose and time dependent 
increase in cell toxicity was reported. An intact surface on the osteochondral core or variation 
in the pH of the treatments (pH 7.4, 7.0, 5.0) failed to confer any protective effect (this is in 
contrast to other studies – see below). Others have also reported time and concentration 
dependent reductions in cell viability using a bovine disc model(Lo et al., 2009). In this case 
osteochondral cores were harvested from the radiocarpal joint of cows and these were treated 
with either lidocaine (1%), bupivacaine (0.25%) or ropivacaine (0.5%).  
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from the femoral head or tibial plateau in in patients underoing surgical procedures. Full 
thickness explants and cultured chondrocytes were treated with either ropivacaine or 
bupivacaine for 30 minutes. Cell viability in the explant cultures fell to 95% and 78% after 
treatment with ropivacaine and bupivacaine respectively. Viability in the cell cultures fell to 
64% and 37%. The viability of the cells in the explant cultures treated with ropivacaine did 
not differ significantly to that in the controls treated with saline. Ropivacaine may therefore 
confer a much more acceptable risk than bupivacaine – an important consideration if using 
it as an intra-articular agent following arthroscopy. 
However, others failed to find a difference between these two agents using a simple 
monolayer culture model. Both ropivacaine and bupivacaine conferred simlar toxic effects to 
the articular chondrocytes either in isolation or if they were used in combination with 
magnesium sulfate(Baker et al., 2011b, Baker et al., 2011d). Lignocaine combined with 
magnesium sulfate was less toxic than either ropivacaine, bupivacaine or levobupivacaine 
combined with magnesium suflate after an exposure time of only 15 minutes(Baker et al., 
2011b). 
A useful finding for the practicing surgeon in the studies that have assessed human cells in in 
vitro settings is the recurrent finding that ropivacaine is less toxic than bupivacaine(Baker et 
al., 2011b, Baker et al., 2011d, Piper and Kim, 2008). If ropivacaine confers a less toxic effect, 
then as long as it provides equally efficacious analgesic control, then these studies support its 
use. Notably, Piper et al also found ropivacaine to be less toxic in the explant culture with cells 
embedded in an intact matrix, potentially a better representation of the in vivo state. 
2.3.2 In vivo studies  
In vivo models shoulde in theory provide the best simulation of what may happen in 
pratcice. However, consideration needs to be given to the culture model used and also the 
species studied. Arguably the ideal model is unknown to date and no human in vivo studies 
at the time of writing have been able to demonstrate a lasting deleterious effect of local 
anaesthetic on articular chondrocytes.  
The effect of a single intra-articular injection of 0.5% bupivacaine into a stifle joint compared 
to 0.9% saline control was studied(Chu et al., 2010). Six months following injection gross and 
histological appearances showed that the chondral surfaces remained intact. They diod note 
howeevr, that there was a reduction in chondrocyte density of up to 50% in the joint treated 
with local anaesthetic compared to the saline control. 
In an in vivo rabbit study three groups recieved continuous infusions of either saline, 
bupivacaine or bupivacaine with epinephrine over 48 hours(Gomoll et al., 2006).  One week 
after treatment the animals were sacrificed and osteochondral and synovial samples analysed. 
Bupivacaine with or without epinephrine resulted in cell viability reduction by 20 to 32%. 
Histological analysis was worse in both treatment gourps compared to saline control.  
A similar treatment regime did not result in long term changes in articular cartilage(Gomoll 
et al., 2009). When the rabbits were sacrificed three months after the infusion of the saline of 
local anaesthetic there was no significant difference found between treatment and control 
groups. An increase in cartilage metabolism in the treatment groups was noted suggesting 
that the cartilage was undergoing a reparative process. This study provides conflicting 
information to the earlier one noted by Chu et al creating more difficulty in ascertaining the 
true chronic effect of intra-articular local anaesthetic use. 
In another, histological changes in rabbit knee joint articular cartilage have been reported 
(Dogan et al., 2004). Knees were injected with either 0.9% saline, bupivacaine or 
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neostigmine. Histological analysis performed at 1, 2 and 10 days confirmed more toxic 
changes in both treatment groups compared to saline control. 
2.3.3 The mechaisn of local anaesthetic mediated chondroctoxicity 
Despite a number of studies reporting the potential toxic effects the mechanism by which 
these agents exert their effect is uncertain. Mitochondrial dysfunction is thought to be a key 
factor in articular chondrocyte death(Grishko et al., 2010). Grishko et al demonstrated 
mitochondrial DNA damage and a reduction in ATP and mitochondrial protein levels in 
response to treatment with a variety of local anaesthetics at varying concentrations. 
In another study cells exposed to lidocaine or bupivacine in isolation had rates of cell death 
just over 10%(Bogatch et al., 2010). When the local anaesthetics were mixed with the cell 
culture medium this rate rose to over 96% in each instance. Crystal formation was seen 
when the bupivacine was mixed with culture medium. Acididc phosphate buffered saline 
resulted in increased cell death only when the acidity was increased to a pH less than 3.4. 
Based on these results the authors propose an incompatibility between the synovial fluid 
and the local anaesthetic is responsible for the majority of chondrocyte death rather than the 
local anaesthetic agent itself.  
3. Summary 
A number of different agents have been trialed as intra-articular analgesic agents following 
arthroscopy in the lower limb. Many of the reported trials have focussed on the use of 
amide local anaesthetic sgents as these are the most widely used in clinical practice. Depsite 
multiple studies there is no agent that appears clearly superior to the rest. Bupivacaine or 
ropivacaine appear the most likely to offer the greatest analgesic control by this route and a 
small number of studies are supportive of a multi-modal infiltration. Magnesium sulfate for 
one may be an ideal synergist. 
Although Townsend et al have offered evidence that intra-articular local anaesthetc can be 
avoided in knee arthroscopy without compromising analgesic control, the ideal mode of 
analgesic control in hip and ankle arthroscopy is still uncertain. Recent reports of 
chondrolysis in shoulder arthroscopy prompted a number of investigations in the potential 
toxic effect that amide local anaesthetcis may have on articular chondrocytes. 
Ropivacaine appears to less toxic than bupivacaine and a combination of ropivacaine and 
magnesium has also been suggested as a more acceptable alternative approach to intra-
articular local anaesthesia(Baker et al., 2011b, Webb and Ghosh, 2009). The potential 
diffculties in applying laboratory findings to the clinical setting has been noted(Webb and 
Ghosh, 2009). In the arthroscopic setting, a number of variables including the articular 
surface disease state, the dilutional effect of the arthroscopic fluid and absorbance of injected 
agents into surrounding synovium and adjacent soft tissues could all modify the effect the 
local anaesthetic has on the articular chondrocyte. The potential for toxic effects on articular 
chondrocytes by local anaesthetic needs to be further investigated.  
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1. Introduction 
The experience of pain is complex, multifaceted, and “an unpleasant sensory and emotional 
experience,” as defined in part by the International Association for the Study of Pain.  It is a 
personal, subjective experience that involves sensory, emotional and behavioral factors 
associated with actual or potential tissue injury (Rawal). The differential behavior response 
to surgical incision can be influenced by many variables including global (i.e., personality, 
gender, age, cultural background, pre-existing pain syndromes, genetic makeup, kind and 
type of surgical approach, cultural background) and specific (i.e., fear, anxiety, depression, 
anger, and coping) psychological factors (Eccleston, 2001). Only by considering all 
concomitant factors can physicians provide optimal treatment. 
Millions of surgeries are performed on an annual basis, necessitating the frequent use of 
acute postoperative pain management. There are many types of surgery and, with few 
exceptions, all are painful. Fear of uncontrolled pain is among the primary concerns of many 
patients who are about to undergo surgery. 
One of the most important factors in determining when a patient can be safely discharged 
from a surgical facility, and that also has a major influence on the patient’s ability to resume 
his/her normal activities of daily living, is the adequacy of postoperative pain control. Pain 
is a predictable part of the postoperative experience. Unrelieved postoperative pain may 
result in clinical and psychological changes that increase morbidity and mortality as well as 
costs and that decrease quality of life (Carr& Goudas, 1999). 
The guidelines for acute pain management in the perioperative setting published in 1992 
and 1995 (Acute Pain, 1992; American Pain, 1995; Practice Guidelines, 1995) promoted 
aggressive treatment of acute pain and educate patients about the need to communicate 
unrelieved pain. Nonetheless these guidelines appear to have had little influence on practice 
patterns or on improved pain control for patients. In a study of Warfield and Kahn 
(Warfield&Kahn, 1995) they found three of four patients reported experiencing pain after 
surgery, and 80% of these patients rated pain after surgery as moderate to extreme.  Since 
their study, newer drugs,  techniques and protocols for postoperative pain management 
have been developed, and minimally invasive surgical techniques, such as endoscopic 
procedures, are used more frequently. These changes in practice patterns thought that they 
could affect the management of postoperative pain and patient attitudes about pain. But in a 
recent study (Apfelbaum, 2003) that assessed patients’ postoperative pain experience and 
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recent study (Apfelbaum, 2003) that assessed patients’ postoperative pain experience and 
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the status of acute pain management in a random sample, approximately 80 percent of 
patients said (not very different the previous study mentioned above) they experienced 
acute pain after surgery. The authors concluded that; despite an increased focus on pain 
management programs and the development of new standards for pain management, many 
patients continue to experience intense pain after surgery.   
Effective and appropriate pain management requires a proactive approach using a variety of 
treatment modalities to obtain an optimal outcome with respect to facilitating rapid 
recovery and returning to full function, allowing early discharge from hospital, improving 
quality of life for the patient and reducing morbidity (Rawal).   Protocols for postoperative 
pain treatment should be made with considering patients’ needs, surgical indications, and 
institutional resources. It is important to use effective state-of-the-art techniques combined 
with hospital protocols for early rehabilitation and recovery. 
Many options are available for the treatment of postoperative pain, including systemic (i.e., 
opioid and nonopioid) analgesics and regional (i.e., neuraxial and peripheral) analgesic 
techniques. Multimodal analgesia is achieved by combining different analgesics that act by 
different mechanisms and at different sites in the nervous system, resulting in additive or 
synergistic analgesia with lowered adverse effects of sole administration of individual 
analgesics (Kehlet&Dahl, 1993). It also refers to concurrent application of analgesic 
pharmacotherapy in combination with regional analgesia (Elvir Lazo&White, 2010). 
This chapter’s aim is to overview on the topic of multimodal analgesia for postoperative 
pain management and to provide an update on the drugs and techniques used for this 
approach. 
2. Consequences of postoperative pain 
When an appropriate analgesic treatment is not given for postoperative pain, various 
adverse effects might occur in the respiratory, cardiovascular, gastrointestinal, urinary, 
endocrinological systems, as well as in patient's metabolisms and mentality. These changes 
were relievable with application of appropriate types of analgesic regimens.   
Postoperative pain, especially when poorly controlled, may produce a range of detrimental 
acute (i.e., adverse physiologic responses) (Vadivelu et al, 2010) and chronic effects (i.e., 
delayed long-term recovery and chronic pain) (Perkins&Kehlet, 2000). Good pain control 
after surgery is important to prevent negative outcomes such as tachycardia, hypertension, 
myocardial ischemia, decrease in alveolar ventilation, immobility, deep venous thrombosis 
and poor wound healing (Vadivelu et al, 2010; Nett, 2010).  
Pathophysiology of acute pain, includes of changes in neuroendocrine, respiratory and renal 
function, gastrointestinal activity, circulatory and autonomic nervous system activity.  
Unsufficient pain management can cause acute and chronic effects: 
2.1 Acute effects 
 Emotional and physical suffering for the patient 
 Sleep disturbance (with negative impact on mood and mobilisation) 
 Respiratory system side effects (leading to atelectasis, retention of secretions and 
pneumonia) 
 Decreased respiratory motion 
 Inhibition of cough and sputum excretion 
 Cardiovascular side effects (such as hypertension and arrhythmias) 
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 Increased oxygen consumption (with negative impact in the case of coronary artery 
disease, leading to coronary ischemia and myocardial infarction) 
 Impaired gastrointestinal motility (while opioids induce constipation or nausea, 
untreated pain may also be an important cause of impaired bowel movement or 
postoperative nausea and vomiting-PONV) 
 Delays mobilisation and promotes thromboembolism (postoperative pain is one of the 
major causes for delayed mobilisation) 
 Increased sympathetic activity 
 increased release of catecholamines (resulting increase in systemic vascular 
resistance, cardiac work and myocardial oxygen consumption associated negative 
effects in patients with coronary artery diseases) 
 reduced blood flow in lower extremities (resulting a higher risk of deep vein 
thrombosis) 
2.2 Chronic effects 
 Severe acute pain is a risk factor for the development of chronic pain 
 Sleep disturbance (with negative impact on mood and mobilisation) 
 Risk of behavioural changes (frequently in children for a prolonged period after 
surgical pain) 
 Poor wound healing  
 Delay in long-term recovery 
Chronic pain is a potential adverse outcome from surgery. It is costly to society in terms of 
suffering and disability. For humanitarian and economic reasons, the problem of chronic 
pain after surgery should be addressed. In a review of Perkins et al. (Perkins&Kehlet, 2000) 
they showed there was a significant variability in the incidence of chronic pain among 
surgical procedures (i.e. 3-56% for cholecystectomy, 0-37% for inguinal hernia surgery, 11-
57% for breast surgery).  They concluded that chronic pain after surgery was common as 
that has been confirmed with another review (Camann, 1998). Another conclusion of this 
study is; the intensity of acute postoperative pain was one of the most striking predictive 
factor for chronic pain, especially following breast surgery (Elia, 2005), thorasic surgery 
(Carli F,2002; Viscusi, 2004) and hernia repair (Birnbach, 1989). 
3. Multimodal approach to postoperative pain 
Advances in the knowledge of molecular mechanisms have led to the development of 
multimodal analgesia and new pharmaceutical products to treat postoperative pain.  
Postoperative pain treatment may not be enough to provide major improvements in some 
outcomes because it is unlikely that a unimodal intervention can be effective in 
addressing a complex problem such as perioperative outcomes (Boisseau, 2001; 
Kehlet&Nolte, 2001). The analgesic benefits of controlling postoperative pain are 
generally maximized when a multimodal strategy to facilitate the patient's convalescence 
is implemented (Kehlet, 1997). Pain involves multiple mechanisms that ideally require 
treatment using a multimodal (or ‘balanced’) analgesic technique (White&Kehlet, 2010) 
Principles of a multimodal strategy include control of postoperative pain to allow early 
mobilization, early enteral nutrition, education, and attenuation of the perioperative stress 
response through the use of regional anesthetic techniques and a combination of analgesic 
agents (i.e., multimodal analgesia).   
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disease, leading to coronary ischemia and myocardial infarction) 
 Impaired gastrointestinal motility (while opioids induce constipation or nausea, 
untreated pain may also be an important cause of impaired bowel movement or 
postoperative nausea and vomiting-PONV) 
 Delays mobilisation and promotes thromboembolism (postoperative pain is one of the 
major causes for delayed mobilisation) 
 Increased sympathetic activity 
 increased release of catecholamines (resulting increase in systemic vascular 
resistance, cardiac work and myocardial oxygen consumption associated negative 
effects in patients with coronary artery diseases) 
 reduced blood flow in lower extremities (resulting a higher risk of deep vein 
thrombosis) 
2.2 Chronic effects 
 Severe acute pain is a risk factor for the development of chronic pain 
 Sleep disturbance (with negative impact on mood and mobilisation) 
 Risk of behavioural changes (frequently in children for a prolonged period after 
surgical pain) 
 Poor wound healing  
 Delay in long-term recovery 
Chronic pain is a potential adverse outcome from surgery. It is costly to society in terms of 
suffering and disability. For humanitarian and economic reasons, the problem of chronic 
pain after surgery should be addressed. In a review of Perkins et al. (Perkins&Kehlet, 2000) 
they showed there was a significant variability in the incidence of chronic pain among 
surgical procedures (i.e. 3-56% for cholecystectomy, 0-37% for inguinal hernia surgery, 11-
57% for breast surgery).  They concluded that chronic pain after surgery was common as 
that has been confirmed with another review (Camann, 1998). Another conclusion of this 
study is; the intensity of acute postoperative pain was one of the most striking predictive 
factor for chronic pain, especially following breast surgery (Elia, 2005), thorasic surgery 
(Carli F,2002; Viscusi, 2004) and hernia repair (Birnbach, 1989). 
3. Multimodal approach to postoperative pain 
Advances in the knowledge of molecular mechanisms have led to the development of 
multimodal analgesia and new pharmaceutical products to treat postoperative pain.  
Postoperative pain treatment may not be enough to provide major improvements in some 
outcomes because it is unlikely that a unimodal intervention can be effective in 
addressing a complex problem such as perioperative outcomes (Boisseau, 2001; 
Kehlet&Nolte, 2001). The analgesic benefits of controlling postoperative pain are 
generally maximized when a multimodal strategy to facilitate the patient's convalescence 
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response through the use of regional anesthetic techniques and a combination of analgesic 
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The concept of multimodal analgesia was introduced more than a decade ago as  
a technique to improve analgesia and reduce the incidence of opioid-related adverse 
events. Multimodal analgesia is achieved by combining different analgesics that act  
by different mechanisms at different sites in the nervous system, reducing the incidence  
of side effects owing to the lower doses of the individual drugs (Buvanendran&Kroin 
2009). For example, epidural opioids can be administered in combination with epidural 
local anesthetics; intravenous opioids can be administered in combination with 
Nonsteroidal Antiinflammatory Drug (NSAID)s, which have a dose sparing effect  
for systemically administered opioids. It also refers to concurrent application of analgesic 
pharmacotherapy in combination with regional analgesia (Elvir Lazo&White, 2010; 
Rawal).  
In the literature some different definitions of multimodal analgesia exists. In some contexts, 
multimodal analgesia refers to systemic administration of analgesic drugs with different 
mechanisms of action, whereas in other situations it refers to concurrent application of 
analgesic pharmacotherapy in combination with regional analgesia. Multimodal analgesia is 
based on to choice paracetamol and NSAIDs for low intensity pain with opioid analgesics 
and/or local analgesia techniques being used for moderate and high intensity pain as 
indicated.  (Elvir Lazo&White, 2010; Rawal) (Table 1) 
 
 











Upper abdominal surgery 
Aortic surgery 
Knee replacement 
(i) Paracetamol and wound 
infiltration with local anesthetic 
(ii) NSAIDs (unless 
contraindicated) and 
(iii) Epidural local analgesia or 
major peripheral nerve or 
plexus block or opioid injection 
(IV PCA) 
(i) Paracetamol and wound infiltration with local anesthetic 
(ii) NSAIDs (unless contraindicated) and 
(iii) Peripheral nerve block 
(single shot or continuous infusion) or opioid injection (IV 
PCA) 
(i) Paracetamol and wound infiltration with local anesthetic 
(ii) NSAIDs (unless contraindicated) and 
(iii) Regional block analgesia 
Add weak opioid or rescue analgesia with small increments of intravenous strong opioid 
if necessary 
Table 1. Treatment options in relation to magnitude of postoperative pain expected 
following different types of surgery (by permission from Publisher AstraZeneca) 
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A lower incidence of adverse effects and improved analgesia has been demonstrated with 
multimodal analgesia techniques, which may provide for shorter hospitalization times, 
improved recovery and function, and possibly decreased healthcare costs (Buvanendran & 
Kroin, 2009). 
To achieve a maximum short-term and long-term benefits from multimodal analgesic 
therapies, the pain management would be initiated as a preventive in the preoperative 
period continued in the early postoperative period  and  extended into  the  postcharge 
period for  3-7 days (Bisgaard, 2006; White et al, 2007). A deficiency in the design of many 
of the published studies involving multimodal analgesic therapies is that the drug 
regimens were not continued into the postdischarge period (Ma, 2004). For example, only 
immediate pre- and postoperative administration of the cyclooxygenase 2 (COX-2) 
inhibitor rofecoxib as part of a multimodal analgesic regimen in outpatients undergoing 
inguinal hernia repair provided limited benefits beyond the early postoperative period 
(White&Kehlet, 2007). However, when the COX-2 inhibitors are administered for 3 to 5 
days after ambulatory surgery, (Gan, 2004;  Joshi, 2004) the greater benefits were achieved 
with respect to clinically relevant patient outcomes (eg, resumption of normal activities) 
and improvements in pain control. Bisgaard et al (Bisgaard, 2006) concluded that a 
multimodal analgesic regimen consisting of a preoperative single dose of dexamethasone, 
incisional local anesthetics (at the beginning and/or end of surgery), and continuous 
treatment with NSAIDs (or COX-2 inhibitors) during the first 3 to 4 days provided the 
best clinical outcome. Moreover, recent clinical studies suggest that when classical 
NSAIDs or more selective COX-2 inhibiting drugs were administered for 3–5 days after 
ambulatory surgery, a significant benefit was achieved with respect to clinically relevant 
patient outcomes (e.g., resumption of normal activities) and improvements in short-term 
pain control (Gan, 2004; White, 2007). 
A multimodal analgesic regimen should be adjusted to meet the needs of the individual 
patient by taking into consideration their pre-existing medical conditions, types of 
surgery, and previous experiences related to both acute and chronic pain management. 
Critical multimodal protocols must be designed based on surgical procedures and 
structural organization to warrant improved outcome including having minimum side 
effects related to the treatment and rapid returning to social life and daily activities 
(Fanelli, 2008). 
Several multimodal approaches have been advocated based on different combinations of 
anti-inflammatory drugs, and regional anesthesia (epidural, peripheral nerve blocks, 
paravertebral blocks, and local injection/infusion of local anesthetics) (Buvanendran, 2010; 
Mathiesen, 2009). Although each of these drugs and/or techniques has been demonstrated 
as being effective in reducing the need for postoperative intravenous opioids alone, the 
evidence supporting specific combinations of drugs and/or regional techniques is still 
limited. 
3.1 Multidisciplinary approach 
Faster recovery, reduced hospital stay, and decreased length of convalescence can occur if 
multimodal analgesia is combined with a rehabilitation program that is multidisciplinary 
and multimodal (Gajraj&Joshi, 2005).  
Treatment of postoperative pain requires good multi-disciplinary and multi-professional co-
operation. Multidisciplinary team consists of the anesthesiologist himself has overall 
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The concept of multimodal analgesia was introduced more than a decade ago as  
a technique to improve analgesia and reduce the incidence of opioid-related adverse 
events. Multimodal analgesia is achieved by combining different analgesics that act  
by different mechanisms at different sites in the nervous system, reducing the incidence  
of side effects owing to the lower doses of the individual drugs (Buvanendran&Kroin 
2009). For example, epidural opioids can be administered in combination with epidural 
local anesthetics; intravenous opioids can be administered in combination with 
Nonsteroidal Antiinflammatory Drug (NSAID)s, which have a dose sparing effect  
for systemically administered opioids. It also refers to concurrent application of analgesic 
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Rawal).  
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indicated.  (Elvir Lazo&White, 2010; Rawal) (Table 1) 
 
 











Upper abdominal surgery 
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contraindicated) and 
(iii) Epidural local analgesia or 
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plexus block or opioid injection 
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(iii) Regional block analgesia 
Add weak opioid or rescue analgesia with small increments of intravenous strong opioid 
if necessary 
Table 1. Treatment options in relation to magnitude of postoperative pain expected 
following different types of surgery (by permission from Publisher AstraZeneca) 
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(Fanelli, 2008). 
Several multimodal approaches have been advocated based on different combinations of 
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paravertebral blocks, and local injection/infusion of local anesthetics) (Buvanendran, 2010; 
Mathiesen, 2009). Although each of these drugs and/or techniques has been demonstrated 
as being effective in reducing the need for postoperative intravenous opioids alone, the 
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Pain Management – Current Issues and Opinions 
 
182 
responsibility, pain nurse and specialist surgeon, sometimes pharmacist. In the ward the 
patient’s physician and nurse, physiotherapist when needed are responsible for all care, in 
partnership with the pain team. The nurse is responsible to report the patient’s  intensity of 
pain to the physician and to treat the pain within the defined rules of the local guidelines. 
Also should pay attention to the effects and side effects of the pain treatment. The pain team 
nurse is the first point of contact while the anesthesiologist and pharmacist are available to 
provide specialist advice (Rawal).  
All staff involved in the treatment of postoperative pain require regularly updated training 
emphasising the importance of team-working and co-operation. In this training programme 
the main headings should be included as; a. Physiology and pathophysiology of pain, b. 
Pharmacology of analgesics, c. Locally available treatment methods d. Monitoring routines 
with regard to treatment of pain and e. Local document for treatment and assessment of pain 
(Rawal). 
It is important to understand of the postoperative pain experience from a patient’s 
perspective, if health care professionals are to identify ways to improve care. In Apfelbaum 
et al study (Apfelbaum et al, 2003); when asked about attitudes regarding pain and pain 
medications, 75% of patients believed that it was necessary to experience some pain after 
surgery, and 8% of patients had postponed surgery because they were worried about the 
possibility of experiencing pain. Although most patients claimed to receive preoperative 
education on postoperative pain management, that study’s findings suggested that a 
patient’s real concern is not adequately addressed. 
The patient himself and family members are also to be undertaken as the members of the 
multidisciplinary team. Education is an important role in this point. Patients are unlikely to 
be aware of postoperative pain treatment techniques and as the success of pain relief is 
influenced by their knowledge and beliefs, it is helpful to give patients (and parents in case 
of cognitively impaired, severely emotionally disturbed, children) detailed information 
about postoperative pain and pain treatment. Adequate information gives the patient 
realistic expectations of the care that can be provided (pain relief, not a "pain free status"). 
Patients who do not speak the local language, and patients whose level of education or 
cultural background differs significantly from that of their health care team need special 
concern. A preoperative discussion with the patient and relatives can be helpful about an 
effective postoperative pain management (Rawal). 
It is important to emphasize the need for collaboration between the various health care 
providers involved in the patient’s perioperative care (eg, anesthesiologists, surgeons, 
nurses, and physiotherapists) to integrate improved perioperative pain management 
strategies with the recently described fast-track recovery paradigms (White, 2007). This type 
of multi-disciplinary approach has been documented to improve the quality of the recovery 
process and reduce the hospital stay and postoperative morbidity, leading to a shorter 
period of convalescence after surgery (White&Kehlet, 2010). 
3.2 Pre-emptive – Preventive analgesia 
The concept of pre-emptive analgesia has its origins in the idea that painful stimuli, if not 
prevented by administration of preoperative analgesic drugs, could lead to spinal 
sensitization and neuroplasticity processes, resulting in increased pain intensity and 
duration after surgery. Many authors have studied the effects of different timing of 
administration of single drugs (e.g., pre-, intra- or postoperative) and have reported no 
differences in efficacy (Moiniche, 2002). 
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This approach does not seem to offer any clinically significant advantages over so-called 
preventative multimodal analgesic regimens when an effective pro-active approach to pain 
management is initiated in the early postoperative period and extended into the 
postdischarge period (Sun, 2008).  Starting with  intensive pain therapy at the beginning and 
analgesia must be continued, using step-down techniques that involve a change in drugs or 
route of administration (i.e., from the epidural and intravenous routes to per os 
administration) (Fanelli, 2008). 
The main goals of preventive analgesia are: to decrease pain after tissue injury, to prevent spinal 
sensitization and to reduce the incidence of inflammatory or chronic pain (Senturk, 2002). 
4. Drugs in postoperative pain management 
Multimodal (or balanced) analgesia represents an increasingly popular approach to 
preventing postoperative pain. The approach involves administering a combination of 
opioid and nonopioid analgesics (and adjuvant agents) that act at different sites within the 
central and peripheral nervous systems in an effort to improve pain control, with fewer 
opioid-related side effects mainly sedation, nausea, vomiting pruritis, constipation (Elvir 
Lazo&White, 2010; Vadivelu, 2010). 
The development of newer agents available for postoperative pain control opens up 
possibilities for newer combinations in multimodal analgesia. Multi-pharmacological 
therapy based on synergistic effects of two or more drugs gives better results than a mono-
pharmacologic approach (Vadivelu, 2010). 
4.1 Opioids 
Opioid analgesics continue to play an important role in the acute treatment of moderate-to-
severe pain in the early postoperative period. The problem about these drugs is the variety 
of perioperative complications eg, drowsiness and sedation, PONV, pruritus, urinary 
retention, ileus, constipation, ventilatory depression of them. These opioid-related adverse 
effects inhibit rapid recovery and rehabilitation (Buvanendran&Kroin, 2009; Vadivelu, 2010). 
Their effects can be summarized as hyperpolarization of first- and second-order sensory 
neurons, with inhibition of synaptic transmission. They act by binding to μ receptors, which 
initially results in increased G protein activity; this, in turn, leads to K+ efflux and inhibition 
of Ca2+ influx into the cell. Opioids also stimulate the supraspinal descending inhibitory 
system, which further increases the hyperpolarization of second-order neurons by releasing 
5-HT and glycine. Opioid receptors have been demonstrated in vitro in peripheral nerve 
terminals, but they are unable to influence the inflammatory reaction, resulting  lack of 
effectiveness on postoperative pain during movement (Christie, 2000). 
Opioids can be used in different ways; i.e intravenous, intramuscular, subcutaneous, 
transmucosal, epidural, intrathecal, transdermal. The most common route of postoperative 
systemic opioid analgesic administration is intravenous. When the most important source of 
nociceptive stimuli is visceral pain, good results may be achieved by intrathecal administration 
of small doses of opioids (Rathmell, 2005). 
Patient controlled analgesia (PCA) optimizes delivery of analgesic opioids and minimizes 
the effects of pharmacokinetic and pharmacodynamics variability in individual patients. It 
can be programmed for several variables: demand (bolus) dose, lockout interval, continuous 
or basal infusion, and 4 h limit (Table 2). PCA provides superior postoperative analgesia 
and improves patient satisfaction when compared with traditional PRN analgesic regimens. 
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This approach does not seem to offer any clinically significant advantages over so-called 
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sensitization and to reduce the incidence of inflammatory or chronic pain (Senturk, 2002). 
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therapy based on synergistic effects of two or more drugs gives better results than a mono-
pharmacologic approach (Vadivelu, 2010). 
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system, which further increases the hyperpolarization of second-order neurons by releasing 
5-HT and glycine. Opioid receptors have been demonstrated in vitro in peripheral nerve 
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Drug *- Concentration Bolus dose Lockout interval (min) 
Basal-Continuous 
infusion ** 
Morphine (1 mg/ml) 0.5-2 mg 5-10 0-2 mg/h 
Fentanyl (0.01 mg/ml) 10-20 µg 5-10 0-60 µg/h 
Alfentanil (0.1 mg/ml) 0.1-0.2 mg 5-8  
Sufentanil (0.002 mg/ml) 2-5 µg 4-10 0-8 µg/h 
Meperidine (10 mg/ml) 5-25 mg 5-10 0-20 mg/h 
Tramadol (4-5 mg/ml) 10-20 mg 6-10 0-20 mg/ml 
* Individual patient requirements vary widely. Titrated loading doses can be used if necessary to 
establish initial analgesia. 
** Continuous infusions are not initially recommended for opioid-naive adult patients 
Table 2. Intravenous PCA Regimens 
Opioid analgesics will likely remain the primary treatment option for patients who require 
rescue analgesic therapy in the postoperative period until more potent and rapid-acting 
nonopioid analgesics become available for routine clinical use. 
4.1.1 Controlled-release opiods 
Controlled-release opioids are not traditionally considered useful in the immediate 
postoperative period, but some studies have demonstrated that controlled-release 
oxycodone may be used for postoperative pain control when  remifentanil is used for 
maintenance of anesthesia. Its preoperative administration leads to adequate plasma 
concentrations for postoperative analgesia and hyperalgesia treatment following short 
surgery (1-2 h) (Nishimori, 2006). In addition, controlled-release opioids are an optimal 
choice for step-down analgesia in the late postoperative and rehabilitation periods following 
orthopedic surgical procedures (de Beer J de, 2005). 
4.1.2 Tramadol 
Tramadol enhances inhibitory effects on pain transmission at the spinal level blocking 
nociceptive signal transduction both by opioid and monoaminergic mechanisms. Its opioid 
and nonopioid modes of action appear to act synergistically. The drug is available in 
formulations suitable for oral, rectal and parenteral administration. Tramadol has been 
shown to provide effective analgesia after intravenous and oral (in a few of newer clinical 
studies) administration for postoperative pain management. The main advantage of 
tramadol in postoperative analgesia is a relative lack of respiratory depression. The potential 
of abuse is also negligible. 
4.2 Nonopioids 
Opioid analgesics, once considered the standard approach to preventing acute postoperative 
pain, are being replaced by a combination of nonopioid analgesic drugs with diverse modes 
of action as part of a multimodal approach to preventing pain after ambulatory surgery.  
Nonopioid analgesics are increasingly being used before, during, and after surgery to facilitate 
the recovery process especially after ambulatory surgery because of their anesthetic-and 
analgesic-sparing effects and their ability to reduce postoperative pain (with movement), 
opioid analgesic requirement, and side effects, thereby shortening the duration of the hospital 
 
Multimodal Analgesia for Postoperative Pain Management 
 
185 
stay. Nonopioid analgesics will likely assume a greater role as preventive analgesics in the 
future as the number of minimally invasive (keyhole) surgery cases continues to expand. 
Recent studies have confirmed that a rational combination of different nonopioid analgesics 
when given as part of multimodal analgesia reduces postoperative pain. The use of 
traditional NSAIDs, COX-2 inhibitors, acetaminophen, ketamine, dexmedetomidine, 
dextromethorphan, alpha2-agonists, gabapentin, pregabalin, and glucocorticoid steroids can 
provide beneficial effects when administered in appropriate doses as part of a multimodal 
analgesic regimen in the perioperative  setting (Elvir Lazo&White, 2010). 
Nonopioid drugs used in postoperative pain management can be classified as:   




a. Alpha-2 adrenergic agonists 
i. Clonidine 
ii. Dexmedetomidine 









e. Newer drugs 
i. Capsaicin 
ii. Glyceryl trinitrate 
iii. Cholinergic drugs 
Nicotine 
5. Local Anesthetics 
4.2.1 NSAIDs and cyclooxygenase-2-selective inhibitors 
NSAIDs are known to achieve pain relief by their effect on COX-1 and 2 with the various 
NSAIDs differing in the proportion to which they inhibit COX-1 and COX-2. They are acid 
compounds with analgesic, antipyretic and anti-inflammatory properties via inhibition of 
prostaglandin (PG) synthesis. Prostaglandins, including PG-E2, are responsible for reducing 
the pain threshold at the site of injury, resulting in central sensitization and a lower pain 
threshold in the surrounding uninjured tissue. The primary site of action of NSAIDs is 
believed to be in the periphery though recent research indicates that central inhibition of 
COX-2 may also play an important role in modulating nociception. NSAIDs inhibit the 
synthesis of prostaglandins both in the spinal cord and at the periphery, thus diminishing 
the hyperalgesic state after surgical trauma (Buvanendran&Kroin, 2009; Fanelli, 2008; 
McClane, 2010). 
NSAIDs are administered orally, parenterally or by the rectal route. 
NSAIDs are useful as the sole analgesic after minor surgical procedures. They provide 
moderate postoperative analgesia and thereby have a significant opioid-sparing effect of 20-
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Opioid analgesics, once considered the standard approach to preventing acute postoperative 
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the recovery process especially after ambulatory surgery because of their anesthetic-and 
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prostaglandin (PG) synthesis. Prostaglandins, including PG-E2, are responsible for reducing 
the pain threshold at the site of injury, resulting in central sensitization and a lower pain 
threshold in the surrounding uninjured tissue. The primary site of action of NSAIDs is 
believed to be in the periphery though recent research indicates that central inhibition of 
COX-2 may also play an important role in modulating nociception. NSAIDs inhibit the 
synthesis of prostaglandins both in the spinal cord and at the periphery, thus diminishing 
the hyperalgesic state after surgical trauma (Buvanendran&Kroin, 2009; Fanelli, 2008; 
McClane, 2010). 
NSAIDs are administered orally, parenterally or by the rectal route. 
NSAIDs are useful as the sole analgesic after minor surgical procedures. They provide 
moderate postoperative analgesia and thereby have a significant opioid-sparing effect of 20-
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30% after major surgery (Power, 1999).  This may be of clinical importance as NSAIDs may 
reduce the incidence of opioid-related side-effects (respiratory depression, sedation, nausea 
and vomiting, ileus, urinary bladder dysfunction and possibly sleep disturbances).  Since 
the COX-2 enzyme, the primary target of NSAIDs, is inducible, it is not found in damaged 
tissues until a few hours following the onset of a noxious stimulus. This could explain the 
lack of efficacy of preemptive administration of these drugs (Ness, 2001). 
NSAID use is not appropriate in all patients because of their age or renal or hematological 
status or because of previous dyspeptic symptoms (McClane, 2010). COX-2-selective 
inhibitors  (celecoxib, etoricoxib, rofecoxib- is no longer in use due to adverse cardiovascular 
events-) have the advantage over NSAIDs in the perioperative setting of not increasing  the 
risk of bleeding (Buvanendran&Kroin, 2009). 
Many patients now receive a NSAID as a routine part of their postoperative analgesic 
management.  Recent practice guidelines for acute pain management in the perioperative 
setting specifically state ‘unless contraindicated, all patients should receive around-the-clock 
regimen of NSAIDs, COX-2 inhibitors, or acetaminophen’ (Ashburn, et al, 2004). 
4.2.2 Acetaminophen 
Acetaminophen is antipyretic and analgesic but has little, if any, anti-inflammatory action. 
Its analgesic efficacy is not more than that of traditional analgesics; however, it has fewer 
side effects. Preparation of intravenous acetaminophen recently has been released in 
Europe.  A 100 ml solution is presented as 10 mg/ml for administration over a period of 15 
minutes. The onset of action is within five to 10 minutes, with the peak at one to two hours. 
Optimal analgesia for moderate to severe postoperative pain cannot be achieved using a 
single agent alone, but a balanced approach in combination with non-steroidal agents can 
result in up to a 40 to 50 percent reduction in opioid requirements (Vadivelu, 2010). 
4.2.3 Paracetamol 
Paracetamol has antipyretic and analgesic properties, but it is devoid of anti-inflammatory 
effects. It has an inhibitory action on central COX-2 and COX-3 enzymes, which would 
explain its antipyretic activity. The analgesic effect seems to be due to activation of 
descending serotonergic inhibitory pathways as well as inhibition of central NO synthases 
(Graham&Scott, 2005). Similar to other analgesic drugs, paracetamol shows differential 
properties in terms of pain control.  Paracetamol may be more effective in treating 
episiotomy or abdominal pain rather than pain following orthopedic surgery or tooth 
extraction (Gray, et al, 2005; macario&Lipman, 2001). The different relative roles of 
peripheral COX enzymes in postoperative pain may explain these differing efficacies. 
When paracetamol and NSAIDs are administered by an intravenous route, they show 
sparing effects on opioid consumption (about 25% and 30%, respectively); this effect begins 
4 h after their first administration and is synergistic (Elia et al, 2005; Mirande, 2006). 
4.2.4 Adjuvants 
Adjuvant drugs are defined as substances that may improve pain treatment and pain 
control, but they are not commonly defined as analgesics. Adjuvants are compounds, which 
by themselves have undesirable side effects or low potency but in combination with opioids 
allow a reduction of narcotic dosing for postoperative pain control. Thus they can provide 
beneficial effects when administered in appropriate doses as part of a multimodal analgesic 
regimen in the perioperative setting (Fanelli et al, 2008; Vadivelu et al, 2010). 
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Multimodal analgesia incorporates the use of analgesic adjuncts with different mechanisms 
of action to enhance postoperative pain management. Adjuvants are important in 
postoperative pain management due to side effects of opioid analgesics, which hinder 
recovery, especially in the increasingly utilized ambulatory surgical procedures 
(Buvanendran&Kroin, 2007). Multiple adjuvants recently have been developed for the 
control of pain.  
4.2.4.1 Alpha-2 adrenergic agonists 
Alpha-2 adrenergic activation represents an intrinsic pain control network of the central 
nervous system. The alpha-2 adrenergic receptor has high density in the substantia 
gelatinosa of the dorsal horn in humans and that is believed to be the primary site  
of action by which alpha-2 adrenergic agonists can reduce pain (Buvanendran&Kroin, 
2007). 
4.2.4.1.1 Clonidine 
Clonidine is originally classified as an anti-hypertensive drug with negative chronotropic 
activity, but has antinociceptive properties as well. In the spinal cord, clonidine acts at 
alpha-2 adrenergic receptors to stimulate acetylcholine release, which acts at both 
muscarinic and nicotinic receptor subtypes with analgesic effects (Fanelli et al, 2008). 
Clonidine can be administered orally, intravenously, neuraxially  or perineurally in 
combination with local anesthetics. However, the side effects could be significant. The most 
important ones are hypotension, bradycardia and sedation (Rawal). Data about the systemic 
administration of clonidine could support the usefulness of low-dose IV administration. 
Nonetheless due to the many side effects of systemic clonidine administration, the spinal 
route is preferred.   
Low doses of clonidine proved to be a useful adjunct analgesic when given neuraxially and 
in combination with peripheral nerve blocks (Habib et al, 2005). Significant results in terms 
of block duration were obtained when clonidine was added to local anesthetics for epidural 
or perineural analgesia. At low doses (2 μg/kg), it was shown to increase the duration of 
perineural blockade. Animal studies suggest that the mechanism of clonidine’s potentiation 
of lidocaine nerve block is inhibition of the hyperpolarization-activated cation current, not 
via its binding to alpha-2 adrenergic receptors (Jurna, 1995). 
4.2.4.1.2 Dexmedetomidine 
Dexmedetomidine is a relatively new, highly selective central alpha-2 agonist.  
Dexmedetomidine, when used as an adjunct, can reduce postoperative morphine 
consumption in various surgical settings using various routes such as intravenous (Dholakia 
et al, 2007; Gurbet et al, 2006; Lin et al, 2009). In a recent study the authors found that;  
the addition of dexmedetomidine to intravenous  PCA morphine resulted in superior 
analgesia, significant morphine sparing, and less morphine-induced nausea,while it  
was devoid of additional sedation and untoward hemodynamic changes (Dholakia et al, 
2007).   
4.2.4.2 N-methyl-D-aspartate antagonists (Antihyperalgesic drugs) 
With the discovery of the N-methyl-D-aspartate (NMDA) receptor and its links to 
nociceptive pain transmission and central sensitization, there has been renewed interest in 
utilizing noncompetitive NMDA receptor antagonists, such as ketamine, dextromethorphan, 
magnesium ions as potential antihyperalgesic agents. 
 
Pain Management – Current Issues and Opinions 
 
186 
30% after major surgery (Power, 1999).  This may be of clinical importance as NSAIDs may 
reduce the incidence of opioid-related side-effects (respiratory depression, sedation, nausea 
and vomiting, ileus, urinary bladder dysfunction and possibly sleep disturbances).  Since 
the COX-2 enzyme, the primary target of NSAIDs, is inducible, it is not found in damaged 
tissues until a few hours following the onset of a noxious stimulus. This could explain the 
lack of efficacy of preemptive administration of these drugs (Ness, 2001). 
NSAID use is not appropriate in all patients because of their age or renal or hematological 
status or because of previous dyspeptic symptoms (McClane, 2010). COX-2-selective 
inhibitors  (celecoxib, etoricoxib, rofecoxib- is no longer in use due to adverse cardiovascular 
events-) have the advantage over NSAIDs in the perioperative setting of not increasing  the 
risk of bleeding (Buvanendran&Kroin, 2009). 
Many patients now receive a NSAID as a routine part of their postoperative analgesic 
management.  Recent practice guidelines for acute pain management in the perioperative 
setting specifically state ‘unless contraindicated, all patients should receive around-the-clock 
regimen of NSAIDs, COX-2 inhibitors, or acetaminophen’ (Ashburn, et al, 2004). 
4.2.2 Acetaminophen 
Acetaminophen is antipyretic and analgesic but has little, if any, anti-inflammatory action. 
Its analgesic efficacy is not more than that of traditional analgesics; however, it has fewer 
side effects. Preparation of intravenous acetaminophen recently has been released in 
Europe.  A 100 ml solution is presented as 10 mg/ml for administration over a period of 15 
minutes. The onset of action is within five to 10 minutes, with the peak at one to two hours. 
Optimal analgesia for moderate to severe postoperative pain cannot be achieved using a 
single agent alone, but a balanced approach in combination with non-steroidal agents can 
result in up to a 40 to 50 percent reduction in opioid requirements (Vadivelu, 2010). 
4.2.3 Paracetamol 
Paracetamol has antipyretic and analgesic properties, but it is devoid of anti-inflammatory 
effects. It has an inhibitory action on central COX-2 and COX-3 enzymes, which would 
explain its antipyretic activity. The analgesic effect seems to be due to activation of 
descending serotonergic inhibitory pathways as well as inhibition of central NO synthases 
(Graham&Scott, 2005). Similar to other analgesic drugs, paracetamol shows differential 
properties in terms of pain control.  Paracetamol may be more effective in treating 
episiotomy or abdominal pain rather than pain following orthopedic surgery or tooth 
extraction (Gray, et al, 2005; macario&Lipman, 2001). The different relative roles of 
peripheral COX enzymes in postoperative pain may explain these differing efficacies. 
When paracetamol and NSAIDs are administered by an intravenous route, they show 
sparing effects on opioid consumption (about 25% and 30%, respectively); this effect begins 
4 h after their first administration and is synergistic (Elia et al, 2005; Mirande, 2006). 
4.2.4 Adjuvants 
Adjuvant drugs are defined as substances that may improve pain treatment and pain 
control, but they are not commonly defined as analgesics. Adjuvants are compounds, which 
by themselves have undesirable side effects or low potency but in combination with opioids 
allow a reduction of narcotic dosing for postoperative pain control. Thus they can provide 
beneficial effects when administered in appropriate doses as part of a multimodal analgesic 
regimen in the perioperative setting (Fanelli et al, 2008; Vadivelu et al, 2010). 
 
Multimodal Analgesia for Postoperative Pain Management 
 
187 
Multimodal analgesia incorporates the use of analgesic adjuncts with different mechanisms 
of action to enhance postoperative pain management. Adjuvants are important in 
postoperative pain management due to side effects of opioid analgesics, which hinder 
recovery, especially in the increasingly utilized ambulatory surgical procedures 
(Buvanendran&Kroin, 2007). Multiple adjuvants recently have been developed for the 
control of pain.  
4.2.4.1 Alpha-2 adrenergic agonists 
Alpha-2 adrenergic activation represents an intrinsic pain control network of the central 
nervous system. The alpha-2 adrenergic receptor has high density in the substantia 
gelatinosa of the dorsal horn in humans and that is believed to be the primary site  
of action by which alpha-2 adrenergic agonists can reduce pain (Buvanendran&Kroin, 
2007). 
4.2.4.1.1 Clonidine 
Clonidine is originally classified as an anti-hypertensive drug with negative chronotropic 
activity, but has antinociceptive properties as well. In the spinal cord, clonidine acts at 
alpha-2 adrenergic receptors to stimulate acetylcholine release, which acts at both 
muscarinic and nicotinic receptor subtypes with analgesic effects (Fanelli et al, 2008). 
Clonidine can be administered orally, intravenously, neuraxially  or perineurally in 
combination with local anesthetics. However, the side effects could be significant. The most 
important ones are hypotension, bradycardia and sedation (Rawal). Data about the systemic 
administration of clonidine could support the usefulness of low-dose IV administration. 
Nonetheless due to the many side effects of systemic clonidine administration, the spinal 
route is preferred.   
Low doses of clonidine proved to be a useful adjunct analgesic when given neuraxially and 
in combination with peripheral nerve blocks (Habib et al, 2005). Significant results in terms 
of block duration were obtained when clonidine was added to local anesthetics for epidural 
or perineural analgesia. At low doses (2 μg/kg), it was shown to increase the duration of 
perineural blockade. Animal studies suggest that the mechanism of clonidine’s potentiation 
of lidocaine nerve block is inhibition of the hyperpolarization-activated cation current, not 
via its binding to alpha-2 adrenergic receptors (Jurna, 1995). 
4.2.4.1.2 Dexmedetomidine 
Dexmedetomidine is a relatively new, highly selective central alpha-2 agonist.  
Dexmedetomidine, when used as an adjunct, can reduce postoperative morphine 
consumption in various surgical settings using various routes such as intravenous (Dholakia 
et al, 2007; Gurbet et al, 2006; Lin et al, 2009). In a recent study the authors found that;  
the addition of dexmedetomidine to intravenous  PCA morphine resulted in superior 
analgesia, significant morphine sparing, and less morphine-induced nausea,while it  
was devoid of additional sedation and untoward hemodynamic changes (Dholakia et al, 
2007).   
4.2.4.2 N-methyl-D-aspartate antagonists (Antihyperalgesic drugs) 
With the discovery of the N-methyl-D-aspartate (NMDA) receptor and its links to 
nociceptive pain transmission and central sensitization, there has been renewed interest in 
utilizing noncompetitive NMDA receptor antagonists, such as ketamine, dextromethorphan, 
magnesium ions as potential antihyperalgesic agents. 
 




Ketamine has been a well known general anesthetic and analgesic for the past 3 decades.  
There is evidence that low-dose ketamine may play an important role in postoperative  
pain management when used as an adjunct to opioids, local anesthetics, and other analgesic 
agents. 
Ketamine, is the most commonly used antihyperalgesic drug. There is a definite role of 
ketamine in preventing opioid-induced hyperalgesia in patients receiving high doses of 
opioid for their postoperative pain relief (Mitra, 2008). It acts as an antagonist of NMDA 
receptors and may reduce the intensity of hyperalgesia following rapid μ opioid receptor 
stimulation by short-acting agonists such as remifentanil and, to a lesser extent, sufentanil 
and fentanyl. Perioperative administration of 2-10 μg/kg/min following a loading dose of 
0.5 mg/kg decreases hyperalgesia and allodynia after thoracic and abdominal surgery 
(Bilgin et al, 2005; Joly et al, 2005), although doses may vary depending on the overall 
duration and amount of exposure to short-acting opioids.  
Routes of administration include oral, intravenous,intramuscular, subcutaneous, epidural, 
transdermal, and intra-articular.  
Clinical use of ketamine can be limited due to psychotomimetic adverse effects such as 
hallucinations, excessive sedation and bad dreams. Other common adverse effects are 
dizziness, blurred vision, and nausea and vomiting  (Bell et al, 2006). Although high doses 
of ketamine have been implicated in causing psychomimetic effects, subanesthetic or low 
doses of ketamine have demonstrated significant analgesic efficacy without these side 
effects (Buvanendran&Kroin, 2009). It can be used in sub-anesthetic doses as an adjunct to 
provide postoperative pain relief in opioid-dependent patients (Mitra et al, 2004). 
4.2.4.2.2 Dextramethorphan 
Dextromethorphan has a similar mechanism of action with a lower affinity for the NMDA 
receptor. Following oral administration, it is rapidly absorbed from the gut and crosses the 
blood-brain barrier. A systematic review of perioperative dextromethorphan treatment for 
acute post-surgical pain concluded that the drug was a safe potential adjunct to classical 
opioid-based analgesia, but the results were inconsistent (Duedahl et al, 2006). 
4.2.4.2.3 Magnesium 
The magnesium ion was the first agent discovered to be an NMDA channel blocker. 
Similarly to ketamine and dextromethorphan, magnesium ions act by blocking the NMDA 
receptor pore. Since magnesium crosses the blood-brain barrier with difficulty in humans, it 
is not clear whether its therapeutic effects are related to NMDA antagonism in the central 
nervous system. 
Several clinical studies have shown that magnesium increases postoperative analgesia, but 
the best dosage regimen remains to be determined (Lysakowski et al, 2007). At very high 
doses, perioperative intravenous magnesium sulfate has been reported to reduce 
postoperative morphine consumption but not postoperative pain scores (Koinig et al, 1998; 
Tramer et al, 1996). 
4.2.4.3 Gabapentin-type drugs 
Pregabalin and gabapentin bind to voltage-gated calcium channels in the spinal cord and 
brain. Both drugs are used for seizures and neuropathic pain. One advantage of pregabalin 
in clinical use is that it has higher bioavailability than gabapentin and linear 
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pharmacokinetics. The gabapentinoid compounds have been used as part of multimodal 
analgesic in the postoperative period. Earlier clinical trials with gabapentin for early 
postsurgical pain have recently been reviewed (Buvanendran&Kroin, 2009).  
4.2.4.3.1 Gabapentin 
Gabapentin, a third-generation anti-epileptic drug, is a structural analogue of Gaba 
Aminobutyric Acid (GABA), an important neurotransmitter in the central nervous system. 
Its main action, however, is to inhibit the alpha2δ subunit of Ca2+ channels with a resultant 
decrease in neuronal hyperexcitability. During the immediate postoperative period, 
however, its activation of descending inhibitory pathways may be more relevant and might 
explain its synergistic effect with opioids (Hurley et al, 2006). 
Most of the reviews and meta-analyses concur that perioperative gabapentin helps to 
produce a significant opioid-sparing effect and probably also improves postoperative pain 
score relative to the control group (Hartrick et al, 2009; Tiipana et al, 2007). 
4.2.4.3.2 Pregabalin 
Pregabalin a structural analog of GABA and a derivative of gabapentin (S+ 3-isobutyl 
GABA). It is a novel drug with a heightened research interest in the analgesic, sedative, 
anxiolytic, and opioid-sparing effects, in various pain settings, including postoperative 
pain. 
Its main advantages may be faster onset and reduced adverse side effects. Some studies 
suggest pregabalin to have effective sedative and opioid-sparing effects (Hartrick et al, 2009; 
Mathiesen et al, 2008), useful characteristics for the control of acute pain. Research on its 
established role as an analgesic adjuvant as a part of multimodal  analgesia for acute pain 
control is ongoing.   
4.2.4.4 Glucocorticoids 
Glucocorticoids, including dexamethasone, have been used to reduce inflammation and 
postoperative pain in surgical procedures (Salerno et al, 2006). Glucocorticoid steroids can 
provide beneficial effects when administered in appropriate doses as part of a multimodal 
analgesic regimen in the perioperative setting (White, 2005, 2007). 
4.2.4.4.1 Dexamethasone 
Dexamethasone is a synthetic glucocorticoid with high potency and a long duration of 
action (half-life: 2 days), and has low mineralocorticoid activity. Although dexamethasone 
reduces PG synthesis, its possible analgesic effects have not yet been demonstrated.  
In patients undergoing total hip arthroplasty under spinal anesthesia with propofol sedation 
a single preoperative intravenous dose of dexamethasone decreased the pain upon standing 
at 24 h compared to placebo (Kardash et al, 2008). In a recent study, it did not reduce 
postoperative pain scores and analgesic requirements after laparoscopic cholecystectomy. 
The main advantage of postoperative dexamethasone is its ability to reduce postoperative 
nausea and vomiting  (Feo et al, 2006). 
4.2.4.5 Newer drugs 
4.2.4.5.1 Capcaisin 
Capsaicin (8-methyl-N-vanillyl-6-nonenamide) is a non narcotic and acts peripherally. It can 
be used as a cream and also as an injectable analgesic. 
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Capsaicin cream is usually combined with narcotic analgesics and NSAIDs to relieve a 
variety of painful ailments such as back pain, arthritic joint pains, and strains and sprains. 
Injectable capsaicin is used for the control of post operative pain, such as after total knee 
replacement, total hip replacement, hernia repair, shoulder arthroscopy, and bunionectomy 
(Aasvang et al, 2008). Pre-administration of neural blockade before injection of capsaicin 
may greatly decrease the burning discomfort. 
Capsaicin appears to be a relatively safe drug. In the elderly who are sensitive to respiratory 
depression that can occur with opioids, capsaicin can be particularly beneficial as an 
adjuvant. The only absolute contraindication being patient hypersensitivity. Relative 
contraindications include age less than 2 years, patients with elevated liver enzymes, 
patients on ACE inhibitors, and patients showing signs of septic arthritis and joint infections 
(Vadivelu et al, 2010).  
4.2.4.5.2 Glyceryl trinitrate 
The organic nitrates, such as glyceryl trinitrate (GTN), act as nitric oxide donors.  
High dose nitroglyserin patches, such as 30 mg daily, are hyperalgesic, whereas doses less 
than 6 mg per day are analgesic under different circumstances. Previously it has been 
observed that patients with past histories of angina who had spinal block, in which the 
nitroglycerin transdermal patch was applied prophylactically, required fewer analgesic after 
operation (Lauretti et al, 1999). 
4.2.4.5.3 Cholinergic drugs 
Acetylcholine may cause analgesia through direct action on spinal cholinergic muscarinic 
receptors M1 and M3 and nicotinic receptors subtypes. 
4.2.4.5.3.1 Nicotine 
In a study in nonsmoker patients having radical retropubic prostatectomy under general 
anesthesia, the application of a 7 mg nicotine patch 30–60 min before surgery for 
postoperative 24 hrs, resulted with lower cumulative PCA morphine consumption versus 
placebo group. But the intensity of nausea was greater in the nicotine group (Habib et al, 
2008). 
Table 3 summarizes the doses and routes of administration of frequently used drugs.  
 
 Administration Dosage 
OPIOIDS 
Morphine (i) Intravenous. 
(ii) Subcutaneous by 
continuous infusion or 
intermittent boluses via 
indwelling cannula. 
(iii) Intramuscular (not 
recommended due to 
incidence of pain.   
5-10 mg 3-4 hourly). 
IV PCA  
Bolus: 1-2 mg, lockout: 5-15 
min (usually 7-8 min), no 
background infusion. 
Subcutaneous  
0.1-0.15 mg/kg 4-6 hourly, 
adapted in relation to pain 
score, sedation and 
respiratory rate. 
Codeine Oral 3 mg/kg/day combined 
with paracetamol. 
A minimum of 30 mg 
codeine/tablet is required 
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 Administration Dosage 
OPIOIDS 
Tramadol (i) Intravenous: inject 
slowly (risk of high 
incidence of nausea and 
vomiting). 
(ii) Intramuscular. 
(iii) Oral administration as 
soon as possible. 
 
0.75-1.0 mg/kg 
50-100 mg 6 hourly. 
NONOPIOIDS 
Paracetamol  Oral 4 x 1 g paracetamol/day (2 g 
propacetamol/day). 
Dose to be reduced (e.g. 3 x 1 
g/day) in case of hepatic 
insufficiency. 
Combination of 
paracetamol and codeine 
Oral Paracetamol 500 mg + 
codeine 30 mg. 
4 x 1 g paracetamol/day. 
NSAIDs (i) Intravenous 
administration should start 
at least 30-60 min before 
end of surgery. 
(ii) Oral administration 
should start as soon as 
possible. 
Duration: 3-5 days. 
(iii) Rectal 
Ketorolac: 3 x 30-40 mg/day  
(only IV form) 
Diclofenac: 2 x 75 mg/day 
Ketoprofen: 4 x 50 mg/day 
(ii) Selective NSAIDs 
include: 
Meloxicam 15 mg once daily 
Celecoxib: 200 mg/day. 
Acetaminophen Intravenous 100 ml solution (10 mg/ml) 
administration over a period 
of 15 minutes. 
ADJUVANTS 
Clonidine (i) Oral 
(ii) Intravenous 
(iii) Combined with local 
anesthetics-neuraxially or 
perineurally 
3- 5 µg/kg (oral) 
1 µg/kg (intravenous) 
1-2 µg/kg (epidural) or 75-
100 µg (intrathecal) 
Ketamine Intravenous Loading dose of 0.5 mg/kg 
followed by 2-10 µg/kg/min 
* The doses and routes of administration of drugs described above are general examples and each 
patient should be assessed individually before prescribing 
Table 3. The doses and routes of administration of frequently used drugs * (modified table 
by permission from Publisher AstraZeneca) 
4.2.5 Local anesthetics 
Sodium channel blocking drugs are usually used in the management of both acute and 
chronic pain. When dealing with postoperative pain, local anesthetics such as lidocaine and 
bupivacaine mostly preferred (McCleane, 2010). 
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Capsaicin cream is usually combined with narcotic analgesics and NSAIDs to relieve a 
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placebo group. But the intensity of nausea was greater in the nicotine group (Habib et al, 
2008). 
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 Administration Dosage 
OPIOIDS 
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NSAIDs (i) Intravenous 
administration should start 
at least 30-60 min before 
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(ii) Oral administration 
should start as soon as 
possible. 
Duration: 3-5 days. 
(iii) Rectal 
Ketorolac: 3 x 30-40 mg/day  
(only IV form) 
Diclofenac: 2 x 75 mg/day 
Ketoprofen: 4 x 50 mg/day 
(ii) Selective NSAIDs 
include: 
Meloxicam 15 mg once daily 
Celecoxib: 200 mg/day. 
Acetaminophen Intravenous 100 ml solution (10 mg/ml) 
administration over a period 
of 15 minutes. 
ADJUVANTS 
Clonidine (i) Oral 
(ii) Intravenous 
(iii) Combined with local 
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perineurally 
3- 5 µg/kg (oral) 
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followed by 2-10 µg/kg/min 
* The doses and routes of administration of drugs described above are general examples and each 
patient should be assessed individually before prescribing 
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4.2.5 Local anesthetics 
Sodium channel blocking drugs are usually used in the management of both acute and 
chronic pain. When dealing with postoperative pain, local anesthetics such as lidocaine and 
bupivacaine mostly preferred (McCleane, 2010). 
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Local anesthetics block sodium channels, thereby, preventing transmission of nerve impulse 
along the axonal fibre. This is a local effect at the site of injection. Tissue anesthesia occurs 
after the injection of the local anesthetics into tissue at appropriate concentration, but it lasts 
after the duration of the drug ended. However, local anesthetics are also absorbed into the 
systemic circulation from the site of injection and, depending on the dose and rate of 
absorption, may have  systemic analgesic effects (Gupta,2010; McCleane, 2010). 
Local anesthetic solutions delivered through an epidural or perineural route are the most 
important treatments for decreasing incident pain, hormonal stress and sympathetic 
responses during and after surgery (Chelly, 2001; Liu, 2007). Generally, higher doses are 
used intraoperatively and then reduced to reach differential motor-sensory block in the 
postoperative period. The best results are achieved when local anesthetic solutions are 
infused neuraxially with lipophilic opioids, such as sufentanil and fentanyl at adequate 
concentrations (George, 2006; de-Leon-Casaola&Lema, 1996). 
In some studies the effectiveness of the intravenous infusion of lidocaine in reducing 
postoperative pain and facilitating the recovery process have been demonstrated (Kaba et al, 
2007; Lauwick et al, 2008). Yardeni and colleagues (Yardeni et al, 2009) suggested that, 
perioperative administration of intravenous lidocaine could improve early postoperative 
pain control and reduce surgery-induced immune alterations. The injection of local 
anesthetic around wound edges has been proven to reduce postoperative pain, but only for 
the duration of that local anesthetic (Moinichi et al, 1998). Several concerns about these 
drugs have been expressed in the literature including the risk of infection, chondrolysis and 
systemic local anesthetics toxicity when they used locally.  
The maximum doses for local anesthetics are summarized in Table 4. 
 
Local anesthetic Maximum total dosage 
Prokain 400 mg 
Chlorprocaine 800 mg 
Lidocaine 4 mg/kg (without epinephrine) 
7 mg/kg(with epinephrine)  or  300 mg 
Prilocaine 6 mg/kg (without epinephrine) 
9 mg/kg(with epinephrine)  or  500 mg 
Bupivacaine 2 mg/kg (without epinephrine) 
2.5 mg/kg(with epinephrine)  or  150 mg 
Levobupivacaine 2.5-3 mg/kg (insufficient data)  or  150 mg  
Ropivacaine 3-4 mg/kg (without or with epinephrine) 
Table 4. Maximum doses of frequently used local anesthetics 
5. Techniques in postoperative pain management 
One approach for multimodal analgesia is the use of regional anesthesia and analgesia to 
inhibit the neural conduction from the surgical site to the spinal cord and decrease spinal cord 
sensitization (Buvanendran&Kroin, 2009). A variety of neuraxial and peripheral regional 
analgesic techniques can provide analgesia superior to that with systemic opioids and may 
even result in improvement in various outcomes.  However, there are some risks associated 
with the use of such techniques. The clinician should evaluate the risks and benefits of these 
techniques on an individual basis in determining the appropriateness of neuraxial or 
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peripheral regional techniques for each patient, especially in light of some of the controversies 
about the use of these techniques in the presence of various anticoagulants.    
Neuraxial (primarily epidural) and peripheral regional analgesic techniques (e.g., brachial 
plexus, lumbar plexus, femoral, sciatic-popliteal, and scalp nerve blocks),  also a variety of 
wound infiltration techniques may be used for the effective treatment of postoperative pain. 
In general, the analgesia provided by epidural and peripheral techniques (particularly when 
local anesthetics are used) is superior to that with systemic opioids, (i.e., superior analgesia 
and decreased opioid-related side effects) and use of these techniques may even reduce 
morbidity and mortality (Wu&Fleisher 2000). 
Techniques used in postopetaive pain management are: 
1. Neuraxial Techniques 
2. Peripheral Regional Analgesia Techniques 
3. Infiltration Techniques  
a. Wound Infiltration 
b. Topical Application 
c. Local Infiltration Analgesia 
4. Other – Nonpharmacological Techniques 
5.1 Neuraxial techniques 
Spinal or epidural analgesia techniques in single or continuous forms can be used in 
postoperative pain management. The use of epidural anesthesia and analgesia is an integral 
part of the multimodal approach because of the superior analgesia and physiologic benefits 
conferred by epidural analgesia. 
Among the most commonly used pain-relieving techniques, there is evidence that the 
epidural local anesthetic or local anesthetic-opioid techniques are the most effective on 
providing dynamic pain relief after major surgical procedures (Kehlet et al, 1999). Epidural 
local anesthetic application comes in as the major component of multimodal analgesia. 
Postoperative epidural analgesia is usually accomplished with a combination of a long-
acting local anesthetic and an opioid, in dilute concentrations (Table 5). Long-acting local 
anesthetics are preferred because they are associated with less tachyphylaxis. Thoracic 
epidural analgesia with local anesthetics and opioids for abdominal, thoracic and vascular 
surgery improves bowel recovery times while decreasing the risks of cardiovascular 
adverse events and of developing persistent pain (Liu, 2004; Nishimori et al, 2006;). In an 
unpublished study of ours (Sivrikaya et al, 2000), preemptive analgesia with epidural 
tramadol has supressed the peroperative stress response and also reduced the pain 
intensity in the early postoperative period in patients had abdominal hysterectomy under 
general anesthesia.     
Maintenance techniques in epidural analgesia include: 
Continuous Infusion: An easy technique that requires little intervention. The cumulative 
dose of local anesthetic is likely to be higher and side effects are more likely than with the 
other two techniques. 
Intermittent Top-up: Results in benefits due to frequent patient/staff contact but can 
produce a high staff workload and patients may have to wait for treatment. 
Patient-Controlled Epidural Analgesia (PCEA): This technique produces high patient 
satisfaction and reduced dose requirements compared with continuous infusion. However, 
sophisticated pumps are required and accurate catheter position is important for optimal 
efficacy (Rawal). 
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perioperative administration of intravenous lidocaine could improve early postoperative 
pain control and reduce surgery-induced immune alterations. The injection of local 
anesthetic around wound edges has been proven to reduce postoperative pain, but only for 
the duration of that local anesthetic (Moinichi et al, 1998). Several concerns about these 
drugs have been expressed in the literature including the risk of infection, chondrolysis and 
systemic local anesthetics toxicity when they used locally.  
The maximum doses for local anesthetics are summarized in Table 4. 
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7 mg/kg(with epinephrine)  or  300 mg 
Prilocaine 6 mg/kg (without epinephrine) 
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inhibit the neural conduction from the surgical site to the spinal cord and decrease spinal cord 
sensitization (Buvanendran&Kroin, 2009). A variety of neuraxial and peripheral regional 
analgesic techniques can provide analgesia superior to that with systemic opioids and may 
even result in improvement in various outcomes.  However, there are some risks associated 
with the use of such techniques. The clinician should evaluate the risks and benefits of these 
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peripheral regional techniques for each patient, especially in light of some of the controversies 
about the use of these techniques in the presence of various anticoagulants.    
Neuraxial (primarily epidural) and peripheral regional analgesic techniques (e.g., brachial 
plexus, lumbar plexus, femoral, sciatic-popliteal, and scalp nerve blocks),  also a variety of 
wound infiltration techniques may be used for the effective treatment of postoperative pain. 
In general, the analgesia provided by epidural and peripheral techniques (particularly when 
local anesthetics are used) is superior to that with systemic opioids, (i.e., superior analgesia 
and decreased opioid-related side effects) and use of these techniques may even reduce 
morbidity and mortality (Wu&Fleisher 2000). 
Techniques used in postopetaive pain management are: 
1. Neuraxial Techniques 
2. Peripheral Regional Analgesia Techniques 
3. Infiltration Techniques  
a. Wound Infiltration 
b. Topical Application 
c. Local Infiltration Analgesia 
4. Other – Nonpharmacological Techniques 
5.1 Neuraxial techniques 
Spinal or epidural analgesia techniques in single or continuous forms can be used in 
postoperative pain management. The use of epidural anesthesia and analgesia is an integral 
part of the multimodal approach because of the superior analgesia and physiologic benefits 
conferred by epidural analgesia. 
Among the most commonly used pain-relieving techniques, there is evidence that the 
epidural local anesthetic or local anesthetic-opioid techniques are the most effective on 
providing dynamic pain relief after major surgical procedures (Kehlet et al, 1999). Epidural 
local anesthetic application comes in as the major component of multimodal analgesia. 
Postoperative epidural analgesia is usually accomplished with a combination of a long-
acting local anesthetic and an opioid, in dilute concentrations (Table 5). Long-acting local 
anesthetics are preferred because they are associated with less tachyphylaxis. Thoracic 
epidural analgesia with local anesthetics and opioids for abdominal, thoracic and vascular 
surgery improves bowel recovery times while decreasing the risks of cardiovascular 
adverse events and of developing persistent pain (Liu, 2004; Nishimori et al, 2006;). In an 
unpublished study of ours (Sivrikaya et al, 2000), preemptive analgesia with epidural 
tramadol has supressed the peroperative stress response and also reduced the pain 
intensity in the early postoperative period in patients had abdominal hysterectomy under 
general anesthesia.     
Maintenance techniques in epidural analgesia include: 
Continuous Infusion: An easy technique that requires little intervention. The cumulative 
dose of local anesthetic is likely to be higher and side effects are more likely than with the 
other two techniques. 
Intermittent Top-up: Results in benefits due to frequent patient/staff contact but can 
produce a high staff workload and patients may have to wait for treatment. 
Patient-Controlled Epidural Analgesia (PCEA): This technique produces high patient 
satisfaction and reduced dose requirements compared with continuous infusion. However, 
sophisticated pumps are required and accurate catheter position is important for optimal 
efficacy (Rawal). 
 




Local anesthetics / 
opioids 
Ropivacaine 2% (2 mg/ml) or  
Levobupivacaine or 
Bupivacaine  
0.1-0.2% (1-2 mg/ml) 
Sufentanil 0.5-1 μg/ml or 
Fentanyl 2-4 μg/ml or 
Morphine 0.05-0.1 mg/ml or 
Clonidine 5-20 μg/ml 
(clinical application is 
limited by its side effects) or 
Epinephrine 2- 5 μg/ml 
Dosage for continuous 
infusion  
(thoracic or lumbar 
level) 
6-12 ml/h  
Dosage for patient 
controlled infusion  
(thorasic or lumbar 
level) ** 
Background: 4-6 ml/h 
Bolus dose: 2 ml (2-4 ml) 




hourly dose (bolus + 
background): 12 ml 
 
* The tip of the catheter should be placed as close as possible to the surgical dermatomes: T6-T10 for 
major intra-abdominal surgery, and L2-L4 for lower limb surgery. 
** There are many possible variations in local anesthetic/opioid concentration yielding good results, the 
examples given here should be taken as a guideline; higher concentrations than the ones mentioned 
here are sometimes required but cannot be recommended as a routine for postoperative pain relief. 
Table 5. Examples of local anesthetics and opioids and doses in epidural analgesia *  
(by permission from Publisher AstraZeneca) 
Continuous central neuraxial blockade is one of the most effective forms of postoperative 
analgesia, but it is also one of the most invasive. However, this technique remains the  
first choice for a number of indications, such as abdominal, thoracic, and major  
orthopedic surgery, where adequate pain relief cannot be achieved with other analgesia 
techniques alone. Continuous central neuraxial blockade can be achieved via two routes: 
Continuous epidural analgesia - the recommended first choice and continuous spinal 
analgesia - should be limited to selected cases only, as there is less experience with this 
technique.   
5.2 Peripheral regional analgesia techniques 
It is clear that local anesthetic techniques, particularly peripheral nerve blockade, will be 
one of the cornerstones of postoperative pain management. A variety of peripheral 
regional analgesic techniques (e.g. brachial plexus, lumbar plexus, femoral, paravertebral 
nerve blocks) as a single injection or continuous infusion can be used to enhance 
postoperative analgesia. Peripheral regional techniques may have several advantages over 
systemic opioids (i.e., superior analgesia and decreased opioid-related side effects). Also 
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the side effects associated with central neuraxial blockade, such as hypotension and wide 
motor blockade with reduced mobility and proprioception, and complications such as 
epidural Hematoma, epidural abscess and paraparesis can be avoided (Liu&Salinas, 
2003). 
Continuous peripheral nerve blocks are being increasingly used since they may provide 
more selective but still excellent postoperative analgesia with reduced need for opioids over 
an extended period (Table 6). The vailability of disposable local anesthetic infusion systems 
and the encouraging results from these early studies have led to the increasing popularity of 
these techniques for pain control in the postdischarge period (Elvir Lazo&White, 2010). This 
technique has become increasingly popular due to its ability to control moderate to severe 
pain  and accelerate recovery especially after orthopedic surgery procedures (Capdevila et 
al, 2005; Ilfeld&Enneking, 2005; White, 2003).  
Patient controlled regional analgesia (PCRA) can also be used to maintain peripheral nerve 
block. A low basal infusion rate (e.g. 3-5 ml/h) associated with small PCA boluses (e.g. 2.5-5 




Site of catheter Local anesthetics and dosage* 
 Ropivacaine 0.2%-0.375% 
Bupivacaine 0.1-0.125% 
Levobupivacaine 0.1-0.2% 
Interscalene 5-9 ml/h 
Infraclavicular 5-9 ml/h 
Axillary 5-10 ml/h 
Femoral 7-10 ml/h 
Popliteal 3-7 ml/h 
Patient controlled regional analgesia Background: 3-5 ml/h 
Bolus dose: 2,5-5 ml 
Lockout interval: 30-60 min 
*Sometimes, higher concentrations are required in individual patients. As a standard, starting with a 
low concentration/dose is recommended to avoid sensory loss or motor block. 
Table 6. Examples of local anesthetics and doses in continuous peripheral nerve analgesia 
and PCA (modified table after using by permission from Publisher AstraZeneca) 
5.2.1 Paravertebral blocks 
The evidence suggests that the use of paravertebral blocks provide effective postoperative 
pain control following breast and thoracic surgery as well as for inguinal hernia repair 
(Greengrass et al, 1996; Karmakar, 2011; Pusch et al, 1999). On their own, paravertebral 
blocks have been demonstrated to provide effective postoperative analgesia lasting up to  
24 hrs (Chelly et al, 2011). 
Chelly et al showed in their study that; a multimodal approach, including paravertebral 
blocks (prior to surgery), celecoxib (pre and post surgey), and ketamine (immediately prior 
to surgery), provides better postoperative pain control than PCA morphine alone in patients 
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the side effects associated with central neuraxial blockade, such as hypotension and wide 
motor blockade with reduced mobility and proprioception, and complications such as 
epidural Hematoma, epidural abscess and paraparesis can be avoided (Liu&Salinas, 
2003). 
Continuous peripheral nerve blocks are being increasingly used since they may provide 
more selective but still excellent postoperative analgesia with reduced need for opioids over 
an extended period (Table 6). The vailability of disposable local anesthetic infusion systems 
and the encouraging results from these early studies have led to the increasing popularity of 
these techniques for pain control in the postdischarge period (Elvir Lazo&White, 2010). This 
technique has become increasingly popular due to its ability to control moderate to severe 
pain  and accelerate recovery especially after orthopedic surgery procedures (Capdevila et 
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undergoing open radical retropubic prostatectomy. This approach also allows a reduction in 
the postoperative need for opioids, lessens the related side effects (e.g., PONV, constipation, 
and bladder spasm), and facilitates earlier patient recovery which can be connoted that it 
fascilitates the patient’s early recovery (Chelly et al, 2011).    
5.3 Infiltration techniques 
Local anesthetics can be administered for perioperative pain management via different routes 
(Table 7). It is crucial for improving the perioperative outcomes especially after day-case 




 Local anesthetic Volume Additives 
Intraarticular instillation  
Knee arthroscopy 0.75% Ropivacaine 20 ml Morphine 1-2 
mg 
0.5% Bupivacaine 20 ml Morphine 1-2 
mg 




Gynecological 0.75% Ropivacaine 20 ml  
Cholecystectomy 0.25% Ropivacaine 40-60 ml  
Wound infiltration  
Inguinal hernia 
Perianal surgery 
0.25-0.5% Ropivacaine 30-40 ml  
0.25-0.5% 
Levobupivacaine 
30-40 ml  
0.25-0.5% Bupivacaine Up to 30 ml  
Thyroid surgery 0.25-0.5% Ropivacaine 10-20 ml  
0.25-0.5% 
Levobupivacaine 
10-20 ml  
0.25-0.5% Bupivacaine Up to 20 ml  
Table 7. Local anesthetic infiltration  (by permission from Publisher AstraZeneca) 
There are a few techniques for the delivery of the drugs locally into the tissues: intermittent 
injection, continuous infusion or a combination of two: Intermittent injections (also 
sometimes referred to as patient-controlled regional analgesia) have the advantage that pain 
relief can be timed in order to achieve maximal effect during the painful periods such as 
during mobilization. However, the disadvantage is that sleep quality may be disturbed, as 
patients sometimes wake up at night due to severe pain, which may be annoying and can 
also be a cause of patient dissatisfaction. Continuous local anesthetic administration has its 
advantage in that the patient has adequate pain relief most of the time. However, during 
periods of activity, the pain could be more severe, which may hamper mobilization. 
Methods using pumps that have a dual function with low-dose continuous infusion 
combined with self-administered bolus doses during mobilization are ideal. Several such 
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pumps are available in the market today, including mechanical (elastometric) and electronic 
(Gupta, 2010).  
5.3.1 Wound infiltration 
Infiltrating local anesthetics into the skin and subcutaneous tissue prior to making an 
incision may be the simplest approach to analgesia. It is a safe procedure with few side 
effects and low risk for toxicity. Particularly, local anesthetic toxicity, wound infection and 
healing do not appear to be major problems (Buvanendran&Kroin, 2009).  
Although the benefit of local wound infiltration has been documented (Barr-Dayan et al, 
2004; Legeby et al, 2009; Park et al, 2002), controversy exists as to the appropriate timing of 
administering local anesthesia for surgery. A single injection of local anesthetics into the 
wound is unlikely to have long-lasting effects. Therefore, new techniques for wound 
infiltration have evolved during the last 10 years and several of them are today used 
routinely during ambulatory surgery and even in the inpatient setting. One such technique 
is the use of catheters inserted into incision, fascia, intra-articularly and intraabdominally for 
the intermittent injection or continuous infusion of local anesthetics and adjuvants for pain 
management (Gupta, 2010). 
Continuous wound infusion of local anesthetics, which is mainly used in general surgery 
and orthopedics, is an interesting technique in postoperative pain therapy. Continuous 
wound infusion of local anesthetics is able to reduce postoperative opioid requirements and 
results in decreased pain scores (Gupta et al, 2004; Rasmussen et al, 2004). Recent studies 
indicate that rehabilitation seems to be enhanced and postoperative hospital stay may be 
shorter. Continuous wound infusion is an effective analgesic technique, which is simple to 
perform. Comparisons with other analgesic techniques, such as peripheral nerve blocks, 
epidural analgesia and other multimodal analgesic concepts are still required.  
Hollmann and Durieux (Hollmann&Durieux, 2000) found that there was a reduction in ileus 
and hospital stay when lidocaine was given intravenously following major abdominal 
surgery. Therefore, when administered in larger doses during wound infiltration analgesia, 
it is possible that some of the analgesic effect seen is via systemic absorption and anti-
inflammation.   
Wound infiltration with local anesthetics is a simple, effective and inexpensive way of 
regimen which can be used in a multimodal analgesic regime without major complications. 
Nonetheless this technique still open some questions to be answered as; to the site of 
catheter placement, catheter type to be placed, the drugs and concentrations recommended, 
the technique of administration and side-effects of the technique, including toxicity of local 
anesthetics.  Also it remains unclear as to whether this technique is useful in all types of 
surgery or should preferably be used for specific operations (Gupta, 2000).  
5.3.2 Topical application 
5.3.2.1 Local anesthetics 
Lidocaine patches were applied to the wound area in the next two studies, and the evidence 
shows that these are particularly effective for wound pain when the patient coughes and 
they reduce the postoperative pain score at discharge (Habib et al, 2009; Saber et al, 2009).  
To place lidocaine patches over or at least close to the wound is suggested as a safe and 
promising modality to consider in the management of postoperative pain control.  
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undergoing open radical retropubic prostatectomy. This approach also allows a reduction in 
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and bladder spasm), and facilitates earlier patient recovery which can be connoted that it 
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sometimes referred to as patient-controlled regional analgesia) have the advantage that pain 
relief can be timed in order to achieve maximal effect during the painful periods such as 
during mobilization. However, the disadvantage is that sleep quality may be disturbed, as 
patients sometimes wake up at night due to severe pain, which may be annoying and can 
also be a cause of patient dissatisfaction. Continuous local anesthetic administration has its 
advantage in that the patient has adequate pain relief most of the time. However, during 
periods of activity, the pain could be more severe, which may hamper mobilization. 
Methods using pumps that have a dual function with low-dose continuous infusion 
combined with self-administered bolus doses during mobilization are ideal. Several such 
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pumps are available in the market today, including mechanical (elastometric) and electronic 
(Gupta, 2010).  
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healing do not appear to be major problems (Buvanendran&Kroin, 2009).  
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routinely during ambulatory surgery and even in the inpatient setting. One such technique 
is the use of catheters inserted into incision, fascia, intra-articularly and intraabdominally for 
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Continuous wound infusion of local anesthetics, which is mainly used in general surgery 
and orthopedics, is an interesting technique in postoperative pain therapy. Continuous 
wound infusion of local anesthetics is able to reduce postoperative opioid requirements and 
results in decreased pain scores (Gupta et al, 2004; Rasmussen et al, 2004). Recent studies 
indicate that rehabilitation seems to be enhanced and postoperative hospital stay may be 
shorter. Continuous wound infusion is an effective analgesic technique, which is simple to 
perform. Comparisons with other analgesic techniques, such as peripheral nerve blocks, 
epidural analgesia and other multimodal analgesic concepts are still required.  
Hollmann and Durieux (Hollmann&Durieux, 2000) found that there was a reduction in ileus 
and hospital stay when lidocaine was given intravenously following major abdominal 
surgery. Therefore, when administered in larger doses during wound infiltration analgesia, 
it is possible that some of the analgesic effect seen is via systemic absorption and anti-
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Wound infiltration with local anesthetics is a simple, effective and inexpensive way of 
regimen which can be used in a multimodal analgesic regime without major complications. 
Nonetheless this technique still open some questions to be answered as; to the site of 
catheter placement, catheter type to be placed, the drugs and concentrations recommended, 
the technique of administration and side-effects of the technique, including toxicity of local 
anesthetics.  Also it remains unclear as to whether this technique is useful in all types of 
surgery or should preferably be used for specific operations (Gupta, 2000).  
5.3.2 Topical application 
5.3.2.1 Local anesthetics 
Lidocaine patches were applied to the wound area in the next two studies, and the evidence 
shows that these are particularly effective for wound pain when the patient coughes and 
they reduce the postoperative pain score at discharge (Habib et al, 2009; Saber et al, 2009).  
To place lidocaine patches over or at least close to the wound is suggested as a safe and 
promising modality to consider in the management of postoperative pain control.  
 




Clonidine is an alpha adrenoreceptor agonist and these receptors are known to be located 
centrally. In a volunteer study (Pratab et al, 2007) clonidine had a significant peripheral 
action in enhancing duration of local anesthesia on superficial co-infiltration with lidocaine. 
Hence an opportunity with this co-administration to prolong the duration of pain relief 
apparent after postoperative wound infiltration could be possible.  
5.3.2.3 Nonsteroidal anti-inflammatory drugs 
The topical application of NSAIDs could produce significant pain relief as the systemic 
levels achieved by transdermal application. Topically use of NSAIDs has become popular in 
the ophthalmic field, in which it has been shown that topically applied NSAIDs can reduce 
postoperative pain and inflammation (Cho, 2009; Jones&Francis, 2009). In a study, the use of 
a topical diclofenac patch resulted with reduced wound pain and analgesic requirement in 
patients who have undergone laparoscopic gynecologic surgery (Alessandri et al, 2006). As 
a result NSAID patch formulations, to be placed directly over the wound, would have a 
useful pain-relieving effect. But there is still some studies needed to compare this  
application with systemic administration of the same drug and what the side effect 
frequency might be with such application (McCleane, 2010). 
5.3.2.4 Glyceryl trinitrate 
Experimental data suggest that the production of endogenous nitric oxide is necessary for 
tonic cholinergic inhibition of spinal pain transmission. In a study; transdermal nitroglycerin 
and the central cholinergic agent neostigmine have enhanced each other's antinociceptive 
effects at the dose studied (Lauretti et al, 2010).  In two recent more studies transdermal 
nitroglycerin enhanced the analgesic effect of intrathecal neostigmine following abdominal 
hysterectomy (Ahmed et al, 2010)  and intrathecal fentanyl with bupivacaine following 
gynecological surgery (Gang et al, 2010).     
5.3.3 Local infiltration analgesia 
The administration of large volumes of local anesthetics with or without adjuvants into 
different tissue planes perioperatively is called local infiltration analgesia (LIA) (Gupta, 
2010). 
It is a multimodal technique developed by Kerr et al. (Kerr at al, 2008) for the control of pain 
following knee and hip surgery. In their study it was based on systematic infiltration of a 
mixture of a long acting local anesthetics (ropivacaine), a NSAID (ketorolac), and adrenaline 
into the tissues around the surgical field (periarticularly intraoperatively and via an intra-
articular catheter postoperatively) to achieve satisfactory pain control with little 
physiological disturbance. The technique allows virtually immediate mobilization and 
earlier discharge from hospital. A recent study by Essving et al  (Essving et al, 2009) on 
unicompartmental knee arthroplasty  performed with minimal invasive technique, using the 
LIA technique found significantly shorter hospital stay, lower morphine consumption and 
pain intensity compared with placebo. 
5.4 Other – Nonpharmacological techniques 
A number of non-pharmacological methods of pain management may be used in 
conjunction with pharmacological methods in the postoperative setting. These 
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nonpharmacologic techniques, such as transcutaneous electrical nerve stimulation, 
acupuncture, psychological approaches (cold) and relaxing therapy and distraction, can be 
used in an attempt to alleviate postoperative pain.    
5.4.1 Transcutaneous electrical nerve stimulation (TENS) 
The use of TENS at paravertebral dermatomes corresponding to the surgical incision and/or 
acupoints  has also been reported to improve postoperative pain management (Chen et al, 
1998). Because this technique cause few if any adverse effects, its use as an adjunct to 
conventional pharmaceutical approaches should be considered as part of multimodal 
analgesic regimens in the future, particularly for patients in whom conventional analgesic 
techniques fail and/or are accompanied by severe medication-related adverse events (Chen 
et al, 1998; Usichenko, 2007; Wang et al, 1997). 
5.4.2 Acupuncture 
The term acupuncture describes a family of procedures involving the stimulation of anatomical 
points on the body using a variety of techniques. Acupuncture theory is based on two 
conditions: “yin,” which is considered feminine, passive, dark, and cold, and “yang,” which is 
masculine, aggressive, bright, and hot, as well as “qi,” which is considered the vital energy that 
flows and cycles throughout the body. The acupuncture theory is to harmonize any imbalance 
in yin-yang and qi in a human body to restore the body to a healthy condition. Acupuncture is  
thought to unblock any obstruction to the flow of qi and, thereby, relieves pain.  
Usichenko et al. (Usichenko, 2008) focused on randomized controlled trials of only auricular 
acupuncture (a popular method in which needles are placed in various parts of the earlobe) 
for postoperative pain control. They identified nine studies of acceptable quality (though 
none of the best quality), and concluded that the evidence that auricular acupuncture 
controls postoperative pain is promising but not compelling. Sun et al. (Sun et al, 2008) 
conducted a systematic review to quantitatively evaluate the efficacy of acupuncture and 
related techniques as adjunct analgesics for acute postoperative pain management. The 
authors concluded that perioperative acupuncture might be a useful adjunct for acute 
postoperative pain management. However, there are issues with applicability and 
generalizability of the procedure (Lee&Chan, 2006).     
5.4.3 Cold 
Iced-water or continuous flow cold therapy is used in orthopedic surgery after knee-surgery 
(Barber et al, 2000). It can be used both at hospital and at home. There are commercial 
systems, which are easy to use. The use of iced-water in other kinds of surgery needs further 
investigation.   
5.4.4 Relaxing therapy and distraction 
Music, or imagery, or hypnosis may have a positive effect in individual cases. There are 
commercial music CDs available for relaxation (Rawal).   
6 Special aspects 
6.1 Ambulatory procedures 
The percentage of surgical procedures being performed on an outpatient basis continues to 
rise. Many more complex and potentially painful procedures in comorbid conditions of the 
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different tissue planes perioperatively is called local infiltration analgesia (LIA) (Gupta, 
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It is a multimodal technique developed by Kerr et al. (Kerr at al, 2008) for the control of pain 
following knee and hip surgery. In their study it was based on systematic infiltration of a 
mixture of a long acting local anesthetics (ropivacaine), a NSAID (ketorolac), and adrenaline 
into the tissues around the surgical field (periarticularly intraoperatively and via an intra-
articular catheter postoperatively) to achieve satisfactory pain control with little 
physiological disturbance. The technique allows virtually immediate mobilization and 
earlier discharge from hospital. A recent study by Essving et al  (Essving et al, 2009) on 
unicompartmental knee arthroplasty  performed with minimal invasive technique, using the 
LIA technique found significantly shorter hospital stay, lower morphine consumption and 
pain intensity compared with placebo. 
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A number of non-pharmacological methods of pain management may be used in 
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nonpharmacologic techniques, such as transcutaneous electrical nerve stimulation, 
acupuncture, psychological approaches (cold) and relaxing therapy and distraction, can be 
used in an attempt to alleviate postoperative pain.    
5.4.1 Transcutaneous electrical nerve stimulation (TENS) 
The use of TENS at paravertebral dermatomes corresponding to the surgical incision and/or 
acupoints  has also been reported to improve postoperative pain management (Chen et al, 
1998). Because this technique cause few if any adverse effects, its use as an adjunct to 
conventional pharmaceutical approaches should be considered as part of multimodal 
analgesic regimens in the future, particularly for patients in whom conventional analgesic 
techniques fail and/or are accompanied by severe medication-related adverse events (Chen 
et al, 1998; Usichenko, 2007; Wang et al, 1997). 
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The term acupuncture describes a family of procedures involving the stimulation of anatomical 
points on the body using a variety of techniques. Acupuncture theory is based on two 
conditions: “yin,” which is considered feminine, passive, dark, and cold, and “yang,” which is 
masculine, aggressive, bright, and hot, as well as “qi,” which is considered the vital energy that 
flows and cycles throughout the body. The acupuncture theory is to harmonize any imbalance 
in yin-yang and qi in a human body to restore the body to a healthy condition. Acupuncture is  
thought to unblock any obstruction to the flow of qi and, thereby, relieves pain.  
Usichenko et al. (Usichenko, 2008) focused on randomized controlled trials of only auricular 
acupuncture (a popular method in which needles are placed in various parts of the earlobe) 
for postoperative pain control. They identified nine studies of acceptable quality (though 
none of the best quality), and concluded that the evidence that auricular acupuncture 
controls postoperative pain is promising but not compelling. Sun et al. (Sun et al, 2008) 
conducted a systematic review to quantitatively evaluate the efficacy of acupuncture and 
related techniques as adjunct analgesics for acute postoperative pain management. The 
authors concluded that perioperative acupuncture might be a useful adjunct for acute 
postoperative pain management. However, there are issues with applicability and 
generalizability of the procedure (Lee&Chan, 2006).     
5.4.3 Cold 
Iced-water or continuous flow cold therapy is used in orthopedic surgery after knee-surgery 
(Barber et al, 2000). It can be used both at hospital and at home. There are commercial 
systems, which are easy to use. The use of iced-water in other kinds of surgery needs further 
investigation.   
5.4.4 Relaxing therapy and distraction 
Music, or imagery, or hypnosis may have a positive effect in individual cases. There are 
commercial music CDs available for relaxation (Rawal).   
6 Special aspects 
6.1 Ambulatory procedures 
The percentage of surgical procedures being performed on an outpatient basis continues to 
rise. Many more complex and potentially painful procedures in comorbid conditions of the 
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surgical outpatients are being routinely performed in the ambulatory setting (White & 
Kehlet, 2010).  
Postoperative pain management have some disadvantages in this population; a. pain after 
minor surgery or in ambulatory patients is more difficult to treat because many of the 
aforementioned techniques are not available or are too risky.  b. The increasing number and 
complexity of elective operations that are being performed on an ambulatory (or short-stay) 
basis in which the use of conventional opioid-based intravenous patient controlled analgesia 
and central neuraxial (spinal and epidural) analgesia techniques are simply not practical for 
acute pain management. c. The pressure to discharge patients after surgery could limit the 
pain medications health care professionals are willing to prescribe and it may explain the 
inadequate management of acute pain after surgery.    
Most common medical causes of delayed discharge after ambulatory surgery are; pain, 
drowsiness and nausea/vomiting (Vadivelu et al, 2010). Although many factors, in addition 
to pain, must be carefully controlled to minimize postoperative morbidity and facilitate the 
recovery process after elective surgery, the adequacy of pain control should remain a major 
focus of health care providers, caring for patients undergoing ambulatory surgical 
procedures (Elvir Lazo&White, 2010). Many patients undergoing ambulatory surgery 
continue to experience unacceptably high levels of pain after their operation.  A survey by 
McGrath et al. showed that 30% of patients suffer moderate-to-severe pain following minor 
surgical procedures (McGrath et al, 2004). 
To have a qualified postoperative pain control after ambulatory surgery, it is required that 
patient discharge is not delayed and that pain control remains effective once the patient is 
at home. It is important to avoid to use of long acting analgesics and to use regional 
anesthesia techniques for the anesthesia. Regional analgesia techniques offer a number of 
advantages for day case surgery patients such as: flexible duration of analgesia (with 
single shot techniques and/or with catheter infusions), flexible intensity of blockade 
(according to the type, concentration and volume of local anesthetic) and reduced need 
for opioids. Wound infiltration, intraperitoneal instillation, peripheral nerve blocks e.g. 
brachial plexus, paravertebral, femoral nerve blocks can be used in ambulatory surgery 
patients.  
The adaptation of multimodal (or balanced) analgesic techniques as the standard approach 
for the prevention of pain in the ambulatory setting is one of the keys to improving the 
recovery process after day-case surgery (McGrath et al, 2004; White, 2007). Early studies 
evaluating approaches to facilitating the recovery process have demonstrated that the use of 
multimodal analgesic techniques can improve early recovery as well as other clinically 
meaningful outcomes after ambulatory surgery. These benefits have been confirmed in more 
recent studies (Elvir Lazo&White, 2010). 
An aggressive multimodal perioperative analgesic regimen that provides effective pain 
relief, has minimal side-effects, is intrinsically safe, and can be managed by the patient 
and their family members away from a hospital or surgical center is the ideal one. Current 
evidence suggests that these improvements in patient outcome related to pain control  
can best be achieved by using a combination of preventive analgesic techniques involving 
both centrally and peripherally acting analgesic drugs, as well as novel approaches  
to administering drugs in locations remote from the hospital setting (White&Kehlet,  
2010).   
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Nonopioid analgesics are increasingly being used as adjuvant before, during, and after 
surgery to facilitate the recovery process after ambulatory surgery because of their 
anesthetic and analgesic-sparing effects, their ability to reduce postoperative pain (with 
movement), and their opioid related side-effects (e.g., gastrointestinal and bladder 
dysfunction), thereby shortening the duration of the hospital stay and the convalescence 
period (White&Kehlet, 2010).   
Patient-controlled regional analgesia (PCRA) encompasses a variety of techniques that 
provide effective postoperative pain relief without systemic exposure to opioids.  Using 
PCRA, patients control the application of pre-programmed doses of local anesthetics, most 
frequently ropivacaine or bupivacaine (occasionally in combination with an opioid), via an 
indwelling catheter, which can be placed in different regions of the body depending upon 
the type of surgery. It is important to use suitable local anesthetics in low concentration and 
to inform patient adequately to avoid the risk of local anesthetic toxicity (Rawal, Vadivelu et 
al, 2010).  
6.2 Stress response 
Many detrimental pathophysiologic effects occur in the perioperative period and are 
associated with activation of nociceptors and the stress response. Uncontrolled pain may 
result in activation of the sympathetic nervous system, which can cause a variety of 
potentially harmful physiologic responses that may adversely influence the extent of 
morbidity and mortality (Vadivelu et al, 2010).  
As afferent neural stimuli and activation of the autonomic nervous system and other 
reflexes by pain may serve as a major release mechanism of the endocrine metabolic 
responses and thus contribute to various organ dysfunctions, pain relief may be a powerful 
technique to modify surgical stress responses. 
Systemic opioids (PCA or intermittent), NSAID, epidural opiod, lumbar and thorasic 
epidural local anesthetics are analgesic techniques are mostly used to supress the 
postoperative surgical stress responces but there is a pronounced differential effect of these 
various techniques on surgical stress responses (Kehlet&Holte, 2001). Any treatment with 
opioids, being epidural or PCA opioids, has very little effect on surgical stress responses and 
organ dysfunctions. Same applies to clonidine and also NSAIDs. Epidural anesthesia has the 
most profound inhibitory effect on surgical stress responses. 
Several studies investigating lower extremity surgery have shown continuous lumbar 
epidural local anesthetic techniques to be most effective, probably because of a more 
effective afferent blockade. In abdominal procedures, there is a somewhat smaller efficacy of 
thoracic epidural local anesthetic techniques in modulating endocrine-metabolic responses, 
probably due to insufficient afferent blockade as well as the presence of other release 
mechanisms in eliciting the surgical stress response. 
The neuraxial application of local anesthetics and opioids combined to general anesthesia 
(especially in patients undergoing major abdominal or thoracic procedures) as a multimodal 
strategy can provide superior pain relief, reduced hormonal and metabolic stress, enhanced 
normalization of gastrointestinal function, and thus a shortened postoperative recovery 
time, facilitating mobilization and physiotherapy (Schug&Chong, 2009). In a study by 
Sivrikaya et al (Sivrikaya et al, 2008) general anesthesia combined lumbar epidural analgesia 
can only partially attenuate the peroperative stress response and has some limited effects on 
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surgical outpatients are being routinely performed in the ambulatory setting (White & 
Kehlet, 2010).  
Postoperative pain management have some disadvantages in this population; a. pain after 
minor surgery or in ambulatory patients is more difficult to treat because many of the 
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drowsiness and nausea/vomiting (Vadivelu et al, 2010). Although many factors, in addition 
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at home. It is important to avoid to use of long acting analgesics and to use regional 
anesthesia techniques for the anesthesia. Regional analgesia techniques offer a number of 
advantages for day case surgery patients such as: flexible duration of analgesia (with 
single shot techniques and/or with catheter infusions), flexible intensity of blockade 
(according to the type, concentration and volume of local anesthetic) and reduced need 
for opioids. Wound infiltration, intraperitoneal instillation, peripheral nerve blocks e.g. 
brachial plexus, paravertebral, femoral nerve blocks can be used in ambulatory surgery 
patients.  
The adaptation of multimodal (or balanced) analgesic techniques as the standard approach 
for the prevention of pain in the ambulatory setting is one of the keys to improving the 
recovery process after day-case surgery (McGrath et al, 2004; White, 2007). Early studies 
evaluating approaches to facilitating the recovery process have demonstrated that the use of 
multimodal analgesic techniques can improve early recovery as well as other clinically 
meaningful outcomes after ambulatory surgery. These benefits have been confirmed in more 
recent studies (Elvir Lazo&White, 2010). 
An aggressive multimodal perioperative analgesic regimen that provides effective pain 
relief, has minimal side-effects, is intrinsically safe, and can be managed by the patient 
and their family members away from a hospital or surgical center is the ideal one. Current 
evidence suggests that these improvements in patient outcome related to pain control  
can best be achieved by using a combination of preventive analgesic techniques involving 
both centrally and peripherally acting analgesic drugs, as well as novel approaches  
to administering drugs in locations remote from the hospital setting (White&Kehlet,  
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Many detrimental pathophysiologic effects occur in the perioperative period and are 
associated with activation of nociceptors and the stress response. Uncontrolled pain may 
result in activation of the sympathetic nervous system, which can cause a variety of 
potentially harmful physiologic responses that may adversely influence the extent of 
morbidity and mortality (Vadivelu et al, 2010).  
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reflexes by pain may serve as a major release mechanism of the endocrine metabolic 
responses and thus contribute to various organ dysfunctions, pain relief may be a powerful 
technique to modify surgical stress responses. 
Systemic opioids (PCA or intermittent), NSAID, epidural opiod, lumbar and thorasic 
epidural local anesthetics are analgesic techniques are mostly used to supress the 
postoperative surgical stress responces but there is a pronounced differential effect of these 
various techniques on surgical stress responses (Kehlet&Holte, 2001). Any treatment with 
opioids, being epidural or PCA opioids, has very little effect on surgical stress responses and 
organ dysfunctions. Same applies to clonidine and also NSAIDs. Epidural anesthesia has the 
most profound inhibitory effect on surgical stress responses. 
Several studies investigating lower extremity surgery have shown continuous lumbar 
epidural local anesthetic techniques to be most effective, probably because of a more 
effective afferent blockade. In abdominal procedures, there is a somewhat smaller efficacy of 
thoracic epidural local anesthetic techniques in modulating endocrine-metabolic responses, 
probably due to insufficient afferent blockade as well as the presence of other release 
mechanisms in eliciting the surgical stress response. 
The neuraxial application of local anesthetics and opioids combined to general anesthesia 
(especially in patients undergoing major abdominal or thoracic procedures) as a multimodal 
strategy can provide superior pain relief, reduced hormonal and metabolic stress, enhanced 
normalization of gastrointestinal function, and thus a shortened postoperative recovery 
time, facilitating mobilization and physiotherapy (Schug&Chong, 2009). In a study by 
Sivrikaya et al (Sivrikaya et al, 2008) general anesthesia combined lumbar epidural analgesia 
can only partially attenuate the peroperative stress response and has some limited effects on 
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recovery of gastrointestinal functions, nevertheless provided a better postoperative 
analgesia compared to general anesthesia alone. Epidural opioid techniques are less 
effective on the stress response, and are comparable with systemic opioid techniques and 
the use of NSAIDs. More data on the use of multimodal analgesic techniques with 
combinations of different analgesics are needed on this issue.  
7. Conclusion 
Postoperative pain is a complication of surgery, which, in turn, complicates recovery with 
functional impairment and drug-related adverse effects.  Despite an increased focus on pain 
management programs and the development of new standards for pain management, many 
patients continue to experience intense pain after surgery. 
Many factors must be considered before deciding on the type of pain therapy to be provided 
to the surgical patient. These include the patients’ co-morbid conditions, psychological 
status, exposure to analgesic therapies, and the type of surgical procedure.    
The multimodal approach may potentially decrease perioperative morbidity, reduce the 
length of hospital stay, and improve patient satisfaction without compromising safety. 
However, widespread implementation of these programs requires multidisciplinary 
collaboration, change in the traditional principles of postoperative care, additional 
resources, and expansion of the traditional acute pain service. Although a multi-
pharmacologic approach may be universally recommended, drugs and their route of 
administration must be changed according to the type of surgery and hospital resources, 
and of course to the patient needs.  
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1. Introduction 
Levobupivacaine, a new long-acting local anesthetic, is reported to achieve an effective and 
safe epidural anesthesia, similar to the anesthesia achieved by bupivacaine. 
Levobupivacaine with a pharmacological structure similar to that of bupivacaine was 
shown to have a wider confidence interval, and less neurotoxic and cardiotoxic effects.  
A large number of trials have been conducted on determining the anesthetic methods that 
decrease the stress response of major surgery. These trials usually compared the effects of 
general, epidural and general + epidural anesthetic methods on the stress response 
occurring in major surgery with respect to mortality and morbidity. While some authors 
recommended general + epidural anesthesia, some only recommended the general 
anesthesia.  
A combination of epidural and general anesthesia is reported to reduce the requirement for 
analgesic and anesthetic agents. Intraoperative hemodynamic stability can be better 
achieved and the metabolic, endocrine and immunologic responses better suppressed. 
Management of these responses is important in reducing postoperative morbidity and 
mortality. With the combination of epidural and general anesthesia, recovery is faster, a 
higher anesthetic quality can be achieved and patients can be mobilized earlier (1-4). There 
are no adequate trials on the novel agent, levobupivacaine.  
This trial was designed to compare the epidural bupivacaine or levobupivacaine combined 
with general anesthesia and general anesthesia alone in patients who will undergo TAH-
BSO, with respect to stress response to surgery, intraoperative hemodynamics, requirement 
for peroperative anesthetics and analgesic agents, the quality of the postoperative analgesia, 
recovery from anesthesia and postoperative side effects.  
2. Methods 
This trial included 54 ASA I-II group patients in the age range of 18-65 who were scheduled 
to undergo TAH-BSO and who gave written consent to participate in the trial. Those with 
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severe cardiac, pulmonary, hepatic diseases, renal failure, hemorrhagic diathesis, fever, 
infection and those with known hypersensitivity to investigational drugs were excluded 
from the trial. Non-premedicated cases were randomly assigned to three groups: general 
anesthesia + epidural bupivacaine (Group I, n=18), general anesthesia + epidural 
levobupivacaine (Group II, n=18) and general anesthesia (Group III, n=18). All the patients 
were monitored for EKG, non-invasive blood pressure, peripheral oxygen saturation (SpO2), 
end-tidal carbon dioxide pressure (EtCO2) and body temperature. 
In Groups I and II, the epidural space was entered by a 16-gauge Tuohy epidural needle 
before the surgery using the loss of resistance method through the L3-L4 space while the 
patient was in the sitting position and an 18-gauge epidural catheter was inserted (Perifix, 
Braun, Germany). As a test dose, 2 ml of 2% lidocaine (Aritmal Ampul® Osel) was 
administered; five minutes later, Group I and Group II were administered 5 ml of 0.25% 
bupivacaine (Marcaine flacon® Eczacbaş, Turkey) and 0.25% levobupivacaine (Chirocaine 
flacon® Abbott, USA) respectively via epidural catheter, followed by administration of 10 
ml of 0.25% bupivacaine to Group I and 10 ml of 0.25% levobupivacaine to Group II via 
epidural catheter five minutes later. The sensory block upper level, time to achieve sensory 
block at T6 dermatome and the Bromage Scale values were assessed.  
Anesthetic induction was achieved in all patients (when  reached the sensorial block level 
dermatome of T6 in Group I and Group II) by 2 mg kg-1 propofol (Propofol ampul® 
Fresenius Kabi) and 1 µg kg-1 remifentanil (Ultiva® Glaxo Wellcome) administered in 60 
seconds. 0.6 mg kg-1 rocuronium (Esmeron® Organon) was used for achieving 
neuromuscular block. For all three groups, the maintenance of anesthesia was achieved 
using 1% sevoflurane (Sevorane® Abbott, USA) in 50% O2-air mixture and 0.1 µg kg-1 min-1 
remifentanil infusion (Perfusor Compact-Braun). Regarding the patients who would require 
an anesthesia duration of more than two hours, Group I was scheduled to receive an 
additional 5 ml of 0.25% bupivacaine and Group II was scheduled to receive an additional 5 
ml of 0.25% levobupivacaine from the epidural catheter.  
When the heart beat rate (HBR) and the mean blood pressure (MBP) was reduced by 20% of 
the control value, the concentration of the inhalation agent was reduced by 50%. 250 ml of 
ringer lactate solution was rapidly administered. In case of absence of improvement, the 
dose of remifentanil was decreased by 50%. If the low level persisted, atropine or ephedrine 
was administered as required. When the HBR and MBP increased by more than 20% of the 
control value, the concentration of the inhalation agent was increased by 50%. In the case of 
persistence of the high level, the dose of remifentanil was increased by 50%. For 
maintenance of the neuromuscular blockage, 0.15 mg kg-1 rocuronium iv was administered, 
where necessary. 
The hemodynamic parameters, systolic blood pressure (SBP), diastolic blood pressure 
(DBP), MBP, HBR, and SpO2 were recorded 2 and 5 minutes after the intubation, 2, 5, 10, 15, 
30, 45, 60, 90 and 120 minutes after the skin incision and after the extubation. For measuring 
the glucose, cortisol, insulin and CRP levels, preoperative venous access was achieved 
followed by blood sampling in the first and 24th hours of operation. The glucose, glucose 
oxidase, cortisol and insulin values were measured by chemiluminescent immunoassay, 
CRP, and the immunoturbidimetric methods. 
The postoperative recovery was evaluated by the spontaneous breathing time, extubation 
time, eye opening time and the time to reach an Aldrete recovery score of ≥9. Data were 
recorded on the amount of sevoflurane used (ml) (Datex Ohmeda, S5. Sweden), the total 
dose of remifentanil (mg), whether muscle relaxant was added and whether atropine or 
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ephedrine were required. Pain intensity was evaluated by the visual analogue scale (VAS) 
and the motor block was assessed by the Bromage scale; the hemodynamic data and the side 
effects (hypotension, respiratory depression, motor block, nausea-vomiting, itching, tremor) 
were recorded at 0 and 30 minutes, and 2, 6, 12 and 24 hours after the operation. 
To relieve the postoperative pain, Group III was administered iv morphine and PCA at a 
concentration of 1 mg ml-1 concentration with a loading dose of 1 mg and a lock-out period 
of 6 minutes. In Group I, 0.125% bupivacaine + 0.025 mg ml-1 morphine, in Group II, 0.125% 
levobupivacaine + 0.025 mg ml-1 morphine and 5 ml of h-1 basal infusion were prepared for 
PCA with a 1 ml loading and a lock-out period of 20 minutes and PCA administration was 
initiated in the recovery room. The total amount of anesthetics used and the administered 
and requested amounts were recorded. 
Statistical analysis were performed using the SPSS 12.0 software. The data were 
summarized as mean ± standard deviation and percentage. Comparisons between the 
three groups were assessed by one way variance analysis (Anova) in cases where the 
parametric conditions could be met and by Kruskal Wallis variance analysis in non-
parametric conditions. In the three-group comparisons, post-hoc Tukey-HSD test and 
Bonferroni correction Mann-Whitney U test were used for significantly differing 
parameters. The comparison between the two groups was made with a t test. The chi-
square test was used for comparing categorical data. Variance analysis was used to 
analysis the parametric data and Wilcoxon Signed Ranks test Bonferroni correction was 
used to analyze the non-parametric data for the analysis of the repeated measurements. 
The level of significance was set at p<0.05. 
3. Results 
The groups showed similarity in the mean values for age, weight, height, the ASA score and 
the duration of surgery (p>0.05) (Table 1). 
 
 GROUP I GROUP II GROUP III P 
Age (year) 46.55 ± 4.97 47.53 ± 6.87 48.44 ± 8.75 0.246 
Weight (kg) 70.88 ± 8.58 75.50 ± 15.27 79.55 ± 8.05 0.075 
Hight (cm) 160.55 ± 5.29 162.16 ± 5.95 160.27 ± 4.61 0.520 
Surgery time (min) 74.88 ± 18.31 72.83 ± 20.47 80.94 ± 13.35 0.365 
ASA I / II 11 / 7 13 / 5 10 / 8 0.574 
Table 1. Patient characteristics (Mean ± SD) 
Time to achieve sensory block at T6 dermatome was 18.72±4.41 and 21.27±4.48 in Group I 
and Group II, respectively; the sensory block upper levels were 5.66±0.68 and 5.88±0.32 
dermatome, respectively (p>0.05). The pre-operative Bromage scores were 0 in Group I and 
II (p>0.05). 
The total doses of the intra-operatively administered remifentanil and sevoflurane were 
similar between Group I and Group II, however, statistically higher in Group III (p<0.000) 
(Table 2). While there was no statistically significant difference between Group I and 
Group II in the postoperative recovery evaluated by spontaneous respiratory time, 
extubation time, eye opening time and the time to reach an Aldrete recovery score of ≥9, 
Group III had a significantly longer recovery time compared to Groups I and II (p<0.000) 
(Table 2). 
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time, eye opening time and the time to reach an Aldrete recovery score of ≥9. Data were 
recorded on the amount of sevoflurane used (ml) (Datex Ohmeda, S5. Sweden), the total 
dose of remifentanil (mg), whether muscle relaxant was added and whether atropine or 
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ephedrine were required. Pain intensity was evaluated by the visual analogue scale (VAS) 
and the motor block was assessed by the Bromage scale; the hemodynamic data and the side 
effects (hypotension, respiratory depression, motor block, nausea-vomiting, itching, tremor) 
were recorded at 0 and 30 minutes, and 2, 6, 12 and 24 hours after the operation. 
To relieve the postoperative pain, Group III was administered iv morphine and PCA at a 
concentration of 1 mg ml-1 concentration with a loading dose of 1 mg and a lock-out period 
of 6 minutes. In Group I, 0.125% bupivacaine + 0.025 mg ml-1 morphine, in Group II, 0.125% 
levobupivacaine + 0.025 mg ml-1 morphine and 5 ml of h-1 basal infusion were prepared for 
PCA with a 1 ml loading and a lock-out period of 20 minutes and PCA administration was 
initiated in the recovery room. The total amount of anesthetics used and the administered 
and requested amounts were recorded. 
Statistical analysis were performed using the SPSS 12.0 software. The data were 
summarized as mean ± standard deviation and percentage. Comparisons between the 
three groups were assessed by one way variance analysis (Anova) in cases where the 
parametric conditions could be met and by Kruskal Wallis variance analysis in non-
parametric conditions. In the three-group comparisons, post-hoc Tukey-HSD test and 
Bonferroni correction Mann-Whitney U test were used for significantly differing 
parameters. The comparison between the two groups was made with a t test. The chi-
square test was used for comparing categorical data. Variance analysis was used to 
analysis the parametric data and Wilcoxon Signed Ranks test Bonferroni correction was 
used to analyze the non-parametric data for the analysis of the repeated measurements. 
The level of significance was set at p<0.05. 
3. Results 
The groups showed similarity in the mean values for age, weight, height, the ASA score and 
the duration of surgery (p>0.05) (Table 1). 
 
 GROUP I GROUP II GROUP III P 
Age (year) 46.55 ± 4.97 47.53 ± 6.87 48.44 ± 8.75 0.246 
Weight (kg) 70.88 ± 8.58 75.50 ± 15.27 79.55 ± 8.05 0.075 
Hight (cm) 160.55 ± 5.29 162.16 ± 5.95 160.27 ± 4.61 0.520 
Surgery time (min) 74.88 ± 18.31 72.83 ± 20.47 80.94 ± 13.35 0.365 
ASA I / II 11 / 7 13 / 5 10 / 8 0.574 
Table 1. Patient characteristics (Mean ± SD) 
Time to achieve sensory block at T6 dermatome was 18.72±4.41 and 21.27±4.48 in Group I 
and Group II, respectively; the sensory block upper levels were 5.66±0.68 and 5.88±0.32 
dermatome, respectively (p>0.05). The pre-operative Bromage scores were 0 in Group I and 
II (p>0.05). 
The total doses of the intra-operatively administered remifentanil and sevoflurane were 
similar between Group I and Group II, however, statistically higher in Group III (p<0.000) 
(Table 2). While there was no statistically significant difference between Group I and 
Group II in the postoperative recovery evaluated by spontaneous respiratory time, 
extubation time, eye opening time and the time to reach an Aldrete recovery score of ≥9, 
Group III had a significantly longer recovery time compared to Groups I and II (p<0.000) 
(Table 2). 
 




 GROUP I GROUP II GROUP III P 
Remifentanil (mg) 0.78 ± 0.38 0.77 ± 0.27 1.24 ± 0.38 * 0.000 
Sevoflurane (ml) 21.38 ± 7.63 21.94 ± 8.93 44.44 ± 14.84 * 0.000 
Spontaneous breathing time (min) 4.58 ± 2.46 4.11 ± 1.17 7.58 ± 2.68 * 0.000 
Extubation time (min) 5.19 ± 2.81 4.27 ± 1.14 8.36 ± 2.66 * 0.000 
Eye opening time (min) 6.36 ± 3.27 5.16 ± 1.79 9.80 ± 3.79 * 0.000 
Time to Aldrete Score ≥9 (min) 7.91 ± 3,19 7.75 ± 2.49 13.11 ± 3.67 * 0.000 
* p< 0.05 Compared with Group I and Group II 
(Mean ± SD) 
Table 2. Mean doses of drugs used in the operation and recovery times.  
There was no statistically significant difference between the groups with respect to 
requirement for atropine and ephedrine (p>0.05). One, two and nine patients received 
additional muscle relaxant administration in Group I, II and III respectively. There was a 
statistically significant difference between the groups with respect to the requirement of 
muscle relaxant (p=0.002), which was higher in Group III relative to Groups I and II.  
Regarding the MBP values, Group III had the highest values at 5, 10, 15, 30, 45 and 60 
minutes of incision and after extubation (p<0.05).  
The intra-group MBP values showed significant reductions relative to the control values 
during induction, 2, 5 minutes after intubation and 2, 5, 10, 15, 30, 45, 60 and 90 minutes 
after the surgical incision in Group 1; during induction, five minutes after the intubation, 
and 2, 5, 10, 15, 30, 45 and 60 minutes after the surgical incision in Group II; and during 
induction, 2, 5 minutes after the intubation and 2, 30 and 45 minutes after the surgical 
incision in Group 3 (p<0.05). While there was no statistically significant difference between 
the post-extubation MBP values and the control MBP values in Groups I and II (p>0.05), 
Group III exhibited a significant increase relative to the control value in Group III (p<0.013).  
The HBR values were lower in Group III compared to Groups I and II in the 2nd and 5th 
minutes of intubation (p<0.05).  
The intra-group HBR values showed significant reductions relative to the control values 
during induction, and 2, 5, 10, 15, 30, 45 and 60 minutes after the surgical incision in Group 
I; during induction, and 10, 15, 30, 45 and 60 minutes after the surgical incision in Group II; 
and during induction, five minutes after intubation, and 2, 5, 10, 45 and 60 minutes after the 
surgical incision in Group III (p<0.05). 
Since the duration of surgery was below 100 minutes in all patients, there was no 
requirement for additional epidural local anesthetic administration and the follow-ups at 
120 minutes could not be conducted (Table 1).  
The mean control values for the parameters used to assess the response to surgical stress 
including glucose, insulin, cortisol and the CRP values were statistically similar between the 
three groups (p>0.05).  
While the postoperative glucose values in the first and 24th hours were not significantly 
different, they were higher in Group III relative to Groups I and II (p>0.05). Regarding the 
intra-group comparison, the glucose values exhibited a significant increase relative to the 
control values one hour after the operation in all groups, and 24 hours after the operation in 
Groups I and III (p<0.05) (Figure 1).  
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requirement for additional epidural local anesthetic administration and the follow-ups at 
120 minutes could not be conducted (Table 1).  
The mean control values for the parameters used to assess the response to surgical stress 
including glucose, insulin, cortisol and the CRP values were statistically similar between the 
three groups (p>0.05).  
While the postoperative glucose values in the first and 24th hours were not significantly 
different, they were higher in Group III relative to Groups I and II (p>0.05). Regarding the 
intra-group comparison, the glucose values exhibited a significant increase relative to the 
control values one hour after the operation in all groups, and 24 hours after the operation in 
Groups I and III (p<0.05) (Figure 1).  
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hour postoperative cortisol values were higher than the control value only in Group III 
(p<0.05) (Figure 3).  
 
 
* Compared with the Groups (p<0.05) 
# Compared with the control values (p<0.05). 
Fig. 3. Changes in Cortisol values when compared to Groups  
There was no difference between the groups in the CRP values. The intra-group comparison 
of the CRP values showed higher postoperative 24th hour values relative to the control 
values and the postoperative 1st hour values in all groups (p<0.05) (Figure 4).  
 
 
# Compared with the control values (p<0.05) 
Fig. 4. Changes in CRP values when compared to Groups 
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The comparison of the postoperative pain scores between the groups demonstrated the 
highest VAS value at minute 0 in Group III (p<0.000). Regarding the other measurement 
times, no significant difference was detected between the groups (p>0.05) (Table 3). 
 
 GROUP I GROUP II GROUP III P 
Postop 0th min. 0.38 ± 1.14 1.33 ± 2.02 5.88 ± 1.99 * 0.000 
Postop 30th min. 4.77 ± 1.95 # 4.50 ± 2.22 # 5.83 ± 1.75 0.172 
Postop 2nd h 3.77 ± 2.21 # 3.22 ± 2.43 2.55 ± 1.72 # 0.388 
Postop 6th h 2.11 ± 2.13 1.33 ± 1.74 1.33 ± 1.13 # 0.465 
Postop 12th h 0.38 ± 0.69 0.50 ± 1.42 0.77 ± 1.16 # 0.325 
Postop 24th h 0.25 ± 0.23 0.27 ± 0.75 0.33 ± 0.76 # 0.355 
P <0.05 <0.05 <0.05  
*Comparisons between-groups (p<0.05) 
# Comparison intra-groups (p<0.05). 
Table 3. VAS values (Mean ± SD) 
The comparison of the postoperative hemodynamic data revealed the highest MBP at 
minute 0 in Group III (p<0.002). None of the three groups exhibited postoperative 
hypotension or respiratory depression. Regarding the motor block, there was no significant 
difference between Groups I and II with respect to nausea-vomiting, itching, or tremor 
(p>0.05).  
4. Discussion 
In this trial investigating the extent of suppression of the stress response to surgery in 
patients undergoing general anesthesia + epidural anesthesia achieved with two different 
local anesthetics relative to the patients only receiving general anesthesia, the intraoperative 
hemodynamics, intraoperative anesthetic and analgesic agent requirement, the 
postoperative analgesia quality, the side effects and the recovery were also compared 
between the groups.  
Bupivacaine is commonly used in epidural analgesia owing to its long-lasting effect and the 
sensory block it achieves that is more marked than the motor block. However, 
levobupivacaine was reported to be safer with respect to the central nervous system toxicity 
and cardiotoxicity in addition to exhibiting a local anesthetic effect similar to bupivacaine in 
the clinical trials. The tendency for sensory block is longer with levobupivacaine relative to 
bupivacaine. Following epidural administration of levobupivacaine, the duration of the 
motor block was observed to be shorter than that of the sensory block. Levobupivacaine was 
reported to be as effective as bupivacaine when combined with morphine or fentanyl in the 
treatment of postoperative pain. Some trials demonstrated that levobupivacaine exhibited 
small increases in the sensory block time relative to bupivacaine, in line with the results 
from this trial. This finding may be attributed to the relatively increased vasoconstrictor 
effect of levobupivacaine compared to bupivacaine (5-8). 
In this trial, there was no difference between Group I and Group II in the time to achieve 
sensory block at T6. There was no difference between the two groups in the motor block 
levels measured until the time to achieve sensory block at T6 dermatome. The follow-ups 
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hour postoperative cortisol values were higher than the control value only in Group III 
(p<0.05) (Figure 3).  
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The comparison of the postoperative pain scores between the groups demonstrated the 
highest VAS value at minute 0 in Group III (p<0.000). Regarding the other measurement 
times, no significant difference was detected between the groups (p>0.05) (Table 3). 
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difference between Groups I and II with respect to nausea-vomiting, itching, or tremor 
(p>0.05).  
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In this trial investigating the extent of suppression of the stress response to surgery in 
patients undergoing general anesthesia + epidural anesthesia achieved with two different 
local anesthetics relative to the patients only receiving general anesthesia, the intraoperative 
hemodynamics, intraoperative anesthetic and analgesic agent requirement, the 
postoperative analgesia quality, the side effects and the recovery were also compared 
between the groups.  
Bupivacaine is commonly used in epidural analgesia owing to its long-lasting effect and the 
sensory block it achieves that is more marked than the motor block. However, 
levobupivacaine was reported to be safer with respect to the central nervous system toxicity 
and cardiotoxicity in addition to exhibiting a local anesthetic effect similar to bupivacaine in 
the clinical trials. The tendency for sensory block is longer with levobupivacaine relative to 
bupivacaine. Following epidural administration of levobupivacaine, the duration of the 
motor block was observed to be shorter than that of the sensory block. Levobupivacaine was 
reported to be as effective as bupivacaine when combined with morphine or fentanyl in the 
treatment of postoperative pain. Some trials demonstrated that levobupivacaine exhibited 
small increases in the sensory block time relative to bupivacaine, in line with the results 
from this trial. This finding may be attributed to the relatively increased vasoconstrictor 
effect of levobupivacaine compared to bupivacaine (5-8). 
In this trial, there was no difference between Group I and Group II in the time to achieve 
sensory block at T6. There was no difference between the two groups in the motor block 
levels measured until the time to achieve sensory block at T6 dermatome. The follow-ups 
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conducted during the 24th postoperative hour revealed a smaller number of patients 
developing motor block in the group using levobupivacaine. 
In the trial by Bader et al (9) where women undergoing cesarean section were administered 
0.5% (150 mg) levobupivacaine or bupivacaine at the same dose via epidural anesthesia, the 
incidence of hypotension was detected to be lower in those receiving levobupivacaine 
(84.4% levobupivacaine, 100% bupivacaine). 
Bardsley et al (10), upon administering 56.1 mg of levobupivacaine and 47.9 mg of 
bupivacaine via the iv route, and Kopacz and Allen (11), upon accidentally administering 17 
ml of 0.75% of levobupivacaine intravenously to a patient, reported that levobupivacaine 
was safer for achieving direct depression of the myocardial contractility relative to 
bupivacaine. 
In this trial, there was one patient in Group I and four patients in Group II who required 
intraoperative ephedrine for hypotension, although this was not statistically significant. In 
Group III, the arterial blood pressure values were higher at various measurement times and 
required higher anesthetic doses to achieve hemodynamic stability. None of the three 
groups exhibited EKG changes. The absence of EKG changes in Groups I and II may be 
attributed to the low concentration of the epidural local anesthetic used. 
Luchetti M et al (12) compared epidural + general anesthesia and total intravenous 
anesthesia in patients undergoing laparoscopic cholecystectomy and reported that the 
epidural + general anesthesia group did not require intraoperative opioid use, did not 
exhibit an increase in side effects and had a faster recovery. In our trial, the amount of 
sevoflurane and remifentanil used was lower in the epidural + general anesthesia groups 
relative to the general anesthesia group and thus, recovery was faster in Groups I and II 
relative to Group III; this finding is in line with the literature. 
In their trial where they compared general anesthesia combined with epidural anesthesia 
achieved by 2% lidocaine to general anesthesia alone, Lu CH et al (13) reported that the 
requirement for volatile anesthetics was lower in the epidural + general anesthesia group, in 
line with our results.  
The stress response can be avoided and the mediator levels can be maintained at the 
preoperative values by epidural anesthesia administered before surgical stimulation (14). In 
addition, epidural analgesia achieved by local anesthetics or opioids should also be 
maintained in the postoperative period to be able to reduce the stress response at the 
maximum level (15). In this trial, Group I and Group II were administered local anesthetic 
solution from the epidural space approximately 20 minutes before the surgery. As the 
sensory block level reached the T6 dermatome, general anesthesia induction was performed 
and the surgery was initiated. Maintenance of analgesia was achieved by using 
postoperative epidural PCA. Postoperative iv morphine PCA was used in Group III. As 
such, suppression of the stress response was observed similarly to these trials (14, 15).  
Latterman et al (16) demonstrated that the glucose response was more limited in the patients 
receiving epidural anesthesia relative to the group undergoing general anesthesia. In this 
trial, the plasma glucose value showed a limited increase relative to the control value at the 
1st and 24th postoperative hours; this increase was slightly more in Group III. None of the 
groups exhibited an increase in the glucose level above 150 mg dL-1.  
The blood glucose level was detected to be lower with postoperative epidural fentanyl 
administration relative to iv fentanyl administration (17). Again after general anesthesia, the 
blood glucose level was observed to be better suppressed in association with general 
anesthesia + paravertebral anesthesia and analgesia versus postoperative iv morphine 
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administration (18). In this trial, epidural morphine was combined with local anesthetic 
agents to achieve postoperative analgesia in Groups I and II. Iv morphine was used in 
Group III. Glucose level was better suppressed in Groups I and II relative to Group III.  
The trials detected that the cortisol levels increased starting from the skin incision in cases 
undergoing general anesthesia + epidural analgesia; however, the blood cortisol levels were 
suppressed relative to the group receiving general anesthesia (19, 20). In another trial (21), 
epidural + general anesthesia and postoperative morphine administration were claimed to 
provide a better suppression of the blood cortisol level relative to the general anesthesia + 
postoperative iv morphine administration. In this trial, the postoperative 1st hour cortisol 
value was higher in Group III relative to Groups I and II. In all groups, the postoperative 1st 
hour cortisol value was higher than the control value; the postoperative cortisol value at 24 
hours was significantly increased only in Group III. This shows that the cortisol response 
was better suppressed in the groups receiving epidural anesthesia and postoperative 
epidural analgesia relative to the group receiving general anesthesia and postoperative iv 
analgesia, even if partially. 
Insulin, an anabolic and hypoglycemic hormone decreases following trauma as opposed to 
glucose and cortisol. This helps to maintain hyperglycemia and protect the metabolic status 
of the vital organs (22). In this trial, there was no difference between the groups in the 
insulin values measured preoperatively and in the first and 24th hours postoperatively. The 
increase in the insulin values in the 24th postoperative hour in Groups I and III may be 
related to the increase in glucose values. 
Compared to general anesthesia, the increase in TNF-a and CRP levels was observed to be 
less with general + epidural anesthesia (1). In this trial, the 24th postoperative hour CRP 
values exhibited an increase compared to the control values in all groups. While there was 
no statistically significant difference between the groups, the values in Group III were 
higher relative to Groups I and II.  
Chu CPW et al (2) compared general anesthesia followed by iv morphine, and combined 
spinal epidural anesthesia followed by epidural 1% bupivacaine and 2 µg ml-1 fentanyl, and 
detected lower VAS scores in the first, 12th and 48th postoperative hours in the group 
receiving epidural anesthesia and postoperative epidural analgesia (p<0.05).  
In this trial, morphine was combined with low-dose local anesthetic in patients using 
epidural PCA. Iv morphine PCA was used in the general anesthesia group. In the treatment 
of postoperative pain, the VAS scores were higher during the first hours in Group III 
relative to Groups I and II (p<0.05). This may result from the postoperative maintenance of 
analgesia in groups receiving preoperative epidural anesthesia. In the group receiving 
intravenous morphine PCA, the VAS scores gradually decreased and exhibited no 
significant difference compared to the other groups. 
Enquist et al (3) demonstrated that epidural anesthesia blocking the neural afferent 
conduction whether combined with general anesthesia or alone resulted in suppression of 
the stress response to surgery in their trial on the effects of epidural anesthesia at various 
doses on surgical stress. The blood pressure values were higher during the first 
postoperative hours in the group of patients receiving epidural + general anesthesia relative 
to the general anesthesia group with no difference detected between the groups after three 
hours. In this trial, the MBP values were similarly higher in Group III during the first two 
hours relative to Groups I and II. 
Nabil W. Doss et al (4) compared the thoracic epidural anesthesia and general anesthesia 
techniques in their trial performed using 0.2% ropivacaine in patients undergoing 
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conducted during the 24th postoperative hour revealed a smaller number of patients 
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administration (18). In this trial, epidural morphine was combined with local anesthetic 
agents to achieve postoperative analgesia in Groups I and II. Iv morphine was used in 
Group III. Glucose level was better suppressed in Groups I and II relative to Group III.  
The trials detected that the cortisol levels increased starting from the skin incision in cases 
undergoing general anesthesia + epidural analgesia; however, the blood cortisol levels were 
suppressed relative to the group receiving general anesthesia (19, 20). In another trial (21), 
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provide a better suppression of the blood cortisol level relative to the general anesthesia + 
postoperative iv morphine administration. In this trial, the postoperative 1st hour cortisol 
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hour cortisol value was higher than the control value; the postoperative cortisol value at 24 
hours was significantly increased only in Group III. This shows that the cortisol response 
was better suppressed in the groups receiving epidural anesthesia and postoperative 
epidural analgesia relative to the group receiving general anesthesia and postoperative iv 
analgesia, even if partially. 
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of the vital organs (22). In this trial, there was no difference between the groups in the 
insulin values measured preoperatively and in the first and 24th hours postoperatively. The 
increase in the insulin values in the 24th postoperative hour in Groups I and III may be 
related to the increase in glucose values. 
Compared to general anesthesia, the increase in TNF-a and CRP levels was observed to be 
less with general + epidural anesthesia (1). In this trial, the 24th postoperative hour CRP 
values exhibited an increase compared to the control values in all groups. While there was 
no statistically significant difference between the groups, the values in Group III were 
higher relative to Groups I and II.  
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detected lower VAS scores in the first, 12th and 48th postoperative hours in the group 
receiving epidural anesthesia and postoperative epidural analgesia (p<0.05).  
In this trial, morphine was combined with low-dose local anesthetic in patients using 
epidural PCA. Iv morphine PCA was used in the general anesthesia group. In the treatment 
of postoperative pain, the VAS scores were higher during the first hours in Group III 
relative to Groups I and II (p<0.05). This may result from the postoperative maintenance of 
analgesia in groups receiving preoperative epidural anesthesia. In the group receiving 
intravenous morphine PCA, the VAS scores gradually decreased and exhibited no 
significant difference compared to the other groups. 
Enquist et al (3) demonstrated that epidural anesthesia blocking the neural afferent 
conduction whether combined with general anesthesia or alone resulted in suppression of 
the stress response to surgery in their trial on the effects of epidural anesthesia at various 
doses on surgical stress. The blood pressure values were higher during the first 
postoperative hours in the group of patients receiving epidural + general anesthesia relative 
to the general anesthesia group with no difference detected between the groups after three 
hours. In this trial, the MBP values were similarly higher in Group III during the first two 
hours relative to Groups I and II. 
Nabil W. Doss et al (4) compared the thoracic epidural anesthesia and general anesthesia 
techniques in their trial performed using 0.2% ropivacaine in patients undergoing 
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mastectomy and detected higher rates of nausea and vomiting in the general anesthesia 
group. Regarding hemodynamics, hypertension was more common in the general 
anesthesia group. The Aldrete recovery scores measured 1, 2 and 3 hours after the 
operation exhibited significant differences between the groups only in the first hour and 
were better in the thoracic epidural anesthesia group. In our trial, nausea-vomiting was 
less and the time of recovery from anesthesia was shorter in Groups I and II relative to 
Group III. 
Morphine-related postoperative complications were most commonly in the form of nausea-
vomiting, similar to the other trials. There was no significant difference between Groups I 
and II, and Group III with respect to nausea and vomiting. However, the number of patients 
with nausea and vomiting was higher in Group III. None of the patients had hypotension 
that required postoperative rapid fluid replacement or vasopressor agent use. Similarly, 
none of the patients developed respiratory depression. While there was no difference 
between the groups in itching, there were more patients with this compliant in Group III. 
There was no significant difference between the groups in tremor and only one patient in 
Group II had tremor. 
In avoiding stress response, individual differences, the type and duration of surgery, tissue 
injury in major surgeries, the type of analgesia and the drugs used are also important as well 
as the method of anesthesia used. 
As a result, we concluded that bupivacaine and levobupivacaine used in epidural anesthesia 
had similar effects, epidural + general anesthesia provided a better intraoperative 
hemodynamic stability relative to general anesthesia and reduced the requirement for 
anesthetic agents, provided a faster recovery, resulted in less side effects and achieved a 
better analgesia, particularly during the first postoperative hours. We believe that the stress 
response can be better suppressed by epidural + general anesthesia. 
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1. Introduction 
If an intravenous or inhalator anesthetic, would include in itself all the components of 
general anesthesia, like hypnoses, analgesia, amnesia etc. it would represent a really ideal 
anesthetic. 
Propofol is the drug of choice for induction and/or maintenance of anesthesia and sedation 
in the operating room and intensive care unit. It is a short-acting intravenous anaesthetic 
that features high blood-tissue solubility and allows a rapid induction and rapid emergence. 
Propofol has γ-aminobutyric acid agonist activity and produces dose dependent central 
nervous system depression resulting in sedation and hypnosis. 
Analgesic properties of propofol are discussed in many studies, in recent years. However, 
evidence suggesting that the drug possesses analgesic activity still remains questionable 
(Fassoulaki, 2011). 
The objective of this study is to systematically determine the effects of propofol in 
postoperative pain. 
We have included double-blind, randomized, and controlled trials in humans, where 
postoperative analgesic effect of propofol was compared with another anesthetic or non-
drug intervention.  
The study was carried out according to the methods recommended by the Cochrane 
Collaboration (Higgins et al., 2009) and written in accordance with the PRISMA statement 
for reporting systematic reviews (Liberati et al., 2009, Moher et al., 2009). 
Reports of randomized controlled trials were systemically sought using the Cochrane 
Library, PubMed, Embase, www.clinicaltrials.gov, and hand searching from the reference 
lists of identified papers. 
Data were analyzed from 25 randomized controlled trials totaling 2033 adults and children. 
We developed standard data collection sheets to record details of trial design, interventions, 
and outcome measures for every trial. We extracted information about propofol and control 
group. Information about number of patients enrolled, type of surgical intervention and side 
effects, were also noted. Data on postoperative pain relief using pain scores time to first 
analgesic request and consumption of supplementary analgesics was taken from each 
report. 
Qualitative analysis of postoperative effectiveness was evaluated by significant difference  
(P < 0.05 as reported in the original investigation) in pain relief using pain scores, time to 
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first analgesic request, and consumption of supplementary analgesics between the treatment 
groups, and by assessment of the clinical importance of observed differences. 
Quantitative analyses of combined data were intended by calculation of the number of 
patients reporting any pain or no pain (pain response rate) between treatment groups.  
Each trial was assessed for different measures of internal sensitivity. First, trials were 
checked for magnitude of pain intensity. Because it is difficult to detect an improvement 
with low or no pain, it was noted that pain scores were less than 30 mm on a visual analog 
scale (VAS) or less than moderate pain on a verbal rating scale or similar score. Second, it 
was noted that a power calculation of the statistical tests was performed. Trials with sample 
sizes less than 10 patients per treatment group were not considered in the study. 
Meta-analyses were carried out by direct comparisons of intervention versus control and 
indirect comparisons between the networks of interventions shown to be significant 
individually. 
2. Propofol 
Propofol (2,6-diisopropyl phenol) is chemically inert phenolic compound with anesthetic 
properties. It has high lipid solubility, but is almost insoluble in water. The original 
preparation contained the solubilizing agent Ctenophore EL (polyethoxylated Castrol oil). 
Reformulation of the drug in an egg-oil-glycerol emulsion has eliminated hypersensitivity 
reactions that occurred with the original formulation (Sebel, 1989). The dose of propofol 
required to induce anesthesia measured by loss of eyelash reflex in 95% of healthy 
unpremedicated patients was 1.5-2.5 mg/kg. The range of induction times was 22-125 seconds. 
The rapid loss of consciousness was realized due to the immediate uptake of the lipid – soluble 
drug by the central nervous system (CNS).Within several minutes of intravenous 
administration, the plasma concentration of propofol decreases due to the distribution of the 
drug throughout the body and its uptake by peripheral tissues. As the plasma concentration 
falls, propofol diffuses from the CNS into the systemic circulation; when bolus doses of the 
anesthetic are used to induce anesthesia, there is a rapid recovery of full consciousness and 
awareness. These advantageous properties have contributed to the popularity of propofol as 
an induction agent for short procedures and day – case surgery (Short, 1999). 
Propofol is also indicated for the maintenance of anesthesia computer-assisted continuous 
infusion and target-controlled infusion of propofol using a monitor of the hypnotic effects of 
propofol on the brain electroencephalographic Bispectral Index [BIS] monitor; it is possible 
to create a closed-loop delivery system for improving the titration of propofol during 
general anesthesia (Kwan, 1989, Singh, 1999). 
Infusions of subanesthetic doses of propofol have been used to sedate patients for surgery 
under regional anesthesia, in diagnostic centers for sedation during gastroenterology and 
pulmonary medicine procedures, as well as in critical care areas for sedation of ventilator-
dependent patients as an alternative to benzodiazepines and/or opioid analgesics 
(Mazurek, 2004). 
Propofol is extensively bound to plasma proteins; approximately 97-98% is bound to 
albumin. After intravenous injection the plasma concentration of propofol decline. The 
initial fall is extremely rapid (half life 1-3 min), reflecting the distribution of the lipid - 
soluble drug from plasma to tissue.  
Approximately 70% of a dose is excreted in the urine within 24 hours after administration, and 
90% is excreted within 5 days. Clearance of propofol ranges from 1.6 to 3.4 liters per minute in 
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healthy 70 kg patients. As the age of the patient increases, total body clearance of propofol may 
decrease. Clearance rates ranging from 1.4 to 2.2 liters per minute in patients 18 to 35 years of 
age have been reported, in contrast to clearance rates of 1 to 1.8 liters per minute in patients 65 
to 80 years of age. The propofol mean total body clearance rate was 2.09 +/- 0.65 1/min (mean 
SD), the volume of distribution at steady state was 159 +/- 57 I, and the elimination half-life 
was 116 +/- 34 min. Elderly patients (patients older than 60 yr ) had significantly decreased 
clearance rates (1.58 +/- 0.42 vs. 2.19 +/- 0.64 1/min), whereas women (vs. men) had greater 
clearance rates (33 +/- 8 vs. 26 +/- 7 1  kg-1 min-1) and volumes of distribution (2.50 +/- 0.81 vs. 
2.05 +/- 0.65 1/kg). Patients undergoing major intraabdominal surgery had longer elimination 
half-life values (136 +/- 40 vs. 108 +/- 29 min). Patients required an average blood propofol 
concentration of 4.05 +/- 1.01 µg/ml for major surgery and 2.97 +/- 1.07 g/ml for nonmajor 
surgery. Blood propofol concentrations at which 50% of patients were awake and oriented 
after surgery were 1.07 and 0.95 µg/ml, respectively. The metabolic clearance of propofol 
exceeds hepatic blood flow, which has leaded to suggestion that propofol is also metabolized 
in extrahepatic sites. Approximately 70% of a dose is excreted in the urine within 24 hours 
after administration, and 90% is excreted within 5 days. Psychomotor performance returned to 
baseline at blood propofol concentrations of 0.38-0.43 g/ml (Shafer et al., 1988, White, 1989, 
Deegan, 1992; Zuppa et al., 2003). 
Propofol causes a significant reduction in systemic blood pressure (more than 50% of 
preoperative level). This increase in blood pressure is a result of decrease in systemic 
vascular resistance. In addition to arterial vasodilatation, propofol produces venodilation 
(due both to a reduction in sympathetic activity and to a direct effect on the vascular smooth 
muscle), which contributes to its hypotensive effect. The fall in cardiac output is manifested 
with decrease in heart rate. (Machała & Szebla, 2008; Frolich, 2011). 
Respiratory depression and apnea are more pronounced with propofol than thiopental. 
Propofol decreases tidal volume and increases respiratory rate. The ventilatory response to 
carbon dioxide and hypoxia is also significantly decreased, but propofol does not inhibit 
hypoxic pulmonary vasoconstriction. Propofol can produce bronchodilation in patients with 
chronic obstructive pulmonary disease and in patients with acute laryngospasm during 
emergence from anesthesia (Zeller et al., 2005).   
Propofol decreases CMRO2 and CBF, as well as ICP.33 However, when larger doses are 
administered, the marked depressant effect on systemic arterial pressure can significantly 
decrease CPP. Cerebrovascular autoregulation in response to changes in systemic arterial 
pressure and reactivity of the cerebral blood flow to changes in carbon dioxide tension are not 
affected by propofol. Evidence for a possible neuroprotective effect has been reported in vitro 
preparations, and the use of propofol to produce EEG burst suppression has been proposed as 
a method for providing neuroprotection during aneurysm surgery. Its neuroprotective effect 
may at least partially be related to the antioxidant potential of propofol's phenol ring structure, 
which may act as a free-radical scavenger, decreasing free-radical induced lipid peroxidation. 
Recent studies reported that this antioxidant activity may offer many advantages in 
preventing the hypoperfusion/reperfusion phenomenon that can occur during surgery (Dagal 
& Lam, 2009; Girard et al., 2009; Ozturk et al., 2009; Menku et al., 2010).  
Propofol produces cortical EEG changes that are similar to thiopental. However, sedative 
doses of propofol increase â-wave activity analogous to the benzodiazepines. Induction of 
anesthesia with propofol is occasionally accompanied by excitatory motor activity (so-called 
nonepileptic myoclonia). In a study involving patients without a history of seizure disorders, 
excitatory movements following propofol were not associated with EEG seizure activity. 
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Propofol appears to possess profound anticonvulsant properties. Propofol has been reported 
to decrease spike activity in patients with cortical electrodes implanted for resection of 
epileptogenic foci and has been used successfully to terminate status epilepticus. The duration 
of motor and EEG seizure activity following electroconvulsive therapy is significantly shorter 
with propofol than with other IV anesthetics. Propofol produces a decrease in the early 
components of somatosensory and motor evoked potentials but does not influence the early 
components of the auditory evoked potentials (Modica et al., 1990).  
There is no evidence to suggest that propofol has any significant effects on renal or hepatic 
function.  
Propofol is known to possess direct antiemetic effects. Its use for induction and maintenance 
of anesthesia has been shown to be associated with a lower incidence of postoperative 
nausea and vomiting (PONV) when compared to any other anesthetic drug or technique. 
The precise mechanism of propofol antiemetic effect of propofol has not been elucidated, 
several mechanisms have been proposed, including a direct depressant effect on the 
chemoreceptor trigger zone (CTZ), the vagal nuclei, and other centers implicated in PONV 
(Becker, 2010). A systematic review of PONV following maintenance of anesthesia with 
propofol or an inhalational anesthetic agent found that patients receiving propofol had a 
significantly lower frequency of PONV, regardless of induction agent, choice of inhalational 
agent, use of nitrous oxide, patient age, or use of an opioid (Soppitt et al., 2000). Another 
systematic review found that propofol may be effective in reducing PONV in the short term, 
but only when given as a continuous infusion for maintenance of anesthesia and when the 
PONV event rate is greater than 20% (Eberhart et al., 2006). There is evidence of a 
relationship between plasma propofol concentration and antiemetic efficacy.  Gan et al., 
1999, found that a median plasma propofol concentration of 343 ng/mL was associated with 
a reduction in PV in surgical patients. After a typical induction dose, plasma propofol levels 
remain above this antiemetic serum concentration threshold for approximately 30 minutes. 
Therefore, the common practice of selecting propofol for inducing anesthesia because of its 
antiemetic effects provides little benefit to a patient in terms of reducing the likelihood that 
the patient will develop PONV during the stay in the postanesthesia care unit and after 
discharge from the ambulatory surgery center. 
Anticonvulsant effect of propofol is always described (Simpson et al., 1988). Theoretically, 
propofol should be strongly anticonvulsant, as it exhibits both GABAergic effects and 
persistent sodium current and calcium current blockade. However, a literature search of 
propofol associated tonic-clonic seizures retrieved more than 500 case reports, of which 81 
were analyzed in more detail. The denominator is missing from these case reports, and hence 
the true incidence is unknown. Among the 172,592 anesthetics analyzed there were 53 
generalized convulsions, of which 16 were thought to be primarily due to anesthesia. Fifteen of 
these cases were attributed to local anesthetic drug error, anti-epileptic drug withdrawal or 
cerebral anoxia/hypercarbia. This left a single case where the seizure was thought to be due to 
the anesthetic, propofol, an incidence of 1 per 172,592 anesthetics (Fredman et al, 1994). 
Propofol has a remarkable safety profile (Sarani B, Gracias, 2008). Dose dependent 
hypotension is the commonest complication; particularly in volume depleted patients. 
Hypertriglyceridemia and pancreatitis are uncommon complications. Allergic 
complications, which may include bronchospasm, have been reported. High dose propofol 
infusions have been associated with the "propofol syndrome"; this is a potentially fatal 
complication characterized by severe metabolic acidosis and circulatory collapse (Murdoch 
&, Cohen, 1999). This is a rare complication first reported in pediatric patients and believed 
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to be due to decreased transmembrane electrical potential and alteration of electron 
transport across the inner mitochondrial membrane. And,  of course pain during injection of 
propofol which could prevent in several ways (Jalota et al., 2011). 
Finally, the favorable pharmacokinetic properties, like short half-life and high clearance rate, 
minimal side effects and other nonhypnotic positive effects make it safe and usefull in 
clinical practice. 
3. Analgesic effects of propofol 
General anesthetics and propofol modulate the function of the gama (γ)-aminobutyric acid 
(GABA)A receptors, the inhibitory neurotransmitter receptors in the central nervous system. 
GABA is the major inhibitory neurotransmitter in the central nervous system, with fast 
synaptic inhibition mediated by postsynaptic GABAA receptors. GABAA receptors are 
members of the superfamily of ligand-gated ion channels and are thought to consist of five 
subunits (α, β, and γ). The GABA-induced chloride current can be potentiated by some 
general anesthetics. The actions of propofol appear to be mediated by β3-containing GABAA 
receptors. Specific residue is located within the second transmembrane region of the β3 
subunit of the GABAA receptor and has a influence in determining the action of propofol 
(Krasowski et. Al., 1998; Siegwart et al. 2002).  
The hypnotic effect of propofol and probably analgesic effect is related to GABA 
accumulation and occupation of the GABA receptor. Occupation of receptors produced 
hyperpolarisation of the postsynaptic cell membrane and neuronal inhibition. Propofol at 
low concentration enhance the amplitude of response of GABA and prolong the duration of 
GABA mediated synaptic inhibition. At supraclinical concentrations propofol directly 
activate the receptors anion channel. 
The analgesic effect of propofol may result as it acts at GABAA receptors (Dong & Xu, 2002). 
On the other hand, propofol induced potentiation of glycin receptors at the spinal level and 
might contribute to its antinociceptive actions and general anesthesia (Xu et al., 2004). 
Spinal (NMDA) receptors were reported to be involved in the antinociceptive action of 
propofol. Prolonged firing of C-fiber nociceptors causes release of glutamate which acts on 
N-methyl-D-aspartate (NMDA) receptors in the spinal cord. Activation of NMDA receptors 
causes the spinal cord neuron to become more responsive to all of its inputs, resulting in 
central sensitization. NMDA-receptor antagonists can suppress central sensitization. 
NMDA-receptor activation not only increases the cell's response to pain stimuli, it also 
decreases neuronal sensitivity to opioid receptor agonists. In addition to preventing central 
sensitization, co-administration of NMDA-receptor antagonists with an opioid may prevent 
tolerance to opioid analgesia. Was reported that intrathecal administration of an NMDA 
receptor agonist inhibited the antinociceptive effect of propofol; in contrast, an NMDA 
receptor antagonist enhanced the antinociceptive action of propofol (Cheng et al., 2008). 
These studies demonstrated that propofol has a synergistic action with several nociceptive 
transmission cascades including amino acid and opioid systems in the spinal cord. 
The above mentioned methods determined the probable way of analgesic action of propofol.  
4. Methods 
We followed the PRIZMA statement that recommends standards to improve the quality of 
reporting of meta-analyses. 
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The study was carried out according to the methods recommended by the Cochrane 
Collaboration and written in accordance with the PRISMA statement for reporting 
systematic reviews (Higgins et al., 2009 & Liberati et al., 2009). 
This systematic review included studies published up to December 2010. We conducted a 
systemic search of the electronic databasas: PubMed, Cochrane Library, and Embase, 
www.clinicaltrials.gov, and hand searching from the reference lists of identified papers.  We 
used the search terms “propofol” and (“postoperative analgesia” OR “analgesic effect”). 
Abstracts and unpublished studies were not considered. The search was limited to clinical 
trials and randomised controlled trials. Reference lists from identified studies and journals 
which appeared to be associated with the most retrieved citations were then hand-searched. 
The trials in languages other than English were not excluded. We prepared a flow diagram to 
summarize the study selection process according to PRISMA (Jaded et al., 1996) (Figure 1.). 
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Fig. 1. Flow diagram of excluded and included studies according to PRIZMA statement 
To minimize data duplication as a result of multiple reporting we compared papers from 
the same author. In addition, we searched www.clinicaltrials.gov for studies. Two authors 
(HJ and AD) screened and retrieved reports and excluded irrelevant studies. Relevant data 
were extracted by one author (VG) and checked by another (AH).  
From each study we extracted details on patients’ characteristics (adults and children, ASA 
status, age), type of surgery or no surgery and use of anesthetics in control group (Table 1.). 
Pain score, pain score method and use of postoperative analgesics, were also noted (Table 2). 
Side effects were noted in Table 3. 
Study selection 
To be considered for the review, the study was evaluated with regard to randomization 
method, allocation concealment, details of blinding measures, and withdrawals and 
dropouts using the modied 7-point 4-item Oxford scale (Figure 2) (Dong et al., 2002). This 
meant that adequate randomization was an absolute requirement for selection. However, 
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double-blinding was not a requirement, because adequate blinding was not felt to be 
possible in most studies. Each study was evaluated independently by authors and 
agreement was reached by consensus.  
Selected studies included 25 randomised controlled trials that compared the use propofol 
during anesthesia and any drug or non-drug intervention, or a combination, with an active or 
inactive control, and reported the response rate and severity of pain after propofol anesthesia.  
 
VALIDITY SCORE (0-7) 
Randomisation   Double blinding 
 
0 None    0 None 
1Mentioned   1 Mentioned 
2Described and adequate  2 Described and adequate 
 
Concealment of allocation  Flow of patients 
 
0 None    0 None 
1 Yes    1 Described but incomplete 
    2 Described and adequate 
Fig. 2. Modified Oxford Scale 
Selected studies included 25 randomised controlled trials that compared the use propofol 
during anesthesia and any drug or non-drug intervention, or a combination, with an active or 
inactive control, and reported the response rate and severity of pain after propofol anesthesia.  
The studies included in this review enrolled 1970, male and female patients, 1 to 80 year old, 
ASA I-III, who underwent surgical or non-surgical treatment resulting in the need for acute 
pain control. Relevant pain outcomes included number of patients who express pain, pain 
intensity, time to first analgesic request and supplemental analgesic demand were noted. All 
included studies had numerical data presented in the text or a table; if data were not 
presented as such, we extracted the information from the graphs if the scale allowed a 
sufficiently precise estimation.  
We excluded trials including less than 10 patients and those reporting on chronic pain. Data 
from animal studies, abstracts, letters or reviews were not considered. 
Information on number of patients, anesthetics and type of surgery was obtained from each 
report.  
The data extracted from each of the included trials included: eligibility and exclusion 
criteria, study design, duration and degree of follow-up, randomization, allocation 
concealment, blinding, number and characteristics of participants, type of surgery, pain 
score, time to first analgesic request, and consumption of supplementary analgesics 
between the propofol and other treatment groups, and by assessment of the side effects 
(Table 1, 2 & 3). 
Meta analyses 
Qualitative analysis of postoperative effectiveness was evaluated by significant difference  
(P < 0.05 as reported in the original investigation) in pain relief using pain scores, time to 
first analgesic request, and consumption of supplementary analgesics between the treatment 
groups, and by assessment of the clinical importance of observed differences. 
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first analgesic request, and consumption of supplementary analgesics between the treatment 
groups, and by assessment of the clinical importance of observed differences. 
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Reference VS Treatment Control No. of Patients Type of Intervention 
Briggs et al. 
1982 3 Propofol Thiopentone 40 Gynecologic procedures 
Doze et al.  
1988 4 Propofol thiopental/isoflurane 120 Abdominal surgery 
Borgeat et al. 
1990  4 Propofol thiopental/halothane 40 ENT surgery 
Anker-Møller 
et al. 1991 4 Propofol thiopental/saline 19 laser stimulation 
V Hemelrijck 
et al. 1991 4 Propofol desflurane 92 
gynecological 
laparascopy 
Hendolin et al. 
1994 5 Propofol thiopental/isoflurane 41 uvuloplasty 
Jellish et al. 
1995 5 Propofol thiopental/isoflurane 102 middle ear surgery 
Petersen-Felix 
et al. 1996 2 Propofol alfentanyl 12 
electric/laser/acoustical 
stimulation 
Eriksson et al. 
1996 5 desflurane propofol 90 
gynecological 
laparascopy 
Zacny et al. 
1966 3 propofol fentanyl 12 ice-cold water 
Davis et al.  
1997 5 reifentanil alfentanil/isofl/prop 129 strabismus surgery 
Boccara et al.  
1998 5 propofol isoflurane 40 
cosmetic 
abdominoplasty 
Ozkose et al. 





Hand et al. 
2001 3 propofol intralipids 48 tourniquet pain 
Mukherjee et 
al. 2003 6 
propofol,fentanyl, 
isoflurane pr, remifentanil 100 middle ear surgery 
Hofer et al. 
2003 7 propofol sevoflurane 305 
gynaecologic or 
orthopedic procedures 
Coolong et al 
2003 4 propofol thiopental 84 laparascopic procedures 
Frölich et al. 
2005 4 propofol placebo 80 thermal pain 
Cheng et al. 
2008 7 propofol isoflurane 80 open uterine surgery 
Fassoulaki et 
al. 2008 7 sevofl/desfl propofol 105 gynecological operations 
Hasani et al. 
2009 5 propofol halothane 83 abdominal surgery 
Bandschapp et 
al. 2010 7 propofol intralipid/saline 14 electrical stimulation 
Tan et al. 
2010 6 propofol sevoflurane 80 
gynecological 
laparascopic 
Pieters et al. 
2010 7 propofol sevoflurane 42 adenotonsillectomy 





remifentanyl 214 brest cancer surgery 
VS-Validity Score (Modified Oxford Scale) 
NS - no significant difference between treatment groups or no significant difference in favor of the treatment; 
P< 0.05 - significant difference between treatment groups in favor of the treatment; NE - not evaluated. 
Table 1. Details of study included. 
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References Pain Score Method Pain Score 






Briggs et al. 
1982 
tibial pressure 
algesimetry P<0.001 NE NE 
Doze et al. 
1988 NE NE p>0.05 p>0.05 
Borgeat et al. 
1990 VAS P<0.05 p>0.05 p>0.05 
Anker-Møller et al. 
1991 laser power meter NS NE NE 
Van Hemelrijck etal. 
1991 VAS NS NS NS 
Hendolin et al. 
1994 VAS P<0.05 NS NS 
Jellish et al. 
1995 VAS NS NS NS 
Petersen-Felix et al. 
1996 VAS NS NE NE 
Eriksson et al. 
1996 VAS NS NS NS 
Zacny et al. 
1966 VAS P<0.05 NE NE 
Davis et al. 
1997 OPDS NS NS NS 
Boccara et al. 
1998 VAS P<0.05 for Iso P<0.05 for Iso P<0.05 for Iso 
Ozkose et al. 
2001 VAS P<0.05 P<0.05 P<0.05 
Hand et al. 
2001 NRS NE P<0.05 P<0.05 
Mukherjee et al. 
2003 VAS P<0.05 P<0.05 P<0.05 
Hofer et al. 
2003 VAS NS NS NS 
Coolong et al 
2003 VNRS NS NS NS 
Frölich et al. 
2005 VAS 
P<0.05 more pain with 
propofol NE NE 
Cheng et al. 
2008 NAS p<0.01 p<0.01 p<0.01 
Fassoulaki et al. 
2008 VAS NS NS NS 
Hasani et al. 
2009 FPS NS NE NE 
Bandschapp et al. 
2010 NRS P<0.05 NE NE 
Tan et al. 
2010 VAS P=0.01 NS NS 
Pieters et al. 
2010 CHEOPS P<0.05 P<0.05 P<0.05 
Shin et al. 
2010 VAS P> 0.001 P> 0.001 P> 0.001 
NS - no significant difference between treatment groups or no significant difference in favor of the treatment;  
P<0.05 - significant difference between treatment groups in favor of the treatment; NE -  not evaluated. 
Table 2. Details of study included. 
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Table 2. Details of study included. 
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 Nauzea   Vomiting  
Other 
side 
effects   
Study Propofol Control P Propofol Control P Propofol Control P 
 n/N n/N  n/N n/N  n/N n/N  Doze 1988 1/ 60 8 /60 P<0.05 3/ 60 16/60 P<0.05 10 në 60 34/60 P<0.05 
Borgeat 1990 0/20 2/20 NS 0/20 2 në 20 NE 16/20 20/20 P<0.05 
Vhemelrijck 1991   P<0.05   P<0.05 9/46 46/46 P<0.05 Hendolin 1994 0/20 2/21 NS 0/20 1/21  2 /21 2 /21 NS Jellish 1995 3/34 20/68 P<0.05 5/34 15/68 NS    Eriksson 1996   NS   NS   NS Davis 1997    6/20 32/57 P<0.05 0/20 23/57 P<0.05 Boccara 1998 5/ 20 12/ 20 P<0.05      NS Ozkose 2001    1 /20 22/40 P<0.05    Mukherjee 2003   NS   NS   NS Hofer 2003 50/155 75/146 P<0.001 34/155 50/146 P<0.01    Coolong 2003   NS   NS   NS Cheng 2008   NS   NS   NS Hasani 2009   NS   NS   NS Tan 2010   NS   NS   NS Pieters 2010 1/19 7/19 P<0.05 1/19 7/19 P<0.05   NS Shin 2010 29/96 40/90 P<0.005 29/ 96 40/90 P<0.005 50/96 42/90 NS 
NS - no significant difference between treatment groups or no significant difference in favor of the 
treatment;   
P<0.05 - significant difference between treatment groups in favor of the treatment;  NE - not evaluated. 
Table 3. Details of study included (side effects). 
Quantitative analyses of combined data were intended by calculation of the number of 
patients reporting any pain or no pain (pain response rate) between treatment groups. For 
studies with multiple intervention groups, we partitioned the count of events and patients 
in the control group into two or more control groups within any meta-analysis to avoid a 
unit of analysis error. For the studies participating in the indirect comparisons, we 
partitioned the comparator group according to how many times it was used for indirect 
comparisons (across meta-analyses). The summary relative risks and 95% confidence 
intervals were estimated using a random effects Mantel-Haenszel method in RevMan 5.0 
(Cochrane Collaboration). Statistical heterogeneity was assessed by the I2 value. 
The weight given to each study in this analysis (i.e., how much influence each study had on 
the overall results) was determined by the precision of its estimate by taking into account 
study size and SDs of the pain in the individual trials. For the current use, a mean for each 
treatment group was calculated in every trial from all available recordings performed after 
anesthesia with propofol. Verbal rating pain scores and similar scores were converted to 
VAS pain scores (e.g., a four-point verbal rating score including no, light, moderate, and 
severe pain was converted to 0, 25, 50, and 75 mm VAS, respectively).  
5. Results 
The systematic search in the databases identified 561 relevant articles. After screening, 25 
studies potentially met the inclusion criteria. The full-text publications of these studies were 
examined in more detail. Four study was excluded, because it was reviews or editorial articles. 
In 90 studies the subject of investigation were animals and also were excluded. (Fig. 1). 
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The data of 25 randomized controlled studies were included in the present meta-analysis 
(Table 1,2 &3). A total of 1970 patients (909 with propofol), male and female were 
included. The patients were 1-85 year old. The 294 patients were children, aged 1-18 year 
(Borgeat et al.,1990, Pieters et al., 2010, Davis et al., 1997 & Hasani et al., 2009).  
The participans undergoing brest, ginecologic, orthopedic, ENT, abdominal, urogenital, 
spine, cosmetic or eye surgery. In 7 studies the participants were volunteer and have no 
surgery (total 163 volunteers) (Briggs et al., 1982, Anker-Møller et al., 1991, Zacny et al., 
1996, Petersen-Felix et al., 1996, Hand et al., 2001, Frolich et al., 2005 & Bandschapp et al. 
,2010). 
The participants were randomly   assigned to receive propofol and in control group: 
thiopental (Briggs et al.,1982 & Coolong et al.,2003);  thiopental and saline (Anker-Møller et 
al., 1991);  thiopental with halothane (Borgeat et al.,1990); or,  thiopenthal with isoflurane 
(Doze et al., 1988 , Hendolin et al.,1994 & Jellish et al.,1995).  In control grup the  inhalation 
anesthetics used were  halothane (Hasani et al., 2009), isoflurane (Boccara et al., 1998&  
Cheng et al.,2008), sevoflurane (Ozkose et al.,2001,  Hofer et al., 2003, Tan et al., 2010, Pieters 
et al., 2010 & Shin et al., 2010)  and desflurane (Van Hemelrijck et al.,1991&Fassoulaki et al., 
2010). Also, the control groups contained opioids: fentanyl, remifentanil (Davis et al., 1997, 
Mukherjee et al., 2003 & Shin et al., 2010) and alfentanil (Petersen-Felix et al., 1996& Davis et 
al., 1997). 
Intensity of pain scores was considered adequate (>30 mm VAS) in all trials. VAS (visual 
analogue score)  pain score was not present in 9 studies. The pain scores used in  studies 
was NRS-numeric rating scale (Hand et al., 2001&Bandschapp et al. ,2010), NAS- 
Numerical analogue score (Cheng et al., 2008), CHEOPS-Children’s Hospital of Eastern 
Ontario Scale (Pieters et al., 2010), tibial pressure algesimetry (Briggs et al., 1982), VNSR- 
verbal numeric rating scale (Coolong et al., 2003), laser power meter (Anker-Møller et al., 
1991), FPS- faces pain scale (Hasani et al., 2009) and OPDS-Objective Pain Discomfort 
Scale (Davis et al., 1997). 
 
I² 64% (95% CI = 10.7% to 80.1%) 
Favours 
control
Cochran Q = 25.00
  (df = 9)  P = 0.003
Favours 
interventions
n N n N
Briggs (1982 1 20 12 20
Doze (1988) 30 60 34 60
Borgeat (1990) 1 20 9 20
Anker-Møller (1991) 1 12 6 7
Van Hemelrijck (1991) 15 46 17 46
Hendolin (1994) 1 21 3 20
Jellish (1995) 14 34 34 68
Eriksson (1996) 2 29 4 58
Davis (1997) 6 20 5 109

















Fig. 3. Risk of postoperative pain after propofol anesthesia. 
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Fig. 3. Risk of postoperative pain after propofol anesthesia. 
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In selected 25 randomized controlled trials the postoperative pain was evaluated in patients 
treated with propofol. In 15 of them the degree of pain was given as the mean and, in our 
research to find risk ratio (Mantel Haenszel, random) we included 10 researches in which 
pain was expressed as present or absent. 








n N n N
Doze (41) 1 60 8 60
Borgeat (42) 0 20 2 20
Hendolin (45) 0 20 2 21
Jellish (46) 3 34 20 68
Boccara (51) 5 20 12 20
Hofer (55) 50 155 75 146
Pieters (63) 1 19 7 19














Fig. 4. Risk of postoperative nauzea after propofol anesthesia. 
To study the presence of nausea we analyzed eight researches that have investigated this 
symptom in postoperative period. Nausea was the rare risk ratio 0.552 in intervention group 
(95% CI 0.407-0.749) (Fig. 4).  
 
Cochran Q = 8.77 (df = 8)  P = 0.3617
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n N n N
Doze (41) 3 60 16 60
Borgeat (42) 0 20 2 20
Hendolin (45) 0 20 1 21
Jellish (46) 5 34 15 68
Davis (50) 6 20 32 57
Ozkose (52) 1 20 22 40
Hofer (55) 34 155 50 146
Pieters (63) 1 19 7 19















Fig. 5. Risk of postoperative vomiting after propofol anesthesia. 
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The presence of vomiting was analyzed in 9 researches. The risk ratio for vomiting was RR= 
0.526 (95% CI 0.371-0.746) in intervention group with propofol (Fig. 5). 
 
Cochran Q = 19.58562  (df = 5)  P = 0.0015
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Doze (41) 10 60 34 60
Borgeat (42) 16 20 20 20
Van Hemelrijck  (44) 9 46 46 46
Hendolin (45) 2 21 2 21
Davis (50) 0 20 23 57












Fig. 6. Risk of the other side effects after propofol anesthesia during the postoperative period. 
The other side effects which occurred in patients anesthetized with propofol were analyzed 
in 9 researches. In the term “the other side effects” was included: pain during propofol 
injection in induction period, bradycardia, hypotension, and spontaneous movements also 
described in perioperative period. Apnea, hypersalivation, laryngospasm and 
bronchospasm are also included in possible complications in postoperative period. The 
other side effects were also rare in the propofol anesthesia treated patients with the risk ratio 
0.46 in intervention group (95% CI 0.21 to 1.02) (Fig. 6).  
6. Discussion 
Is propofol analgesic? ; still remain unclear. Experts held very different opinions on the 
value and clinical utility of an analgesic effect of propofol. The answers for this question 
were evaluated with pro versus con debates. 
PRO: Propofol has analgesic effect 
Discussions about analgesic effect of propofol restarted with the study published in 
Anesthesia & Analgesia in January 2008 by Cheng et al. The trial was based in hypothesis that 
women scheduled for hysterectomy or myomectomy and anesthetized with volatile 
anesthesia, isoflurane induces a hyperalgesic state, and that patients anesthetized with 
propofol was neutral in its modulation of pain sensitivity. They found that patients 
anesthetized with isoflurane reported more postoperative pain than those anesthetized with 
propofol. The other finding was the difference in postoperative opioid use with more 
requirements in those anesthetized with isoflurane. 
Two years later, in 2010 issue of Anesthesia & Analgesia, Tan et al. report on a trial that tests 
the hypothesis that patients undergoing day surgery anesthetized with propofol have less 
pain and a better quality of recovery compared with patients anesthetized with sevoflurane. 
In this prospective, double-blind, randomized trial, the authors used a  study design in 
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in 9 researches. In the term “the other side effects” was included: pain during propofol 
injection in induction period, bradycardia, hypotension, and spontaneous movements also 
described in perioperative period. Apnea, hypersalivation, laryngospasm and 
bronchospasm are also included in possible complications in postoperative period. The 
other side effects were also rare in the propofol anesthesia treated patients with the risk ratio 
0.46 in intervention group (95% CI 0.21 to 1.02) (Fig. 6).  
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Discussions about analgesic effect of propofol restarted with the study published in 
Anesthesia & Analgesia in January 2008 by Cheng et al. The trial was based in hypothesis that 
women scheduled for hysterectomy or myomectomy and anesthetized with volatile 
anesthesia, isoflurane induces a hyperalgesic state, and that patients anesthetized with 
propofol was neutral in its modulation of pain sensitivity. They found that patients 
anesthetized with isoflurane reported more postoperative pain than those anesthetized with 
propofol. The other finding was the difference in postoperative opioid use with more 
requirements in those anesthetized with isoflurane. 
Two years later, in 2010 issue of Anesthesia & Analgesia, Tan et al. report on a trial that tests 
the hypothesis that patients undergoing day surgery anesthetized with propofol have less 
pain and a better quality of recovery compared with patients anesthetized with sevoflurane. 
In this prospective, double-blind, randomized trial, the authors used a  study design in 
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which one group had an induction with inhalation of sevoflurane followed by sevoflurane 
maintenance, whereas the other group had an IV induction with propofol followed by 
propofol maintenance. The subjects were treated during surgery with alfentanil, 
paracetamol, and diclofenac for pain and dexamethasone and ondansetron for nausea. Pain 
was treated after surgery using morphine until visual analog scale score was <4 and then 
oral oxycodone. The authors found that propofol provided a statistically significant (P < 
0.01) difference, decrease in postoperative pain. Hendolin et al., 1994, found that propofol 
significantly reduced pain in the second hour compared with patients receiving isoflurane, 
corroborating the results of the present study. 
The other study published in Anesthesiology August 2010 by Bandschapp et al., investigated 
the pain perception or central sensitization effects of propofol and its solvent (10% 
Intralipid) in healthy volunteers. They experienced decreased pain, hyperalgesia and 
allodynia elicited by intra-cutaneous electrical stimulation when they received a target-
control infusion of propofol (2µg/ml) compared with controls (the solvent 10% Intralipid 
and saline). However, the results provide no evidence for a modulatory role of the solvent of 
propofol (10% Intralipid) in the analgesic and antihyperalgesic properties of propofol. 
Propofol reduced pain by 40% and nearly abolished hypersensitivity which disappears on 
discontinuation of the drug. The EC50 for the analgesic effect of propofol was 3.2 µg/ml.  
There is animal literature that addresses the modulatory effects of anesthetics in different 
nociceptive models.  
In the 1990s, Ewen et al., found that in rats an IV infusion of propofol resulted in an initial 
decline followed by a rise in nociceptive threshold as the plasma concentration and degree 
of sedation increased. They suggest that smaller concentrations of propofol than sedative 
doses are responsible for hyperalgesia. However, the similar experiments in a postoperative 
pain models in mice were unable to detect any hyperalgesic phase at lower than sedative 
doses of propofol or on emergence (Udesky et al., 2005). Other groups have found an 
analgesic response to propofol, particularly in inflammatory pain models (Daniels&Roberts, 
1998). A study in rodents by Guindon et al., 2007, demonstrated that in a test of 
inflammatory pain, locally injected propofol decreased pain behavior in a dose-dependent 
manner. The authors hypothesized that this antinociceptive activity was mediated, in part, 
by cannabinoid receptors 1 and 2 (CB1 and CB2). Gilron et al., 1999, however, showed that 
propofol suppressed hindpaw formalin-evoked expression of fos-like immunoreactivity 
(FLI) in spinal neurons, suggesting an important analgesic effect. 
Clearly, most of the animal and human data on nociceptive effects mediated by propofol 
may provide advantages. 
CON: Propofol has not analgesic effect 
On the other hand, many studies with propofol in both animals and humans have failed to 
demonstrate any evidence of analgesic-like activity.  
In an animal study by Merrill et al., 2006, propofol produced anesthesia but failed to 
produce the experimental findings typically associated with nociception, suggesting that 
propofol lacks analgesic properties. Accurately, propofol sufficient to produce immobility 
did not prevent increased activation (c-fos expression) of spinal neurons by intraplantar 
formalin injection, a finding consistent with propofol lacking analgesic properties. Mice with 
a mutation of the gamma-aminobutyric acid type A receptor were resistant to propofol 
anesthesia, supporting the importance of this receptor for propofol’s action. Another rodent 
study (Ng & Antognini, 2006) found that isoflurane and propofol both had similar effects on 
 
Propofol and Postoperative Pain: Systematic Review and Meta-Analysis 
 
237 
neuronal “windup” in the spinal cord, a factor associated with persistent pain. The study 
from Goto et al., 1994,  reported that propofol, unlike pentobarbital, had no effect on second-
phase nocifensive behavioral responses elicited by formalin injection in the hind paws of 
rats. Wilder-Smith et al. , 1995, also determined that propofol infusions did not affect 
thermal pain thresholds. 
The human studies of interest, (Boccara et al., 1998) compared postoperative pain and 
analgesic requirements in patients receiving propofol or isoflurane for maintenance of 
anesthesia and reported that patients receiving propofol actually had increased pain and 
opioid requirements for the first 6 hours after surgery compared with patients receiving 
isoflurane. These findings were exactly the opposite of the findings of Cheng et al. 
We conduct a more recent clinical study, published in Anesthesia & Analgesia in November 
2008, by Fassoulaki et al., in patients undergoing abdominal hysterectomy or myomectomy 
under sevoflurane, desflurane or propofol anesthesia.  Anesthesia was induced with 
propofol, morphine and cisatracrium; and maintained with sevoflurane or desflurane or 
propofol. Postoperative analgesia was maintained with morphine. They were unable to 
demonstrate any difference in postoperative pain scores or in the requirement for opioid 
analgesic medication among patients maintained with propofol, sevoflurane, or desflurane.  
Presented data explained the inconsistency between the studies regarding the post-
operative analgesic effect of propofol.  
Our findings support the analgesic effect of propofol. 
Postoperative nausea and vomiting (PONV) are unpleasant, often underestimated side 
effects of anesthesia and surgery, not devoid of medical complications. Prevention with 
antiemetics is only partially effective. Propofol has been shown recently to possess 
antiemetic properties in several situations.  
The limitation of our analysis is mainly related to the methodological heterogeneity of 
several studies. The dose of propofol varied between the studies and my influenced the 
postoperative analgesic effect. The methods of postoperative pain assessment my bias the 
results of our meta-analyses. On the other hand, the number of analyzed clinical trials may 
also bias our results. 
7. Conclusions 
Our meta-analysis indicates that propofol provides a prolonged and improved 
postoperative analgesia with few adverse effects compared with an other inhalation and 
intravenous anaesthetics.  However, propofol have improved antiemetic effect. The other 
side effects are minimal, with exception of pain during injection of propofol. 
Propofol changed the practice of anesthesia, nevertheless postoperative analgesia with 
ordinary analgesics must be sustained. 
Finally, we accomplished that propofol is not an analgesic, but many studies have certainly 
demonstrated analgesic properties of propofol. 
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1. Introduction 
A femoral nerve block is simple to perform, has a high rate success, carries a low risk of 
complications, and it is widely used technique for surgical anesthesia and post-operative 
pain management of the lower extremity. It provides analgesia to the anterior thigh, 
including the flexor muscles of the hip and extensor muscles of the knee and therefore, it is 
well suited for surgeries that involve the hip, the knee or the anterior thigh zone. The 
femoral nerve block is often associated with sciatic nerve block in order to achieve a lower 
extremity analgesia. 
The anterior approach to the femoral nerve block initially described as a 3-in-1 block by 
Winnie et al (Winnie et al., 1973), suggested that the femoral, lateral femoral cutaneous, and 
obturator nerves could be blocked from a single paravascular injection at a point inferior to 
the inguinal crease. Studies have since showed that the femoral can be reliably blocked by a 
single injection, the lateral femoral cutaneous nerves is blocked in 95%, but the obturator 
nerve is almost always spared (Parkinson et al., 1989).  Therefore, a 3-in-1 block with the 
paravascular approach seems difficult to obtain, and, as a consequence, when all three 
nerves need to be anesthetized a posterior lumbar plexus block or a multitruncular block 
should be performed. The anterior approach to the femoral nerve is similar for “single shot” 
or continuous nerve blocks. A femoral nerve block can be obtained with single shot of local 
anesthetic or by using a continuous catheter technique. The localization of the femoral nerve 
can be obtained by the use of nerve stimulator or with ultrasound guidance. When using 
single shot technique, the local anesthetic agent is injected through the needle after location 
of the nerve with the nerve stimulator. When using continuous catheter techniques, the 
nerve can be stimulated via the needle through which the catheter is placed, or via both the 
needle and the catheter itself.   
This narrative review summarizes the evidence derived from randomized controlled trials 
(RCTs) and retrospective analysis, in order to determine the efficacy of continuous femoral 
nerve block comparing the use of stimulating catheters with non-stimulating catheters for 
lower-extremity surgery. Furthermore, we explore the adjunctive use of ultrasonography for 
femoral nerve block. 
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single injection, the lateral femoral cutaneous nerves is blocked in 95%, but the obturator 
nerve is almost always spared (Parkinson et al., 1989).  Therefore, a 3-in-1 block with the 
paravascular approach seems difficult to obtain, and, as a consequence, when all three 
nerves need to be anesthetized a posterior lumbar plexus block or a multitruncular block 
should be performed. The anterior approach to the femoral nerve is similar for “single shot” 
or continuous nerve blocks. A femoral nerve block can be obtained with single shot of local 
anesthetic or by using a continuous catheter technique. The localization of the femoral nerve 
can be obtained by the use of nerve stimulator or with ultrasound guidance. When using 
single shot technique, the local anesthetic agent is injected through the needle after location 
of the nerve with the nerve stimulator. When using continuous catheter techniques, the 
nerve can be stimulated via the needle through which the catheter is placed, or via both the 
needle and the catheter itself.   
This narrative review summarizes the evidence derived from randomized controlled trials 
(RCTs) and retrospective analysis, in order to determine the efficacy of continuous femoral 
nerve block comparing the use of stimulating catheters with non-stimulating catheters for 
lower-extremity surgery. Furthermore, we explore the adjunctive use of ultrasonography for 
femoral nerve block. 
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1.1 Anatomy (Gray & Henry, 1918) 
The Femoral Nerve, the largest branch of the lumbar plexus, arises from the dorsal divisions 
of the second, third, and fourth lumbar nerves. It descends through the fibers of the Psoas 
major, emerging from the muscle at the lower part of its lateral border, and passes down 
between it and the Iliacus, behind the iliac fascia; it then runs beneath the inguinal ligament, 
into the thigh, and splits into an anterior and a posterior division. At this level it is located 
lateral and posterior to the femoral artery. 
The anterior division of the femoral nerve gives off (Table 1 ): 
 Anterior cutaneous branches. The anterior cutaneous branches comprise the 
intermediate and medial cutaneous nerves  
o The intermediate cutaneous nerve pierces the fascia lata (and generally the 
Sartorius) and divides into two branches which supply the skin as low as the front 
of the knee. Here they communicate with the medial cutaneous nerve and the 
infrapatellar branch of the saphenous, to form the patellar plexus. 
o The medial cutaneous nerve passes obliquely across the upper part of the sheath of 
the femoral artery, and divides into two branches, an anterior and a posterior. 
Before dividing it gives off a few filaments, which supply the integument of the 
medial side of the thigh, accompanying the long saphenous vein. The anterior 
branch divides into two branches: one supplies the integument as low down as the 
medial side of the knee; the other crosses to the lateral side of the patella. The 
posterior branch descends along the medial border of the Sartorius muscle to the 
knee, where it pierces the fascia lata, communicates with the saphenous nerve, and 
gives off several cutaneous branches. It then passes down to supply the integument 
of the medial side of the leg.   
 Muscular branches—The nerve to the Pectineus and the nerve to the Sartorius  
The posterior division of the femoral nerve gives off (Table 1): 
 The saphenous nerve - the largest cutaneous branch of the femoral nerve. It approaches 
the femoral artery where this vessel passes beneath the Sartorius, and lies in front of it, 
behind the aponeurotic covering of the adductor canal, as far as the opening in the 
lower part of the Adductor magnus. It descends vertically along the medial side of the 
knee behind the Sartorius, pierces the fascia lata, between the tendons of the Sartorius 
and Gracilis, and becomes subcutaneous. The nerve then passes along the tibial side of 
the leg, accompanied by the great saphenous vein, descends behind the medial border 
of the tibia, and, at the lower third of the leg, divides into two branches: one continues 
its course along the margin of the tibia, and ends at the ankle; the other passes in front 
of the ankle, and is distributed to the skin on the medial side of the foot, as far as the 
ball of the great toe. The saphenous nerve, about the middle of the thigh, gives off a 
branch which joins the subsartorial plexus. At the medial side of the knee it gives off 
a large infrapatellar branch, which pierces the Sartorius and fascia lata, and is 
distributed to the skin in front of the patella. Below the knee, the branches of the 
saphenous nerve are distributed to the skin of the front and medial side of the leg, 
communicating with the cutaneous branches of the femoral, or with filaments from 
the obturator nerve. 
 Muscular branches supply the four parts of the Quadriceps femoris. The branch to the 
Rectus femoris enters the upper part of the muscle, and supplies a filament to the hip-
joint. The branch to the Vastus lateralis enters the lower part of the muscle and gives off 
an articular filament to the knee-joint. The branch to the Vastus medialis enters the 
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muscle about its middle, and gives off a filament to the knee-joint. The branches to the 
Vastus intermedius, two or three in number, enter the muscle about the middle of the 
thigh and give off filament to the Articularis genu and the knee-joint.  
 Articular branches 
o articular branch to the hip-joint is derived from the nerve to the Rectus 
femoris.  
o articular branches to the knee-joint are three in number. One is derived 
from the nerve to the Vastus lateralis, the second derived from the nerve 
to the Vastus medialis and the third branch is derived from the nerve to 




provides sensory innervation 
to the skin of the anterior 
and medial thigh and motor 
innervation to the Sartorius 
and Pectineus muscles. 
 Anterior cutaneous branches 
o intermediate cutaneous nerves 
o medial cutaneous nerves  
 Muscular branches  
o nerve to the Pectineus  
o nerve to the Sartorius 
Posterior division 
provides sensory innervation 
to the medial part of the 
lower leg and motor 
innervation to the quadriceps 
muscle  
 Saphenous nerve  
 Muscular branches (individual heads of the quadriceps 
muscle) 
 Articular branches  
o to the hip-joint 
o branches to the knee-joint 
Table 1. Anatomy of femoral nerve 
1.2 Indications 
The femoral nerve block is mainly indicated for the pain control associated with unilateral 
anterior knee surgery (total knee arthroplasty, ACL). It is also ideal for surgery that 
involves the hip (femoral fracture repair) or anterior thigh. The block is often combined 
with a sciatic nerve block or with obturator nerve block if surgery is distal or posterior to 
the knee join. 
1.3 Contraindications  
 Infection or haematoma In the puncture site  
 Local anesthetic allergy  
 Lesion of the nerves to be stimulated distal to the puncture site 
 Neurological deficit of the leg to be anaesthetised 
  Refusal of the procedure by the patient 
2. History of continuous nerve blocks 
The first attempt to practice a continuous peripheral nerve blockade was done by Ansbro in 
1946, who described a continuous block of the brachial plexus at a supraclavicular level 
(Ansbro, 1946). A continuous axillary block was performed in 1977  by Selander in patients 
who underwent hand surgery. (Selander, 1977).  
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1.1 Anatomy (Gray & Henry, 1918) 
The Femoral Nerve, the largest branch of the lumbar plexus, arises from the dorsal divisions 
of the second, third, and fourth lumbar nerves. It descends through the fibers of the Psoas 
major, emerging from the muscle at the lower part of its lateral border, and passes down 
between it and the Iliacus, behind the iliac fascia; it then runs beneath the inguinal ligament, 
into the thigh, and splits into an anterior and a posterior division. At this level it is located 
lateral and posterior to the femoral artery. 
The anterior division of the femoral nerve gives off (Table 1 ): 
 Anterior cutaneous branches. The anterior cutaneous branches comprise the 
intermediate and medial cutaneous nerves  
o The intermediate cutaneous nerve pierces the fascia lata (and generally the 
Sartorius) and divides into two branches which supply the skin as low as the front 
of the knee. Here they communicate with the medial cutaneous nerve and the 
infrapatellar branch of the saphenous, to form the patellar plexus. 
o The medial cutaneous nerve passes obliquely across the upper part of the sheath of 
the femoral artery, and divides into two branches, an anterior and a posterior. 
Before dividing it gives off a few filaments, which supply the integument of the 
medial side of the thigh, accompanying the long saphenous vein. The anterior 
branch divides into two branches: one supplies the integument as low down as the 
medial side of the knee; the other crosses to the lateral side of the patella. The 
posterior branch descends along the medial border of the Sartorius muscle to the 
knee, where it pierces the fascia lata, communicates with the saphenous nerve, and 
gives off several cutaneous branches. It then passes down to supply the integument 
of the medial side of the leg.   
 Muscular branches—The nerve to the Pectineus and the nerve to the Sartorius  
The posterior division of the femoral nerve gives off (Table 1): 
 The saphenous nerve - the largest cutaneous branch of the femoral nerve. It approaches 
the femoral artery where this vessel passes beneath the Sartorius, and lies in front of it, 
behind the aponeurotic covering of the adductor canal, as far as the opening in the 
lower part of the Adductor magnus. It descends vertically along the medial side of the 
knee behind the Sartorius, pierces the fascia lata, between the tendons of the Sartorius 
and Gracilis, and becomes subcutaneous. The nerve then passes along the tibial side of 
the leg, accompanied by the great saphenous vein, descends behind the medial border 
of the tibia, and, at the lower third of the leg, divides into two branches: one continues 
its course along the margin of the tibia, and ends at the ankle; the other passes in front 
of the ankle, and is distributed to the skin on the medial side of the foot, as far as the 
ball of the great toe. The saphenous nerve, about the middle of the thigh, gives off a 
branch which joins the subsartorial plexus. At the medial side of the knee it gives off 
a large infrapatellar branch, which pierces the Sartorius and fascia lata, and is 
distributed to the skin in front of the patella. Below the knee, the branches of the 
saphenous nerve are distributed to the skin of the front and medial side of the leg, 
communicating with the cutaneous branches of the femoral, or with filaments from 
the obturator nerve. 
 Muscular branches supply the four parts of the Quadriceps femoris. The branch to the 
Rectus femoris enters the upper part of the muscle, and supplies a filament to the hip-
joint. The branch to the Vastus lateralis enters the lower part of the muscle and gives off 
an articular filament to the knee-joint. The branch to the Vastus medialis enters the 
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muscle about its middle, and gives off a filament to the knee-joint. The branches to the 
Vastus intermedius, two or three in number, enter the muscle about the middle of the 
thigh and give off filament to the Articularis genu and the knee-joint.  
 Articular branches 
o articular branch to the hip-joint is derived from the nerve to the Rectus 
femoris.  
o articular branches to the knee-joint are three in number. One is derived 
from the nerve to the Vastus lateralis, the second derived from the nerve 
to the Vastus medialis and the third branch is derived from the nerve to 




provides sensory innervation 
to the skin of the anterior 
and medial thigh and motor 
innervation to the Sartorius 
and Pectineus muscles. 
 Anterior cutaneous branches 
o intermediate cutaneous nerves 
o medial cutaneous nerves  
 Muscular branches  
o nerve to the Pectineus  
o nerve to the Sartorius 
Posterior division 
provides sensory innervation 
to the medial part of the 
lower leg and motor 
innervation to the quadriceps 
muscle  
 Saphenous nerve  
 Muscular branches (individual heads of the quadriceps 
muscle) 
 Articular branches  
o to the hip-joint 
o branches to the knee-joint 
Table 1. Anatomy of femoral nerve 
1.2 Indications 
The femoral nerve block is mainly indicated for the pain control associated with unilateral 
anterior knee surgery (total knee arthroplasty, ACL). It is also ideal for surgery that 
involves the hip (femoral fracture repair) or anterior thigh. The block is often combined 
with a sciatic nerve block or with obturator nerve block if surgery is distal or posterior to 
the knee join. 
1.3 Contraindications  
 Infection or haematoma In the puncture site  
 Local anesthetic allergy  
 Lesion of the nerves to be stimulated distal to the puncture site 
 Neurological deficit of the leg to be anaesthetised 
  Refusal of the procedure by the patient 
2. History of continuous nerve blocks 
The first attempt to practice a continuous peripheral nerve blockade was done by Ansbro in 
1946, who described a continuous block of the brachial plexus at a supraclavicular level 
(Ansbro, 1946). A continuous axillary block was performed in 1977  by Selander in patients 
who underwent hand surgery. (Selander, 1977).  
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The first use of an epidural catheter at the level of the lumbar plexus was reported by Brands 
and Callanan. Their conclusion was that continuous lumbar plexus blockade reduced 
administration of opioids and resulted in effective pain relief. (Brands E& Callanan VI, 1987 as 
cited in Navas et al., 2005). A continuous sciatic nerve block to relieve pain from ischaemic 
gangrene of the foot was described in 1984 by Smith et al. (Smith et al, 1984 as cited by Navas 
et al., 2005).  
In order to provide reliable post-operative analgesia and prevent readmission due to failed 
catheter placement, it was necessary to develop methods to ensure accurate catheter 
positioning and to prevent catheter dislodgment.  
Improvements in techniques and instruments have led to a painless, longer-lasting 
postoperative analgesia, with reduction of Opioids consumption, better functional recovery, 
increased patient satisfaction and reduced side-effects. New techniques and devices are 
increasingly appearing, and catheters are constantly being developed and improved (Navas 
et al., 2005) 
3. Continuous femoral catheter placement technique (Fig 1- 2) 
The patient should be in the supine position with legs spread slightly apart. After aseptic skin 
disinfection and sterile draping of the inguinal region, a local anesthetic is injected 
superficially. The stimulating needle insertion site is immediately below the inguinal crease, 1 
to 2 cm lateral to the femoral artery pulsation. A 50-mm 18-gauge insulated stimulating needle 
is then connected to the peripheral nerve stimulator (PNS) with an initial current output of 1 
mA (2 Hz, 0.1 ms). The stimulating needle has to be inserted with a 45° angle and advanced in 
a cephalad direction until quadriceps femoris muscle contractions were elicited (as evidenced 
by cephalad patellar movements). The needle position has to be adjusted until quadriceps 
femoris contractions are still elicited at a current of 0.5 mA or less. At this point, a 20-gauge 
catheter is introduced through the needle. The catheter is then advanced for 10 to 15 cm 
beyond the needle tip, needle is withdrawn and the catheter has to be secured in place. The 
local anesthetic of choice, has to be injected slowly through the catheter. 
 
 
Fig. 1. Equipement 
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When stimulating catheter is being used, the catheter has to be connected to the PNS 
without changing the current output. The catheter is advanced 5 to 15 cm past the needle 
tip, and its position is adjusted until quadriceps femoris contractions are still elicited at a 
current output between 0.4 to 0.5 mA. At this point, the needle is withdrawn and quadriceps 
contractions are elicited via the catheter again to confirm the final perineural position of the 
catheter. (Dauri et al., 2007)  
 
 
Fig. 2. Catheter placement 
3.1 Local anesthetics 
A number of local anesthetics may be used for femoral nerve blocks. In general, the volume 
of local anesthetic used to achieve a surgery anesthesia for a femoral nerve block will range 
from 15-20 ml. For 3-in-1 nerve block, the volume ranges from 25-30 ml. When postoperative 
analgesia is required, 0.5% of long acting anesthetic agents ropivacaine or levobupivacaine 
is often used. For postoperative analgesia, 1-2 mg/ml  ropivacaine or 0.625-1.25 mg/ml 
levobupivacaine are used. The drugs are best administered by PCA pump with a basal rate 
infusion of 5-8 ml/h and bolus option. 
3.2 Complications 
 Vascular puncture  
 Local infection 
 Seizures (from systemic injection and local anesthetic toxicity)  
 Neural ischemia and/or neural toxicity 
 Local anesthetic toxicity:  
o CNS: tinnitus, confusion, metallic taste in the mouth  
o Cardiac: tachycardia, hypertension, arrhythmia  
 Dislocation of the catheter 
 Catheter breakage, formation of knots or loops 
 Local anesthetic leakage (Gurnaney et al., 2011) 
4. Continuous femoral block versus other techniques 
Many studies were conducted in order to explore the benefits arising from continuous 
femoral nerve block compared with other analgesic techniques. Some of the studies 
conclusions are reported below: 
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The first use of an epidural catheter at the level of the lumbar plexus was reported by Brands 
and Callanan. Their conclusion was that continuous lumbar plexus blockade reduced 
administration of opioids and resulted in effective pain relief. (Brands E& Callanan VI, 1987 as 
cited in Navas et al., 2005). A continuous sciatic nerve block to relieve pain from ischaemic 
gangrene of the foot was described in 1984 by Smith et al. (Smith et al, 1984 as cited by Navas 
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In order to provide reliable post-operative analgesia and prevent readmission due to failed 
catheter placement, it was necessary to develop methods to ensure accurate catheter 
positioning and to prevent catheter dislodgment.  
Improvements in techniques and instruments have led to a painless, longer-lasting 
postoperative analgesia, with reduction of Opioids consumption, better functional recovery, 
increased patient satisfaction and reduced side-effects. New techniques and devices are 
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by cephalad patellar movements). The needle position has to be adjusted until quadriceps 
femoris contractions are still elicited at a current of 0.5 mA or less. At this point, a 20-gauge 
catheter is introduced through the needle. The catheter is then advanced for 10 to 15 cm 
beyond the needle tip, needle is withdrawn and the catheter has to be secured in place. The 
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When stimulating catheter is being used, the catheter has to be connected to the PNS 
without changing the current output. The catheter is advanced 5 to 15 cm past the needle 
tip, and its position is adjusted until quadriceps femoris contractions are still elicited at a 
current output between 0.4 to 0.5 mA. At this point, the needle is withdrawn and quadriceps 
contractions are elicited via the catheter again to confirm the final perineural position of the 
catheter. (Dauri et al., 2007)  
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A number of local anesthetics may be used for femoral nerve blocks. In general, the volume 
of local anesthetic used to achieve a surgery anesthesia for a femoral nerve block will range 
from 15-20 ml. For 3-in-1 nerve block, the volume ranges from 25-30 ml. When postoperative 
analgesia is required, 0.5% of long acting anesthetic agents ropivacaine or levobupivacaine 
is often used. For postoperative analgesia, 1-2 mg/ml  ropivacaine or 0.625-1.25 mg/ml 
levobupivacaine are used. The drugs are best administered by PCA pump with a basal rate 
infusion of 5-8 ml/h and bolus option. 
3.2 Complications 
 Vascular puncture  
 Local infection 
 Seizures (from systemic injection and local anesthetic toxicity)  
 Neural ischemia and/or neural toxicity 
 Local anesthetic toxicity:  
o CNS: tinnitus, confusion, metallic taste in the mouth  
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Many studies were conducted in order to explore the benefits arising from continuous 
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 Continuous peripheral nerve blocks improve postoperative analgesia, patient 
satisfaction, and rehabilitation compared with IV narcotic therapy for lower extremity 
procedures (Capdevila et al., 1999; Singelyn et al., 1998; Ganapathy et al., 1999)  
 Continuous femoral nerve blocks have been demonstrated to improve the outcome of 
total knee arthroplasty (capdevila et al., 1999; Chelly et al, 2001)  
 Continuous femoral nerve block technique provides similar or better analgesia with 
fewer undesirable effects than intravenous PCA and the epidural technique during the 
first 48 h of postoperative management after total knee arthroplasty and after total hip 
arthroplasty (Singelyn et al., 1998; Singelyn et al., 1999).  
 Outcome with continuous femoral nerve block has shown to be better than “single 
shot” femoral block and continuous epidural anesthesia. For analgesia after proximal 
lower limb orthopedic surgery, continuous three-in-one nerve blockade is as effective as 
epidural analgesia, with fewer side effects (urinary retention, nausea, and risk of spinal 
subarachnoid hemorrhage in anticoagulated patients) (Capdevila et al., 1999; Singelyn 
et al 1998)  
5. Correlation between catheter position and the rate of effective sensory and   
motor blockades 
Continuous femoral nerve block is commonly obtained with a peripheral nerve stimulator 
connected to a stimulating needle to localize the femoral nerve. The localization of the nerve 
is then followed by insertion of the catheter through the needle. Studies using blind 
advancement of femoral catheters indicate that catheter position in relation to the nerve is 
unpredictable. (Ganapathy et al., 1999; Capdevila et al., 2002) Therefore, even if the initial 
injection of local anesthetic through the needle produces adequate intraoperative 
anesthesia/analgesia, subsequent infusion through the catheter may not provide adequate 
postoperative analgesia. Furthermore,  it is difficult to determine the correct catheter’s 
position in order to obtain an effective postoperative analgesia; on the other side the 
proximity of the catheter to the femoral nerve could guarantee a better analgesia.  
Few studies were conducted on the matter: 
 Marhofer et al. used MRI scans in order to verify the distribution of local anesthetic. 
They showed that there is no evidence of cephalad spread of 30 ml of local anaesthetic 
when a 3-in-1 blockade is performed (Marhofer et al., 2000) . 
 Ganapathy et al. used CT scans to verify the catheter position. They observed that only 
40% of catheters are located in an ‘ideal’ position, defined as catheter-tip position at 2 
cm of the cephalad extremity of the sacroiliac joint or between the sacral promontory 
and the lateral portion of the vertebral bodies of L4 and L5. (Ganapathy et al., 1999)  
 Capdevila et al. used anteroposterior pelvic radiograph to determine the location of the 
distal tip of the catheter. They showed catheter location in a continuous 3-in-1 block to 
be unpredictable. Their conclusion was that during a continuous three-in-one block, the 
threaded catheter rarely reached the lumbar plexus and that the quality of sensory and 
motor blockade and initial pain relief depend on the location of the catheter tip under 
the fascia iliaca. (Capdevila et al., 2002) . 
The reported results may highlight the theoretical advantages of using a stimulating 
catheter to ensure proper perineural catheter placement. The catheter’s position could be 
fixed at a point where the desired motor response is observed at a stimulation intensity that 
guarantees its proximity to the femoral nerve.  
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6. Aim of the review 
This narrative review summarizes the evidence derived from randomized controlled trials 
(RCTs) and retrospective analysis, in order to determine the benefits and harm comparing 
continuous femoral nerve block with stimulating catheters versus non-stimulating 
catheters for lower-extremity surgery; moreover we will explore the association  with 
adjunctive ultrasonography (US) and stimulating perineural catheters for femoral nerve 
block. 
7. Methods of searching literature 
We searched PubMed, EMBASE, and the Cochrane Database using the following search 
terms: "ACL or anterior cruciate ligament" OR “knee arthroplasty” OR “knee surgery” 
AND "femoral nerve block” OR “ peripheral nerve block" OR "regional anesthesia" AND 
“stimulating catheters” OR “non-stimulating catheters” AND “ultrasonography”. Study 
were included in the review if they were randomized clinical trial (RCTs) and non 
randomized clinical trial comparing femoral nerve block with stimulating catheters versus 
non-stimulating catheters for elective knee surgery or RCTs comparing the insertion of 
stimulating catheters with or without  ultrasonographic guidance; limits: English 
language, human adults. In addition to the systematic search of the bibliographic 
databases, the reference lists of all retrieved articles were screened for additional relevant 
trials. 
8. Study description and results (Table 2 ) 
An initial search yielded 8  potentially relevant  clinical trial that were further examined. 
Two of these was subsequently excluded because it did not meet the inclusions criteria. A 
total of 733  patients were investigated: 311 patients with stimulating and 422 with 
nonstimulating catheters . 
Salinas et Al. in 2004 (Salinas et al., 2004) published a prospective comparison of continuous 
femoral nerve block with nonstimulating  catheter placement versus stimulating catheter-
guided perineural placement, randomizing  twenty volunteers; a stimulating catheter was 
placed on one side and an identical non-stimulating catheter on the contralateral side. 
Success of femoral block was defined as loss of sensation to cold and pinprick stimuli. 
Quality of successful block was determined by tolerance to transcutaneous electrical 
stimulation and force dynamometry of quadriceps strength. Despite the trial shown that 
block success was 100% via the stimulating catheters versus 85% via the nonstimulating 
catheters, they concluded that there was no statistically significant difference in block 
success between the two techniques. 
Morin et Al. (Morin et al., 2005) in the following year published the results from the 
comparison between  femoral nerve catheters inserted under continuous stimulation and 
catheters that were placed using the conventional technique of blind advancement in 81 
patients undergoing major knee surgery. The aim of his randomized double blind trial was 
to determine whether accurate catheter positioning under continuous stimulation 
accelerates the onset of sensory and motor block, improves the quality of postoperative 
analgesia, and enhances functional recovery. He concluded that with continuous femoral 
nerve blocks, blind catheter advancement is as effective as the stimulating catheter 
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 Continuous peripheral nerve blocks improve postoperative analgesia, patient 
satisfaction, and rehabilitation compared with IV narcotic therapy for lower extremity 
procedures (Capdevila et al., 1999; Singelyn et al., 1998; Ganapathy et al., 1999)  
 Continuous femoral nerve blocks have been demonstrated to improve the outcome of 
total knee arthroplasty (capdevila et al., 1999; Chelly et al, 2001)  
 Continuous femoral nerve block technique provides similar or better analgesia with 
fewer undesirable effects than intravenous PCA and the epidural technique during the 
first 48 h of postoperative management after total knee arthroplasty and after total hip 
arthroplasty (Singelyn et al., 1998; Singelyn et al., 1999).  
 Outcome with continuous femoral nerve block has shown to be better than “single 
shot” femoral block and continuous epidural anesthesia. For analgesia after proximal 
lower limb orthopedic surgery, continuous three-in-one nerve blockade is as effective as 
epidural analgesia, with fewer side effects (urinary retention, nausea, and risk of spinal 
subarachnoid hemorrhage in anticoagulated patients) (Capdevila et al., 1999; Singelyn 
et al 1998)  
5. Correlation between catheter position and the rate of effective sensory and   
motor blockades 
Continuous femoral nerve block is commonly obtained with a peripheral nerve stimulator 
connected to a stimulating needle to localize the femoral nerve. The localization of the nerve 
is then followed by insertion of the catheter through the needle. Studies using blind 
advancement of femoral catheters indicate that catheter position in relation to the nerve is 
unpredictable. (Ganapathy et al., 1999; Capdevila et al., 2002) Therefore, even if the initial 
injection of local anesthetic through the needle produces adequate intraoperative 
anesthesia/analgesia, subsequent infusion through the catheter may not provide adequate 
postoperative analgesia. Furthermore,  it is difficult to determine the correct catheter’s 
position in order to obtain an effective postoperative analgesia; on the other side the 
proximity of the catheter to the femoral nerve could guarantee a better analgesia.  
Few studies were conducted on the matter: 
 Marhofer et al. used MRI scans in order to verify the distribution of local anesthetic. 
They showed that there is no evidence of cephalad spread of 30 ml of local anaesthetic 
when a 3-in-1 blockade is performed (Marhofer et al., 2000) . 
 Ganapathy et al. used CT scans to verify the catheter position. They observed that only 
40% of catheters are located in an ‘ideal’ position, defined as catheter-tip position at 2 
cm of the cephalad extremity of the sacroiliac joint or between the sacral promontory 
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6. Aim of the review 
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technique with respect to onset time of sensory and motor block as well as for postoperative 
pain reduction and functional outcome. 
A retrospective non randomized study of 419 patients was published in 2005 (Jack et al., 
2005) comparing stimulating versus nonstimulating femoral catheter; it  demonstrated  no 
differences in term of visual analogue scale  score and total morphine consumption with 3 
days follow up. The conclusion was that the practical advantages of the stimulating catheter, 
as reported by previous investigators, were not obvious in this clinical situation. 
In 2006 (Hayek et al., 2006) a randomized study was performed to evaluate whether a 
stimulating catheter allowed the use of lesser amounts of local anesthetics than a 
nonstimulating catheter concluding that the use of stimulating catheters in continuous 
femoral nerve blocks for TKA does not offer significant benefits over traditional 
nonstimulating catheters.  
The experience from our department   (Dauri et al., 2007) is about the evaluation of   the 
efficacy of stimulating catheter to perform continuous femoral nerve block for anterior 
cruciate ligament reconstruction; data collection from 70 patient regarded pain scores, 
adverse effects, and need for supplemental anesthesia and analgesia other than a continuous 
postoperative infusion of ropivacaine 2 mg/mL through the continuous femoral nerve 
catheter set at 7 mL/h. Data collected shown that  although the use of a stimulating catheter 
was associated with faster onset time for the femoral nerve block and lower additional 
analgesics postoperatively, the conclusions was that the clinical superiority (analgesia; 
lateral femoral cutaneous, and obturator nerve block) of stimulating catheters was not 
evident in this clinical setting.  
 
 Study design Results Conclusions 
Salinas et al., 
2004 
 Prospective , 
randomized double 
blind study in 
volounteers 
 SC= 20, NSC=20 
Outcomes: 
 Block success 
 Overall tolerance to 
transcutaneous 
electrical stimulation 
 Overall depth of 
motor block 
 Block success : 
 SC 100% , NSC 85%(p0.07)  
 Overall tolerance to 
transcutaneous electrical 
stimulation (p 0.009) and 
 overall depth of motor 
block(p 0.03) was 
significantly higher in the 
stimulating catheter-guided 
femoral nerve blocks 
There was no 
statistically significant 
difference in block 




provided an increased 
overall quality of 
continuous femoral 
perineural blockade. 
Morin et al., 
2005 
 Randomized,controlle
d observer blinded 
trial in patients after 
major knee surgery 
 SC=38, NSC=43 
Outcomes: 
 onset of sensory and 
motor block, 
  quality of 
postoperative 
analgesia 
 functional recovery 
 onset time of sensory and 
motor block  similar in both 
groups 
  no differences in the 
postoperative IV opioid 
consumption, and visual 
analog scale pain scores at 
rest and movement 
 No differences in  maximal 
bending and stretching of the 
knee joint during the 5 days 
after surgery. 
With continuous 
femoral nerve blocks, 
blind catheter 
advancement is as 
effective as the 
stimulating catheter 
technique with respect 
to onset time of 
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 Study design Results Conclusions 
Hayek et al., 
2006 
 randomized 
prospective study of 
patients undergoing 
TKA 
 SC=19, NSC=22 
Outcomes: 
 amounts of local 
anesthetics 
 postoperative pain 
scores, 
 opioid use 
 side effects 
  acute functional 
orthopedic outcomes 
 no statistically significant 
differences in the amount of 
ropivacaine administered (MD 
– 0.6, CI – 2.3 to 0.6. P=0.26) 
 No significant differences 
between  groups  for the 
amount of fentanyl dispensed 
by the IV patient-controlled 
anesthesia 
 No differences in numeric 
pain rating scale scores 
 No differences in acute 
functional orthopedic 
outcomes, side effects, or 
amounts of oral opioids 
consumed. 
The use of stimulating 
catheters in continuous 
femoral nerve blocks 
for TKA does not offer 












 SC=35, NSC=35 
Outcomes: 
 pain score 
  adverse effects 
 need for supplemental 
anesthesia and 
analgesia other than a 
continuous 
 postoperative infusion 
of ropivacaine 2 
mg/mL set at 7 mL/h. 
 Onset time was faster in the 
SC group (SC: 6.4± 2.5, NSC: 
8.3±2.9 min, P 0.006).  
 No differences in Visual 
analog scale.  
 The number of patient-
controlled regional analgesia 
boluses (SC: 14.6  ± 12.6, 
NSC:23.2±13.6 mg ropivacaine 
2 mg/mL, P_.008) as well as 
intravenous rescue ketorolac 
(SC: 34.3±35.7, NSC: 54±39.7 
mg, P 0 .033) administered 
were higher in the NSC group. 
Although the use of a 
stimulating catheter 
was associated with 
faster onset time for the 
femoral nerve block 





femoral cutaneous, and 
obturator nerve block) 
of stimulating catheters 






blind trial in patient 
undergoing TKA 
 SC=40, NSC=42 
Outcomes: 
 Sensory blockade at 10 
min, 20 min after 
injection of, lidocaine 
via femoral catheter 
and at postoperative 




 pain scores 
  markers of early 
recovery 
 No differences on sensory 
blockade in the femoral nerve 
distribution  
  At 24 h, the 95% confidence 
interval for difference in 
morphine consumption 
between groups was -8 to 5 
mg. 
 No difference between groups 
in visual analog scale scores at 
rest on POD 1 and POD 2, 
during active and passive 
physiotherapy 
 No differences in markers of 
early recovery after surgery. 
In this study, blind 
catheter advancement 
was as reliable as a SC 
technique for 
establishing and 
maintaining CFNB for 
postoperative analgesia 
as a part of multimodal 
analgesia technique 
after TKA. 
Table 2. Study included in analysis  (SC= stimulating catheter, NSC= non stimulating 
catheter, TKA= Total knee arthroplasty, CFNB= continuous femoral nerve block) 
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Recently, a randomized clinical trial (Barrington et al., 2008) compared a stimulating 
catheter  with a nonstimulating catheter  technique for institution of continuous femoral 
nerve block and its effects on quality of analgesia after total knee arthroplasty performed 
under general anesthesia in 82 patients. Patients were randomized to have continuous 
femoral nerve block  instituted using either a non-stimulating or a stimulating catheter  
technique. There were no differences in term of included morphine requirements, pain 
scores, and markers of early recovery. There was an increase in procedural time required for 
insertion of a SC compared with a NSC (10 and 6 min, respectively); however, this is of 
debatable clinical significance. 
They concluded that blind catheter advancement was as reliable as a stimulating catheter  
technique for establishing and maintaining continuous femoral nerve block for 
postoperative analgesia as a part of multimodal analgesia technique after total knee 
arthroplasty.  
In summary, although advantageous from a theoretical standpoint and in experimental 
designs (Salinas et al., 2004), randomized controlled trials in the clinical environment  have 
yielded limited evidence to justify use of stimulating catheters for continuous femoral nerve 
block after knee surgery. The increased cost and need for additional catheter adjustments 
compared with nonstimulating catheter also make it hard to justify their use in this clinical 
setting. 
9. Discussion: Focus on 
Postoperative pain after major knee surgery is a major concern. It is severe in 60% of 
patients and moderate in another 30% (Singelyn et al., 1998; 2000). Pain has a major impact 
on patient satisfaction and postoperative well-being. In addition, pain impairs early 
intensive physical therapy and rehabilitation, probably the most influential factor for good 
postoperative knee rehabilitation (Singelyn & Gouverneur, 2000; Capdevila et al., 1999). 
Continuous peripheral nerve blocks offer the potential benefits of extended postoperative 
analgesia, few side effects, improved patient satisfaction, and accelerated functional 
recovery after major knee surgery (Liu & Salinas, 2003); for this reason  continuous femoral 
nerve block is often used to provide postoperative analgesia in this clinical setting (Singelyn 
et al.,1998; Capdevila et al., 1999)  
9.1 Catheter tip 
When performing a continuous femoral nerve block, efforts are made to place the catheter 
close to the nerve to achieve effective perioperative analgesia. Traditionally, catheter 
placement is performed through a stimulating needle, followed by injection of the local 
anesthetic and then blind advancement of the peripheral catheter beyond the needle tip. 
Secondary analgesic block failure rate (failure of a catheter to produce postoperative 
analgesia after having provided sufficient intraoperative analgesia with the bolus 
administration) with this technique ranges from 10% (Grant et al., 2001; Chelly & Casati, 
2003) up to 40% (Salinas, 2003). This may be explained by the fact that the catheter can 
curl away from the needle during uncontrolled advancement (Salinas 2003). Correct 
catheter placement is confirmed by testing for a clinical effect of satisfactory analgesia or 
by sensory modality testing within the desired sensory distribution after injection of the 
local anesthetic. However, in case of insufficient block, the catheter cannot be further 
redirected. 
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The rational for using stimulating catheters, introduced in 1999 (Boezaart et al., 1999) is 
based on the assumption that catheter tips are directed close to nerves; in fact it provide the 
possibility to verify the position the catheter takes during advancement through the 
cannula. A study performed by Pham Dang et al (Pham Dang et al., 2003) concluded that the 
ability to electrostimulate nerves using an in situ catheter increases success rate in catheter 
placement for continuous peripheral nerve blocks. However, they were surprised to find 
that the amperage required to elicit  motor responses is higher with the stimulating catheter 
than with the introducer needle. In a study performed by Morin et al (Morin et al., 2005), the 
authors did not find a relationship between the current that had to be applied via the 
stimulating catheter to evoke a motor response and any of the variables determined to judge 
the success of the catheter positioning. Viewing this works, doubts may arise regarding the 
reliability of stimulating catheter to elucidate motor contruction and to determine correct 
catheter positioning. Furthermore, A stimulation current 0.5mA or less is considered safe in 
order to avoid nerve injury and to deliver adequate stimulus to provoke a motor response. 
A stady performed by Bigeleisen et al (Bigeleisen et al., 2009) suggest that stimulation 
currents of more than 0.2 and no more than 0.5 mA could not rule out  an intraneural 
position of the needle or catheter tip. Therefore, even with the use of low stimulation (0.2-0.5 
mA) the tip of the stimulating catheters are not ascertained to be in the vicinity of the nerve 
of might be inside the nerve. 
Placement of the catheter tip should ideally be as close as possible to the nerve to attain the 
minimal blocking concentration that will block the fibers responsible for transmission of 
painful stimuli. From a practical point, use of larger volumes may permit more successful 
blocks when nerves are less than ideally localized. This concept is expressed also by Pham 
Dang et al. (Pham Dang et al.,  2009) affirming  that interpretation of their  data suggests that 
the failure of previous studies to show a superiority of stimulating catheters has perhaps been 
masked by methodological problems in previous investigations on the subject. In fact in their 
study, stimulating catheters seem to provide early analgesia within the femoral nerve 
distribution using low-dose initial bolus and subsequent low-volume infusion. Small doses of 
local anesthetics suffice if a catheter is correctly placed next the femoral nerve and that pain 
from unblocked obturator and sciatic nerves should be treated specifically (Pham Dang 2009). 
Moreover, use of larger volumes of local anesthetics may potentially increase the risk of 
systemic toxicity and potentially increase motor block (Borgeat et al., 2001; Bergman et al., 
2000). 
More importantly, minimal motor weakness is desired for continuous femoral analgesia after 
total knee arthroplasty, because excessive quadriceps motor block may impair active knee 
extension required for rehabilitation protocols and potentially delay achievement of 
predetermined functional physical therapy goals.  To better ascertain the difference between a  
well placed and a  poorly placed catheter, one should use smaller amounts of local anesthetics. 
Hayek et al.  (Hayek et al., 2006), analyzed  data regarding the total amount of local anesthetic 
used in patient treated with stimulating catheter versus nonstimulating group founding  no 
statistically significant differences in the amount of ropivacaine administered . 
The question arises whether nerve proximity is really needed for the femoral nerve to be 
blocked effectively in routine clinical use. Several reasons argue against this necessity, 
particularly when larger volumes (40 ml) of local anaesthetic are used. Firstly, anatomical 
review suggests that, once the iliac fascia is penetrated, there are no relevant diffusion 
barriers for local anaesthetics. Secondly, catheters threaded 16–20 cm from the inguinal level 
radiographically deviated in 77% of cases but were as effective in motor blockade of the 
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femoral nerve, and only marginally less effective in sensory blockade of the femoral nerve, 
compared with radiographically well placed catheters (Capdevila et al., 2002). Thirdly, iliac 
fascia blocks performed without any nerve stimulation are as effective as femoral nerve 
blocks, in both children (Dalens et al.,1989) and adults (Capdevila et al., 1998), suggesting no 
clinically meaningful reason for placing catheter tips in close proximity to the femoral nerve. 
For these reasons, Birbaum affirmed that well designed studies should to be done to prove the 
superiority of stimulating catheters, but not for the femoral nerve (Birnbaum &  Volk., 2006). 
However ,  without direct visualization, catheter positions corresponding to the various 
stimulating tip-to-nerve distances could only be inferred on the basis of the 
neurostimulation recently developed by Johnson et al. (Jonson et al., 2007).  
Another common problem to underling  is the lack of control of the pain transmitted by the 
unblocked obturator nerve in all studies (Morin et al., 2005; Barrington et al., 2008)  and the 
unblocked sciatic nerve in 2 studies (Morin et al., 2005; Hayek et al., 2006).  These unblocked 
nerves constitute major confounding factors during assessment of the femoral block based 
on pain scores, given that the knee is innervated principally by the femoral, obturator, and 
sciatic nerves. In contrast to these studies, ours used a low dose of ropivacaine (0.2%) for 
initiation and maintenance of femoral nerve block and eliminated pain from obturator and 
sciatic nerves by blocking them.(Pham Dang et al., 2009). 
It is conceivable that clinicians with less experience might find that the ability to verify 
accuracy of catheter placement with the stimulating catheter system improves their clinical 
outcomes. However the introduction of the stimulating catheter requires more expertise than 
introduction of the non-stimulating catheter.  Placing the catheter to give good contractions 
often involves extra manipulation, reintroduction of the needle, or both. Thus, it would not 
(necessarily) expect the stimulating catheter to give better results in inexperienced hands. 
9.2 Effect on neurostimulation of injectates used for perineural space expansion 
A randomized clinical trial (Pham Dang et al., 2009) clinically assessed the electrophysiologic 
effect of dextrose 5% in water and of normal saline  used for expansion of the perineural space 
before placing a stimulating catheter. They questioned if higher current was required with 
normal saline but not with dextrose 5% in water, as has been observed experimentally. This 
was a prospective randomized double-blind study of ASA I to II patients scheduled for total 
knee replacement. Patients  were randomly assigned to receive unidentified injectate dextrose 
5% in water (n = 25) or normal saline (n = 25). The primary outcome was the minimal intensity 
of stimulation (MIS) recorded before and after 2 and 5 mL of study injectates were flushed 
through the needle before placing a stimulating catheter for continuous femoral and sciatic 
nerve blocks. Secondary outcomes included, among other parameters, minimal intensity of 
stimulation recorded during placement of stimulating catheters. 
Analysis of the primary outcome using a between-group comparison showed that minimal 
intensity of stimulation recorded during electrostimulation via the needle was significantly 
higher after normal saline than after dextrose 5% in water in all blocks and at each volume 
of injectate. This presumably reflects the electrophysiologic properties of normal saline 
versus dextrose 5% in water given the absence of difference between groups with all other 
parameters assessed in this study. To conclude, the use of normal saline for expanding the 
perineural space led to increased intensity for nerve electrostimulation, which may lead to 
potential errors when electrolocating the nerve. Dextrose 5% in water seemed to be a 
superior medium for perineural space expansion, which is in agreement with the animal 
and clinical studies of Tsui et al.(Tsui et al., 2005). 
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9.3 An alternative: Ultrasonographic guidance 
Continuous femoral nerve blocks, have recently evolved towards being the gold standard 
for acute pain therapy after major reconstructive knee surgery, including total knee 
arthroplasty and certain techniques for anterior cruciate ligament reconstruction. As shown 
previously,  accurate placement of femoral nerve catheters in close proximity to the femoral 
nerve, allows for a therapy with low infusion rates and minimal boluses, thus increasing its 
effectiveness and allowing for prolonged analgesia (48-72hours) with small portable 
disposable pumps in the outpatient setting. Neuro-stimulation and stimulating catheters, 
were the basis for perfecting continuous femoral blocks. While usually a simple technique, 
with minimal risks, occasionally, even in experienced hands, stimulating catheters present 
several shortcomings: lack of placement time consistency, increased costs, lack of direct 
visualization of local anesthetic spread, variability in stimulating catheter design and 
quality, uncertainty about nerve stimulation endpoints ( Hayek, 2006; Jack et al., 2005; Morin 
et al., 2005; Salinas et al., 2004; Birnbaum et al., 2007). 
An alternative for assisting with correct catheter placement is ultrasonographic guidance 
(Fig. 3- 4- 5). 
 
 
Fig. 3. Ultrasound-guided femoral nerve block: in plane approach 
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Fig. 4. Ultrasound guided femoral nerve block: needle insertion 
 
 
Fig. 5. Ultrasound guided femoral nerve block: catheter insertion 
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Ultrasound-guided regional anesthesia is an evolving field and its use has gained enormous 
popularity in the last 10 years.  In one investigation, the onset of sensory blockade with 
ultrasound guidance was significantly shorter and the quality of sensory block significantly 
better compared with the nerve stimulator needle-assisted application of local anesthetic 
(Marhofer et al., 1997). Addition of ultrasound guidance to nerve stimulation could offer the 
benefits of rapid localization and visualization of local anesthetic spread, at the cost of 
several disadvantages: need for multiple assistants, increased time and cost; moreover the 
tip position can suggest proximity even though sufficient nerve stimulation is not achieved, 
injection of local anaesthetic usually produces a clinically effective block. 
Other authors have reported both increased block density and lower anesthetic dose 
requirements with US-guided techniques when compared with conventional techniques 
using nerve stimulators (Marhofer, 1997-1998). 
Mariano et al. (Mariano et al., 2009) performed a study were patients receiving a femoral 
perineural catheter for knee surgery were randomly assigned to either ultrasound guidance 
with a nonstimulating catheter or electrostimulation guidance  with a stimulating catheter. 
The primary outcome was the catheter placement procedure time (minutes) starting when 
the ultrasound transducer (ultrasound group) or catheter insertion needle (electrostimulator 
group) first touched the patient and ending when the catheter insertion needle was removed 
after catheter insertion.  He concluded that for femoral perineural catheter placement, an 
ultrasound-guided technique decreases the procedure time compared with nerve electro-
stimulation  alone while maintaining a similar success rate. Furthermore, patients in the 
ultrasound group reported less procedure-related pain during perineural catheter 
placement and had fewer inadvertent vascular punctures (20% less). 
It is possible that using a combination of both approaches may offer additional benefits over 
either technique alone for brachial plexus perineural catheters (Mariano et al., 
2009;Fredricksonet al., 2008). For continuous femoral nerve block the needle is inserted at 
the level of the inguinal crease along the long axis of the ultrasound probe. The needle shaft 
and needle tip are clearly visible with this approach during advancement of the needle 
toward the femoral nerve. Once the needle pierces the fascia iliaca lateral to the nerve, the 
needle tip is advanced 2 to 3 mm toward the nerve. This is contrary to the common method 
of placing the needle tip in close proximity to the nerve. At this point, 5 mL of dextrose 5% 
solution is injected to expand the perineural space, and electrical stimulation conforms a 
quadriceps or patellar twitch. The position of the needle in conjunction with the injected 
dextrose provides a path for catheter advancement toward the nerve and the catheter tip to 
lie in close approximation to the nerve. Had the needle tip initially been placed next to the 
femoral nerve, the catheter would have advanced medially past the nerve. 
Another method to possibly improve catheter advancement is slight withdrawal of the 
catheter guide wire by 1 to 2 cm from the tip. This will provide more flexibility to the 
catheter tip but stiffness to the remainder of the catheter during advancement. This may 
further decrease the likelihood of catheter advancement away from the tract formed by the 
injected dextrose solution, thereby improving the ease of catheter insertion (Niazi et al., 
2009). To date, however, the need for electro-stimulation  in addition to ultrasound guidance 
remains controversial, especially for lower extremity perineural catheter placement (Chan et 
al., 2007; Walker & Roberts, 2007; Beach et al., 2006; Gürkan et al., 2008; Dingemans et al., 
2007). 
Moreover combining ultrasound with electro-stimulation  does negate any cost advantages 
attributed to ultrasound guidance alone (Sandhu et al., 2004).  
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Fig. 5. Ultrasound guided femoral nerve block: catheter insertion 
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Randomized controlled trials in the clinical environment  have yielded limited evidence to 
justify use of stimulating catheters for continuous femoral nerve block after knee surgery. It 
can be affirmed that failure of previous studies to show a superiority of stimulating 
catheters has perhaps been masked by methodological problems, above all regarding the 
dose and volume of local anesthetics used. However ultrasound guidance offer a safe and 
cost/effective technique for femoral catheter placement. 
11. Future directions 
It is important to design future trials in a consistent manner to make studies comparable and 
to enable a standard quantitative meta-analysis. Future study designs need to account for 
differences between the primary anesthetic block (bolus or a relatively large mass of 
concentrated local anesthetic via either the needle or catheter, typically with a long-acting 
agent) and the secondary analgesic block (infusion of a dilute local anesthetic). Injection of 
long-acting local anesthetic as the primary block renders interpretation of the secondary 
analgesic infusion difficult if not impossible for the first 12 to 24 hrs as the residual analgesic 
effects of the primary block may still be effective.  
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1. Introduction 
Trauma is the sixth most common cause of death globally [WHO, 2011]. In the United States, 
almost 30 million patients receive medical care for trauma every year [CDC, 2011], and 
trauma results in 30% of intensive care unit (ICU) admissions in the United States 
[Mackenzie et al., 2007]. In the Emergency Department, 91% of trauma patients are in pain 
[Berben et al., 2008], and two-thirds of those patients are discharged from the Emergency 
Department with moderate to severe pain [Berben et al., 2008]. Regional anesthesia (RA) can 
reduce pain in many of these patients. In this chapter, common problems with managing 
trauma patients that can be addressed with RA, and data suggesting that regional anesthesia 
can improve outcomes will be presented, as well as the different challenges to using RA in 
this patient population. We will also look into new and controversial areas of inquiry in this 
field.  
2. Patients with traumatic injuries who can benefit from regional anesthesia 
2.1 Thoracic trauma and rib fractures 
Thoracic injury accounts for 25% of deaths among trauma patients. It is second only to head 
injury as a cause of trauma-related deaths in the United States [Trunkey & Lewis, 1980]. Rib 
fractures are common, and morbidity and mortality are directly correlated with the number 
of rib fractures [Flagel et al., 2005].Elderly patients have a particularly high incidence of rib 
fractures, with a higher rate of morbidity and mortality from these fractures than younger 
patients [Bulger et al., 2000; Shorr et al., 1989]. Improved analgesia, by various methods, has 
been shown to improve pulmonary function, including peak expiratory flow, maximum 
inspiratory force, tidal volume, and oxygen saturation [Luchette et al., 1994; Moon et al., 
1999; Osinowo et al., 2004]. 
Thoracic epidural analgesia (TEA) has been shown to improve outcome after multiple rib 
fractures [Bulger et al., 2004;Flagel et al., 2005; Moon et al., 1999; Wisner, 1990].As early as 
1990, a retrospective regression analysis of a trauma database revealed decreased 
pulmonary complications and decreased mortality in elderly patients with rib fractures 
that were treated with TEA as compared to parenteral opiates [Wisner, 1990].Moon et al 
showed improved pulmonary mechanics and decreased levels of the proinflammatory 
chemoattractant, interleukin 8, in a prospective, randomized trial that compared TEA 
with parenteral opioids in patients with thoracic trauma [Moon et al., 1999]. Another 
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with parenteral opioids in patients with thoracic trauma [Moon et al., 1999]. Another 
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prospective study comparing TEA and parenteral opioid analgesia for patients with rib 
fractures showed decreased rates of nosocomial pneumonia and a shorter duration of 
mechanical ventilation in the TEA group [Bulger et al., 2004].However, one frequently 
cited meta-analysis is noteworthy to illustrate its limitations. Carrier et al reported that 
there was no significant difference when using epidural analgesia over other methods  
in terms of mortality, ICU length of stay, and duration of mechanical ventilation [Carrier 
et al., 2009]. Their analysis is of limited utility, however, because they included two 
studies using lumbar epidural catheters and three studies using only opiate medications 
with the epidural infusions; these are significant departures from recommended practices. 
Flagel et al performed a thorough analysis of a large, sophisticated trauma database 
[Flagel et al., 2005].They showed that TEA was associated with a reduction in mortality 
for all patients who sustained rib fractures, particularly those having more than four 
fractures. These findings have resulted in the recommendation that TEA be included in a 
widely proliferated pain management guideline for blunt thoracic trauma [Simon et al., 
2005]. 
Despite all of the enthusiasm for epidural analgesia in patients with blunt thoracic 
trauma, there are considerable limitations to this approach. In the previously mentioned 
study by Bulger et al [Bulger et al., 2004], 282 patients of 408 admitted to the hospital had 
to be excluded for a variety of reasons. Thoracic epidural analgesia is contraindicated in 
patients on anticoagulants or those who have developed a coagulopathy [Horlocker et al., 
2010].Brain or spinal injuries represent, at minimum, relative contraindications to the use 
of TEA, as most practitioners are uncomfortable placing epidurals in the face of elevated 
intracranial pressure. Possible spinal cord injury, even remote from the proposed 
insertion site, presents a dilemma, as an epidural may obscure or alter the neurologic 
examination. Spinal bone injuries may also make epidural placement more technically 
challenging. The hypotension caused by epidurals can frequently be a significant 
deterrent in critically ill patients who are already hemodynamically unstable from other 
causes.  
Thoracic paravertebral catheterization (TPVC) has emerged as an enticing answer to 
some, if not all of the above mentioned concerns. A small pilot study showed comparable 
outcomes between TEA and TPVC when they were used in patients with unilateral rib 
fractures [Mohta et al., 2009].These findings are bolstered by similar results in the 
analogous case of analgesia after thoracotomy [Davies et al., 2006; Pintaric et al., 2011; 
Powell et al., 2011]. Davies et al presented a systematic review and meta-analysis of 10 
randomized clinical trials comparing TPVC and TEA for thoracic surgery. They found no 
difference in pain scores, but did note a lower incidence of pulmonary complications, 
urinary retention, nausea and vomiting, and hypotension in the TPVC groups [Davies et 
al., 2006]. A large, prospective multicenter study of pneumonectomy in the United 
Kingdom found that TEA was associated with a higher incidence of major complications 
compared to TPVC [Powell et al., 2011]. A recent prospective randomized study 
comparing TEA and TPVC, with a primary endpoint of hemodynamic stability, found that 
TPVC was associated with similar analgesia levels to TEA, but with greater hemodynamic 
stability [Pintaric et al., 2011]. 
Should TPVC supplant TEA as the primary modality for providing analgesia for blunt 
thoracic trauma? A few caveats are in order. Epidural spread has been reported with 
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thoracic paravertebral block [Purcell-Jones et al., 1989]. The authors have also experienced 
and reported the unintended placement of a catheter in the epidural space during TPVC 
placement [Lucas et al., 2011, Epub ahead of print]. Considerable controversy exists 
regarding the relative safety of paravertebral blocks vs. epidurals in the face of 
anticoagulation and coagulopathy, which will be discussed later in the chapter. Frequently, 
bilateral rib fractures or other injuries, such as an exploratory laparotomy incision, require 
bilateral blockade. Although studies on the use of TPVC are still quite undeveloped, 
findings by Richardson et al, in a literature review on bilateral paravertebral blocks, found a 
favorable side effect profile. The high local anesthetic load associated with bilateral TPVC is 
a worthwhile consideration for analgesia in thoracic trauma patients [Richardson et al., 
2011]. 
The clinician is faced with a number of questions about how to proceed with regional 
analgesia techniques for blunt thoracic trauma. Does the patient need a catheter or not? The 
literature supports using either TEA or TPVC for more than three rib fractures, and in the 
elderly. The timing of catheter placement should be as early as practicable, although 
sometimes a short delay may be prudent to allow the anticoagulant effects to dissipate. 
Patients with very severe injuries may not benefit from early catheter placement, as the 
improvement in analgesia from RA may not likely alter the length of ventilator 
management. However, continuous and close monitoring in close consultation with Trauma 
Surgery and Critical Care Medicine can be used to determine when a patient will benefit 
from TPVC. Should TEA or bilateral TPVC be used? Extensive bilateral pathology is 
considered an indication for using thoracic epidural catheters over thoracic paravertebral 
catheters because of the extensive amount of local anesthetic required for multiple bilateral 
TPVC; however, there is scant literature to address this question. Another area of practical 
practice management in question is in regard to the number of catheters to place. Studies 
have shown loss of pinprick sensation in one to 13 dermatomes after a single-shot 
paravertebral block [Cheema et al., 1995; Saito et al., 2001]. Richardson et al measured 
somatosensory evoked potentials of the intercostal nerves and reliably ablated one, but only 
occasionally two or three nerve potentials [Richardson et al., 1998]. Most patients appear to 
reliably experience analgesia in approximately five dermatomes; therefore we recommend 
placing a second unilateral catheter for greater than four fractured ribs. This will provide 
some margin for error. As the process of adequately positioning and sedating these types of 
patients can be quite challenging, this seems to be a prudent approach. Figure 1 provides a 
simplified algorithm for managing these patients. 
A number of different techniques have been reported for TPVC. When advancing a 
predetermined, fixed distance (1.0-1.5 cm) beyond the transverse process, loss of resistance, 
peripheral nerve stimulation(PNS), and various ultrasound-guided techniques have been 
described [Ben-Ari et al., 2009; Eason & Wyatt, 1979; Luyet et al., 2009; Naja et al., 2006]. 
Although any of these techniques can be used in different situations, it should be noted that 
ultrasound guidance and peripheral nerve stimulation can be technically limited in these 
patients, as they often have subcutaneous emphysema and hematomas. Measuring the 
depth of the transverse process and the parietal pleura on CT scan provides definitive 
information that can be used to guide the depth of needle insertion, thereby improving the 
safety margin and significantly expediting catheter placement. A CT scan also helps to 
determine the most severely injured ribs and flail segments. 
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Fig. 1. Algorithm for managing analgesia in patients with multiple rib fractures. 
2.2 Long bone fractures 
Long bones are composed of a diaphysis, or hollow shaft, connected to the physis, or 
growth plate, at each end via the metaphysis. Long bones in the body include the humerus, 
radius, ulna, femur, tibia, fibula, and phalanges. Long bone fractures can result in significant 
pain, especially prior to stabilization, due to the significant number of nerve endings located 
in the periosteum and mineralized bone [Mach et al., 2002]. While sclerotome maps have 
been created to assist in the understanding of innervation to the bones, little evidence exists 
to confirm their accuracy. Classic studies, including those by Inman and Saunders in 1944 
[Inman & Saunders, 1944], provide some evidence for the skeletal innervation [Ivanusic, 
2007]. We will review anatomical considerations of the most common fractures and suggest 




Fracture Innervation Recommended Nerve 
Block for Analgesia 
Considerations 
Proximal femur Femoral nerve  Sciatic 
nerve   Obturator 
nerve 
-Single injection or 
continuous   
-Femoral nerve block, 
fascia iliaca block, or 
lumbar plexus block 
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Midshaft and distal 
femur 
Femoral nerve  Sciatic 
nerve 
-Single injection or 
continuous 
-Femoral nerve block  
-Sciatic nerve block  
 
Greater predominance 
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Fig. 1. Algorithm for managing analgesia in patients with multiple rib fractures. 
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2.2.1 Femur fractures  
Femur fractures represent a majority of the patients who suffer from long bone fractures, 
with one-third of these eventually undergoing surgical stabilization. Regional anesthesia for 
lower extremity fractures, including femur and hip fractures, has been extensively studied 
in the literature. Meta-analyses suggest that regional anesthesia, specifically neuraxial 
anesthesia, decreases the incidence of DVT and pulmonary embolism as well as the 
incidence of postoperative confusion, in addition to reducing the risk of postoperative 
pneumonia in patients who require surgical stabilization. Whether regional anesthesia 
affects mortality in the patient with a femur fracture has yet to be determined [Luger et al., 
2010; Parker et al., 2004]. Evidence does suggest that analgesia is improved, and systemic 
analgesics are spared, when regional anesthesia techniques, such as perineural nerve blocks, 
are used to help manage pain in patients with hip fractures [Parker, 2002]. Femoral nerve 
blocks have also been shown to optimize patient positioning for performance of a neuraxial 
block [Sia et al., 2004; Yun, 2009]. 
Analgesia for proximal femur fractures may be obtained by blocking the femoral nerve, 
whether via a single injection or continuous block technique. Although the femur has 
innervations from multiple nerves, proximally, the femur is predominantly innervated by 
the femoral nerve, with contributions from the sciatic nerve and an articular branch of the 
obturator nerve [Locher et al., 2008].  
There are a variety of methods available for performance of femoral nerve blocks. The 
femoral nerve can be anesthetized using stimulation, ultrasound [Beaudoin et al., 2010; 
Marhofer et al., 1998], or a fascial-pop technique [Candal-Couto et al., 2005; Dalens et al., 
1989; Haddad et al., 1995] 
Nerve stimulation approaches to the femoral nerve block are common but may cause 
significant discomfort in a patient with a fracture. The use of ultrasound has been 
popularized in the past decade for its various benefits. The femoral nerve can be easily 
visualized at the inguinal crease lateral to the femoral artery, below the fascia lata and iliaca, 
on the anteromedial aspect of the iliopsoas muscle as it attaches to the proximal femur. The 
needle can be readily identified since the femoral nerve is typically superficial in nature, and 
local anesthetic spread is obvious on ultrasound as it encircles the nerve.  
In the absence of available ultrasound machines or nerve stimulators, the fascia  
iliaca compartment block can be easily performed using a simple blunt needle and  
local anesthetic. This technique has been successfully used in the emergency department 
setting [Foss et al., 2007; Monzon et al., 2007; Wathen et al., 2007]. The proceduralist draws 
a line connecting the pubic bone to the anterior superior iliac spine, and divides this line 
into thirds. At the marking between the distal third (near the anterior superior iliac  
spine) and middle third, a blunt needle is advanced one centimeter below this point until 
two pops are felt, the first as the needle punctures the fascia lata and the second as the 
needle punctures the fascia iliaca. Local anesthetic volumes similar to those used for 
stimulation-based approaches (20 mL) have been used successfully with the fascia iliaca 
block with good efficacy [Lopez et al., 2003]; however, weight-based dosing (0.3 mL/kg) 
[Monzon et al., 2007; Mouzopoulos et al., 2009] and higher doses may be considered to 
improve local anesthetic delivery [Candal-Couto et al., 2005]. As with any block 
performed with high volume, confirmation that no intravascular injection has occurred is 
necessary.  
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Sciatic nerve blocksbecome more important in more distal femur fractures and fractures of 
the leg and ankle. Various approaches to the sciatic nerve are utilized. For femur fractures, 
more proximal approaches, such as the classic Labat technique or the subgluteal approach 
[Di Benedetto et al, 2002; Franco et al., 2006], are appropriate. For leg and ankle fractures, a 
more distal approach, such as a popliteal catheter, may be more suitable, as sparing of the 
hamstring musculature is important for ambulation. 
The subgluteal approach can be achieved with stimulation or ultrasound. Using the 
stimulation technique, the proceduralist elicits appropriate motor twitches, such as 
plantar/dorsiflexion and gastrocnemius twitches. When employing ultrasound [Danelli et 
al., 2009; Karmaker et al., 2007], a low frequency ultrasound probe allows visualization of 
the proximal femur and ischial tuberosity, as well as the sciatic nerve between these two 
bones. Confirmation of the nerve location on ultrasound can be done by tracing the nerve 
distally to the popliteal crease as the nerve divides into its two terminal branches: the 
common perineal and posterior tibial nerve [Bruhn et al., 2008]. 
2.2.2 Humerus and clavicle fractures 
Proximal humerus fractures are the third, most common fracture in the elderly patient (4-5% 
of all fractures) after femur fractures and radial fractures [Court-Brown et al., 2001]. The 
most common mechanism of proximal humeral fractures in the elderly are falls [Chu et al., 
2004]. Midhumeral fractures occur in 1-2% of patients, with the mechanism of this injury 
usually resulting from a direct blow to the arm or application of a bending force to the 
humeral shaft. This type of fracture typically occurs in the young, physically active patient 
[Ogawa et al., 1998]. Documentation of any radial nerve injury is important prior to 
proceeding with a regional anesthetic technique, especially with midhumeral shaft fractures 
in which the radial nerve may be injured from the trauma as it courses posteriorly alongside 
the humerus in the spiral groove [Ekholm et al., 2006]. Clavicle fractures also occur in the 
younger population and are usually related to direct or indirect trauma to the clavicle, 
commonly due to traffic accidents or a sports-related injury [Pecci et al., 2008; Postacchini et 
al., 2002; Robinson et al., 1998].  
The humerus receives its innervation from the brachial plexus. Like the femur, multiple 
nerves are involved in providing sensation to the bone. Derivations of the C5 and C6 nerve 
root predominantly innervate the humerus. As the fracture becomes more distal, the 
innervation emanates from derivations of the C7 nerve root, and a regional anesthetic 
technique should be targeted accordingly.  
Single injections may be performed using a cervical paravertebral, interscalene,  
or supraclavicular block. However, fractures of the humerus are painful, even after 
surgical stabilization, and a continuous approach is recommended for prolonged 
analgesia. Both stimulation and ultrasound-guided approaches have been utilized 
successfully. If using stimulation, biceps and deltoids are elicited as endpoints for a 
proximal humerus fracture and triceps stimulation for distal humeral fractures. As with 
femur fractures, use of stimulation may result in severe pain, and short but intense 
systemic analgesia may be needed for patient comfort. Ultrasound allows visualization of 
the brachial plexus from the root all the way to the terminal nerve, and can assist in 
minimizing needle attempts. By using ultrasound, nerves can be traced to their origin 
where they exit the intervertebral foramen as they convene in the interscalene groove, and 
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further down as they become situated posterolateral to the subclavian artery in the 
supraclavicular approach. 
The clavicle is innervated from nerve roots that are more cephalad in origin [Choi et al., 
2005]. While distal clavicle fractures can be anesthetized with a C5/C6 block, more medial 
fractures, which are more common, may be anesthetized as well by depositing local 
anesthetic near the C4 nerve root, which can be blocked and confirmed by ultrasound. 
The physician should be aware that numbness across the shoulder and upper chest wall 
may occur from surgical fixation due to injury to the supraclavicular nerve [Wang et al., 
2010]. Furthermore, the brachial plexus lies between the first rib and clavicle as it courses 
to the upper extremity, and may be at risk for injury due to its proximity to a clavicle 
fracture. 
2.2.3 Radial/ulnar fractures 
Repair of radial and ulnar fractures are typically carried out in an outpatient setting, and 
analgesia prior to surgery is usually provided using oral systemic analgesics. Reduction of a 
dislocated fracture, however, is extremely painful and may be alleviated by either potent 
and short-acting anesthetics or a regional anesthetic technique [McManus et al., 2008]. Pain 
from the surgery itself is typically not severe beyond the initial perioperative phase [Chung 
et al., 2010], and single-injection brachial plexus blocks using a supraclavicular, 
infraclavicular [Chin et al., 2010], or axillary approach usually results in adequate 
intraoperative anesthesia and postoperative analgesia. Ultrasound guidance allows for 
minimal needle passes, sparing of volumes of local anesthetics, and faster onset [Liu et al., 
2010; McCartney et al., 2010; Neal et al., 2010]. Because the radius and ulna are innervated 
by the entire brachial plexus, all branches of the brachial plexus should be considered when 
providing surgical anesthesia in the operating room; at the trunk level (supraclavicular), this 
includes the superior, middle and lower trunk, and at the cord level (infraclavicular), the 
lateral, posterior and medical cord should be covered. At the axillary level, all terminal 
nerves should be blocked, which includes the median, ulnar, radial, musculocutaneous, and 
medial cutaneous nerve of the forearm. 
2.2.4 Tibia/fibula fractures  
Fractures of the tibia and fibula may occur due to indirect (torsional injuries) or direct 
impact [Johner et al., 2000]. Open tibia and fibula fracture injuries occur due to high-velocity 
trauma, such as motor vehicle accidents [Ivarsson et al., 2008], while closed injuries occur 
due to falls or a sports-related injury. Isolated fibula fractures without concurrent tibial 
fractures are rare and usually require nonoperative treatment.  
The tibia and fibula are predominantly innervated by the sciatic nerve. More proximally, the 
bones may receive innervation from the femoral nerve. For proximal tibia and fibula 
fractures, a combined femoral and sciatic nerve block is needed for more complete 
analgesia, especially if regional anesthesia is utilized for surgical repair Continuous 
blockade is the technique typically employed for proximal fractures, as many of these 
patients continue to have severe pain after surgical stabilization. Continuous blockade will 
also allow monitoring for severe pain out of proportion to what is deemed an appropriate 
analgesic regimen, as this may signify a developing compartment syndrome. It is important 
to be aware that patients with tibial fractures are at a particularly high risk of developing 
compartment syndrome [Park et al., 2009] (discussed in more detail below). Distal tibia and 
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fibula fractures, if uncomplicated, normally do not require more than a single-injection 
sciatic nerve block, with or without a saphenous nerve block depending on the medial 
cutaneous involvement of the injury or location of the surgical incision.  
3. Challenges and opportunities 
The anesthesiologist who performs RA for trauma patients has several challenges that must 
be addressed, and, thus, it is imperative to have a solid understanding of the complexities of 
compartment syndrome and coagulation issues in the trauma patient. Included in this 
chapter is a discussion on a number of technical challenges that frequently arise in trauma 
patients will be discussed, along with various solutions to these challenges. There are 
presently exciting opportunities in the field of RA for the trauma patient, one of which will 
be elucidated: the provision of RA in the prehospital or early hospital period. 
3.1 Compartment syndrome 
Compartment syndrome has been defined as a condition in which increased pressure within 
a closed compartment is compromising the circulation and function of the tissues within 
that space [Matsen, 1975]. 
In the setting of patients who have experienced trauma, we are primarily concerned with 
acute compartment syndrome (ACS). The most common sites of ACS are the forearm or leg, 
although it can occur in any closed compartment. Over 200,000 patients are diagnosed with 
ACS in the United States every year [Konstanantakos et al., 2007];fractures and various soft 
tissue injuries are the most common causes (Table 2) [McQueen et al., 2000] .Men are at a 
substantially greater risk than women, as are patients <35 years old [McQueen et al., 2000]. 
 
Tibial diaphyseal fracture 
Soft tissue injury 
Distal radius fracture 
Crush syndrome 
Diaphyseal fracture of the radius or ulna 
Table 2. Most Common Causes of Acute Compartment Syndrome 
The sine qua non of ACS management is early diagnosis and treatment, with extensive 
fasciotomy [Kashuk et al., 2009].Classically, the diagnosis of ACS is made by recognition of the 
6 P's (Table 3) [Elliott & Johnstone, 2003].Of these, pulselessness and paralysis occur too late to 
effectively provide an intervention, and palpation abnormalities are difficult to discern in the 
traumatized patient. The other signs and symptoms all involve the need for the patient to 
sense the pain or parasthesia. For this reason, the use of RA in patients at risk for developing 
compartment syndrome is controversial [Davis et al., 2005; Thonse et al., 2004]. 
 
Pain out of proportion to injury 
Parasthesia 




Table 3. The 6 P's: Signs and Symptoms of Acute Compartment Syndrome 
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further down as they become situated posterolateral to the subclavian artery in the 
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There are no randomized controlled trials comparing outcomes in patients at risk for ACS 
who had local anesthetic-based analgesia versus opioid-based analgesia. Clinical practice 
and recommendations have been founded on case reports and retrospective case series [Mar 
et al., 2009]; Clark’s recent excellent editorial pointed out the usefulness of these case reports 
[Clark, 2011]. However, it is imperative that we carefully review these reports and not over-
interpret their significance. It would seem an archaic practice to simply allow all patients at 
risk for ACS to suffer. Alternatives to RA, such as patient-controlled analgesia, have also 
been implicated as obscuring an ACS diagnosis [Richards et al., 2004].The literature on these 
topics will be briefly reviewed, and several recommendations for reasonable practices will 
be offered.  
Recommendations against RA in patients at risk for ACS are based on the premise that any 
degree of sensory blockade will block the ischemic pain the patient is experiencing in a 
compromised compartment. Little distinction is made between a limb in which a patient has 
analgesia but still can sense a pinprick exam, and one that is completely insensate. A recent 
case report by Cometa illustrated a scenario of a patient with an initially good analgesic 
block who experienced increasing pain as he developed ACS [Cometa et al., 2011].Because 
of the prompt recognition of this increasing pain by the anesthesiologists involved, the 
patient underwent a timely and limb-saving fasciotomy. Although no clear-cut evidence 
exists to support it, most experts suspect that somewhere on a continuum of density of 
nerve blockade lies the “danger zone” of sensory blockade in which we are at risk of 
masking the symptoms of ACS. For this reason, prolonged duration of a dense blockade, 
such as with a long-acting, potent neuraxial block, are to be discouraged. Intraoperatively 
and immediately postoperatively, these patients will not be able to report the pain of ACS, 
so RA and general anesthesia (GA) represent a similar risk. If, however, a dense sensory 
block persists long after the operative period, then the choice of RA may place the patient 
at increased risk. For that reason, intraoperative RA - whether neuraxial, single shot 
peripheral nerve block, or dosing of a continuous perineural catheter - should be limited 
to short-acting local anesthetic regimens. A much more controversial question is whether 
a continuous regional anesthetic technique, aimed at providing analgesia but avoiding the 
“danger zone”, should be offered to these patients. Epidural infusions have been 
implicated in delayed diagnosis of lower extremity ACS [Mar et al., 2009].Unfortunately, 
in this review of 35 cases, the infusion drugs and concentrations were not reported in the 
majority of the patients. Of those that were reported, some involved infusates that are 
much more concentrated than current practices. Eighteen of the 35 patients had symptoms 
of ACS while the epidural infusions were running. Interestingly, there is a paucity of 
reports of ACS diagnosis delay in peripheral nerve blockade (PNB), in either single-shot 
or continuous infusions. Upper limb nerve block has not been associated with delayed 
ACS diagnosis, but lower limb PNB has been reported in two cases, but the validity of 
that attribution is extremely doubtful [Mar et al., 2009].In one report, a femoral nerve 
block was cited for masking a lower leg ACS; as discussed previously, it is obvious that 
the femoral nerve supplies only cutaneous innervation of the medial lower leg via the 
saphenous nerve and a small portion of the proximal tibia anteriorly. It cannot block 
ischemic pain coming from lower leg muscles, all of which are innervated by the sciatic 
nerve. In the other case, an ankle block was presumed to mask an ACS in the foot, but 
although severe pain was reported, it was ignored.  
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There are no reported cases of delayed ACS diagnosis attributed to continuous perineural 
infusions. The absence of reports certainly does not imply that RA poses no risk to these 
patients, but may represent a number of factors, such as failure to report complications or 
avoidance of RA in these patients. Conversely, the literature certainly does not support a 
wholesale abandonment of RA in patients at risk. We would recommend avoiding long-
lasting dense blockade, using minimally effective infusions, and promptly addressing 
insensate limbs by withholding infusions until pinprick sensation returns. Perhaps even 
more importantly is a high level of vigilance as was exhibited by Cometa et al [Cometa et al., 
2011] and close cooperation between the orthopedic surgeons and anesthesiologists 
involved. Using RA in these patients should only be considered in centers with a 
willingness to dedicate resources to the close monitoring of these patients and with 
caregivers who are acutely aware of the risks involved.  
Despite all the attention to the subjective symptoms of ACS, they have actually been found 
to be quite unreliable [Ulmer, 2002 ]. A reliable objective measure to diagnose ACS would 
drastically improve care. Most of the attention in the past has been centered on direct, 
invasive measurement of intracompartmental pressures [Al-Dadah et al., 2008; Harris, et al., 
2006].These techniques have, to date, been somewhat limited by technical problems. The 
most promising use of this approach would appear to be the series reported by McQueen 
and Court-Brown, who suggest that maintaining a differential pressure between the 
diastolic blood pressure and an intracompartmental pressure greater than 30 mm Hg is 
protective [McQueen et al., 1996].Much more exciting is the prospect of a noninvasive 
modality, such as near-infrared spectroscopy or laser Doppler flowmetry capable of 
diagnosing ACS [Elliott & Johnstone, 2003]. Evidently, further research is needed in this 
area.  
3.2 Regional anesthesia and anticoagulation 
The trauma patient, depending on the injury, may be at risk for bleeding or clotting. Patients 
with a high volume blood loss and massive resuscitation can end up with a dilutional 
coagulopathy, while patients with lower extremity fractures, intracranial injuries, and 
immobility may be at risk for thromboembolic complications necessitating aggressive 
anticoagulation strategies. An increasing number of patients present with anticoagulants as 
part of their home medicine regimen (e.g. Plavix for patients with coronary stents). Close 
vigilance of the patient’s coagulation status, whether hyper- or hypocoagulable, is important 
prior to initiation of a regional technique. 
3.2.1 Venous thromboembolism risk in the trauma patient  
Venous thromboembolism can lead to pulmonary embolism, the most common 
preventable cause of hospital death. In patients with major trauma who are not receiving 
thromboprophylaxis, rates of DVT can range anywhere between 40 and 80% [Geerts et al., 
2008], with rates of pulmonary embolism between 1 and 2% depending on severity of the 
injury [Schuerer et al., 2005]. Pulmonary embolism is the 3rd leading cause of death for 
patients who survive beyond the first day [Geerts et al., 2008]. Independent predictors of 
DVT include spinal cord injury, lower extremity or pelvic fracture, surgery, increasing 
age, prolonged immobility, and delay in institution of thromboprophylaxis [Geerts et al., 
2008]. 
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prior to initiation of a regional technique. 
3.2.1 Venous thromboembolism risk in the trauma patient  
Venous thromboembolism can lead to pulmonary embolism, the most common 
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2008], with rates of pulmonary embolism between 1 and 2% depending on severity of the 
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age, prolonged immobility, and delay in institution of thromboprophylaxis [Geerts et al., 
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The American College of Chest Physicians published their updated guidelines on 
antithrombotic and thrombolytic therapy in 2008 [Geerts et al., 2008]. Low-dose 
unfractionated heparin alone appears to be insufficient as thromboprophylaxis in trauma 
patients. The recommendation for patients with major trauma is the use of low molecular 
weight heparin (LMWH) thromboprophylaxis in the absence of major contraindications. If 
active bleeding or high risk for clinically significant bleeding is a contraindication for 
LMWH, mechanical thromboprophylaxis is appropriate. In the patient with hip fracture 
awaiting surgery, the recommendations include routine use of thromboprophylaxis with 
fondaparinux, LMWH, adjusted dose of a vitamin K antagonist, or low-dose unfractionated 
heparin if not at high risk for bleeding. Based on evidence and expert opinion, all these 
recommendations were grade 1 recommendations, indicating that the benefits of 
thromboprophylaxis outweigh the risks, burden, and costs of implementation. The panel 
did recognize that, for patients undergoing neuraxial procedures and deep peripheral 
blocks, the physician should exercise caution when selecting anticoagulant 
thromboprophylaxis [Geerts et al., 2008]. 
The EAST Practice Parameter Workgroup for DVT Prophylaxis also published guidelines on 
anticoagulation focusing on the trauma patient [Simon et al., EAST Practice Management 
Guidelines Work Group, 2005]. This group states that, while there is inadequate class I 
evidence for the general use of LMWH in venous thromboembolism prophylaxis, they do 
recommend that LMWH be standard for thromboprophylaxis in patients with complex 
pelvic, lower extremity, and spinal cord injuries who are not at risk for significant bleeding. 
These authors acknowledge that appropriate selection of the subset of patients to administer 
LMWH without increasing the risk of significant bleeding may be challenging. 
3.2.2 American Society of Regional Anesthesia and Pain Medicine (ASRA) guidelines 
The American Society of Regional Anesthesia and Pain Medicine (ASRA) convened a 3rd 
Consensus Conference on anticoagulation and published the guidelines in 2010 [Horlocker 
et al., 2010] .Recommendations were made with regard to optimal timing and placement of 
regional anesthetic techniques when patients have received anticoagulants. The guidelines 
focus on the appropriate timing of needle placement and catheter manipulation until the 
patient achieves a reasonable state of coagulation in order to avoid significant bleeding 
complications associated with needle and catheter placement (spinal hematomas, 
retroperitoneal hemorrhage). These recommendations were made for patients in the 
inpatient and outpatient setting, including patients in the intensive care unit who are to 
receive neuraxial, plexus, or deep peripheral blockade. Little mention is made of the trauma 
or ICU patient, and much of the literature presented was focused on the patient receiving a 
regional anesthetic technique in the perioperative setting.  
The authors of the ASRA guidelines did acknowledge that fewer recommendations were 
being presented to allow for “flexibility and individuality in patient management”, but 
stressed proper vigilance when managing a patient with a regional anesthetic and 
anticoagulation [Horlocker et al., 2010]. The guidelines represent a conservative but safe 
way to practice regional anesthesia in the anticoagulated patient, and are based on the 
pharmacologic activity of anticoagulants and large case series reported over a 20-year 
period. Recently, Chelly et al [Chelly & Schilling, 2008] described a series of orthopedic 
patients undergoing lumbar paravertebral and perineural blocks placed prior to the 
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administration of thromboprophylaxis. The catheters were maintained during routine use of 
prophylactic dosing and withdrawn regardless of timing of the anticoagulant. The authors 
noted no significant hematomas.In another study, Buckenmeier described no bleeding 
complications in a series of 187 patients receiving continuous nerve blocks and LMWH 
[Buckenmaier et al., 2006]. These series might suggest that, with a high amount of vigilance 
and a great deal of technical skill, the ASRA guidelines (Table 4) [Horlocker et al., 2010] may 
represent too conservative an approach to the use of peripheral nerve blocks. However, 
neither series was powered to detect serious bleeding complications, and, thus, judgment 
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Warfarin -Discontinue 4-5 d 
prior to procedure 
-INR < 1.5 
Consider reversal 
agent to normalize 
INR 
-INR < 1.5 ideal 
-Caution in INR 1.5-3 
-Contraindicated INR 
>3 
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Contraindicated Avoidance for 10days 








tirofiban 4-8 hours 
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conditions in 2 studies 
Contraindicated while 
continuous catheter in 
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Thrombin inhibitors Contraindication Contraindication Contraindication 
Herbals No contraindication No contraindication No contraindication 
*Note these recommendations are for single drug therapy and may not apply if patient receives 
concomitant anticoagulation with other agents 
Table 4. ASRA guidelines for common anticoagulant management in the patient receiving a 
neuraxial, plexus or deep peripheral nerve block[Horlocker et al., 2010].* 
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3.2.3 Risks versus benefits 
In the trauma patient, the risks of bleeding must be weighed against the benefits of regional 
anesthesia - for instance, the risk of bleeding from TPVC or thoracic epidural catheterization 
in a patient on LMWH versus the benefit of improved pulmonary function due to improved 
analgesia with minimal sedative effects, resulting in decreased incidence of hospital-
acquired pneumonia [Bulger et al., 2004; Flagel et al., 2005; Karmakor et al, 2003]. 
When comparing a central neuraxial technique to a more peripheral technique (TEA versus 
TPVC or lumbar plexus block versus a lumbar epidural), one must always consider the 
closed nature of the spinal column. With a central neuraxial technique, compression of the 
epidural space may lead to devastating neurologic injury, including paraplegia, compared 
to a more peripheral technique in which bleeding into the paravertebral space may lead to 
extensive blood loss or compression neuropraxia but not paraplegia. The choice of a 
paravertebral block may be more appropriate in a patient on thromboprophylaxis therapy. 
Perineural blocks are usually performed at the terminal branches of the nerve (e.g. sciatic 
nerve block, popliteal nerve block, femoral nerve block, saphenous nerve block, axillary 
nerve block), and, while bleeding may result in neuropraxia and hematoma formation, the 
severity of the complications is less than that involving neuraxial or deep plexus blocks. 
The decision to proceed should be based on a careful review of the patient’s medical record. 
Informed consent for the patient and/or their family should include a review of the risks 
and benefits of the procedure, and their input into medical decision-making should be 
sought. While normal coagulation status would be preferable prior to the placement of a 
continuous catheter, this may not be possible or desirable. This decision requires astute 
clinical judgment on the part of the physician and a careful consideration of the risks versus 
benefits. 
Even if the physician and patient both agree to maintain continuous epidural or 
paravertebral block with thromboprophylactic doses of anticoagulants, waiting until after 
the peak effect of a potent anticoagulant is prudent in order to avoid further bleeding 
complications in the already injured patient. Once a neuraxial technique or deep 
paraneuraxial or perineural technique is performed, maintenance on a prophylactic dose of 
a potent anticoagulant is reasonable to allow the patient to not only have improved 
analgesic but effective deep vein thrombosis prophylaxis as well. However, extreme 
vigilance is required, particularly during the high risk period that occurs when the catheter 
is removed. 
4. Technical considerations 
Anatomy can be distorted due to the patient’s injuries. Swelling and subcutaneous 
emphysema may result in a difference in the standard sensations felt as the needle is 
advanced. If a loss of resistance approach is utilized, this may result in an indistinct or false 
sensation of loss. Even the use of ultrasound may not be helpful in the patient with 
subcutaneous emphysema, as the image is altered by the air underneath the skin. The use of 
CT scans to gauge the depth of the epidural space and paravertebral space is very important 
in allowing the physician to have an intelligent “guesstimate” of the depth of the targeted 
space.  
Stimulating catheters may be utilized to guide catheters based on the motor response 
elicited via the catheter. While this provides an extra endpoint for confirmation of catheter 
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CT scans to gauge the depth of the epidural space and paravertebral space is very important 
in allowing the physician to have an intelligent “guesstimate” of the depth of the targeted 
space.  
Stimulating catheters may be utilized to guide catheters based on the motor response 
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In the patient with perineural catheters, spread of local anesthetic, while not resulting in 
hemodynamic effects, can be visualized using ultrasound guidance, as these structures are 
superficial and can be visualized readily with this mode. In patients with paravertebral 
continuous blocks, the spread of local anesthetic is difficult to assess and may be 
inconsistent in its distribution. Therefore, dye injection through the catheter and 
visualization under fluoroscopy can be used as an alternative gauge of local anesthetic 
spread, assuming that the patient has no contraindications to contrast dye (Figure 2).  
Nursing staff spend the most amount of time with these patients, and can provide important 
information concerning their perception of whether the patient demonstrates signs of 
improved or adequate comfort.  
4.2 Early management with regional anesthesia 
As previously noted, trauma patients often suffer moderate to severe pain in the Emergency 
Department [Berben et al., 2008]. In Europe, emergency response teams are frequently 
physician-based. Regional anesthesia performed in the field, prior to hospital admission, has 
been described for patients with femoral fractures [Lopez et al., 2003; Schiferer et al., 2007]. 
A simple fascia iliaca block and a nerve stimulator-guided femoral nerve block have been 
described. Both studies showed reasonably high success rates, with Schiferer reporting a 
90% success rate in the RA group [Schiferer et al., 2007].Pain and anxiety scores were much 
lower in the RA group, as was heart rate. A mean treatment time of seven minutes in the RA 
group did delay transport time, which is of concern in this setting. While this paradigm will 
probably not take hold in the rest of the world, including the United States, it surely 
represents a call to action, to set up processes to provide earlier RA in the hospital setting. 
5. Conclusion 
Trauma patients represent a significant proportion of current surgical volume and of 
patients being cared for ICUs. Estimates suggest that this proportion will increase [Lopez et 
al., 2006]. These patients present many challenges and require extreme vigilance on the part 
of the health care team. An in-depth understanding of anatomy, physiology, and 
pharmacology is important when dealing with the trauma patient. Flexibility on the part of 
the physician to respond to the myriad challenges by adapting to different approaches and 
modalities is key. Clearly, RA can safely decrease suffering and improve outcomes in these 
patients when applied judiciously. 
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In the patient with perineural catheters, spread of local anesthetic, while not resulting in 
hemodynamic effects, can be visualized using ultrasound guidance, as these structures are 
superficial and can be visualized readily with this mode. In patients with paravertebral 
continuous blocks, the spread of local anesthetic is difficult to assess and may be 
inconsistent in its distribution. Therefore, dye injection through the catheter and 
visualization under fluoroscopy can be used as an alternative gauge of local anesthetic 
spread, assuming that the patient has no contraindications to contrast dye (Figure 2).  
Nursing staff spend the most amount of time with these patients, and can provide important 
information concerning their perception of whether the patient demonstrates signs of 
improved or adequate comfort.  
4.2 Early management with regional anesthesia 
As previously noted, trauma patients often suffer moderate to severe pain in the Emergency 
Department [Berben et al., 2008]. In Europe, emergency response teams are frequently 
physician-based. Regional anesthesia performed in the field, prior to hospital admission, has 
been described for patients with femoral fractures [Lopez et al., 2003; Schiferer et al., 2007]. 
A simple fascia iliaca block and a nerve stimulator-guided femoral nerve block have been 
described. Both studies showed reasonably high success rates, with Schiferer reporting a 
90% success rate in the RA group [Schiferer et al., 2007].Pain and anxiety scores were much 
lower in the RA group, as was heart rate. A mean treatment time of seven minutes in the RA 
group did delay transport time, which is of concern in this setting. While this paradigm will 
probably not take hold in the rest of the world, including the United States, it surely 
represents a call to action, to set up processes to provide earlier RA in the hospital setting. 
5. Conclusion 
Trauma patients represent a significant proportion of current surgical volume and of 
patients being cared for ICUs. Estimates suggest that this proportion will increase [Lopez et 
al., 2006]. These patients present many challenges and require extreme vigilance on the part 
of the health care team. An in-depth understanding of anatomy, physiology, and 
pharmacology is important when dealing with the trauma patient. Flexibility on the part of 
the physician to respond to the myriad challenges by adapting to different approaches and 
modalities is key. Clearly, RA can safely decrease suffering and improve outcomes in these 
patients when applied judiciously. 
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1. Introduction 
Intensive research on the neurobiology of pain over the past two decades has revealed many 
receptors, ion channels and enzymes with potential as novel targets for development of a 
new generation of analgesic agents. However, despite large investment in preclinical and 
clinical development of small molecules and biologics as potential novel pain therapeutics, 
very few have reached the clinic. Hence, drugs used in the clinical setting for the 
pharmacological management of pain continue to be those that were first recommended in 
1986 by the World Health Organisation (WHO) for the management of chronic cancer pain 
(WHO, 1986). Twenty-five years on, the WHO 3-step Analgesic Ladder (Figure 1) is still 
used widely to guide the pharmacological management of pain and opioid analgesics are 
the mainstay for alleviation of moderate to severe nociceptive pain.  
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2. WHO Analgesic Ladder 
The WHO Analgesic Ladder provides a succinct encapsulation of the guidelines for the 
management of chronic pain according to intensity (WHO, 1986). Specifically, for mild 
pain, non-opioid analgesics on Step 1 of the Analgesic Ladder including acetaminophen, 
aspirin and nonsteroidal anti-inflammatory drugs such as ibuprofen, are recommended. 
When the pain has a neuropathic component, addition of an adjuvant agent such as a 
tricyclic antidepressant, anticonvulsant or anti-arrhythmic agent, is recommended. Weak 
opioid analgesics such as codeine, tramadol and dextropropoxyphene are added to  
non-opioid analgesics when mild pain progresses to moderate pain (Step 2); adjuvants  
are again co-administered when the pain has a neuropathic component. Strong opioid 
analgesics are recommended for the management of moderate to severe nociceptive  
pain (Step 3) with morphine the strong opioid analgesic of choice due to its ready 
availability world-wide at low cost. Strong opioid analgesics are often co-administered 
with non-opioids, and adjuvants are added when pain has a neuropathic component 
(WHO, 1986). 
According to the WHO guidelines, each patient should receive a period of individualized 
dose titration on a ‘round the clock’ rather than an ‘as required’ basis as this facilitates 
dosage optimization for the selected analgesic and/or adjuvant (WHO, 1986). Although 
many opioid analgesics have relatively short elimination half-lives (Table 1), most are 
available as sustained-release formulations that are administered once or twice-daily to 
optimize patient compliance as well as pain relief. For patients who experience break-
through pain during ambulation or activities of daily living, additional bolus doses of 
immediate-release formulations are given on an “as required” basis. For most patients, the 
oral dosing route is preferred except where impaired gastrointestinal transit makes this 
impractical as in the immediate post-operative period or during labor.  
3. Opioid analgesics 
Opioid analgesics commonly used for the control of clinical pain include morphine, codeine, 
oxycodone, hydromorphone, buprenorphine, tramadol, fentanyl, remifentanil, pethidine 
and methadone. The potencies of these opioid analgesics differ markedly. Equi-analgesic 
doses and usual starting doses for the oral route derived from the acute pain setting are 
shown in Tables 2 and 3 respectively. 
3.1 Opioid-related adverse effects 
Apart from their desired analgesic action, clinically prescribed opioids also produce many 
undesired effects including respiratory depression, sedation, nausea, vomiting, 
constipation, pruritus, tolerance and dependence, to name but a few (Zollner & Stein, 
2007). Although studies using -opioid (MOP) receptor knockout mice suggest that the 
analgesic and adverse effects of opioid analgesics are all produced by activation of the 
MOP receptor, clinical experience shows that there are marked between-opioid 
differences with respect to analgesic and tolerability profiles within the same patient 
(Smith, 2008). However, the precise mechanistic basis underpinning these observations is 
not well understood.  
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3.1.1 Respiratory depression 
Opioid-related deaths continue to be reported in the acute pain setting underpinned by 
opioid-induced ventilatory impairment that often develops due to a combination of factors 
including opioid-induced central respiratory depression, sedation and/or upper airway 
obstruction (Macintyre et al., 2011). It is recommended that all patients be monitored for 
opioid-induced ventilatory impairment using sedation scores as a ‘6th vital sign’ so that it 
can be detected early and appropriate intervention initiated (Macintyre et al., 2011). 
3.2 Strategies for minimizing opioid-related adverse effects 
It is essential to assess patients to ensure that adverse effects are genuinely opioid-related 
rather than being due to another medical problem. Strategies recommended (Swegle & 
Logemann, 2006) for minimizing opioid-related adverse effects are as follows: 
1. Titrating opioid doses slowly 
2. Dose reduction to assess if satisfactory analgesia can be obtained with tolerable side-
effects 
3. Symptom management including pro-active preventative treatment of nausea and 
constipation 
4. Addition of, or increasing non-opioid or adjuvant analgesic doses for an opioid sparing 
effect 
5. Opioid rotation  
6. Changing the route of administration 
7. Frequent re-assessment 
3.3 Strategies for managing intolerable opioid-related adverse effects 
For patients experiencing poor pain relief together with intolerable opioid-related side-effects 
such as severe vomiting, severe dysphagia or bowel obstruction, changing from the oral to the 
parenteral (e.g. intravenous, subcutaneous, intramuscular), rectal, buccal, sublingual, 
transdermal or spinal (epidural, intrathecal) route of administration, may reduce adverse 
effects to a tolerable level and restore satisfactory analgesia (Walsh, 2005). Another strategy for 
restoring satisfactory analgesia with tolerable side-effects in such patients is ‘opioid rotation’ 
that involves switching from one strong opioid analgesic to another (Smith, 2008; Knotkova et 
al., 2009; Vissers et al., 2010). Additional clinical strategies for restoring analgesia in patients 
experiencing inadequate pain relief and intolerable opioid-related side-effects include use of 
neurolytic blocks as an adjunct or alternative to pharmacotherapy (Eisenberg et al., 2005) or 
progression to use of anaesthetic intervention if ‘opioid rotation’ fails (Riley et al., 2007). 
3.4 Tolerance to the analgesic effects of opioids 
In the absence of disease progression, tolerance to the analgesic effects of an opioid manifests 
in patients with clinical pain as the need for progressively higher opioid doses in order to 
maintain the same level of pain relief (South & Smith, 2001). In rodent studies, analgesic 
tolerance is demonstrated by a rightward shift in the analgesia dose-response curve for a 
particular opioid administered after a period of chronic dosing relative to the dose-response 
curve determined for the same opioid in opioid-naïve animals (South & Smith, 2001).  
3.5 Tolerance to opioid-related side-effects 
As already noted, opioid-related adverse effects that may occur after the initation of opioid 
analgesic treatment in opioid-naïve patients include respiratory depression, somnolence, 
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nausea, vomiting, miosis, pruritus, constipation, and euphoria/dysphoria. With chronic 
dosing, tolerance often develops to sedation, nausea and respiratory depression whereas 
tolerance to constipation and miosis is minimal (Chang et al., 2007).  
3.6 Opioid analgesics and renal impairment 
Several opioid analgesics including morphine, hydromorphone and meperidine are 
metabolized in the liver to pharmacologically active metabolites that may accumulate in 
patients with renal impairment. Hence, for patients with renal impairment, opioid 
analgesics including oxycodone and fentanyl that are devoid of active metabolites, are 
preferred (King et al., 2011). 
4. Weak opioid analgesics 
4.1 Codeine 
Codeine (7,8-didehydro-4,5-epoxy-3-methoxy-17-methylmorphinan-6-ol) is an opioid 
alkaloid found in opium, the dried exudate of the unripe seed capsule of the opium poppy, 
Papaver somniferum, at 0.7 to 2.5% (Boerner, 1975). Due to its high consumption rates 
globally, codeine is generally synthesized by O-methylation of morphine, an abundant 
opium constituent at 10-15% (Lenz et al., 1986).  
Codeine is a weak opioid analgesic that binds to the -opioid (MOP) receptor with low 
affinity (Ki = 0.7 M) (Volpe et al., 2011). Its analgesic properties are generally thought to be 
derived from the fact that it is a prodrug for morphine as up to 10% of oral doses are O-
demethylated to morphine by cytochrome P450 2D6 (CYP2D6), an enzyme subject to genetic 
polymorphism (Kadiev et al., 2008, Somogyi et al., 2007, Zollner & Stein, 2007). Supporting 
this notion, plasma morphine concentrations are virtually undetectable and codeine lacks 
efficacy in individuals with the poor metabolizer (PM) CYP2D6 phenotype (Poulsen et al., 
1996). By contrast, codeine is extensively metabolized to morphine in those with the ultra-
metabolizer (UM) phenotype who also have an increased risk of respiratory depression after 
regular doses of codeine (Kirchheiner et al., 2007).  
Doses of codeine generally do not exceed 60 mg (Trescot et al., 2008). Codeine is available in 
a range of prescription and over-the-counter medicines, often in combination with 
paracetamol, aspirin or ibuprofen for pain relief (Moore et al., 1997; Moore et al., 2011). It is 
also the active ingredient in many cough suppressant mixtures and anti-diarrhoeal products 
(Schiller, 1995; Wee, 2008). Codeine is susceptible to metabolic drug-drug interactions with 
other commonly prescribed medications that are also metabolized by CYP2D6 including 
both CYP2D6 inhibitors (e.g. cimetidine) and CYP2D6 inducers (e.g. rifampicin) (Caraco et 
al., 1997; Zhou, 2009).  
4.2 Meperidine (pethidine) 
Meperidine (pethidine; ethyl-1-methyl-4-phenylpiperidine-4-carboxylate), is a synthetic 
MOP receptor agonist that binds with low affinity (Ki = 450 nM) at the MOP receptor (Volpe 
et al., 2011). Meperidine is a weak opioid analgesic with potency at 10% that of morphine 
for the relief of acute post-operative pain (Latta et al., 2002). Meperidine is metabolized by 
hepatic esterases to pethidinic acid, an inactive metabolite, and by N-demethylation to a 
neurotoxic metabolite, normeperidine (Gilman et al., 1980, Armstrong et al., 2009). After 
multiple doses, normeperidine may accumulate in plasma and cerebrospinal fluid causing 
tremors, twitches, myoclonus and seizures as it has a longer plasma half-life than 
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meperidine itself (Plummer et al., 1995; Simopoulos et al., 2002). Meperidine is contra-
indicated in patients with impaired renal function as they are at increased risk of 
normeperidine neurotoxicity due to its faster accumulation (Marinella, 1997; Reutens & 
Stewart-Wynne, 1989). Generally, meperidine use is discouraged in favour of more 
efficacious and less toxic opioid analgesics (Latta et al., 2002). 
4.3 Tramadol 
Tramadol ((1RS,2RS)-2-[(dimethylamino)methyl]- 1 -(3-methoxyphenyl)-cyclo-hexanol 
hydrochloride)  is a synthetic analgesic that is a racaemic mixture of two enantiomers that 
bind to the MOP receptor with low (10 M) affinity (Volpe et al., 2011). After systemic 
administration, tramadol is metabolized in the liver by the enzyme CYP2D6, to its O-
demethylated M1 metabolite, a potent -opioid agonist that contributes to its analgesic 
actions (Subrahmanyam et al., 2001). The (-)-enantiomer of tramadol mainly inhibits 
noradrenaline reuptake in the central nervous system (CNS) to augment descending 
inhibition of pain transmission in the spinal cord whereas the (+)-enantiomer preferentially 
inhibits serotonin reuptake (Reimann & Hennies, 1994). Thus, the pharmacology of 
tramadol is complex with its analgesic action being due to the combined effects of its two 
enantiomers and the M1 metabolite. For this reason, the US Food and Drug Administration 
(FDA) has classified tramadol as a nontraditional, centrally acting analgesic (Grond & 
Sablotzki, 2004).  
For the relief of post-operative pain relief, tramadol is regarded as a “weak” opioid 
analgesic with potency at 10% that of morphine but it does not produce significant 
constipation or respiratory depression and it has low abuse potential (Grond & Sablotzki, 
2004). When tramadol is given in doses larger than the recommended doses, or if it is co-
administered with medications that lower the seizure threshold such as selective serotonin 
reuptake inhibitors, tricyclic antidepressants and antipsychotic drugs, seizures may be 
induced (Gardner et al., 2000). 
5. Strong opioid analgesics 
5.1 Morphine 
Morphine (7,8-didehydro-4,5,-epoxy-17-methyl-(5,6)-morphinan-3,6-diol) is extracted 
from opium due to its relatively high abundance at 10-15% by weight (Boerner, 1975). 
Morphine was first isolated from opium in 1805 by Freidrich Sertűrner, a German 
pharmacist who named it “morphium” after Morpheus the Greek God of Dreams (Milne et 
al., 1996).  
Morphine is the prototypic strong opioid analgesic that binds with high affinity (Ki = 1.2 
nM) at the MOP receptor (Volpe et al., 2011). After oral administration in humans, morphine 
has low oral bioavailability at 20% due to extensive first-pass metabolism in the liver to 
two major metabolites, viz morphine-6-glucuronide (M6G) and morphine-3-glucuronide 
(M3G) that account for 10% and >50% of each dose, respectively (Milne et al., 1996). 
Morphine has a short elimination half-life at 2 h consistent with its short duration of action 
at 4 h (Mather & Smith, 1998). 
M6G, like morphine, binds with high affinity at the MOP receptor and it is a more potent 
analgesic than morphine when given by central routes (Smith & South, 2001). By contrast, 
supraspinally administered M3G evokes dose-dependent neuro-excitatory effects and its 
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actions generally oppose those of morphine in animal studies (Smith, 2000). The elimination 
half-lives of M3G and M6G are in the range 3-4 h (Mather & Smith, 1998). 
After administration of single doses of morphine to patients with clinical pain, the plasma 
and CSF concentrations of M3G exceed those of morphine by several-fold (Hasselström & 
Säwe, 1993) and after chronic dosing, the plasma M3G concentrations exceed the 
corresponding morphine levels by as much as 10-20 fold (Smith et al., 1999). In patients with 
renal impairment, M6G and M3G may accumulate in the plasma and CSF, thereby 
increasing the risk of M6G-induced respiratory depression (Smith & South, 2001) and/or 
M3G-induced neuro-excitation (Smith, 2000). 
Morphine is available in immediate-release and sustained-release oral tablet and capsule 
formulations as well as oral mixtures, rectal suppositories and sterile ampoules for 
parenteral administration by the intramuscular, intravenous, subcutaneous, epidural and 
intrathecal routes (Argoff & Silvershein, 2009). The duration of action for immediate-release 
oral morphine preparations is approximately 3-4 h whereas for oral sustained-released 
morphine tablets and capsules, the duration of action is 12-24 h (Mather & Smith, 1998). The 
convenience of once or twice daily dosing provided by sustained-release formulations 
improves patient compliance and pain relief outcomes (Argoff & Silvershein, 2009).  
5.2 Oxycodone 
Oxycodone ((5-4,5-epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one) is a strong 
opioid analgesic that is a semi-synthetic derivative of the abundant opium alkaloid, thebaine 
(Lenz et al., 1986). After oral administration, the bioavailability of oxycodone is high at 60-
87% (Leow et al., 1992; Lalovic et al., 2006). Oxycodone is extensively N-demethylated by 
the enzyme, CYP3A4, to the analgesically inactive metabolite, noroxycodone (Poyhia et al., 
1992; Davis et al., 2003; Lalovic et al., 2004, 2006) with up to another 10% of each dose 
undergoing CYP2D6-catalyzed O-demethylation to the high affinity MOP receptor agonist 
oxymorphone (Lalovic et al., 2006). However, metabolically-derived oxymorphone does not 
contribute significantly to the analgesic actions of oxycodone for the relief of clinical pain 
because its circulating plasma concentrations are very low (1 ng/mL) in both extensive 
metabolisers (EMs) and PMs (0.3 ng/mL) as it is rapidly further metabolized to its 
analgesically-inactive glucuronide conjugate (Lalovic et al., 2006; Zwisler et al., 2010). For 
patients with post-operative pain, there is no difference in analgesic outcomes between PMs 
and EMs (Zwisler et al., 2010), affirming earlier work by others showing that the analgesic 
effects of oxycodone are attributable to the parent opioid alone (Heiskanen et al., 1998; 
Lalovic et al., 1996). 
Radioligand binding studies show that oxycodone has relatively low affinity (Ki = 26 nM) at 
the cloned MOP receptor (Volpe et al., 2011) and that it has a distinctly different binding 
profile from morphine in rat brain homogenate (Nielsen et al., 2007). This likely underpins 
the low extent of cross-tolerance between oxycodone and morphine in rodents (Nielsen et 
al., 2000) and the success of opioid rotation from morphine to oxycodone for the restoration 
of analgesia with tolerable opioid-related side-effects in humans (Narabayashi et al., 2008). 
The potency of intravenous and oral oxycodone for the relief of both post-operative and 
chronic cancer pain is 1.5 times that of morphine (Kalso et al., 1991; Heiskanen & Kalso, 
1997; Bruera et al., 1998). However, when given by the epidural route for the relief of post-
operative pain, the potency of oxycodone is much lower than that of morphine at 11% 
(Backlund et al., 1997).  
 
Pain Management – Current Issues and Opinions 
 
292 
meperidine itself (Plummer et al., 1995; Simopoulos et al., 2002). Meperidine is contra-
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actions generally oppose those of morphine in animal studies (Smith, 2000). The elimination 
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Oxycodone, like morphine, is available in immediate-release and sustained-release tablet 
formulations as well as in oral mixtures, rectal suppositories and ampoules for parenteral 
administration (Argoff & Silvershein, 2009). 
5.3 Methadone 
Methadone, 6-dimethylamino-4,4-diphenyl-heptan-3-one, is a synthetic, strong opioid 
analgesic that is a racaemic mixture of two enantiomers. The analgesic efficacy of 
methadone is multi-faceted as the R-enantiomer is a high affinity MOP receptor agonist  
(Ki = 3.4nM) whereas the S-enantiomer augments descending noradrenergic inhibition to 
block nociceptive signaling in the spinal cord, and both enantiomers have NMDA receptor 
antagonist activity (Davis and Walsh, 2001). 
In humans, methadone has high but unpredictable oral bioavailability at 80% (range  
41-99%) with peak plasma concentrations observed at 2-4 h post-dosing (Trescot et al., 2008; 
Modesto-Lowe et al., 2010). There is a large degree of inter-individual variability in its long 
elimination half-life (12-150 h) (Trescot et al., 2008). These properties make it difficult to use 
for the relief of acute pain or for pain that is poorly controlled where rapid dose adjustments 
are needed (Davis & Walsh, 2001). Further adding to these difficulties, methadone is 
metabolized by CYP3A4-catalyzed N-demethylation to the analgesically inactive metabolite, 
normethadone, such that methadone is potentially subject to a large number of metabolic 
drug-drug interactions as many clinically used drugs are either CYP3A4 inhibitors or 
inducers (Fishman et al., 2002).  
Apart from its use as a strong opioid analgesic for relief of moderate to severe pain, 
methadone is also widely used for opioid maintenance therapy in patients with heroin 
addiction (Fishman et al., 2002). Commercially available methadone formulations include 
oral tablets and mixtures, rectal suppositories and ampoules for parenteral administration 
(Manfredi et al., 2003). When converting patients from a strong opioid analgesic such as 
morphine to methadone, caution needs to be exercised. This is because morphine-
methadone analgesic ratios vary significantly according to the previous morphine dosing 
regimen (Mancini et al., 2000).  
For individuals receiving chronic methadone treatment for opioid dependence, 
cardiotoxicity characterized by prolonged QTc intervals are associated with methadone dose 
and concurrent stimulant use (Modesto-Lowe et al., 2010; Mayet et al., 2011). For individuals 
receiving methadone at doses exceeding 60 mg/day together with tricyclic antidepressants 
or other drugs that inhibit methadone metabolism, the QTc interval is lengthened thereby 
initiating Torsades de Pointes (Krantz et al., 2002, Ehret et al., 2007). QT prolongation with 
methadone is also influenced by other factors including hypokalaemia, hepatic failure and 
pre-existing heart disease (Ehret et al., 2007). Unfortunately, the general lack of awareness of 
the long and highly variable elimination half-life of methadone together with its many 
metabolic drug-drug interactions,  has led to a dramatic increase in methadone-associated 
deaths (Trescot et al., 2008).  
5.4 Hydromorphone 
Hydromorphone, 4,5 alpha-epoxy-3-hydroxy-17-methyl morphinan-6-one, is a semi-
synthetic opioid analgesic (Murray & Hagen, 2005) that binds with high affinity (Ki = 0.37 
nM) at the MOP receptor (Volpe et al., 2011) and to a lesser extent at the -opioid (DOP) 
receptor but not at the -opioid (KOP) receptor (Murray & Hagen, 2005). Orally 
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administered hydromorphone undergoes extensive first-pass metabolism in the liver to 
hydromorphone-3-glucuronide (H3G) that accounts for more than 50% of each dose. 
Although H3G, like M3G, is analgesically inactive, it produces dose-dependent neuro-
excitatory effects after supraspinal administration in rodents with a potency 2.5-fold higher 
than M3G (Wright et al., 2001). Chronic administration of hydromorphone in patients with 
renal impairment will result in H3G accumulation, raising the risk that neuro-excitatory 
side-effects will be produced (Smith, 2000; Mercadante & Arcuri, 2004). 
The analgesic potency of parenteral hydromorphone is  5-fold higher than that of 
morphine for the alleviation of moderate to severe acute pain (Bruera et al., 1996; Dunbar et 
al., 1996; Quigley, 2002; Horn & Nesbit, 2004) whereas for chronic cancer pain, the analgesic 
potency of hydromorphone is similar to that of morphine (Murray & Hagen, 2005). 
Hydromorphone is available as immediate-release and controlled-release oral formulations 
(Guay, 2010) as well as ampoules for parenteral administration by either the epidural or 
intrathecal routes (Lee et al., 2011; Liu et al., 2011). 
5.5 Buprenorphine 
Buprenorphine, ((2S)-2-[(-)-(5R,6R,7R,14S)-9α-cyclopropylmethyl-4,5-epoxy-6,14-ethano-3-
hydroxy-6-methoxymorphinan-7-yl]-3,3-dimethylbutan-2-ol), is also a semi-synthetic 
derivative of thebaine. Buprenorphine binds with high affinity (Ki = 0.2nM) at the MOP 
receptor (Volpe et al., 2011) and functionally it is a partial agonist (Pick et al., 1997). 
Buprenorphine also has antagonist actions at the -opioid (KOP) receptor and it interacts 
with the nociceptin (ORL-1) receptor (Pick et al., 1997). Buprenorphine produces dose-
dependent analgesia with potency at 25-50 times higher than morphine (Evans & Easthope, 
2003). The slow onset and long duration of buprenorphine’s pharmacodynamic actions are 
thought to be due to its slow binding to and dissociation from the MOP receptor (Evans & 
Easthope, 2003).  
Consistent with its partial agonist activity at the MOP receptor, sublingual buprenorphine 
administered to healthy male volunteers in doses up to 70-fold higher than the 
recommended analgesic dose (0.3 mg) and 4-8 fold higher than doses (4-8 mg) used to treat 
opioid addiction, produced ceiling responses for subjective measures of drug liking in doses 
at 8 to 16 mg (Walsh et al., 1994). In the same subjects a ceiling effect for respiratory 
depression was observed at 16mg (Walsh et al., 1994). Because buprenorphine exhibited 
linear pharmacokinetics across the dose range tested, dose-limited sublingual absorption is 
not responsible for the ceiling effects (Walsh et al., 1994). The KOP antagonist activity of 
buprenorphine is thought to contribute to its good tolerability characterized by limited 
dysphoria or psychotomimetic effects (Johnson et al., 2005).  
After oral administration, buprenorphine undergoes extensive first-pass metabolism in the 
liver catalyzed by the enzymes, CYP3A4 and CYP2C8 to produce the active N-dealkylated 
metabolite, norbuprenorphine (Picard et al., 2005). Consequently the oral bioavailability is 
low at 14% and so buccal, sublingual, intranasal and transdermal formulations of 
buprenorphine have been developed that effectively by-pass first-pass metabolism and 
increase bioavailability to 30-60% (Evans & Easthope, 2003; Johnson et al., 2005; Davis, 2005). 
Due to its long half-life (26 h) and ceiling pharmacodynamic effects, buprenorphine is used 
as an alternative to methadone for opioid maintenance therapy in opioid-dependent 
individuals (Robinson, 2002; Johnson et al., 2005). A combination product containing 
buprenorphine and naloxone in a 4:1 ratio respectively is available in some countries as a 
deterrent to illicit use of buprenorphine tablets for parenteral injection (Harris et al., 2004). 
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Fentanyl, N-(1-(2-phenylethyl)-4-piperidinyl)-N-phenyl-propanamide, is a synthetic opioid 
analgesic (Horn & Nesbit, 2004) that binds with high affinity (Ki = 1.3 nM) at the MOP 
receptor (Volpe et al., 2011). Fentanyl is metabolized by CYP3A4 to its N-dealkylated 
metabolite, norfentanyl that is pharmacologically inactive (Horn & Nesbit, 2004). 
After parenteral dosing, fentanyl is ~80-100 fold more potent than morphine with a rapid 
onset of action but only a short duration at < 60 min (Horn & Nesbit, 2004; Pasero, 2005; 
Stanley, 2005). For post-operative pain relief, fentanyl may be given by spinal routes whereas 
for breakthrough or procedural pain, the sublingual, transmucosal, intra-nasal, inhaled or 
parenteral routes are preferred (Lennernas et al., 2005; Hair et al., 2008; Peng & Sandler, 1999). 
Fentanyl has high lipophilicity making it suitable for transdermal delivery. To this end, 
there are several transdermal patch formulations of fentanyl available for clinical use that 
effectively overcome fentanyl’s short duration of action (Cachia & Ahmedzai, 2011). There is 
now a large body of evidence to support the use of fentanyl patches for the management of 
moderate to severe chronic cancer pain, with data suggesting improved pain relief and 
reduced opioid-related side-effects compared with sustained release oral morphine (Cachia 
& Ahmedzai, 2011). 
5.7 Tapentadol 
Tapentadol, [(-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol], is a recently 
approved centrally acting analgesic with two complementary modes of action, viz moderate 
affinity activity at the MOP receptor (Ki = 0.1 M) together with inhibitory effects on the 
NET transporter (Ki = 0.5 M) to block the re-uptake of norepinephrine in the CNS and so 
augment descending inhibition to attenuate pain at the level of the spinal cord (Tzschentke 
et al., 2007; Hartrick, 2009; Wade & Spruill, 2009). After oral dosing, the oral bioavailability 
of tapentadol is relatively low at 32% (Tzschentke et al., 2006) due to significant first-pass 
metabolism in the liver to the inactive glucuronide metabolite, tapentadol-O-glucuronide 
(Terlinden et al., 2010).  
The immediate-release (IR) formulation of tapentadol was approved by the FDA in 2008 for 
the management of moderate-to-severe acute pain as the first new analgesic developed in 
over 25 years (Vadivelu et al., 2011). When compared with oxycodone in a head-to-head 
clinical trial for the relief of post-operative pain in patients following bunionectomy, 
tapentadol provided non-inferior analgesia to oxycodone with a superior gastrointestinal 
adverse effect profile characterized by significantly less nausea, vomiting, and constipation 
when compared with oxycodone (Hartrick, 2009; Vadivelu et al., 2011).  
More recently, the FDA has approved an extended-release (ER) formulation of tapentadol 
for twice-daily oral administration for the management of moderate to severe chronic pain 
in adult patients (Vadivelu et al., 2011). In patients with end-stage joint disease administered 
IR tapentadol for two weeks followed by the ER formulation for a further 4-weeks, the 
superior gastrointestinal tolerability of tapentadol relative to oxycodone, was affirmed 
(Etropolski et al., 2011). Mechanistically, this may be due to an ‘opioid-sparing’ effect of the 
inhibitory actions of tapentadol at the NET transporter (Tzschentke et al., 2006).  
5.8 Ultra-short acting opioid analgesics 
For patients with cardiovascular instability, ultra-short acting structural analogues of 
fentanyl such as remifentanil, alfentanil and sufentanil are preferred for use as part of 
balanced analgesic regimens during anaesthesia (Horn & Nesbit, 2004). 
 





acid, methyl ester) is a synthetic derivative of fentanyl with an ester function in its structure 
that makes it susceptible to hydrolysis by non-specific blood and tissue esterases (Egan et 
al., 1993). The very rapid metabolism of remifentanil to the inactive remifentanil acid 
metabolite by non-specific esterases underpins its activity as an ultra-short acting MOP 
agonist (Egan et al., 1993). 
Parenteral remifentanil has a rapid onset of action (~1 min) and a rapid offset of action 
following discontinuation (~3–10 min) (Stroumpos et al., 2010) and it is indicated for the relief 
of pain associated with surgical procedures (Mesolella et al., 2004, Kucukemre et al., 2005). 
Remifentanil’s pharmacokinetics favour its use as an analgesic during labour (Leong et al., 
2011), a notion supported by the findings of two recent clinical studies (Buehner et al., 2011; 
Ng et al., 2011). In the first study, 94% of 244 consecutive women in a small maternity unit 
who received remifentanil by patient-controlled analgesia (PCA) for relief of labour pain 
rated their analgesic outcomes as excellent, very good or good (Buehner et al., 2011). The 
safety profile of remifentanil was also good as the Apgar scores of neonates born to these 
women did not differ significantly from those for neonates born by normal vaginal delivery 
to women who received no analgesia (Buehner et al., 2011). In the second study, maternal 
satisfaction was higher in laboring women who received PCA remifentanil for analgesia 
compared with intramuscular pethidine (Ng et al., 2011) with no difference in the safety 
profile between these two opioid analgesics in the newborn infants (Ng et al., 2011).  
6. Opioid rotation 
For patients experiencing poor pain relief and intolerable opioid-related side-effects on one 
strong opioid analgesic, switching to a second strong opioid analgesic often results in 
restoration of satisfactory pain relief with tolerable opioid-related adverse effects (Knotkova 
et al., 2009; Vissers et al., 2010). The starting dose of the second opioid is selected to 
minimize potential risks whilst ideally restoring analgesic efficacy and must be informed by 
an estimate of its potency relative to the first opioid (Fine et al., 2009; Mercadante & 
Caraceni, 2011). 
Both pharmacokinetic and pharmacodynamic factors may contribute to the clinical success 
of opioid rotation. For opioid analgesics such as morphine and hydromorphone that are 
avidly metabolized to the neuro-excitatory ‘anti-analgesic’ glucuronide metabolites, M3G 
and H3G respectively, opioid rotation facilitates clearance of these metabolites from the 
body enabling restoration of analgesia with the second opioid and resolution of neuro-
excitatory side-effects (Smith, 2000). Additionally, opioid rotation exploits incomplete cross-
tolerance between opioids possibly underpinned by subtle differences in their modulation 
of MOP receptor function (Smith, 2008; Slatkin, 2009).  
7. Peripherally selective opioid antagonists for improving opioid-induced 
constipation 
In patients receiving opioid analgesics for treatment of chronic pain, constipation is a very 
common side-effect that impairs quality of life and has a prevalence of >80% despite 
proactive laxative use (Clemens & Mikus, 2010; Diego et al., 2011). A recent approach to the 
treatment of opioid-induced constipation involves the recent development of quarternary 
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ammonium opioid antagonists such as alvimopan and methylnaltrexone that have limited 
absorption across the gastrointestinal mucosa and do not cross the blood-brain-barrier, as 
well as products that incorporate low-dose oral naloxone that has very low oral 
bioavailability at 2% (Diego et al., 2011). These products selectively target opioid receptors 
in the gastrointestinal tract without affecting centrally-mediated analgesic mechanisms 
(Diego et al., 2011). 
7.1 Alvimopan 
Alvimopan, 2-([(2S)-2-([(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethylpiperidin-1-yl]methyl) -3-
phenylpropanoyl]amino)acetic acid, is an orally active synthetic MOP receptor antagonist 
that is unable to cross the blood-brain-barrier due to the presence of a quaternary 
ammonium group in its chemical structure that is fully ionized at physiological pH (Foss et 
al., 2008; Diego et al., 2011). Thus after oral administration, its actions are confined to 
peripheral sites such as the gastrointestinal tract and it does not reverse centrally mediated 
analgesia (Foss et al., 2008; Karuppiah & Farrah, 2011). Alvimopan has been approved by 
the FDA for short-term use (maximum of 15 doses at twice-daily intervals) in hospitals to 
treat post-operative ileus that may be caused or exacerbated by opioid analgesics (Diego et 
al., 2011). Alvimopan accelerates the time to upper and lower gastrointestinal recovery 
following partial large or small bowel resection with primary anastomosis and decreases the 
time to hospital discharge by approximately one day (Diego et al., 2011; Karuppiah & 
Farrah, 2011).  
The recommended dosing regimen for alvimopan is 12 mg at 0.5-5 h pre-surgery followed 
by 12 mg twice daily for a maximum of 15 doses (Karuppiah & Farrah, 2011). Alvimopan is 
generally well-tolerated when administered for seven days or less (Karuppiah & Farrah, 
2011). However, with long-term use (e.g. 12 months) there is an increased risk of myocardial 
events (Bader et al., 2011; Karuppiah & Farrah, 2011).  
7.2 Methylnaltrexone 
Methylnaltrexone, (5α)-17-(cyclopropylmethyl)-3,14-dihydroxy-17-methyl-4,5-
epoxymorphinanium-17-ium-6-one, is a quaternary ammonium derivative of the opioid 
receptor antagonist, naltrexone (Bader et al., 2011; Diego et al., 2011). Due to the quaternary 
ammonium group in its chemical structure that is ionized at physiological pH, 
methylnaltrexone does not cross the blood-brain-barrier and so centrally mediated analgesia 
is not reversed (Bader et al., Diego et al., 2011).  
Methylnaltrexone has 8-fold and 120-fold higher binding affinity at the MOP receptor 
relative to the KOP and DOP receptors respectively (Bader et al., 2011). Following 
administration by the subcutaneous route at 0.15-5 mg/kg in humans, mean peak plasma 
concentrations of methylnaltrexone are observed at 0.5 h post-dosing and the elimination 
half-life is in the range 8-9 h (Rotshteyn et al., 2011). The mean bioavailability is high at 82% 
with minimal metabolism and so it has low potential for drug-drug interactions (Rotshteyn 
et al., 2011). 
Methylnaltrexone is approved by the FDA and the European Medicines Agency (EMA) to 
treat opioid induced constipation in patients with advanced disease where other laxative 
regimens have failed (Iskedjian et al., 2010; Bader et al., 2011). Methylnaltrexone causes 
laxation in at least 50% of patients in less than 24 h over the first two weeks of treatment 
without impairing analgesia or causing serious adverse events (Bader et al., 2011). 
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7.3 Oral naloxone 
Naloxone, (1S,5R,13R,17S)-10,17-dihydroxy- 4-(prop-2-en-1-yl)-12-oxa-4-azapentacyclo 
[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10-trien-14-one, is a non-selective opioid receptor 
antagonist (Lenz et al., 1986). In the clinical setting, parenteral naloxone is used to reverse 
life-threatening opioid agonist-induced respiratory depression (Diego et al., 2011). However, 
as naloxone crosses the blood-brain-barrier, it also reverses centrally mediated analgesia 
(Diego et al., 2011). 
After oral administration, the bioavailability of naloxone is very low at 2% due to extensive 
first-pass metabolism which makes it possible to obtain a highly localized opioid antagonist 
action in the gastrointestinal tract whilst sparing the centrally mediated opioid analgesic 
effects of oral oxycodone (Leppert, 2010; Diego et al., 2011). The negligible oral 
bioavailability of naloxone is exploited in an oral prolonged-release tablet that contains 
oxycodone in combination with naloxone in a fixed 2:1 ratio resulting in less constipation 
and less laxative consumption relative treatment with oxycodone alone (Leppert, 2010).   
The oxycodone plus naloxone oxycodone tablet is available in four tablet strengths; 5/2.5 
mg, 10/5 mg, 20/10 mg and 40/20 mg oxycodone/naloxone respectively (Leppert, 2010). 
8. Conclusion 
Moderate to severe acute and chronic pain continues to be managed with opioid analgesics 
according to the principles succinctly summarized by Steps 2 and 3 of the WHO 3-step 
Analgesic Ladder. Weak opioid analgesics are added to non-opioid analgesics for the 
management of moderate pain with adjuvants added if pain has a neuropathic component. 
For moderate to severe pain, strong opioid analgesics are recommended with the addition of 
non-opioids and adjuvants, as required.  
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1. Introduction 
In industrial nations, low back pain (lbp) is one of the leading causes of physical limitation. 
It is also a main source of incapacitation, suffering and expense. According to the national 
institute of neurological disorders and stroke in the US, LBP accounts for more sick leave 
and disability than any other medical condition. In Germany, life time prevalence of LBP 
reaches up to 84 %, with the highest rate for people aged between 35 and 55. According to 
the German Health Report of the year 2002, the costs of rehabilitation and early retirement 
amounted to more than 15 billion € , and direct and indirect cost of illness up to 26 billion 
EURO. Thus the effective management of low back pain is a major health and economic 
concern. 
In a minority of patients presenting for evaluation in a primary care setting, lbp can be 
reliably attributed to a specific underlying pathology, such as malignancy, vertebral 
compression fracture or inflammatory/infectious processes. The majority, 80-90%, of 
patients present primary or non-specific lbp. There is little documented knowledge of 
possible causes of non-specific lbp. Risk factors are probably related to genetic 
predisposition, lifestyle (e.g., overweight, lack of physical activity), physical strain and 
psychological distress. 
Opioid analgesics are well established in the treatment of severe pain conditions and have 
internationally gained a strong position as a potent daily pain treatment option. Many 
physicians are still apprehensive about the administration of opioids within a continuous 
therapy, due to potential drug abuse and possible adverse effects, such as impaired 
gastrointestinal functioning.  
To achieve a satisfactory balance between analgesia and side effects, the assessment and 
treatment of opioid side effects are fundamental aspects of the therapy. This may increase 
the likelihood of a favourable treatment outcome, potentially allow higher and more 
efficacious opioid doses, and improve quality of life by reducing other discomforting 
symptoms. Economic consequences of insufficiently treated chronic lbp and treatment of 
potential adverse drug effects also play a significant role from the society’s point of view. 
Additional expenses may include costs that emerge from additional obligatory treatments, 
hospitalization and work incapacity. 
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2. Primary objective 
The primary objective of this health services research study was to assess the health-related 
quality of life and the total costs (direct and indirect) of patients in Germany suffering from 
chronic back pain. Therapy with oxycodone + naloxone1 was compared to therapy with 
other strong opioids (WHO-step III opioids). 
Main aims are: 
 Health related quality of life over a period of one year – patients on therapy with 
oxycodone + naloxone compared to therapy with other WHO-step III opioids. 
 Costs for the pain therapy and therapy of AE/ADR in in- and out-patients. 
 Patients’ inability to work, days off work compared between both cohorts. 
 The incidence of early retirement due to chronic back pain and the average age of these 
patients. 
3. Secondary objective 
The secondary objective of the study was to evaluate the data for effectiveness under daily 
routine conditions of the therapy with oxycodone + naloxone or other WHO-step III opioids 
(strong opioids). 
Main issues were: 
 The long-term effectiveness of treatment of chronic back pain under daily routine 
conditions with oxycodone + naloxone or other strong opioids (WHO-step III opioids). 
 Frequency of the administration of rescue-medication (drugs additionally taken once 
only, as an emergency treatment of pain) under therapy with oxycodone + naloxone 
compared to other strong opioids (WHO-step III opioids). 
4. Methods 
In order to portray the actual costs (“true costs”) incurred for patients suffering from 
chronic back pain, data had to be documented under daily routine conditions (“real-
world-design”). Therefore, a cohort study design was chosen. Two cohorts were observed: 
Patients in the first cohort were treated with oxycodone + naloxone (cohort 1). Patients in 
the second cohort were treated with another WHO-step III opioid (cohort 2). In 
accordance with the statistical analysis plan, each participating physician was asked to 
document five patients per cohort. Because of the non-interventional study design, 
individual site-specific imbalances due to the cohort recruitment will be discussed from a 
statistical point of view. 
4.1 Patient population 
Opioid-naive and opioid-pretreated female and male adults (> 18 years) who suffered 
from chronic back pain below the costal arch and above the gluteal groove, who require a 
round-a-clock-treatment with WHO-step III opioids, were considered. Patients with 
cancer pain, herniated vertebral disks, or pain caused by an accident, were excluded. 
Patients who recently started therapy with oxycodone + naloxone or another WHO-step 
III opioid were also considered, as well as patients, who were switched from a WHO-step 
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II to a WHO-step III opioid or from one WHO-step III opiod to another WHO. The  
change of therapy was not allowed to be correlated to the study. Consequently, patients 
treated with oxycodone + naloxone or other WHO-step III opioids were eligible for the 
study.  
For all patients, the summary of product characteristics (SPC) was considered with regard to 
patient’s safety and need to perform daily activities.  
Patients not treated according to the SPC were excluded from the study.  
4.2 Inclusion and exclusion criteria 
 Therapy with oxycodone + naloxone or another WHO-step III opioid was documented 
for all patients over an observation period of approximately twelve months, including 
prescription and administration of the medication (regular daily administration, period 
of administration). 
 Patients were informed about the study and agreed to participate by signing and dating 
the informed consent form. 
 Patients were able to comprehend the language as well as the contents of the study 
materials (patient information, informed consent form and patient questionnaires). 
 Patients suffered from chronic back pain below the costal arch and above the gluteal 
groove. 
 Patients with tumor pain, herniated vertebral disks, or pain caused by an accident, were 
excluded. 
 Patients were more than 18 years old. 
 oxycodone + naloxone or another WHO-step III opioids were not contraindicated. 
 Female patients were neither pregnant nor breastfeeding. 
Patients were excluded from the study if any of the following applied: 
 A contraindication to the planned treatment regime occurred. 
 The patient withdrew his/her consent to participate in the study. 
 Newly diagnosed pregnancy. 
 Administration of oxycodone + naloxone or another WHO-step III opioid was not in 
accordance with the specifications of the SPC. 
4.3 Duration and conduct of the study  
4.3.1 Study sites and number of patients 
200 general practitioners and orthopedics, some of them specializing in pain therapy, should 
be achieved to participate at in this nation-wide, multi-center, non-interventional study. As 
stated in the observational plan, the enrolment of 2,000 patients (10 patients per physician, 5 
patients per cohort) with chronic back pain was required to document patients at baseline 
(V1), after one week (V2), four weeks (V3), six months (V4) and after 12 months.  
4.3.2 Time schedule 
Screening and recruitment of the participating physicians were conducted by the Institute of 
Empirical Health Economics (IfEG) prior to the start of the study. IfEG CRAs started to visit 
the physicians´ medical centers in September 2008. Patients were enrolled by the physicians 
and observed for one year. Documentation started according to the project schedule after 
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approximately six months after the beginning of the observation period. The study-report 
was due three months after last patient last visit (LPLV). 
4.3.3 Patient information and informed consent form (ICF) 
Prior to their participation, patients had to sign the ICF. The patient information describes 
the objectives, contents and risks of the study. Furthermore, the patients were informed that 
withdrawal from the observational study was possible at any point in time without further 
consequences. The patient obtained a copy of the patient information and the ICF. The 
physician is obligated to keep the signed ICF records at least for 15 years. 
4.3.4 Documentation of treatment  
Socio-demographic data, the clinical variables regarding progress of the disease, as well as 
the treatment costs incurred for the attending physician were documented on standardized 
case report forms (CRF). All consultations during the observation period due to chronic 
back pain were documented. The consultations took place as they would within the scope of 
the treatment of chronic back pain and no study-specific visits were indicated. Physicians 
sent the completed CRF by postal service to IfEG. 
4.3.5 Documentation by patients 
During the observation period, patients actively participated in the documentation by 
completing standardized health-related quality of life questionnaires (SF-36 v2 Health 
Survey) at four points in time. Visits took place every quarter and the quality of life 
questionnaires were completed during the visits. 
Intensity of pain and stool consistency was recorded daily for the first four weeks, followed 
by recording every two weeks on patient diaries.  
The patients also completed standardized questionnaires regarding constipation and the 
pain intensity of the last seven days during each consultation. 
4.4 Variables  
The variables considered for this report are described in the following sections.  
4.4.1 Socio-demographic and administrative variables  
The following data were collected regarding at the first visit (V1): 
 gender 
 date of birth (month/year) 
 height 
 weight 
 ethnic group 
 patient’s ability to comprehend the patient information and informed consent 
 family status 
 educational school level and training level 
 status of occupation 
 status of ability to work (and correlation with chronic back pain) 
 exemption from additional payments 
 type of health insurance 
 physicians’ specialization and additional pain therapy qualifications 
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4.4.2 Clinical variables 
The following clinical data were collected at V1: 
 diagnosis of chronic back pain (back pain causing disease) 
 concomitant diseases 
 medical pre-treatment outside of pain therapy 
 assessment of previous pain therapy prior to enrolment (by physician and patient) 
 other disorders apart from pain indication experienced within the last week before the 
beginning of observational study (separately for opioid-naive patients and opioid-
pretreated patients) 
 previous and current drug therapy for chronic back pain treatment 
 change/adjustment/withdrawal of therapy with oxycodone + naloxone or another 
opioid of WHO-step III 
 dosage and application times of the therapy with oxycodone + naloxone or another 
opioid of WHO-step III 
 concomitant medication 
 rescue-medication 
 assessment of pain, intensity of pain and general mobility of the patient (patient  
diary) 
 average period of analgesia experienced by the patient 
4.4.3 Variables of costs 
The following variables of costs were included in the cost calculation. For all costs, a causal 
correlation to the underlying chronic back pain had to exist. Costs for the treatment of 
adverse events or adverse drug reactions were also included. 
 ambulatory treatment costs (consultations including house calls, emergency treatments 
and medical specialist consultation) contributable to chronic back pain 
 type (trade name and active ingredient) and amount (number of packages and package 
size) of prescribed and recommended drugs  
 non-medicinal therapies 
 inability to work within the last twelve months before the start and during the 
observation period 
 early retirement 
 reduction in earning capacity 
 hospitalizations 
 other medicinal interventions 
 remedies and medical devices 
 consultations at other physicians 
 emergency treatments 
 additional acquisitions or measures taken (e.g. conversion of an apartment) 
4.5 Quality of life questionnaires 
4.5.1 Quality of life questionnaires (SF-36 v2 Health Survey) 
The SF-36 is a multi-purpose, short-form health survey with 36 questions. It provides an 8-
scale profile of functional health and well-being scores, as well as a psychometrically-based 
physical and mental health summary and a preference-based health utility index. It is a 
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generic measure, as opposed to surveys that target a specific age, disease, or treatment 
group [16]. 
The taxonomy has three levels: (1) items; (2) eight scales with 2-10 items each; and (3) two 
summaries. All but one of the 36 items (self-reported health transition) are used to score the 
eight SF-36 scales. Each item is used in scoring only one scale. 
The SF-36 has the following composition: 
 Physical Functioning 
 Role-Physical 
 Physical Pain 
 General Health 
 Vitality 
 Social Functioning 
 Role-Emotional 
 Mental Health 
The calculations (pole reversal and recalibration of items, missing values, and 
transformation of scales) of the SF-36-subscales and the physical and mental summation 
scales are performed with the SSPS-program by Mogens Trab Damsgaard. The SSPS-
program is described in the SF-36 manual. The totals from the 8 subscales are subsequently 
transformed to a percentage scale (co-domain 0-100). Norm-based scoring (NBS) algorithms 
are introduced for all eight scales and employ a linear T-score transformation with mean = 
50 and standard deviation = 10. The weightings of subscales within summation scales are 
performed with the weight factor used in the American standard sample. 
The SF-36 was completed for V1, V3 (after 4 weeks), V4 (after 6 months) and V5 (after 12 
months). 
4.5.2 Brief Pain Inventory Short Form (BPI-SF) 
The Brief Pain Inventory is a standardized method applied for self assessment of pain and 
its outcomes in an abbreviated form. This inventory encompasses numeric rating scales for 
pain intensity and reduction in pain contributable to the treatment, as well as a graphic 
picture. Emphasise is placed on sensory pain components and the documentation of pain-
related impairments.  
The sum scale for pain intensity contains four questions: to most severe, minimum, and 
average pain severity experienced during the last 24 hours and at that moment (range 0-10 
points per questions, total range 0-40 points). An increase in point score implies an increase 
in pain.  
The sum scale for pain-related impairment consists of seven questions to self assessment of 
impairment in the daily routine (activity, mood, movement, occupation, relationships, sleep 
and vitality) within the last 24 hours (range 0-10 points per question, total range 0-70 
points). 
Cumulative values for pain intensity and pain-related impairment were calculated. An 
increase in cumulative values implies an increase in pain. 
The third factor evaluated pain relief due to the analgesic therapy expressed as a percentage 
from the baseline value.  
The BPI-SF was completed for V1 (beginning), V3 (after 4 weeks), V4 (after 6 months) and 
V5 (after 12 months). 
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4.6 Statistical analysis 
4.6.1 Data entry 
A data entry template for the complete documentation was designed by IfEG by using  
the program Oracle 11.1.06G. Data entry was conducted successively after CRFs were 
received. 
4.6.2 Handling of dropouts 
Patients were defined as dropouts if they were enrolled although the population criteria 
were not fulfilled, andif they did not receive any study-related medication. Dropouts were 
completely excluded from the effectiveness analysis. 
Withdrawal patients were defined as patients who also include those patients who 
discontinued the therapy with oxycodone + naloxone or another WHO-step III opioid before 
the end of the observation period, withdrew their consent, or who became pregnant during 
the observation period. These patients are included in the effectiveness and efficacy analysis 
and are not considered to be dropouts, unless the therapy with oxycodone + naloxone or 
another WHO-step III opioid was administered for less than three months 
4.6.3 Study population  
The following populations were defined before data analysis: 
 Safety-Population (SP): all patients who were included in the observational study and 
attended at least one follow-up visit 
 Intent-to-Treat-Population (ITT-P): all patients for whom at least one examination 
regarding effectiveness (pain and bowel function) was conducted 
 Per-Protocol-Population (PPP): all patients for whom all quarter and all BPI-SF 
assessment were completely documented  
For the Per-Protocol-Population, only the CRFs completed for the whole observation  
period were considered, whereas for the Intent-To-Treat-Population, all available data  
were considered. Data in this paper refer to safety-population and intent-to-treat population 
only. 
4.6.4 Statistical analysis 
The data analyses are conducted with the software PASW 18.0 for Windows, as well as  
MS-Excel 2007 and MS-Access 2007. The evaluation is descriptive, based on the character  
of the documentation. An inferential statistic is performed for the comparison of the 
cohorts. 
5. Analysis and results 
5.1 Description of the study population 
A total of 1.013 patients from 134 physicians were entered into the database (figure 1). 43 
patients had to be excluded from the analysis: Of these, 24 patients did not receive any 
study-related medication and for 19 patients the physicians did not complete documentation 
to the end of the study. Therefore, 970 patients were included in the safety population (SP) 
comprising 583 patients from the cohort “oxycodone + naloxone” (cohort 1) and 371 from 
the cohort “other WHO-step III opioids” (cohort 2). No cohort classification was possible for 
16 patients, because these patients did not take any strong opioid (oxycodone + naloxone or 
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other WHO-step III opioids). 560 cohort 1 and 364 cohort 2 patients were feasible for the 
Intent-To-Treat-Population. For the Per-Protocol-Population, 569 patients were included: 





Fig. 1. Organigram of the study population 
The majority of the patients were female (~60%) which refers to the epidemiological 
distribution in Germany within an aging population: the average age was around 64 years 
and by this most patients had been retired or were of least unable to work. Only 20% of the 




cohort 1 cohort 2 
 
 
N rate N rate p-value 
female 350 62,5% 221 60,7% 
P= 0,585 
male 210 37,5% 143 39,3% 
age 560 63,4 364 64,9 p = 0,084 
employed 121 21,6% 62 17,0% p = 0,088 
number of days 
off work                
12 months 
before inclusion 
81 75,0 40 95,4 p = 0,496 
Table 1. Gender and age of the population 
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Almost all patients were classified as caucasians, more than half of the patients were 
married and app. 50% had an educational level above secondary general school. Less than 
7% were ensured privately.  
At visit 1 924 days off work in the last year were documented for both cohorts (560 in cohort 
1). 17% of the included patients reported a reduction in earning capacity. 14,6% in cohort 1 
and 16,8% in cohort 2 had been retired early due to chronic back pain. 
Nearly 45% (!) of all patients reported a poor effectiveness of the applied pain therapies.  
During the course of the study both physicians and patients assessed a higher effectiveness 
increase in cohort 1 compared to cohort 2. This refers also to tolerability. 
5.2 Quality of life 
5.2.1 SF-36 





 cohort 1 cohort 2  




356 9,65 10,29 244 4,55 8,90 p < 0,001 
Fig. 2. Standardized physical health SF-36 (means) 
The difference between the physical health of cohort 1 compared to cohort 2 were 
significant for the periods V5>V3, V3>V1, V4 >V1 and V4>V1 but not for V4>V3 and 
V5>V4. The results for both cohorts indicate a continuous improvement, which was more 
pronounced in cohort 1. This result is also mirrored by the data on standardized mental 
health (Figure 3). 
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 cohort 1 cohort 2  
 number mean SD number mean SD p-value 
Standardized 
mental health 356 6,34 12,82 244 2,58 12,33 p < 0,001 
Fig. 3. Standardized mental health SF-36 (means) 
In total statistical power reached significant level for all SF-36 positions except “Role-
emotional” (Table 2). All items and positions of the SF-36 were in favour of the combination 
of oxycodone + naloxone.  
 
SF-36 Positions 
cohort 1 cohort 2 
p-value 
number mean SD number mean SD 
1 Physical function 392 23,09 29,79 272 8,52 26,36 < 0,001 
2 Role-physical 370 31,28 44,62 261 16,44 41,15 < 0,001 
3 Bodily Pain 379 25,66 25,97 263 11,97 19,10 < 0,001 
4 General health 375 13,32 22,64 257 6,16 17,76 < 0,001 
5 Vitality 376 16,21 22,64 261 5,77 18,69 < 0,001 
6 Social functioning 377 19,46 28,50 263 6,65 25,91 < 0,001 
7 Role-emotional 363 22,87 56,34 252 14,02 54,19 0,057 
8 Mental health 376 15,13 22,88 261 6,27 19,75 < 0,001 
Table 2. Summary of SF-36 positions  
5.2.2 Brief Pain Inventory Short Form (BPI-SF) 
The Brief Pain Inventory Short Form (BPI-SF) contains numeric rating scales for pain 
intensity and pain impairment as well as for pain relief. Fig. 4 shows the differences between 
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the total scores of pain intensity. Significant differences were found between cohort 1 and 
cohort 2 at V5, V4 and V3 compared to V1. Significant differences were also determined for 
the time periods V3 to V5 and V3 to V4. 
 
 
Fig. 4. Sum scale of pain intensity (means)  
Brief Pain Inventory (BPI-Shortform)  
Worst pain in the last 24 hours decreased in cohort 1 more over all periods than in cohort 2 
although worst pain was significantly higher in cohort 1 at baseline (V1). 
After 12 months (V5) both cohorts revealed highly significant differences (Fig. 5). 
 
 
Fig. 5. Worst pain in the last 24 hours (means) 
Brief Pain Inventory (BPI-Shortform) 
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Pain relief treatments or medications administered were also recorded. The patients had to 
mark the percentage that represents how much pain relief they have experienced  
(0%=no relief, 100%=complete relief). The pain relief of cohort 1 patients compared to cohort 
2 was significant at V1 (p < 0.001) and at V5 (p = 0.001). At visit 1 the pain relief on average 
amounted to 39.2 % in cohort 1 and to 46.02 % in cohort 2. At the end of the study (V5) the 
averaged pain relief was 64.2 % in cohort 1 and 58.9 % in cohort 2 (Fig. 6). 
 
 
Fig. 6. Pain relief (means) 
Brief Pain Inventory (BPI-Shortform) 
6. Costs 
Annual average direct costs of 2,403.45 € accumulated per patient in cohort 1 and 2,772.98 € per 
patient in cohort 2. The difference in annual average costs was not significant (p = 0.195). The 
approximately 13 % lower amount incurred in cohort 1 can be attributed to drug expenses, 
emergency treatment and hospitalisation/rehabilitation. The differences between both cohorts 
were significant for co-medication (p < 0.001) and rescue-medication (p = 0.021) (Tab. 3). 
 
cost category  total  cohort 1 cohort 2 
out-patient treatment 477,03 € 481,79 € 469,71 € 
drug expenses 1.653,73 € 1.532,69 € 1.839,93 € 
     oxycodone + naloxone 812,17 € 1.270,16 € 107,57 € 
     opioid WHO-III 611,68 € 65,04 € 1.452,67 € 
     comedication 211,51 € 181,83 € 257,16 € 
     rescue medication 18,37 € 15,67 € 22,54 € 
remedies 34,20 € 31,07 € 39,03 € 
non-medical therapy 54,95 € 53,11 € 57,79 € 
emergency treatments 64,76 € 52,57 € 83,52 € 
hospitalization/rehabilitation 264,35 € 252,22 € 283,01 € 
direct costs 2.549,02 € 2.403,45 € 2.772,98 € 
Table 3. Direct costs categories 
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Fig. 7 shows the indirect costs for the cohorts. Higher averaged indirect costs per patient 
were calculated for cohort 2. The higher indirect costs resulted from higher costs due to 
reduction in earning capacity. Approximately 26 % less costs were documented for cohort 1 
patients than for cohort 2 patients in this part of indirect costs. 
 
 
Fig. 7. Indirect cost categories for the cohorts 
The incremental cost-effectiveness ratio (ICER) represents the ratio between the differences 
in treatment costs (ΔC) and treatment effects (ΔE) for cohort OXN and cohort “other strong 
opioids”. It presents the cost of an additional effect unit. The ICER was tested against the 
main parameters (Tab. 4). 
 
 CER  CER
direct costs (C) --- -370 €
SF-36 (physical health) 9.65 249 € 4.55 610 € -72 € -370 €/5.10
SF-36 (mental health) 6.34 379 € 2.58 1,074 € -98 € -370 €/3.76
BPI-SF (pain relief) 24.14 100 € 12.44 223 € -32 € -370 €/11.7
CER: Cost-Effectiveness Ratio; ICER: Incremental Cost-Effectiveness Ratio
parameter
cohort 1 cohort 2
ICER C/E
2,403 € 2,773 €
 
Table 4. Cost-effectiveness ratio  
The following formula was used for the calculation of the incremental cost-effectiveness 
ratio: 
ICER (costs of cohort OXN)-(costs  of cohort "other  strong  opioids") cost difference
(effect of cohort OXN)-(effect  of cohort "other  strong  opioids") effect difference
   
C C CICER
E E E
cohort OXN cohort "other  strong  opioids"





Negative values were calculated for the ICER of the main parameters, which implies more 
effectiveness at a lower price for the alternative therapy with Oxycodone + Naloxone (Fig. 8). 
 
Pain Management – Current Issues and Opinions 
 
318 
Pain relief treatments or medications administered were also recorded. The patients had to 
mark the percentage that represents how much pain relief they have experienced  
(0%=no relief, 100%=complete relief). The pain relief of cohort 1 patients compared to cohort 
2 was significant at V1 (p < 0.001) and at V5 (p = 0.001). At visit 1 the pain relief on average 
amounted to 39.2 % in cohort 1 and to 46.02 % in cohort 2. At the end of the study (V5) the 
averaged pain relief was 64.2 % in cohort 1 and 58.9 % in cohort 2 (Fig. 6). 
 
 
Fig. 6. Pain relief (means) 
Brief Pain Inventory (BPI-Shortform) 
6. Costs 
Annual average direct costs of 2,403.45 € accumulated per patient in cohort 1 and 2,772.98 € per 
patient in cohort 2. The difference in annual average costs was not significant (p = 0.195). The 
approximately 13 % lower amount incurred in cohort 1 can be attributed to drug expenses, 
emergency treatment and hospitalisation/rehabilitation. The differences between both cohorts 
were significant for co-medication (p < 0.001) and rescue-medication (p = 0.021) (Tab. 3). 
 
cost category  total  cohort 1 cohort 2 
out-patient treatment 477,03 € 481,79 € 469,71 € 
drug expenses 1.653,73 € 1.532,69 € 1.839,93 € 
     oxycodone + naloxone 812,17 € 1.270,16 € 107,57 € 
     opioid WHO-III 611,68 € 65,04 € 1.452,67 € 
     comedication 211,51 € 181,83 € 257,16 € 
     rescue medication 18,37 € 15,67 € 22,54 € 
remedies 34,20 € 31,07 € 39,03 € 
non-medical therapy 54,95 € 53,11 € 57,79 € 
emergency treatments 64,76 € 52,57 € 83,52 € 
hospitalization/rehabilitation 264,35 € 252,22 € 283,01 € 
direct costs 2.549,02 € 2.403,45 € 2.772,98 € 
Table 3. Direct costs categories 
Pain Management and Costs of a  
Combination of Oxycodone + Naloxone in Low Back Pain Patients 
 
319 
Fig. 7 shows the indirect costs for the cohorts. Higher averaged indirect costs per patient 
were calculated for cohort 2. The higher indirect costs resulted from higher costs due to 
reduction in earning capacity. Approximately 26 % less costs were documented for cohort 1 
patients than for cohort 2 patients in this part of indirect costs. 
 
 
Fig. 7. Indirect cost categories for the cohorts 
The incremental cost-effectiveness ratio (ICER) represents the ratio between the differences 
in treatment costs (ΔC) and treatment effects (ΔE) for cohort OXN and cohort “other strong 
opioids”. It presents the cost of an additional effect unit. The ICER was tested against the 
main parameters (Tab. 4). 
 
 CER  CER
direct costs (C) --- -370 €
SF-36 (physical health) 9.65 249 € 4.55 610 € -72 € -370 €/5.10
SF-36 (mental health) 6.34 379 € 2.58 1,074 € -98 € -370 €/3.76
BPI-SF (pain relief) 24.14 100 € 12.44 223 € -32 € -370 €/11.7
CER: Cost-Effectiveness Ratio; ICER: Incremental Cost-Effectiveness Ratio
parameter
cohort 1 cohort 2
ICER C/E
2,403 € 2,773 €
 
Table 4. Cost-effectiveness ratio  
The following formula was used for the calculation of the incremental cost-effectiveness 
ratio: 
ICER (costs of cohort OXN)-(costs  of cohort "other  strong  opioids") cost difference
(effect of cohort OXN)-(effect  of cohort "other  strong  opioids") effect difference
   
C C CICER
E E E
cohort OXN cohort "other  strong  opioids"





Negative values were calculated for the ICER of the main parameters, which implies more 
effectiveness at a lower price for the alternative therapy with Oxycodone + Naloxone (Fig. 8). 
 




Fig. 8. Cost-effectiveness area  
7. Conclusion 
As a final conclusion it can be stated that patients of cohort 1 (oxycodone  + naloxone) 
experienced a better quality of life and less back pain after twelve months compared to 
patients of cohort 2 (other WHO-step III opioids). According to the cost effectiveness-analysis 
therapy with oxycodone + naloxone is more effective and generates lower costs than cohort 2. 
These results and findings should be confirmed by a randomized, blinded controlled trial. 
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1. Introduction 
Cancer pain treatment is based on the analgesic ladder, established in 1986 by the World 
Health Organization (WHO; see Fig. 1) (WHO, 1996). Cancer pain management guidelines 
in Europe are based on EAPC (European Association for Palliative Care) recommendations. 
Oral morphine is recommended by the Expert Working Group of the EAPC at the third step 
of the WHO analgesic ladder, which comprises additional opioids (i.e. oxycodone, fentanyl, 
buprenorphine, methadone, and hydromorphone) for the treatment of moderate-to-severe 
pain intensity (Hanks et al., 2001). The use of an analgesic ladder should be individualized 
with an appropriate application of supportive drugs (laxatives and antiemetics) for the 
prevention and treatment of opioid adverse effects (Leppert, 2009a) and 
nonpharmacological measures, such as radiotherapy and invasive procedures (nerve 
blockades and neurolytic blocks) (Eidelman et al., 2007). 
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Fig. 1. World Health Organization three-step analgesic ladder 
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Each step of the WHO analgesic ladder: nonopioids (analgesics for mild pain, step 1 
analgesics), weak opioids (analgesics for mild to moderate pain, step 2 opioid analgesics), 
and strong opioids (opioids for moderate-to-severe pain intensity, step 3 opioid analgesics) 
may be accompanied with adjuvant analgesics (coanalgesics), which can enhance opioid 
analgesia. In patients with bone pain, opioids may be combined with non-steroidal anti-
inflammatory drugs (NSAIDs), glucocorticoids, and bisphosphonates along with local or 
systemic radiotherapy (Lussier et al., 2004). In patients with very severe neuropathic pain, a 
combination of opioids and NMDA (N-methyl D-aspartate)-receptor antagonists (e.g. 
ketamine) are recommended (Leppert, 2010a). Patients with neuropathic pain along with 
opioids may also receive anticonvulsants, and antidepressants (Bennett, 2011). Other drug 
groups used in patients with neuropathic pain component comprise local anesthetics and 
antiarrhytmics (Freynhagen & Bennett, 2009). Opioid analgesics should be supplemented 
with spasmolytics in patients with visceral colicky pain, especially in the course of bowel 
obstruction (Ripamonti et al., 2008). 
2. Opioids for mild to moderate pain (weak opioids, step 2 opioid analgesics) 
2.1 Tramadol 
Tramadol displays opioid properties and acts on neurotransmission of noradrenalin and 
serotonin. Both enantiomers act synergistically and improve analgesia without increasing 
adverse effects. Tramadol is metabolized in the liver and excreted by the kidneys. The main 
metabolite is O-desmethyltramadol (M1), which displays analgesic activity with a higher 
affinity to μ-opioid receptors than the parent compound; (+)-M1 has 300 to 400 times greater 
affinity to μ-opioid receptors than tramadol and (-)-M1 mainly inhibits noradrenalin 
reuptake. Apart from O,N-didesmethyltramadol (M5, which has weak analgesic activity) 
and M1, other metabolites are inactive (Leppert and Mikolajczak, 2011). The elimination 
half-life of tramadol is 5 to 6 hours and that if M1 is 8 hours. During oral administration, 
90% of tramadol is excreted by the kidneys and 10% in feces. Patients with renal impairment 
show a decreased excretion of tramadol and M1. In patients with advanced cirrhosis, there 
is a decrease in tramadol metabolism with decrease of hepatic clearance and increase in 
blood serum levels. In these patients, elimination half-life is increased 2.5-fold. The starting 
dose of immediate-release (IR) tramadol is 25 to 50 mg every 4 to 6 hour and that of 
controlled-release (CR) tablets or capsules is 50 to 100 mg twice daily; the daily dose should 
not exceed 400 mg (Dickman, 2007). 
Patients devoid of CYP2D6 activity (poor metabolizers) need a tramadol dose higher by 30% 
than those with normal CYP2D6 activity (extensive metabolizers) (Stamer et al., 2003). 
Tramadol analgesia depends on CYP2D6 genotype, with less analgesia in poor metabolizers 
being associated with lack of (+)-M1 formation (Stamer et al., 2007). Genotyping is helpful in 
patients with duplication of CYP2D6 gene (ultrarapid metabolizers [UM]) who are at greater 
risk to develop tramadol adverse effects. Tramadol metabolism through CYP2D6 may cause 
interactions with drugs inhibiting this enzyme (eg, cimetidine and ranitidine). 
Serotonin syndrome has been reported in patients taking selective serotonin reuptake 
inhibitors (SSRIs) in conjunction with tramadol or opioids (Gnanadesigan et al., 2005). SSRIs 
(eg, fluoxetine, paroxetine, and, to less extent, sertraline) used in conjunction with tramadol 
may cause serotonin syndrome because SSRIs inhibit tramadol metabolism and increase 
serotonin level; generally, they should not be coadministered with tramadol. Serotonin 
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syndrome may appear with monoamine oxidase (MAO) inhibitors, olanzapine, risperidone, 
venlafaxine and mirtazapine (Davies and Glare, 2009).  
The inhibition of tramadol metabolism to (+)M1 may attenuate tramadol analgesia.  
For example, coadministration of ondansetron (selective 5-HT3 [hydroxytryptamine] 
receptor antagonist) blocks spinal 5-HT3 receptors and competitively inhibits CYP2D6 
although recent studies did not confirm such interaction (Rauers et al., 2010). Tramadol 
analgesia also may be impaired by coadministration of carbamazepine, which accelerates 
tramadol and M1 metabolism. Concomitant administration of tricyclic antidepressants 
increases the risk of seizures. Tramadol should be avoided in patients with history of 
epilepsy. In rats and mice, concomitant administration of tramadol and β-blocker and the 5-
HT1A/1B antagonist pindolol enhances analgesia (Leppert, 2009b). 
Respiratory depression is rare in the chronic use of tramadol. When it does occur, 
respiratory depression is connected with the opioid mode of tramadol action, so naloxone 
should be administered. For example, respiratory depression was reported in a cancer 
patient with renal impairment (creatinine clearance 30 mL/min) and with UM genotype 
after renal carcinoma resection. As respiratory symptoms appeared more than 10 hours after 
the first tramadol dose, the accumulation of M1 was the cause. The patient recovered after 
intravenous (IV) naloxone bolus administration (0.4 mg). This case highlights that tramadol 
should not be prescribed in patients with UM genotype and renal impairment (Stamer et al., 
2008).  
2.2 Codeine 
Codeine is a methylated morphine derivative that is found naturally, along with morphine, 
in the poppy seed. Codeine displays analgesic and antitussive activity. Codeine is available 
as IR and CR formulations but also in the form of paracetamol combined preparations. IR 
codeine is administered every 4-6 h in chronic pain with a starting single dose of about  
30 mg. The daily doses of dihydrocodeine and codeine usually do not exceed 240 mg and 
300 mg, respectively; when these analgesics are ineffective, opioids for moderate-to-severe 
pain (strong opioids) are introduced. 
Codeine is metabolized in the liver and its bioavailability is 30% to 40% after oral 
administration. After oral administration of codeine, maximal plasma concentration is 
attained within 1 to 2 hours with plasma half-life of 2.5 to 3.5 hours and analgesia 
maintained for 4 to 6 hours (IR formulations). Codeine is partially metabolized to morphine 
and its metabolites and to codeine metabolites norcodeine (NORC) and codeine-6-
glucuronide (C-6-G) (Lötsch et al., 2006). The analgesic effect of codeine is about equal to 
1/10th of morphine analgesia. Polymorphism of CYP2D6 is responsible for the formation of 
morphine, and its metabolites may affect codeine analgesia. Other codeine metabolites, C-6-
G predominantly, also display analgesic activity and contribute to codeine analgesia (Vree  
et al., 2000). In healthy volunteers, codeine is metabolized to C-6-G (81.0% ± 9.3%), NORC 
(2.16% ± 1.44%), morphine (0.50% ± 0.39%), morphine-3-glucuronide (M-3-G; 2.10% ± 
1.24%), morphine-6-glucuronide (M-6-G; 0.80% ± 0.63%), and normorphine (NORM; 2.44% ± 
2.42%). The half-life of codeine is 1.47 hours ± 0.32 hours, and that of C-6-G is 2.75 hours ± 
0.79 hours. The plasma AUC of C-6-G is about tenfold higher than that of codeine. Protein 
binding of codeine and C-6-G in vivo is 56.1% ± 2.5% and 34.0% ± 3.6%, respectively (Vree & 
Verwey-van Wissen, 1992). 
Lötsch et al. explored the contributions from codeine and its metabolites to central nervous 
analgesic effects independent from O-demethylation of codeine to morphine. A 
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patients with duplication of CYP2D6 gene (ultrarapid metabolizers [UM]) who are at greater 
risk to develop tramadol adverse effects. Tramadol metabolism through CYP2D6 may cause 
interactions with drugs inhibiting this enzyme (eg, cimetidine and ranitidine). 
Serotonin syndrome has been reported in patients taking selective serotonin reuptake 
inhibitors (SSRIs) in conjunction with tramadol or opioids (Gnanadesigan et al., 2005). SSRIs 
(eg, fluoxetine, paroxetine, and, to less extent, sertraline) used in conjunction with tramadol 
may cause serotonin syndrome because SSRIs inhibit tramadol metabolism and increase 
serotonin level; generally, they should not be coadministered with tramadol. Serotonin 
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syndrome may appear with monoamine oxidase (MAO) inhibitors, olanzapine, risperidone, 
venlafaxine and mirtazapine (Davies and Glare, 2009).  
The inhibition of tramadol metabolism to (+)M1 may attenuate tramadol analgesia.  
For example, coadministration of ondansetron (selective 5-HT3 [hydroxytryptamine] 
receptor antagonist) blocks spinal 5-HT3 receptors and competitively inhibits CYP2D6 
although recent studies did not confirm such interaction (Rauers et al., 2010). Tramadol 
analgesia also may be impaired by coadministration of carbamazepine, which accelerates 
tramadol and M1 metabolism. Concomitant administration of tricyclic antidepressants 
increases the risk of seizures. Tramadol should be avoided in patients with history of 
epilepsy. In rats and mice, concomitant administration of tramadol and β-blocker and the 5-
HT1A/1B antagonist pindolol enhances analgesia (Leppert, 2009b). 
Respiratory depression is rare in the chronic use of tramadol. When it does occur, 
respiratory depression is connected with the opioid mode of tramadol action, so naloxone 
should be administered. For example, respiratory depression was reported in a cancer 
patient with renal impairment (creatinine clearance 30 mL/min) and with UM genotype 
after renal carcinoma resection. As respiratory symptoms appeared more than 10 hours after 
the first tramadol dose, the accumulation of M1 was the cause. The patient recovered after 
intravenous (IV) naloxone bolus administration (0.4 mg). This case highlights that tramadol 
should not be prescribed in patients with UM genotype and renal impairment (Stamer et al., 
2008).  
2.2 Codeine 
Codeine is a methylated morphine derivative that is found naturally, along with morphine, 
in the poppy seed. Codeine displays analgesic and antitussive activity. Codeine is available 
as IR and CR formulations but also in the form of paracetamol combined preparations. IR 
codeine is administered every 4-6 h in chronic pain with a starting single dose of about  
30 mg. The daily doses of dihydrocodeine and codeine usually do not exceed 240 mg and 
300 mg, respectively; when these analgesics are ineffective, opioids for moderate-to-severe 
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Codeine is metabolized in the liver and its bioavailability is 30% to 40% after oral 
administration. After oral administration of codeine, maximal plasma concentration is 
attained within 1 to 2 hours with plasma half-life of 2.5 to 3.5 hours and analgesia 
maintained for 4 to 6 hours (IR formulations). Codeine is partially metabolized to morphine 
and its metabolites and to codeine metabolites norcodeine (NORC) and codeine-6-
glucuronide (C-6-G) (Lötsch et al., 2006). The analgesic effect of codeine is about equal to 
1/10th of morphine analgesia. Polymorphism of CYP2D6 is responsible for the formation of 
morphine, and its metabolites may affect codeine analgesia. Other codeine metabolites, C-6-
G predominantly, also display analgesic activity and contribute to codeine analgesia (Vree  
et al., 2000). In healthy volunteers, codeine is metabolized to C-6-G (81.0% ± 9.3%), NORC 
(2.16% ± 1.44%), morphine (0.50% ± 0.39%), morphine-3-glucuronide (M-3-G; 2.10% ± 
1.24%), morphine-6-glucuronide (M-6-G; 0.80% ± 0.63%), and normorphine (NORM; 2.44% ± 
2.42%). The half-life of codeine is 1.47 hours ± 0.32 hours, and that of C-6-G is 2.75 hours ± 
0.79 hours. The plasma AUC of C-6-G is about tenfold higher than that of codeine. Protein 
binding of codeine and C-6-G in vivo is 56.1% ± 2.5% and 34.0% ± 3.6%, respectively (Vree & 
Verwey-van Wissen, 1992). 
Lötsch et al. explored the contributions from codeine and its metabolites to central nervous 
analgesic effects independent from O-demethylation of codeine to morphine. A 
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pharmacokinetic/pharmacodynamic fit of the miotic effects by use of morphine as the only 
active compound was most significantly (P < 0.0001) improved when C-6-G as a second 
active moiety was added. CYP2D6-dependent formation of morphine does not explain 
exclusively the central nervous effects of codeine, and C-6-G is the most likely additional 
active moiety with possible contribution of NORC and the parent compound (Lötsch et al., 
2006). 
Gasche et al. depicted a patient who received oral codeine in a daily dose of 75 mg (25 mg 
three times a day) and who, after 4 days of treatment, experienced respiratory depression. 
The patient recovered after IV administration of naloxone (0.4 mg). The cause of the 
symptoms was CYP2D6 UM phenotype. The patient was concomitantly treated with 
clarithromycin and voriconazole, both known inhibitors of CYP3A4. This together with 
CYP2D6 gene duplication led to increased morphine formation. Blood concentrations of M-
3-G and M-6-G were substantially elevated, also due to renal failure (Gasche et al., 2004). 
Recent reports (Kircheiner et al., 2007; Voronov et al., 2007) indicate that there is a significant 
risk of respiratory depression in infants whose mothers with CYP2D6 UM and 
UGT2B7•2/•2 genotypes taking codeine during breastfeeding (Madadi et al., 2009b). 
Guidelines for maternal codeine use during breastfeeding were issued in Canada (Madadi et 
al., 2009a) but it seems safer not to use codeine and substitute it with other analgesics in this 
patient group. Apart from morphine glucuronides, codeine and its metabolites (C-6-G and 
NORC) also contribute to codeine analgesic effects (Lötsch et al., 2006). 
2.3 Dihydrocodeine 
Dihydrocodeine (DHC) is a semi synthetic analogue of codeine. Apart from analgesic and 
antitussive activity, DHC also is used in the treatment of opioid addiction. After 
subcutaneous (sc) administration of DHC, 30 mg, analgesia is similar to that induced by 
10 mg of morphine. After parenteral administration, DHC is twice as potent as codeine. 
Bioavailability of DHC after oral administration is 20%, which indicates that its analgesia 
after oral administration is slightly stronger than that of codeine (bioavailability after oral 
administration equals 30%–40%). After oral administration of DHC, the maximal serum 
concentration appears after 1.7 hours, plasma half-life varies 3.5 to 5.5 hours, and 
analgesia lasts 4-6 hours. DHC pharmacokinetics was assessed in 12 extensive 
metabolizers of CYP2D6 (Ammon et al., 1999). They received a single oral DHC dose of 60 
mg, then after 60 hours, they were treated for 3 days with 60 mg dosed twice daily; for the 
next 3 days with 90 mg twice daily; and for 3 subsequent days 120 mg twice daily. In the 
60 to 120 mg DHC dose range, pharmacokinetics of DHC and dihydromorphine (DHM) 
displayed linear characteristics: area under the curve (AUC), c max (maximum serum 
concentration), and cssmin (minimum serum concentration at steady state) for both 
compounds increased depending on the drug dose (Rowell et al., 1983). Even though 
DHM displays higher affinity (about 100-fold) to the µ-opioid receptors and exhibits 
higher analgesic activity in comparison to the parent compound, the role of DHM and its 
glucuronides in DHC analgesia has not been unequivocally established. The starting dose 
of IR DHC is usually 30 mg every 4 to 6 hours, and that of CR tablets is 60 mg twice daily 
(Leppert, 2010b). 
Renal clearance and the clearance to DHC metabolites, glucuronidation, and O-
demethylation to dihydrocodeine-6-glucuronide (DHC-6-G) and DHM, respectively, are not 
dose dependent, which indicates that metabolism and excretion of DHC and its metabolites 
are also not dose dependent. Moreover, the ratio of DHC to DHM for AUC does not change 
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depending on the dose, which suggests a lack of saturation effect of the O-demethylation 
process of DHC to DHM depending on CYP2D6 in patients normally metabolizing the 
substrates of this enzyme. Pharmacokinetic parameters were similar after single and 
multiple doses of 60 mg of DHC (Ammon et al., 1999). Single-dose and multiple-dose 
pharmacokinetics of IR and CR DHC formulations provide support for a twice-daily dosage 
schedule of CR DHC. DHC is metabolized in the liver to main metabolites: DHM, DHC-6-G, 
and nordihydrocodeine (NORDHC). NORDHC is further glucuronidated to NORDHC-6-
glucuronide and O-demethylated to nordihydromorphine (NDHM). DHM undergoes 
glucuronidation to dihydromorphine-3-glucuronide (DHM-3-G) and dihydromorphine-6-
glucuronide (DHM-6-G) and N-demethylation to NDHM. It may be concluded that DHC 
undergoes the first pass effect after oral administration, which is connected with the 
formation of significantly higher amount of metabolites after oral than after parenteral 
administration (Rowell et al., 1983). Studies performed to date (Schmidt et al., 2003; Webb et 
al., 2001) indicate that DHC analgesia is independent of CYP2D6 activity (Leppert and 
Majkowicz, 2010). 
3. Opioids for moderate to severe pain (strong opioids, step 3 opioid 
analgesics) 
3.1 Morphine 
Morphine is the standard drug for the treatment of moderate to severe cancer pain and is a 
comparator for other strong opioids (Caraceni et al., 2011). This is predominantly due to 
large clinical experience and different routes of morphine administration (eg, oral, SC, IV, 
intrathecal, topical). Morphine is a hydrophilic opioid and a pure opioid agonist that acts 
predominantly through the activation of µ-opioid receptors (Flemming, 2010). Plasma half-
life of IR formulations equals 2 to 3 hours and the bioavailability after oral morphine 
administration equals about 30% to 40%. Morphine undergoes glucuronidation; thus, there 
is little risk of pharmacokinetic interactions with other drugs. 
The active metabolite responsible for analgesia is morphine-6-glucuronide (M-6-G). The 
accumulation of morphine and M-6-G may cause nausea and vomiting, sedation, and 
finally, respiratory depression. Morphine-3-glucuronide (M-3-G) is devoid of analgesic 
properties but may be responsible for neurotoxic effects and opioid hyperalgesia 
(paradoxical pain) (Gretton & Riley, 2008). The main drawback of morphine is the fact that 
M-3-G and M-6-G may accumulate especially in patients with renal impairment and renal 
failure, leading to possible intense adverse effects associated with accumulation of 
metabolites. In severe pain syndromes a change from oral to parenteral or intrathecal route 
of morphine administration may be beneficial. In case of renal problems, a switch from 
morphine to other opioids, such as fentanyl, methadone, or buprenorphine, is 
recommended. Similar to other opioids, morphine often causes constipation; therefore, the 
use of laxative prophylaxis is recommended. Common morphine adverse effects and 
possible management possibilities are showed in Table 1. 
Numerous oral CR formulations of morphine, designed for 12-hour and 24-hour 
administration, were developed (Ridgway et al., 2010). Local administration of morphine 
prevents systemic adverse effects. The starting daily dose of oral morphine is usually 20 to 
30 mg (for opioid-naïve patients) or 40 to 60 mg (for patients unsuccessfully treated with 
weak opioids) (Ripamonti et al., 2009). The dose of parenteral (SC or IV) morphine is one 
third of the morphine oral dose (Donnelly et al., 2002).  
 
Pain Management – Current Issues and Opinions 
 
324 
pharmacokinetic/pharmacodynamic fit of the miotic effects by use of morphine as the only 
active compound was most significantly (P < 0.0001) improved when C-6-G as a second 
active moiety was added. CYP2D6-dependent formation of morphine does not explain 
exclusively the central nervous effects of codeine, and C-6-G is the most likely additional 
active moiety with possible contribution of NORC and the parent compound (Lötsch et al., 
2006). 
Gasche et al. depicted a patient who received oral codeine in a daily dose of 75 mg (25 mg 
three times a day) and who, after 4 days of treatment, experienced respiratory depression. 
The patient recovered after IV administration of naloxone (0.4 mg). The cause of the 
symptoms was CYP2D6 UM phenotype. The patient was concomitantly treated with 
clarithromycin and voriconazole, both known inhibitors of CYP3A4. This together with 
CYP2D6 gene duplication led to increased morphine formation. Blood concentrations of M-
3-G and M-6-G were substantially elevated, also due to renal failure (Gasche et al., 2004). 
Recent reports (Kircheiner et al., 2007; Voronov et al., 2007) indicate that there is a significant 
risk of respiratory depression in infants whose mothers with CYP2D6 UM and 
UGT2B7•2/•2 genotypes taking codeine during breastfeeding (Madadi et al., 2009b). 
Guidelines for maternal codeine use during breastfeeding were issued in Canada (Madadi et 
al., 2009a) but it seems safer not to use codeine and substitute it with other analgesics in this 
patient group. Apart from morphine glucuronides, codeine and its metabolites (C-6-G and 
NORC) also contribute to codeine analgesic effects (Lötsch et al., 2006). 
2.3 Dihydrocodeine 
Dihydrocodeine (DHC) is a semi synthetic analogue of codeine. Apart from analgesic and 
antitussive activity, DHC also is used in the treatment of opioid addiction. After 
subcutaneous (sc) administration of DHC, 30 mg, analgesia is similar to that induced by 
10 mg of morphine. After parenteral administration, DHC is twice as potent as codeine. 
Bioavailability of DHC after oral administration is 20%, which indicates that its analgesia 
after oral administration is slightly stronger than that of codeine (bioavailability after oral 
administration equals 30%–40%). After oral administration of DHC, the maximal serum 
concentration appears after 1.7 hours, plasma half-life varies 3.5 to 5.5 hours, and 
analgesia lasts 4-6 hours. DHC pharmacokinetics was assessed in 12 extensive 
metabolizers of CYP2D6 (Ammon et al., 1999). They received a single oral DHC dose of 60 
mg, then after 60 hours, they were treated for 3 days with 60 mg dosed twice daily; for the 
next 3 days with 90 mg twice daily; and for 3 subsequent days 120 mg twice daily. In the 
60 to 120 mg DHC dose range, pharmacokinetics of DHC and dihydromorphine (DHM) 
displayed linear characteristics: area under the curve (AUC), c max (maximum serum 
concentration), and cssmin (minimum serum concentration at steady state) for both 
compounds increased depending on the drug dose (Rowell et al., 1983). Even though 
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(Leppert, 2010b). 
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depending on the dose, which suggests a lack of saturation effect of the O-demethylation 
process of DHC to DHM depending on CYP2D6 in patients normally metabolizing the 
substrates of this enzyme. Pharmacokinetic parameters were similar after single and 
multiple doses of 60 mg of DHC (Ammon et al., 1999). Single-dose and multiple-dose 
pharmacokinetics of IR and CR DHC formulations provide support for a twice-daily dosage 
schedule of CR DHC. DHC is metabolized in the liver to main metabolites: DHM, DHC-6-G, 
and nordihydrocodeine (NORDHC). NORDHC is further glucuronidated to NORDHC-6-
glucuronide and O-demethylated to nordihydromorphine (NDHM). DHM undergoes 
glucuronidation to dihydromorphine-3-glucuronide (DHM-3-G) and dihydromorphine-6-
glucuronide (DHM-6-G) and N-demethylation to NDHM. It may be concluded that DHC 
undergoes the first pass effect after oral administration, which is connected with the 
formation of significantly higher amount of metabolites after oral than after parenteral 
administration (Rowell et al., 1983). Studies performed to date (Schmidt et al., 2003; Webb et 
al., 2001) indicate that DHC analgesia is independent of CYP2D6 activity (Leppert and 
Majkowicz, 2010). 
3. Opioids for moderate to severe pain (strong opioids, step 3 opioid 
analgesics) 
3.1 Morphine 
Morphine is the standard drug for the treatment of moderate to severe cancer pain and is a 
comparator for other strong opioids (Caraceni et al., 2011). This is predominantly due to 
large clinical experience and different routes of morphine administration (eg, oral, SC, IV, 
intrathecal, topical). Morphine is a hydrophilic opioid and a pure opioid agonist that acts 
predominantly through the activation of µ-opioid receptors (Flemming, 2010). Plasma half-
life of IR formulations equals 2 to 3 hours and the bioavailability after oral morphine 
administration equals about 30% to 40%. Morphine undergoes glucuronidation; thus, there 
is little risk of pharmacokinetic interactions with other drugs. 
The active metabolite responsible for analgesia is morphine-6-glucuronide (M-6-G). The 
accumulation of morphine and M-6-G may cause nausea and vomiting, sedation, and 
finally, respiratory depression. Morphine-3-glucuronide (M-3-G) is devoid of analgesic 
properties but may be responsible for neurotoxic effects and opioid hyperalgesia 
(paradoxical pain) (Gretton & Riley, 2008). The main drawback of morphine is the fact that 
M-3-G and M-6-G may accumulate especially in patients with renal impairment and renal 
failure, leading to possible intense adverse effects associated with accumulation of 
metabolites. In severe pain syndromes a change from oral to parenteral or intrathecal route 
of morphine administration may be beneficial. In case of renal problems, a switch from 
morphine to other opioids, such as fentanyl, methadone, or buprenorphine, is 
recommended. Similar to other opioids, morphine often causes constipation; therefore, the 
use of laxative prophylaxis is recommended. Common morphine adverse effects and 
possible management possibilities are showed in Table 1. 
Numerous oral CR formulations of morphine, designed for 12-hour and 24-hour 
administration, were developed (Ridgway et al., 2010). Local administration of morphine 
prevents systemic adverse effects. The starting daily dose of oral morphine is usually 20 to 
30 mg (for opioid-naïve patients) or 40 to 60 mg (for patients unsuccessfully treated with 
weak opioids) (Ripamonti et al., 2009). The dose of parenteral (SC or IV) morphine is one 
third of the morphine oral dose (Donnelly et al., 2002).  
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Adverse effect Symptomatology Treatment Comments 
Gastric stasis Epigastric fullness, nausea 
Metoclopramide 10 mg 
t.i.d. 
If the symptom persists a 
switch to alternative opioid 
may be useful 
Nausea/vomit





Promethazine or cyclizine 
25 mg t.i.d. 







Stool softener (macrogol 
or lactulose) plus 
stimulant (senna or 
bisacodyl). 
If no effect rectal 
measures or 
methylnaltrexone 
If no effect consider switch to 
transdermal fentanyl or 
transdermal buprenorphine 
Sedation Drowsiness 








antidepressants and co 
morbidities (hepatic/renal 










Reduce dose of 
morphine, haloperidol – 1 
– 2 mg b.d. or risperidone 
1 – 2 mg o.d.-b.d. 
If no improvement consider  
opioid switch 
Table 1. Common adverse effects of morphine and management possibilities 
3.2 Oxycodone 
Oral oxycodone is along with oral morphine recommended as a first choice opioid 
analgesic for the treatment of moderate to severe cancer-related pain (King et al., 2011). It 
is a semi synthetic thebaine derivative, a strong opioid that displays a significant affinity 
to κ-opioid receptors along with agonistic effect mediated by µ-opioid receptors. Limited 
cross-tolerance is observed between oxycodone and morphine in rats and in clinical 
studies (Maddocks et al, 1996). In comparison to morphine, oxycodone possesses lower 
affinity to µ-opioid receptors and similar lipid solubility. Oxycodone permeates the 
blood–brain barrier very quickly, which may explain its stronger analgesic effect in 
comparison to other opioids. Oxycodone does not display immunosuppressive effects in 
experimental studies. It has high oral bioavailability (60%–87%); the plasma half-life is 2 
to 3 hours after IV administration, 3 hours after treatment with IR oral solution, and 8 
hours after CR tablets. The bioavailability of rectal administration is similar to oral route 
(61%), but it displays greater variability. 
Oxycodone is metabolized in the liver primarily to noroxycodone through CYP3A4 and, 
to a much less extent, to oxymorphone via CYP2D6. Noroxycodone is metabolized to 
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noroxymorphone through CYP2D6, and oxymorphone is metabolized to 
noroxymorphone by CYP3A4. However, analgesia observed after oxycodone 
administration relies primarily on the parent compound. Noroxycodone has 17% of the 
potency of oxycodone. Oxymorphone, in spite of high affinity for µ-opioid receptors, is 
produced in very small amounts. Noroxymorphone is produced in a significant amount 
and displays significant affinity for opioid receptors. However, the blood–brain barrier is 
extremely impermeable to noroxymorphone; thus, its role in analgesia is negligible. Low 
blood–brain barrier permeability is also characteristic of noroxycodone and oxymorphone 
(Leppert, 2010c). 
In patients with liver cirrhosis and hepatic diseases, the oxycodone dose should be reduced 
by half. Oxycodone is excreted through the kidneys. In patients with renal insufficiency, the 
oxycodone dose also should be reduced. In patients with renal failure, the oxycodone half-
life is prolonged and ranges from 1.8 to 26 hours. The elimination of noroxycodone and 
oxymorphone also is impaired in patients with renal failure. CYP2D6 polymorphism 
probably does not influence oxycodone analgesia and adverse effects. Sertraline minimally 
inhibits CYP2D6 and intensifies adverse effects of oxycodone (eg, hallucinations, tremors), 
whereas fluoxetine and quinidine (significant CYP2D6 inhibitors) do not intensify 
oxycodone adverse effects. Oxycodone reduces oral bioavailability of cyclosporine by half. 
In healthy patients, rifampin, a CYP3A4 inducer, greatly decreased oral and IV oxycodone 
AUC by 86% and 53%, respectively (P < 0.001), and modestly reduced analgesia and 
increased plasma metabolite-to–parent compound ratios for noroxycodone and 
noroxymorphone (P < 0.001) (Nieminen et al., 2009). A pharmacodynamic interaction of 
oxycodone with other drugs acting on the central nervous system, such as benzodiazepines, 
neuroleptics, and antidepressants, may intensify oxycodone adverse effects, especially 
sedation, and respiratory depression may be intensified in the case of patients who are more 
sensitive to opioids. 
3.3 Hydromorphone 
Oral hydromorphone is an alternative to oral morphine and oral oxycodone as a first choice 
opioid analgesic for the treatment of moderate to severe cancer pain (Pigni et al, 2011). 
Hydromorphone has about 5 to 10 times more potent analgesic effect than morphine and 
similar pharmacodynamic properties. Hydromorphone analgesia is mainly due to µ-opioid–
receptor agonist effects; it also features some affinity for δ- but not for κ-opioid receptors 
(Murray & Hagen, 1995). After hydromorphone administration, analgesia lasts for about 4 
to 6 hours and the plasma half-life is about 2.5 hours; sustained-release oral preparations 
provide analgesia for 12-24 hours (Gardner-Nix & Mercadante, 2010). 
The drug is metabolized mainly to hydromorphone-3-glucuronide that is devoid of 
analgesic activity and may accumulate in patients with renal failure; it may induce 
neurotoxic adverse effects to larger extent than the respective morphine metabolite 
(morphine-3-glucuronide) (Wright et al., 2001). Hydromorphone in small amount is also 
metabolized to 6-hydroxy-hydromorphone, but its role is unknown. Due to glucuronidation, 
the risk of hydromorphone pharmacokinetic interactions with other drugs seems to be low 
(Sarhill et al., 2001). Adverse effects are similar to those of morphine; however, 
hydromorphone less frequently induces nausea and vomiting, constipation, itching, and 
probably more slowly develops tolerance to analgesia (Wirz et al., 2008). In comparative 
studies conducted in cancer patients with pain hydromorphone displays similar analgesic 
efficacy to morphine (Miller et al., 1999) and oxycodone (Hagen and Babul, 1997). 
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noroxymorphone through CYP2D6, and oxymorphone is metabolized to 
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by half. Oxycodone is excreted through the kidneys. In patients with renal insufficiency, the 
oxycodone dose also should be reduced. In patients with renal failure, the oxycodone half-
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oxycodone adverse effects. Oxycodone reduces oral bioavailability of cyclosporine by half. 
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Hydromorphone has about 5 to 10 times more potent analgesic effect than morphine and 
similar pharmacodynamic properties. Hydromorphone analgesia is mainly due to µ-opioid–
receptor agonist effects; it also features some affinity for δ- but not for κ-opioid receptors 
(Murray & Hagen, 1995). After hydromorphone administration, analgesia lasts for about 4 
to 6 hours and the plasma half-life is about 2.5 hours; sustained-release oral preparations 
provide analgesia for 12-24 hours (Gardner-Nix & Mercadante, 2010). 
The drug is metabolized mainly to hydromorphone-3-glucuronide that is devoid of 
analgesic activity and may accumulate in patients with renal failure; it may induce 
neurotoxic adverse effects to larger extent than the respective morphine metabolite 
(morphine-3-glucuronide) (Wright et al., 2001). Hydromorphone in small amount is also 
metabolized to 6-hydroxy-hydromorphone, but its role is unknown. Due to glucuronidation, 
the risk of hydromorphone pharmacokinetic interactions with other drugs seems to be low 
(Sarhill et al., 2001). Adverse effects are similar to those of morphine; however, 
hydromorphone less frequently induces nausea and vomiting, constipation, itching, and 
probably more slowly develops tolerance to analgesia (Wirz et al., 2008). In comparative 
studies conducted in cancer patients with pain hydromorphone displays similar analgesic 
efficacy to morphine (Miller et al., 1999) and oxycodone (Hagen and Babul, 1997). 
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Hydromorphone is especially useful for patients requiring high opioid doses via parenteral 
route due to strong analgesic effects and increased solubility that enables the possibility 
administering small volumes of the drug in SC injections.  
3.4 Fentanyl 
Fentanyl is a lipophilic opioid, µ-opioid–receptor agonist, with analgesic effect about 100 
times more potent than that of morphine. In chronic pain treatment, transdermal fentanyl 
(TF) patches are applied, usually on the upper trunk. There are five types of patches that 
release 12, 25, 50, 75, and 100 µg/h equal to approximately 0.3, 0.6, 1.2, 1.8, and 2.4 mg 
fentanyl dose per day, respectively. Patches are changed every 72 hours. Patients need 
access to short-acting opioid preparations (i.e. oral or parenteral morphine, buccal fentanyl 
tablets, oral transmucosal fentanyl citrate [OTFC] or fentanyl spray) during TF therapy to 
effectively manage breakthrough pain episodes. Fentanyl is metabolized mainly to inactive 
norfentanyl; thus, it may be used in patients with renal impairment. Because the fentanyl 
metabolic pathway is through CYP3A4, the drugs inhibiting or inducing this enzyme should 
be avoided. Caution is recommended when using drugs metabolized via CYP3A4. In 
comparison to morphine, the advantages of TF include milder constipation, nausea, and 
drowsiness (Ahmedzai & Brooks, 1997). 
When starting TF in opioid-naive or strong opioid–naïve patients, one patch at a dose of 
12 and 25 µg/h is recommended, respectively. TF also may be used in opioid switch, 
especially in patients treated with morphine who suffer from intractable constipation. In 
an open-label study of 16 patients with cancer pain unable to take oral opioids, TF was 
effective and well tolerated (Leppert et al., 2000). A good analgesic effect was achieved in 
11 patients, with a partial effect in an additional 2 patients. TF was effective and well-
tolerated in patients formerly treated with weak opioids that did not provide satisfactory 
analgesia (Vielvoye-Kerkmeer et al., 2000). The indications for TF include patients’ 
preferences, intense constipation during morphine treatment, morphine intolerance, 
nausea, and vomiting. TF should not be used in patients with unstable pain syndromes, 
especially with neuropathic pain component due to the long plasma half-life (20 h) of the 
drug, which hinders quick and effective dose titration. Fentanyl may be successfully used 
by other routes (e.g. SC, IV, intranasal inhaled, buccal) in the treatment of breakthrough 
pain (Slatkin et al., 2008). 
3.5 Buprenorphine 
Buprenorphine is a partial µ-opioid–receptor agonist and κ-receptor antagonist. A ceiling 
analgesic effect may be obtained at high doses (ie, 15 mg); however, such high doses are not 
used in clinical practice. The analgesic potency of buprenorphine is about 100 times greater 
than oral morphine (Likar et al., 2008). Buprenorphine may be administered sublingually 
due to low oral bioavailability at doses 0.2 to 0.8 mg, usually 3 times daily. It also may be 
administered by parenteral route (SC or IV). 
Buprenorphine is metabolized to the active metabolite norbuprenorphine via CYP3A4. The 
parent compound and norbuprenorphine undergo glucuronidation; thus, the risk of 
pharmacokinetic interactions with other drugs is low. Compared with morphine, 
buprenorphine less frequently induces constipation, nausea, and vomiting, which is 
probably associated with higher lipophilicity. Buprenorphine is mainly excreted with feces 
(2/3) and 1/3 of the drug is excreted with urine therefore, it may be used in patients with 
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renal failure. Respiratory depression is rare; however, when the symptom appears, naloxone 
injection should be administered at a dose of 2 mg, followed by continuous infusion (4 
mg/h). Buprenorphine displays antihyperalgesic activity and may be successfully used in 
the treatment of neuropathic pain (Mercadante et al., 2007). 
Buprenorphine is administered in transdermal patches (TB) releasing 35, 52.5, and 70 g/h, 
which corresponds to 0.8, 1.2, and 1.6 mg/d, respectively. The patches are changed every 84 
to 96 hours. In some countries, patches releasing 5 and 10 g/h, changed weekly, are 
available. The starting dose for strong opioid–naïve patients is usually one patch of 35 g/h. 
However, opioid-naive patients and those with renal or hepatic impairment may start with 
a dose of 17.5 g/h. The treatment is usually well-tolerated. At doses up to 140 g/h, TB 
does not display ceiling analgesia (Kress, 2009). Breakthrough pain may be treated with 
sublingual buprenorphine tablets or with IR morphine administered by oral or parenteral 
route (Mercadante et al., 2006). 
3.6 Methadone 
Methadone is a synthetic opioid and a racemate of dextrorotatory (S-methadone) and 
levorotatory (D-methadone) isomers. Methadone activates μ, κ, and Δ receptors (D-
methadone); it displays moderate antagonistic effect to NMDA receptors (both enantiomers) 
and strongly inhibits the reuptake of serotonin and noradrenalin in the central nervous 
system (S-methadone). In high doses, methadone blocks potassium channels required for 
rapid cardiac muscle repolarization, which may explain the risk of developing ventricular 
arrhythmia. 
Methadone is administered mostly to patients with cancer pain who undergo opioid switch; 
usually methadone is given every 8 hours. In comparison to morphine, 10 times less 
demand for laxatives and 2 times less nausea and vomiting were observed. Methadone may 
be administered as the first strong opioid to patients who have been treated with opioids for 
moderate pain or to opioid-naïve patients (the starting dose is usually 3–5 mg every 8 h) 
(Ripamonti et al., 1998) although EAPC recommends methadone as the second or the third-
line opioid. Methadone can be administered to patients with renal impairment. It has weak 
immunosuppressive effect and does not suppress the functioning of natural killer cells. 
Methadone is tenfold less expensive than the CR morphine and 25-fold cheaper than TF. 
Methadone is a highly lipophilic and basic drug with a high distribution volume (4.1 ±  
0.65 L/kg) and a high affinity to tissues, where it cumulates after multiple administrations 
(in brain, lung, liver, gut, kidney, and muscles). The high affinity to tissues together with a 
gradual, retarded release to plasma is the cause of a prolonged half-life. The bioavailability 
of the drug after oral administration oscillates between 70% and 90%. The half-life is about 
24 hours, but it occurs in the range of 8 to 120 hours. Analgesia lasts for 6 to 12 hours.  
A stable level is reached within 2 to 4 days. Methadone is metabolized mostly via liver 
enzymes, but also in the intestine wall via N-demethylation to inactive metabolites. The 
main enzyme responsible for methadone N-demethylation is CYP3A4 with a lesser CYP1A2 
and CYP2D6 involvement and a significant CYP2B6 role. The drug is excreted mainly via 
the alimentary tract, but also through kidneys (depending on the urine pH). In chronic renal 
disease, methadone does not accumulate; in severe renal failure, a dose reduction may be 
considered. Methadone is not eliminated in the process of hemodialysis. Methadone is more 
difficult to use than other opioids due to complicated pharmacokinetics, numerous drug 
interactions, and possible QT prolongation; therefore, it should be used by physicians 
experienced in chronic pain management (Leppert, 2009c). 
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a dose of 17.5 g/h. The treatment is usually well-tolerated. At doses up to 140 g/h, TB 
does not display ceiling analgesia (Kress, 2009). Breakthrough pain may be treated with 
sublingual buprenorphine tablets or with IR morphine administered by oral or parenteral 
route (Mercadante et al., 2006). 
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Methadone is a synthetic opioid and a racemate of dextrorotatory (S-methadone) and 
levorotatory (D-methadone) isomers. Methadone activates μ, κ, and Δ receptors (D-
methadone); it displays moderate antagonistic effect to NMDA receptors (both enantiomers) 
and strongly inhibits the reuptake of serotonin and noradrenalin in the central nervous 
system (S-methadone). In high doses, methadone blocks potassium channels required for 
rapid cardiac muscle repolarization, which may explain the risk of developing ventricular 
arrhythmia. 
Methadone is administered mostly to patients with cancer pain who undergo opioid switch; 
usually methadone is given every 8 hours. In comparison to morphine, 10 times less 
demand for laxatives and 2 times less nausea and vomiting were observed. Methadone may 
be administered as the first strong opioid to patients who have been treated with opioids for 
moderate pain or to opioid-naïve patients (the starting dose is usually 3–5 mg every 8 h) 
(Ripamonti et al., 1998) although EAPC recommends methadone as the second or the third-
line opioid. Methadone can be administered to patients with renal impairment. It has weak 
immunosuppressive effect and does not suppress the functioning of natural killer cells. 
Methadone is tenfold less expensive than the CR morphine and 25-fold cheaper than TF. 
Methadone is a highly lipophilic and basic drug with a high distribution volume (4.1 ±  
0.65 L/kg) and a high affinity to tissues, where it cumulates after multiple administrations 
(in brain, lung, liver, gut, kidney, and muscles). The high affinity to tissues together with a 
gradual, retarded release to plasma is the cause of a prolonged half-life. The bioavailability 
of the drug after oral administration oscillates between 70% and 90%. The half-life is about 
24 hours, but it occurs in the range of 8 to 120 hours. Analgesia lasts for 6 to 12 hours.  
A stable level is reached within 2 to 4 days. Methadone is metabolized mostly via liver 
enzymes, but also in the intestine wall via N-demethylation to inactive metabolites. The 
main enzyme responsible for methadone N-demethylation is CYP3A4 with a lesser CYP1A2 
and CYP2D6 involvement and a significant CYP2B6 role. The drug is excreted mainly via 
the alimentary tract, but also through kidneys (depending on the urine pH). In chronic renal 
disease, methadone does not accumulate; in severe renal failure, a dose reduction may be 
considered. Methadone is not eliminated in the process of hemodialysis. Methadone is more 
difficult to use than other opioids due to complicated pharmacokinetics, numerous drug 
interactions, and possible QT prolongation; therefore, it should be used by physicians 
experienced in chronic pain management (Leppert, 2009c). 
 




Tapentadol chloride ([-]-[1R,2R]-3-[3-Dimethylamino-1-ethyl-2-methyl-propyl]-phenol 
hydrochloride) is an opioid with two analgesic mechanisms: agonist of µ-opioid receptors 
with 50 times less affinity than morphine, and inhibition of norepinephrine reuptake 
(Tzschentke et al., 2007). Bioavailability after oral administration is over 30%, the drug is 
metabolized to inactive metabolites through glucuronidation and excreted via kidneys 
(Kneip et al., 2008). In experimental studies tapentadol is effective in the treatment of 
neuropathic pain and in inflammatory pain. In clinical studies conducted in patients with 
low back pain, those with postoperative pain, and those with osteoarthritis, IR tapentadol at 
doses 50, 75, and 100 mg had more favorable adverse-effects profiles with less intense 
gastrointestinal adverse effects (ie, nausea, vomiting, constipation) in comparison to IR 
oxycodone at doses 10 and 15 mg. Clinical studies on tapentadol use in patients with cancer 
pain are ongoing. 
4. Conclusions 
Opioids are usually effective when administered alone or with adjuvant analgesics. The 
traditional WHO step-by-step approach should be used individually, based on the clinical 
assessment of pain type and intensity. Patients with severe pain intensity should use strong 
opioids (opioids for moderate-to-severe pain) without climbing up the analgesic ladder. 
Opioids may be combined with nonopioid analgesics and adjuvant analgesics appropriate 
for a given pain type. Understanding important attributes of commonly used opioids can 
help assist selection. 
In case of lack of efficacy of orally or transdermally administered opioids, it may be 
beneficial to change the route of administration to parenteral or intrathecal (Enting et al., 
2002). Another possibility is opioid switch that may improve analgesia and reduce adverse 
effects (Mercadante & Bruera, 2006). A good example may be patients suffering from severe 
constipation who may benefit when switching from morphine to TF (Ahmedzai & Brooks, 
1997) and from codeine or DHC to tramadol (Leppert & Majkowicz, 2010). A newer 
approach is the concomitant use of two opioids, although little evidence supports such 
procedure (Fallon & Laird, 2011). Future studies may address genetic disposition 
responsible for individual patients’ response to opioid analgesics (Lötsch et al., 2009). 
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1. Introduction 
Chances are relatively high that each of us will experience low back pain at some point in 
our lives. The usual course is rapid improvement with 5% to 10% developing persistent 
symptoms.1 In the 1990s the estimated cost of low back pain to the health industry was in 
the billions of dollars, and with a larger proportion of our population now reported to be 
older, this number can only be expected to increase. 2, 3 Treatment typically begins with 
conservative measures such as medication and physical therapy and may even include 
minimally and highly invasive pain management interventions. Surgery is sometimes 
required in patients who have progressive neurologic deficits or those who do not respond 
to conservative treatment sometimes chose surgery. A quandary sometimes arises, 
following a primary surgery, as to whether repeat surgery should be attempted or another 
alternative technique should be tried. This is the exact problem that the epidural 
adhesiolysis procedure was designed to address. Failed back surgery or postlaminectomy 
syndrome led to the development of the epidural adhesiolysis procedure.  
It was shown to be effective in many patients with chronic pain after back surgery 
presumably by freeing up nerves and breaking down scar formation, delivering site-specific 
corticosteroids and local anesthetics, and reducing edema with the use of hyaluronidase and 
hypertonic saline. Epidural adhesiolysis has afforded patients a reduction in pain and 
neurologic symptoms without the expense and occasional long recovery period associated 
with repeat surgery, and often prevents the need for surgical intervention. Epidural 
adhesiolysis was given an evidence rating of strong correlating to a 1B or 1C evidence level 
for post–lumbar surgery syndrome in the most recent American Society of Interventional 
Pain Physicians evidence-based guidelines. The therapy is supported by observational 
studies and case series along with randomized-control trials. The recommendation was also 
made that this therapy could apply to most patients with post laminectomy syndrome or 
failed back syndrome in many circumstances with informed consent.4 Additionally, current 
procedural terminology (CPT) codes have been assigned to the two different kinds of 
adhesiolysis: CPT 62263 for the three-times injections over 2 to 3 days, usually done in an 
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inpatient hospital setting, and CPT 62264 for the one-time injection series surgery-center 
model that may need to be repeated 3 to 3.5 times in a 12-month period. 
2. Pathophysiology of epidural fibrosis (scar tissue) as a cause of low back 
pain with radiculopathy 
The etiology of chronic low back pain with radiculopathy after appropriate surgery is not 
well understood. Kuslich et al5 addressed this issue when they studied 193 patients who had 
undergone lumbar spine operations given local anesthesic int the epidural space. It was 
postulated that sciatica could only be produced by stimulation of a swollen, stretched, 
restricted (i.e., scarred) or compressed nerve root.5 Back pain could be produced by 
stimulation of several tissues, but the most common tissue of origin was the outer layer of 
the annulus fibrosus and the posterior longitudinal ligament. Stimulation for pain 
generation of the facet joint capsule rarely generated low back pain, and facet synovium and 
cartilage surfaces of the facet or muscles were never tender.6  
The contribution of fibrosis to the etiology of low back pain has been debated.7–9 There are 
many possible etiologies of epidural fibrosis, including surgical trauma, an annular tear, 
infection, hematoma, or intrathecal contrast material.10 These etiologies have been well 
documented in the literature. LaRocca and Macnab11 demonstrated the invasion of fibrous 
connective tissue into postoperative hematoma as a cause of epidural fibrosis, and Cooper et 
al12 reported periradicular fibrosis and vascular abnormalities occurring with herniated 
intervertebral disks. McCarron et al13 investigated the irritative effect of nucleus pulposus 
on the dural sac, adjacent nerve roots, and nerve root sleeves independent of the influence of 
direct compression on these structures. Evidence of an inflammatory reaction was identified 
by gross inspection and microscopic analysis of spinal cord sections after homogenized 
autogenous nucleus pulposus was injected into the lumbar epidural space of four dogs. In 
the control group consisting of four dogs injected with normal saline, the spinal cord 
sections were grossly normal. Parke and Watanabe14 showed significant evidence of 
adhesions in cadavers with lumbar disk herniation.  
It is widely accepted that postoperative scar renders the nerve susceptible to injury by a 
compressive phenomena.9 It is natural for connective tissue or any kind of scar tissue to 
form fibrous layers (scar tissue) as a part of the process that transpires after disruption of the 
intact milieu.15 Scar tissue is generally found in three components of the epidural space. 
Dorsal epidural scar tissue is formed by reabsorption of surgical hematoma and may be 
involved in pain generation.16 In the ventral epidural space, dense scar tissue is formed by 
ventral defects in the disk, which may persist despite surgical treatment and continue to 
produce low back pain and radiculopathy past the surgical healing phase.17 The lateral 
epidural space includes the epiradicular structures outside the root canals, known as the 
lateral recesses or “sleeves,” which are susceptible to lateral disk defects, facet hypertrophy, 
and neuroforaminal stenosis.18  
Although scar tissue itself is not tender, an entrapped nerve root is. Kuslich et al5 surmised 
that the presence of scar tissue compounded the pain associated with the nerve root by 
fixing it in one position and thus increasing the susceptibility of the nerve root to tension or 
compression. They also concluded that no other tissues in the spine are capable of 
producing leg pain. In a study of the relationship between peridural scar evaluated by 
magnetic resonance imaging (MRI) and radicular pain after lumbar diskectomy, Ross et al19 
demonstrated that subjects with extensive peridural scarring were 3.2 times more likely to 
experience recurrent radicular pain.  
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This evidence also parallels a new study by Gilbert et al20 in which lumbosacral nerve roots 
were identified as undergoing less strain than previously published during straight leg raise 
and in which hip motion greater than 60 degrees was determined to cause displacement of 
the nerve root in the lateral recess. 
3. Fluid foraminotomy: Foraminal adhesiolysis or disentrapment  
Relative or functional foraminal root entrapment syndrome secondary to epidural fibrosis 
with corresponding nerve root entrapment is frequently evident after an epidurogram and 
signified by lack of epidural contrast flow into epidural finger projections at those levels. The 
lysis procedure effectively serves as a fluid foraminotomy reducing foraminal stenosis caused 
by epidural fibrosis. In addition to increasing foraminal cross-sectional area, adhesiolysis 
serves to decompress distended epidural venous structures that may exert compression at 
nearby spinal levels (Fig. 1) and inevitably cause needle stick related epidural hematomas. 
Adhesiolysis has led to the development of flexible epiduroscopy that is being pioneered by, 
primarily initiated, pursued and to this day supported by Dr. James Heavner.21,22 
 
 
Fig. 1. Engorged blood vessels in the epidural cavity as observed during epiduroscopy. 
Insert in upper right corner is fluoroscopy showing location for epiduroscopy tip (left 
anterior border of L5) 
4. Diagnosis and radiologic diagnosis of epidural fibrosis 
As with any patient, a thorough musculoskeletal and neurologic examination should be 
performed. In addition to standard dural tension provocative tests, we recommend a 
provocative test called ‘dural tug’. To perform the test, the patient should be instructed to sit 
 
Pain Management – Current Issues and Opinions 
 
338 
inpatient hospital setting, and CPT 62264 for the one-time injection series surgery-center 
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up with a straight leg, bend forward flexing the lumbar spine until their back pain starts to 
become evident, and the head and neck flexed rapidly forward. During this maneuver, the 
dura is stretched cephalad and if adhered to structures such as the posterior longitudinal 
ligament, the most heavily innervated spinal canal structure, the movement of the dura will 
elicit back pain that is localized to the pain generator. A positive dural tug maneuver has 
been observed to resolve after percutaneous neuroplasty. (Fig 2 A-E) 
 
 
A    B  
 
C  
Fig. 2. A-C. A) The ‘dural tug’ maneuver being performed prior to percutaneous 
neuroplasty. B) Note pain reproduction prior to full neck flexion secondary to dural 
adhesions. C) Patient after percutaneous neuroplasty with pain free neck and back flexion 
due to treatment of dural adhesions. 
 






Fig. 2. D-E. D) There is decreased spine flexion prior to treatment secondary to dural 
adhesions. E) After treatment, the same patient demonstrates increased painless flexion of 
the spine.  
MRI and computed tomography (CT) are diagnostic tools; sensitivity and specificity are 50% 
and 70%, respectively.15 CT myelography may also be helpful, although none of the 
aforementioned modalities can identify epidural fibrosis with 100% reliability. In contrast, 
epidurography is a technique used with considerable success and it is believed that epidural 
fibrosis is best diagnosed by performing an epidurogram.23–26 It can detect filling defects in 
good correlation with a patient's symptoms in real time.26 A combination of several of these 
techniques would undoubtedly increase the ability to identify epidural fibrosis. 
5. Current Procedural Terminology or CPT codes 
The American Medical Association has developed Current Procedural Terminology codes 
for epidural adhesiolysis, which include 62264 for a single infusion and 62263 for a staged 
three-series infusion. 
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6. Indications for epidural adhesiolysis 
Although originally designed to treat radiculopathy secondary to epidural fibrosis following 
surgery, the use of epidural adhesiolysis has been expanded to treat a multitude of pain 
etiologies. These include the following27: 
1. Failed back surgery syndrome  
2. Postlaminectomy syndrome of the neck and back after surgery 
3. Disk disruption 
4. Metastatic carcinoma of the spine leading to compression fracture 
5. Multilevel degenerative arthritis 
6. Facet pain 
7. Spinal stenosis 
8. Pain unresponsive to spinal cord stimulation and spinal opioids 
9. Thoracic disk related chest wall and abdominal pain (after mapping) 
7. Contraindications 
The following are absolute contraindications for performing epidural adhesiolysis: 
1. Sepsis 
2. Chronic infection 
3. Coagulopathy 
4. Local infection at the procedure site 
5. Patient refusal 
6. Syrinx formation 
A relative contraindication is the presence of arachnoiditis. With arachnoiditis, the tissue 
planes may be adherent to one another, increasing the chance of loculation of contrast or 
medication. It may also increase the chance of spread of the medications to the subdural or 
subarachnoid space, which can increase the chance of complications. Practitioners with 
limited experience with epidural adhesiolysis should consider referring these patients to a 
clinician with more training and experience. 
8. Patient preparation 
When epidural adhesiolysis has been deemed an appropriate treatment modality, the risks 
and benefits of the procedure should be discussed with the patient and informed consent 
obtained. The benefits are pain relief, improved physical function, and possible reversal of 
neurologic symptoms. Risks include, but are not limited to, bruising, bleeding, infection, 
reaction to medications used (i.e., hyaluronidase, local anesthetic, corticosteroids, hypertonic 
saline), damage to nerves or blood vessels, no or little pain relief, bowel/bladder 
incontinence, worsening of pain, and paralysis. Patients with a history of urinary 
incontinence should have a urodynamic evaluation by a urologist before the procedure to 
document the preexisting urodynamic etiology and pathology. 
9. Anticoagulant medication 
Medications that prolong bleeding and clotting parameters should be withheld before 
performing epidural adhesiolysis. The length of time varies depending on the medication 
taken. A consultation with the patient's primary physician should be obtained before 
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stopping any of these medications, particularly in patients who require chronic 
anticoagulation such as those with drug-eluting heart stents or prosthetic heart valves. 
Nonsteroidal anti-inflammatory drugs and aspirin, respectively, should be withheld 4 days 
and 7 to 10 days before the procedure. Although there is much debate regarding these 
medications and neuraxial procedures, we tend to be on the conservative side. Clopidogrel 
(Plavix) should be stopped 7 days before, whereas ticlopidine (Ticlid) is withheld 10 to 14 
days before the adhesiolysis.28 Warfarin (Coumadin) stoppage is variable but 5 days is 
usually adequate.27 Patients on subcutaneous heparin should have it withheld a minimum 
of 12 hours before the procedure, whereas those on low-molecular-weight heparin require a 
minimum of 24 hours.28 Over-the-counter homeopathic medications that prolong bleeding 
parameters should also be withheld. These include fish oil, vitamin E, gingko biloba, garlic, 
ginseng, and St. John's Wort. Adequate coagulation status can be confirmed by the history, 
INR, prothrombin time, partial thromboplastin time, and a platelet function assay or 
bleeding time. The tests should be performed as close to the day of the procedure as 
possible. Tests performed only a few days after stopping the anticoagulant medication may 
come back elevated because not enough time has elapsed to allow the anticoagulant effects 
of the medication to resolve. The benefits of the procedure must be weighed against the 
potential sequelae of stopping the anticoagulant medication and this should be discussed 
thoroughly with the patient. 
10. Preoperative laboratory 
Before the procedure, a complete blood count and a clean-catch urinalysis are obtained to 
check for any undiagnosed infections. An elevated white count and/or a positive urinalysis 
should prompt the physician to postpone the procedure and refer the patient to the primary 
care physician for further workup and treatment. In addition, history of bleeding, 
abnormalities a prothrombin time, partial thromboplastin time, and platelet function assay 
or bleeding time, are obtained to check for coagulation abnormalities. Any elevated value 
warrants further investigation and postponement of the procedure until those studies are 
complete.  
11. Technique 
This procedure can be performed in the cervical, thoracic, lumbar, and caudal regions of the 
spine. The caudal and transforaminal placement of catheters will be described in detail, 
whereas highlights and slight changes in protocol will be provided for cervical and thoracic 
catheters. Our policy is to perform this procedure under strict sterile conditions in the 
operating room. Prophylactic antibiotics with broad neuraxial coverage are given before the 
procedure. Patients will receive either ceftriaxone 1 g intravenously or Levaquin 500 mg 
orally in those allergic to penicillin. The same dose is also given on day 2. An 
anesthesiologist or nurse anesthetist provides monitored anesthesia care. 
12. Caudal approach 
The patient is placed in the prone position with a pillow placed under the abdomen to 
correct the lumbar lordosis and a pillow under the ankles for patient comfort. The patient is 
asked to put his or her toes together and heels apart. This relaxes the gluteal muscles and 
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facilitates identification of the sacral hiatus. After sterile preparation and draping, the sacral 
hiatus is identified via palpation just caudal to the sacral cornu or with fluoroscopic 
guidance. A skin wheal is raised with local anesthetic 1-inch lateral and 2 inches caudal to 
the sacral hiatus on the side opposite the documented radiculopathy. A distal subcutaneous 
approach theoretically provides some protection from meningitis, as a local skin infection 
would be much preferred over infection closer to the caudal epidural space. The skin is 
nicked with an 18-gauge cutting needle, and a 15- or 16-gauge RX Coudé (Epimed 
International) epidural needle is inserted through the nick at a 45-degree angle and guided 
fluoroscopically or by palpation to the sacral hiatus (Figs. 3 and 4). 
When the needle is through the hiatus, the angle of the needle is dropped to 
approximately 30 degrees and advanced. The advantages of the RX Coudé needle over 
other needles are the angled tip, which enables easier direction of the catheter, and the tip 
of the needle is less sharp. The back edge of the distal opening of the needle is designed to 
be a noncutting surface that allows manipulation of the catheter in and out of the needle. 
A Touhy needle has the back edge of the distal opening, which is a cutting surface and 
can more easily shear a catheter. A properly placed needle will be inside the caudal canal 
below the level of the S3 foramen on anteroposterior (AP) and later fluoroscopic images. 
A needle placed above the level of the S3 foramen could potentially puncture a low-lying 





Fig. 3. Caudal lysis sequence—first find sacral hiatus and tip of coccyx. 
 








Fig. 4. Roll palpating index finger to identify the sacral cornu and thus the target sacral 
hiatus. 
An epidurogram is performed using 10 mL of a non-ionic, water-soluble contrast  
agent. Confirm a negative aspiration for blood or cerebrospinal fluid before any injection 
of the contrast or medication. Omnipaque and Isovue are the two agents most frequently 
used and are suitable for myelography.29, 30 Do not use ionic, water-insoluble agents such 
as Hypopaque or Renografin or ionic, water-soluble agents such as Conray. 31,32 These 
agents are not indicated for myelography. Accidental subarachnoid injections can lead to 
serious untoward events such as seizure and possibly death. Slowly inject the contrast 
agent and observe for filling defects. A normal epidurogram will have a “Christmas tree” 
pattern with the central canal being the trunk and the outline of the nerve roots making 
up the branches. An abnormal epidurogram will have areas where the contrast does not 
fill (Fig. 5). These are the areas of presumed scarring and typically correspond to the 
patient's radicular complaints. If vascular uptake is observed, the needle needs to be 
redirected. 
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Fig. 5. Initial dye injection Omnipaque 240 (10 mL) showing sacral S3 runoff and filling 
defects at S2, S1, and right L5 
After turning the distal opening of the needle ventral lateral, insert a TunL Kath or TunL-XL 
(stiffer) catheter (Epimed International) with a bend on the distal tip through the needle 
(Figs. 6 and 7). The bend should be 2.5 cm from the tip of the catheter and at a 30-degree 
angle. The bend will enable the catheter to be steered to the target level (Fig 8). Under 
continuous AP fluoroscopic guidance, advance the tip of the catheter toward the ventral-
lateral epidural space of the desired level. The catheter can be steered by gently twisting the 
catheter in a clockwise or counterclockwise direction. Avoid “propellering” the tip (i.e., 
twisting the tip in circles) because this makes it more difficult to direct the catheter. Do not 
advance the catheter up the middle of the sacrum because this makes guiding the catheter to 
the ventral-lateral epidural space more difficult. Ideal location of the tip of the catheter in 
the AP projection is in the foramen just below the midportion of the pedicle shadow (Figs 9 




Fig. 6. The needle is placed through the sacral hiatus into the sacral canal and rotated in the 
direction of the target. Do not advance beyond the S3 foramen. 
 




Fig. 7. The Epimed Racz catheter is marked for the location of the bend, or use the thumb as 
reference for the 15-degree angle bend 
 
 
Fig. 8. The direction of the catheter is just near the midline; direct the curve under 
continuous fluoroscopic guidance to the ventral lateral target site. The needle rotation, as 
well as the catheter navigation, may need to be used to reach the target 
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Fig. 9. The needle is removed, and the catheter is placed in the ventral lateral epidural space 
ventral to the nerve root 
 
 
Fig. 10. Catheter (24xL) is threaded to lateral L5 neural foramen 
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Under real-time fluoroscopy, inject 2 to 3 mL of additional contrast through the catheter in 
an attempt to outline the “scarred in” nerve root (Fig 11). If vascular uptake is noted, 
reposition the catheter and reinject contrast. Preferably there should not be vascular runoff, 
but infrequently secondary to venous congestion, an epidural pattern is seen with a small 
amount of vascular spread. This is acceptable as long as the vascular uptake is venous in 
nature and not arterial. Extra caution should be taken when injecting the local anesthetic to 
prevent local anesthetic toxicity. Toxicity is volume and dose related and so far there has not 
been any reported complications from small volume venous spread. Any arterial spread of 
contrast always warrants repositioning of the catheter. We have never observed intra-
arterial placement in 25 years of placing soft, spring-tipped catheters.  
 
 
Fig. 11. Contrast injection Omnipaque 240, additional 5 mL opening right L5, S1, S2, and S3 
perineural spaces; also left L5, S1, S2, and S3 in addition to right L4 spread in cephalad 
direction 
Inject 1500 U of hyaluronidase dissolved in 10 mL of preservative-free normal saline. A newer 
development is the use of Hylenex or human-recombinant hyaluronidase, which carries the 
advantage of a reportedly increased effectiveness at the body's normal pH compared to 
bovine-recombinant hyaluronidase.33 This injection may cause some discomfort, so a slow 
injection is preferable. Observe for “opening up”(i.e. visualization) of the “scarred in” nerve 
root (Figs 12 and 13 ; see also Fig. 11). A 3 mL test dose of a 10 mL local anesthetic/steroid 
(LA/S) solution is then given. Our institution used 4 mg of dexamethasone mixed with 9 mL 
of 0.2% ropivacaine. Ropivacaine is used instead of bupivacaine for two reasons: the former 
produces a preferential sensory versus a motor block, and it is less cardiotoxic than a racemic 
bupivacaine. Doses for other corticosteroids commonly used are 40 to 80 mg of 
methylprednisolone (Depo-Medrol), 25 to 50 mg of triamcinolone diacetate (Aristocort), 40 to 
80 mg of triamcinolone acetonide (Kenalog), and 6 to 12 mg of betamethasone (Celestone Solu 
span). If, after 5 minutes, there is no evidence of intrathecal or intravascular injection of 
medication, inject the remaining 7 mL of the LA/S solution.  
 




Fig. 9. The needle is removed, and the catheter is placed in the ventral lateral epidural space 
ventral to the nerve root 
 
 
Fig. 10. Catheter (24xL) is threaded to lateral L5 neural foramen 
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Fig. 12. Additional contrast and hyaluronidase injection opens up bilaterally formerly 




Fig. 13. Catheter advances to the desired symptomatic level of right L5 in the ventral lateral 
epidural space. Injection of contrast followed by 10 mL hyaluronidase 1,500 units opens up 
bilaterally L3-5, S1, S2, and S3 neural foramina. 
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Remove the needle under continuous fluoroscopic guidance to ensure the catheter remains 
at the target level (Fig 14). Secure the catheter to the skin using nonabsorbable suture and 
coat the skin puncture site with antimicrobial ointment. Apply a sterile dressing and attach a 
0.2 μ m filter to the end of the catheter. Affix the exposed portion of the catheter to the 
patient with tape and transport the patient to the recovery area.  
 
 
Fig. 14. Five picture sequence of removal of the needle to prevent dislodging the catheter 
from target site before suturing and application of dressing. 
A 20- to 30-minute period should elapse between the last injection of the LA/S solution and 
the start of the hypertonic saline (10%) infusion. This is necessary to ensure that a subdural 
injection of the LA/S solution has not occurred. A subdural block mimics a subarachnoid 
block but it takes longer to establish, usually 16 to 18 minutes. Evidence for subdural or 
subarachnoid spread is the development of motor block. If the patient develops a 
subarachnoid or subdural block at any point during the procedure, the catheter should be 
removed and the remainder of the adhesiolysis canceled. The patient needs to be observed 
to document the resolution of the motor and sensory block and to document that 10 mL of 
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the hypertonic saline is then infused through the catheter over 15 to 30 minutes. If the 
patient complains of discomfort, the infusion is stopped and an additional 2 to 3 mL of 0.2% 
ropivacaine is injected and the infusion is restarted. Alternatively, 50 to 75 μ g of fentanyl 
can be injected epidurally in lieu of the local anesthetic. After completion of the hypertonic 
saline infusion, the catheter is slowly flushed with 2 mL of preservative-free normal saline 
and the catheter is capped.  
Our policy is to admit the patient for 24-hour observation status and do a second and a third 
hypertonic saline infusion the following day. On post–catheter insertion day 2, the catheter 
is twice injected (separated by 4- to 6-hour increments) with 10 mL of 0.2% ropivacaine 
without steroid and infused with 10 mL of hypertonic saline (10%) using the same technique 
and precautions as the day 1 infusion. At the end of the third infusion, the catheter is 
removed and a sterile dressing applied. The patient is discharged home with 5 days of oral 
cephalexin at 500 mg twice a day or oral levofloxacin (Levaquin) at 500 mg once a day for 
penicillin-allergic patients. Clinic follow-up is in 30 days.  
13. Transforaminal catheters 
Patients with an additional level of radiculopathy or those in whom the target level cannot 
be reached by the caudal approach may require placement of a second catheter. The second 
catheter is placed into the ventral epidural space via a transforaminal approach.  
After the target level is identified with an AP fluoroscopic image, the superior endplate of the 
vertebra that comprises the caudal portion of the foramina is “squared,” that is, the anterior 
and posterior shadows of the vertebral endplate are superimposed. The angle is typically 15 to 
20 degrees in a caudocephalad direction. The fluoroscope is then oblique approximately 15 
degrees to the side of the radiculopathy and adjusted until the spinous process is rotated to the 
opposite side. This fluoroscope positioning allows the best visualization of the superior 
articular process (SAP) that forms the inferoposterior portion of the targeted foramen. The 
image of the SAP should be superimposed on the shadow of the disk space on the oblique 
view. The tip of the SAP is the target for the needle placement (Fig 15). Raise a skin wheal 
slightly lateral to the shadow of the tip of the SAP. Pierce the skin with an 18-gauge needle and 
then insert a 15- or 16-gauge RX Coudé needle and advance using gun-barrel technique 
toward the tip of the SAP. Continue to advance the needle medially toward the SAP until the 
tip contacts bone. Rotate the tip of the needle 180 degrees laterally and advance about 5 mm 
(Fig 16). Rotate the needle back medially 180 degrees (Fig 17).  
 
 
Fig. 15. Transforaminal lateral-oblique view. Target the SAP with the advancing RX Coude 
needle. 
 





Fig. 16. Following bony contact with SAP. Lateral rotation of 180 degrees to allow passage 
toward the target. 
 
 
Fig. 17. Note the intertransverse ligament. The needle tip with the RX Coude 2 that has 1 
mm protruding blunt stylet will pass through the ligament and will be less likely to damage 
the nerve. 
As the needle is advanced slowly, a clear “pop” is felt as the needle penetrates the inter 
transverse ligament. Obtain a lateral fluoroscopic image. The tip of the needle should be just 
past the SAP in the posterior foramen. In the AP plane, the tip of the needle under 
continuous AP fluoroscopy, insert the catheter slowly into the foramen and advance until 




Fig. 18. The distal tip of the catheter may be bent 15-degrees, 3/4 inch length. 
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Fig. 18. The distal tip of the catheter may be bent 15-degrees, 3/4 inch length. 
 





Fig. 19. Once the intertransverse ligament is perforated, the catheter is steered to the ventral 




Fig. 20. Transforaminal 15-gauge RX-Coude 2 (Epimed International, Johnstown, NY) 
catheter at left L3-4 threaded almost to near midcanal position (anteroposterior view). 
Confirm that the catheter is in the anterior epidural space with a lateral image (Fig 21). 
Anatomically, the catheter is in the foramen above or below the exiting nerve root (Fig 22). If 
the catheter cannot be advanced, it usually means the needle is either too posterior or too 
lateral to the foramen. It can also indicate that the foramen is too stenotic to allow passage of 
the catheter. The needle can be advanced a few millimeters anteriorly in relation to the 
foramen, and that will also move it slightly medial into the foramen. If the catheter still will 
not pass, the initial insertion of the needle will need to be more lateral. Therefore the 
fluoroscope angle will be about 20 degrees instead of 15 degrees. The curve of the needle 
usually facilitates easy catheter placement. The final position of the catheter tip is just short 
of the midline. 
 





Fig. 21. Lateral view of Fig. 169-13 . Transforaminal-ventral-anterior catheter dye spread to 
epidural and L3-4 intradiscal area (through annular tear). 
 
 
Fig. 22. Anteroposterior view. The catheter is in optimal position near midline via the 
transforaminal placement. 
Inject 1 to 2 mL of contrast to confirm epidural spread. When a caudal and a transforaminal 
catheter are placed, the 1500 U of hyaluronidase are divided evenly between the two 
catheters (5 mL of the hyaluronidase/saline solution into each). The LA/S solution is also 
divided evenly, but a volume of 15 mL (1 mL steroid and 14 mL 0.2% ropivacaine; of the 
total volume, 5 mL is transforaminal and 10 mL is caudal) is used instead of 10 mL. Remove 
the needle under fluoroscopic guidance to make sure the catheter does not move from the 
original position in the epidural space. Secure and cover the catheter as described 
previously. The hypertonic saline solution is infused at a volume of 4 to 5 mL per 
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transforaminal and 8 to 10 mL per caudal catheter over 30 minutes. The hypertonic saline 
injection volume should always be less than or equal to the local anesthetic volume injected 
to avoid pain from injection. It behooves the practitioner to check the position of the 
transforaminal catheter under fluoroscopy before performing the second and third 
infusions. The catheter may advance across the epidural space into the contralateral foramen 
or paraspinous muscles or more commonly back out of the epidural space into the 
ipsilateral paraspinous muscles. 
This results in deposition of the medication in the paravertebral tissue rather than in the 
epidural space. As with the caudal approach, remove the transforaminal catheter after the 
third infusion. A recent development is the R-X Coude 2 needle in which a second 
protruding stylet may allow closer needle placement and less chance of nerve injury. 
14. Cervical lysis of adhesions 
The success of the caudal approach for lysis of adhesions led to the application of the same 
technique to the cervical epidural space. The indications and preprocedure workup are the 
same as those for the caudal lysis technique, but there are a few differences in technique and 
volumes of medication used.  
The epidural space should be entered via the upper thoracic interspaces using a paramedian 
approach on the contralateral side. The most common levels are T1-2 and T2-3. Entry at 
these levels allows for a sufficient length of the catheter to remain in the epidural space after 
the target level has been reached. If the target is the lower cervical nerve roots, a more 
caudal interspace should be selected. We place the patient in the left lateral decubitus 
position, but use a prone approach in larger patients.  
A technique referred to as the “3-D technique” is used to facilitate entry into the epidural 
space. The “3-D” stands for direction, depth, and direction. Using an AP fluoroscopic image, 
the initial direction of the 15- or 16-gauge RX Coudé needle is determined. Using a modified 
paramedian approach with the skin entry one and a half levels below the target interlaminar 
space, advance and direct the needle toward the midpoint of the chosen interlaminar space 
with the opening of the needle pointing medial. Once the needle engages the deeper tissue 
planes (usually at 2 to 3 cm), check the depth of the needle with a lateral image. Advance the 
needle toward the epidural space and check repeat images to confirm the depth. The 
posterior border of the dorsal epidural space can be visualized by identifying the junction of 
the base of the spinous process of the vertebra with its lamina. This junction creates a 
distinct radiopaque “straight line.” Once the needle is close to the epidural space, obtain an 
AP fluoroscopic image to recheck the direction of the needle. If the tip of the needle has 
crossed the midline as defined by the spinous processes of the vertebral bodies, pull the 
needle back and redirect. The “3-D” process can be repeated as many times as is necessary 
to get the needle into the perfect position. 
Using loss-of-resistance technique, advance the needle into the epidural space with the tip of 
the RX-Coudé needle, pointed caudally. Once the tip is in the epidural space, rotate the tip 
cephalad, and inject 1 to 2 mL of contrast to confirm entry. Rotation or movement of any 
needle in the epidural space can cut the dura. This technique has been improved with the 
advent of the RX Coudé 2 needle, which has a second interlocking stylet that protrudes 
slightly beyond the tip of the needle and functions to push the dura away from the needle 
tip as it is turned 180 degrees cephalad (Fig. 23 A-E).  
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Fig. 23. Sequence of stages to place a catheter using the R-X Coude. A and B. The needle is 
inserted into the epidural space with the tip directed as shown. C. The protruding stylet is 
inserted. D. Then the needle is rotated so the tip is parallel to the dura. E. The catheter is 
inserted. 
Inject an additional small volume as needed to complete the epidurogram. If there is no free 
flow of injected contrast, pressure may build up in the lateral epidural space. Characteristic 
fluid spread by the path of least resistance can be recognized as perivenous counter spread 
(PVCS). Presence of PVCS means pressure builds up in the lateral epidural space that is 
unable to spread laterally to decompress. The dye spread picks the path of least resistance to 
the opposite side. Pressure may build up and lead to ischemic spinal cord injury. Flexion 
and rotation of the head and neck can open up lateral runoff and release the pressure 
through the enlarged neural foramina (Fig 24)34 
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Fig. 24. Flexion rotation, left to right regardless patient position. The neural foramen 
enlarges on flexion rotation and gets smaller with extension. The inferior pars slides forward 
over the superior pars to enlarge the foramen. This allows lateral run off and pressure 
release with PVCS. 
As with the caudal epidurogram, look for filling defects. It is extremely important to 
visualize spread of the contrast in the cephalad and caudal directions. Loculation of 
contrast in a small area must be avoided as this can significantly increase the pressure in 
the epidural space and can compromise the already tenuous arterial blood supply to the 
spinal cord. Place a bend on the catheter as previously described for the caudal approach 
and insert it through the needle (Fig 23E). The opening of the needle should be directed 
toward the target side. Slowly advance the catheter to the lateral gutter and direct it 
cephalad. Redirect the catheter as needed and once the target level has been reached, turn 
the tip of the catheter toward the foramen (Fig 25A). Inject 0.5 to 1 mL of contrast to 
visualize the target nerve root. Make sure there is runoff of contrast out of the foramen 
(Fig 25B). Slowly instill 150 U of Hylenex dissolved in 5 mL of preservative-free normal 
saline. Follow this with 1 to 2 mL of additional contrast and observe for “opening up” of 
the “scarred in” nerve root. Give a 2 mL test dose of a 6 mL solution of LA/S. Our 
combination is 5 mL of 0.2% ropivicaine and 4 mg of dexamethasone. If after 5 minutes 
there is no evidence of intrathecal or intravascular spread, inject the remaining 4 mL. 
Remove the needle, and secure and dress the catheter as previously described. Once 20 
minutes have passed since the last dose of LA/S solution and there is no evidence of a 
subarachnoid or subdural block, start an infusion of 5 mL of hypertonic saline over 30 
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minutes. At the end of the infusion, flush the catheter with 1 to 2 mL of preservative-free 





Fig. 25. A & B. A Cervical left ventral lateral catheter to the upper level of fusion C5-7.  
B Cervical-left ventral lateral catheter threaded to above level of fusion of C4. The dye 
injection spreads cephalad and lateral. 
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minutes have passed since the last dose of LA/S solution and there is no evidence of a 
subarachnoid or subdural block, start an infusion of 5 mL of hypertonic saline over 30 
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minutes. At the end of the infusion, flush the catheter with 1 to 2 mL of preservative-free 





Fig. 25. A & B. A Cervical left ventral lateral catheter to the upper level of fusion C5-7.  
B Cervical-left ventral lateral catheter threaded to above level of fusion of C4. The dye 
injection spreads cephalad and lateral. 
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The second and third infusions are performed on the next day with 6 mL of 0.2% 
ropivacaine without spread and 5 mL of hypertonic saline using the same technique and 
precautions described for the first infusion. The catheter is removed and prophylactic 
antibiotics are prescribed. Clinic follow-up is 30 days.  
15. Thoracic lysis of adhesions 
The technique for entry into the thoracic epidural space for adhesiolysis is identical to that 
for the cervical region. Always remember the 3-D technique. Make sure to get a true lateral 
when checking the depth of the needle. This can be obtained by superimposing the rib 
shadows on one another. The target is still the ventrolateral epidural space with the tip of 
the catheter in the foramen of the desired level. The major difference for thoracic lysis 
compared to the caudal and cervical techniques is the volumes of the various injectates. 
Volumes of 8 mL are used for the contrast, Hylenex, LA/S, and hypertonic saline. (Table 1) 











Caudal 10 mL 10 mL 10 mL 10 mL 
Caudal and 
transforaminal 
5 mL in each 
catheter 
5 mL in each 
catheter 
5 mL in each 
catheter 
8 mL in caudal 
catheter and  
4 mL in 
transforaminal 
catheter 
Thoracic 8 mL 8 mL 8 mL 8 mL 
Cervical 5 mL 6 mL 6 mL 5 mL 
Table 1. Typical Infusion Volumes for Epidural Adhesiolysis 
16. Neural flossing 
The protocol for epidural adhesiolysis has been aided by neural flossing exercises that were 
designed to mobilize nerve roots by “sliding” them in and out of the foramen (Fig 26). This 
breaks up weakened scar tissue from the procedure and prevents further scar tissue 
deposition. If these exercises are done effectively three to four times per day for a few 
months after the procedure, the formation of scar tissue will be severely restricted. 
In patients with multilevel radiculopathy and complex pain, it can be difficult to determine 
from where the majority of the pain is emanating. We have been using a technique that we 
have termed mapping to locate the most painful nerve root with stimulation and then carry 
out the adhesiolysis at that level. There are several references in the literature regarding the 
use of stimulation to confirm epidural placement of a catheter and for nerve root 
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localization.35 The TunL Kath and the TunL-XL catheter can be used as stimulating catheters 





Fig. 26. A-F Neural flossing exercises. A, Standing erect, firmly grasp a stable surface  
(e.g., a door frame) with outstretched arm. Press elbow and shoulder forward. B, Next, 
slowly tilt head in opposite direction from outstretched arm to achieve gentle tension.  
C, Finally, rotate chin toward opposite shoulder as is comfortable. Hold this final position 
for approximately 20 to 30 seconds. D, Lay down supine on an exercise mat without a 
pillow. Slowly bring both knees close to the chest with bent legs and hold this position  
for 20 seconds. Release and assume a neutral position. E, Again in supine position, raise 
both legs to 90 degrees, with knees straight while laying flat on a firm surface. Hold for 20 
seconds. Assume a neutral position and rest briefly. F, Bring both legs to a 90-degree angle 
while lying supine. Slowly spread legs in a V shape, as much as is comfortable, and hold for 
20 seconds.Epidural Mapping 
After entering the epidural space, advance the catheter into the ventrolateral epidural 
space past the suspected target level. Make sure the tip of the catheter is pointing laterally 
toward the foramina, just below the pedicle. Pull the catheter stylet back approximately 1 
cm. Using alligator clips, attach the cathode to the stylet and ground the anode on the 
needle or ground pad or a 22-gauge needle inserted into the skin. Apply electrical 
stimulation with a stimulator box with a rate of 50 pulses per second and a pulse width of 
450 milliseconds, dialing up the amplitude until a paresthesia is perceived in small 
increments, usually less than 2 or 3 volts. Inquire of the patient as to whether or not the 
paresthesia is felt in the area of the patient's recognized greatest pain. This process is 
repeated at each successive level until the most painful nerve root is identified. Once 
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The second and third infusions are performed on the next day with 6 mL of 0.2% 
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the catheter in the foramen of the desired level. The major difference for thoracic lysis 
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localization.35 The TunL Kath and the TunL-XL catheter can be used as stimulating catheters 
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for approximately 20 to 30 seconds. D, Lay down supine on an exercise mat without a 
pillow. Slowly bring both knees close to the chest with bent legs and hold this position  
for 20 seconds. Release and assume a neutral position. E, Again in supine position, raise 
both legs to 90 degrees, with knees straight while laying flat on a firm surface. Hold for 20 
seconds. Assume a neutral position and rest briefly. F, Bring both legs to a 90-degree angle 
while lying supine. Slowly spread legs in a V shape, as much as is comfortable, and hold for 
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After entering the epidural space, advance the catheter into the ventrolateral epidural 
space past the suspected target level. Make sure the tip of the catheter is pointing laterally 
toward the foramina, just below the pedicle. Pull the catheter stylet back approximately 1 
cm. Using alligator clips, attach the cathode to the stylet and ground the anode on the 
needle or ground pad or a 22-gauge needle inserted into the skin. Apply electrical 
stimulation with a stimulator box with a rate of 50 pulses per second and a pulse width of 
450 milliseconds, dialing up the amplitude until a paresthesia is perceived in small 
increments, usually less than 2 or 3 volts. Inquire of the patient as to whether or not the 
paresthesia is felt in the area of the patient's recognized greatest pain. This process is 
repeated at each successive level until the most painful nerve root is identified. Once 
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identified, the adhesiolysis is carried out at that level. The mapping procedure is also 
useful to identify the optimal site of surgery either before the first surgery or when 
surgery has failed one or more times.  
17. Complications 
As with any invasive procedure, complications are possible. These include bleeding, 
infection, headache, damage to nerves or blood vessels, catheter shearing, bowel/bladder 
dysfunction, paralysis, spinal cord compression from loculation of the injected fluids or 
hematoma, subdural or subarachnoid injection of local anesthetic or hypertonic saline, and 
reactions to the medications used. We also include on the consent form that the patient may 
experience an increase in pain or no pain relief at all. Although the potential list of 
complications is long, the frequency of complications is very rare. However, there is clearly 
a learning curve, and recent studies reflect this by the significantly improved long-term 
outcome and the very rare publications of complications and medicolegal consequences 
when one considers the ever-increasing clinical experience.  
Subdural spread is a complication that should always be watched for when injecting local 
anesthetic. During the caudal adhesiolysis, particularly if the catheter is advanced along the 
midline, subdural catheter placement is a risk (Figs 27 and 28). Identification of the subdural 
motor block should occur within 16 to 18 minutes. Catheters used for adhesiolysis should 







Fig. 27. Midline catheter placement enters subdural space. There is also some epidural dye 
spread. But the patient starts to complain of bilateral leg pain. 
 





Fig. 28. A 22-gauge spinal needle and extension set with syringe placed in the subdural 
space and 12 mL fluid aspirated. The patient reported immediate reversal of bilateral leg 
pain. Note the dye in the extension tubing and syringe at the 7-o'clock position. 
18. Outcomes 
Initially in the early 1980s the protocol was designed to direct site-specific medication onto 
the dorsal root ganglion; however, after performing a number of the procedures, it was 
found that the dorsal root ganglion was exceptionally hard to reach secondary to 
developing scar tissue or adhesions. In the early days, our understanding was coming from 
the use of local anesthetics for surgery giving a 2- to 4-hour block for the surgeon to operate. 
It was gratifying to see chronic pain patients get months and years of pain relief following 
the placement of the new steerable x-ray visible catheter. The early report in 1985 by Racz et 
al36 described the use of phenol at the dorsal root ganglion followed by an observational 
listing of outcomes that were clearly not as good as the latest studies on failed back surgery 
and spinal stenosis showing 75% to 80% improvement at 12 months' follow-up by 
Manchikanti.34 Initially we were pleased to see some patients getting 3 to 4 months of relief 
and report seeing recovery of footdrops. This philosophy still proves to be true even in 
studies in 2008 by Sakai et al 37 in which they found that adhesiolysis with catheter-directed 
steroid and local anesthetic injection during epiduroscopy alleviated pain and reduced 
sensory nerve dysfunction in patients with chronic sciatica. The evolution of these findings 
has changed the process into what it is today.38 Racz and Holubec first reported on epidural 
adhesiolysis in 1989.39 There were slight variations in the protocol compared to today's 
protocol, namely the dose of local anesthetic and the fact that hyaluronidase was not used. 
Catheter placement was lesion-specific (i.e., the tip of the catheter was placed in the foramen 
corresponding to the vertebral level and side of the suspected adhesions). The retrospective 
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analysis conducted 6 to 12 months after the procedure reported initial pain relief in 72.2% of 
patients ( N = 72) at time of discharge. Relief was sustained in 37.5% and 30.5% of patients at 
1 and 3 months, respectively. Forty-three percent decreased their frequency and dosage of 
medication use and 16.7% discontinued their medications altogether. In total, 30.6% of 
patients returned to work or returned to daily functions. In April 1990, at a presentation of 
the 7th IASP World Congress on Pain in Adelaide, Austraila, Arthur et al40 reported on 
epidural adhesiolysis in 100 patients, 50 of whom received hyaluronidase as part of the 
procedure. In the hyaluronidase group, 81.6% of the participants had initial pain relief, with 
12.3% having persistent relief; 68% of the no hyaluronidase group had relief of pain, with 
14% having persistent relief at the end of the 3-year follow-up period from which the study 
sample was randomly selected. 
In 1994 Stolker et al41 added hyaluronidase to the procedure, but omitted the hypertonic 
saline. In a study of 28 patients, they reported greater than 50% pain reduction in 64% of 
patients at 1 year. They stressed the importance of the patient selection and believed that the 
effectiveness of adhesiolysis was based on the effect of the hyaluronidase on the adhesions 
and the action of the local anesthetic and steroids on the sinuvertebral nerve.  
Devulder et al42 published a study of 34 patients with failed back surgery syndrome in 
whom epidural fibrosis was suspected or proved with MRI.42 An epidural catheter was 
inserted via the sacral hiatus to a distance of 10 cm into the caudal canal. Injections of 
contrast dye, local anesthetic, corticosteroid, and hypertonic saline (10%) were carried out 
daily for 3 days. No hyaluronidase was used. Filling defects were noted in 30 of 34 patients, 
but significant pain relief was noted in only 7 patients at 1 month, 2 patients at 3 months, 
and no patients at 12 months. They concluded that epidurography may confirm epidural 
filling defects for contrast dye in patients with filling defects, but a better contrast dye 
spread, assuming scar lysis does not guarantee sustained pain relief. This study was 
criticized for lack of lesion-specific catheter placement resulting in nonspecific drug 
delivery.43 The catheter was never directed to the ventral lateral epidural space where the 
dorsal root ganglion is located and the lateral recess scarring occurs.  
Heavner et al44 performed a prospective randomized trial of lesion-specific epidural 
adhesiolysis on 59 patients with chronic intractable low back pain. The patients were 
assigned to one of four epidural adhesiolysis treatment groups: (1) hypertonic (10%) saline 
plus hyaluronidase, (2) hypertonic saline, (3) isotonic (0.9%) saline, or (4) isotonic saline plus 
hyaluronidase. All treatment groups received corticosteroid and local anesthetic. Overall, 
across all four treatment groups, 83% of patients had significant pain relief at 1 month 
compared to 49% at 3 months, 43% at 6 months, and 49% at 12 months. The hyaluronidase 
and the hypertonic saline study group had a much lower incidence of additional need for 
pain procedures than the placebo groups, showing that site-specific catheter placement is 
important. Active substances and preservative free normal saline were blinded for the 
placebo effect. 
Manchikanti et al45 performed a retrospective randomized evaluation of a modified Racz 
adhesiolysis protocol in 232 patients with low back pain. The study involved lesion specific 
catheter placement, but the usual 3-day procedure was reduced to a 2-day (group 1) or a 1-
day (group 2) procedure. Group 1 had 103 patients and group 2 had 129 patients. Other 
changes included changing the local anesthetic from bupivacaine to lidocaine, substituting 
methylprednisolone acetate or betamethasone acetate and phosphate for triamcinolone 
diacetate, and reduction of the volume of injectate. Of the patients in groups 1 and 2, 62% 
and 58% had greater than 50% pain relief at 1 month, respectively, with these percentages 
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decreasing to 22% and 11% at 3 months, 8% and 7% at 6 months, and 2% and 3% at 1 year. 
Of significant interest is that the percentage of patients receiving greater than 50% pain relief 
after four procedures increased to 79% and 90% at 1 month, 50% and 36% at 3 months, 29% 
and 19% at 6 months, and 7% and 8% at 1 year for groups 1 and 2, respectively. Short-term 
relief of pain was demonstrated, but long-term relief was not.  
Manchikanti, in 1999, evaluated two groups of randomly pulled, 150 patients for a 2-day 
reinjection procedure, and a second 150 patients for a one-day procedure out of a pool of 536 
patients. It was concluded that repeat use of the one-day procedure is also cost effective 
when evaluated on a 12-month follow-up. The cost effectiveness indicated the lysis 
procedure to be superior to surgery or the rehabilitation activity program.45  
In a randomized, prospective study, Manchikanti et al46 evaluated a 1-day epidural 
adhesiolysis procedure against a control group of patients who received conservative 
therapy. Results showed that cumulative relief, defined as relief greater than 50% with 
one to three injections, in the treatment group was 97% at 3 months, 93% at 6 months, and 
47% at 1 year. The study also showed that overall health status improved significantly in 
the adhesiolysis group. Conservative therapy consisted of physical therapy and 
medications. 
In 2004 Manchikanti et al47 published their results of a randomized, double-blind, 
controlled study on the effectiveness of 1-day lumbar adhesiolysis and hypertonic saline 
neurolysis in treatment of chronic low back pain. Seventy-five patients whose pain was 
unresponsive to conservative modalities were randomized into one of three treatment 
groups. Group 1 (control group) underwent catheterization where the catheter was in the 
sacral canal without adhesiolysis, followed by injection of local anesthetic, normal saline, 
and steroid. Group 2 consisted of catheterization with site-specific catheter placement 
being ventral-lateral for adhesiolysis, followed by injection of local anesthetic, normal 
saline, and steroid. Group 3 consisted of site-specific catheter placement for adhesiolysis, 
followed by injection of local anesthetic, hypertonic saline, and steroid. Patients were 
allowed to have additional injections based on the response, either after unblinding or 
without unblinding after 3 months. Patients without unblinding were offered either the 
assigned treatment or another treatment based on their response. If the patients in group 1 
or 2 received adhesiolysis and injection and injection of hypertonic saline, they were 
considered withdrawn, and no subsequent data were collected. Outcomes were assessed 
at 3, 6, and 12 months using visual analog scale pain scores, Oswestry Disability Index, 
opioid intake, range-of-motion measurement, and P-3. Significant pain relief was defined 
as average relief of 50% or greater. Seventy-two percent of patients in group 3, 60% of 
patients in group 2, and 0% of patients in group 1 showed significant pain relief at 12 
months. The average number of treatments for 1 year was 2.76 in group 2 and 2.16 in 
group 3. Duration of significant relief with the first procedure was 2.8 + 1.49 months and 
3.8 + 3.37 months in groups 2 and 3, respectively. Significant pain relief (>50%) was also 
associated with improvement in Oswestry Disability Index, range of motion, and 
psychologic status.  
Manchikanti et al48,49, furthered this research using comparisons of percutaneous 
adhesiolysis versus fluoroscopically guided caudal epidural steroid injections. The first 
study involved a population of patients with chronic low back pain and known spinal 
stenosis. The results showed a 76% reduction in pain relief at 1 year with epidural 
adhesiolysis compared to 4% in the control group. The second study performed in a 
population of patients with post–lumbar surgery syndrome showed a reduction in pain and 
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assigned treatment or another treatment based on their response. If the patients in group 1 
or 2 received adhesiolysis and injection and injection of hypertonic saline, they were 
considered withdrawn, and no subsequent data were collected. Outcomes were assessed 
at 3, 6, and 12 months using visual analog scale pain scores, Oswestry Disability Index, 
opioid intake, range-of-motion measurement, and P-3. Significant pain relief was defined 
as average relief of 50% or greater. Seventy-two percent of patients in group 3, 60% of 
patients in group 2, and 0% of patients in group 1 showed significant pain relief at 12 
months. The average number of treatments for 1 year was 2.76 in group 2 and 2.16 in 
group 3. Duration of significant relief with the first procedure was 2.8 + 1.49 months and 
3.8 + 3.37 months in groups 2 and 3, respectively. Significant pain relief (>50%) was also 
associated with improvement in Oswestry Disability Index, range of motion, and 
psychologic status.  
Manchikanti et al48,49, furthered this research using comparisons of percutaneous 
adhesiolysis versus fluoroscopically guided caudal epidural steroid injections. The first 
study involved a population of patients with chronic low back pain and known spinal 
stenosis. The results showed a 76% reduction in pain relief at 1 year with epidural 
adhesiolysis compared to 4% in the control group. The second study performed in a 
population of patients with post–lumbar surgery syndrome showed a reduction in pain and 
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improvement in functional status in 73% of the epidural adhesiolysis group compared to 
12% in the control group.  
In 2006 a study by Veihelmann et al50 evaluated patients with a history of chronic low back 
pain and sciatica. Inclusion criteria were radicular pain with a corresponding nerve root 
compressing substrate found on MRI or CT. All patients were randomized to receive 
physiotherapy, analgesics, or lysis of adhesions. The lysis group had statistically 
significantly better outcome than the physical therapy treatment group.  
Two other prospective evaluations by Chopra et al and Gerdesmeyer et al51, 52 evaluated 
patients with monosegmental radiculopathy of the lumbar spine. All the patients suffered 
from chronic disk herniations or failed back syndrome. All these randomized trials showed 
positive short-term and long-term relief. Two prospective evaluations also showed positive 
short- and long-term relief.51,52 
19. Conclusion 
Epidural adhesiolysis has evolved over the years as an important treatment option for 
patients with intractable cervical, thoracic, and low back and leg pain. Studies show that 
patients are able to experience significant pain relief and restoration of function. 
Manchikanti's studies show that the amount and duration of relief can be achieved by repeat 
procedures. Recent prospective randomized double-blind studies on failed back surgery and 
spinal stenosis show 75% and 80% improvement in visual analog scale scores and functional 
improvements at 12 months' follow-up. There have been no negative studies to date where 
the lysis target was the ventral-lateral epidural space. The one negative study used a 10 cm 
sacral mid-canal catheter placement which was non-target specific.43 This negative study 
was subsequently used as the placebo group in a study performed by Manchikanti.47 
Manchikanti’s study consisted of 3 treatment groups: placebo (sacral mid-canal catheter 
placement), target specific ventral-lateral epidural without hypertonic saline and target 
specific ventral-lateral epidural with hypertonic saline . The later two treatment groups had 
positive outcomes with the hypertonic saline group superior; whereas, the placebo group 
did not. 47 The evolution in the recognition of the site-specific importance of the catheter and 
medication delivery together with the fact that physicians need to acquire the skills to be 
able to carry out the procedure led to the improved outcomes seen in recent prospective 
randomized studies.  
The management of failed back surgery syndrome and post laminectomy syndrome will 
likely continue to be controversial among the multitude of practitioners who treat these 
patients. However, in experienced hands, it is established as a reasonable option for many 
patients. 
Percutaneous neuroplasty via a transforaminal approach evolved from the caudal approach. 
Lysis of adhesions via the caudal approach involves introducing a catheter through the 
sacral hiatus and advancing it to the affected nerve root in the ventral-lateral epidural space. 
On the other hand, transforaminal percutaneous neuroplasty achieves a midline catheter 
placement in the epidural space that is able to target the two most heavily innervated 
structures in the spine—the posterior annulus fibrosus and the posterior longitudinal 
ligament.5 Apart from a surgical approach, the ventral epidural structures have been 
otherwise inaccessible.  
Endoscopy offers direct visualization of the affected nerve roots in addition to mechanical 
adhesiolysis, and may become more mainstream as the technique is refined.  
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Facet pain is commonly associated with the postlysis period or after provocative testing a 
month or so later if two-facet diagnostic blocks show efficacy. In addition to epidural lysis of 
adhesions, the combined use of radiofrequency facet denervation gives us the best long-
term outcome.  
Epidural adhesiolysis has been accepted as a treatment for post laminectomy syndrome, 
failed back syndrome, and cervical and thoracic radicular syndromes. Additional studies are 
underway to further refine the technique and indications. The combined use of long term 
patient education for neural flossing exercises and the inclusion of the facet delayed 
treatment in the algorithm further improves patient outcome. The identification of back pain 
provocation by saline injection and the successful use of percutaneous neuroplasty in the 
treatment represents hopeful promise for a cost effective treatment of back pain.  
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significantly better outcome than the physical therapy treatment group.  
Two other prospective evaluations by Chopra et al and Gerdesmeyer et al51, 52 evaluated 
patients with monosegmental radiculopathy of the lumbar spine. All the patients suffered 
from chronic disk herniations or failed back syndrome. All these randomized trials showed 
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Manchikanti's studies show that the amount and duration of relief can be achieved by repeat 
procedures. Recent prospective randomized double-blind studies on failed back surgery and 
spinal stenosis show 75% and 80% improvement in visual analog scale scores and functional 
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was subsequently used as the placebo group in a study performed by Manchikanti.47 
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positive outcomes with the hypertonic saline group superior; whereas, the placebo group 
did not. 47 The evolution in the recognition of the site-specific importance of the catheter and 
medication delivery together with the fact that physicians need to acquire the skills to be 
able to carry out the procedure led to the improved outcomes seen in recent prospective 
randomized studies.  
The management of failed back surgery syndrome and post laminectomy syndrome will 
likely continue to be controversial among the multitude of practitioners who treat these 
patients. However, in experienced hands, it is established as a reasonable option for many 
patients. 
Percutaneous neuroplasty via a transforaminal approach evolved from the caudal approach. 
Lysis of adhesions via the caudal approach involves introducing a catheter through the 
sacral hiatus and advancing it to the affected nerve root in the ventral-lateral epidural space. 
On the other hand, transforaminal percutaneous neuroplasty achieves a midline catheter 
placement in the epidural space that is able to target the two most heavily innervated 
structures in the spine—the posterior annulus fibrosus and the posterior longitudinal 
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Facet pain is commonly associated with the postlysis period or after provocative testing a 
month or so later if two-facet diagnostic blocks show efficacy. In addition to epidural lysis of 
adhesions, the combined use of radiofrequency facet denervation gives us the best long-
term outcome.  
Epidural adhesiolysis has been accepted as a treatment for post laminectomy syndrome, 
failed back syndrome, and cervical and thoracic radicular syndromes. Additional studies are 
underway to further refine the technique and indications. The combined use of long term 
patient education for neural flossing exercises and the inclusion of the facet delayed 
treatment in the algorithm further improves patient outcome. The identification of back pain 
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Chronic Pain in People with Physically 
Disabling Conditions: A Review of the 
Application of Biopsychosocial Models 
Kathryn Nicholson Perry 
University of Western Sydney, 
Australia 
1. Introduction 
There are a wide range of conditions which can result in physical disabilities, affecting more 
than a billion people or approximately 15% of the population worldwide (World Health 
Organisation, 2011). Disability is an umbrella term for the restrictions and impairments arising 
from the interaction between an individual with a health condition and the environment 
(World Health Organisation, 2011). The physical conditions from which disability arises are 
diverse and heterogeneous, but include both diseases, such as multiple sclerosis, as well as 
traumatic and non-traumatic injuries, including spinal cord injury and brain injuries. Research 
concerning the occurrence of chronic pain (defined as pain persisting beyond the period of 
healing, usually operationalized as three or six months) among people with physical 
disabilities, and the impact upon those individuals affected, is relatively limited compared to 
that focusing on primary pain conditions, such as low back pain. Within the available 
literature the focus is largely biomedical, with the majority of available research exploring 
biological factors and medical interventions. A great deal has been gained in the management 
of primary pain conditions through investigating psychological and social factors, and 
developing interventions such as cognitive behavioural pain management programs to target 
these factors. This chapter will describe the current understanding of the role of psychological 
and social factors in understanding the experience of chronic pain in the context of a physically 
disabling condition, and the use of interventions addressing these factors in this population. 
2. The nature of chronic pain in people with physically disabling conditions 
What is known about the nature of chronic pain among those with physically disabling 
conditions varies depending on the condition of interest. An examination of those 
publishing in the area suggests that often there are only a small number of groups involved 
in this research. Most of these research groups only work with one specific condition, with 
only a very small number working across a range of physically disabling conditions. As a 
result of these research silos, there are many inconsistencies in the approaches taken in 
investigating pain in the different conditions. Interpreting the findings of this body of work, 
particularly attempting to make comparisons across conditions, should therefore be done 
with caution keeping in mind some important caveats. First, there are variations across 
studies concerning the nature of the pain conditions which are the subject of investigation, 
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including the duration of the pain condition being explored. Some studies focus on chronic 
pain (with various criterion applied, commonly either three or six months duration), where 
others report on episodic, procedural or acute pain or do not specify which type of pain 
participants are experiencing. Second, some studies restrict their attention to pain thought to 
be specific to the physically disabling condition in question (such as headaches in those with 
traumatic brain injury), putting aside those deemed to be general (such as low back pain) 
which may be overlooked by teams specialising in a specific disabling condition rather than 
pain itself (Ivanhoe & Hartman, 2004). Finally, studies draw samples from a number of 
different populations including community samples, membership organisations for people 
with the physically disabling condition in question, and clinical services, including tertiary 
services for either pain or a specific physically disabling condition. There are also the usual 
methodological issues associated with the use of cross-sectional designs and the inevitable 
reliance upon self-report measures which is a hallmark of this area of research. Despite these 
issues, there is increasing evidence of a significant prevalence of chronic pain among those 
with physically disabling conditions.  
2.1 Injury related conditions 
Injury related conditions for which there is data regarding the nature of chronic pain 
includes those with a traumatic onset, such as traumatic brain injury and spinal cord injury, 
and those with a non-traumatic onset, such as cerebral palsy which is thought to be due to 
an injury to the developing brain. The kinds of traumatic events from which these injuries 
arise, such as motor vehicle accidents and sporting injuries, may mean that the individual 
has acquired multiple injuries which may complicate the assessment of the relationship 
between specific pain conditions and the physically disabling condition of interest. 
2.1.1 Traumatic brain injury 
Specific pain conditions of interest among those with traumatic brain injury include 
headaches of various types, but others noted include complex regional pain syndrome 
(CRPS), heterotopic ossification, and pain due to spasticity (Ivanhoe & Hartman, 2004; 
Nampiaparampil, 2008). A recent systematic review of chronic pain among those with 
traumatic brain injury identified 23 studies meeting their criteria, from which they estimated 
the overall prevalence of chronic pain in people with traumatic brain injury at 51.5% among 
civilians, with 57.8% reporting chronic headache  (Nampiaparampil, 2008). An interesting 
aspect of findings among this group is that prevalence of chronic headaches differs 
depending on the severity of the traumatic brain injury (Lahz & Bryant, 1996; 
Nampiaparampil, 2008), with higher prevalence reported among those with mild traumatic 
brain injury. It has been observed that those with traumatic brain injury may have other 
traumatic injuries, and studies regarding the pain conditions in this poly-trauma group are 
very limited (Dobscha, et al., 2009). The assessment of pain in those with traumatic brain 
injury, particularly those with severe enough injuries to result in significant impairments to 
cognition, language or behaviour, may be challenging and so result in less accurate 
estimates than in some other groups with physically disabling conditions. 
2.1.2 Spinal cord injury 
Relative to other conditions, there have been a larger number of studies examining chronic 
pain among those with spinal cord injury. Classifying the pain conditions associated with 
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spinal cord injury has been undertaken by a number of groups, with more concordance 
among the groups in relation to some pain types than others, such as neuropathic pains 
(Cardenas, Felix, Cardenas, & Felix, 2009; Finnerup, Baastrup, & Jensen, 2009; Siddall, 
Yezierski, & Loeser, 2000). A recent systematic review of the prevalence of chronic pain of 
all causes among those with traumatic spinal cord injury have identified more than forty 
high quality studies from across the world, but the authors note that despite this there are 
many contradictions and unanswered questions about the nature of chronic pain in this 
group (Dijkers, Bryce, & Zanca, 2009). Prevalence rates of the studies included ranged from 
26 to 98 percent, but the authors cautioned that the heterogeneity of the studies involved 
precluded calculation of an overall prevalence rate. It should be noted that co-morbid 
traumatic brain injury are not uncommon among this group, often within the mild range 
(Bradbury, et al., 2008). While spinal cord injury has been included in the section on 
traumatic injuries, some spinal cord injuries develop as a result of disease activity, such as 
cancer, which may mean the individual experiences other chronic pain conditions. As with 
many other physically disabling conditions, pain is only one of many troublesome 
complications. However, a recent study found that relative to others it is the most common 
and is closely associated with functioning (Jensen, Kuehn, Amtmann, & Cardenas, 2007). 
2.1.3 Amputation 
Studies of pain post-amputation are largely related to either upper or lower limb 
amputations. Most studies report on traumatically acquired amputations, although those 
related to vascular or other conditions are also relatively common. The most common type 
of pain problems reported in these studies is phantom limb pain and residual (or stump) 
pain, although it is also possible for people to develop musculoskeletal pain following 
amputation, for example in the back (Hammarlund, Carlström, Melchior, & Persson, 2011; 
Kooijman, Dijkstra, Geertzen, Elzinga, & van der Schans, 2000). Prevalence estimates 
suggest that phantom limb pain occurs in approximately 45 to 80% of people post-
amputation, depending partly upon whether those with upper or lower limb amputations 
are considered, with rates of residual pain similarly high but varying (Behr, et al., 2009; 
Desmond & Maclachlan, 2010; Dijkstra, et al., 2002; Ehde, et al., 2000; Kooijman, et al., 2000; 
Schley, et al., 2008).  
2.1.4 Cerebral palsy 
In contrast to many of the other physically disabling conditions upon which this chapter 
focuses, research on cerebral palsy related pain is not confined to studies of adults. The 
common use of registries in a number of countries also means that the populations from which 
samples are drawn are more complete than in many other conditions. A French study of adults 
with cerebral palsy found that 75% reported pain of any sort (Gallien, et al., 2007). 
Musculoskeletal pain has been the subject of most investigation among this population. 
Prevalence estimates range from approximately one third to two thirds, with the pattern of 
distribution across the body different depending on the type of cerebral palsy (Engel, Jensen, 
Hoffman, & Kartin, 2003; Jahnsen, Villien, Aamodt, Stanghelle, & Holm, 2004; Schwartz, 
Engel, & Jensen, 1999; Vogtle, 2009). Although studies of children are more common in this 
group, they are limited by a number of factors regarding the measurement of pain and often 
rely on parental report. However, the available studies suggest 50 to 75 % of children are 
affected by pain, with approximately one third experiencing moderate to severe pain 
(Parkinson, Gibson, Dickinson, & Colver, 2010; Russo, Miller, Haan, Cameron, & Crotty, 2008). 
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2.2 Disease related conditions 
Chronic pain has been investigated in the context of a range of diseases which are associated 
with physical disability. Some of the central pains, such as central post-stroke pain, 
associated with these conditions have only been recognized relatively recently, and have 
been subject to intense investigation. 
2.2.1 Multiple sclerosis 
A range of pain conditions, both general and specific, have been reported in people with 
multiple sclerosis. These include those related to spasm, neuropathic pains of various types 
(including trigeminal neuralgia and L’hermitte’s sign), back pain and headaches. A recent 
systematic review of pain among people with multiple sclerosis found twenty-one studies 
reporting pain prevalence, with an overall range of 29 to 86%, and with few consistent 
findings related to the relationship between the report of pain and multiple sclerosis 
characteristics (O'Connor, Schwid, Herrmann, Markman, & Dworkin, 2008). Further, this 
study reported that between 11 and 23% of people reported pain as a symptom at the onset 
of their multiple sclerosis. Central pain, including trigeminal neuralgia, has been reported in 
approximately one third of people with MS (Osterberg, Boivie, & Thuomas, 2005). 
2.2.2 Stroke 
A number of chronic pain conditions are observed in people who have had a stroke, 
including shoulder pain, spasticity related pain and headaches, and central post-stroke pain 
is a uncommon condition particular to stroke. Estimates of the prevalence of chronic pain 
between studies are variable. Approximately 11 to 21% of people following a first stroke 
have been reported to have a stroke related pain condition up to 16 months following the 
stroke (Appelros, 2006; Jonsson, Lindgren, Hallstrom, Norrving, & Lindgren, 2006; 
Lundstrom, Smits, Terent, & Borg, 2009), whereas 42% of people following stroke attending 
an out-patient rehabilitation clinic had chronic musculoskeletal pain (Kong, Woon, & Yang, 
2004). Neuropathic and central pain conditions occur at a significant level among those who 
have had a stroke, including estimates of complex regional pain syndrome in 15% of those 
undergoing inpatient post-stroke rehabilitation and 7% with central poststroke pain 
(Kitisomprayoonkul, Sungkapo, Taveemanoon, & Chaiwanichsiri, 2010; Klit, Finnerup, 
Andersen, & Jensen, 2011).  
2.2.3 Parkinson’s Disease 
Relatively little is known about the prevalence and nature of pain in people with Parkinson’s 
Disease, although clinically it is reported to be observed frequently (Beiske & Loge, 2009). Ford 
(2010) has classified pain problems associated with Parkinson’s Disease in five categories: 
musculoskeletal pain; radicular or neuropathic pain; dystonia-related pain; akathitic 
discomfort; and central or primary pain. Overall estimates of the prevalence of pain in this 
group range between and 40 and 83% (Beiske & Loge, 2009; Ford, 2010). Pain has been 
reported to be the first reported symptom of Parkinson’s Disease among a significant minority 
of those who initially present with non-motor symptoms (O'Sullivan, et al., 2008). 
2.2.4 Muscular dystrophy 
Duchenne muscular dystrophy, myotonic muscular dystrophy, type I and 
facioscapulohumeral muscular dystrophy have all been found to be associated with chronic 
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pain (Engel, Kartin, Carter, Jensen, & Jaffe, 2009; Jensen, Abresch, Carter, & McDonald, 2005; 
Jensen, et al., 2008; Miro, et al., 2009) although there are limited studies with these groups. 
More than half of the respondents in these studies reported the presence of chronic pain, 
with pain in the back and legs most commonly reported but with a large number of sites 
reported to be involved. 
2.3 Summary 
Although not a comprehensive review of all of those physically disabling conditions which 
may result in the experience of chronic pain, the above summary suggests that chronic pain 
is a relatively common but perhaps neglected consequence of physically disabling 
conditions (Osterberg, et al., 2005). The specific causes and the nature of chronic pain 
experienced may differ between physically disabling conditions, but its high prevalence 
indicates that it is a legitimate concern for health practitioners and researchers. Awareness 
of the likelihood of pain is a necessary, although not sufficient, condition for the effective 
management of such pain. There is evidence that there are misconceptions among health 
professionals about the likely occurrence of pain in those with physically disabling 
conditions (Piwko, et al., 2007). Indeed, studies of people with pain associated with various 
conditions, including spinal cord injury, cerebral palsy, and multiple sclerosis, indicate that 
those affected perceive the available treatments and access to them to be inadequate 
(Cardenas, et al., 2009; Henwood & Ellis, 2004; Kennedy, Lude, & Taylor, 2006; Pollmann, 
Feneberg, & Erasmus, 2004; Wartan, Hamann, Wedley, & McColl, 1997). In addition, the 
economic costs of pain among those with physically disabling conditions appears to be 
large, with a Canadian study estimating that the cost of pain among people multiple 
sclerosis over a 6 month period was Can$80 million (Piwko, et al., 2007). 
3. Psychological and social factors in chronic pain among those with 
physically disabling conditions 
Biopsychosocial models of pain, which are characterized by a focus on the interaction 
between biological, psychological and social variables in the pain experience, dominate the 
contemporary understanding of primary pain conditions, such as headache and low back 
pain (Gatchel, Peng, Peters, Fuchs, & Turk, 2007). The use of biopsychosocial models has 
also been promoted as the most appropriate framework for the understanding and 
management of disability of all types (World Health Organisation, 2011).The importance of 
these models is that they broaden the focus of health professionals to consider psychological 
and social factors which affect the course of a chronic pain condition. Crucially, where many 
chronic pain conditions were resistant to the available medical interventions, resulting in a 
significant proportion of the population living with chronic pain, biopsychosocial models 
offered a new treatment target focused on reducing the psychological distress and 
functional disability experienced by those with persisting pain (Blyth, et al., 2001).  
Within the broad category of biopsychosocial models, those informed by cognitive 
behavioural theories are most common. These models particularly address the role of 
cognitions and behaviours in the development and maintenance of pain, as well as 
associated pain-related distress and disability. A wide range of cognitive and behavioural 
constructs have been investigated to determine their relationship with the experience of 
pain and associated disability and distress (Vlaeyen & Linton, 2000). There is some support 
for many of these constructs in individual studies. However, among these constructs, pain 
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pain and associated disability and distress (Vlaeyen & Linton, 2000). There is some support 
for many of these constructs in individual studies. However, among these constructs, pain 
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catastrophizing, pain self-efficacy, and avoidance have all been found to be consistently 
related to the experience of pain and associated disability or distress across different 
populations and methodologies. In addition, the presence of altered mood, such as 
symptoms of depression and anxiety, or the co-existence of psychiatric disorders such as 
post-traumatic stress disorder, all seem to be important in influencing the course of a 
chronic pain condition. 
The application of biopsychosocial models to chronic pain among those with physically 
disabling conditions has lagged significantly behind its use among primary pain conditions, 
where it has long been acknowledged that presence of pain or the intensity of pain does not 
fully explain pain-related disability or distress (Heneweer, et al., 2007). Among the 
physically disabling conditions outlined above with documented, significant rates of 
associated chronic pain there were no peer-reviewed publications available addressing 
psychosocial variables in the case of Parkinson’s Disease. In addition, the investigation of 
variables has been patchy across the different conditions, and there are few specific models 
proposed for those with chronic pain in the context of physically disabling conditions. Some 
of the reasons for this are unclear, although it may be suggested that the obvious presence of 
pathology among those with physically disabling conditions results in a tendency to 
discount the possible role of other factors in causing pain-related disability or distress. This 
is despite repeated findings across a number of diagnoses that condition-related variables, 
such as severity of injury or illness, are frequently not at all or only weakly related to pain 
intensity and related disability or distress (Hoffman, et al., 2007). 
It is notable that while biopsychosocial models do not dictate that only negative or adverse 
outcomes are possible following development of pain, much of the available research 
focuses on factors associated with poor outcomes. In contrast, a study of people with spinal 
cord injuries or multiple traumas examined factors which differentiated different 
adjustment trajectories and identified three: the resilience trajectory, characterized by low 
levels of mental health symptoms at both early and late stage of admission following injury, 
the recovery trajectory where the individual shows an improving pattern of mental health 
symptoms, and the distress trajectory, where higher levels of mental health symptoms at the 
early stage are sustained in the longer term (Quale & Schanke, 2010). The study reports that 
the latter accounted for only one fifth of the participants in their study, and that maximum 
pain at admission differentiated those in the resilience vs the distress trajectory. 
Studies investigating the relationship between psychosocial factors and chronic pain in 
people with physically disabling conditions fall into two main categories. First, psychosocial 
factors are examined as predictors of chronic pain or pain-related disability, for example 
does a particular way of thinking about pain have an impact on how much pain is 
experienced. Second, chronic pain is examined as a contributor to adjustment following 
onset of a physically disabling condition, for example do those with chronic pain as a result 
of a physically disabling condition have higher levels of depressive symptomatology. The 
rapid development of theory and research related to biopsychosocial models of chronic pain 
has led to some overlap of concepts. A good example of this being that pain catastrophizing 
first appeared as one of many unhelpful coping strategies, but has now been reframed as a 
belief alongside others such as self-efficacy or helplessness. It is therefore somewhat difficult 
to categorize the current literature into particular themes. The purpose of this section is to 
describe the current evidence regarding the relationship between psychological and social 
factors and chronic pain in people with physically disabling conditions, and to identify gaps 
in the current literature which require further investigation. 
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3.1 Psychological factors 
Under the category psychological factors, the main variables to consider are mood and 
mental health, cognitive responses to pain, and behavioural responses to pain. The extent of 
the literature in these three areas varies markedly across the various physically disabling 
conditions under consideration. 
3.1.1 Mood and mental health 
The association between chronic pain and changes in mood and mental health, including 
symptoms of depression and anxiety, is perhaps the most frequently explored aspect of 
biopsychosocial models among those with physically disabling conditions. In some 
physically disabling conditions, a clear relationship between chronic pain and psychological 
distress has been consistently demonstrated, whereas in others the findings are more mixed. 
Pain has been found to be associated with psychological distress in most of the studies 
identified in cerebral palsy, traumatic brain injury, multiple sclerosis, amputation, spinal 
cord injury,  and muscular dystrophy  (Engel, et al., 2003; Engel, Schwartz, Jensen, & 
Johnson, 2000; Hoffman, et al., 2007; Kalia & O'Connor, 2005; Kratz, et al., 2010; Middleton, 
Tran, & Craig, 2007; Miro, et al., 2009; Motl, McAuley, Snook, & Gliottoni, 2009; Nicholson 
Perry, Nicholas, & Middleton, 2009; Nicholson Perry, Nicholas, Middleton, & Siddall, 2009; 
Norrbrink Budh, Hultling, & Lundeberg, 2005; Stormer, et al., 1997; Turner, Jensen, Warms, 
& Cardenas, 2002), although the strength of the relationship has varied across studies and 
conditions. In addition, studies in people with spinal cord injury pain found that continuous 
pain, as opposed to intermittent pain, was associated with higher levels of depression and 
anxiety, and conversely more stress among women with spinal cord injuries was associated 
with consistent reports of pain over a ten year period (Norrbrink Budh & Osteraker, 2007; 
Rintala, Hart, & Priebe, 2004). Negative mood has also been reported to be a trigger to 
exacerbations in chronic pain among people with spinal cord injury (Widerstrom-Noga & 
Turk, 2004). Some studies have presented exceptions to this general rule in the case of 
cerebral palsy, multiple sclerosis and stroke (Hirsh, Gallegos, Gertz, Engel, & Jensen, 2010; 
Kong, et al., 2004; Newland, Naismith, & Ullione, 2009; Newland, Wipke-Tevis, Williams, 
Rantz, & Petroski, 2005). Moderators of this relationship include gender, with the 
relationship not being found in males with multiple sclerosis in one study, and aetiology 
(traumatic versus non-traumatic) for amputation in one study moderating the relationship 
at early time points (Kalia & O'Connor, 2005; Kratz, et al., 2010). Physically disabling 
conditions in which findings are mixed in this regard include those with phantom limb pain 
and stump pain following amputation  (Fisher & Hanspal, 1998). While most of these 
studies have been conducted with adults with physically disabling conditions, a study with 
a large sample of older children with cerebral palsy suggests that children with moderate or 
severe pain are significantly more likely to have higher levels emotional and behavioural 
problems (Parkes, et al., 2008). One study in people with multiple sclerosis found that 
affective memory biases, a measure of vulnerability to depression, may mediate the 
relationship between chronic pain and depressive symptoms in this group (Bruce, Polen, & 
Arnett, 2007). 
Most studies of the relationship between pain and depression in physically disabling 
conditions solely report on cross-sectional associations. In some studies, however, they 
specifically examine pain as a predictor of depression, or in other cases the reverse. 
Determining the direction of the relationship have proved problematic, although there is some 
evidence among people with spinal cord injury to support the hypothesis than persisting pain 
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Determining the direction of the relationship have proved problematic, although there is some 
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is a driver of depression rather than the converse (Cairns, Adkins, & Scott, 1996; Putzke, 
Richards, Hicken, & DeVivo, 2002).The presence of depression at one time point has been 
reported to be a risk factor for pain at a later time point among those with multiple sclerosis 
and spinal cord injury (Buchanan, Wang, Tai-Seale, & Ju, 2003; Putzke, et al., 2002).  
Depression is associated with pain-related interference in a number of physically disabling 
conditions, including amputation, multiple sclerosis and spinal cord injury (Kratz, et al., 2010; 
Nicholson Perry, Nicholas, & Middleton, 2009;  Nicholson Perry, Nicholas, Middleton, et al., 
2009; Norrbrink Budh, et al., 2005; Norrbrink Budh & Osteraker, 2007; Osborne, et al., 2006; 
Turner, et al., 2002). There is evidence of a similar moderating effect of depression upon the 
relationship between pain and disability among those with spinal cord injury as is seen in 
other chronic pain populations (Borsbo, Peolsson, & Gerdle, 2009), and a similar but less clear 
interaction between these variables in those with traumatic brain injury (Hoffman, et al., 2007). 
The impairment to quality of life attributable to chronic pain has been reported to be related to 
depressive symptoms among individuals with spinal cord injury (Cruz-Almeida, Alameda, & 
Widerstrom-Noga, 2009). In addition, negative moods, boredom and stress reported in a large 
sample of older children with cerebral palsy was found to be significantly predicted by the 
presence of pain, although only to contribute a relatively small proportion of variation in this 
aspects of quality of life and interestingly overall quality of life was found to be consistent with 
other children without cerebral palsy (Dickinson, et al., 2007). 
Studies of the relationship between chronic pain and anxiety among people with physically 
disabling conditions are less common. However, in studies of people with multiple sclerosis, 
anxiety has been found to be positively associated with pain severity, particularly among 
women (Kalia & O'Connor, 2005; Motl, et al., 2009). Studies among people with spinal cord 
injury have also shown a significant relationship between anxiety and pain severity 
(Nicholson Perry, Nicholas, & Middleton, 2009; Nicholson Perry, Nicholas, Middleton, et al., 
2009; Norrbrink Budh, et al., 2005; Norrbrink Budh & Osteraker, 2007). There are a few 
studies examining the relationship between pain and post-traumatic stress disorder (PTSD). 
In a study of people with both traumatic and non-traumatic amputation, pain and pain-
related interference was positively correlated with PTSD symptoms in both groups (Kratz, 
et al., 2010). Pain-related anxiety, often measured as a combination of cognitions, behaviours 
and emotion, has also been found to moderate the relationship between chronic pain and 
disability among those with spinal cord injury, with those reporting higher levels of pain 
related anxiety experiencing greater disability (Borsbo, et al., 2009). Anger has been less well 
investigated, although it has been shown to moderate the perception of pain in people with 
spinal cord injury (Conant, 1998; Summers, Rapoff, Varghese, Porter, & Palmer, 1991).  
3.1.2 Cognitive responses to pain 
The relationship between cognitive responses to pain, or beliefs, and pain-related disability 
and distress has been explored in those with a number of the physically disabling conditions 
of interest. Pain catastrophizing, characterized by a tendency to negative and unrealistic 
beliefs in response to pain, and is the cognitive factor with the greatest body of evidence 
supporting its role. While pain catastrophizing has often been measured in questionnaires 
designed to measure coping strategies, it is best considered alongside other beliefs, and so 
will be reported on in this section.  
Pain catastrophizing has been found to be associated with pain intensity among people with 
chronic phantom limb pain post-amputation, multiple sclerosis and spinal cord injury (Hill, 
Niven, & Knussen, 1995; Nicholson Perry, Nicholas, & Middleton, 2009; Osborne, Jensen, 
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Ehde, Hanley, & Kraft, 2007; Turner, et al., 2002; Vase, et al., 2011; Wollaars, Post, van 
Asbeck, & Brand, 2007). In a study of people with phantom limb pain, pain catastrophizing 
was also shown to significantly contribute to wind-up-like pain when anxiety and 
depression were controlled for (Vase, et al., 2011)  
Pain catastrophizing has been found to be positively associated with pain-related disability 
among those with spinal cord injury, cerebral palsy, phantom limb pain, muscular 
dystrophy and multiple sclerosis (Borsbo, et al., 2009; Douglas, Wollin, & Windsor, 2008; 
Engel, et al., 2000; Hill, et al., 1995; Miro, et al., 2009; Molton, et al., 2009; Nicholson Perry, 
Nicholas, & Middleton, 2009; Nicholson Perry, Nicholas, Middleton, et al., 2009; Osborne, et 
al., 2007). Psychological functioning among people with spinal cord injury, multiple 
sclerosis, phantom limb pain, muscular dystrophy and cerebral palsy has been found to be 
negatively associated with pain catastrophizing (Douglas, et al., 2008; Engel, Jensen, & 
Schwartz, 2006; Engel, et al., 2000; Hanley, et al., 2004; Hill, et al., 1995; Miro, et al., 2009; 
Molton, et al., 2009; Nicholson Perry, Nicholas, & Middleton, 2009; Nicholson Perry, 
Nicholas, Middleton, et al., 2009; Osborne, et al., 2007; Smedema, Catalano, & Ebener, 2011; 
Ullrich, Jensen, Loeser, & Cardenas, 2007; Wollaars, et al., 2007). Pain catastrophizing has 
also been shown to mediate the relationship between pain severity and psychological 
distress and pain-related disability among people with spinal cord injury (Ullrich, et al., 
2007). It has been suggested that pain catastrophizing may, in fact, be a function of 
disturbed mood. This suggestion is brought into question by findings in both phantom limb 
pain and spinal cord injury related chronic pain which shows that pain catastrophizing is 
associated with pain intensity when mood is controlled for (Ullrich, et al., 2007; Vase, et al., 
2011). Among the many studies of individuals with spinal cord injury pain, veterans with 
the condition appear to have higher levels of pain catastrophizing than non-veterans 
(Ullrich, Jensen, Loeser, Cardenas, & Weaver, 2008). 
While most of these studies are cross-sectional in nature, a prospective study of people with  
spinal cord injury with chronic pain found that over a six month period decreases in pain 
catastrophizing were associated with decreased pain interference and improved 
psychological functioning (Hanley, Raichle, Jensen, & Cardenas, 2008). Conversely, a similar 
study in phantom limb pain found that pain catastrophizing at one month following 
amputation (that is, before chronic pain had developed) was predictive of decreased 
depressive symptoms and pain-related interference at both 12 and 24 months (Hanley, et al., 
2004). While this may appear counter-intuitive, the authors suggest that the function of pain 
catastrophizing soon after amputation may be different to that in those with established 
chronic pain, who are the subject of most other studies on the subject. 
Perceived control over pain has also been investigated, and there is less extensive evidence 
to support its role in relation to psychological functioning and disability in those with 
chronic pain secondary to physically disabling conditions. A study of people with spinal 
cord injury related chronic pain found that increases in perceived control over pain in a six 
month period was related to decreased pain intensity and pain interference, as well as 
increased psychological functioning, although the former was a non-significant finding 
(Hanley, et al., 2008). External locus of control in relation to pain as also been positively 
associated with depression among people with spinal cord injury related pain (Wollaars, et 
al., 2007). In addition, two studies of people with phantom limb pain, including a 
prospective study of people with phantom limb pain from one to 24 months, demonstrated 
some weak evidence for its influence on pain intensity, psychological functioning, and pain-
related disability (Hanley, et al., 2004; Hill, et al., 1995).  
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Other findings related to pain-related beliefs have also been noted but with much less 
consistency. A belief that pain is constant or enduring has been found to significantly 
predict both pain intensity and interference to activities due to pain among those with 
multiple sclerosis (Douglas, et al., 2008). The lower endorsement of the belief that others 
should be solicitous in response to pain behaviours was associated with better psychological 
functioning among people with muscular dystrophy (Miro, et al., 2009) 
3.1.3 Behavioural responses to pain 
Comparison of the use of behavioural responses to pain, also commonly referred to as 
coping strategies, among people with chronic pain secondary to physically disabling 
conditions to those with chronic primary pain conditions has revealed both similarities and 
differences. In people with cerebral palsy, use of behavioural coping strategies such as 
guarding and rest was reported to be less common and task persistence more common 
(Engel, et al., 2000). Conversely, cognitive coping strategies, such as diverting attention, 
reinterpreting sensations, and praying and hoping, were reportedly used more commonly. 
The authors suggest that some of these differences may be attributable to different 
background levels of the use of behavioural strategies such as resting and guarding, which 
may already be employed for non-pain related reasons among those with physically 
disabling conditions, and increased reliance on cognitive strategies over which they may be 
hypothesized to have more control. 
The association of particular coping strategies with pain intensity or associated 
psychological distress or disability has been explored in a number of physically disabling 
conditions, including spinal cord injury, but with few significant relationships detected 
(Hanley, et al., 2008; Turner, et al., 2002). In some other studies, however, significant 
relationships have been found. In a study of people with phantom limb pain, behavioural 
activity was found to be associated with higher levels of pain, in contrast with findings in 
those with chronic primary pain conditions (Hill, et al., 1995). Passive coping strategies, 
including guarding, resting, asking for assistance, seeking social support and pacing, were 
found to be predictive of pain interference but not psychological functioning among people 
with spinal cord injury and muscular dystrophy (Miro, et al., 2009; Molton, et al., 2009). 
Reduction of activity, through resting or avoidance, has been associated with positively 
associated with pain interference in people with cerebral palsy and muscular dystrophy, 
and with symptoms of depression in people with cerebral palsy (Engel, et al., 2000; Miro, et 
al., 2009). 
Seeking social support has been found to be positively associated with pain-related 
disability among people with cerebral palsy and muscular dystrophy (Engel, et al., 2006; 
Miro, et al., 2009), a finding that may initially appear counter-intuitive. The authors of the 
cerebral palsy study identified the fact that the items on the scale potentially reflect both 
adaptive and maladaptive aspects of social support seeking (Engel, et al., 2006). However, 
operant models of chronic pain suggest that pain contingent social support would result in 
increased disability, which may also provide a parsimonious explanation of the findings. 
The extent to which respondents with multiple sclerosis believed they were able to control 
or decrease their pain through use of their coping strategies has been found to be associated 
with decreased pain intensity, however no specific coping strategy was predictive (Douglas, 
et al., 2008). Further, in the same study no coping strategy was found to be predictive of life 
interference due to pain and only coping by increasing activities was found to be associated 
with improved psychological functioning. 
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3.2 Social factors 
Although clearly identified as part of the various biopsychosocial models of pain proposed, 
social factors have been relatively less well represented in the literature. Studies examining 
social factors most often report on perceived social support and partner responses to pain 
behaviours.  
3.2.1 Social support 
Studies examining the associations between social support and pain are available in people 
with limb loss, spinal cord injury, multiple sclerosis and muscular dystrophy.  
Social support was found to be negatively associated with pain in studies among people 
with traumatic limb loss, whereas no relationship was found in people with spinal cord 
injury pain (Kratz, et al., 2010; Stroud, Turner, Jensen, & Cardenas, 2006). Studies of people 
with multiple sclerosis have resulted in mixed findings, with negative associations with pain 
in one study and no association in the other (Motl, et al., 2009; Osborne, et al., 2007). A study 
designed to identify factors which were predictive of consistency of pain over ten years 
among people with spinal cord injury found that among male respondents, receiving less 
social support during the first phase of the study was predictive of continuing pain over the 
life of the study (Rintala, et al., 2004) 
Associations between lower levels of social support and greater pain-related disability has 
been found in people with non-traumatic limb loss, multiple sclerosis and muscular 
dystrophy, but not in people with spinal cord injury (Kratz, et al., 2010; Miro, et al., 2009; 
Motl, et al., 2009; Osborne, et al., 2007; Stroud, et al., 2006). In one study, greater social 
support at one month post amputation was predictive of greater reduction in pain 
interference at 12 and 24 months (Hanley, et al., 2004). In addition, increased social support 
has been found to be associated with lower levels of anxiety and depression in people with 
multiple sclerosis and with depression in people with spinal cord injury (Motl, et al., 2009; 
Stroud, et al., 2006). Among people with muscular dystrophy, social support was associated 
positively with psychological functioning (Miro, et al., 2009). Hanley et al. (2004) also looked 
at the relationship between social constraint, which is the need to hide one’s feelings about 
the amputation from others, and pain and pain-related interference. Increased need for 
social constraint was associated with pain intensity and interference in both those with 
traumatic and non-traumatic limb loss in the 6 to 12 month period.  
3.2.2 Partner responses to pain behaviours 
The most common maladaptive form of partner response to pain behaviours reported in the 
general chronic pain literature is that of solicitous responding, which is a key mechanism in 
operant models of pain, hypothesized to increase pain-related disability. A study in people 
with spinal cord injury chronic pain found perceived solicitous responding from partners 
were unrelated to pain intensity, pain-related disability, or depression (Stroud, et al., 2006). 
One study in people with limb loss found that less frequent solicitous responding at one 
month post amputation was predictive of greater reductions in pain interference at 12 and 
24 months (Hanley, et al., 2004). Other forms of partner responses to pain behaviour 
measured in people with spinal cord injury related chronic pain are negative and distracting 
responses (Stroud, et al., 2006). Negative responses, such as criticism, and distracting 
responses were both associated with higher depression, but not pain intensity or pain 
related disability. Most studies which report upon partner responses to pain behaviours in 
the context of physically disabling conditions provide information about participants 
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Other findings related to pain-related beliefs have also been noted but with much less 
consistency. A belief that pain is constant or enduring has been found to significantly 
predict both pain intensity and interference to activities due to pain among those with 
multiple sclerosis (Douglas, et al., 2008). The lower endorsement of the belief that others 
should be solicitous in response to pain behaviours was associated with better psychological 
functioning among people with muscular dystrophy (Miro, et al., 2009) 
3.1.3 Behavioural responses to pain 
Comparison of the use of behavioural responses to pain, also commonly referred to as 
coping strategies, among people with chronic pain secondary to physically disabling 
conditions to those with chronic primary pain conditions has revealed both similarities and 
differences. In people with cerebral palsy, use of behavioural coping strategies such as 
guarding and rest was reported to be less common and task persistence more common 
(Engel, et al., 2000). Conversely, cognitive coping strategies, such as diverting attention, 
reinterpreting sensations, and praying and hoping, were reportedly used more commonly. 
The authors suggest that some of these differences may be attributable to different 
background levels of the use of behavioural strategies such as resting and guarding, which 
may already be employed for non-pain related reasons among those with physically 
disabling conditions, and increased reliance on cognitive strategies over which they may be 
hypothesized to have more control. 
The association of particular coping strategies with pain intensity or associated 
psychological distress or disability has been explored in a number of physically disabling 
conditions, including spinal cord injury, but with few significant relationships detected 
(Hanley, et al., 2008; Turner, et al., 2002). In some other studies, however, significant 
relationships have been found. In a study of people with phantom limb pain, behavioural 
activity was found to be associated with higher levels of pain, in contrast with findings in 
those with chronic primary pain conditions (Hill, et al., 1995). Passive coping strategies, 
including guarding, resting, asking for assistance, seeking social support and pacing, were 
found to be predictive of pain interference but not psychological functioning among people 
with spinal cord injury and muscular dystrophy (Miro, et al., 2009; Molton, et al., 2009). 
Reduction of activity, through resting or avoidance, has been associated with positively 
associated with pain interference in people with cerebral palsy and muscular dystrophy, 
and with symptoms of depression in people with cerebral palsy (Engel, et al., 2000; Miro, et 
al., 2009). 
Seeking social support has been found to be positively associated with pain-related 
disability among people with cerebral palsy and muscular dystrophy (Engel, et al., 2006; 
Miro, et al., 2009), a finding that may initially appear counter-intuitive. The authors of the 
cerebral palsy study identified the fact that the items on the scale potentially reflect both 
adaptive and maladaptive aspects of social support seeking (Engel, et al., 2006). However, 
operant models of chronic pain suggest that pain contingent social support would result in 
increased disability, which may also provide a parsimonious explanation of the findings. 
The extent to which respondents with multiple sclerosis believed they were able to control 
or decrease their pain through use of their coping strategies has been found to be associated 
with decreased pain intensity, however no specific coping strategy was predictive (Douglas, 
et al., 2008). Further, in the same study no coping strategy was found to be predictive of life 
interference due to pain and only coping by increasing activities was found to be associated 
with improved psychological functioning. 
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3.2 Social factors 
Although clearly identified as part of the various biopsychosocial models of pain proposed, 
social factors have been relatively less well represented in the literature. Studies examining 
social factors most often report on perceived social support and partner responses to pain 
behaviours.  
3.2.1 Social support 
Studies examining the associations between social support and pain are available in people 
with limb loss, spinal cord injury, multiple sclerosis and muscular dystrophy.  
Social support was found to be negatively associated with pain in studies among people 
with traumatic limb loss, whereas no relationship was found in people with spinal cord 
injury pain (Kratz, et al., 2010; Stroud, Turner, Jensen, & Cardenas, 2006). Studies of people 
with multiple sclerosis have resulted in mixed findings, with negative associations with pain 
in one study and no association in the other (Motl, et al., 2009; Osborne, et al., 2007). A study 
designed to identify factors which were predictive of consistency of pain over ten years 
among people with spinal cord injury found that among male respondents, receiving less 
social support during the first phase of the study was predictive of continuing pain over the 
life of the study (Rintala, et al., 2004) 
Associations between lower levels of social support and greater pain-related disability has 
been found in people with non-traumatic limb loss, multiple sclerosis and muscular 
dystrophy, but not in people with spinal cord injury (Kratz, et al., 2010; Miro, et al., 2009; 
Motl, et al., 2009; Osborne, et al., 2007; Stroud, et al., 2006). In one study, greater social 
support at one month post amputation was predictive of greater reduction in pain 
interference at 12 and 24 months (Hanley, et al., 2004). In addition, increased social support 
has been found to be associated with lower levels of anxiety and depression in people with 
multiple sclerosis and with depression in people with spinal cord injury (Motl, et al., 2009; 
Stroud, et al., 2006). Among people with muscular dystrophy, social support was associated 
positively with psychological functioning (Miro, et al., 2009). Hanley et al. (2004) also looked 
at the relationship between social constraint, which is the need to hide one’s feelings about 
the amputation from others, and pain and pain-related interference. Increased need for 
social constraint was associated with pain intensity and interference in both those with 
traumatic and non-traumatic limb loss in the 6 to 12 month period.  
3.2.2 Partner responses to pain behaviours 
The most common maladaptive form of partner response to pain behaviours reported in the 
general chronic pain literature is that of solicitous responding, which is a key mechanism in 
operant models of pain, hypothesized to increase pain-related disability. A study in people 
with spinal cord injury chronic pain found perceived solicitous responding from partners 
were unrelated to pain intensity, pain-related disability, or depression (Stroud, et al., 2006). 
One study in people with limb loss found that less frequent solicitous responding at one 
month post amputation was predictive of greater reductions in pain interference at 12 and 
24 months (Hanley, et al., 2004). Other forms of partner responses to pain behaviour 
measured in people with spinal cord injury related chronic pain are negative and distracting 
responses (Stroud, et al., 2006). Negative responses, such as criticism, and distracting 
responses were both associated with higher depression, but not pain intensity or pain 
related disability. Most studies which report upon partner responses to pain behaviours in 
the context of physically disabling conditions provide information about participants 
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perception of their significant others solicitous responses to their pain behaviours. One 
study in people with spinal cord injury reported on partner’s ratings of their own responses 
to pain behaviour, and it was notable that these were unrelated to pain intensity, depression 
or pain-related disability in their partner (Stroud, et al., 2006). 
3.3 Summary 
Reviewing the evidence presented here, a number of issues are apparent. First, that there is 
a great deal of variation across physically disabling conditions in the extent to which 
biopsychosocial factors have been investigated. Second, that over all the conditions 
considered, social factors are relatively less well explored and this remains a significant 
omission in the literature. Despite this, and the variation in the patterns in each specific 
physically disabling condition, across the majority of the conditions for which data is 
available it is clear that there is evidence to suggest that psychological and social factors are 
broadly related to pain intensity, as well as associated disability and distress. Across all the 
factors which have been investigated thus far, it appears that the findings related to pain 
catastrophizing and its association with pain intensity and related disability and distress are 
the most consistent. This suggests that pain catastrophizing should be explored as part of 
assessment protocols for people with chronic pain associated with physically disabling 
conditions. Further research in the area is clearly needed, particularly prospective studies 
that begin prior to the development of chronic pain, and which are sufficiently large to 
permit demographic and medical factors to be controlled for in the analyses.  
4. Interventions focused on psychological and social factors 
There are two major reasons why psychosocial interventions for pain might be considered 
for people with chronic pain secondary to physically disabling conditions. The first, that 
psychosocial variables are important contributors to variance in pain itself, as well as pain 
related distress or disability, and the second, that existing interventions based on biomedical 
models of pain are insufficient. The evidence presented in the previous section suggests 
that, while there are gaps in the literature, there is sufficient reason to think that 
psychosocial variables do make a significant contribution to pain and associated distress 
and disability. In addition, there is evidence that people with chronic pain secondary to a 
range of physically disabling conditions, including cerebral palsy, stroke and multiple 
sclerosis, are unlikely to be receiving treatment for their pain, are dissatisfied with the pain 
treatment available to them or report limited improvement in pain despite treatment (Engel, 
et al., 2003; Hirsh, et al., 2010; Kalia & O'Connor, 2005; Kong, et al., 2004). 
Psychosocial interventions for people with chronic pain, predominantly behavioural and 
cognitive behavioural in origin, are well-established and supported by an extensive evidence 
base (Meldrum, 2007). A series of systematic reviews and meta-analyses attest to the efficacy of 
these programs among child and adults with primary chronic pain conditions, as well as early 
interventions designed to reduce the development of pain-related disability (Eccleston, 
Morley, Williams, Yorke, & Mastroyannopoulou, 2002; Eccleston, Yorke, Morley, Williams, & 
Mastroyannopoulou, 2003; Linton & Nordin, 2006; Morley, Eccleston, & Williams, 1999).  
4.1 The nature of psychosocial interventions 
A very small number of studies have been published that specifically report on the use of 
psychosocial interventions among people with physically disabling conditions. The majority 
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of these have involved group-based cognitive behavioural pain management programs, but 
they also include cognitive restructuring and hypnosis. The potential use of such 
interventions in people with spinal cord injury was identified in the early 1990’s (Umlauf, 
1992), but a review of the literature concerning the application and evaluation of these 
programs among any group with a physically disabling condition reveals a disappointingly 
small number of studies and little translation into standard practice. 
4.2 Feasibility and acceptability of psychosocial interventions 
A study undertaken in the US specifically examined the issue of the feasibility and 
acceptability of psychosocial interventions, with a mixed sample of individuals with chronic 
pain of more than six months duration occurring secondary to multiple sclerosis, 
amputations, spinal cord injury and cerebral palsy (Ehde & Jensen, 2004). The study found 
that both the cognitive restructuring intervention, and the control condition which was an 
educational intervention, were both rated positively by the participants. A study of a 
cognitive behavioural pain management program for people with spinal cord injury 
neuropathic pain reported that attendance at the group was high and participants reported 
that they were very satisfied with the program (Norrbrink Budh, Kowalski, & Lundeberg, 
2006). Authors of another study, examining the effectiveness of a cognitive behavioural pain 
management program for people with spinal cord injury, provide an analysis of the issues 
encountered in the implementation of the program (Nicholson Perry, Nicholas, & 
Middleton, 2010; Nicholson Perry, Nicholas, & Middleton, 2011). These findings suggest that 
these interventions are potentially acceptable, at least to people with spinal cord injury 
related pain. 
4.3 Use and effectiveness of psychosocial interventions 
Psychosocial interventions for pain either described for use with or evaluated with people 
with physically disabling conditions are extremely few. They are mainly cognitive 
behavioural, group-based pain management programs, but examples of the use of cognitive 
restructuring alone and hypnosis are also reported. 
4.3.1 Cognitive behavioural group-based pain management programs 
Four group-based, cognitive behavioural pain management program of various sorts are 
described in the literature (Cundiff, Blair, & Puckett, 1995; Gironda, 2004; Nicholson Perry, 
et al., 2010; Norrbrink Budh, et al., 2006). The main components of such interventions are 
represented in Table 1. The earliest reports in the literature of cognitive behavioural pain 
management programs in physically disabling conditions were for spinal cord injury pain 
and were descriptive. Cundiff and colleagues (1995) described the development of a group-
based cognitive behavioural pain management program for people with spinal cord injury 
pain of all types. This involved many of the common components of pain management 
programs for primary pain diagnoses, including: the explanation of the self-management 
model, relaxation (including diaphragmatic breathing, guided imagery), the role of self-talk, 
and pain behaviours and their impact. Gironda (2004) reported on an intervention which 
was characterized as an interdisciplinary pain management program for spinal cord injury 
shoulder pain. It was described as a functional preservation approach aimed at enabling 
individuals to maintain and improve functional capacities where injuries had already been 
sustained. The program was provided during a two week in-patient stay and comprised of: 
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perception of their significant others solicitous responses to their pain behaviours. One 
study in people with spinal cord injury reported on partner’s ratings of their own responses 
to pain behaviour, and it was notable that these were unrelated to pain intensity, depression 
or pain-related disability in their partner (Stroud, et al., 2006). 
3.3 Summary 
Reviewing the evidence presented here, a number of issues are apparent. First, that there is 
a great deal of variation across physically disabling conditions in the extent to which 
biopsychosocial factors have been investigated. Second, that over all the conditions 
considered, social factors are relatively less well explored and this remains a significant 
omission in the literature. Despite this, and the variation in the patterns in each specific 
physically disabling condition, across the majority of the conditions for which data is 
available it is clear that there is evidence to suggest that psychological and social factors are 
broadly related to pain intensity, as well as associated disability and distress. Across all the 
factors which have been investigated thus far, it appears that the findings related to pain 
catastrophizing and its association with pain intensity and related disability and distress are 
the most consistent. This suggests that pain catastrophizing should be explored as part of 
assessment protocols for people with chronic pain associated with physically disabling 
conditions. Further research in the area is clearly needed, particularly prospective studies 
that begin prior to the development of chronic pain, and which are sufficiently large to 
permit demographic and medical factors to be controlled for in the analyses.  
4. Interventions focused on psychological and social factors 
There are two major reasons why psychosocial interventions for pain might be considered 
for people with chronic pain secondary to physically disabling conditions. The first, that 
psychosocial variables are important contributors to variance in pain itself, as well as pain 
related distress or disability, and the second, that existing interventions based on biomedical 
models of pain are insufficient. The evidence presented in the previous section suggests 
that, while there are gaps in the literature, there is sufficient reason to think that 
psychosocial variables do make a significant contribution to pain and associated distress 
and disability. In addition, there is evidence that people with chronic pain secondary to a 
range of physically disabling conditions, including cerebral palsy, stroke and multiple 
sclerosis, are unlikely to be receiving treatment for their pain, are dissatisfied with the pain 
treatment available to them or report limited improvement in pain despite treatment (Engel, 
et al., 2003; Hirsh, et al., 2010; Kalia & O'Connor, 2005; Kong, et al., 2004). 
Psychosocial interventions for people with chronic pain, predominantly behavioural and 
cognitive behavioural in origin, are well-established and supported by an extensive evidence 
base (Meldrum, 2007). A series of systematic reviews and meta-analyses attest to the efficacy of 
these programs among child and adults with primary chronic pain conditions, as well as early 
interventions designed to reduce the development of pain-related disability (Eccleston, 
Morley, Williams, Yorke, & Mastroyannopoulou, 2002; Eccleston, Yorke, Morley, Williams, & 
Mastroyannopoulou, 2003; Linton & Nordin, 2006; Morley, Eccleston, & Williams, 1999).  
4.1 The nature of psychosocial interventions 
A very small number of studies have been published that specifically report on the use of 
psychosocial interventions among people with physically disabling conditions. The majority 
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of these have involved group-based cognitive behavioural pain management programs, but 
they also include cognitive restructuring and hypnosis. The potential use of such 
interventions in people with spinal cord injury was identified in the early 1990’s (Umlauf, 
1992), but a review of the literature concerning the application and evaluation of these 
programs among any group with a physically disabling condition reveals a disappointingly 
small number of studies and little translation into standard practice. 
4.2 Feasibility and acceptability of psychosocial interventions 
A study undertaken in the US specifically examined the issue of the feasibility and 
acceptability of psychosocial interventions, with a mixed sample of individuals with chronic 
pain of more than six months duration occurring secondary to multiple sclerosis, 
amputations, spinal cord injury and cerebral palsy (Ehde & Jensen, 2004). The study found 
that both the cognitive restructuring intervention, and the control condition which was an 
educational intervention, were both rated positively by the participants. A study of a 
cognitive behavioural pain management program for people with spinal cord injury 
neuropathic pain reported that attendance at the group was high and participants reported 
that they were very satisfied with the program (Norrbrink Budh, Kowalski, & Lundeberg, 
2006). Authors of another study, examining the effectiveness of a cognitive behavioural pain 
management program for people with spinal cord injury, provide an analysis of the issues 
encountered in the implementation of the program (Nicholson Perry, Nicholas, & 
Middleton, 2010; Nicholson Perry, Nicholas, & Middleton, 2011). These findings suggest that 
these interventions are potentially acceptable, at least to people with spinal cord injury 
related pain. 
4.3 Use and effectiveness of psychosocial interventions 
Psychosocial interventions for pain either described for use with or evaluated with people 
with physically disabling conditions are extremely few. They are mainly cognitive 
behavioural, group-based pain management programs, but examples of the use of cognitive 
restructuring alone and hypnosis are also reported. 
4.3.1 Cognitive behavioural group-based pain management programs 
Four group-based, cognitive behavioural pain management program of various sorts are 
described in the literature (Cundiff, Blair, & Puckett, 1995; Gironda, 2004; Nicholson Perry, 
et al., 2010; Norrbrink Budh, et al., 2006). The main components of such interventions are 
represented in Table 1. The earliest reports in the literature of cognitive behavioural pain 
management programs in physically disabling conditions were for spinal cord injury pain 
and were descriptive. Cundiff and colleagues (1995) described the development of a group-
based cognitive behavioural pain management program for people with spinal cord injury 
pain of all types. This involved many of the common components of pain management 
programs for primary pain diagnoses, including: the explanation of the self-management 
model, relaxation (including diaphragmatic breathing, guided imagery), the role of self-talk, 
and pain behaviours and their impact. Gironda (2004) reported on an intervention which 
was characterized as an interdisciplinary pain management program for spinal cord injury 
shoulder pain. It was described as a functional preservation approach aimed at enabling 
individuals to maintain and improve functional capacities where injuries had already been 
sustained. The program was provided during a two week in-patient stay and comprised of: 
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medication adjustment; an exercise regimen designed to increase range of motion, 
endurance and stretch in upper limbs; biomechanical education; a psychoeducational 
component designed to enhance understanding of the self-management approach, promote 
problem-solving and implementation of strategies at home, raise awareness of 
compensatory responses that may be impacting upon psychological or physical well-being; 
and recreation therapy to encourage return to social and leisure interests. Preliminary data 
from eight participants in the program suggested improvements across a range of domains, 





Information is presented about the underlying pain mechanisms 
relevant to chronic pain, including central sensitization, as well as 
the limitations of medical treatment for chronic pain. 
Goal-setting 
Collaborative goal-setting related to a variety of goals across a 
wide spread of domains, including physical activities or mood, 
emphasizing the identification of short-term goals building 
towards long-term goals that are challenging but achievable in 
order to increase a sense of mastery. 
Activity pacing Adoption of quota or time based activities, systematically upgraded over time and linked to goals. 
Relaxation Applied relaxation to reduce muscle tension and improve sleep. 
Functional exercise Whole body reconditioning exercise programme related functional physical goals. 
Stretch Whole body daily stretch programme. 
Cognitive therapy Identification and modification of unhelpful thoughts regarding pain, such as catastrophizing.  
Medication reduction Gradual reduction of inappropriate or excessive pain medications using an agreed schedule. 
Flare-up management 
& relapse prevention 
Development of a plan to manage temporary increases in pain 
(flare ups) or other situations likely to trigger relapse. 
Table 1. Common components of cognitive behavioural pain management programs 
Two controlled studies have been published which have examined the effectiveness of 
cognitive behavioural group pain management programs for people with physically 
disabling conditions, both in those with spinal cord injury (Nicholson Perry, et al., 2010; 
Norrbrink Budh, et al., 2006). The first controlled study in the literature described a 
cognitive behavioural pain management program for people with neuropathic pain arising 
from a spinal cord injury (Norrbrink Budh et al., 2006). The program developed was very 
like the pain management programs described for people with primary pain diagnoses in 
content, although of shorter duration (totalling 50 hours over ten weeks). Compared with 
those in the no-treatment control group, those participating in the program showed 
significant improvements in depression and sense of coherence (a concept comprising 
comprehensibility, manageability and meaningfulness of the injury) over 12 months. While 
there were no other significant differences between the groups, the treatment group showed 
improvements in anxiety symptoms, emotional reaction and sleep from baseline to the 12-
month evaluation, but no significant changes over time were observed in the other outcome 
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measures (including pain intensity and unpleasantness, health-related quality of life and life 
satisfaction). An Australian study compared a cognitive behavioural pain management 
program with standard care in a tertiary pain management service in Australia. The 
program was a modification of an existing program, the design and implementation of 
which is reported in depth elsewhere, which was approximately half of the usual number of 
contact hours (Nicholson Perry, et al., 2011). The group attending the pain management 
program showed an overall improved in mood and pain-related disability at the end of the 
program compared with the controlled group. This was associated with significant 
decreases in pain catastrophizing and anxiety in the pain management program group. 
Three-quarters of people completing the pain management program reported a clinically 
significant improvement, in contrast to less than a third in the usual care comparison group, 
however long-term follow up data in this group suggested that benefits were not 
maintained at six months. Both programs were approximately half of the optimal dose (100 
hours) recommended for the management of patients with heterogeneous, disabling chronic 
pain in a pain management program (Guzman, et al., 2001). While it may appear at first 
sight that there is a degree of inconsistency in providing an intervention incorporating 
pacing, where other evidence suggests pacing is an unhelpful strategy among those with 
chronic pain due to physically disabling conditions, this may be a matter of definition; 
pacing as taught in cognitive behavioural pain management programs takes a systematic 
approach to continuing to build up quotas of activity which it may be hypothesized is 
absent in what respondents would endorse as pacing in surveys of pain-related coping 
strategies. However, the findings from the evaluation of the programs suggested that there 
was merit in pursuing the use of cognitive behavioural pain management programs in the 
context of refractive spinal cord injury pain.  
4.3.2 Cognitive restructuring 
A pilot program exploring the use of a cognitive restructuring intervention targeting 
catastrophizing for a heterogeneous group of people with disability related chronic pain has 
recently been reported (Ehde & Jensen, 2004). The authors compared eight 90-minute sessions 
of cognitive restructuring with an education control intervention among 18 people with 
disability-related chronic pain (including those with amputations, spinal cord injury, cerebral 
palsy and multiple sclerosis). The cognitive restructuring intervention included: the role of 
negative cognitions; how to identify maladaptive thinking; thought-stopping and cognitive 
restructuring techniques; and use of reassuring self-statements. The education control 
intervention included pain education (underlying mechanisms and theories of pain), sleep 
problems in pain and common pain treatments. The authors report that nine of those who 
attended the first session did not return, but of the eighteen who did continue with their 
treatment all reported benefiting from the intervention regardless of the group attended. The 
preliminary results reported by the authors, describing mean pain intensity on a range of 0 to 
10 before and after attendance, suggested that whereas pain intensity was unchanged in those 
attending the education group there was a reduction of approximately 0.2 of a standard 
deviation among those participating in the cognitive intervention. The authors conclude that a 
properly powered controlled trial would be required to establish the effectiveness of this 
approach, but that it was certainly feasible to provide and regarded as acceptable by at least 
half the patients. Although the literature on the use of psychosocial interventions in people 
with physically disabling conditions is limited, there is some evidence of similar therapeutic 
mechanisms operating in these populations as in chronic primary pain conditions (Burns, 
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medication adjustment; an exercise regimen designed to increase range of motion, 
endurance and stretch in upper limbs; biomechanical education; a psychoeducational 
component designed to enhance understanding of the self-management approach, promote 
problem-solving and implementation of strategies at home, raise awareness of 
compensatory responses that may be impacting upon psychological or physical well-being; 
and recreation therapy to encourage return to social and leisure interests. Preliminary data 
from eight participants in the program suggested improvements across a range of domains, 





Information is presented about the underlying pain mechanisms 
relevant to chronic pain, including central sensitization, as well as 
the limitations of medical treatment for chronic pain. 
Goal-setting 
Collaborative goal-setting related to a variety of goals across a 
wide spread of domains, including physical activities or mood, 
emphasizing the identification of short-term goals building 
towards long-term goals that are challenging but achievable in 
order to increase a sense of mastery. 
Activity pacing Adoption of quota or time based activities, systematically upgraded over time and linked to goals. 
Relaxation Applied relaxation to reduce muscle tension and improve sleep. 
Functional exercise Whole body reconditioning exercise programme related functional physical goals. 
Stretch Whole body daily stretch programme. 
Cognitive therapy Identification and modification of unhelpful thoughts regarding pain, such as catastrophizing.  
Medication reduction Gradual reduction of inappropriate or excessive pain medications using an agreed schedule. 
Flare-up management 
& relapse prevention 
Development of a plan to manage temporary increases in pain 
(flare ups) or other situations likely to trigger relapse. 
Table 1. Common components of cognitive behavioural pain management programs 
Two controlled studies have been published which have examined the effectiveness of 
cognitive behavioural group pain management programs for people with physically 
disabling conditions, both in those with spinal cord injury (Nicholson Perry, et al., 2010; 
Norrbrink Budh, et al., 2006). The first controlled study in the literature described a 
cognitive behavioural pain management program for people with neuropathic pain arising 
from a spinal cord injury (Norrbrink Budh et al., 2006). The program developed was very 
like the pain management programs described for people with primary pain diagnoses in 
content, although of shorter duration (totalling 50 hours over ten weeks). Compared with 
those in the no-treatment control group, those participating in the program showed 
significant improvements in depression and sense of coherence (a concept comprising 
comprehensibility, manageability and meaningfulness of the injury) over 12 months. While 
there were no other significant differences between the groups, the treatment group showed 
improvements in anxiety symptoms, emotional reaction and sleep from baseline to the 12-
month evaluation, but no significant changes over time were observed in the other outcome 
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measures (including pain intensity and unpleasantness, health-related quality of life and life 
satisfaction). An Australian study compared a cognitive behavioural pain management 
program with standard care in a tertiary pain management service in Australia. The 
program was a modification of an existing program, the design and implementation of 
which is reported in depth elsewhere, which was approximately half of the usual number of 
contact hours (Nicholson Perry, et al., 2011). The group attending the pain management 
program showed an overall improved in mood and pain-related disability at the end of the 
program compared with the controlled group. This was associated with significant 
decreases in pain catastrophizing and anxiety in the pain management program group. 
Three-quarters of people completing the pain management program reported a clinically 
significant improvement, in contrast to less than a third in the usual care comparison group, 
however long-term follow up data in this group suggested that benefits were not 
maintained at six months. Both programs were approximately half of the optimal dose (100 
hours) recommended for the management of patients with heterogeneous, disabling chronic 
pain in a pain management program (Guzman, et al., 2001). While it may appear at first 
sight that there is a degree of inconsistency in providing an intervention incorporating 
pacing, where other evidence suggests pacing is an unhelpful strategy among those with 
chronic pain due to physically disabling conditions, this may be a matter of definition; 
pacing as taught in cognitive behavioural pain management programs takes a systematic 
approach to continuing to build up quotas of activity which it may be hypothesized is 
absent in what respondents would endorse as pacing in surveys of pain-related coping 
strategies. However, the findings from the evaluation of the programs suggested that there 
was merit in pursuing the use of cognitive behavioural pain management programs in the 
context of refractive spinal cord injury pain.  
4.3.2 Cognitive restructuring 
A pilot program exploring the use of a cognitive restructuring intervention targeting 
catastrophizing for a heterogeneous group of people with disability related chronic pain has 
recently been reported (Ehde & Jensen, 2004). The authors compared eight 90-minute sessions 
of cognitive restructuring with an education control intervention among 18 people with 
disability-related chronic pain (including those with amputations, spinal cord injury, cerebral 
palsy and multiple sclerosis). The cognitive restructuring intervention included: the role of 
negative cognitions; how to identify maladaptive thinking; thought-stopping and cognitive 
restructuring techniques; and use of reassuring self-statements. The education control 
intervention included pain education (underlying mechanisms and theories of pain), sleep 
problems in pain and common pain treatments. The authors report that nine of those who 
attended the first session did not return, but of the eighteen who did continue with their 
treatment all reported benefiting from the intervention regardless of the group attended. The 
preliminary results reported by the authors, describing mean pain intensity on a range of 0 to 
10 before and after attendance, suggested that whereas pain intensity was unchanged in those 
attending the education group there was a reduction of approximately 0.2 of a standard 
deviation among those participating in the cognitive intervention. The authors conclude that a 
properly powered controlled trial would be required to establish the effectiveness of this 
approach, but that it was certainly feasible to provide and regarded as acceptable by at least 
half the patients. Although the literature on the use of psychosocial interventions in people 
with physically disabling conditions is limited, there is some evidence of similar therapeutic 
mechanisms operating in these populations as in chronic primary pain conditions (Burns, 
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Kubilus, Bruehl, Harden, & Lofland, 2003). In particular, the observation of the association 
between decreased pain catastrophising and improvements in mood and disability in those 
who participate in the interventions is consistent with findings in other chronic pain 
populations (Jensen, et al., 2011; Nicholson Perry, et al., 2010). This cognitive restructuring 
intervention therefore has particular promise as it targets pain catastrophizing, but requires 
implementation of a smaller range of treatment strategies than traditional cognitive 
behavioural pain management programs as described above.  
4.3.3 Hypnosis 
Hypnosis has also been applied to spinal cord injury related pain in a series of studies (Ehde 
& Jensen, 2007) using individual hypnosis treatments with 10 sessions over four weeks and 
daily practice. The suggestions used were reported to include imagery, changing sensations 
and ignoring pain, with associated post-hypnotic suggestions that a relaxed state and the 
ability to ignore pain will become increasingly easy. The case studies found that a sub-group 
of individuals with disability-related pain were able to obtain decreases in pain severity, 
with associated improvements in mood, sleep and general well-being in individual cases. 
However, in the absence of randomized controlled trials, no firm conclusions can be drawn 
about the effectiveness of hypnosis in this context. 
In a variation of the more common cognitive behavioural interventions reported in the 
literature, a cognitive restructuring approach combined with self-hypnosis training was 
reported in people with multiple sclerosis (Jensen, et al., 2011). This intervention was 
intended to target pain catastrophising as well as pain intensity. When compared with 
either cognitive restructuring or hypnosis alone, or the control condition, the combined 
approach resulted in a decrease in the frequency of pain catastrophising and increase in 
the frequency of reassuring cognitions, as well as improved average and worst pain 
intensity. 
4.4 Barriers to the use of psychosocial interventions 
While access to specialist pain management services of any type is problematic, there are 
some additional reasons to think that access to psychosocial pain interventions will be 
particularly difficult for those with physically disabling conditions. Broadly, these include 
the demands of providing such services and accessibility of such services. Health 
professionals specialising in the provision of psychosocial interventions for chronic pain, 
such as clinical psychologists, tend to be limited in supply and concentrated in specialist 
services in major cities. The skills and expertise required to provide psychosocial pain 
management interventions to those with physically disabling conditions requires expertise 
in both pain and some of the specific aspects of the physically disabling condition which 
may impact upon the delivery of the intervention. This includes having an understanding of 
the physically disabling conditions and its associated symptoms, such as motor function or 
fatigue, and how these may impact upon the relevance or implementation of the strategies 
taught. The additional challenges to mobility from having a physically disabling conditions, 
as well as chronic pain, in combination with environmental barriers which must be 
overcome to attend a specialist pain management service reduces the chances that an 
individual with a chronic pain problem due to a physically disabling condition will be able 
to attend. The costs of living with a physically disabling condition may result in limited 
financial resources available to fund travel or accommodation in locations where specialist 
pain management services are available. 
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Service delivery models which are able to overcome some of these barriers are yet to be 
designed, and many of the interventions with a research pedigree to support them have not 
generalized to routine care due to the lack of support to assist with translation into routine 
clinical practice. The increased availability of high speed internet may permit the use of 
online interventions to provide at least some access to some of the components of effective 
psychosocial interventions for chronic pain, either for use alone or with the support of a 
health professional, and this may be of particular benefit to those with pain secondary to 
physically disabling conditions. 
4.5 Summary  
Despite the limited evidence available about the effective of psychosocial interventions in 
people with physically disabling conditions, the findings suggest that there is merit in 
further research to evaluate their usefulness in a broader range of conditions. Intervention 
studies in this area are notoriously difficult, due to the many barriers to participation and 
retention in trials. National and international collaborations are likely to be necessary to 
ensure a sufficient sample size for such studies to be adequately powered. Provision of these 
services is impeded by a number of practical barriers, some of which might at least partially 
addressed by making more effective use of information technology (World Health 
Organisation, 2011). While there is currently insufficient evidence to support a wholesale 
recommendation to use these interventions in all physically disabling conditions, in light of 
the dissatisfaction with pain treatment among many with chronic pain secondary to 
physically disabling conditions they may be considered for use on an individual basis. 
5. Conclusion 
It can be concluded based upon the data presented that the application of biopsychosocial 
models to the understanding, assessment and management of chronic pain associated with 
physically disabling conditions is at an early stage of development. There is a well-established 
body of research in some conditions, such as spinal cord injury, whereas almost nothing is 
known about the application of these models to other conditions, notably Parkinson’s Disease. 
Many of the patterns observed in primary pain conditions are replicated in these conditions, 
but the exceptions noted underscore the importance of caution in generalising findings from 
one condition to another. Relatively, research concerning the use of psychosocial interventions 
is less well-developed that research examining the relationships between psychosocial and 
pain variables in physically disabling conditions. Despite this, the findings generally are 
suggestive of an important role of including psychosocial variables in our conceptualization of 
individual differences in the experience of chronic pain and its consequences in people with 
physically disabling conditions, and the possibility of improved outcomes through the use of 
psychosocial interventions. 
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1. Introduction 
Chronic pain of childhood is an extremely complex condition which can lead to damaging 
effects on physical and social wellbeing. Some children with severe chronic pain embark on 
a downward spiral of decreased physical, psychological and social functioning. This 
includes loss of mobility and inability to participate in physical and sporting activities, poor 
sleep, difficulty concentrating on school work, school absenteeism, social isolation and 
family stress. As chronic pain persists the child can experience increased pain intensity, 
distress, anxiety and depression. When enmeshed in this disordered lifestyle the child and 
their family require coordinated integrated care. The interdisciplinary team management 
approach, based on pharmacology, physiotherapy and psychology, is now well established 
to be the standard of care for children with chronic pain. Treatment goals are targeted to 
individual children after careful consideration of the history and examination. In 
appropriately selected children peripheral nerve blocks can provide immediate and effective 
pain relief. This chapter will present a referenced review of the literature on 
interdisciplinary paediatric chronic pain management whilst highlighting the role of 
peripheral nerve blocks.  The case histories of eight paediatric patients with chronic pain 
who gained significant relief from peripheral nerve blocks will be presented.  
The International Association for the Study of Pain (IASP) defines pain as “an unpleasant 
sensory or emotional experience associated with actual or potential tissue damage, or 
described in terms of such damage” (1986). One defining characteristic of pain is its 
duration. Acute pain is relatively short-term pain that typically lasts until the underlying 
cause has been identified and treated. On the other hand, chronic pain is understood to 
mean prolonged pain or “pain that extends beyond the expected period of healing" (Turk & 
Okifuji, 2001) and while defined time frames that determine a diagnosis of chronic pain 
vary, the definition adopted by most studies, including those cited here, is pain lasting 
longer than three months.  
Chronic pain can have its roots in one or a combination of types of pain mechanism. Types 
of pain include nociceptive, inflammatory, neuropathic or psychogenic pain (DSM-IV “Pain 
Disorder”). Extreme caution is required before labelling a patient with a diagnosis of 
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psychogenic pain, functional pain or somatisation disorder as the true prevalence of these 
conditions is extremely low. Most patients with chronic pain will have psychosocial 
elements to their suffering, but this does not mean that the pain is “psychogenic”.  
Nociceptive pain is felt in response to noxious stimuli, such as the trauma associated with 
injury, oncological and other disease processes as well as following surgery. This pain 
functions as a protective and interpretable symptom: ‘it hurts here’ means ‘here is the 
damage’ and can be a straightforward guide to what needs to be treated or allowed to 
heal. Inflammatory pain occurs as a result of inflammatory mediators in many disease 
processes or associated with healing following acute trauma or surgery. If either 
nociceptive or inflammatory pains are left unrecognised or undertreated they can lead to 
ongoing and then chronic pain. Neuropathic pain signifies some dysfunction in the nervous 
system itself and is a major cause of chronic suffering, occurring in about 6-7% of the 
population (Vinik, 2010).  
Neuropathic pain may derive from some identifiable damage to the nerves, resulting from a 
disease process, inflammation or accidental damage during trauma or surgery, or may result 
from a failure of integration and function of the peripheral and central nervous systems. Many 
conditions previously labelled as functional pain are now known to have peripheral and 
central nervous elements, which would re-class them as neuropathic pain. Complex regional 
pain syndrome (CRPS) is an immuno-neurological disorder (Fechir et al, 2008). It may be 
associated with no nerve lesion (type I) or may be related to some identifiable nerve lesion 
(type II). Chronic conditions like functional abdominal pain syndrome (FAPS) and CRPS have 
been under-recognised by physicians, but are experienced by a significant number of 
adolescents (Clouse et al, 2006; Kachko et al, 2008). In summary, a combination of pain 
mechanisms may be involved in the development of chronic pain conditions. 
1.1 The epidemiology of paediatric chronic pain 
The epidemiology of chronic pain in children is less well understood than it is in adults, 
but some useful studies have been published in the last decade that help us to understand 
the overall scale of the problem and to elicit some socio-demographic particulars of the 
affected population. A survey of over 5,000 children aged 0 – 18 years in the Netherlands 
reported that 25% had experienced some form of chronic or recurrent pain (Perquin et al, 
2000). A Spanish study, of 561 schoolchildren aged 8 – 16 years, reported an incidence of 
37%, but concluded that only 5% suffer moderate or severe chronic pain (Huguet & Miró, 
2008). In a Canadian study of 495 schoolchildren aged 9 - 13, more than half reported 
having experienced at least one recurrent pain, typically characterised as a headache, 
stomach pain or 'growing pain'. Although 46% reported a 'long-lasting' pain, the 
researchers judged that in many cases this represented a recurrent pain condition; 
nonetheless, 6% of children were classified as having possible, probable or definite 
chronic pain (van Dijk et al, 2006).  
While these studies highlight the methodological difficulties in distinguishing acute, 
recurrent and chronic pain from children's responses to questionnaire and interview 
questions, these statistics clearly also demonstrate that childhood chronic pain is a 
significant problem: slightly more than one child in every twenty is a chronic pain sufferer; 
that is, at least one child in every average-sized classroom in every school. Perquin et al 
(2000) conclude that childhood chronic pain is 'a common experience' and that the incidence 
of severe chronic pain amongst adolescents should provoke both concern and further 
research from the healthcare community. 
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Previous pain experiences, cognitive, emotional and behavioural factors, family 
background, environment, peer group and culture have an influence on the impact, 
perception and biopsychosocial outcomes of chronic pain. Children living in lower 
educated, lower income families have been found to be at a greater risk of suffering 
recurrent pain, which is consistent with adult studies (Grøholt et al, 2003). Children 
suffering chronic pain themselves are quite likely to be living with another chronic pain 
sufferer, whether parent or sibling, and further investigation suggests that pre-existing 
chronic pain in the family environment is a predictor of both physical and psychological 
effects on the child (Lynch et al, 2006). Ethnicity and area of residence also appear to affect 
prevalence rates. For example, in Canada, the incidence of chronic pain is higher among 
Aboriginal people and, for males, is higher in rural areas (Ramage-Morin & Gilmour, 2010). 
There may also be cultural differences in the perception and reporting of pain (Mailis-
Gagnon et al, 2007).  
While chronic pain is clearly not confined to the developed world, most published studies 
provide figures for European or North American children, which may not be 
generalisable to different environments. A US study found that 13% of 12-13 year-olds 
and 17% of 15-16 year-olds experience abdominal pain every week (Hyams et al, 1996), 
while Dutta et al (1999) reported a considerably higher incidence (74%) in India. However, 
with gastrointestinal infections more widespread than the inflammatory bowel disease 
seen in developing countries, these figures probably represent the outcome of different 
disease processes (Ganesh et al, 2010). Abu-Saad Huijer (2010) considers the effects of war 
and traumatic events. Despite an absence of research in this area, he argues that chronic 
pain has been linked with post-traumatic stress disorders and that, as a consequence, we 
may expect to see a different profile of chronic pain among children affected by armed 
conflict.  
In developed countries, headache, abdominal and musculoskeletal pain form the primary 
foci of chronic and recurrent pain among the paediatric population. In their study of 
Canadian 9-13 year olds, van Dijk et al (2006) received reports of recurrent headaches (32%), 
growing pains (21%), stomach pains (19%) and muscle aches (2%). Perquin et al (2000) had 
published similar findings from their survey of Dutch schoolchildren, in which they also 
analysed reports of pain at multiple locations. They found that the single location pain was 
most often reported. The combination of headache and abdominal pain was the most 
commonly reported multiple pain, found in 25% of all children. This greater than one pain 
profile was significantly more prevalent in adolescent girls.  
Recent figures from a Statistics Canada health report identify chronic pain among 2.4% of 
males and 5.9% of females aged 12 to 17 years (Ramage-Morin & Gilmour, 2010). It has been 
reported that girls are as much as three times more likely to report chronic pain than boys 
(Martin et al, 2007). Perquin et al (2000) also showed a significant increase in the prevalence 
of chronic pain in girls. These girls were aged between 12 and 14 which may well be linked 
with the onset of menstruation. In general, abdominal pain is significantly more likely to be 
reported by girls and limb pain (or growing pains/muscle aches) is significantly more likely 
to be reported by boys (Perquin et al, 2000; van Dijk et al, 2006). A review on gender and 
pain suggests potential mechanisms within social and psychological processes, such as 
coping processes and catastrophising, are likely to contribute to the repeatedly observed sex 
differences in pain (Fillingim et al, 2009). 
Aetiology and predisposition to chronic pain in children is largely unknown and depends 
on the type of pain. Factors associated with the development of chronic pain include 
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with the onset of menstruation. In general, abdominal pain is significantly more likely to be 
reported by girls and limb pain (or growing pains/muscle aches) is significantly more likely 
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surgery, trauma, emotional distress and chronic disease. In many cases, a definitive 
aetiology is difficult to establish. Even chronic post-surgical pain (CPSP) can be difficult to 
diagnose and consequently remains under-recognised. However, it represents a significant 
clinical problem. A 2006 review suggests that CPSP occurs after 10-50% of operations and 
results in severe chronic pain in 2-10% of these patients (Kehlet et al, 2006). This may, in fact, 
represent a significant portion of chronic pain sufferers. A UK study found that 22.5% of 
chronic pain patients developed their condition after surgery (Crombie et al, 1998). CPSP 
will often be neuropathic, resulting from nerve damage during surgery, though it could also 
be an ongoing inflammatory/nociceptive mechanism. The incidence of CPSP in the adult 
population is found to depend on a number of perioperative factors which include: genetic 
predisposition, degree of pre-operative anxiety, depression, pre-operative pain status, the 
surgical pain model, surgical technique, length of surgery and the quality of acute 
postoperative pain management (Kehlet et al, 2006; Macrae, 2008). The probability of an 
adult developing chronic pain after mastectomy or hernia surgery is decreased with 
increased age (Poleshuck et al, 2006; Poobalan et al, 2003). How this relationship to age 
translates to children and adolescents is not known as there is no published literature on 
CPSP in children. Six out of the eight paediatric cases presented in this chapter developed 
chronic pain following surgery. 
Untangling factors to establish clear causality for the development of paediatric chronic pain 
is a challenge. Whether initiated by surgery or injury or other cause, it is a complex multi-
factorial process. Understanding this mechanism requires not only a search for a cause, but 
also a clearer understanding of the effects of chronic pain. It is established that some 
paediatric chronic pain conditions have been under-diagnosed. Better recognition and early 
treatment of these conditions requires that healthcare providers understand the effects of 
chronic pain on a child and their family.  
1.2 The impact of chronic pain on children and their families 
Childhood chronic pain has a negative impact on physical, psychological and social 
function. It can prevent a child participating in sporting activities and other forms of 
exercise. It can cause sleep disruption and fatigue. It can contribute to depression and 
anxiety. It can affect school work through fatigue, poor memory and concentration and 
result in reduced school attendance. Friendships and family relationships are disrupted 
which may lead to varying degrees of social isolation. An Australian study of 207 children 
and adolescents attending a paediatric pain management clinic found that 95% had missed 
school, 90% had been unable to participate in some sporting activity and 71% had suffered 
some sleep disruption (Chalkiadis, 2001). Roth-Isigkeit et al (2005) found that 30-40% of 
children/adolescents with pain reported effects of their pain on school attendance, hobbies, 
social contacts, appetite, sleep, as well as increased utilization of health services because of 
their pain. An understanding of the range and interaction of all these different effects is 
crucial to the effective recognition and treatment of chronic pain in children.  
These impacts on daily living can be bundled into the notion of Health-Related Quality of 
Life (HRQoL), which may be defined as “an individual’s subjective assessment of his or her 
functioning and emotional state” (Gold et al, 2009) and can be used for comparative purposes. 
One such measurement instrument is the Pediatric Quality of Life Inventory (PedsQL), 
which contains items relating specifically to both physical and psychosocial function (the 
latter comprising emotional, social and school function) and can be completed by self-report 
or parent-proxy (Varni et al, 2001). Using this instrument, a US study of 100 patients, aged 
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2–21 years, attending a chronic pain clinic found that the HRQoL scores of these patients 
were not only considerably lower than scores obtained from normal healthy children, but 
were significantly lower than scores observed in children with rheumatological or cancer 
disease (Vetter, 2008). Another US study found that the mean PedsQL score for a cohort of 
69 children and adolescents (aged 8 – 18 years) seeking outpatient pain management 
services, fell below the ‘at-risk cut-off score’ for all dimensions except social functioning, 
suggesting that the majority of these children were experiencing significant disruption in 
their day-to-day lives. The message from these studies is clear: the effects of chronic pain on 
a child’s quality of life are wide-ranging and profound. 
School functioning has received perhaps the most attention (Palermo, 2000). It demonstrates 
the most marked detriment of all the psychosocial dimensions of the PedsQL scale (Vetter, 
2008; Gold et al, 2009) and clearly illustrates the complex effects of chronic pain on quality of 
life. A child with chronic pain may experience a range of problems which impact on their 
schooling: fatigue and/or poor sleep profile prevents early morning waking; pain inhibits 
physical ability to get to school, to sit in a classroom for long periods or to participate in 
physical activities; fear of pain by accidentally being knocked during recess times inhibits 
social interaction and imparts a sense of isolation, difference and not being involved with 
peers; poor memory and concentration affects schoolwork; as school work becomes missed 
or incomplete these unfinished projects become a barrier to return to school if workload is 
not controlled; and the school may represent an environment where their pain condition is 
not properly understood or tolerated. 
For all these reasons school absences are common. In a survey of adolescent chronic pain 
sufferers aged 12-17 in Boston USA, 44% missed more than one-quarter of school days 
and 20% had missed more than half (Logan et al, 2008). Of course, schools typically offer 
only a limited degree of health-related support. In the Boston study, two-thirds of 
participants had received some form of accommodation from their school, such as being 
sent to the nurse's office, being sent home in pain, reduction in workload, extension on an 
assignment, and so on. Nonetheless, 44.3% of parents reported their child's grades had 
suffered (Logan et al, 2008) and missing school can clearly have negative consequences 
that extend beyond academic performance to a child's physical, emotional and social 
development. Six of the eight cases presented in this chapter had missed significant 
amounts of school. 
Assessing the impact of chronic pain on a child's life is an important but problematic task. 
There are a number of reasons for this difficulty.  
Firstly, the specific effects of chronic pain are not easily isolated from one another. For 
example, fatigue may be a mediating factor between pain and school functioning (Gold et al, 
2009). Anxiety also plays a complex role in moderating the relationship between pain and 
function. Tsao et al (2007) studied anxiety sensitivity, or the fear of anxiety sensations, in 87 
children aged 10-18 presenting at a US chronic pain clinic. Anxiety sensitivity was found to 
be linked with academic and/or social limitations, where those limitations arose from 
emotional rather than physical difficulties. Greater anxiety sensitivity was associated with 
lower self-esteem and perceived general and mental health, and with more behavioural 
problems and family disruption, but did not appear to affect physical functioning (Tsao et 
al, 2007). In a similar study of 222 adolescents aged 11 to 19 years attending two chronic 
pain clinics in the UK, Cohen et al (2010) found that in children with low anxiety, level of 
pain was a good predictor of physical and social function, but that high levels of anxiety 
prompted poorer function regardless of the level of pain. 
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Secondly, the impact of chronic pain on health and quality of life often extends beyond any 
immediate effects. For example, more than 50% of adolescents with chronic pain report 
some symptoms of insomnia (compared with less than 20% of healthy adolescents), and 
while these may initially be related directly to the experience of pain, behavioural patterns 
can transform this disruption into a primary sleep disorder (Palermo et al, 2010). 
Furthermore, chronic pain in childhood appears to increase the risk of developing further 
chronic conditions in adulthood. Adults, who have suffered recurrent headaches as 
children, are at an increased risk not only of headaches, but other physical and psychiatric 
symptoms (Fearon & Hotopf, 2001). Similarly, a longitudinal cohort study of paediatric 
FAPS patients, aged 6 to 18 at enrolment, found that, 15 years later, those with unresolved 
FAPS experienced higher levels of non-abdominal chronic pain (including migraine, 
tension-type headaches, and pelvic, back and limb pain) than those with resolved FAPS or 
normal controls (Walker et al, 2010). 
Thirdly, the effects of chronic pain are felt not just by the child, but become a burden for the 
whole family. The child may no longer participate in shared physical activities, limiting 
family excursions and fun. Relationships with parents, siblings and other family members 
are put under strain resulting in anxiety and depression (Eccleston et al, 2004). A number of 
studies report associations between family functioning and the level of a child’s pain-related 
disability, generally finding that the worse the disability, the greater the family dysfunction 
(Lewandowski et al, 2010). While it is difficult to interpret the causal relationship 
underpinning this association with confidence, it is likely that causation runs in both 
directions: a child’s chronic pain has an adverse effect on family life; family problems make 
it more difficult for the child to cope and so worsen the experience of pain. The impact of 
chronic pain on the family matches the adverse impact experienced by families caring for 
children at home with severe cerebral palsy or birth defects (Vetter, 2008). 
Daily care arrangements for the child/adolescent with chronic pain require additional 
support, which may cost money or require a parent to give up a job. The direct and indirect 
costs of caring for a child with chronic pain have been estimated. A UK study calculated, 
from a sample of 52 families, that the total annual cost, to a family living with a child in 
chronic pain, was as much as £14,160 or, approximately, $25,000 (Sleed et al, 2005). This 
figure included direct healthcare costs for the child and other family members and indirect 
costs such as loss of earnings, adaptations to housing, over-the-counter medications and 
care assistance. This is a potentially ruinous sum for low-income families.  
Fourthly, physical and social effects of chronic pain carry another associated economic 
burden, which may be less easily identified and difficult to quantify. Diminished school 
function and educational achievement will have potential long-term career and economic 
cost for both the child and for society.  
Finally, the immediate effects of chronic pain have the potential to feed back negatively on 
the physical and psychosocial health of children and their families. This further reduces 
their capacity to cope. Unremitting pain can cause sleep disruption and fatigue. Missing 
school leads to social isolation. The extra burden of stress and financial hardship on families 
makes them less able to provide the required care.  The physical, psychological and social 
effects of chronic pain can lead the child and their family into a downward spiral, from 
which it is difficult to emerge without inter-disciplinary support. It is crucial that physicians 
not only identify the wider psychosocial effects of chronic pain, but recognise that these 
effects are contributory factors which play an important role in the ongoing pain and 
functioning of their patient (Jensen, 2011). With the goal of optimal patient care in mind, a 
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clinician should consider including interventions that address these factors in their 
treatment strategies for children with chronic pain.  
1.3 Interdisciplinary team management of children with chronic pain 
Management of children and adolescents with severe suffering and extensive pain-related 
disability as a result of chronic pain requires an interdisciplinary approach (Eccleston et al, 
2003). This includes the treatment modalities of pharmacology, physiotherapy and 
psychology running in parallel or, more importantly, enmeshed with one another. How 
these elements are balanced is dependant on each individual child and takes into 
consideration the type and duration of pain, as well as the impact of pain on particular 
biopsychosocial aspects of the child’s life. 
1.3.1 Pharmacology 
The pharmacological approach to management of a child with chronic pain requires 
consideration of the type of pain, the impact of the pain on the child’s biopsychosocial 
functions and the potential side effects of the medications. Medications need to be 
individualised to each child and continually re-assessed for efficacy and side effects. If 
medications are having no impact at therapeutic dosage they need to be discontinued and 
the child re-evaluated for consideration of other appropriate agents. Close liaison with 
psychiatry is advised prior to and following up on prescription of mood stabilising 
medications. It is important to emphasise that pharmacological interventions are only one 
part of an interdisciplinary approach to improve function in children/adolescents with 
chronic pain. Table 1 provides a summary of the medications that may be considered in the 
pharmacological treatment of paediatric chronic pain. 
 
Drug Dose Comments 
Acetamin-
ophen  
>3 months of age to 
adolescents:  
10-15 mg/kg/dose PO 
Q4H PRN (max 75 
mg/kg/day) 
 
Central analgesic action via cannabinoid  or prostaglandin 
mechanism 
Hepatotoxic in acute overdose or with chronic long term use; 
risk factors for toxicity include fever, prolonged fasting 
 (>48 hrs), concomitant interacting drugs, obesity, poorly 
controlled diabetes, liver disease, viral infections and 
malnutrition 
Doses apply to normal healthy children (i.e. no hepatic or renal 
compromise) 
Ibuprofen 5-10 mg/kg/dose PO Q6-
8H (max 40 mg/kg/day) 
Non steroidal anti-inflammatory agent; should not be used 
concomitantly with other NSAIDs 
Use caution in patients with aspirin hypersensitivity, hepatic 
or renal insufficiency 
Administer with food or milk to lessen GI upset; 
contraindicated with active GI bleeding and ulcer disease 
Naprosyn Children >2 years: 
5-7 mg/kg/dose PO/PR 
Q8-12H 
 
Non steroidal anti-inflammatory agent; should not be used 
concomitantly with other NSAIDs 
Contraindicated with active GI bleeding and ulcer disease; 
administer with food or milk to avoid GI upset; common GI 
side effects include abdominal pain, appetite loss, stomatitis or 
constipation 
May cause photosensitive vesicular rash (pseudoporphyria) 
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Finally, the immediate effects of chronic pain have the potential to feed back negatively on 
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their capacity to cope. Unremitting pain can cause sleep disruption and fatigue. Missing 
school leads to social isolation. The extra burden of stress and financial hardship on families 
makes them less able to provide the required care.  The physical, psychological and social 
effects of chronic pain can lead the child and their family into a downward spiral, from 
which it is difficult to emerge without inter-disciplinary support. It is crucial that physicians 
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Immediate-release form:  
Children: 1-2 mg/kg Q4-
6H PRN (max: 400 
mg/day or 8 mg/kg/day) 
Adolescents: 
50-100 mg Q4-6H PRN 
(max: 400 mg/day) 
 
Extended-release form: 
Adolescents: Initial: 100 
mg PO daily; titrate by 100 
mg increments every 2-3 
days PRN (max: 300 
mg/day). 
An opioid analgesic with norepinephrine and serotonin effects 
Side effects include nausea and vomiting; tolerability is 
improved by gradual dose titration.   
Caution in renal and/or hepatic impairment 
Tramadol is metabolized to active form (i.e. a prodrug) 
Inter-individual pharmacogenomic variations affect  
efficacy 
Serotonin syndrome reported with concurrent use of 
serotonergic drugs 
Seizures reported with concurrent TCAs, SSRIs, and opioids or 
with conditions that lower seizure threshold 
Withdrawal symptoms may develop if abruptly discontinued; 
do not suddenly stop long-term treatment; wean dose by 25% 
per week 
Extended release product given ONCE daily. 
Topical 
Lidocaine  
Topical: 5% under 
occlusive  
dressing for 12 hours 
(once per day) 
Blockade of upregulated sodium channel receptors in injured 
nerves.  
Useful for very localised pain  
Minimal side effects (mild skin reactions) 
Amitriptyline Initial: 0.1 mg/kg/dose 
PO HS; increase as needed 
and tolerated over 2-3 wks 
to 0.5-2 mg/kg/dose HS 
Tricyclic antidepressant agent (TCA) used in low dose for 
chronic neuropathic pain; prevents the re-uptake of serotonin 
and norepinephrine. 
Pretreatment ECG required to exclude arrhythmia potential. 
Drug interactions via cytochrome p450 system; 
contraindicated if MAO inhibitors used within 14 days; 
tricyclics have limited efficacy for treatment of depression in 
children and adolescents 
Side effects include: sedation, confusion, weakness, fatigue, 
tremor, sweating, headache, anticholinergic effects, 
cardiovascular effects (including orthostatic hypotension, 
tachycardia, prolonged QTc and arrhythmias at higher plasma 
levels), decreased seizure threshold. 
Sedative side effect used to help with improved sleep profile 
If one TCA not helpful due to intolerable side effects try 
another with a different SE profile before abandoning this 
modality of pharmacological therapy (Nortriptyline is less 
sedating, doxepin less anticholinergic). 
Analgesic effect may not occur for 2 weeks from 
commencement.  
A withdrawal syndrome is documented for Tricyclics (flu-like 
symptoms, dizziness, mood changes). Assess patient carefully 
and limit prescribed quantities to minimum effective dose; do 
not suddenly stop long-term treatment; wean dose by 25% per 
week. 
 Gabapentin Children: titrate to effect 
over a few days, starting 
at 2 mg/kg once or twice 
daily, then increase to TID 
dosing to a maximum of 
35 mg/kg/24hr  
(max 3600 mg/day) 
Calcium channel α 2-δ ligand; calcium channel blocker when 
neuron hyperexcited 
Analgesic, anticonvulsant, anxiolytic, and sleep-modulating 
activities. 
Side effects may include somnolence, ataxia, fatigue and 
behaviour change. 
Gradual dose increase helps to minimize sedation; increased 
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Drug Dose Comments 
oral doses are associated with decreased bioavailability; do not 
administer with antacids; primarily excreted unchanged in the 
urine, therefore need to adjust dose in renal impairment 
Maximum dose often not be needed for maximum effect; do 
not suddenly stop long-term treatment; wean dose by 25% per 
week. 
Pregabalin Children > 10 years: 
Initial: 25 mg PO daily 
Titrate upward to effect to 
2.5 mg/kg PO BID or max 
300 mg/day  
Calcium channel α 2-δ ligand; calcium channel blocker when 
neuron hyperexcited.  
Similar in mechanism to gabapentin 
Side effects may include somnolence, ataxia, fatigue and 
behaviour change. 
Gradual dose increase helps to minimize sedation; increased 
oral doses are associated with increased bioavailability; do not 
administer with antacids; primarily excreted unchanged in the 
urine, therefore need to adjust dose in renal impairment. 
Maximum dose often not be needed for maximum effect; do 
not suddenly stop long-term treatment; wean dose by 25% per 
week. 
Opioids For dosing of different 
agents see Compendium 
of Pharmaceuticals and 
Specialties 
mu-opioid agonist 
Additive sedative effects with other medications and/or 
alcohol 
Side effects include sedation, nausea, vomiting, constipation, 
pruritis, tolerance dependance opioid induced hyperalgesia, 
addiction 
Long-term use rarely indicated in children; addiction potential 
should be assessed prior to commencement of opioids; opioid 
prescription should follow national guidelines for safe practice 
Venlafaxine Initial Dose: 
37.5 – 75 mg PO Once 
DAILY 
Increment: 
37.5-75 mg  every 4-7 days 
Usual Dose Range: 
75-225 mg/day  
Serotonin/norepinephrine reuptake inhibitor (SNRI) 
Effective in the treatment of Depression, Generalized Anxiety 
Disorder, Social Anxiety Disorder, Panic Disorder. Also used 
to treat ADHD, Post-Traumatic Stress Disorder and   
Obsessive-Compulsive Disorder. 
Side effects include: headache, nausea, increased heart rate 
and blood pressure (more prominent at higher doses), 
anorexia/weight loss, drowsiness, dizziness, dry  mouth, 
sweating, tremor and impaired sexual function 
(adolescents/adults). 
Administer with food or milk to decrease GI upset; full 
beneficial effects may not be seen until 4 weeks of therapy 
completed. 
Warnings issued by Health Canada regarding use of 
antidepressants in pediatric patients.  
Clonidine 1-4 micrograms/kg/dose 
PO Q4-6H 
An alpha adrenergic receptor antagonist; metabolism is 
hepatic and renal (roughly 50:50); drug interactions with beta 
blockers, tricyclic anti-depressants 
Sedative, anxiolytic and analgesic effects; a useful adjunct used 
to minimise other analgesic drug doses such as opioids 
Side effects include sedation, dry mouth, hypotension 
Do not suddenly stop long-term treatment; wean dose by 25% 
per week to prevent rebound hypertension 
Table 1. Modalities of medications that may be considered in outpatient paediatric chronic 
pain management 
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Chronic pain sufferers often experience some level of physical incapacity and many adopt 
activity patterns that can make their pain worse, such as alternating episodes of over-
activity and under-activity (Birkholtz et al, 2004). Physiotherapy plays an important role in 
the interdisciplinary treatment of chronic pain in children and adolescents. Eccleston & 
Eccleston (2004) divide it into the following four components:  
 Exercise – this is used to increase aerobic endurance, flexibility, strength and overall 
fitness, which all  have potential benefits for pain reduction;  
 Education – this helps the patient relate their pain to their anatomy, physiology and 
activity levels and to address issues such as fear of movement and the potential for re-
injury;  
 Behavioural management – this may involve physical retraining and activity pacing, 
aiming for a gradual increase in the range and extent of movement, including a steady 
return to any activities abandoned since the onset of pain (see also Harding et al, 1998);  
 Performance assessment – there is a clear link between reduced pain and improved 
physical function; the physiotherapist is well-placed to assess treatment progress. 
Other reports of physiotherapy interventions in the treatment of chronic pain stress the 
importance of the interdisciplinary approach. For example, a combination of physical 
therapy and CBT has been shown to be effective in treating CRPS in children (Lee et al, 
2002). Harding et al (1998) also highlight the need to integrate behavioural and cognitive 
components in activity training to minimise distress and unhelpful beliefs. 
1.3.3 Psychology 
There are a number of psychological factors, which are directly involved in the perception, 
reporting and self-management of pain. These include fear, vigilance to the feeling and 
threat of pain, catastrophising, avoidance of pain-inducing activity, sadness, depression, 
anger and self-denigration. Psychological factors are also important in coping mechanisms, 
taking action, and being able to predict or make sense of pain and its consequences 
(Eccleston, 2001). Psychologists provide continual education/reassurance on the 
pathophysiology of the chronic pain condition and teach mind-body techniques like 
breathing, muscle relaxation exercises, self-hypnosis, imagery, and cognitive strategies. 
These techniques help reduce the impact of pain on daily living and mood.  
Cognitive behaviour therapy (CBT) is central to the notion of interdisciplinary care. CBT 
refers to an “integration of treatments aimed at reducing or extinguishing the influence of the 
factors that maintain patients' maladaptive behaviours, beliefs and patterns of thought... and is 
delivered by a team of pain therapists, including anaesthetists, clinical psychologists and 
physiotherapists” (Eccleston, 2001). Interdisciplinary CBT programmes aimed at adolescents 
with chronic musculoskeletal pain have been found to improve physical function, reduce 
emotional distress, increase attendance at school and reduce medicine consumption 
(Eccleston et al, 2003; de Blécourt et al, 2008). Furthermore, there is evidence to suggest that 
an interdisciplinary framework is beneficial for the family members involved. Schurman & 
Friesen (2010) report that an 'integrative care' approach in a paediatric Abdominal Pain 
Clinic (that is, service delivered by a gastroenterologist and a psychologist) was acceptable 
to families, produced higher satisfaction scores and, crucially, improved receptivity to 
treatment recommendations.  
Relaxation strategies and plans to improve sleep hygiene are a vital part of the 
psychologist’s role. When schooling has been impacted by pain, the psychologist helps 
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teachers become more aware of the condition and its impact on schoolwork. The 
psychologist helps to negotiate or advocate for any accommodations needed in order to help 
the child succeed at school. Psychologists help the child and their family identify and 
resolve stresses such as anxiety or depression that could be preventing return to function.  
A Cochrane Review determined that there is strong evidence for psychological therapies 
being effective in the treatment of headaches in children and some evidence for their 
efficacy in the treatment of musculoskeletal and recurrent abdominal pain (Eccleston et al, 
2009). Psychological interventions are often, and ideally, delivered as part of an 
interdisciplinary approach and consequently there are few randomized-controlled-trial 
(RCT) studies providing definite evidence for individual therapies (McGrath & Holahan, 
2003). Nonetheless, psychological techniques are a vital component of the interdisciplinary 
approach and experienced therapists will select particular techniques according to the needs 
of the individual patient.  
1.3.4 Interventional therapies  
Interventional procedures offered at Canadian paediatric multidisciplinary pain treatment 
facilities (MPTFs) include continuous epidural infusions, single epidural injections, facet 
injections, stellate ganglion nerve blocks, peripheral nerve blocks, trigger point injections, 
sympathetic blocks with local anaesthetic, Botox injections, intravenous regional 
anaesthesia, paravertebral nerve blocks and radiofrequency lesioning (Peng et al, 2007). 
Nerve blocks are used widely among Canadian anaesthesiologists who specifically 
practice chronic pain management: of those, 84% perform nerve blocks, compared with 
60% who use pharmacotherapy, and a majority of them estimated that more than 40% of 
their patients require some form of nerve block as part of their treatment programme 
(Peng & Castano, 2005). 
However, there is very little evidence to demonstrate that interventions benefit a patient 
more than would be seen from a placebo response. The literature is comprised of case 
reports and small case series, along with a few randomized, placebo-controlled trials 
(RCTs). For example, therapeutic lumbar facet joint nerve blocks can provide effective 
pain relief and functional improvement (Manchikanti et al, 2010). However, epidural 
corticosteroid injections for sciatica appear to offer only transient benefit (Arden et al, 
2005). Results of RCTs are not always consistent, however. For example, one RCT has 
shown that radiofrequency lesioning of the dorsal root ganglion for treatment of chronic 
lumbosacral radicular pain appears not to be more effective than control treatment with 
local anaesthetic (Geurts et al, 2003); on the the other hand, another RCT has shown that it 
is both safe and effective (Simopoulos et al, 2008). For some techniques, such as 
myofascial trigger point injections, it has not even been possible to establish a consensus 
on methods for diagnosis or treatment (Tough et al, 2007). Furthermore, any RCTs that 
have been done mainly comprise adult studies. The evidence of efficacy in 
children/adolescents is even more limited and more research is required. There are also 
rare but significant iatrogenic risks associated with some of these interventions. Injection 
therapies for lower back pain carry the risk of paraspinal, spinal end epidural abscesses or 
meningitis (Gaul et al, 2005). 
Despite this negative portrayal of interventional medicine for chronic pain “absence of 
evidence is not evidence of absence” (Altman & Bland, 1995) and there are many pain 
physicians and patients, including those in this case series, who have derived enormous 
benefit from interventional treatments.  
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2. Case reports 
The cases are described below and summarised in table 2.  
 
No Gender Age Weight Site  of pain 
Duration 
(months) Diagnosis Block(s) performed 
1 Male 16 60kg Chest 5 Intercostal neuralgia related to Nuss bar 
Intercostal nerve blocks (1 
diagnostic and 3 
therapeutic) 
2 Male 14 56kg Abdomen 9 Abdominal wall pain 
Bilateral rectus abdominis 
sheath blocks (diagnostic 
and therapeutic) 




Ilioinguinal nerve blocks (1 
diagnostic and 3 
therapeutic ) 
4 Male 15 66kg Abdomen 3 Neuropathic pain, not incisional hernia 
Intercostal nerve block; 
rectus sheath block. 




Rectus abdominis sheath 
block 
6 Female 15 45kg Rib 8 Intercostal neuralgia, post-surgery 
intercostal nerve blocks 
(diagnostic and 
therapeutic) 
7 Female 9 33kg Abdomen 2 
Abdominal wall pain 
following laparascopic 
appendectomy 
Bilateral rectus abdominis 
sheath blocks (diagnostic 
and therapeutic) 
8 Female 17 66kg Rib 7 Intercostal neuralgia 
Intercostal nerve blocks 
(diagnostic and 
therapeutic) 
Table 2. Summary of cases 
2.1 Case 1: A 16-year-old adolescent with chest pain related to a Nuss bar 
A 60kg 16-year-old male presented with a 5 month history of right sided chest wall pain.  
He had undergone a Nuss procedure for cosmetic repair of pectus excavatum one year prior 
to presentation and had received satisfactory acute pain management with epidural 
analgesia. He was referred to the Pain Service by his surgeon. His pain was precipitated  
by a sudden lateral movement, but aggravated by activity, laughter and bending down.  
The pain was described as “shooting”. The pain was not relieved by ibuprofen and/or 
acetaminophen. 
This young man, an active kick-boxer, was extremely fit and well. However, his pain was so 
unremitting that he had to stop all sporting activities and was completely sedentary. His 
sleep was not disrupted, nor was his school attendance or academic performance. However, 
he was very frustrated that his pain prevented him pursuing his kick-boxing and his ability 
to perform simple physical tasks. He was able to maintain friendships, but could not engage 
in some of the more physical social activities. 
On examination, his pain was found to radiate laterally from the site of his Nuss bar on the 
right side, in one dermatomal level at the level of the 7th rib from midaxillary line to 
sternum. There was no pain on palpation or deep inspiration/expiration. There was no 
numbness, allodynia or skin changes. Palpation of the thoracic spines, costochondral 
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junctions, and left side of chest were unremarkable and pain free. His chest X-ray (CXR) 
revealed that his Nuss bar had not moved, with no bony reaction or wire migration. The 
CXR was otherwise normal. The presumed diagnosis was intercostal neuralgia. 
A diagnostic intercostal nerve block was performed, which provided effective short-term 
symptomatic relief so a follow-up therapeutic block was done 10 days later.  For the 
therapeutic block, 5mls of 0.25% bupivicaine with 1/200,000 epinephrine and 10mg 
triamcinolone was injected at four sites: at the affected rib, one above, one below and at the 
right sided Nuss bar insertion scar site. This provided complete pain relief to allow the 
patient to return to his previous physical activities.  
He required repeat therapeutic blocks at 3 months and 1 year from the initial block for 
resurgence of pain, but had no further pain up to and after the removal of the Nuss bar. 
2.2 Case 2: A 14-year-old male with abdominal pain 
A 56kg 14-year-old male presented with a 9 month history of abdominal pain. There was no 
apparent precipitating event. He was referred to the Pain Service after multiple referrals and 
investigations had excluded a remedial cause for his pain but drawn a blank on a diagnosis. 
The pain was described as a dull, aching pain, present all the time, but worse with exercise 
and on palpation. There was no pattern to his pain or any relation to his diet. There were no 
other symptoms related to the abdominal system. The pain was not relieved by ibuprofen, 
acetaminophen or homeopathic remedies.  
This young man had been extremely fit and well. However his pain was such that he had to 
stop all his sporting activities, experienced difficulty getting to sleep, was depressed and 
grumpy with his family and had been absent from school for the preceding 6 months.  
On examination, his abdomen was slim and soft, with normal bowel sounds, no masses and 
no organomegaly. There was tenderness in the midline above the umbilicus, which was 
worse on abdominal wall tensing (Carnett’s test positive). The presumed diagnosis was 
chronic abdominal wall pain. 
A diagnostic bilateral rectus sheath block was performed above the umbilicus under 
ultrasound control which provided effective short-term symptomatic relief so a follow-up 
therapeutic block was done two weeks later.  For the therapeutic block 10mls of 0.25% 
bupivicaine with 1/200,000 epinephrine and 20mg triamcinolone was injected at each site. 
He did not require repeat therapeutic blocks.  
Two weeks after his therapeutic block, he slowly returned to his normal activity levels, 
sleeping and eating patterns and resumed his previous happy demeanour. The following 
term, he returned to school and reported no subsequent absences.  
2.3 Case 3: An 18-year-old with groin pain after hydrocele repair 
A 60kg 18-year-old male presented with a 1 year history of a shooting pain in his groin, 
which was present all the time and radiated down the medial aspect of his thigh to his knee. 
There was no apparent precipitating event; however, he was a competitive fencer and had 
undergone a left hydrocele repair 6 months prior to the onset of pain. The pain was worse in 
morning, walking up stairs and mobilizing from lying down. He had episodes of severe 
pain 2-3 times per day, which lasted several hours. 
He was referred to the Pain Service after multiple referrals and investigations had excluded 
a remedial cause for his pain, but drawn a blank on a diagnosis. The pain was not relieved 
by acetaminophen.  
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2. Case reports 
The cases are described below and summarised in table 2.  
 
No Gender Age Weight Site  of pain 
Duration 
(months) Diagnosis Block(s) performed 
1 Male 16 60kg Chest 5 Intercostal neuralgia related to Nuss bar 
Intercostal nerve blocks (1 
diagnostic and 3 
therapeutic) 
2 Male 14 56kg Abdomen 9 Abdominal wall pain 
Bilateral rectus abdominis 
sheath blocks (diagnostic 
and therapeutic) 




Ilioinguinal nerve blocks (1 
diagnostic and 3 
therapeutic ) 
4 Male 15 66kg Abdomen 3 Neuropathic pain, not incisional hernia 
Intercostal nerve block; 
rectus sheath block. 




Rectus abdominis sheath 
block 
6 Female 15 45kg Rib 8 Intercostal neuralgia, post-surgery 
intercostal nerve blocks 
(diagnostic and 
therapeutic) 
7 Female 9 33kg Abdomen 2 
Abdominal wall pain 
following laparascopic 
appendectomy 
Bilateral rectus abdominis 
sheath blocks (diagnostic 
and therapeutic) 
8 Female 17 66kg Rib 7 Intercostal neuralgia 
Intercostal nerve blocks 
(diagnostic and 
therapeutic) 
Table 2. Summary of cases 
2.1 Case 1: A 16-year-old adolescent with chest pain related to a Nuss bar 
A 60kg 16-year-old male presented with a 5 month history of right sided chest wall pain.  
He had undergone a Nuss procedure for cosmetic repair of pectus excavatum one year prior 
to presentation and had received satisfactory acute pain management with epidural 
analgesia. He was referred to the Pain Service by his surgeon. His pain was precipitated  
by a sudden lateral movement, but aggravated by activity, laughter and bending down.  
The pain was described as “shooting”. The pain was not relieved by ibuprofen and/or 
acetaminophen. 
This young man, an active kick-boxer, was extremely fit and well. However, his pain was so 
unremitting that he had to stop all sporting activities and was completely sedentary. His 
sleep was not disrupted, nor was his school attendance or academic performance. However, 
he was very frustrated that his pain prevented him pursuing his kick-boxing and his ability 
to perform simple physical tasks. He was able to maintain friendships, but could not engage 
in some of the more physical social activities. 
On examination, his pain was found to radiate laterally from the site of his Nuss bar on the 
right side, in one dermatomal level at the level of the 7th rib from midaxillary line to 
sternum. There was no pain on palpation or deep inspiration/expiration. There was no 
numbness, allodynia or skin changes. Palpation of the thoracic spines, costochondral 
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junctions, and left side of chest were unremarkable and pain free. His chest X-ray (CXR) 
revealed that his Nuss bar had not moved, with no bony reaction or wire migration. The 
CXR was otherwise normal. The presumed diagnosis was intercostal neuralgia. 
A diagnostic intercostal nerve block was performed, which provided effective short-term 
symptomatic relief so a follow-up therapeutic block was done 10 days later.  For the 
therapeutic block, 5mls of 0.25% bupivicaine with 1/200,000 epinephrine and 10mg 
triamcinolone was injected at four sites: at the affected rib, one above, one below and at the 
right sided Nuss bar insertion scar site. This provided complete pain relief to allow the 
patient to return to his previous physical activities.  
He required repeat therapeutic blocks at 3 months and 1 year from the initial block for 
resurgence of pain, but had no further pain up to and after the removal of the Nuss bar. 
2.2 Case 2: A 14-year-old male with abdominal pain 
A 56kg 14-year-old male presented with a 9 month history of abdominal pain. There was no 
apparent precipitating event. He was referred to the Pain Service after multiple referrals and 
investigations had excluded a remedial cause for his pain but drawn a blank on a diagnosis. 
The pain was described as a dull, aching pain, present all the time, but worse with exercise 
and on palpation. There was no pattern to his pain or any relation to his diet. There were no 
other symptoms related to the abdominal system. The pain was not relieved by ibuprofen, 
acetaminophen or homeopathic remedies.  
This young man had been extremely fit and well. However his pain was such that he had to 
stop all his sporting activities, experienced difficulty getting to sleep, was depressed and 
grumpy with his family and had been absent from school for the preceding 6 months.  
On examination, his abdomen was slim and soft, with normal bowel sounds, no masses and 
no organomegaly. There was tenderness in the midline above the umbilicus, which was 
worse on abdominal wall tensing (Carnett’s test positive). The presumed diagnosis was 
chronic abdominal wall pain. 
A diagnostic bilateral rectus sheath block was performed above the umbilicus under 
ultrasound control which provided effective short-term symptomatic relief so a follow-up 
therapeutic block was done two weeks later.  For the therapeutic block 10mls of 0.25% 
bupivicaine with 1/200,000 epinephrine and 20mg triamcinolone was injected at each site. 
He did not require repeat therapeutic blocks.  
Two weeks after his therapeutic block, he slowly returned to his normal activity levels, 
sleeping and eating patterns and resumed his previous happy demeanour. The following 
term, he returned to school and reported no subsequent absences.  
2.3 Case 3: An 18-year-old with groin pain after hydrocele repair 
A 60kg 18-year-old male presented with a 1 year history of a shooting pain in his groin, 
which was present all the time and radiated down the medial aspect of his thigh to his knee. 
There was no apparent precipitating event; however, he was a competitive fencer and had 
undergone a left hydrocele repair 6 months prior to the onset of pain. The pain was worse in 
morning, walking up stairs and mobilizing from lying down. He had episodes of severe 
pain 2-3 times per day, which lasted several hours. 
He was referred to the Pain Service after multiple referrals and investigations had excluded 
a remedial cause for his pain, but drawn a blank on a diagnosis. The pain was not relieved 
by acetaminophen.  
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This young man had been extremely fit and well. However his pain was such that his 
appetite was reduced, he was losing weight and he had to stop all his physical activities to 
the point that his future competitive aspirations were severely compromised. He continued 
to attend school, but was under pressure to compete in the fencing team. His mood during 
this period was described as ‘testy’.  
On examination, he had pain on palpation of the hydrocele repair scar, but no pain on 
palpation underneath inguinal ligament. He had a full range of non-painful movements of 
his lumbar spine, hips and knees with normal bulk, tone & power in his lower limbs, and 
brisk but equal knee and ankle jerk reflexes. He exhibited a downgoing plantar reflex and 
bilateral abdominal reflexes. His abdomen was slim and soft, with normal bowel sounds, no 
masses and no organomegaly. There was no apparent numbness to light touch of his scar or 
thigh and no allodynia, skin or hair changes. There was no pain to palpation in his scrotum 
or penis. The presumed diagnosis was ilioinguinal neuralgia. 
A diagnostic ilioinguinal nerve block was performing under ultrasound control which 
provided effective short-term symptomatic relief so a follow-up therapeutic block was done 
one week later.  For the therapeutic block 20mls of 0.25% bupivacaine with 1/200,000 
epinephrine and 20mg triamcinolone was injected between the internal oblique and 
transverse abdominis muscles; some was also injected under the scar site from his hydrocele 
repair. This provided complete pain relief. 
His mood and eating pattern improved within the first month, but he did require repeat 
therapeutic blocks at 5 months and 11 months following the initial block. These provided 
good pain relief to allow the patient to make a graded return to competitive fencing.  
2.4 Case 4: A 15-year-old male with a suspected incisional hernia 
A 66kg 15-year-old male presented with a 3 month history of left upper quadrant pain 
associated with a bulge just lateral & inferior to the incision from a congenital 
diaphragmatic hernia repair when he was 14 months old. The pain was described as a 
burning, stabbing sensation. He exhibited no symptoms related to the respiratory, 
cardiovascular or abdominal systems.  
He had been extremely fit and well. However his pain was such that he could not stand up 
straight, suffered pain with all activity and was unable to sleep soundly because he could 
not get comfortable. He had completely lost his appetite and had lost 10kg in weight. He 
became depressed and ceased to interact with friends. His suffering affected his family 
deeply: his parents’ relationship suffered, his sister became depressed. He could not sit or 
concentrate and consequently missed 5 months of school. 
An upper gastrointestinal endoscopy was normal.  Surgical repair of the suspected 
incisional hernia revealed no hernia of the abdominal wall. Pain occurred in the immediate 
postoperative period. This pain did not respond to simple analgesics or hydromorphone. He 
was referred to the Pain Service and a diagnosis of neuropathic pain was made.  
Intercostal nerve blocks were administered to the left sided 9th, 10th, and 11th ribs. This 
provided effective short-term symptomatic relief, so a follow-up therapeutic block was done 
a week later. For the therapeutic block, 5ml of 0.25% bupivacaine with 1/200,000 
epinephrine & 10mg triamcinolone was injected at the same 3 intercostal spaces; in addition, 
the same amount was administered as a left rectus sheath block under ultrasound control, 
adjacent to the site of surgery. On awakening, the patient reported that his pain had gone.  
This treatment provided immediate pain relief, which allowed the patient to return to his 
normal self. His appetite returned the next day. Within a few days, he was laughing again 
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and was sleeping normally. Within 2 months he had started gym. He quickly caught up 
with most of his schoolwork and was now motivated to do additional study during the 
summer vacation. He resumed contact with friends and his family were able to return to 
normal. He did not require repeat therapeutic blocks.  
2.5 Case 5: A 9-year-old with post-orchidopexy pain 
A 25kg 9-year-old male presented with a 4 month history of left sided groin pain. He had 
been experiencing this pain for three years on and off, but it had been worse since his 
orchidopexy surgery 4 months prior to the consultation. He was referred to the Pain Service 
by his surgeon.  
He continued to attend school, but had to visit the nurse twice a day and lie down to recover 
his strength. Often the school requested that he be collected and taken home early. He found 
it difficult to engage in physical or social activities and had to give up Tae Kwon Do. He was 
often woken with pain and cramps and cried as a result of his pain. 
The pain was described as “stabbing”. It was not relieved by ibuprofen and/or acetaminophen. 
On examination, there was no numbness, allodynia or skin changes and Carnett’s test was 
positive. The presumed diagnosis was genitofemoral or ilioinguinal neuralgia. 
A diagnostic rectus abdominis sheath block was performed, under ultrasound control: 15ml 
0.25% bupivicaine, 1/200,000 epinephrine was injected into the rectus sheath and between 
the transverse abdominis and internal oblique; 10ml was injected at his flank at the anterior 
superior iliac spine; and some was injected at his orchidopexy scar site. On awakening, the 
patient reported the pain was gone.  
A therapeutic block was not done in this case. He was able to resume a normal sleeping 
pattern within 2 weeks, was much happier and once again able to spend time with friends. 
He made a gradual return to Tae Kwon Do and normal schooling with no absences. 
2.6 Case 6: A 15-year-old female with chest pain following removal of exostosis 
A 45 kg 15-year-old female presented at the Complex Pain Clinic with post-surgical chest 
pain. Successful removal of an exostosis from her right rib cage was followed by the gradual 
emergence of a new, sharp pain, which was present every day. It worsened during the day 
and with sitting or physical activity.  
It was 8 months since her surgery. She had missed some school, had stopped gymnastics 
classes and soccer training completely and had to limit her social activities. She was grumpy 
with friends and family. Physiotherapy had not helped, but ketorolac (10mg twice a day as 
needed), psychology, TENS and laser therapy were judged to have provided some benefit. 
She was examined by the interdisciplinary team. Physical examination revealed that her 
pain was localised to the right anterolateral aspect of her 10th rib, close to the exostosis 
excision; there was no associated numbness, no allodynia and no skin colour change. The 
physiotherapist noted that her right waist crease and elevated iliac crest suggested a 
protective response, but that she had a full range of motion in spine and extremities. The 
psychologist determined that she was not overly anxious or depressed, despite some 
ongoing family conflicts. A preliminary diagnosis of intercostal neuralgia was made.  
A diagnostic intercostal nerve block was performed. This provided effective short-term 
symptomatic relief so a follow-up therapeutic block was done 3 weeks later. The therapeutic 
block comprised: 5ml 0.25% bupivicaine with 1/200,000 epinephrine & 2mg/ml 
triamcinolone injected at 3 sites above & below the affected rib; and 4ml 0.25% bupivicaine 
with 1/200,000 epinephrine & 1mg/ml triamcinolone injected under the scar site. 
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This young man had been extremely fit and well. However his pain was such that his 
appetite was reduced, he was losing weight and he had to stop all his physical activities to 
the point that his future competitive aspirations were severely compromised. He continued 
to attend school, but was under pressure to compete in the fencing team. His mood during 
this period was described as ‘testy’.  
On examination, he had pain on palpation of the hydrocele repair scar, but no pain on 
palpation underneath inguinal ligament. He had a full range of non-painful movements of 
his lumbar spine, hips and knees with normal bulk, tone & power in his lower limbs, and 
brisk but equal knee and ankle jerk reflexes. He exhibited a downgoing plantar reflex and 
bilateral abdominal reflexes. His abdomen was slim and soft, with normal bowel sounds, no 
masses and no organomegaly. There was no apparent numbness to light touch of his scar or 
thigh and no allodynia, skin or hair changes. There was no pain to palpation in his scrotum 
or penis. The presumed diagnosis was ilioinguinal neuralgia. 
A diagnostic ilioinguinal nerve block was performing under ultrasound control which 
provided effective short-term symptomatic relief so a follow-up therapeutic block was done 
one week later.  For the therapeutic block 20mls of 0.25% bupivacaine with 1/200,000 
epinephrine and 20mg triamcinolone was injected between the internal oblique and 
transverse abdominis muscles; some was also injected under the scar site from his hydrocele 
repair. This provided complete pain relief. 
His mood and eating pattern improved within the first month, but he did require repeat 
therapeutic blocks at 5 months and 11 months following the initial block. These provided 
good pain relief to allow the patient to make a graded return to competitive fencing.  
2.4 Case 4: A 15-year-old male with a suspected incisional hernia 
A 66kg 15-year-old male presented with a 3 month history of left upper quadrant pain 
associated with a bulge just lateral & inferior to the incision from a congenital 
diaphragmatic hernia repair when he was 14 months old. The pain was described as a 
burning, stabbing sensation. He exhibited no symptoms related to the respiratory, 
cardiovascular or abdominal systems.  
He had been extremely fit and well. However his pain was such that he could not stand up 
straight, suffered pain with all activity and was unable to sleep soundly because he could 
not get comfortable. He had completely lost his appetite and had lost 10kg in weight. He 
became depressed and ceased to interact with friends. His suffering affected his family 
deeply: his parents’ relationship suffered, his sister became depressed. He could not sit or 
concentrate and consequently missed 5 months of school. 
An upper gastrointestinal endoscopy was normal.  Surgical repair of the suspected 
incisional hernia revealed no hernia of the abdominal wall. Pain occurred in the immediate 
postoperative period. This pain did not respond to simple analgesics or hydromorphone. He 
was referred to the Pain Service and a diagnosis of neuropathic pain was made.  
Intercostal nerve blocks were administered to the left sided 9th, 10th, and 11th ribs. This 
provided effective short-term symptomatic relief, so a follow-up therapeutic block was done 
a week later. For the therapeutic block, 5ml of 0.25% bupivacaine with 1/200,000 
epinephrine & 10mg triamcinolone was injected at the same 3 intercostal spaces; in addition, 
the same amount was administered as a left rectus sheath block under ultrasound control, 
adjacent to the site of surgery. On awakening, the patient reported that his pain had gone.  
This treatment provided immediate pain relief, which allowed the patient to return to his 
normal self. His appetite returned the next day. Within a few days, he was laughing again 
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and was sleeping normally. Within 2 months he had started gym. He quickly caught up 
with most of his schoolwork and was now motivated to do additional study during the 
summer vacation. He resumed contact with friends and his family were able to return to 
normal. He did not require repeat therapeutic blocks.  
2.5 Case 5: A 9-year-old with post-orchidopexy pain 
A 25kg 9-year-old male presented with a 4 month history of left sided groin pain. He had 
been experiencing this pain for three years on and off, but it had been worse since his 
orchidopexy surgery 4 months prior to the consultation. He was referred to the Pain Service 
by his surgeon.  
He continued to attend school, but had to visit the nurse twice a day and lie down to recover 
his strength. Often the school requested that he be collected and taken home early. He found 
it difficult to engage in physical or social activities and had to give up Tae Kwon Do. He was 
often woken with pain and cramps and cried as a result of his pain. 
The pain was described as “stabbing”. It was not relieved by ibuprofen and/or acetaminophen. 
On examination, there was no numbness, allodynia or skin changes and Carnett’s test was 
positive. The presumed diagnosis was genitofemoral or ilioinguinal neuralgia. 
A diagnostic rectus abdominis sheath block was performed, under ultrasound control: 15ml 
0.25% bupivicaine, 1/200,000 epinephrine was injected into the rectus sheath and between 
the transverse abdominis and internal oblique; 10ml was injected at his flank at the anterior 
superior iliac spine; and some was injected at his orchidopexy scar site. On awakening, the 
patient reported the pain was gone.  
A therapeutic block was not done in this case. He was able to resume a normal sleeping 
pattern within 2 weeks, was much happier and once again able to spend time with friends. 
He made a gradual return to Tae Kwon Do and normal schooling with no absences. 
2.6 Case 6: A 15-year-old female with chest pain following removal of exostosis 
A 45 kg 15-year-old female presented at the Complex Pain Clinic with post-surgical chest 
pain. Successful removal of an exostosis from her right rib cage was followed by the gradual 
emergence of a new, sharp pain, which was present every day. It worsened during the day 
and with sitting or physical activity.  
It was 8 months since her surgery. She had missed some school, had stopped gymnastics 
classes and soccer training completely and had to limit her social activities. She was grumpy 
with friends and family. Physiotherapy had not helped, but ketorolac (10mg twice a day as 
needed), psychology, TENS and laser therapy were judged to have provided some benefit. 
She was examined by the interdisciplinary team. Physical examination revealed that her 
pain was localised to the right anterolateral aspect of her 10th rib, close to the exostosis 
excision; there was no associated numbness, no allodynia and no skin colour change. The 
physiotherapist noted that her right waist crease and elevated iliac crest suggested a 
protective response, but that she had a full range of motion in spine and extremities. The 
psychologist determined that she was not overly anxious or depressed, despite some 
ongoing family conflicts. A preliminary diagnosis of intercostal neuralgia was made.  
A diagnostic intercostal nerve block was performed. This provided effective short-term 
symptomatic relief so a follow-up therapeutic block was done 3 weeks later. The therapeutic 
block comprised: 5ml 0.25% bupivicaine with 1/200,000 epinephrine & 2mg/ml 
triamcinolone injected at 3 sites above & below the affected rib; and 4ml 0.25% bupivicaine 
with 1/200,000 epinephrine & 1mg/ml triamcinolone injected under the scar site. 
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Though she did not return to gymnastics, her tiredness was resolved and she was able to 
begin soccer refereeing a week later. She was more energetic, happier and able to spend time 
with friends again. Her concentration and focus improved which enabled her to achieve 
better grades at school. 
2.7 Case 7: A 9-year-old female with persistent pain following appendectomy 
A 33kg 9-year-old female presented with right-sided abdominal pain, which had begun 3 
days after a laparoscopic appendectomy two months previously. The pain, present all the 
time, but varying in intensity, was described as ‘stabbing’. It was worse with activity and at 
the end of the day.  
She had experienced disturbed sleep and was often woken by pain. She had only attended 
school for only three or four days since her surgery and was completely unable to attend her 
rhythmic gymnastics classes. Her appetite was reduced and her pain was worse after eating. 
She became anxious and this period of uncertainty was a tremendously stressful time for her 
whole family. Tramadol, ibuprofen and acetaminophen had not helped her pain.  
A physical examination revealed a positive Carnett’s test and normal bowel sounds. Her 
femoral pulses were present and equal. There was no lymphadenopathy in the inguinal 
region or neck and no organomegaly. There was no allodynia, no numbness and no skin 
colour change at the site of her pain. Pain was increased by squatting, walking, use of upper 
extremities and right leg raises. Right hip flexor function and ability to do sit-ups were 
limited by pain. She was diagnosed with abdominal wall pain secondary to surgery for 
laparoscopic appendectomy. 
A diagnostic abdominal wall block was performed, which provided effective short-term 
symptomatic relief so a follow-up therapeutic block was performed two weeks later. The 
therapeutic block was administered on the right side using ultrasound control, with a 22-
gauge IV cannula. A total of 10ml 0.25% bupivicaine with 2mg/ml triamcinolone was 
injected: 4ml into rectus sheath and 6ml between the transverse abdominus and internal 
oblique muscles.  
On awakening she reported her right side was numb. She experienced an achy bruising pain 
for 36 hours, which settled down. She was soon able to return to normal sleeping, eating and 
activity levels. She returned to gymnastics within 3 weeks and was back to her previous 
level of activity within 2 months. She was significantly happier and quickly re-established 
her relationships with friends. She returned to school within 2 weeks and was back to a full 
timetable within a month. 
2.8 Case 8: A 17-year-old female with rib pain 
A 66kg 17-year-old female presented with a 6 month history of right-sided lower rib pain. It 
may have been caused by an injury incurred playing volleyball. She described it as a 
‘stabbing’, burning pain that sometimes radiated to the back or the epigastrum. She had no 
pain-free days. The pain was worse at night, with deep-breathing and with sitting for long 
periods of time.  
She experienced considerable difficulty maintaining a normal sleep balance: she had trouble 
getting to sleep and was woken at least once a night in pain, often for long periods. As a 
consequence, she was often very fatigued, which she felt made her pain worse. She had a 
reduced appetite in the morning and had stopped all sporting activities. She showed some 
signs of depression and isolated herself from friends and family. She struggled to 
concentrate and missed approximately 40% of school. 
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A variety of therapies had been tried, including psychology, physiotherapy, acupuncture, 
TENS and two sessions with a chiropractor, but these had afforded only partial pain relief. 
Acetaminophen and non-steroidal anti-inflammatory agents were not effective. She 
obtained some relief from morphine, consuming up to 50mg each day. The presumed 
diagnosis was intercostal neuralgia. 
A diagnostic intercostal nerve block was performed, which provided effective short term 
symptomatic relief so a follow-up therapeutic block was done three weeks later. For the 
therapeutic block, a total of 12ml 0.25% bupivicaine with 1/200,000 epinephrine was 
injected at 3 sites; one above & below and at the site of the affected rib on the right side. 
This treatment allowed her to make a gradual return to normal. She began exercising again 
after 2 weeks, started sleeping deeper and longer and was generally in much better mood. 
She was able to sit and concentrate once again and resumed social activities with friends. 
3. Discussion 
3.1 Diagnosis and selection criteria for the use of peripheral nerve blocks 
The cases described in this chapter demonstrate that, in properly selected children and 
adolescents, a peripheral nerve block can be an extremely beneficial component of 
interdisciplinary care. The case histories demonstrate the effective use of targeted nerve 
blocks for specific pain conditions such as ilioinguinal block for ilioinguinal neuralgia. The 
children and adolescents affected are often extremely physically active prior to the first 
reports of pain. They are usually previously fit and well with no previous pain or medical 
problems. There is typically an inciting event.  The pain is characteristically neuropathic in 
description with sharp shooting elements and allodynia. The pain distribution is often 
dermatomal but not necessarily associated with numbness. The pain is not responsive or 
resolved with simple medications. The impact of the pain is considerable in its effects on 
physical function, schooling, mood and family dynamics.  
3.2 Effective techniques in the use of peripheral nerve blocks 
Peripheral nerve blockade in paediatric chronic pain has previously been described 
specifically for chronic abdominal wall pain (Skinner & Lauder, 2007). Due to the lack of 
evidence to guide therapy, the following recommendations are the opinion of the author 
(GL). Peripheral nerve blocks are done under sedation or general anesthesia to minimise 
further stress and pain to children and adolescents. Strict sterile procedure is followed. Plain 
local anaesthetic is used for the initial block to ensure that the diagnosis is correct prior to 
installation of steroids. Peripheral nerve blocks are done whenever possible under 
ultrasound control to maximise the chance of an effective block by ensuring the local 
anaesthetic is deposited in the correct plane or near the correct nerve. A diagnostic 
peripheral nerve block is considered to have worked if the local anaesthetic provided 
numbness in the dermatomal region to be blocked and also resulted in a clinically 
significant reduction in pain (>50% reduction).  A therapeutic block is only performed after 
a positive diagnostic block. To achieve a therapeutic peripheral nerve block the same block 
is performed under ultrasound control with local anaesthetic and steroid (1-2mg/ml of 
trimcinolone to a maximum dose of 40mg). Peripheral nerve blocks are only offered if 
children and adolescents are willing to participate in the whole team approach with 
adherence to paced activity and integration with psychology. The duration of effect of a 
therapeutic block is extremely varied and may be related to time from diagnosis as well as 
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Though she did not return to gymnastics, her tiredness was resolved and she was able to 
begin soccer refereeing a week later. She was more energetic, happier and able to spend time 
with friends again. Her concentration and focus improved which enabled her to achieve 
better grades at school. 
2.7 Case 7: A 9-year-old female with persistent pain following appendectomy 
A 33kg 9-year-old female presented with right-sided abdominal pain, which had begun 3 
days after a laparoscopic appendectomy two months previously. The pain, present all the 
time, but varying in intensity, was described as ‘stabbing’. It was worse with activity and at 
the end of the day.  
She had experienced disturbed sleep and was often woken by pain. She had only attended 
school for only three or four days since her surgery and was completely unable to attend her 
rhythmic gymnastics classes. Her appetite was reduced and her pain was worse after eating. 
She became anxious and this period of uncertainty was a tremendously stressful time for her 
whole family. Tramadol, ibuprofen and acetaminophen had not helped her pain.  
A physical examination revealed a positive Carnett’s test and normal bowel sounds. Her 
femoral pulses were present and equal. There was no lymphadenopathy in the inguinal 
region or neck and no organomegaly. There was no allodynia, no numbness and no skin 
colour change at the site of her pain. Pain was increased by squatting, walking, use of upper 
extremities and right leg raises. Right hip flexor function and ability to do sit-ups were 
limited by pain. She was diagnosed with abdominal wall pain secondary to surgery for 
laparoscopic appendectomy. 
A diagnostic abdominal wall block was performed, which provided effective short-term 
symptomatic relief so a follow-up therapeutic block was performed two weeks later. The 
therapeutic block was administered on the right side using ultrasound control, with a 22-
gauge IV cannula. A total of 10ml 0.25% bupivicaine with 2mg/ml triamcinolone was 
injected: 4ml into rectus sheath and 6ml between the transverse abdominus and internal 
oblique muscles.  
On awakening she reported her right side was numb. She experienced an achy bruising pain 
for 36 hours, which settled down. She was soon able to return to normal sleeping, eating and 
activity levels. She returned to gymnastics within 3 weeks and was back to her previous 
level of activity within 2 months. She was significantly happier and quickly re-established 
her relationships with friends. She returned to school within 2 weeks and was back to a full 
timetable within a month. 
2.8 Case 8: A 17-year-old female with rib pain 
A 66kg 17-year-old female presented with a 6 month history of right-sided lower rib pain. It 
may have been caused by an injury incurred playing volleyball. She described it as a 
‘stabbing’, burning pain that sometimes radiated to the back or the epigastrum. She had no 
pain-free days. The pain was worse at night, with deep-breathing and with sitting for long 
periods of time.  
She experienced considerable difficulty maintaining a normal sleep balance: she had trouble 
getting to sleep and was woken at least once a night in pain, often for long periods. As a 
consequence, she was often very fatigued, which she felt made her pain worse. She had a 
reduced appetite in the morning and had stopped all sporting activities. She showed some 
signs of depression and isolated herself from friends and family. She struggled to 
concentrate and missed approximately 40% of school. 
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A variety of therapies had been tried, including psychology, physiotherapy, acupuncture, 
TENS and two sessions with a chiropractor, but these had afforded only partial pain relief. 
Acetaminophen and non-steroidal anti-inflammatory agents were not effective. She 
obtained some relief from morphine, consuming up to 50mg each day. The presumed 
diagnosis was intercostal neuralgia. 
A diagnostic intercostal nerve block was performed, which provided effective short term 
symptomatic relief so a follow-up therapeutic block was done three weeks later. For the 
therapeutic block, a total of 12ml 0.25% bupivicaine with 1/200,000 epinephrine was 
injected at 3 sites; one above & below and at the site of the affected rib on the right side. 
This treatment allowed her to make a gradual return to normal. She began exercising again 
after 2 weeks, started sleeping deeper and longer and was generally in much better mood. 
She was able to sit and concentrate once again and resumed social activities with friends. 
3. Discussion 
3.1 Diagnosis and selection criteria for the use of peripheral nerve blocks 
The cases described in this chapter demonstrate that, in properly selected children and 
adolescents, a peripheral nerve block can be an extremely beneficial component of 
interdisciplinary care. The case histories demonstrate the effective use of targeted nerve 
blocks for specific pain conditions such as ilioinguinal block for ilioinguinal neuralgia. The 
children and adolescents affected are often extremely physically active prior to the first 
reports of pain. They are usually previously fit and well with no previous pain or medical 
problems. There is typically an inciting event.  The pain is characteristically neuropathic in 
description with sharp shooting elements and allodynia. The pain distribution is often 
dermatomal but not necessarily associated with numbness. The pain is not responsive or 
resolved with simple medications. The impact of the pain is considerable in its effects on 
physical function, schooling, mood and family dynamics.  
3.2 Effective techniques in the use of peripheral nerve blocks 
Peripheral nerve blockade in paediatric chronic pain has previously been described 
specifically for chronic abdominal wall pain (Skinner & Lauder, 2007). Due to the lack of 
evidence to guide therapy, the following recommendations are the opinion of the author 
(GL). Peripheral nerve blocks are done under sedation or general anesthesia to minimise 
further stress and pain to children and adolescents. Strict sterile procedure is followed. Plain 
local anaesthetic is used for the initial block to ensure that the diagnosis is correct prior to 
installation of steroids. Peripheral nerve blocks are done whenever possible under 
ultrasound control to maximise the chance of an effective block by ensuring the local 
anaesthetic is deposited in the correct plane or near the correct nerve. A diagnostic 
peripheral nerve block is considered to have worked if the local anaesthetic provided 
numbness in the dermatomal region to be blocked and also resulted in a clinically 
significant reduction in pain (>50% reduction).  A therapeutic block is only performed after 
a positive diagnostic block. To achieve a therapeutic peripheral nerve block the same block 
is performed under ultrasound control with local anaesthetic and steroid (1-2mg/ml of 
trimcinolone to a maximum dose of 40mg). Peripheral nerve blocks are only offered if 
children and adolescents are willing to participate in the whole team approach with 
adherence to paced activity and integration with psychology. The duration of effect of a 
therapeutic block is extremely varied and may be related to time from diagnosis as well as 
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to the degree in which paced return to activity is adhered to following successful block. 
Subsequent therapeutic blocks tend to last longer than the previous.  
3.2.1 Pharmacology 
The steroid element of the therapeutic peripheral nerve block is considered to either reduce 
inflammation or result in thinning of the connective tissue around painful nerves (Suleiman 
& Johnston, 2001). There is no consensus on the correct dose of steroid that should be used 
for peripheral nerve blocks in children. Steroids have local and systemic side effects. The 
local effect of fascial thinning may have detrimental effects with repeat injections (Suleiman 
& Johnston, 2001). Side effects of ongoing or chronic systemic steroids include carbohydrate 
intolerance, hypothalamic-pituitary-adrenal suppression, growth failure (Hochberg, 2002) 
and others such as immunosuppression, cataracts, pseudomotor cerebri, pancreatitis steroid 
psychosis, and steroid myopathy (Rimsza, 1978). The incidence of major systemic side 
effects to infrequent intermittent steroid injections is not known. 
3.3 The mechanism and effects of the treatment 
The specific effects of peripheral nerve blocks rely on the action of pharmacological agents 
such as local anaesthetics and triamcinolone.  However, broader elements of care are also 
significant. In the context of an ongoing treatment regime, it is particularly important to 
consider the psychosocial dynamics of the diagnosis and treatment processes, including 
development of trust in the healthcare team and springboard effects from the realization of 
interim treatment goals. It is presumed that the combination of these effects creates/initiates 
a break or change in the pain cycle and reverses the changes that occurred within the 
peripheral and central nervous system to cause chronic pain. 
3.3.1 Nonspecific treatment effects 
We may like to think that when a patient gets better, it is the direct and intentional result of 
medical intervention, but it may not be quite so straightforward. Jamison (2011) identifies 
three mechanisms, which may contribute to any improvement in a patient’s pain or 
functioning – (i) the specific or intended effects of any treatment, (ii) natural history and (iii) 
nonspecific effects of treatment – and there may be some interaction between these 
elements. Nonspecific treatment effects are the outcomes of patient encounters with 
healthcare providers. These include attention, stimulation of the desire to get better, reduced 
anxiety, increased understanding, trust, hope, optimism and improved ability to cope 
(Jamison, 2011). One important nonspecific treatment effect with children and adolescents is 
for others, including healthcare providers, to believe that they have pain. These non-specific 
treatment effects represent a complex array of psychosocial variables that, when utilized 
correctly, can bestow huge benefit to the patient’s sense of wellbeing and outcomes. 
The team’s attention to the broader effects of pain on daily functioning and quality of life is 
crucial. What does the child’s pain mean to them? What does it mean to their family? What 
are the patient goals of therapy and are they achievable? As discussed, psychosocial effects 
of pain such as sadness, frustration, anxiety or depression can become contributory factors 
to the continuation or worsening of pain in a vicious circle that is hard to escape without 
effective support. If they remain unrecognized and untreated, these factors may hinder the 
progress of any management plan.  
It has been established that the style of communication adopted by a physician can have a 
dramatic effect on patient patient’s health outcomes (Di Blasi et al, 2001; Griffin et al, 2004; 
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Verheul et al, 2010). Meaningful two-way communication between healthcare provider and 
patient is crucial. However, a patient-centred dialogue may depend on circumstances, as 
physicians appear to adopt a more patient-centred style of communication with patients 
who participate actively in the discussion (Cegala & Post, 2009). In paediatric care, the 
communication is, typically, three-way between provider, patient and parent or caregiver 
which makes adopting a patient-centred approach will often be more challenging. Effective 
communication, in this context, means using appropriate terminology and actively listening 
to both patient and parent as well as giving attention to their body language. Factors which 
have to be considered include: identifying patient and parental expectations, i.e. goal 
directed therapy; devoting enough time to acquire the whole pain-related history; 
interpreting non-responsiveness; identifying hidden messages conveyed in what’s being 
said and not said; understanding family beliefs, hopes and fears; asking potentially 
embarrassing questions separately and in confidence; conveying empathy; introducing 
appropriate humour into the dialogue; conveying expertise and credibility in pain 
management; establishing trust; not causing more pain on examination; providing an agreed 
workable goal-directed and achievable management plan. 
3.3.2 Placebo response to peripheral nerve block intervention 
Without the evidence of a randomized double blind placebo controlled trial, it is not easy to 
stipulate that the interventional blocks are the overriding therapeutic modality in this case 
series. Many would argue that this represents a placebo response. A placebo response refers 
to the psychobiological response seen after administration of a placebo (a non therapeutic 
modality) in an individual or groups of patients. Placebo treatments have known effects on 
the endogenous pharmacology, cognitive and conditioning systems in humans (Fields & 
Levine, 1981; de la Fuente-Fernandez et al, 2001; Meissner et al, 2007; Wager et al, 2007; 
Benedetti, 2008; Scott et al, 2008; Eippert et al, 2009; Finniss et al, 2009). 
Expectations have the strongest evidence for contributing to the placebo response, especially 
placebo analgesia. Within the neuro-pharmacological aspect of an analgesic placebo 
response, there is evidence for the role of endogenous endorphins as some placebo analgesic 
responses are reversed with naloxone. The respiratory centres, serotonin secretion, hormone 
secretion, immune responses and heart function are also involved in the biological response 
to placebo analgesic treatments (Finniss et al, 2009). 
Whatever the mechanism of therapeutic benefit, placebo responses are potentially 
embedded in every intervention for pain relief (Robinson, 2009). The key message from our 
case series is that plain local anaesthetic nerve block provided only temporary relief for 7 
out of 8 cases. Only when local anaesthetic and steroid was used, in conjunction with their 
ongoing interdisciplinary care, did these children and adolescents turn their lives around to 
their pre-pain level of functioning. If only a placebo response, it would be expected to last 1-
3 months only. Only 2 of the cases required repeat therapeutic blocks which were performed 
greater than three months after the initial therapeutic block. This all points to a mainly 
therapeutic effect, but would have to be supported by a properly conducted study. 
4. Conclusion  
Chronic pain of childhood is an extremely complex condition which can have devastating 
effects on physical, psychological and social functioning. The interdisciplinary team 
management approach, based on pharmacology, physiotherapy and psychology, is the 
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to the degree in which paced return to activity is adhered to following successful block. 
Subsequent therapeutic blocks tend to last longer than the previous.  
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and others such as immunosuppression, cataracts, pseudomotor cerebri, pancreatitis steroid 
psychosis, and steroid myopathy (Rimsza, 1978). The incidence of major systemic side 
effects to infrequent intermittent steroid injections is not known. 
3.3 The mechanism and effects of the treatment 
The specific effects of peripheral nerve blocks rely on the action of pharmacological agents 
such as local anaesthetics and triamcinolone.  However, broader elements of care are also 
significant. In the context of an ongoing treatment regime, it is particularly important to 
consider the psychosocial dynamics of the diagnosis and treatment processes, including 
development of trust in the healthcare team and springboard effects from the realization of 
interim treatment goals. It is presumed that the combination of these effects creates/initiates 
a break or change in the pain cycle and reverses the changes that occurred within the 
peripheral and central nervous system to cause chronic pain. 
3.3.1 Nonspecific treatment effects 
We may like to think that when a patient gets better, it is the direct and intentional result of 
medical intervention, but it may not be quite so straightforward. Jamison (2011) identifies 
three mechanisms, which may contribute to any improvement in a patient’s pain or 
functioning – (i) the specific or intended effects of any treatment, (ii) natural history and (iii) 
nonspecific effects of treatment – and there may be some interaction between these 
elements. Nonspecific treatment effects are the outcomes of patient encounters with 
healthcare providers. These include attention, stimulation of the desire to get better, reduced 
anxiety, increased understanding, trust, hope, optimism and improved ability to cope 
(Jamison, 2011). One important nonspecific treatment effect with children and adolescents is 
for others, including healthcare providers, to believe that they have pain. These non-specific 
treatment effects represent a complex array of psychosocial variables that, when utilized 
correctly, can bestow huge benefit to the patient’s sense of wellbeing and outcomes. 
The team’s attention to the broader effects of pain on daily functioning and quality of life is 
crucial. What does the child’s pain mean to them? What does it mean to their family? What 
are the patient goals of therapy and are they achievable? As discussed, psychosocial effects 
of pain such as sadness, frustration, anxiety or depression can become contributory factors 
to the continuation or worsening of pain in a vicious circle that is hard to escape without 
effective support. If they remain unrecognized and untreated, these factors may hinder the 
progress of any management plan.  
It has been established that the style of communication adopted by a physician can have a 
dramatic effect on patient patient’s health outcomes (Di Blasi et al, 2001; Griffin et al, 2004; 
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Verheul et al, 2010). Meaningful two-way communication between healthcare provider and 
patient is crucial. However, a patient-centred dialogue may depend on circumstances, as 
physicians appear to adopt a more patient-centred style of communication with patients 
who participate actively in the discussion (Cegala & Post, 2009). In paediatric care, the 
communication is, typically, three-way between provider, patient and parent or caregiver 
which makes adopting a patient-centred approach will often be more challenging. Effective 
communication, in this context, means using appropriate terminology and actively listening 
to both patient and parent as well as giving attention to their body language. Factors which 
have to be considered include: identifying patient and parental expectations, i.e. goal 
directed therapy; devoting enough time to acquire the whole pain-related history; 
interpreting non-responsiveness; identifying hidden messages conveyed in what’s being 
said and not said; understanding family beliefs, hopes and fears; asking potentially 
embarrassing questions separately and in confidence; conveying empathy; introducing 
appropriate humour into the dialogue; conveying expertise and credibility in pain 
management; establishing trust; not causing more pain on examination; providing an agreed 
workable goal-directed and achievable management plan. 
3.3.2 Placebo response to peripheral nerve block intervention 
Without the evidence of a randomized double blind placebo controlled trial, it is not easy to 
stipulate that the interventional blocks are the overriding therapeutic modality in this case 
series. Many would argue that this represents a placebo response. A placebo response refers 
to the psychobiological response seen after administration of a placebo (a non therapeutic 
modality) in an individual or groups of patients. Placebo treatments have known effects on 
the endogenous pharmacology, cognitive and conditioning systems in humans (Fields & 
Levine, 1981; de la Fuente-Fernandez et al, 2001; Meissner et al, 2007; Wager et al, 2007; 
Benedetti, 2008; Scott et al, 2008; Eippert et al, 2009; Finniss et al, 2009). 
Expectations have the strongest evidence for contributing to the placebo response, especially 
placebo analgesia. Within the neuro-pharmacological aspect of an analgesic placebo 
response, there is evidence for the role of endogenous endorphins as some placebo analgesic 
responses are reversed with naloxone. The respiratory centres, serotonin secretion, hormone 
secretion, immune responses and heart function are also involved in the biological response 
to placebo analgesic treatments (Finniss et al, 2009). 
Whatever the mechanism of therapeutic benefit, placebo responses are potentially 
embedded in every intervention for pain relief (Robinson, 2009). The key message from our 
case series is that plain local anaesthetic nerve block provided only temporary relief for 7 
out of 8 cases. Only when local anaesthetic and steroid was used, in conjunction with their 
ongoing interdisciplinary care, did these children and adolescents turn their lives around to 
their pre-pain level of functioning. If only a placebo response, it would be expected to last 1-
3 months only. Only 2 of the cases required repeat therapeutic blocks which were performed 
greater than three months after the initial therapeutic block. This all points to a mainly 
therapeutic effect, but would have to be supported by a properly conducted study. 
4. Conclusion  
Chronic pain of childhood is an extremely complex condition which can have devastating 
effects on physical, psychological and social functioning. The interdisciplinary team 
management approach, based on pharmacology, physiotherapy and psychology, is the 
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standard of care for children with severe or ongoing chronic pain. However, in a small 
proportion of appropriately selected children peripheral nerve blocks can provide 
immediate, effective and long-term pain relief. The case histories outlined in this chapter 
demonstrate the enormous impact that pain can have on a child, their functioning and their 
families. The significant relief received from peripheral nerve blockade indicates that this is 
a modality that must be considered when the history and examination findings match those 
presented. However, formal studies are required to definitively evaluate the effectiveness of 
the peripheral nerve block intervention.  
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Italy 
1. Introduction 
When pain becomes chronic it assumes an almost absolute central role in the disease 
experience: it characterises and qualifies it, and constantly interferes with the daily life of the 
patient (Bonica, 1992). It could be said that chronic pain becomes a disease in itself in the 
patient’s perception; daily activities, interpersonal relationships, feelings, are profoundly 
disturbed by living with pain (Loeser, 2000).   
While modern medicine has made notable progress in understanding, diagnosing and 
treating chronic pain, it continues to be a very widespread problem that significantly 
compromises the professional, social and family life of the patient, and is often not 
adequately managed (Manchikanti et al., 2010).  
The problem of inadequately managed pain is still a considerable one (Breivik et al., 2006), 
although the World Health Organization [WHO] (1990) has stated that to be pain free 
should be considered a right of every patient. The consequences of inadequately treated 
pain not only have an impact in terms of the physical and psychological suffering of the 
patient and his family, they also have an enormous economic impact on society as a whole 
(Brennan et al., 2007; van Leeuwen et al., 2006).   
Options for the treatment of chronic pain include both pharmacological treatments (e.g. non 
steroidal anti-inflammatory drugs, opioids) and non-pharmacological treatments (e.g. 
physical therapies, acupuncture, cognitive-behavioural therapy, surgical procedures). 
Choice of treatment should be guided by a complex initial assessment of the patient, which 
includes the collection of historical information (e.g. pain history and treatments tried, 
surgical procedures, psychosocial and family history), a physical examination and 
appropriate diagnostic tests (Passik, 2009).  
Opioids are considered one of the most efficacious groups of drugs in treating medium-
severe pain (Portenoy, 2000), and their use can result in a significant improvement in the 
patient’s quality of life (Dillie et al., 2008); while there is unanimous agreement on their use 
in acute and cancer pain, their long-term use for non-cancer chronic pain remains 
controversial (Dews & Mekhail, 2004; Manchikanti et al., 2010; Rosenblum et al., 2008). The 
discovery of the properties of these substances, and their use as analgesics, is lost in the 
mists of time: the Sumerians were starting to cultivate poppies as early as 3400 B.C. (Booth, 
1986, as cited in Dews & Mekhail, 2004). In 1803, Friedrich Serturner, a German pharmacist, 
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1. Introduction 
When pain becomes chronic it assumes an almost absolute central role in the disease 
experience: it characterises and qualifies it, and constantly interferes with the daily life of the 
patient (Bonica, 1992). It could be said that chronic pain becomes a disease in itself in the 
patient’s perception; daily activities, interpersonal relationships, feelings, are profoundly 
disturbed by living with pain (Loeser, 2000).   
While modern medicine has made notable progress in understanding, diagnosing and 
treating chronic pain, it continues to be a very widespread problem that significantly 
compromises the professional, social and family life of the patient, and is often not 
adequately managed (Manchikanti et al., 2010).  
The problem of inadequately managed pain is still a considerable one (Breivik et al., 2006), 
although the World Health Organization [WHO] (1990) has stated that to be pain free 
should be considered a right of every patient. The consequences of inadequately treated 
pain not only have an impact in terms of the physical and psychological suffering of the 
patient and his family, they also have an enormous economic impact on society as a whole 
(Brennan et al., 2007; van Leeuwen et al., 2006).   
Options for the treatment of chronic pain include both pharmacological treatments (e.g. non 
steroidal anti-inflammatory drugs, opioids) and non-pharmacological treatments (e.g. 
physical therapies, acupuncture, cognitive-behavioural therapy, surgical procedures). 
Choice of treatment should be guided by a complex initial assessment of the patient, which 
includes the collection of historical information (e.g. pain history and treatments tried, 
surgical procedures, psychosocial and family history), a physical examination and 
appropriate diagnostic tests (Passik, 2009).  
Opioids are considered one of the most efficacious groups of drugs in treating medium-
severe pain (Portenoy, 2000), and their use can result in a significant improvement in the 
patient’s quality of life (Dillie et al., 2008); while there is unanimous agreement on their use 
in acute and cancer pain, their long-term use for non-cancer chronic pain remains 
controversial (Dews & Mekhail, 2004; Manchikanti et al., 2010; Rosenblum et al., 2008). The 
discovery of the properties of these substances, and their use as analgesics, is lost in the 
mists of time: the Sumerians were starting to cultivate poppies as early as 3400 B.C. (Booth, 
1986, as cited in Dews & Mekhail, 2004). In 1803, Friedrich Serturner, a German pharmacist, 
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isolated an alkaloid from opium that he named morphine, and in 1853 Scottish physician 
Alexander Wood introduced the hypodermic needle and successfully used injections of 
morphine to treat neuralgia. As Way (1982, as cited in Dews & Mekhail, 2004) highlighted, 
morphine was the “mainstay” of medical treatment in the United States throughout the 
nineteenth century, used to treat pain, anxiety and respiratory problems as well as 
“consumption” and “women’s ailments”. Opium cultivation was legal in some states, and 
opium-based products could be bought over the counter (Dews & Mekhail, 2004). Between 
1875 and 1877, German physician Eduard Levinstein published a series of articles calling 
attention to the problem of morphine dependence: his was one of the first studies on the risk 
of dependence on narcotics, which he estimated to be 75% (White et al., 2001a). In 1914 
Kennedy Foster wrote, in New York Medical Journal, “...morphinism is a disease, in the 
majority of cases, initiated, sustained and left uncured by members of the medical profession” (White 
et al., 2001b); in the same year the US Congress approved the Harrison Anti-Narcotic Act, 
the first federal law to limit the sale of any drug. Opioids and cocaine were included in the 
list of drugs that could only be obtained from a physician or authorised pharmacist. 
Physicians were authorised to prescribe these substances, but not to patients with 
dependence problem; given the likelihood of arrest or prosecution, physicians became 
increasingly cautious in prescribing opioids even for chronic pain (Dews & Mekhail, 2004). 
In 1969, the WHO abandoned the belief that the medical use of morphine led inevitably to 
dependence; the WHO clarified that tolerance and physical dependence did not in itself 
constitute “drug dependence”, a diagnosis characterised by typical behaviours, including 
difficulty in controlling the assumption of drugs, compulsive use of the substance and 
inappropriate social behaviours (WHO, 1986). In 1970 the Harrison Anti-Narcotic Act and 
the other federal laws on drugs were replaced by the Comprehensive Drug Abuse and 
Control Act, which divided substances into six categories, according to their risk of 
addiction: category I includes heroin and marijuana, category II includes cocaine, opium 
and morphine, category III includes codeine, category IV includes diazepam and 
alprazolam, category V includes drugs with small quantities of codeine and category VI 
includes penicillin and ibuprofen (Dews & Mekhail, 2004). This law established that there 
were no impediments to prescribing drugs in categories II, III or IV provided there were 
indications for their use, including chronic non-cancer pain. There was a further 
development when the WHO Expert Committee on Essential Drugs recognised morphine, 
codeine and other opioids as “essential drugs,” defining them as: “those that satisfy the health 
care needs of the majority of the population; they should therefore be available at all times in adequate 
amounts and in the appropriate dosage forms...” (WHO, 1998). The WHO also introduced the 
“pain analgesia scale” (figure 1) which distinguishes between strong and weak opioids, and 
establishes their clear roles in pain relief. In Italy, which is one of the countries with the 
lowest morphine consumption in Europe, several measures have been developed to 
eliminate the bureaucratic obstacles to the use of opioid analgesics, starting with Law no. 12 
of 2001. With Law no. 38 of 2010, opioids may finally be prescribed for pain relief in the 
same way as other prescription-only drugs.  
As illustrated, the use of opioids has historically been subject to  cycles of liberalisation 
and prohibition in clinical practice that account for their still-limited use today (WHO, 
1998).  
The potential barriers to treatment with opioids may be due to inadequate beliefs of both 
medical personnel and the patients themselves (Garcia & Altman, 1997).  
 





Fig. 1. The WHO pain analgesia scale 
Physicians may not prescribe opioids at adequate doses because they do not know how to 
use them effectively, because they do not assess the pain or effects of treatment 
systematically, because of fear of sanctions by medical commissions. But some data lead one 
to believe that the overestimation of the risk of addiction is a significant problem (Dews & 
Mekhail, 2004); in this respect, the term opiophobia has been coined, to refer to the practice of 
under-prescription of opioid medication due to the fear of inducing addiction in patients 
(Collett, 1998). By interviewing over 248 US physicians, Bhamb et al. (2006) recently 
reported that just over half of those interviewed (55.9%), had specific clinical protocols for 
the prolonged use of opioids in patients with chronic non-cancer pain. 35.1% believed they 
prescribed opioids less frequently than their colleagues; while the most frequent concerns 
about starting treatment with opioids were the fear of abuse (84.2%) and addiction (74.9%). 
Concerns of patients should also be considered: they may not communicate their pain 
symptoms to their physicians, or may not take the drugs as instructed for fear of becoming 
dependent on “narcotics” (Dews & Mekhail, 2004). Furthermore, both physicians and 
patients may develop unjustified anxiety about the side effects of opioid use, believing that 
these drugs must therefore be reserved for cancer pain (Brennan et al., 2007). Finally, a 
further barrier to the use of these drugs may be due to overly restrictive national control 
laws and regulations. Because of this, the WHO has issued guidelines on legislative policies 
that enable Governments to check if their national laws ensure the availability of opioid 
analgesics to treat severe pain (WHO, 2002).  
Given the importance of these drugs in pain management, as well as the concerns about 
their use, a series of investigations were carried out in the last twenty years to identify the 
risk factors that promote or exacerbate opioid misuse. In fact, for physicians, determining 
the patient’s risk of addiction to opioids is of fundamental importance, so that a series of 
measures can be taken to limit the negative consequences of this (such as constantly 
monitoring the patient during treatment, planning interdisciplinary treatment or scheduling 
regular urine toxicology screening).  
The intention of this chapter is to examine the principal risk factors for opioid misuse in 
patients with chronic non-cancer pain. It will also describe the principal tools for selecting 
patients who are candidates for opioid treatment and for stratifying the risk of misuse. This 
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list of drugs that could only be obtained from a physician or authorised pharmacist. 
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dependence problem; given the likelihood of arrest or prosecution, physicians became 
increasingly cautious in prescribing opioids even for chronic pain (Dews & Mekhail, 2004). 
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dependence; the WHO clarified that tolerance and physical dependence did not in itself 
constitute “drug dependence”, a diagnosis characterised by typical behaviours, including 
difficulty in controlling the assumption of drugs, compulsive use of the substance and 
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the other federal laws on drugs were replaced by the Comprehensive Drug Abuse and 
Control Act, which divided substances into six categories, according to their risk of 
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and morphine, category III includes codeine, category IV includes diazepam and 
alprazolam, category V includes drugs with small quantities of codeine and category VI 
includes penicillin and ibuprofen (Dews & Mekhail, 2004). This law established that there 
were no impediments to prescribing drugs in categories II, III or IV provided there were 
indications for their use, including chronic non-cancer pain. There was a further 
development when the WHO Expert Committee on Essential Drugs recognised morphine, 
codeine and other opioids as “essential drugs,” defining them as: “those that satisfy the health 
care needs of the majority of the population; they should therefore be available at all times in adequate 
amounts and in the appropriate dosage forms...” (WHO, 1998). The WHO also introduced the 
“pain analgesia scale” (figure 1) which distinguishes between strong and weak opioids, and 
establishes their clear roles in pain relief. In Italy, which is one of the countries with the 
lowest morphine consumption in Europe, several measures have been developed to 
eliminate the bureaucratic obstacles to the use of opioid analgesics, starting with Law no. 12 
of 2001. With Law no. 38 of 2010, opioids may finally be prescribed for pain relief in the 
same way as other prescription-only drugs.  
As illustrated, the use of opioids has historically been subject to  cycles of liberalisation 
and prohibition in clinical practice that account for their still-limited use today (WHO, 
1998).  
The potential barriers to treatment with opioids may be due to inadequate beliefs of both 
medical personnel and the patients themselves (Garcia & Altman, 1997).  
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diagnostic protocol for patients undergoing long-term treatment with opioids in a 
multidisciplinary pain relief unit. 
2. Risk factors in opioid treatment of patients with chronic pain: Theoretical 
and research aspects 
Over the last twenty years, opioids have been used increasingly to treat chronic non-cancer 
pain (Ballantyne & Shin, 2008). A broad US investigation fund that, between 1980 and 2000, 
prescriptions of opioids for musculoskeletal pain doubled from 8% to 16%. Over the same 
two decades, the use of more powerful opioids for chronic pain (hydrocodone, oxycodone, 
morphine) increased from 2% to 9% (Caudill-Slosberg et al., 2004). However, if some 
patients benefit from such treatment in terms of reduction of pain and improvement in 
quality of life (Dillie et al., 2008), others do not (Ballantyne, 2007; Trescot et al., 2008). Side 
effects, the absence of any improvement in physical function, the excessive use of opioids, 
abuse and addiction are common problems that may present during the administration of 
opioid analgesics (Manchikanti et al., 2010). So in recent years experts and researchers have 
sought to answer many questions regarding risk factor for opioid misuse, selection of 
patients, efficacy of treatment particularly over time, whether opioids are able to improve 
physical function and quality of life. The clear and urgent need to answer these questions is 
reflected in the considerable increase in studies on this topic in the last decade (Ballantyne & 
Shin, 2008). Moreover, many guidelines for the use of opioids in patients with chronic non-
cancer pain have been produced, which recommend their use for those patients who have 
not benefited from other pharmacological and non-pharmacological treatments (Chou, 2009; 
Chou et al, 2009a; Chou et al, 2009b; Chou et al, 2009c; Kalso et al., 2003; Trescot et al., 2006; 
Trescot at al., 2008). 
The following section will provide some notes on pain, on the recommendations contained 
in the guidelines for the prolonged use of opioids and on the terminology used. The 
intention is to offer adequate context for the subsequent discussion of the risk factors related 
to abuse of opioids and the tools that have been developed to select patients to treat with 
these drugs.  
Finally, the preliminary data of our experience using two of these tools, the Pain Medication 
Questionnaire (PMQ; Adams et al., 2004) and the Diagnosis Intractability Risk and Efficacy Score 
(DIRE; Belgrade et al., 2006) in the Italian population are presented.  
2.1 The definition and classification of pain 
Pain is an extremely complex and subjective phenomenon, defined by the International 
Association for the Study of Pain [IASP] as “an unpleasant sensory and emotional experience, 
associated with real or potential tissue damage or described in terms of such damage” (Merskey, 
1986a). Whether acute or chronic, pain is above all a subjective and multidimensional 
experience, influenced by biological, psychological and socio-environmental factors. 
Pain may be distinguished as acute or chronic based on its duration in time and underlying 
pathology. Acute pain is produced by lesions to body tissues and the activation of the 
nociceptive transducers at the site of the tissue damage. It may be consequent on a trauma, a 
surgical procedure or an inflammatory process, and generally lasts for a relatively short 
period of time (hours, days or weeks) and stops when the underlying pathology is resolved. 
Chronic pain lasts for a long period of time (continuously or recurring at intervals of months 
or years), and is generally accompanies by a low level of underlying pathology which fully 
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explains neither the presence nor the intensity of the pain (Bonica, 1992). Disputes remain 
about the interval of time that needs to have elapsed since the trauma for pain to be defined 
as chronic; in clinical practice, a pain is generally described as chronic when it persists for 
more than 3-6 months (Bonica, 1991; Loeser & Melzack, 1999; Merskey, 1986b; Merskey & 
Bogduk, 1994).  
From a pathogenic perspective, pain may be classified as nociceptive, neuropathic or mixed. 
Nociceptive pain (somatic or visceral pain) is determined by the activation of nociceptors 
located in the somatic and visceral structures. It may be further classified as superficial or 
deep, according to the structure involved, and is due to a tissue lesion that is often evident. 
Neuropathic pain is typically caused by a change or alteration in the transmission of 
impulses along the somato-sensorial pathways and is indicative of damage to the 
conduction systems or to the integration and transmission systems of the central or 
peripheral nervous system; often it is not accompanied by tissue damage. Finally, when 
these two types of pain (nociceptive and neuropathic) are both present, this is referred to as 
mixed pain (Mannion & Woolf, 2000).  
Pain is physiological, i.e. it is a vital sign, and a defence system when it constitutes an alarm 
signal for tissue damage. It becomes pathological when it maintains itself, losing its initial 
meaning and becoming an illness in itself (pain syndrome) (Mannion & Woolf, 2000).  
In biopsychosocial terms, the experience of pain and its impact on the individual are due to 
the complex interaction of somatic inputs (nociception), psychological processes (e.g. 
thoughts, coping strategies and emotions) and social contingencies (e.g. social context, 
significant others, roles and expectations) (Turk & Okifuji, 2002). In persistent pain 
syndromes, the weight of these three factors can change at different moments of the illness, 
and none alone can explain the pain situation as a whole. The biological factors can origin, 
maintain and modulate the physical disorder, the psychological factors influence perception 
and evaluation of body signals and the social factors give form to the patients’ behavioural 
responses and their perception of their physical condition. Given this complexity, an 
adequate approach to chronic pain requires multidisciplinary intervention; the treatment 
aims in these patients are not only pharmacological treatment but also reduction of 
affective/emotional discomfort, functional recovery, return to work and improvement in 
family and social relationships.  
2.1.1 The prevalence of chronic pain and its socio-economic impact 
Chronic pain is a common and persistent problem in society, with a relatively high 
incidence and a low remission rate (Elliott et al., 2002). Verhaak et al. (1998), after reviewing 
15 epidemiological studies on chronic pain in the adult population, concluded that its 
prevalence varied from 2% to 40%, with a mean value of 15%. Back pain is one of the most 
frequent forms of chronic pain, with a prevalence rate of approximately 48% (Gureje et al., 
1998). Based on interviews of 2305 subjects aged between 35 and 45, Linton et al. (1998) 
showed that the prevalence of back pain is 66% with slightly higher incidence in women; in 
particular, 56% of the subjects complained of low back pain, 44% complained of neck pain, 
and 15% complained of pain in the thoracic spine.  
A recent epidemiological study about the prevalence of chronic pain in European countries 
involving 46,394 subjects found that approximately 19% of adults suffer continuous pain of 
medium-high intensity that seriously compromises quality of their emotional, social and 
working life. The prevalence of chronic pain varies from 12% to 20%, and is highest in 
Norway, Poland and Spain. In Italy, people who suffer from chronic pain syndromes 
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2.1.1 The prevalence of chronic pain and its socio-economic impact 
Chronic pain is a common and persistent problem in society, with a relatively high 
incidence and a low remission rate (Elliott et al., 2002). Verhaak et al. (1998), after reviewing 
15 epidemiological studies on chronic pain in the adult population, concluded that its 
prevalence varied from 2% to 40%, with a mean value of 15%. Back pain is one of the most 
frequent forms of chronic pain, with a prevalence rate of approximately 48% (Gureje et al., 
1998). Based on interviews of 2305 subjects aged between 35 and 45, Linton et al. (1998) 
showed that the prevalence of back pain is 66% with slightly higher incidence in women; in 
particular, 56% of the subjects complained of low back pain, 44% complained of neck pain, 
and 15% complained of pain in the thoracic spine.  
A recent epidemiological study about the prevalence of chronic pain in European countries 
involving 46,394 subjects found that approximately 19% of adults suffer continuous pain of 
medium-high intensity that seriously compromises quality of their emotional, social and 
working life. The prevalence of chronic pain varies from 12% to 20%, and is highest in 
Norway, Poland and Spain. In Italy, people who suffer from chronic pain syndromes 
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account for approximately 27% of the population. It also emerged that: 59% of those 
interviewed had been experiencing pain for at least 2-15 years, 21% had been diagnosed 
with depression consequent on pain, 61% reported great difficulty or incapacity in working 
outside home, 19% had lost their job and 13% had been forced to change jobs because of the 
pain. Just 2% of patients reported they were being treated by pain specialists, and about half 
of these were receiving inadequate treatment (Breivik et al., 2006).  
Therefore chronic pain has serious negative effects on the quality of life of the millions of 
people who experience it, and on the quality of life of their families. In the absence of 
adequate treatments, patients with chronic pain are often unable to work or even to carry 
out their normal daily activities.  
As well as causing unspeakable suffering to millions of people all over the world, chronic 
pain has high social cost too. Analysing data from the 1997 Medical Expenditures Panel 
Survey, which involved 14,147 families, Yelin et al.(2004) found that expenditure by patients 
with rheumatic disorders was US $ 4,865 per head, for a total of US $ 186.9 million. In 1998, 
US healthcare expenditure on lower back pain was US $ 90.7 billions (Luo et. al., 2004). A 
similar investigation found that in 2003 overall spending in the US on care for arthritis and 
other rheumatic disorders was approximately US $ 128 billion, equivalent to 1.2% of the US 
gross domestic product in 2003 (Centers for Disease Control and Prevention, 2007).  
So far as Europe is concerned, a study of the socio-economic costs of pain syndromes in the 
United Kingdom estimated that the cost of direct healthcare was £ 1.6 billion in 1998. But 
this direct cost is insignificant compared to the indirect costs (e.g. days of work lost and loss 
of productivity) associated with back pain, totalling 10.7 billion (Maniadakis & Gray, 2000). 
Winkelmann et al. (2011) estimated the annual costs per fibromyalgia patient for 2008 as € 
7,900 in France (of which €960 direct costs, €6,990 indirect costs), and € 7,256 in Germany  (€ 
1,756 direct costs, € 5,491 indirect costs). 
2.2 Opioid treatment of chronic non-cancer pain 
In recent years, many guidelines for the use of opioids in patients with chronic non-cancer 
pain have been drawn up. In general the objectives of such documents are: to bring 
consistency in opioid prescribing to the many diverse groups involved; to provide analysis 
of evidence to treat a chronic pain patient with opioids, thus, maintaining reasonable patient 
access while reducing the risk of drug diversion; to provide practical prescribing guidelines 
for physicians to reduce the risk of legal and regulatory sanctions; and to emphasize the 
need for systematic evaluation and ongoing care of patients with chronic or persistent pain 
(Trescot et al., 2006). The perceived benefits of these guidelines include: increased physician 
awareness about the current issues involving opioids and non-cancer pain; improved 
patient access; reduced level of opioid abuse; improved ability to manage patient 
expectations; reduced diversion; improved understanding by law enforcement about proper 
prescribing patterns; improved cooperation among patients, providers, and regulatory 
agencies; improved understanding by patients regarding their rights as well as their 
responsibilities when taking opioid medications (Trescot et al., 2008). These guidelines 
should be applied flexibly: every physician must establish a treatment plan that takes 
account of the specific medical conditions of the patient and his personal preferences and 
needs, and of the physician’s own professional experience (Trescot et al., 2006; 2008). Based 
on a systematic review of the efficacy of treatment with opioids in chronic non-cancer pain 
by a multidisciplinary group of experts, the American Academy of Pain Medicine 
formulated a series of recommendations for: patient selection and the stratification of risk of 
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abuse, informed consent to treatment with opioids, initiation and titration of chronic opioid 
therapy, the use of methadone, patient monitoring, the use of opioids in high risk patients, 
the assessment of the effectiveness of the drug and the aberrant drug-related behaviours, 
dose escalation and high dose therapy, opioid rotation, indications for discontinuation of 
therapy, prevention and management of opioid-related side effects and issues about driving 
and work safety during treatment with such drugs (Chou, 2009; Chou et al, 2009a; Chou et 
al, 2009b; Chou et al, 2009c). The recommendations of the American Pain Society and the 
American Academy of Pain Medicine are shown in table 1.  
 
TOPIC AREA RECOMENDATIONS 
Patient selection and 
risk stratification 
Prior to initiating chronic opioid therapy, clinicians should conduct a history, 
physical examination and appropriate testing, including an assessment of risk of 
substance abuse, misuse, or addiction (strong recommendation, low-quality 
evidence). 
 
Clinicians may consider a trial of chronic opioid therapy as an option if chronic non-
cancer pain is moderate or severe, pain is having an adverse impact on function or 
quality of life, and potential therapeutic benefits outweigh or are likely to outweigh 
potential harms (strong recommendation, low-quality evidence). 
 
A benefit-to-harm evaluation including a history, physical examination, and 
appropriate diagnostic testing, should be performed and documented prior to and 
on an ongoing basis during chronic opioid therapy (strong recommendation, 
low-quality evidence). 
Informed consent and 
opioid management 
plans 
When starting chronic opioid therapy, informed consent should be obtained. A 
continuing discussion with the patient regarding chronic opioid therapy should 
include goals, expectations, potential risks, and alternatives to chronic opioid 
therapy (strong recommendation, low-quality evidence). 
 
Clinicians may consider using a written chronic opioid therapy management plan to 
document patient and clinician responsibilities and expectations and assist in 
patient education (weak recommendation, low-quality evidence). 
Initiation and titration 
of chronic opioid 
therapy 
Clinicians and patients should regard initial treatment with opioids as a therapeutic 
trial to determine whether chronic opioid therapy is appropriate (strong 
recommendation, low-quality evidence). 
 
Opioid selection, initial dosing, and titration should be individualized according to 
the patient’s health status, previous exposure to opioids, attainment of therapeutic 
goals, and predicted or observed harms (strong recommendation, low-quality 
evidence). There is insufficient evidence to recommend short-acting versus 
long-acting opioids, or as-needed versus around-the-clock dosing of opioids. 
Methadone 
Methadone is characterized by complicated and variable pharmacokinetics and 
pharmacodynamics and should be initiated and titrated cautiously, by clinicians 
familiar with its use and risks (strong recommendation, moderate-quality evidence). 
Monitoring 
Clinicians should reassess patients on chronic opioid therapy periodically and as 
warranted by changing circumstances. Monitoring should include documentation of 
pain intensity and level of functioning, assessments of progress towards achieving 
therapeutic goals, presence of adverse events, and adherence to prescribed therapies 
(strong recommendation, low-quality evidence). 
 
In patients on chronic opioid therapy who are at high risk or who have engaged in 
aberrant drug-related behaviours, clinicians should periodically obtain urine drug 
screens or other information to confirm adherence to the chronic opioid therapy 
plan of care (strong recommendation, low-quality evidence). 
 
In patients on chronic opioid therapy not at high risk and not known to have 
engaged in aberrant drug-related behaviors, clinicians should consider  
periodically obtaining urine drug screens or other information to confirm adherence 
to the chronic opioid therapy plan of care (weak recommendation, low-quality 
evidence). 
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of evidence to treat a chronic pain patient with opioids, thus, maintaining reasonable patient 
access while reducing the risk of drug diversion; to provide practical prescribing guidelines 
for physicians to reduce the risk of legal and regulatory sanctions; and to emphasize the 
need for systematic evaluation and ongoing care of patients with chronic or persistent pain 
(Trescot et al., 2006). The perceived benefits of these guidelines include: increased physician 
awareness about the current issues involving opioids and non-cancer pain; improved 
patient access; reduced level of opioid abuse; improved ability to manage patient 
expectations; reduced diversion; improved understanding by law enforcement about proper 
prescribing patterns; improved cooperation among patients, providers, and regulatory 
agencies; improved understanding by patients regarding their rights as well as their 
responsibilities when taking opioid medications (Trescot et al., 2008). These guidelines 
should be applied flexibly: every physician must establish a treatment plan that takes 
account of the specific medical conditions of the patient and his personal preferences and 
needs, and of the physician’s own professional experience (Trescot et al., 2006; 2008). Based 
on a systematic review of the efficacy of treatment with opioids in chronic non-cancer pain 
by a multidisciplinary group of experts, the American Academy of Pain Medicine 
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abuse, informed consent to treatment with opioids, initiation and titration of chronic opioid 
therapy, the use of methadone, patient monitoring, the use of opioids in high risk patients, 
the assessment of the effectiveness of the drug and the aberrant drug-related behaviours, 
dose escalation and high dose therapy, opioid rotation, indications for discontinuation of 
therapy, prevention and management of opioid-related side effects and issues about driving 
and work safety during treatment with such drugs (Chou, 2009; Chou et al, 2009a; Chou et 
al, 2009b; Chou et al, 2009c). The recommendations of the American Pain Society and the 
American Academy of Pain Medicine are shown in table 1.  
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Patient selection and 
risk stratification 
Prior to initiating chronic opioid therapy, clinicians should conduct a history, 
physical examination and appropriate testing, including an assessment of risk of 
substance abuse, misuse, or addiction (strong recommendation, low-quality 
evidence). 
 
Clinicians may consider a trial of chronic opioid therapy as an option if chronic non-
cancer pain is moderate or severe, pain is having an adverse impact on function or 
quality of life, and potential therapeutic benefits outweigh or are likely to outweigh 
potential harms (strong recommendation, low-quality evidence). 
 
A benefit-to-harm evaluation including a history, physical examination, and 
appropriate diagnostic testing, should be performed and documented prior to and 
on an ongoing basis during chronic opioid therapy (strong recommendation, 
low-quality evidence). 
Informed consent and 
opioid management 
plans 
When starting chronic opioid therapy, informed consent should be obtained. A 
continuing discussion with the patient regarding chronic opioid therapy should 
include goals, expectations, potential risks, and alternatives to chronic opioid 
therapy (strong recommendation, low-quality evidence). 
 
Clinicians may consider using a written chronic opioid therapy management plan to 
document patient and clinician responsibilities and expectations and assist in 
patient education (weak recommendation, low-quality evidence). 
Initiation and titration 
of chronic opioid 
therapy 
Clinicians and patients should regard initial treatment with opioids as a therapeutic 
trial to determine whether chronic opioid therapy is appropriate (strong 
recommendation, low-quality evidence). 
 
Opioid selection, initial dosing, and titration should be individualized according to 
the patient’s health status, previous exposure to opioids, attainment of therapeutic 
goals, and predicted or observed harms (strong recommendation, low-quality 
evidence). There is insufficient evidence to recommend short-acting versus 
long-acting opioids, or as-needed versus around-the-clock dosing of opioids. 
Methadone 
Methadone is characterized by complicated and variable pharmacokinetics and 
pharmacodynamics and should be initiated and titrated cautiously, by clinicians 
familiar with its use and risks (strong recommendation, moderate-quality evidence). 
Monitoring 
Clinicians should reassess patients on chronic opioid therapy periodically and as 
warranted by changing circumstances. Monitoring should include documentation of 
pain intensity and level of functioning, assessments of progress towards achieving 
therapeutic goals, presence of adverse events, and adherence to prescribed therapies 
(strong recommendation, low-quality evidence). 
 
In patients on chronic opioid therapy who are at high risk or who have engaged in 
aberrant drug-related behaviours, clinicians should periodically obtain urine drug 
screens or other information to confirm adherence to the chronic opioid therapy 
plan of care (strong recommendation, low-quality evidence). 
 
In patients on chronic opioid therapy not at high risk and not known to have 
engaged in aberrant drug-related behaviors, clinicians should consider  
periodically obtaining urine drug screens or other information to confirm adherence 
to the chronic opioid therapy plan of care (weak recommendation, low-quality 
evidence). 
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TOPIC AREA RECOMENDATIONS 
High-risk patients 
Clinicians may consider chronic opioid therapy for patients with chronic non-cancer 
pain and history of drug abuse, psychiatric issues, or serious aberrant drug-related 
behaviours only if they are able to implement more frequent and stringent 
monitoring parameters. In such situations, clinicians should strongly consider 




Clinicians should evaluate patients engaging in aberrant drug-related behaviours 
for appropriateness of chronic opioid therapy or need for restructuring of therapy, 
referral for assistance in management, or discontinuation of chronic opioid therapy 
(strong recommendation, low-quality evidence). 
Dose escalations and 
high-dose therapy 
When repeated dose escalations occur in patients on chronic opioid therapy, 
clinicians should evaluate potential causes and re-assess benefits relative to harms 
(strong recommendation, low-quality evidence). 
 
In patients who require relatively high doses of chronic opioid therapy clinicians 
should evaluate for unique opioid-related adverse effects, changes in health status, 
and adherence to the chronic opioid therapy treatment plan on an ongoing basis, 
and consider more frequent follow-up visits (strong recommendation, low-quality 
evidence). 
Opioid rotation 
Clinicians should consider opioid rotation when patients on chronic opioid therapy 
experience intolerable adverse effects or inadequate benefit despite dose increases 




Clinicians should taper or wean patients off of chronic opioid therapy who engage 
in repeated aberrant drug-related behaviours or drug abuse/diversion, experience 
no progress towards meeting therapeutic goals, or experience intolerable adverse 
effects (strong recommendation, low-quality evidence). 
Opioid-related adverse 
effects 
Clinicians should anticipate, identify, and treat common opioid-associated adverse 




As chronic noncancer pain is often a complex biopsychosocial condition, clinicians 
who prescribe chronic opioid therapy should routinely integrate psychotherapeutic 
interventions, functional restoration, interdisciplinary therapy, and other adjunctive 
non-opioid therapies (strong recommendation, moderate-quality evidence). 
Driving and work safety 
Clinicians should counsel patients on chronic opioid therapy about transient or 
lasting cognitive impairment that may affect driving and work safety. Patients 
should be counselled not to drive or engage in potentially dangerous activities when 
impaired or if they describe or demonstrate signs of impairment (strong 
recommendation, low-quality evidence). 
Identifying a medical 
home and when to 
obtain consultation 
Patients on chronic opioid therapy should identify a clinician who accepts primary 
responsibility for their overall medical care. This clinician may or may not prescribe 
chronic opioid therapy, but should coordinate consultation and communication 
among all clinicians involved in the patient’s care (strong recommendation, 
low-quality evidence). 
 
Clinicians should pursue consultation, including interdisciplinary pain 
management, when patients with chronic non-cancer pain may benefit from 
additional skills or resources that they cannot provide (strong recommendation, 
moderate-quality evidence). 
Breakthrough pain 
In patients on around-the-clock chronic opioid therapy with breakthrough pain, 
clinicians may consider as-needed opioids based upon an initial and ongoing 
analysis of therapeutic benefit versus risk (weak recommendation, low-quality 
evidence). 
Table 1. Guidelines recommended by the American Pain Society and the American 
Academy of Pain Medicine for the long-term treatment with opioids of patients with chronic 
non-cancer pain (adapted from Chou, 2009). 
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Trescot et al. (2006, 2008) confirmed the importance of an overall patient assessment 
(physical and psychological) before initiating long-term opioid therapy; this assessment 
must include an appropriate assessment of treatment efficacy at regular intervals (in 
terms of both pain reduction and recovery of physical function), the identification and 
treatment of side effects and the monitoring of any abuse or misuse of the drug. The 
authors proposed a ten step algorithm that physicians could use for this purpose during 
treatment with opioids.  
2.2.1 Terminology of opioid abuse: Dependence, tolerance, addiction 
To ensure effective communication between physicians, researchers and legislators, a clear 
common terminology is needed. Many drugs, including opioids, play an important role in 
the treatment of pain. However, as shown earlier, the use of opioids is often limited by 
concerns about abuse, dependence and their possible use for non-medical reasons. 
Addiction, tolerance and physical dependence are distinct and different phenomena that are 
often used in a confused way. Since their clinical implications and management are clearly 
different, it is important to establish uniform definitions based on current scientific and 
clinical knowledge, to improve the care of patients with chronic pain and encourage 
appropriate policies for the regulation and control of drugs.  For this purpose, the American 
Academy of Pain Medicine, the American Pain Society and the American Society of 
Addiction Medicine (American Society of Addiction Medicine, 2001) have recognised the 
following definitions, and recommend their use: 
Addiction is a primary, chronic, neurobiologic disease, with genetic, psychosocial, and 
environmental factors influencing its development and manifestations. It is characterized by 
behaviours that include one or more of the following: impaired control over drug use, 
compulsive use, continued use despite harm, and craving.  
Physical dependence is a state of adaptation that is manifested by a drug class specific 
withdrawal syndrome that can be produced by abrupt cessation, rapid dose reduction, 
decreasing blood level of the drug, and/or administration of an antagonist. 
Tolerance is a state of adaptation in which exposure to a drug induces changes that result in a 
diminution of one or more of the drug’s effects over time. 
Pseudoaddiction is a term that has been used to describe behaviour that can occur when the 
pain is undertreated. Patients with inadequately managed pain may in fact become 
excessively focused on obtaining drugs. In their intent to obtain relief, patients may also 
resort to trickery and the use of unlawful substances. Pseudoaddiction may be distinguished 
from true addiction by the fact that the behaviour disappears when the pain is treated 
efficaciously.  
Misuse is defined as the use of any psychoactive substance in a way other than that for 
which it has been indicated or prescribed (Wasan et al., 2007). In practical terms, opioid 
misuse means: inadequate pain management, ineffective treatment, excessive focus on the 
drug and its effects which does not allow the patient to use other strategies efficaciously to 
cope with the pain, and finally, worsening of quality of life and altered social, working and 
psychological functioning.  
The term aberrant drug-related behaviours has been used to indicate the broad array of 
problematic nonadherence behaviours (Passik et al., 2006), the nature of which is uncertain 
until a diagnosis can be developed based on astute clinical assessment (Rosenblum et al., 
2008). Portenoy (1996; 2004) has listed a series of behaviours that should engender suspicion 
of addiction in patients with pain being treated with opioids (table 2). Moreover, Savage 
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TOPIC AREA RECOMENDATIONS 
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Clinicians may consider chronic opioid therapy for patients with chronic non-cancer 
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Clinicians should evaluate patients engaging in aberrant drug-related behaviours 
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evidence). 
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experience intolerable adverse effects or inadequate benefit despite dose increases 
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in repeated aberrant drug-related behaviours or drug abuse/diversion, experience 
no progress towards meeting therapeutic goals, or experience intolerable adverse 
effects (strong recommendation, low-quality evidence). 
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As chronic noncancer pain is often a complex biopsychosocial condition, clinicians 
who prescribe chronic opioid therapy should routinely integrate psychotherapeutic 
interventions, functional restoration, interdisciplinary therapy, and other adjunctive 
non-opioid therapies (strong recommendation, moderate-quality evidence). 
Driving and work safety 
Clinicians should counsel patients on chronic opioid therapy about transient or 
lasting cognitive impairment that may affect driving and work safety. Patients 
should be counselled not to drive or engage in potentially dangerous activities when 
impaired or if they describe or demonstrate signs of impairment (strong 
recommendation, low-quality evidence). 
Identifying a medical 
home and when to 
obtain consultation 
Patients on chronic opioid therapy should identify a clinician who accepts primary 
responsibility for their overall medical care. This clinician may or may not prescribe 
chronic opioid therapy, but should coordinate consultation and communication 
among all clinicians involved in the patient’s care (strong recommendation, 
low-quality evidence). 
 
Clinicians should pursue consultation, including interdisciplinary pain 
management, when patients with chronic non-cancer pain may benefit from 
additional skills or resources that they cannot provide (strong recommendation, 
moderate-quality evidence). 
Breakthrough pain 
In patients on around-the-clock chronic opioid therapy with breakthrough pain, 
clinicians may consider as-needed opioids based upon an initial and ongoing 
analysis of therapeutic benefit versus risk (weak recommendation, low-quality 
evidence). 
Table 1. Guidelines recommended by the American Pain Society and the American 
Academy of Pain Medicine for the long-term treatment with opioids of patients with chronic 
non-cancer pain (adapted from Chou, 2009). 
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terms of both pain reduction and recovery of physical function), the identification and 
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authors proposed a ten step algorithm that physicians could use for this purpose during 
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concerns about abuse, dependence and their possible use for non-medical reasons. 
Addiction, tolerance and physical dependence are distinct and different phenomena that are 
often used in a confused way. Since their clinical implications and management are clearly 
different, it is important to establish uniform definitions based on current scientific and 
clinical knowledge, to improve the care of patients with chronic pain and encourage 
appropriate policies for the regulation and control of drugs.  For this purpose, the American 
Academy of Pain Medicine, the American Pain Society and the American Society of 
Addiction Medicine (American Society of Addiction Medicine, 2001) have recognised the 
following definitions, and recommend their use: 
Addiction is a primary, chronic, neurobiologic disease, with genetic, psychosocial, and 
environmental factors influencing its development and manifestations. It is characterized by 
behaviours that include one or more of the following: impaired control over drug use, 
compulsive use, continued use despite harm, and craving.  
Physical dependence is a state of adaptation that is manifested by a drug class specific 
withdrawal syndrome that can be produced by abrupt cessation, rapid dose reduction, 
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Tolerance is a state of adaptation in which exposure to a drug induces changes that result in a 
diminution of one or more of the drug’s effects over time. 
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pain is undertreated. Patients with inadequately managed pain may in fact become 
excessively focused on obtaining drugs. In their intent to obtain relief, patients may also 
resort to trickery and the use of unlawful substances. Pseudoaddiction may be distinguished 
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which it has been indicated or prescribed (Wasan et al., 2007). In practical terms, opioid 
misuse means: inadequate pain management, ineffective treatment, excessive focus on the 
drug and its effects which does not allow the patient to use other strategies efficaciously to 
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of addiction in patients with pain being treated with opioids (table 2). Moreover, Savage 
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(1993), suggested that the following aspects should also be considered: frequent cancellation 
of appointments; asking for medicines at the end of every appointment; a history of non-
responsiveness to treatment, apart from opioids; a history of negative relationships with 
many physicians; many “drug allergies” that limit treatment options; finally, a degree of 
disability that is disproportionate to the basic disorder.  
As described above, the use of opioids has raised many concerns; in fact, the use of 
analgesics without medical prescription, or just to test their effects (“non medical use”) 
represents the second most frequent form of illicit substance use in the United States, after 
marijuana use (Office of Applied Studies, Substance Abuse and Mental Health Services 
Administration [SAMHSA], 2008). The National Survey on Drug Use and Health (Office of 
Applied Studies, SAMHSA, 2009) report on the use of opioids for non-medical purposes in 
the United States from 2002 to 2007 showed that: in 2007 approximately 5.2 million people of 
12 years of age or more had used prescription-only analgesics for non-medical purposes in 
the previous month; from 2002 to 2007 the use of opioids for non-therapeutic purposes 
decreased among young people between 12 and 17 years of age (from 3.2% to 2.7%) , while 
it increased in young adults between 18 and 25 years of age (4.1% to 4.6%) and in adults 
over 26 (from 1.3% to 1.6%). 
 
Behaviours probably more predictive of addiction 
Selling prescriptions drugs 
Prescription forgery 
Stealing or “borrowing” drugs from others 
Injection oral formulations 
Obtaining prescription drugs from non-medical sources 
Concurrent abuse of alcohol or illicit drugs 
Multiple dose escalation or other non-compliance with therapy despite warnings 
Multiple episodes of prescription “loss” 
Repeatedly seeking prescription from other clinicians or from emergency rooms without 
informing prescriber or after warning to desist 
Evidence of deterioration in the ability to function in work, in the family, or socially that 
appear to be related to the drug use 
Repeated resistance to changes in therapy despite clear evidence of adverse physical or 
psychological effect from the drug 
Behaviours probably less predictive of addiction 
Aggressive complaining about the need for more drug 
Drug hoarding during periods of reduced symptoms 
Requesting specific drugs 
Openly acquiring similar drugs from other medical sources 
Unsanctioned dose escalation or other non-compliance with therapy on one or two 
occasions 
Reporting psychic effects not intended by the clinician 
Resistance to change in therapy associated with “tolerable” adverse effects with expression 
of anxiety related to the return of severe symptoms  
Table 2. Behaviours predictive of addiction (adapted from Portenoy 1996, 2004).  
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Many studies have been carried out about the prevalence of opioid addiction in patients 
with chronic pain, but one of the limitations in interpreting their results is the fact that the 
researchers have used different criteria to establish problematic opioid use; some studies are 
based on behavioural observations, others on the results of urine toxicology screening, 
others again on the criteria Diagnostic and Statistical Manual of mental disorders – III or IV 
[DSM-III-IV] and yet other studies are based on definitions established by the authors 
themselves.  
Based on an extensive literature review, Højsted & Sjøgren (2007) estimated that the 
prevalence of addiction in the population with chronic non-cancer pain varies from 0% to 
50%. In particular, in the studies based on urine toxicology screening the prevalence varies 
from 17.2% to 39%; in the studies using the DSM-III or DSM-IV criteria it varied from 1.9% 
to 37%; and, finally, in the studies based on the various behavioural indicators, the 
prevalence varied from 0% to 50%. In a study of 100 patients with chronic pain in treatment 
with opioids, Manchikanti et al. (2001) found a prevalence of drug abuse, defined as the 
occurrence of obtaining a prescription of a controlled substance at least once a month from 
another physician without approval of the pain physician signing the controlled substance 
contract, of 24%. Fleming et al. (2007), considering 801 patients with non-cancer pain in 
chronic treatment with opioids, reported that 9.7% of the sample met the DSM-IV diagnostic 
criteria for opioid use disorder; the prevalence found by the authors was four times the 
prevalence in the general population.  
Finally, a recent review of the prolonged use of opioids in patients with non-cancer pain 
estimated the prevalence of addiction indicators as 0.27% of the total number of patients 
examined (Noble et al., 2010); the authors also observed that minor unwanted effects (e.g. 
nausea, headache) are frequent during treatment with opioids, but more serious adverse 
events, such as addiction, are rare.  
The hypothesis that short acting drugs such as hydrocodone may make patients more liable 
to ineffective pain management and misuse or abuse of the drugs than long acting drugs 
such as methadone was investigated by Manchikanti et al. (2005), who analysed 200 patients 
with chronic pain, half being treated with hydrocodone and the remainder with methadone. 
The study found no significant differences in the use of illegal substances and/or opioid 
abuse in patients treated with short- or long-acting drugs.  
So addiction is a well documented problem in pain patients, although it is difficult to 
estimate its exact prevalence. It is therefore important that clinicians consider the risk of 
opioid addiction without this prejudicing their use where indicated. In fact, those who use 
opioids constitute a heterogeneous category that includes extreme cases of patients who 
abuse medical and non-medical substances, and patients who adhere to treatment (Passik, 
2009). For adequate management and treatment of pain, physicians must balance the costs 
and benefits of opioid treatment; to maximise the benefits they can use different strategies, 
such as risk assessment and stratification, using specific tools, constant monitoring of 
treatment and any aberrant drug behaviours, regular urine screening and the possible 
involvement of another specialist (e.g. psychotherapist, addiction expert).  
2.3 Risk factors for opioid abuse 
Risk factors for opioid abuse and addiction may be divided into three categories: 
psychosocial factors, substance-related factors and genetic factors (figure 2). The risk of 
addiction is highest when the various categories of risk factor are combined. Pain patients 
without a genetic predisposition, without psychiatric comorbidity who take a stable dose of 
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(1993), suggested that the following aspects should also be considered: frequent cancellation 
of appointments; asking for medicines at the end of every appointment; a history of non-
responsiveness to treatment, apart from opioids; a history of negative relationships with 
many physicians; many “drug allergies” that limit treatment options; finally, a degree of 
disability that is disproportionate to the basic disorder.  
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analgesics without medical prescription, or just to test their effects (“non medical use”) 
represents the second most frequent form of illicit substance use in the United States, after 
marijuana use (Office of Applied Studies, Substance Abuse and Mental Health Services 
Administration [SAMHSA], 2008). The National Survey on Drug Use and Health (Office of 
Applied Studies, SAMHSA, 2009) report on the use of opioids for non-medical purposes in 
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12 years of age or more had used prescription-only analgesics for non-medical purposes in 
the previous month; from 2002 to 2007 the use of opioids for non-therapeutic purposes 
decreased among young people between 12 and 17 years of age (from 3.2% to 2.7%) , while 
it increased in young adults between 18 and 25 years of age (4.1% to 4.6%) and in adults 
over 26 (from 1.3% to 1.6%). 
 
Behaviours probably more predictive of addiction 
Selling prescriptions drugs 
Prescription forgery 
Stealing or “borrowing” drugs from others 
Injection oral formulations 
Obtaining prescription drugs from non-medical sources 
Concurrent abuse of alcohol or illicit drugs 
Multiple dose escalation or other non-compliance with therapy despite warnings 
Multiple episodes of prescription “loss” 
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Table 2. Behaviours predictive of addiction (adapted from Portenoy 1996, 2004).  
 
Risk Factors in Opioid Treatment of Chronic Non-Cancer Pain: A Multidisciplinary Assessment 
 
429 
Many studies have been carried out about the prevalence of opioid addiction in patients 
with chronic pain, but one of the limitations in interpreting their results is the fact that the 
researchers have used different criteria to establish problematic opioid use; some studies are 
based on behavioural observations, others on the results of urine toxicology screening, 
others again on the criteria Diagnostic and Statistical Manual of mental disorders – III or IV 
[DSM-III-IV] and yet other studies are based on definitions established by the authors 
themselves.  
Based on an extensive literature review, Højsted & Sjøgren (2007) estimated that the 
prevalence of addiction in the population with chronic non-cancer pain varies from 0% to 
50%. In particular, in the studies based on urine toxicology screening the prevalence varies 
from 17.2% to 39%; in the studies using the DSM-III or DSM-IV criteria it varied from 1.9% 
to 37%; and, finally, in the studies based on the various behavioural indicators, the 
prevalence varied from 0% to 50%. In a study of 100 patients with chronic pain in treatment 
with opioids, Manchikanti et al. (2001) found a prevalence of drug abuse, defined as the 
occurrence of obtaining a prescription of a controlled substance at least once a month from 
another physician without approval of the pain physician signing the controlled substance 
contract, of 24%. Fleming et al. (2007), considering 801 patients with non-cancer pain in 
chronic treatment with opioids, reported that 9.7% of the sample met the DSM-IV diagnostic 
criteria for opioid use disorder; the prevalence found by the authors was four times the 
prevalence in the general population.  
Finally, a recent review of the prolonged use of opioids in patients with non-cancer pain 
estimated the prevalence of addiction indicators as 0.27% of the total number of patients 
examined (Noble et al., 2010); the authors also observed that minor unwanted effects (e.g. 
nausea, headache) are frequent during treatment with opioids, but more serious adverse 
events, such as addiction, are rare.  
The hypothesis that short acting drugs such as hydrocodone may make patients more liable 
to ineffective pain management and misuse or abuse of the drugs than long acting drugs 
such as methadone was investigated by Manchikanti et al. (2005), who analysed 200 patients 
with chronic pain, half being treated with hydrocodone and the remainder with methadone. 
The study found no significant differences in the use of illegal substances and/or opioid 
abuse in patients treated with short- or long-acting drugs.  
So addiction is a well documented problem in pain patients, although it is difficult to 
estimate its exact prevalence. It is therefore important that clinicians consider the risk of 
opioid addiction without this prejudicing their use where indicated. In fact, those who use 
opioids constitute a heterogeneous category that includes extreme cases of patients who 
abuse medical and non-medical substances, and patients who adhere to treatment (Passik, 
2009). For adequate management and treatment of pain, physicians must balance the costs 
and benefits of opioid treatment; to maximise the benefits they can use different strategies, 
such as risk assessment and stratification, using specific tools, constant monitoring of 
treatment and any aberrant drug behaviours, regular urine screening and the possible 
involvement of another specialist (e.g. psychotherapist, addiction expert).  
2.3 Risk factors for opioid abuse 
Risk factors for opioid abuse and addiction may be divided into three categories: 
psychosocial factors, substance-related factors and genetic factors (figure 2). The risk of 
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opioids for the treatment of severe pain in a controlled clinical setting are most unlikely to 
develop addiction. In contrast, patients with a personal or family history of substance abuse, 
and with one or more psychosocial issues are at greater risk of developing addiction, 




Fig. 2. Genetic, psychosocial and drug-related factors associated with the development of 
addiction. Adapted from Ballantyne (2007). 
The psychosocial factors considered to be most predictive of opioid abuse are the presence 
of psychiatric disorders (Compton et al., 1998; Sullivan et al., 2006) and a personal and/or 
family history of substance abuse or drug abuse (Dunbar & Katz, 1996; Schieffer et al., 2005). 
A significant correlation has been found between chronic pain, mood disorders and aberrant 
drug use: patients with chronic pain report higher levels of anxiety and depression than 
patients with other medical conditions, and the incidence of mood disorders has been 
shown to be higher in patients at high risk of opioid misuse or dependence (Bair et al., 2003; 
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Using logistic regression, the authors showed that panic attacks, high trait anxiety and the 
presence of a personality disorder are able to explain the 38% variance in potential abuse of 
prescribed opioids. To investigate the role of psychological adjustment and psychiatric 
symptoms in aberrant drug behaviours in pain patients, Wasan et al. (2007) divided the 228 
patients enrolled into high-psychiatric and low-psychiatric morbidity, based on the 
responses to the psychiatric subscale of the Prescription Drug Use Questionnaire (PDUQ; 
Compton et al., 2008; see § 2.4.). Patients with high psychiatric comorbidity were 
significantly younger, with a longer mean opioid assumption time (p<0.05); altered urine 
toxicology screening results were also more frequent among these patients (p<0.01), and 
they often displayed aberrant drug-related behaviours. 
Edlund et al. (2007) conducted a broad prospective study of the risk factors for opioid abuse 
and addiction using the South Central Veterans Affairs Health Care Network databank. The 
sample included 15.160 chronic users of opioids in 2002; 45.3% of the sample had a 
psychiatric diagnosis and 7.6% had a non-opioid substance abuse diagnosis. The results 
show that prior abuse of non-opioid substances is a strong predictor of abuse/addiction to 
opioid drugs, while mental disorders are moderately strong predictors. The authors also 
found that the risk of abuse decreases uniformly with age. Other risk factors for opioid 
abuse/addiction were male gender, being divorced/separated or single and, finally, being 
in treatment with opioids for longer. A broad retrospective cohort study that involved 704 
patients with chronic pain being treated with opioids was carried out by Banta-Green et al. 
(2009a) to further comprehend the complex interaction between pain, mental health and 
addiction. The patients were initially assessed using a structured interview based on DSM-
IV criteria for abuse and dependence on opioids, misuse of opioids, anxiety and depression. 
By regression analysis, the authors identified three distinct categories of patients which they 
called: a) Typical group (characterised by moderate pain symptoms and limited psychiatric 
problems); b) Addictive Behaviours group (high psychiatric symptoms, misuse of opioids 
and moderate pain symptoms); c) Pain Dysfunction group (high intensity and interference 
of pain, high psychiatric symptoms and consistent misuse of opioids). The patients in the 
last two groups took an average daily dose of opioids that was three times that of the typical 
group. The authors suggest that the use of high doses of drugs could constitute a simple 
indicator to identify those patients that might benefit from further medical or psychiatric 
assessment, or assessment of drug misuse behaviours.  
To determine the incidence of opioid addiction, and the factors predictive for abuse, Ives 
et al. (2006) carried out a prospective cohort study of 196 patients with chronic pain being 
treated with opioids. Patients were monitored at regular intervals for an entire year. 
Opioid abuse was defined based on the presence of: negative urine toxicology screening 
for prescribed opioids; positive urine toxicology screening for non-prescribed drugs or 
opioids; supplies of opioids obtained from more than one provider; diversion of opioids, 
prescription forgery and positive urine toxicology screening for narcotics (cocaine or 
amphetamines). Opioid abuse was observed in 32% of patients; the most common form of 
misuse was the detection of cocaine or amphetamine in urine (40.3% of misusers). 
Abusers were found to be significantly younger (p<0.001); male (p= 0.023); with a history 
of abuse of alcohol (p= 0.004) and cocaine (p<0.001) than non-abusers. Ethnicity, income, 
education, levels of depression or disability and pain intensity were not found to be 
associated with drug misuse. Manchikanti et al. (2006) carried out a prospective 
longitudinal study of 500 patients with chronic pain to evaluate and correlate multiple 
variables with the abuse of opioids and illegal substances. Patients who obtained opioid 
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opioids for the treatment of severe pain in a controlled clinical setting are most unlikely to 
develop addiction. In contrast, patients with a personal or family history of substance abuse, 
and with one or more psychosocial issues are at greater risk of developing addiction, 
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Using logistic regression, the authors showed that panic attacks, high trait anxiety and the 
presence of a personality disorder are able to explain the 38% variance in potential abuse of 
prescribed opioids. To investigate the role of psychological adjustment and psychiatric 
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last two groups took an average daily dose of opioids that was three times that of the typical 
group. The authors suggest that the use of high doses of drugs could constitute a simple 
indicator to identify those patients that might benefit from further medical or psychiatric 
assessment, or assessment of drug misuse behaviours.  
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education, levels of depression or disability and pain intensity were not found to be 
associated with drug misuse. Manchikanti et al. (2006) carried out a prospective 
longitudinal study of 500 patients with chronic pain to evaluate and correlate multiple 
variables with the abuse of opioids and illegal substances. Patients who obtained opioid 
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drugs from sources other than the physicians at the clinic where the study was carried out 
were considered abusers; use of narcotics was ascertained through urine toxicology 
screening. Opioid abuse was observed in 9% of patients, while the use of illegal 
substances (e.g. cocaine, marijuana, metamphetamines) was detected in 16% of the 
sample. Opioid abuse was found to be more frequent in patients with pain due to road 
traffic accidents, pain in more than one region of the body and subjects with prior 
substance abuse. The use of illegal substances was more frequent among women and in 
patients under 45 years of age. The onset of pain after a road traffic accident and the 
presence of pain in more than one part of the body were also risk factors for narcotic 
substance abuse. To investigate the effect of gender on aberrant drug-related behaviours, 
Back et al. (2009) carried out a study on 121 patients (49 make and 72 female), who had to 
complete a set of tests designed to collect personal and clinical information and data on 
aberrant drug behaviours (e.g. prescription fraud, using other drug administration routes) 
and the use of nicotine, alcohol, marijuana, cocaine and hallucinogens. The results show 
that men were taking the prescribed drug significantly more regularly than women (91.7% 
v 77.8%, p<0.05), while women tend to keep unused drugs (67.6% v 47.7%; p=0.04) and to 
use other drugs (e.g. sedatives) to enhance the efficacy of analgesics (38.8% v 20%; p=0.04) 
more than men. Men tend to use other drug administration routes (e.g. crushing and 
snorting pills) than women, although this difference was not statistically significant. For 
men, there was an association between alcohol abuse, use of oxycodone or morphine and 
aberrant drug behaviours, while in women the aberrant drug behaviours were associated 
with the use of hydrocodone.  
In conclusion, the presence of psychiatric disorders and a personal and/or family history of 
substance abuse seem to be the most predictive factors of risk of opioid misuse in patients 
with chronic pain. Other variables such as gender, age and marital status may influence the 
risk of abuse, although the relationship is less clear, and further investigation is required 
(Savage, 2002). 
2.4 Tools to assess the risk of addiction and dependence 
Guidelines suggest that the use of opioids in patients with chronic non-cancer pain must be 
preceded by an initial stratification of the risk of drug misuse; this evaluation should include 
even a psychological and psychiatric assessment (Chou, 2009; Chou et al, 2009a; Chou et al, 
2009b; Chou et al, 2009c; Kalso et al., 2003; Trescot et al., 2006; Trescot at al., 2008). In recent 
years, many tools have been developed and examined for this purpose; most investigate the 
presence of a family and/or personal history of addiction and other factors correlated with 
opioid misuse, such as age, history of childhood sexual abuse and the presence of mental 
distress. Some of these tools, were created specifically for use in a population of patients 
with chronic pain, while others assess the addiction risk factors in general. Table 3 
summarises the tools that will then be described in greater detail; however, it is important to 
bear in mind that none is able to produce an accurate diagnosis about the presence of 
addiction, abuse or dependence. Besides, many of these are self-assessment tools, and 
therefore potentially at risk of falsification by the respondent. It is therefore advisable to 
supplement the information obtained with such tools with data obtained from direct 
observation of the patient during medical appointments. Anyhow, for patients who are 
found to be at high risk of misuse of the drug from the initial assessment with one of these 
scales, it is advisable to provide for constant monitoring of treatment, with regular urine 
toxicology screening.  
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a CAGE- questions Adapted to Include Drugs 
CAGE-
AID Brown & Rounds 1995 Self-administered 4 
b1 Prescription Drug Use Questionnaire PDUQ 
Compton et al. 
1998 Interview 42 
b2 
Prescription Drug Use 
Questionnaire – patient 
version 
PDUQp 2008 Self-administered 31 
c Screening Tool for Addiction Risk STAR Friedman et al. 2003 Self-administered 14 
d Pain Medication Questionnaire PMQ Adams et al. 2004 Self-administered 26 
e1 
Screener and Opioid 
Assessment for Patients with 
Pain 
SOAPP 





Screener and Opioid 
Assessment for Patients with 
Pain – Revised 
SOAPP-R 2008 24 
f Opioid Risk Tool ORT Webster et al. 2005 Self-administered 5 
g Addiction Behaviour Checklist ABC Wu et al. 2006 Interview 20 
h Diagnosis Intractability Risk and Efficacy Score DIRE Belgrade et al. 2006 Team assessment 7 
i Drug Abuse Screening Test DAST Yudko et al 2007 Self-administered 28 
Table 3. Principal tools for the stratification of the risk of opioid addiction and abuse.  
a. The CAGE questions Adapted to Include Drugs (CAGE-AID; Brown & Rounds, 1995) is an 
adaptation of the CAGE questionnaire, used for a short screening for alcohol abuse, 
which also includes substance use.   The name CAGE is derived from 4 key words: 
“cut”, “annoyed”, “guilty” and “eye-opener”. The questionnaire consists of the 
following 4 questions, to which the subject must reply “yes” or “no”: 1) Have you felt 
you ought to cut down your drinking or drug use?; 2) Have people annoyed you by 
criticizing your drinking or drug use?; 3) Have you felt bad or guilty about your 
drinking or drug use?; 4) Have you ever had a drink or used drugs first thing in the 
morning to steady your nerves or to get rid of a hangover (eye-opener)?. The addiction 
screening is positive with at least 2 affirmative responses. The CAGE-AID has been 
validated on a sample of 124 pain patients, demonstrating high values of sensitivity 
(0.70) and specificity (0.85). 
b1. Prescription Drug Use Questionnaire (PDUQ, Compton et al., 1998) is a tool, consisting of 
42 items to be administered in the form of an interview, that assesses the degree of 
abuse / misuse of the drug in patients with chronic pain. Care staff trained in the use of 
the tool take about twenty minutes to complete the interview. The patient must answer 
yes/no to questions that investigate: pain condition (e.g. “Has the patient explored 
and/or tried non-opioid or non-pharmacological pain management techniques?”), the 
ways in which they use drugs (e.g. “Does the patient have more than one prescription 
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drugs from sources other than the physicians at the clinic where the study was carried out 
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bear in mind that none is able to produce an accurate diagnosis about the presence of 
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adaptation of the CAGE questionnaire, used for a short screening for alcohol abuse, 
which also includes substance use.   The name CAGE is derived from 4 key words: 
“cut”, “annoyed”, “guilty” and “eye-opener”. The questionnaire consists of the 
following 4 questions, to which the subject must reply “yes” or “no”: 1) Have you felt 
you ought to cut down your drinking or drug use?; 2) Have people annoyed you by 
criticizing your drinking or drug use?; 3) Have you felt bad or guilty about your 
drinking or drug use?; 4) Have you ever had a drink or used drugs first thing in the 
morning to steady your nerves or to get rid of a hangover (eye-opener)?. The addiction 
screening is positive with at least 2 affirmative responses. The CAGE-AID has been 
validated on a sample of 124 pain patients, demonstrating high values of sensitivity 
(0.70) and specificity (0.85). 
b1. Prescription Drug Use Questionnaire (PDUQ, Compton et al., 1998) is a tool, consisting of 
42 items to be administered in the form of an interview, that assesses the degree of 
abuse / misuse of the drug in patients with chronic pain. Care staff trained in the use of 
the tool take about twenty minutes to complete the interview. The patient must answer 
yes/no to questions that investigate: pain condition (e.g. “Has the patient explored 
and/or tried non-opioid or non-pharmacological pain management techniques?”), the 
ways in which they use drugs (e.g. “Does the patient have more than one prescription 
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provider?”), social/family factors (e.g. “Have family members expressed concerns that 
the patient is addicted?”), family history of chronic pain and/or addiction (e.g. “Is there 
a positive history of chronic pain in the patient’s mother, father, sibling or blood 
relative?”), personal history of substance abuse (e.g. “Has the patient ever been 
diagnosed with addiction to any drug or alcohol”) and psychiatric history (e.g. “Has the 
patient ever been diagnosed with a psychiatric disorder?”). The tool has good internal 
consistency (Cronbach’s α = 0.79). To identify a cut-off, the 52 patients with chronic 
pain who participated in the pilot study to validate the PDUQ were initially classified 
as addicted or non-addicted based on criteria developed by the American Society of 
Addiction Medicine (see § 2.2.2.). Patients with scores of less than 11 did not meet the 
criteria for a substance abuse disorder, while patients with scores of 15 or more 
reflected the criteria for a substance abuse disorder. So those who achieved scores of 
less than 11 use the drug in a suitable way. Moreover, positive answers to 3 specific 
items of the tool (notably “patient believes he/she is addicted”; “increases analgesic 
dose/frequency”; “specific drug or route of administration preference”) have been 
identified as more predictive of addiction, with a 92.9% of correct classification. Banta-
Green et al. (2009b) carried out a study of 704 patients who had been prescribed long-
term treatment with opioids, aimed to examine the factorial structure of the PDUQ. The 
results show that the items may be grouped into three distinct types of factor “addictive 
behaviours”, “addiction concerns” and “pain treatment problems”. The limits of the 
PDUQ concern the fact that it relies solely on the sincerity of the patient and is difficult 
to use in an overloaded clinical context.  
b2. The Prescription Drug Use Questionnaire – patient version (PDUQp) was created by 
Compton et al. (2008) to obviate the difficulty mentioned above. The PDUQp is a self-
administered instrument which consists of 31 items and the total score can vary from 0 
to 30. Analysis of the psychometric properties of the new self-administered version was 
carried out on 135 patients with chronic pain being treated with opioids, monitored for 
12 months. The PDUQp proved to have good concurrent validity, calculated by 
comparing the scores obtained with the scores obtained with the PDUQ (r = 0.64). The 
tool also proved to have good test-retest reliability, assessed at 4, 8 and 12 months after 
its first administration (r = 0.67, r = 0.61 and r = 0.40 respectively). A cut-off of 10 is 
suggested as indicative of drug misuse. 
c. The Screening Tool for Addiction Risk (STAR, Friedman et al., 2003) consists of 14 questions 
with true/false responses that investigate potential risk factors for drug. The items were 
developed based on a literature review carried out by a team of specialists in pain and 
addiction. Validation of the questionnaire was carried out on 48 patients with chronic 
pain, 14 of whom had a diagnosis of addiction based on the DSM-IV criteria. The authors 
found a close correlation between addiction and prior treatment in a rehabilitation unit for 
alcohol or drug dependence, smoking, and intensity of nicotine craving. In particular, the 
item on prior experience of alcohol and/or substance detoxification was able to identify 
correctly 93% of the patients who met the addiction criteria.  
d. The Pain Medication Questionnaire (PMQ, Adams et al., 2004) is a self-administered 
questionnaire that describes a series of dysfunctional behaviours and characteristics 
that underlie the use of drugs for the treatment of pain. The tool consists of 26 items, for 
each of which the subject must indicate his degree of agreement or disagreement on a 5 
point Likert scale, and a score is attributed to the selected response (disagree = 0, 
somewhat disagree = 1, neutral = 3, somewhat agree = 4, agree = 5). The sum of the 
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scores of the single items gives a total score, which can vary from a minimum of 0 to a 
maximum of 104. High scores are correlated with a high risk of opioid misuse. In 
particular, scores of 25 or more are indicative of  opioid misuse, while scores of 30 or 
more suggest that the patient should be constantly monitored during treatment 
(Dowling et al., 2007). The validity of the tool was investigated by Adams et al. (2004) 
on 184 patients with chronic pain, comparing the results obtained with the PMQ with a 
series of assessment of substance abuse, degree of psychosocial distress, and some 
indicators of psychological and physical functioning; the test-retest reliability coefficient 
is 0.85 and the internal consistency is acceptable (Cronbach’s α = 0.73). A further study 
to examine the psychometric characteristics of the PMQ in greater depth was carried 
out by Buelow et al. (2009). One of the aims was to examine the accuracy of the short 
form of the PMQ (from which items 5, 10 and 23 had been eliminated, since they had 
the lowest correlation coefficients) in predicting opioid misuse. Examining 4.182 
subjects, of whom 1.813 were involved in an interdisciplinary treatment programme 
(that included physical, pharmacological and psychological therapy) the authors 
confirmed the adequate internal consistency of the abbreviated form (Cronbach’s α = 
0.70) e and of test-retest reliability (r= 0.77). Significant differences also emerged in the 
mean PMQ score of patients with a history of substance abuse (mean = 24.39) and of 
patients without a history of abuse (mean = 21.95). Moreover, those patients who 
interrupted the treatment had mean scores that were significantly higher than those of 
patients who displayed good compliance. By logistic regression, the authors showed 
that early request of opioids is the only factor able to predict high or low questionnaire 
scores of those assessed (age, history of alcohol and/or substance abuse). 
e1. The Screener and Opioid Assessment for Patients with Pain (SOAPP, Butler et al., 2004) 
is a self-administered tool with 14 items that investigate potential risk factors for opioid 
misuse (e.g. “How often do you take more medications than you are supposed to?”; 
“How often have others expressed concerns over your use of medication?”). These 
items were proposed and voted on by a team of experts; the patient must indicate the 
frequency of each behaviour on a 5 point Likert scale (0 = “never”; 4 = “very often”). 
The tool was administered to 175 patients with chronic pain and readministered 6 
months later to 95 of these patients, to test its reliability over time. The SOAPP proved 
to have adequate internal consistency (Cronbach’s α= 0.74) and good test-retest 
reliability six months after its first administration (r = 0.71). Scores of 8 or more are 
indicative of high risk of abuse (sensitivity: 0.91; specificity: 0.69). In a study 
investigating the psychometric characteristics and clinical utility of the SOAPP in 397 
patients, Akbik et al. (2006) found patients classified at high risk were significantly 
younger, with altered urine screening results (p<0.05) than low risk patients. The factor 
analysis also revealed the presence of 5 factors, called: 1) History of substance abuse; 2) 
Legal problems; 3) Craving medications; 4) Heavy smoking and 5) Mood swings. Moore 
et al. (2009), in a study to examine the efficacy of the SOAPP and other tools in 
predicting the risk of opioid misuse, found good sensitivity for the tool (0.72); 
combining the data from the SOAPP with those from a semi-structured clinical 
interview designed to investigate prior treatments used, the presence of emotional 
distress and prior substance abuse, the sensitivity increased to 0.90.  
e2. The Screener and Opioid Assessment for Patients with Pain – Revised (SOAPP-R) is a 24-item 
version developed by Butler et al. (2008) in order to overcome some limitations of the 
original SOAPP. The new version, tested on a sample of 283 patients, proved to have 
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comparing the scores obtained with the scores obtained with the PDUQ (r = 0.64). The 
tool also proved to have good test-retest reliability, assessed at 4, 8 and 12 months after 
its first administration (r = 0.67, r = 0.61 and r = 0.40 respectively). A cut-off of 10 is 
suggested as indicative of drug misuse. 
c. The Screening Tool for Addiction Risk (STAR, Friedman et al., 2003) consists of 14 questions 
with true/false responses that investigate potential risk factors for drug. The items were 
developed based on a literature review carried out by a team of specialists in pain and 
addiction. Validation of the questionnaire was carried out on 48 patients with chronic 
pain, 14 of whom had a diagnosis of addiction based on the DSM-IV criteria. The authors 
found a close correlation between addiction and prior treatment in a rehabilitation unit for 
alcohol or drug dependence, smoking, and intensity of nicotine craving. In particular, the 
item on prior experience of alcohol and/or substance detoxification was able to identify 
correctly 93% of the patients who met the addiction criteria.  
d. The Pain Medication Questionnaire (PMQ, Adams et al., 2004) is a self-administered 
questionnaire that describes a series of dysfunctional behaviours and characteristics 
that underlie the use of drugs for the treatment of pain. The tool consists of 26 items, for 
each of which the subject must indicate his degree of agreement or disagreement on a 5 
point Likert scale, and a score is attributed to the selected response (disagree = 0, 
somewhat disagree = 1, neutral = 3, somewhat agree = 4, agree = 5). The sum of the 
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scores of the single items gives a total score, which can vary from a minimum of 0 to a 
maximum of 104. High scores are correlated with a high risk of opioid misuse. In 
particular, scores of 25 or more are indicative of  opioid misuse, while scores of 30 or 
more suggest that the patient should be constantly monitored during treatment 
(Dowling et al., 2007). The validity of the tool was investigated by Adams et al. (2004) 
on 184 patients with chronic pain, comparing the results obtained with the PMQ with a 
series of assessment of substance abuse, degree of psychosocial distress, and some 
indicators of psychological and physical functioning; the test-retest reliability coefficient 
is 0.85 and the internal consistency is acceptable (Cronbach’s α = 0.73). A further study 
to examine the psychometric characteristics of the PMQ in greater depth was carried 
out by Buelow et al. (2009). One of the aims was to examine the accuracy of the short 
form of the PMQ (from which items 5, 10 and 23 had been eliminated, since they had 
the lowest correlation coefficients) in predicting opioid misuse. Examining 4.182 
subjects, of whom 1.813 were involved in an interdisciplinary treatment programme 
(that included physical, pharmacological and psychological therapy) the authors 
confirmed the adequate internal consistency of the abbreviated form (Cronbach’s α = 
0.70) e and of test-retest reliability (r= 0.77). Significant differences also emerged in the 
mean PMQ score of patients with a history of substance abuse (mean = 24.39) and of 
patients without a history of abuse (mean = 21.95). Moreover, those patients who 
interrupted the treatment had mean scores that were significantly higher than those of 
patients who displayed good compliance. By logistic regression, the authors showed 
that early request of opioids is the only factor able to predict high or low questionnaire 
scores of those assessed (age, history of alcohol and/or substance abuse). 
e1. The Screener and Opioid Assessment for Patients with Pain (SOAPP, Butler et al., 2004) 
is a self-administered tool with 14 items that investigate potential risk factors for opioid 
misuse (e.g. “How often do you take more medications than you are supposed to?”; 
“How often have others expressed concerns over your use of medication?”). These 
items were proposed and voted on by a team of experts; the patient must indicate the 
frequency of each behaviour on a 5 point Likert scale (0 = “never”; 4 = “very often”). 
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reliability six months after its first administration (r = 0.71). Scores of 8 or more are 
indicative of high risk of abuse (sensitivity: 0.91; specificity: 0.69). In a study 
investigating the psychometric characteristics and clinical utility of the SOAPP in 397 
patients, Akbik et al. (2006) found patients classified at high risk were significantly 
younger, with altered urine screening results (p<0.05) than low risk patients. The factor 
analysis also revealed the presence of 5 factors, called: 1) History of substance abuse; 2) 
Legal problems; 3) Craving medications; 4) Heavy smoking and 5) Mood swings. Moore 
et al. (2009), in a study to examine the efficacy of the SOAPP and other tools in 
predicting the risk of opioid misuse, found good sensitivity for the tool (0.72); 
combining the data from the SOAPP with those from a semi-structured clinical 
interview designed to investigate prior treatments used, the presence of emotional 
distress and prior substance abuse, the sensitivity increased to 0.90.  
e2. The Screener and Opioid Assessment for Patients with Pain – Revised (SOAPP-R) is a 24-item 
version developed by Butler et al. (2008) in order to overcome some limitations of the 
original SOAPP. The new version, tested on a sample of 283 patients, proved to have 
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good internal consistency (Cronbach’s α = 0.88); the cut-off of 18 shows adequate 
sensitivity (0.81) and specificity (0.68). Patients with low SOAPP-R scores appear to be 
at less risk of developing a substance abuse disorder.  
f. The Opioid Risk Tool (ORT, Webster et al., 2005) is a self-administered tool developed to 
estimate the probability that the patient displays aberrant drug behaviours during long-
term opioid treatment. The ORT consists of 5 items which investigate the following risk 
factors: family history of substance abuse (alcohol, drugs or prescribed medicines); 
personal history of substance abuse (alcohol, drugs or prescribed medicines); age (if 
between 16 and 45 years); history of childhood sexual abuse; presence of psychological 
distress (attention deficit disorder, obsessive-compulsive disorder, bipolar disorder, 
schizophrenia and depression). Each factor has a different weight in determining the 
potential risk of drug misuse, and so a specific numerical value is assigned to each, 
which also varies according to the sex of the respondent. There are three risk levels: 
scores from 0 to 3 are indicative of low risk; scores from 4 to 7 determine moderate risk; 
finally, scores of 8 or more are indicative of a high risk of misuse. This questionnaire 
was validated on 108 women and 77 men with chronic pain, followed for a period of 12 
months from the initial appointment. 94% of the patients classified as low risk based on 
the total ORT score did not display aberrant drug behaviours in the year in which they 
were monitored, while 90.9% of the patients with scores of the cut-off value of 8 or more 
displayed aberrant drug behaviours.  
g. The Addiction Behaviour Checklist (ABC, Wu et al., 2006) consists of 20 items to be 
administered in the form of an interview. The items are grouped in two principal 
categories: 1) addicted behaviours noted during visit (e.g. “patient running out of 
medications early”; “receiving narcotics from other providers”); 2) addictive behaviours 
observed within the visit (e.g. “patient appearing sedated”; “patient expressing concern 
about the future availability of narcotics”). Finally, there is a further question that can be 
used if family members of the patient are present during the medical appointment 
(“significant others express concern over patient’s use of analgesic”). The answer system 
is binary (yes/no): each affirmative answer is assigned a point and the total score can vary 
from 0 to 20. To investigate its psychometric characteristics, the ABC was administered to 
136 patients with chronic pain prescribed long-term opioid treatment. The tool proved to 
have high inter-rater validity (0.94 – 0.95) and significant concurrent validity: a significant 
correlation  (r=0.40; p< .01) was found between the ABC score and the  Prescription Drug 
Use Questionnaire (PDUQ, Compton et al., 1998) score. A cut-off value of 3 on this tool is 
able to provide a good estimate of appropriate/inappropriate use that the patient will 
make of the drug. For scores of 3 or more, the authors suggest that the patient should be 
monitored frequently, including more frequent urine toxicology screening.  
h. The Diagnosis Intractability Risk and Efficacy Score (DIRE, Belgrade et al., 2006) is a tool that 
is compiled by a multidisciplinary team of physicians and psychologists. It consists of 4 
scales: Diagnosis, Intractability, Risk (4 subcategories) Efficacy. Each class requires 
assessment on a 3 point scale, where a score of 1 corresponds to characteristics and 
behaviours that are indicative of a negative prognosis, and a score of 3 is indicative of 
suitability for treatment with opioids. The Diagnosis factor requires the clinician to 
determine the extent to which the patient’s diagnosis is sufficiently compelling or 
advanced to warrant an aggressive pharmacological approach. The Intractability factor 
requires a determination of how many appropriate treatments the patient has undergone 
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and how he or she is involved in the treatment, i.e. if they play a passive or an active role 
in managing their pain. The Risk factor was created to estimate the extent to which the 
patient would adhere to the instructions of the clinician during treatment. As stated 
above, it comprises four categories: Psychological health assesses the psychiatric and 
psychological status of the patient; Chemical health assesses the patient’s relationship 
with substances with potential risk of abuse; Reliability assesses compliance with 
treatment in the past, whether or not the patient attends appointments and following the 
physician’s recommendations fully; Social support assesses the patient’s support network 
and his or her ability to function in life roles, such as work, school, parenting, etc. Efficacy 
assesses the analgesic effectiveness of opioids, based on physical functionality and 
patient’s pain self-report. When efficacy cannot be assessed because the patient has not yet 
started to take opioids, or takes them in quantities that are too low (less than the 
equivalent of 30 mg/day of morphine) a score of 2 is attributed. All the scales and 
subscales of the Risk factor are firstly assessed individually and then added together to 
obtain the DIRE score. The total score can vary from a minimum of 7 to a maximum of 21; 
scores between 14 and 21 are indicative of a greater degree of patient compliance and, in 
general, greater treatment efficacy. The psychometric analyses of the original version, 
carried out on a group of 61 patients with chronic pain, shown an internal consistency 
alpha coefficient of 0.80 and an inter-rater validity of 0.95.  
i. The Drug Abuse Screening Test (DAST, Yudko et al., 2007) is a self-administered 
questionnaire consisting of 28 items with binary (yes/no) answers. Scores of 6 or more 
indicate the presence of substance dependence or abuse. In addition to the complete 
version of the questionnaire, which can be too time-consuming in some clinical contexts, 
there are various short versions of the DAST, based on 10 items instead of 28. The 28-item 
DAST has proved to have high test-retest reliability (r = 0.85) and good internal 
consistency (Cronbach’s α 0.92-0.94). The tool has shown good sensitivity, between 81% 
and 96%, and good specificity (from 71% to 94%). One limitation of the tool is the fact that 
it is susceptible to falsification and may therefore not identify those people who, while 
abusing the drug, intentionally give false answers. Moreover, the tool is predictive of 
substance abuse but does not specifically examine the aberrant drug behaviours.  
2.4.1 Ways of monitoring treatment 
A number of different tools have been created for clinicians to monitor opioid treatment and 
as checklists for the systemic observation of aberrant drug behaviours.  The tools most 
widely mentioned in the literature are described briefly below. 
The Prescription Opioid Therapy Questionnaire (POTQ; Michna et al., 2004) is a tool  with 11 
items to which the clinician must answer yes or no to assess opioid misuse. The items reflect 
the behaviours suggested by Chabal et al. (1997) as indicative of substance abuse. These 
behaviours include multiple unauthorised dosage increases, episodes of lost or stolen 
prescriptions, frequent unplanned visits to the clinic or emergency room, excessive 
telephone calls and inflexibility about treatment options. Patients who were positively rated 
on two or more of the items met criteria for prescription opioid misuse.  
The Pain Assessment and Documentation Tool (PADT; Passik et al., 2004; Passik et al., 2005) is a 
brief (takes between 10 to 20 minutes to complete) clinician-directed interview. The clinician 
asks the patients questions that are organized in four primary areas called the “Four A’s” 
and are notably: Analgesia - focuses on pain intensity (numeric rating scales) and pain relief; 
Activities of Daily Living - focuses on whether the patient’s functioning since the last 
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good internal consistency (Cronbach’s α = 0.88); the cut-off of 18 shows adequate 
sensitivity (0.81) and specificity (0.68). Patients with low SOAPP-R scores appear to be 
at less risk of developing a substance abuse disorder.  
f. The Opioid Risk Tool (ORT, Webster et al., 2005) is a self-administered tool developed to 
estimate the probability that the patient displays aberrant drug behaviours during long-
term opioid treatment. The ORT consists of 5 items which investigate the following risk 
factors: family history of substance abuse (alcohol, drugs or prescribed medicines); 
personal history of substance abuse (alcohol, drugs or prescribed medicines); age (if 
between 16 and 45 years); history of childhood sexual abuse; presence of psychological 
distress (attention deficit disorder, obsessive-compulsive disorder, bipolar disorder, 
schizophrenia and depression). Each factor has a different weight in determining the 
potential risk of drug misuse, and so a specific numerical value is assigned to each, 
which also varies according to the sex of the respondent. There are three risk levels: 
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months from the initial appointment. 94% of the patients classified as low risk based on 
the total ORT score did not display aberrant drug behaviours in the year in which they 
were monitored, while 90.9% of the patients with scores of the cut-off value of 8 or more 
displayed aberrant drug behaviours.  
g. The Addiction Behaviour Checklist (ABC, Wu et al., 2006) consists of 20 items to be 
administered in the form of an interview. The items are grouped in two principal 
categories: 1) addicted behaviours noted during visit (e.g. “patient running out of 
medications early”; “receiving narcotics from other providers”); 2) addictive behaviours 
observed within the visit (e.g. “patient appearing sedated”; “patient expressing concern 
about the future availability of narcotics”). Finally, there is a further question that can be 
used if family members of the patient are present during the medical appointment 
(“significant others express concern over patient’s use of analgesic”). The answer system 
is binary (yes/no): each affirmative answer is assigned a point and the total score can vary 
from 0 to 20. To investigate its psychometric characteristics, the ABC was administered to 
136 patients with chronic pain prescribed long-term opioid treatment. The tool proved to 
have high inter-rater validity (0.94 – 0.95) and significant concurrent validity: a significant 
correlation  (r=0.40; p< .01) was found between the ABC score and the  Prescription Drug 
Use Questionnaire (PDUQ, Compton et al., 1998) score. A cut-off value of 3 on this tool is 
able to provide a good estimate of appropriate/inappropriate use that the patient will 
make of the drug. For scores of 3 or more, the authors suggest that the patient should be 
monitored frequently, including more frequent urine toxicology screening.  
h. The Diagnosis Intractability Risk and Efficacy Score (DIRE, Belgrade et al., 2006) is a tool that 
is compiled by a multidisciplinary team of physicians and psychologists. It consists of 4 
scales: Diagnosis, Intractability, Risk (4 subcategories) Efficacy. Each class requires 
assessment on a 3 point scale, where a score of 1 corresponds to characteristics and 
behaviours that are indicative of a negative prognosis, and a score of 3 is indicative of 
suitability for treatment with opioids. The Diagnosis factor requires the clinician to 
determine the extent to which the patient’s diagnosis is sufficiently compelling or 
advanced to warrant an aggressive pharmacological approach. The Intractability factor 
requires a determination of how many appropriate treatments the patient has undergone 
 
Risk Factors in Opioid Treatment of Chronic Non-Cancer Pain: A Multidisciplinary Assessment 
 
437 
and how he or she is involved in the treatment, i.e. if they play a passive or an active role 
in managing their pain. The Risk factor was created to estimate the extent to which the 
patient would adhere to the instructions of the clinician during treatment. As stated 
above, it comprises four categories: Psychological health assesses the psychiatric and 
psychological status of the patient; Chemical health assesses the patient’s relationship 
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treatment in the past, whether or not the patient attends appointments and following the 
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patient’s pain self-report. When efficacy cannot be assessed because the patient has not yet 
started to take opioids, or takes them in quantities that are too low (less than the 
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The Pain Assessment and Documentation Tool (PADT; Passik et al., 2004; Passik et al., 2005) is a 
brief (takes between 10 to 20 minutes to complete) clinician-directed interview. The clinician 
asks the patients questions that are organized in four primary areas called the “Four A’s” 
and are notably: Analgesia - focuses on pain intensity (numeric rating scales) and pain relief; 
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assessment is better, same, or worse; Adverse Events - identifies whether the patient is 
experiencing side effects from current pain relievers, and if so, what they are; potentially 
Aberrant Drug-Related Behaviours - assesses 17 aberrant behaviours. The availability of this 
checklist is likely to improve the ability of clinicians to capture problematic behaviours and 
implement appropriate actions in response. In addition, there is a fifth section on 
“Assessment” which identifies a specific analgesic plan.  
The Current Opioid Misuse Measure (COMM, Bultler at al., 2007) is a tool with 17 items, 
asking the patient how he or she currently uses pain medication. For each behaviour listed 
(e.g. “how often have you needed to take pain medications belonging to someone else?”), 
the patient must indicate the frequency of each behaviour on a 5 point Likert scale (0 = 
“never”; 4 = “very often”). The current 17-item version of COMM was created from the 40-
item version produced from the concept mapping work carried out by 26 pain and addiction 
professionals. Validation of the tool was carried out on 227 patients with chronic pain. 
Scores of 9 or more (sensitivity=0.77; specificity=0.68)  are considered to be indicative of 
high risk of drug abuse. The tool has excellent internal consistency (Cronbach’s α= 0.86) and 
very good test-retest reliability one week after its first administration (r = 0.86).  
As well as the tools mentioned above, urine drug screens and other laboratory tests can help 
the clinician to understand if the patient is using illegal substances or non-prescribed drugs. It 
is important to supplement the observation-based tools with laboratory tests. In fact, Katz et al. 
(2003) showed that even if a clinician has been very careful to detect aberrant drug behaviours, 
some signals may be missed: approximately 20% of patients considered compliant with the 
treatment prescribed by expert clinicians actually tested positive in urine toxicology screening. 
Urine screening is an economical and non-invasive monitoring strategy that enables most 
drugs to be identified between 1 and 3 days after they were taken (Heit & Gourley, 2004). In 
addition, urine screening may be very useful in preventing opioid abuse, detecting the 
presence of illegal substances, identifying those patients who are not taking the prescribed 
drugs, or those who are using non-prescribed opioids (Atluri & Sudarshan, 2003). However, 
the results of urine toxicology screening must be interpreted with caution, since they may not 
always be correct, and in some cases can produce false positives and false negatives. 
Moreover, some substances are not detected by standard urine screening, and so clinicians 
must result to more specific or costly urine tests (or to blood or hair analysis). For this reason 
the results of urine drug screen should be considered a further piece of the puzzle in assessing 
patients with problematic opioid use behaviours (Ballantyne, 2009).  
2.5 The research 
This section describes the preliminary results of a prospective longitudinal study to identify 
some procedures that allow the risk of opioid misuse to be determined in patients with chronic 
non-cancer pain. Specifically, the study examines the efficacy and clinical utility of the Pain 
Medication Questionnaire – PMQ (Adams et al. 2004) and the Diagnosis, Intractability, Risk 
and Efficacy – DIRE (Belgrade et al. 2006). The PMQ was selected because it is a self-
administered scale that can easily be integrated into clinical-care routine, and the DIRE 
because it is an assessment tool used in a multidisciplinary setting that requires a medical and 
psychological assessment of the patient. In addition, both tools have been shown to possess 
characteristics that make them suitable for use in clinical practice: good psychometric properties 
in their original version, easy to complete, and sufficiently short to administer and score.  
The specific aim of the study is to identify and examine the efficacy of a clinical protocol for 
the systematic assessment of patients who are candidates for starting opioid treatment. As a 
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preliminary step, the predictive validity of the Italian versions of the PMQ and the DIRE 
was investigated: until now the Italian versions of these instrument are not available. 
Besides, the capacity of the two tools to predict opioid misuse was compared to the 
subjective estimate made by the physician based on his or her clinical experience. 
Furthermore, the presence of possible relationships between aberrant drug behaviours and 
the presence of risk factors for treatment compliance was examined, as was any use of illegal 
substances established by urine drug tests. Finally, the efficacy of the treatment was 
analysed the patient’s perceived quality of life and pain experience after 2 and 4 months 
after the start of treatment. 
2.5.1 Subjects 
The preliminary data presented below refer to 25 patients treated in the Pain Relief and 
Palliative Care Unit. The inclusion criteria were: age between 18 and 70 years; presence of 
non-cancer pain for at least 6 months; pain intensity assessed on an 11 point Numerical 
Rating Scale of at least 4 in the last month; good knowledge/understanding of Italian; 
absence of cognitive deficit; use of fixed regime weak opioids insufficiently efficacious; other 
pharmacological and non-pharmacological treatments used for at least 3 months not 
sufficiently efficacious; no significant decrease in life expectancy; informed consent to 
participation in the study obtained. 
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The socio-demographic and clinical characteristics of the group of subjects are represented 
in table 4. The mean age is 56.2 years (±10.6) and 68% are women. Most subjects were not 
working at the time of the study due to their pain condition. Regarding the characteristics of 
their pain symptoms, the most prevalent types were nociceptive (40%) or mixed (40%); the 
average duration of the pain condition was 88.2 months (±57.7). There were no statistically 
significant differences between men and women in any of the descriptive variables 
considered. 
2.5.2 Instruments 
The Checklist for medical selection is a tool constructed ad hoc that enabled physicians to 
collect information needed to check the suitability of the patient for inclusion in the study. It 
includes the collection of personal data (age, sex, nationality), clinical data (disorder causing 
the pain, characteristics of the pain, prior pharmacological and non-pharmacological 
treatments) and the assessment of pain intensity (in the last month) using the 11-point 
Numerical Rating Scale (NRS-11). The doctor must also indicate the drug administration route 
(oral or transdermal) and the initial dosage. 
The 11-point Numerical Rating Scale (NRS-11) is a pain assessment scale in which the patient 
is asked to report the intensity of the pain, over a specific time interval, with a number from 
0 to 10, where 0 indicates no pain and 10 the worst possible pain. 
The risk opioid misuse was assessed using the Pain Medication Questionnaire-  PMQ 
(Adams et al., 2004) and the Diagnosis Intractability Risk and Efficacy Score  - DIRE; 
Belgrade et al. 2006): see § 2.4 for a detailed description of these tools. The Italian version of 
the tools elaborated for this study was authorised and approved by the original Authors. 
The Medical risk prediction requires the physician to provide an estimate, based on his or her 
clinical experience, of the risk of opioid misuse, answering 3 questions on an 11 point 
numerical scale: compliance with medical treatment (0=no compliance; 10=maximum 
compliance),  risk of abuse and/or underuse of the drug (0=no risk, 10=maximum risk) and 
expected efficacy of treatment (0=no efficacy, 10=maximum efficacy). 
The Medical control form was designed to collect clinical information about the progress of 
the treatment, any side effects, and the intention to continue or suspend treatment. It 
contains also a list of aberrant drug behaviours, based on the reference literature; the 
physician must tick those behaviours displayed by the patient (e.g. The patient uses other 
opioids in addition to those prescribed, The patient displays little interest in managing 
himself and his rehabilitation).  
Urine toxicology screening was performed with fast immunodosages that could be read 
visually, allowing the qualitative determination of the pharmacological substances and their 
metabolites present in the urine. For opiates, marijuana and buprenorfin, QuikStripTM 
OneStep immunodosages were used; QuikPac IITM OneStep were used to detect the 
presence of amphetamines, metamphetamines and cocaine.  
Regarding the psychological assessment the following tools were used. 
The Initial pain interview is a semi—structured interview designed to reconstruct the clinical 
history of the pain, and its progress over time. The interview is used to gather a wide range 
of personal information (e.g. marital status, level of education, employment status, etc.) and 
other information about the pain and its interference in daily activities. The habits and 
behaviours that, based on the literature, are considered risk factors for aberrant opioid use 
were also investigated (smoking, alcohol consumption patterns, use of drugs, family history 
of alcohol and/or drug abuse, sexual abuse). 
 
Risk Factors in Opioid Treatment of Chronic Non-Cancer Pain: A Multidisciplinary Assessment 
 
441 
The Visual Analogue Scale (VAS) consists of a 10 cm long horizontal line, the start and end 
points of which are labelled “no pain” and “worst possible pain”. The patient is asked to 
mark the precise points corresponding to his or her maximum, minimum and habitual pain 
in the last month. 
The Minnesota Multiphasic Personality Inventory II (MMPI-2; Hataway e McKinley, 1989; 
Italian adaptation by Pancheri et al., 1996) is a self-administered questionnaire used to assess 
personality characteristics. It consists of 567 items to be answered “true” or “false”. Scores 
are obtained referred to three control scales and ten clinical scales (Hypochondria, 
Depression, Hysteria, Psychopathic Deviate, Masculinity – Femininity, Paranoia, 
Psychasthenia, Schizophrenia, Hypomania and Social Introversion).  
The Beck Depression Inventory II (BDI-II; Beck et al., 1996; Italian adaptation by Ghisi et al., 
2006) is a 21-item self-administered questionnaire commonly used among chronic pain 
patients to determine their depressive reaction, assessing both the cognitive component (e.g. 
sadness, pessimism) and the somatic component (e.g. loss of appetite, sleep disorders).  
The State Trait Anxiety Inventory-Y (STAI-Y, Spielberger,1983; Italian adaptation by 
Pedrabissi and Santinello, 1989) is a 40-item questionnaire that assesses the level of patient 
anxiety. Two scores can be obtained, referring to two subscales that assess state anxiety (i.e. 
the anxiety experienced by the patient at the time they complete the questionnaire) and trait 
anxiety (i.e. the anxiety that the patient habitually experiences).  
The Pain Related Self-Statement Scale (PRSS; Flor and Turk, 1988; Italian adaptation by Ferrari 
et al., 2004) is a self-administered scale developed to assess the cognitions specifically 
triggered in the pain situation that might inhibit or promote coping responses. The tool 
consists of 18 items, from which two total scores can be obtained for the subscales called 
Catastrophizing and Coping. 
The Nottingham Health Profile (NPH, Hunt et al., 1985; Italian adaptation by Bertin et al, 1992) 
was used to assess quality of life. It consists of 38 items covering 6 content areas: physical 
mobility, energy, sleep, pain, social isolation, emotional reactions. The scores are expressed 
on percentage scales and correspond to the level of compromise perceived by the subject in 
the quality of life area considered. 
The Multidimensional Pain Inventory (MPI, Kerns et al., 1985; Italian adaptation by Ferrari 
et al., 2000) is a 61-item self-administered questionnaire that allow a multidimensional 
assessment of the pain experience. The tool is divided into 3 parts: the first focuses on 
assessing the intensity of the pain, its interference in the life of the patient, the patient’s 
perceived control of the pain and of events in his or her life (it consists of the following 
subscales: pain severity, interference, life-control, affective distress and support). The 
second part investigates the patient’s perception of the responses of his or her significant 
others to his or her pain communications (negative/solicitous and distracting responses). 
The third part examines the frequency with which the patient carries out common daily 
activities (household chores, outdoor work, distant activities, social activities and general 
activity). 
Finally, the McGill Pain Questionnaire (MPQ, Melzack, 1983; Italian adaptation by Maiani and 
Sanavio, 1985) is a tool consisting of a list of 78 adjectives related to pain grouped into 20 
subclasses of homogeneous content; within each subgroup the descriptors are arranged in 
order of increasing intensity. The subject is invited to choose the adjective that best describes 
his or her pain in each category. The tool allows the pain to be assessed as an experience 
with three major dimensions: sensory-discriminative, motivational-affective and cognitive-
evaluative.  
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The study is observational prospective and longitudinal; patient selection, data collection 
and the subsequent follow-ups took place from December 2009 to March 2011 in the Pain 
Relief and Palliative Care Unit of Vicenza hospital. The study consisted of the following 
assessment phases: patient selection, collection of pre-treatment data, 2 and 4 month follow-
ups (figure 3). 
The specialist physician selected patients according to the personal and clinical criteria 
indicated above, as well as by using the numerical scale to assess pain intensity. Patients 
who were candidates for opioid treatment were asked to undergo psycho-clinical 
assessment in accordance with the multidisciplinary care diagnostic protocol, for patients 
with chronic non-cancer pain referred for opioid treatment at our Centre. 
Pre-treatment data were collected in the two week period following selection. It consisted of 
the compilation of the questionnaire to determine the risk of opioid misuse (PMQ) by the 
patient, and the compilation of the DIRE by the team of pain specialists. Questionnaires to 
assess the intensity and experience of pain (VAS, MPI, MPQ, PRSS) and affective/emotional 
state (STAI-Y, BDI-II), quality of life (NHP) and personality characteristics (MMPI-2) were 
also administered. Medical and psychological follow-ups were scheduled 2 and 4 months 
after the start of treatment. At 2 months, medical data such as the presence of any side 
effects, changes in dosage, presence of aberrant drug behaviours and any intention to stop 
treatment were collected for treatment monitoring.  The PMQ was administered again, to 
assess its reliability over time, and the questionnaires assessing quality of life and pain 
experience (VAS, MPI and NHP) were also administered. The same medical and 
psychological data were collected at 4 months, apart from the PMQ. At both follow-up 
appointment urine drug test was proposed. The study protocol was approved by the 
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2.5.4 Statistical analysis 
Continuous variables are expressed with mean, standard deviation, minimum and 
maximum and centiles into which the variables fall, when possible. Discrete and nominal 
variables are reported in frequency tables with the related percentages. To examine the 
differences between continuous variables, Student’s parametric t test was used, with Chi 
squared for the comparison of frequency distributions. 
The reliability of the PMQ was assessed using test-retest, and Cronbach’s α, while the 
internal consistency of the DIRE was determined from Cronbach’s α. 
Correspondence Analysis was used to examine the relationship between the PMQ and DIRE 
scores obtained by the patients in the pre-treatment phase and the number of aberrant drug 
behaviours detected in the patients at the medical follow-ups recorded in the “Medical 
control form”, the duration of treatment and the presence of the drug in the urine. Analysis 
of variance and correlational analysis with Spearman’s non-parametric coefficient were used 
to analyse the relationship between the PMQ scores and the DIRE and the clinical variables 
related to pain, psychological function and quality of life. 
2.5.5 Results 
All the patients reported continuous pain; table 5 shows the mean values for pain intensity 
(assessed using the VAS) and the data on pharmacological treatment in the three assessment 
phases. No significant gender differences were found in maximum, minimum or habitual 
pain intensity. However, there was a statistically significant reduction in maximum and 
minimum pain intensity from the pre-treatment to the 2 month follow-up (F1,24= 4.64; F1,24= 
6.75 respectively; both for p<0.05); from pre-treatment to the 4 month follow-up the only 
difference was in maximum VAS (F1,24= 8.21; p<0.01). This variation was not influenced by 
the active substance administration route. 
Analysing the type of pharmacological treatment, it may be noted that at both the start of 
the pharmacological treatment and at the subsequent follow-ups, the most frequently 
administered active substance was oxycodone. The administration route during the data 
collection phases remained primarily oral. The drug dosages were transformed into 
equivalent mg of morphine, and classified as mild/average/high based on the indications 
supplied by Bruera et al. (1995). Regarding the dosage, it showed a tendency to increase at 
the 4 month follow-up.  
Approximately half (46%) of the patients reported the presence of at least one side effect at 
the follow-ups; the most frequently reported side effects were sleepiness (29%), constipation 
(29%) and nausea (21%). The drug administration route did not appear to have any effect on 
the number and type of side effects reported by the patients. 
With respect to the psychological indicators investigated in the pre-treatment assessment, it 
was found that, based on the personality profile obtained with the MMPI-2, 56.2% of women 
and 33.3% of men had clinically significant scores in at least one of the clinical scales with 
psychopathological content (Paranoia, Schizofrenia, Hypomania). As for the affective-
emotional variables, the mean total score at BDI-II in the initial treatment phase was 24.6 (SD= 
13.40) in women and 18.2 (SD= 9.94) in men; the level of depression was clinically significant 
(scores higher than 95th percentile) in 61% of women and 50% of men. Considering trait 
anxiety, the mean score was 52.7 (SD= 11.97) in women and 46.2 (SD= 7.22) in men,  with 
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2.5.4 Statistical analysis 
Continuous variables are expressed with mean, standard deviation, minimum and 
maximum and centiles into which the variables fall, when possible. Discrete and nominal 
variables are reported in frequency tables with the related percentages. To examine the 
differences between continuous variables, Student’s parametric t test was used, with Chi 
squared for the comparison of frequency distributions. 
The reliability of the PMQ was assessed using test-retest, and Cronbach’s α, while the 
internal consistency of the DIRE was determined from Cronbach’s α. 
Correspondence Analysis was used to examine the relationship between the PMQ and DIRE 
scores obtained by the patients in the pre-treatment phase and the number of aberrant drug 
behaviours detected in the patients at the medical follow-ups recorded in the “Medical 
control form”, the duration of treatment and the presence of the drug in the urine. Analysis 
of variance and correlational analysis with Spearman’s non-parametric coefficient were used 
to analyse the relationship between the PMQ scores and the DIRE and the clinical variables 
related to pain, psychological function and quality of life. 
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minimum pain intensity from the pre-treatment to the 2 month follow-up (F1,24= 4.64; F1,24= 
6.75 respectively; both for p<0.05); from pre-treatment to the 4 month follow-up the only 
difference was in maximum VAS (F1,24= 8.21; p<0.01). This variation was not influenced by 
the active substance administration route. 
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and 33.3% of men had clinically significant scores in at least one of the clinical scales with 
psychopathological content (Paranoia, Schizofrenia, Hypomania). As for the affective-
emotional variables, the mean total score at BDI-II in the initial treatment phase was 24.6 (SD= 
13.40) in women and 18.2 (SD= 9.94) in men; the level of depression was clinically significant 
(scores higher than 95th percentile) in 61% of women and 50% of men. Considering trait 
anxiety, the mean score was 52.7 (SD= 11.97) in women and 46.2 (SD= 7.22) in men,  with 
27.7% clinically significant levels of anxiety only in women (scores higher than 95th percentile).  
Regarding PRSS, the subjects reported a mean score of 3.20 (range 0-5, SD= 1.15) on the 
Catastrophizing scale and 2.76 on the Coping scale (range 0-5, SD= 0.88).  
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Table 5. Pain intensity, active medication taken, administration route and dosage in initial 
treatment and in subsequent follow-ups.  
In the description of the pain characteristics at the MPQ, higher scores emerged in the 
evaluative and affective -evaluative dimensions (means 0.87 and 0.73, respectively) , while 
the lower scores referred to the affective and mixed-sensory dimensions (means 0.4 and 0.52, 
respectively). 
In the MPI the subjects reported high mean on “Pain severity” (mean: 4.6; SD= 0.9), 
“Interference” (mean: 4.3; SD= 1.1) and “Affective distress” (mean: 3.6; SD= 1.1) in the pre-
treatment assessment. Quality of life, measured using the NHP, appears more compromised 
in the following areas: “Emotional reactions” (mean: 80; SD= 56), “Pain” (mean: 77; SD= 
26.2) and “Energy” (mean: 64; SD= 40). There were no statistically significant variations in 
the mean scores at the start of treatment and at the subsequent follow-ups for either the MPI 
or the NHP. 
As for the tools to assess the risk of opioid misuse, the mean score at the PMQ was 24.59 
(SD=9.43); there were no significant gender differences in the PMQ scores. Figure 4 shows the 
three different levels of the PMQ scores that, according to the cut-offs established by Dowling 
et al. (2007), identify a low/moderate or high risk of drug misuse. Overall, 36% of the subjects 
were found to be at high risk of misuse, 20% at moderate risk, and the remaining 44% at low 
risk. The distribution in the three risk levels between men and women was comparable.  
The group was subsequently divided into patients with high PMQ scores (H-PMQ; n=9) and 
patients with low PMQ scores (L-PMQ; n=11) in order to analyse the presence of any 
significant differences in the psychological variables considered in the study. The patients 
with H-PMQ had a mean score of 3.78 on the Catastrophizing scale of the PRSS, statistically 
higher than that of the L-PMQ patients (mean 2.61) (t=-3.16; p<0.01); while on the Coping 
scale the H-PMQ subjects had mean scores that were significantly lower than those of the L-
PMQ group (t=-2.18; p<0.05). Further statistical differences were found for the “HS” scale 
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(Hypocondria) of the MMPI-2, in which the H-PMQ subjects had scores that were 
significantly higher than the L-PMQ subjects (means 21 and 16.5 respectively, t=23.60; 
p<0.05) and for the total depression score in the BDI-II (H-PMQ mean =27.36; L-PMQ mean 
=17.88; t=26.18, p<0.05).  
As for the predictive validity of the tool, a highly significant correlation was found between 
the total PMQ score (high risk of opioid misuse) and the number of aberrant drug-related 
behaviours noted by the physician at the 4 month follow-up (r=0.95; p<0.01). Significant 
correlations were also found between the PMQ score and the “HS” (Hypochondria) scale of 
the MMPI-2 (r=0.49; p<0.01), the total score in the BDI-II (r=0.43; p<0.05), the trait anxiety score 
of the STAI-Y (r=0.38; p<0.05) and the “emotional reaction” scale of the NHP (r=0.39; p<0.05).  
The mean time required by the patient to complete the tool was 12’02” (SD=6.35; range: 4-
30). Finally, analysis of internal consistency produced an alpha coefficient of 0.82, indicating 
that the tool has excellent internal coherence; the test-retest reliability at 2 months was very 
high (r= 0.76; p<0.001).  
In the DIRE, the mean score assigned by the multidisciplinary team was 15.35; in this case too 
there were no significant differences in the mean scores of men and women. Figure 5 shows 
the percentage of patients suitable or not suitable for treatment based on DIRE total Score 
according to the cut-offs established by Belgrade et al. (2006). Most women (81.2%) and men 
(87.5%) were found suitable to start chronic opioid treatment according to the DIRE score.  
 
 
Fig. 4. Percentage of patients with low/moderate/high risk level for opioid misuse, based 
on PMQ scores. 
The total DIRE score was not found to be significantly correlated with the number of 
aberrant drug behaviours recorded by the physician at 2 and 4 months; however, a 
significant negative correlation (r=0.83; p<0.05) was found between the scores in the “Risk” 
category of the DIRE (psychological risk, chemical health, reliability, social support) and the 
number of aberrant drug behaviours recorded by the physician at the 4 month follow-up.  
The total DIRE score correlates negatively with the total BDI-II score (r=0.46, p<0.01) and 
with many of the MMPI-2 scales, and specifically: “PD” (Psychopathic Deviate) (r= 0.44; 
p<0.05), “PA” (Paranoia) (r= 0.40; p<0.05), “D” (Depression) (r= 039; p<005); “FAM” (Family 
Problems) (r= 044; p<005), “WRK” (Work Interference) (r= 040; p<005) and “TRT”( Negative 
Treatment Indicators) (r= 0.39; p<0.05).  
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(Hypocondria) of the MMPI-2, in which the H-PMQ subjects had scores that were 
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p<0.05) and for the total depression score in the BDI-II (H-PMQ mean =27.36; L-PMQ mean 
=17.88; t=26.18, p<0.05).  
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In the DIRE, the mean score assigned by the multidisciplinary team was 15.35; in this case too 
there were no significant differences in the mean scores of men and women. Figure 5 shows 
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The mean time required by the multidisciplinary team to complete the tool was 7’23” 
(SD=3.38; range: 1-16). The internal consistency of the Italian version of the tool was 0.48, 
which is very low; the item that contributed least to the internal consistency of the DIRE was 
Diagnosis (α if item deleted=0.51).  
 
 
Fig. 5. Percentage of patients suitable or not suitable for treatment based on DIRE total Score.  
As for the concurrent validity of the two tools, there were no significant correlations 
between the total scores of the PMQ and the DIRE. However, there was a moderate negative 
correlation (r=0.36; p< 0.05) between high total PMQ scores (high risk of opioid misuse) and 
low scores in the Risk category of the  DIRE. 
Both the PMQ and the DIRE proved to be more effective than the Medical risk prediction in 
estimating the risk of drug misuse: the subjective estimate of the physician based on his or 
her clinical experience does not in fact correlate with the aberrant drug behaviours 
displayed by the patient at 2 and 4 months.  
In the urine toxicology screening, only one patient tested negative for the active principle at 
the two month follow-up, while all the patients were positive for the drug used at the four 
month follow-up. None of the patients tested positive for illegal substances.  
In relation to aberrant drug behaviours, most of the subjects (71%) displayed no aberrant 
drug behaviour at the two month follow-up; there was a potential misuse indicator in 19%, 
and the remaining 10% displayed three or more. At the 4 month follow-up, 22% of the 
patients displayed three or more aberrant drug behaviours while no indicators of misuse 
were found in 56% of the subjects. 
Regarding other factors that according to the literature might be predictive for improper use 
of opioids, none of the patients reported that they abused alcohol or narcotic substances at 
assessment; 4.9% reported a personal history of alcohol abuse and 5.4% stated that they had 
abused illegal substances in the past. 7.3% of the subjects had a family history of alcohol 
abuse and 2.4% had a family history of the use of narcotic substances. None of the patients 
reported that they had suffered sexual abuse in childhood or adolescence, 17.1% of the 
patients had a prior psychiatric diagnosis and 9.8% of the subjects were being treated by a 
psychiatrist at the time of the evaluation.  
 




The main purpose of this study was to identify clinical procedures that allow to estimate the 
risk of opioid misuse in patients with chronic non-cancer pain treated as outpatients in a 
pain relief centre. With this aim, two tools were selected and adapted in Italian – the Pain 
Medication Questionnaire (PMQ) and the Diagnosis, Intractability, Risk and Efficacy Score 
(DIRE). These tools examine the perspectives of the patient and the multispecialist team, 
respectively.   
The preliminary results reported above show that the PMQ has a good capacity to predict 
the risk of drug misuse by the patient. A strong correlation was found between high PMQ 
scores and the number of aberrant drug behaviours reported by the physician 4 months 
after the start of the study.  
From the PMQ scores, 36% of the subjects were found to be at high risk of misuse, 20% at 
moderate risk, and the remaining 44% at low risk. High PMQ scores (high risk of misuse) 
were found to be associated with higher levels of anxiety, depression and persistent body-
related worries. Furthermore, those patients classified as high risk of misuse, based on the 
cut-offs suggested by Dowling et al. (2007),  were found to be significantly more depressed, 
and with a greater tendency to somatise their emotional distress than those classified as low 
risk. High risk patients were also found to be less active in managing their pain condition, 
and to have a greater propensity to produce pessimistic and catastrophic thoughts about 
their pain symptoms. The association that emerged, between high PMQ scores and the 
presence of symptoms of depression, appears to be in line with the findings of Holmes et al. 
(2006) in their work assessing the long-term utility of the PMQ in 271 subjects. In this study 
the low risk patients had mean BDI scores that were significantly lower than those of the 
high risk of misuse group.  
Furthermore, based on the initial results, the PMQ has demonstrated adequate internal 
consistency and good reliability over time. This suggests that the items composing it 
measure a single construct, and that the tool provides a reliable estimate of the risk of 
medication misuse. In addition, completing the PMQ requires just over ten minutes of the 
patient’s time, and this makes it easy to incorporate into clinical practice.  
To summarise, the tool seems to possess a good predictive capacity in relation to the use 
that the patient will make of the drug, and his or her compliance with treatment. The total 
score on the questionnaire, and the stratification of risk based on the cut-offs suggested by 
the authors therefore appear to be reliable indicators that the clinician can use to plan 
regular treatment monitoring. The strong association between high PMQ scores and the 
presence of symptoms of depression, tendency to somatisation and catastrophization, 
suggest that pharmacological treatment with opioids needs to be combined with 
psychological treatment to reduce the affective and emotional distress and modify the 
patient’s  dysfunctional convictions and behaviours in relation to use of the drug.  
As for the Italian version DIRE, the preliminary results show that the total score for risk of 
drug misuse is a poor predictor with limited psychometric quality. The Risk category, which 
specifically assesses psychosocial aspects such as psychological adaptation, substance abuse, 
reliability in complying with previous treatments and perceived social support in life 
context, is an exception to this. The tool in fact has low internal consistency, which improves 
slightly when the Diagnosis factor is removed. This means that the items of which the tool is 
composed are very heterogeneous, and that the tool probably has a multifactorial structure. 
Our finding does not agree with the results reported by Belgrade et al. (2006) in the original 
validation study, in which the DIRE displayed a very high internal consistency. The total 
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score of the DIRE - Italian version - is not at present predictive of the number of aberrant 
drug behaviours detected by the physician at the follow-ups. This seems to be in line with 
the work of Moore et al. (2007), who found that the DIRE had low sensitivity (0.17) in 
predicting aberrant drug behaviours. The authors suggest that the DIRE is more than simply 
an addiction risk tool and some of its items may not to be appropriate to predict drug 
misuse. However, as mentioned above, the score of the Risk category was found to be 
predictive of the number of aberrant drug behaviours at 4- months follow-up. This result is 
coherent with the findings of many studies on opioid abuse risk factors, which found that 
the factors considered to be most predictive of opioid abuse are the presence of psychiatric 
disorders (Compton et al., 1998; Sullivan et al., 2006) and a personal and/or family history 
of substance abuse or drug abuse (Dunbar & Katz, 1996; Schieffer et al., 2005). Our data 
indicate that a low score (not suitable for opioid treatment) is associated with depressive 
symptoms, the presence of paranoid personality traits and family and work difficulties. 
Completing the DIRE requires a few minutes of the team’s time, but this must be preceded 
by an in-depth psychological assessment of the patient to determine if psychiatric disorders 
and past abuse, or current alcohol or substance abuse, are present.  
The two tools selected do not appear to be correlated; instead, it is clear that there is an 
association between high PMQ scores (high risk of misuse) and low scores in the DIRE Risk 
category. 
The prediction made by the physician based on his or her clinical experience was not found 
to be valid in estimating the risk of opioid misuse. This result highlights the need to use 
tools specifically created to assess the risk of opioid addiction in the chronic pain patient; 
clinical experience can be used to understand and contextualize the results obtained from 
these scales, but seems to be insufficient on its own. 
So far as the experience of pain and the indicators of psychophysical function are concerned, 
the use of opioid drugs proved efficacious in reducing the maximum and minimum 
intensity of the perceived pain 2 months after the start of the treatment. A parallel 
improvement in the quality of life of the patients was not recorded by the questionnaire 
used in this study. This result seems to be in line with the data in the literature: despite 
ongoing research and the growing use of opioids in clinical practice, the effect of this 
treatment on the quality of life of the patient remains a subject of debate (Dillie et al., 2008). 
The reduction in pain, unaccompanied by an improvement in physical function and quality 
of life, indicates that these patients need psychological support, to examine their life habits, 
coping strategies and any secondary gain that might interfere with recovery of a state of 
psychophysical well-being. Quality of life is in fact a wide ranging concept, influenced by 
perception of one’s health in a biopsychosocial sense, level of independence, social 
relationships and interaction with one’s own specific environmental context in a complex 
way (Apolone et al., 1997).  
As for the psychological variables considered in the study, half of the men and 60% of the 
women reported clinically significant levels of depression; and almost 30% of the women 
displayed high levels of anxiety. These data are in line with the findings of many authors, 
that clinically significant levels of depression and anxiety are very frequent in patients with 
chronic pain (Banks & Kerns, 1996; Boersma & Linton, 2006; Dersh et al., 2006; Gatchel, 2005; 
Vlayen & Linton, 2000). In addition, there was a high incidence of alterations in patients’ 
personality profiles: over half of the women and approximately one third of the men 
reported high scores in at least one of the clinical content scales of the MMPI-2. This result 
too seems coherent with the reports in the literature, that the presence of psychiatric and 
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personality disorders is more frequent in these patients (Banta-Green et al., 2009a; Haller & 
Acosta; 2010), and therefore it is advisable to involve a psychotherapist or psychiatrist in the 
treatment process (Chou, 2009; Chou et al, 2009a; Chou et al, 2009b; Chou et al, 2009c; 
Trescot et al., 2006; Trescot at al., 2008). 
The analyses carried out to date have shown that only one patient in twenty five did not test 
positive to the prescribed drug; and no patients tested positive for illegal substances in the 
urine toxicology screening. These data seem very different to those of other studies, which 
found the prevalence of abuse of illegal substances in patients being treated with opioid to 
be 16% (Machikanti et al., 2006), 20% (Heit & Gourlay, 2004) or 40.3% (Ives et al., 2006). The 
preliminary results seem to suggest that in our context the more frequent problem may be 
the underuse of opioid analgesics rather than their compulsive use and abuse: this 
interpretation is supported by the difficulty, frequently expressed by our patient, in 
accepting these drugs for fear of dependence, loss of mental lucidity or being socially 
stigmatised as drug addicted. A further important objective of the management of patients 
who are candidates for opioid treatment in a multidisciplinary setting is thus to assess their 
convictions about the use of these drugs and their expectations of treatment, so as to be able 
to modify any dysfunctional beliefs and unrealistic hopes for the outcome of treatment.  
The limitations of this study are primarily the small number of subjects examined and the 
differing distribution of men and women. In addition, the limited number of patients did 
not allow us to examine the effect of other variables that, based on the reference literature, 
can constitute risk factors for opioid addiction, such as a personal or family history of 
alcohol and/or substance abuse, or episodes of sexual abuse in childhood or adolescence.  
Despite these limits, the high degree of correlation between risk of misuse and the 
psychological aspects supports the view that an in-depth assessment of the affective-
emotional, cognitive and behavioural variables of the patient is crucial. So future research 
may be focused on understanding which psychological variables are most connected to the 
risk of opioid misuse (e.g. personality traits, anxiety, depression, etc.) so as to be able to 
develop tailored psychological interventions that maximise treatment efficacy, with positive 
outcomes for quality of life and overall well-being, as well.  
Overall the results that have emerged so far highlight the need for a multidisciplinary 
assessment of patients who are candidates for opioid treatment so as to improve compliance 
and treatment benefits. The use of tools specifically designed to determine the risk of 
inappropriate use of the drug has proved to be more efficacious that the opinion expressed 
by the clinician based on his or her experience. The strong association between psychosocial 
distress and high risk of opioid misuse also suggests that pharmacological treatment should 
be combined with psychological interventions that can reduce the anxiety-depression 
symptoms and correct any irrational ideas about the use of these drugs. Furthermore, 
systemic monitoring of treatment and regular urine drug screen can contribute to improve 
adherence to treatment.  
3. Conclusions 
Chronic non-cancer pain remains a condition that affects a large number of people 
throughout the world, and is associated with significantly compromised quality of life. 
Although many pharmacological and non-pharmacological treatments have been proposed 
to manage chronic pain, the results have proved disappointing for a significant proportion 
of patients.  
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Opioid drugs seem promising for the management of chronic pain of medium-severe 
intensity, but many uncertainties remain about the long-term use of these drugs and the risk 
of dependence and abuse. In this respect, many guidelines and protocols with 
recommendations have been developed in recent years precisely to allow safer and more 
targeted use of opioid drugs in chronic non-cancer pain syndromes; these recommendations 
highlight, primarily, the importance of carrying out stratification of risk in the patient who is 
a candidate for pharmacological treatment with opioids. A number of standardised tools 
have been developed with the aim of identifying and objectively measuring the risk of 
abuse, dependence and aberrant drug behaviours.  
This chapter has presented the preliminary results of a study that aims to analyse the clinical 
utility of the Italian adaptation of two tools for stratification of the risk: a self-administered 
patient questionnaire, the Pain Medication Questionnaire, and a team assessment tool, the 
Diagnosis Intractability Risk and Efficacy Score.  
These tools have been used as part of a multidisciplinary medical and psychological 
assessment and treatment protocol; the data in the literature, confirmed in our study, clearly 
indicates that there is a frequent association between high risk of opioid misuse and the 
presence of psychological distress (Banta-Green et al., 2009a; Haller & Acosta; 2010). This 
emphasizes the importance of a physical, psychological and social assessment before 
starting treatment with opioids. In this respect, based on literature data and the preliminary 
results of the study described, we believe that an effective psychological assessment must 
consist of an initial clinical interview, specific tools to assess the risk of drug misuse, and 
questionnaires that investigate the patient’s subjective experience of pain, perceived quality 
of life and personality characteristics. The interview, which may be more or less structured, 
is essential to understand the individual’s experience of pain and its interference in the 
patient’s family, professional, social and emotional life; it also allows the clinician to 
investigate behaviour habits related to opioid misuse (e.g. prior abuse of alcohol or illegal 
substances) and the presence of traumatic experiences such as sexual abuse in childhood or 
adolescence. During the interview the clinician may also identify any fears and worries 
about taking these drugs, the patient’s expectations of the treatment and their reliability in 
following the indications of the therapist. Further areas of investigation concern the 
strategies that the patient uses to deal with the pain, and the possible presence of secondary 
gain that could compromise the efficacy of the treatment. Our results show that the 
indications provided by the specifically designed tools are more reliable than the clinical 
experience of the specialist physician in estimated aberrant drug behaviours. Investigation 
of the emotional-affective state of the patient, and his or her personality characteristics, 
always an important aspect of the multidimensional assessment of chronic pain, appears 
indispensable when long-term opioid therapy is initiated, since the presence of depression, 
anxiety or personality disorders has been found to be correlated with a greater risk of 
addiction. Pain coping strategies and any tendency to “catastrophize” must also be 
investigated using suitable questionnaires. Based on our experience, patients at greater risk 
of opioid misuse in fact seem to display a passive attitude to the management of their pain 
condition, and to have exaggeratedly pessimistic expectations of the progress of their 
symptoms. Finally, it is important to systematically assess the quality of life of these 
patients, as effective pain relief should always be accompanied by functional improvements 
in their physical, psychological and social area. The preliminary results of our study show 
that reduction in pain intensity of pain due to opioids does not seem to be accompanied by 
an improvement in physical and psychological functionality. This indicates that the patient 
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needs to be monitored not only in medical term, but also from a psychological perspective, 
to be able to make cognitive, emotional and behavioural changes that can enhance and 
consolidate the efficacy of the treatment.  
From our experience in the Italian context, the prevalence of addiction or misuse in patients 
with chronic pain in treatment with opioids appears to be low. The systematic assessment of 
risk using the tools created in recent years allows the clinician to overcome some biases, 
such as the overestimation of the risk of addiction, and hence avoid considering the entire 
population of chronic pain patients to be at risk of abuse.  
The treatment of pain is a public health problem that is of such critical importance as to 
constitute an international imperative, as well as a fundamental human right (Brennan et al., 
2007); opioid drugs appear as a potential resource to manage chronic pain efficaciously. 
However, their targeted use must be preceded by a suitable assessment of the patient by a 
multidisciplinary team that clarifies not only the causes of the pain, but also any risk factors 
or dysfunctional psychological aspects related to use of the drug, so as to increase the 
benefits of treatment and reduce the costs. 
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1. Introduction 
Pain is the most awful sensory suffering that makes people exhausted. Although pain itself 
possesses protective role in keeping patients from further injury, it is still obliged to be treated 
for its negative effect on patients’ physiological and psychological well-beings. Great progress 
has been made in our understanding of the therapeutic strategies with different agents and 
techniques on pain in the past decades, but the analgesic result is not as effective as we desired 
specifically when the acute process tends to be chronic (Li et al., 2011). As one of the important 
parts of somatosensory system, pain nets closely with spiritual and psychological feelings, 
which often results in analgesic failure when conventional pharmacological methods and 
means are used, and also raises questions on how to alleviate pain through psychotherapeutics 
(Manchikanti et al., 2011). Given the big difference in methods of psychological interventions 
and the association with the changing therapeutic context, the analgesic efficacy of 
psychosocial support fluctuates. Therefore, standardizing and optimizing the 
psychotherapeutic strategies in clinical practice would make it more effective in relieving pain. 
Here we review and prospect the psychological management of pain, and then give a 
recommendation of the therapeutic flow of the standardized optimal procedures. 
2. Origins of psychological analgesia 
Two hundreds years ago, the word “placebo” was defined by Robert Hooper in his 
dictionary to a more modern medical meaning as “any medicine adapted more to please 
than benefit the patient” (Hooper, 1811). In fact, this is the original description of 
psychological intervention in the field of medicine of which the meaning is broadened 
further during the following years. However, placebo therapies were becoming popular 
until the past century. To date, placebo medicine generally means (i) containing 
pharmacologically inactive ingredients, and (ii) the contents have pharmacological activity. 
The effect of placebo is mainly dependent on the psychological state of patients, therapeutic 
context and physicians’ console. In contrast to placebo, nocebo was adapted to describe the 
negative effect (i.e. unpleasant consequence) occurs in expectation of a harmful occurrence 
when an inert substance was used. In pain medicine, both placebo and nocebo are also two 
majorities that can be used in psychological intervention. Therefore, psychological placebo 
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1. Introduction 
Pain is the most awful sensory suffering that makes people exhausted. Although pain itself 
possesses protective role in keeping patients from further injury, it is still obliged to be treated 
for its negative effect on patients’ physiological and psychological well-beings. Great progress 
has been made in our understanding of the therapeutic strategies with different agents and 
techniques on pain in the past decades, but the analgesic result is not as effective as we desired 
specifically when the acute process tends to be chronic (Li et al., 2011). As one of the important 
parts of somatosensory system, pain nets closely with spiritual and psychological feelings, 
which often results in analgesic failure when conventional pharmacological methods and 
means are used, and also raises questions on how to alleviate pain through psychotherapeutics 
(Manchikanti et al., 2011). Given the big difference in methods of psychological interventions 
and the association with the changing therapeutic context, the analgesic efficacy of 
psychosocial support fluctuates. Therefore, standardizing and optimizing the 
psychotherapeutic strategies in clinical practice would make it more effective in relieving pain. 
Here we review and prospect the psychological management of pain, and then give a 
recommendation of the therapeutic flow of the standardized optimal procedures. 
2. Origins of psychological analgesia 
Two hundreds years ago, the word “placebo” was defined by Robert Hooper in his 
dictionary to a more modern medical meaning as “any medicine adapted more to please 
than benefit the patient” (Hooper, 1811). In fact, this is the original description of 
psychological intervention in the field of medicine of which the meaning is broadened 
further during the following years. However, placebo therapies were becoming popular 
until the past century. To date, placebo medicine generally means (i) containing 
pharmacologically inactive ingredients, and (ii) the contents have pharmacological activity. 
The effect of placebo is mainly dependent on the psychological state of patients, therapeutic 
context and physicians’ console. In contrast to placebo, nocebo was adapted to describe the 
negative effect (i.e. unpleasant consequence) occurs in expectation of a harmful occurrence 
when an inert substance was used. In pain medicine, both placebo and nocebo are also two 
majorities that can be used in psychological intervention. Therefore, psychological placebo 
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(positive) or psychological nocebo (negative) are derived from the traditional conceptions of 
placebo or nocebo. Although the key patterns of psychological therapy is on the basis of the 
linguistic console from physicians or investigators, psychological analgesia with series of 
strategies of psychology is the result of the above-mentioned placebo or nocebo. 
3. Mechanisms of psychological analgesia 
Psychological analgesia is a broad concept that includes all aspects referring to the 
psychological intervention. Hypnosis, music therapy, preoperative education, and linguistic 
suggestion all belong to psychological approaches in pain control (Hobson et al., 2006; 
Patterson et al., 2010; Sen et al., 2010; Wang et al., 2008). Whatever psychological methods 
used in analgesia, common neurophysiological mechanisms exist and different models 
explain its function. 
Functional magnetic resonance imaging (fMRI) verified an increase in neural activity during 
placebo associated psychological stimulation that is related to two major pain modulation 
mechanisms (Craggs et al., 2008): i) affective regulation which includes activation of the 
rostral anterior cingulate cortex, bilateral amygdala, and medial prefrontal cortex; and ii) 
higher cognitive regulation during which the posterior cingulate, pre-cuneus, rostral 
anterior cingulate cortex, perihippocampal gyrus, and the temporal lobes are activated. As 
the “gate theory” described that afferent inhibition blocks ascending signals from the 
periphery, psychological stimuli at the early period produce analgesic effect through a self-
reinforcing feedback mechanism (Vase et al., 2005). 
Several models give an in-depth understanding of the psychological stimulation associated 
analgesia. Conditioning, expectancy, motivation, and emotion are four psychological 
mediators involving in the process of analgesia. Conditioning model says that the 
interventional effect presented when the individual without knowing the stimulation would 
be and this process would not produce cognition (Williams & Rhudy, 2007). In this model, 
the perception of pain after psychological treatment largely depends on the learning history 
of the individual which determines the response variability under different context. The 
psychological conditioning as well as the verbal suggestion can turn tactile stimuli into pain 
and low-intensity pain into high-intensity pain. For this, the direct evidence was the 
conditioned pain reduction could be absolutely removed when the psychological stimuli 
were explained (Montgomery & Kirsch, 1997). Originally, conditioning is the primary 
response to psychological analgesia. Following conditioning, expectancy of the 
psychological stimuli to produce an effective analgesia takes place. Once the patients expect 
to have an improvement in pain management, the effect of psychological analgesia would 
play its role. Due to anxiety and fear to pain, patients generally want to have rapid and 
effective methods that can relieve their pain (Cornally & McCarthy, 2011; den Hollander et 
al., 2010; Kennedy et al., 2011), which consequently leads to an expectancy of their pain 
therapies. Under this condition, physicians’ attitude and enthusiasm takes an important part 
in whether or not the psychological analgesia comes into play (Weintraub, 2005). Give 
patients the hope to conquer pain accompanying with a warmth care, the expected effect of 
psychological analgesia would be maximized. After expectancy, motivation of analgesia is 
another aspect in determining the effect of psychological interventions. If the patient desires 
for a relief of pain, the real analgesic role of psychological stimuli would be magnitude 
(Radat & Koleck, 2011). The motivation itself whether or not could predict the psychological 
effect on one type of pain needs to be explored at length, and could it be effective for 
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different types of pain is also yet to be guaranteed. A body of literature has confirmed the 
role of emotions in pain perception and alleviation. Anxiety and stress are two main factors 
of emotion-associated psychological mediator. It is believed that anxiety is the cause of 
increased levels of pain, and reduction in anxiety produces analgesia (Luciano et al., 2011). 
Stress sometimes is related with increased levels of pain, but in some contexts, stress can 
produce analgesia (Donello et al., 2011; Wang et al., 2008). Therefore, the purpose of 
psychological suggestion in pain control is to alleviate patients’ anxiety and stress, which in 
turn produces a feedback analgesia effect. 
As described in the general model of the placebo-associated psychological analgesia, three 
consecutive stages exist when psychological treatment was given: the induction, 
psychophysiological mediation, and actualization (Goffaux et al., 2010). In the induction 
stage, three aspects compose the major contents including the introduction or initiation 
(therapeutic message; method of administration; follow-up and booster sessions; 
assessment of side effects), idiosyncratic variables (beliefs and values; personal history; 
innate predisposition) and therapeutic context (treatment objectives; therapeutic alliance; 
sociocultural factors). In the second stage, psychophysiological mediation composes of 
psychological and biological mechanisms. Psychological mechanisms include above-
mentioned conditioning, expectancy, motivation, and emotion, and the biological 
mechanisms include neurochemical mediators (endorphins, dopamine, and other 
neurotransmitters/neuromodulators) and neurophysiology (activation of central 
modulatory mechanisms including descending inhibitory circuits). In the actualization 
stage, three main aspects exist including subjective experience (pain, emotions, quality of 
life, satisfaction, and related relief), behavioral markers (amount of analgesics consumed 
and overt pain behaviors), and physiological markers (physiological nociceptive activity, 
objective clinical indicators). As thus, when a psychological intervention is given, these 
three stages would be experienced. However, in consideration of the multiple phases of 
these stages, the actual effect of psychological analgesia may be variable in different 
individuals under different circumstances. 
4. Efficacy of psychological analgesia 
The analgesic effect of psychological approaches depends on types of pain, individual 
status, caregivers’ attitude and contextual frame, which finally determines the efficacy of 
psychological analgesia. For postoperative pain, preoperative hypnosis could accelerate 
wound healing and alleviate pain intensity after mammoplasty (Ginandes et al., 2003), and 
reduce post-surgical pain and distress in patients undergone excisional breast biopsy 
(Schnur et al., 2008). However, in other surgical contexts, psychological interventions did 
not produce detectable difference compared with the control: relaxation training for spinal 
surgeries could not reduce postoperative pain (Gavin et al., 2006), and intraoperative music 
therapy also could not produce analgesia in Cesarean patients (Reza et al., 2007). Contrary 
to this, postoperative music can alleviate the pain and reduce the need for analgesics in 
patients who undergone Cesarean section (Ebneshahidi & Mohseni, 2008). Besides, in 
cardiac surgeries, music therapy produced effective role in alleviating anxiety and pain 
(Sendelbach et al., 2006). These different even controversial results raise questions on the 
real analgesia efficacy of psychological interventions. In fact, difference in interventional 
methods, types of surgeries, and professionals of investigators may all contribute to the 
changeable results of psychological analgesia. An attractive study performed to observe the 
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(positive) or psychological nocebo (negative) are derived from the traditional conceptions of 
placebo or nocebo. Although the key patterns of psychological therapy is on the basis of the 
linguistic console from physicians or investigators, psychological analgesia with series of 
strategies of psychology is the result of the above-mentioned placebo or nocebo. 
3. Mechanisms of psychological analgesia 
Psychological analgesia is a broad concept that includes all aspects referring to the 
psychological intervention. Hypnosis, music therapy, preoperative education, and linguistic 
suggestion all belong to psychological approaches in pain control (Hobson et al., 2006; 
Patterson et al., 2010; Sen et al., 2010; Wang et al., 2008). Whatever psychological methods 
used in analgesia, common neurophysiological mechanisms exist and different models 
explain its function. 
Functional magnetic resonance imaging (fMRI) verified an increase in neural activity during 
placebo associated psychological stimulation that is related to two major pain modulation 
mechanisms (Craggs et al., 2008): i) affective regulation which includes activation of the 
rostral anterior cingulate cortex, bilateral amygdala, and medial prefrontal cortex; and ii) 
higher cognitive regulation during which the posterior cingulate, pre-cuneus, rostral 
anterior cingulate cortex, perihippocampal gyrus, and the temporal lobes are activated. As 
the “gate theory” described that afferent inhibition blocks ascending signals from the 
periphery, psychological stimuli at the early period produce analgesic effect through a self-
reinforcing feedback mechanism (Vase et al., 2005). 
Several models give an in-depth understanding of the psychological stimulation associated 
analgesia. Conditioning, expectancy, motivation, and emotion are four psychological 
mediators involving in the process of analgesia. Conditioning model says that the 
interventional effect presented when the individual without knowing the stimulation would 
be and this process would not produce cognition (Williams & Rhudy, 2007). In this model, 
the perception of pain after psychological treatment largely depends on the learning history 
of the individual which determines the response variability under different context. The 
psychological conditioning as well as the verbal suggestion can turn tactile stimuli into pain 
and low-intensity pain into high-intensity pain. For this, the direct evidence was the 
conditioned pain reduction could be absolutely removed when the psychological stimuli 
were explained (Montgomery & Kirsch, 1997). Originally, conditioning is the primary 
response to psychological analgesia. Following conditioning, expectancy of the 
psychological stimuli to produce an effective analgesia takes place. Once the patients expect 
to have an improvement in pain management, the effect of psychological analgesia would 
play its role. Due to anxiety and fear to pain, patients generally want to have rapid and 
effective methods that can relieve their pain (Cornally & McCarthy, 2011; den Hollander et 
al., 2010; Kennedy et al., 2011), which consequently leads to an expectancy of their pain 
therapies. Under this condition, physicians’ attitude and enthusiasm takes an important part 
in whether or not the psychological analgesia comes into play (Weintraub, 2005). Give 
patients the hope to conquer pain accompanying with a warmth care, the expected effect of 
psychological analgesia would be maximized. After expectancy, motivation of analgesia is 
another aspect in determining the effect of psychological interventions. If the patient desires 
for a relief of pain, the real analgesic role of psychological stimuli would be magnitude 
(Radat & Koleck, 2011). The motivation itself whether or not could predict the psychological 
effect on one type of pain needs to be explored at length, and could it be effective for 
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different types of pain is also yet to be guaranteed. A body of literature has confirmed the 
role of emotions in pain perception and alleviation. Anxiety and stress are two main factors 
of emotion-associated psychological mediator. It is believed that anxiety is the cause of 
increased levels of pain, and reduction in anxiety produces analgesia (Luciano et al., 2011). 
Stress sometimes is related with increased levels of pain, but in some contexts, stress can 
produce analgesia (Donello et al., 2011; Wang et al., 2008). Therefore, the purpose of 
psychological suggestion in pain control is to alleviate patients’ anxiety and stress, which in 
turn produces a feedback analgesia effect. 
As described in the general model of the placebo-associated psychological analgesia, three 
consecutive stages exist when psychological treatment was given: the induction, 
psychophysiological mediation, and actualization (Goffaux et al., 2010). In the induction 
stage, three aspects compose the major contents including the introduction or initiation 
(therapeutic message; method of administration; follow-up and booster sessions; 
assessment of side effects), idiosyncratic variables (beliefs and values; personal history; 
innate predisposition) and therapeutic context (treatment objectives; therapeutic alliance; 
sociocultural factors). In the second stage, psychophysiological mediation composes of 
psychological and biological mechanisms. Psychological mechanisms include above-
mentioned conditioning, expectancy, motivation, and emotion, and the biological 
mechanisms include neurochemical mediators (endorphins, dopamine, and other 
neurotransmitters/neuromodulators) and neurophysiology (activation of central 
modulatory mechanisms including descending inhibitory circuits). In the actualization 
stage, three main aspects exist including subjective experience (pain, emotions, quality of 
life, satisfaction, and related relief), behavioral markers (amount of analgesics consumed 
and overt pain behaviors), and physiological markers (physiological nociceptive activity, 
objective clinical indicators). As thus, when a psychological intervention is given, these 
three stages would be experienced. However, in consideration of the multiple phases of 
these stages, the actual effect of psychological analgesia may be variable in different 
individuals under different circumstances. 
4. Efficacy of psychological analgesia 
The analgesic effect of psychological approaches depends on types of pain, individual 
status, caregivers’ attitude and contextual frame, which finally determines the efficacy of 
psychological analgesia. For postoperative pain, preoperative hypnosis could accelerate 
wound healing and alleviate pain intensity after mammoplasty (Ginandes et al., 2003), and 
reduce post-surgical pain and distress in patients undergone excisional breast biopsy 
(Schnur et al., 2008). However, in other surgical contexts, psychological interventions did 
not produce detectable difference compared with the control: relaxation training for spinal 
surgeries could not reduce postoperative pain (Gavin et al., 2006), and intraoperative music 
therapy also could not produce analgesia in Cesarean patients (Reza et al., 2007). Contrary 
to this, postoperative music can alleviate the pain and reduce the need for analgesics in 
patients who undergone Cesarean section (Ebneshahidi & Mohseni, 2008). Besides, in 
cardiac surgeries, music therapy produced effective role in alleviating anxiety and pain 
(Sendelbach et al., 2006). These different even controversial results raise questions on the 
real analgesia efficacy of psychological interventions. In fact, difference in interventional 
methods, types of surgeries, and professionals of investigators may all contribute to the 
changeable results of psychological analgesia. An attractive study performed to observe the 
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influence of linguistic suggestion on postoperative pain management after abdominal 
surgeries, and found that negative words from nursing professionals results in therapeutic 
failure of patient-controlled analgesia, and suggested that a trusting psychological 
relationship between medical caregivers and patients should be established (Wang et al., 
2008). Therefore, it is necessary to seek a standardized effective psychological method that 
can be employed at any time to alleviate pain and pain-associated psychological 
contributors. 
Chronic pain, due to its multi-original property and hypo-responsiveness to traditional 
analgesics, is a complex pathological condition that needs to be cared with specific 
concentration. How to predict psychological problems in patients with chronic pain and 
then to take steps to overcome them plays pivotal role in alleviating this kind of pain. 
Modified Somatic Perception, Zung Questionnaires and Catastrophizing Scale are major 
means in predicting possible psychological factors in patients with chronic pain (Mannion et 
al., 1996; Meyer et al., 2008). These tools can help to identify psychological problems at early 
period that is crucial for understanding the development of acute pain into chronic and also 
possibly preventing its chronicity. Several studies considered psychological factors are 
contributors to patients’ chronicity, but others did not find such a relationship (Roth et al., 
2011a; Roth et al., 2011b; Roth et al., 2011c; Wallin et al., 2011; Xu et al., 2011). Various results 
in different studies questioned the real analgesic effect of psychological approaches in 
chronic pain management. Also, seek an optimized psychological procedure in chronic pain 
management is necessary for pain physicians. 
5. Optimizing psychological analgesic procedure 
Difference in methods of psychological interventions makes it difficult to reach a 
standardized uniform procedure that could be used for each individual at different 
pathological conditions. No matter what kind of methods employed, following four aspects 
are constant and also can be the interventional entry points: types of pain, individual 
expectancy status, therapeutic context, and professional level of physicians. Therefore, 
standardized psychological approach in analgesia should be based on these four factors. 
Besides, an optimized interventional flow of psychological analgesia from induction to 
performance to completion also will be standardized. 
How to standardize the types of pain is so difficult because of its property of multiple 
originalities plus difference in its duration, intensity and responsiveness to pharmacological 
analgesics. To have a clear description and avoid an extra complexity of the standardization 
of the psychological procedure in the types of pain, here two major types of pain, acute and 
chronic, are discussed. First, acute pain is relatively easier to treat and generally resulted 
from traceable causes. So herein the acute pain is standardized on the basis of postoperative 
pain: surgical procedures → tissue injury → afferent fibers activation → dorsal root ganglion 
→ spinal cord dorsal horn → ascending modulatory tracts → hypothalamus → cerebral 
cortex. However, chronic pain is refractory to pharmacological treatments and without 
assured causes. Here the standardization is based on chronic low back pain: regional chronic 
injury → persistent activation of peripheral fibers → spinal sensitization → reduction in 
pain threshold → activation of multiple brain regions. Although acute pain and chronic pain 
have different transduction pathways, they finally reach brain and then the perception is 
occur. This is the basis of the standardization when it is treated with psychological 
approaches. 
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Individual expectancy status is the second factor that needs to be standardized. Every one 
expects to have an effective method that can conquer the pain because of the unpleasant 
experience. Once a patient has such a hope, the psychological analgesia would play its role. 
However the psychological complexity makes people doubt the real efficacy of the 
analgesia. Therefore, give a timely psychological intervention along with patients’ 
expectancy is the best way for analgesia through matching their different time windows. 
Under this condition, careful assessment of patients’ psychological status with proper 
means would give physicians more information on what, how and when a psychological 
stimulation could be employed. In fact, psychological intervention if given appropriately at 
this moment exactly fills patients’ psychological gap. If want take effective steps to control 
the pain, time communication with patients is the guarantee. So, the following flow is 
recommended: talk to confirm the expectancy → predisposition for psychological 
intervention → psychological preparation → increase confidence of conquering. 
Therapeutic context is the environment where the patients go and seek for pain 
management. Whether clinics could provide proper and humanistic care or not 
determines the final conclusion of psychological analgesia. Due to big difference in the 
contextual background, it is hard to standardize the consulting environment. Here just 
give a proposal that should at least be followed when administering psychological 
interventions for pain control: i) avoiding negative stimuli; ii) establishing a warm setting; 
iii) patient-centered communication; iv) one-stop services. A trusting relationship 
between medical environment and patients could pave the way to a successful analgesia 
with psychological approaches. 
Professional level of physician is the “software” that needs to be updated step by step and 
improved gradually with practice. Of course, personal morality is another crucial part that 
can give patients the “be-taken-seriously” feeling. Further, if the physician trained in 
psychological treatment, such professional knowledge in psychology would make the 
psychological analgesia more effective, and would produce the best efficacy in alleviating 
pain. This section, in fact, is the easiest one that can be improved after training and practice. 
Following is the suggestion on how to get better results in psychological analgesia: i) take 
patients’ claim into heart; ii) build friend relationship with patients; iii) serve with the best 
professional knowledge; iv) psycho-language communication; v) unchangeable attitude and 
performance. 
The changing window of man’s mind is wide, and it is so easy to change when each above-
mentioned part cannot satisfy the expectancy. Besides, the prone-to-be-broken psychological 
state would be shattered by improper intervention. Therefore, patients with different types 
of pain have various expectancy of analgesia that needs to be treated with optimal 
psychological procedures even at different clinics. 
When performing psychological analgesia, following three-step procedure should be 
referred to. First step, induction: i) communicate without hint of psychological intervention; 
ii) confirm patient’s psychological state; iii) predict patient’s expectancy; iv) increase 
confidence that is bound to succeed. After this, the next step should be followed without 
interruption, i.e. performance: i) select a relatively quiet environment; ii) build a kind talking 
ambient; iii) give personalized linguistic intervention; iv) choose an interesting topic; v) talk 
without constraint; vi) observe psychological change during talking; vii) fine regulation in 
communication strategies. Following these procedures, the whole process of psychological 
intervention needs to be finalized, namely completion: i) conclude what have been talked; ii) 
thank patient’s patience; iii) assess pain intensity with appropriate tools. Application of 
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influence of linguistic suggestion on postoperative pain management after abdominal 
surgeries, and found that negative words from nursing professionals results in therapeutic 
failure of patient-controlled analgesia, and suggested that a trusting psychological 
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standardized uniform procedure that could be used for each individual at different 
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are constant and also can be the interventional entry points: types of pain, individual 
expectancy status, therapeutic context, and professional level of physicians. Therefore, 
standardized psychological approach in analgesia should be based on these four factors. 
Besides, an optimized interventional flow of psychological analgesia from induction to 
performance to completion also will be standardized. 
How to standardize the types of pain is so difficult because of its property of multiple 
originalities plus difference in its duration, intensity and responsiveness to pharmacological 
analgesics. To have a clear description and avoid an extra complexity of the standardization 
of the psychological procedure in the types of pain, here two major types of pain, acute and 
chronic, are discussed. First, acute pain is relatively easier to treat and generally resulted 
from traceable causes. So herein the acute pain is standardized on the basis of postoperative 
pain: surgical procedures → tissue injury → afferent fibers activation → dorsal root ganglion 
→ spinal cord dorsal horn → ascending modulatory tracts → hypothalamus → cerebral 
cortex. However, chronic pain is refractory to pharmacological treatments and without 
assured causes. Here the standardization is based on chronic low back pain: regional chronic 
injury → persistent activation of peripheral fibers → spinal sensitization → reduction in 
pain threshold → activation of multiple brain regions. Although acute pain and chronic pain 
have different transduction pathways, they finally reach brain and then the perception is 
occur. This is the basis of the standardization when it is treated with psychological 
approaches. 
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However the psychological complexity makes people doubt the real efficacy of the 
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stimulation could be employed. In fact, psychological intervention if given appropriately at 
this moment exactly fills patients’ psychological gap. If want take effective steps to control 
the pain, time communication with patients is the guarantee. So, the following flow is 
recommended: talk to confirm the expectancy → predisposition for psychological 
intervention → psychological preparation → increase confidence of conquering. 
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determines the final conclusion of psychological analgesia. Due to big difference in the 
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The changing window of man’s mind is wide, and it is so easy to change when each above-
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intervention needs to be finalized, namely completion: i) conclude what have been talked; ii) 
thank patient’s patience; iii) assess pain intensity with appropriate tools. Application of 
 
Pain Management – Current Issues and Opinions 464 
psychological linguistic suggestion should not be similar for one person at different visits, 
and the communicating environment should be changed time after time. The schematic flow 
of psychological intervention is presented in the Figure 1. 
 
 
Fig. 1. Schematic flow of psychological analgesia. 
6. Concluding remarks 
Psychological activity is a complex emotional response that can be influenced by many 
factors. Psychological analgesia itself, however, is so complex that its efficacy is uncertain 
for different types of pain at different conditions. Therefore, how to select interventional 
methods and how to perform them for different patients with various psychological states is 
a thorny problem. Although here the optimized procedure of psychological analgesia is 
presented, it is necessary to be changed for different patients under different contextual 
conditions. Also this recommendation should favor the improvement of psychological 
intervention in pain management in future work. 
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of psychological intervention is presented in the Figure 1. 
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1. Introduction 
Mucosal injury remains an undesirable, painful, and expensive side effect of cytotoxic 
cancer therapy and is disheartening for patients and frustrating for caregivers.[1,2] Mucositis 
and associated outcomes in patients receiving radiotherapy (RT) for head and neck cancer 
shows that the mean incidence was 80%.[3] Rates of hospitalization due to mucositis are 
reported to be 16% overall and 32% for RT-AF (altered fraction radio therapy) patients.[3 
Patients in the high risk of developing oral mucositis group fall into the head and neck 
cancer population where the incidence of mucositis is high in this group.[3] 
Oral mucositis is a distressing toxic effect of chemotherapy and radiotherapy. It can increase 
the need for total parenteral nutrition and opioids analgesics, prolong hospital stays, 
increase the risk of infection, and greatly affect the patient’s quality of life [4]. All patients 
treated with high-dose chemotherapy requiring hematopoietic stem cell or bone marrow 
transplantation develop oral mucositis of varying severity. In addition, up to 80% of patients 
receiving radiotherapy for head or neck tumours and almost 90% of pediatric patients 
treated for cancer also develop oral mucositis[5,6] 
2. Mechanism of development 
Radiation induced mucositis is initiated by direct injury to basal epithelial cells and cells in 
the underlying tissue. DNA-strand breaks can result in cell death or injury. Non-DNA injury 
is initiated through a variety of mechanisms, some of which are mediated by the generation 
of reactive oxygen species. Radiation and chemotherapy are effective activators of several 
injury-producing pathways in endothelia, fibroblasts, and epithelia. In these cells, the 
activation of transcription factors such as nuclear factor-κB (NF-κB) and NRF-2 leads to the 
upregulation of genes that modulate the damage response. Immune cells (macrophages) 
produce pro-inflammatory cytokines, such as tumor-necrosis factor-α (TNF-α) and 
interleukin-6, which causes further tissue injury.[7] These signaling molecules also 
participate in a positive-feedback loop that amplifies the original effects of radiation and 
chemotherapy. For example, TNF-α activates NF-κB and sphingomyelinase activity in the 
mucosa, leading to more cell death. In addition, direct and indirect damages to epithelial 
stem cells result in a loss of renewal capacity. As a result, the epithelium begins to thin and 
patients start to experience the early symptoms of mucositis.[8] 
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An oropharyngeal epithelial surface has a rapid rate of cell turnover and appears to be at 
high risk of injury from ionizing radiation. A healthy oral mucosa serves to clear 
microorganism and provides a chemical barrier that limits penetration of many compounds 
into the epithelium. A damaged mucosal surface increases the risk of a secondary infection. 
Acute mucositis results from the loss of squamous epithelial cells owing to the sterilization 
of mucosal stem cells and the inhibition of transit cell proliferation. This leads to a gradual 
linear decrease in epithelial cell numbers. Normally, cells of the mouth undergo rapid 
renewal over a 7–14 day cycle. Radiation therapy interferes with cellular mitosis and 
reduces the ability of the oral mucosa to regenerate. [9] 
As radiation therapy continues, a steady state between mucosal cell death and regeneration 
may occur because of an increased cell production rate from the surviving cells. Usually, 
however, cell regeneration cannot keep up with cell death, and therefore, partial or complete 
denudation develops. This presents as patchy or confluent mucositis. As the mucositis 
becomes more severe, pseudomembranes and ulceration develops. Poor nutritional status 
further interferes with mucosal regeneration by decreasing cellular migration and renewal. 
The loss of the epithelial barrier enhances insults from physical, chemical, and microbial 
agents. 
Stages of mode l[10] for the pathogenesis of mucositis are based on the evidence available to 
date: 
1. Initiation of tissue injury: Radiation and/or chemotherapy induce cellular damage 
resulting in death of the basal epithelial cells. The generation of reactive oxygen species 
(free radicals) by radiation or chemotherapy is also believed to exert a role in the 
initiation of mucosal injury. These small highly reactive molecules are by-products of 
oxygen metabolism and can cause significant cellular damage. 
2. Up-regulation of inflammation via generation of messenger signals: In addition to 
causing direct cell death, free radicals activate second messengers that transmit signals 
from receptors on the cellular surface to the inside of cell. This leads to up-regulation of 
pro-inflammatory cytokines, tissue injury, and cell death. 
3. Signaling and amplification: Up-regulation of pro-inflammatory cytokines, such as 
TNF-a, produced mainly by macrophages, causes injury to mucosal cells, and also 
activates molecular pathways that amplify mucosal injury. 
4. Ulceration and inflammation: There is a significant inflammatory cell infiltrate 
associated with the mucosal ulcerations, based in part on metabolic by-products of the 
colonizing oral microflora. Production of pro-inflammatory cytokines is also further up-
regulated as a result of this secondary infection.[10] 
5. Healing: This phase is characterized by epithelial proliferation, as well as, cellular and 
tissue differentiation,[11] restoring the integrity of the epithelium. 
A number of authors have reported that the oropharyngeal flora may contribute to 
radiation-induced mucositis. In health, the oral mucosa has a number of distinct habitats 
which are colonized by micro-organism that are able to establish a homeostatic 
community.[12] These homeostatic microbial communities are protective for the host by 
preventing or interfering with the colonization of exogenous pathogens; this potent defense 
mechanism is called “colonization resistance”. When the oral tissues are irradiated, the 
colonization resistance is practically abolished. Irradiation mucositis is caused by a 
combination of alteration of the normal oral microflora with concomitant changes in the 
tissues. However, healing eventually occurs when cells regenerate from the surviving 





3. Clinical presentation 
Clinically, mucositis presents with multiple complex symptoms. It begins with a 
symptomatic redness and erythema and progresses through solitary white elevated 
desquamative patches that are slightly painful to contact pressure. Following this, large, 
painful contiguous pseudo membranous lesions develop with associated dysphagia and 
decreased oral intake. The nonkeratinized mucosa is the most affected one. The most 
common sites include the labial, buccal, and soft palate mucosa, as well as, the floor of the 
mouth and the ventral surface of the tongue. Oral lesions usually heal within two to three 
weeks [Figure 1]. 
 
 
Fig. 1. Oral mucositis in a patient. 
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Mucositis is an inevitable side effect of radiation. Its severity is dependent on the type of 
ionizing radiation, the volume of irradiated tissue, the dose per day, and cumulative dose. It 
has been noted in a considerable number of clinical trials that the severity of acute normal 
tissue responses, particularly oral mucositis, is significantly increased when the overall 
treatment time is shortened.[12,13] The clinical course of oral mucositis may sometimes be 
complicated by local infection, particularly in immunosuppressed patients. Viral infections 
such as herpes simplex virus (HSV), and fungal infections such as candidiasis can 
sometimes be superimposed on oral mucositis. Although HSV infections do not cause oral 
mucositis, they can complicate its diagnosis and management. 
Histopathologically, edema of the retepegs is noted, along with vascular changes that 
demonstrate a thickening of the tunica intima with concomitant reduction in the lumen size 
and destruction of the elastic and muscle fibers of the vessel walls. The loss of the epithelial 
cells to the basement membrane exposes the underlying connective tissue stroma with its 
associated innervations, which, as the mucosal lesions enlarge, contributes to increasing 
pain. If the patient develops both severe mucositis and thrombocytopenia, oral bleeding 
may occur, which is very difficult to treat. 
4. Clinical management of oral mucositis 
Management of oral mucositis can be divided into the following sections: pain control, 
nutritional support, oral decontamination, palliation of dry mouth, management of oral 
bleeding, and therapeutic interventions for oral mucositis. 
4.1 Pain control 
The most common symptom of oral mucositis is pain. Pain significantly affects the 
nutritional intake, the mouth care, and the quality of life. Thus, management of mucositis 
pain is a primary component of any mucositis management strategy. Many centers use 
saline mouth rinses, ice chips, and topical mouth rinses containing an anesthetic, such as 2% 
viscous lidocaine, which may be mixed with equal volumes of diphenhydramine and a 
soothing covering agent in equal volumes. Such topical anesthetic agents may provide 
short-term relief. Sucralfate is the most commonly used and widely studied, even though 
there is no significant decrease in the pain control.[14,15] In addition to the use of topical 
agents, most patients with severe mucositis require systemic analgesics, often including 
opioids, for satisfactory pain relief. Though, the so called ‘magic mouthwash’ (lidocaine, 
diphenhydramine, magnesium aluminum hydroxide) has been observed to be beneficial, 
morphine mouth washes are preferable.[16,17] It was significantly better at reducing intensity 
and duration of pain and functional impairment, with fewer adverse effects. 
4.1.1 Sucralfate 
Sucralfate also has been tested in patients receiving radiation therapy. One study compared 
21 patients who received standard oral care to the head and neck with 24 patients who 
received sucralfate suspension four times daily. Results revealed a significant difference in 
mucosal edema, pain, dysphagia, and weight loss in patients receiving sucralfate [18]. In a 
pilot study done by Pfeiffer et al. [19], sequential patients who received radiation therapy to 
the head and neck received sucralfate at the onset of mucositis. Most patients had a decrease 
in pain following the use of sucralfate. A double-blind, placebo-controlled study with 





stastitically significant differences in mucositis; however, the sucralfate group reported less 
oral pain, and other topical and systemic analgesics were started later in the course of 
radiation [20]. A prospective double-blind study compared the effectiveness of sucralfate 
suspension versus diphenhydramine syrup plus kaolin-pectin on radiotherapy-induced 
mucositis. Data were collected daily, including perceived pain, helpfulness of mouth rinses, 
weekly mucositis grade, weight change, and interruption of therapy. Analysis of the two 
groups revealed no statistically significant differences between the two groups. In a 
retrospective review, 15 patients who had not used daily oral rinses were compared with the 
two groups, and the results suggested that the use of a daily oral rinse with a mouth-coating 
agent may result in less pain, reduce weight loss, and help prevent interruption of radiation 
because of severe mucositis[21]. 
 
 
Fig. 2. Oral mucositis in a patient. 
 
Pain Management – Current Issues and Opinions 
 
472 
Mucositis is an inevitable side effect of radiation. Its severity is dependent on the type of 
ionizing radiation, the volume of irradiated tissue, the dose per day, and cumulative dose. It 
has been noted in a considerable number of clinical trials that the severity of acute normal 
tissue responses, particularly oral mucositis, is significantly increased when the overall 
treatment time is shortened.[12,13] The clinical course of oral mucositis may sometimes be 
complicated by local infection, particularly in immunosuppressed patients. Viral infections 
such as herpes simplex virus (HSV), and fungal infections such as candidiasis can 
sometimes be superimposed on oral mucositis. Although HSV infections do not cause oral 
mucositis, they can complicate its diagnosis and management. 
Histopathologically, edema of the retepegs is noted, along with vascular changes that 
demonstrate a thickening of the tunica intima with concomitant reduction in the lumen size 
and destruction of the elastic and muscle fibers of the vessel walls. The loss of the epithelial 
cells to the basement membrane exposes the underlying connective tissue stroma with its 
associated innervations, which, as the mucosal lesions enlarge, contributes to increasing 
pain. If the patient develops both severe mucositis and thrombocytopenia, oral bleeding 
may occur, which is very difficult to treat. 
4. Clinical management of oral mucositis 
Management of oral mucositis can be divided into the following sections: pain control, 
nutritional support, oral decontamination, palliation of dry mouth, management of oral 
bleeding, and therapeutic interventions for oral mucositis. 
4.1 Pain control 
The most common symptom of oral mucositis is pain. Pain significantly affects the 
nutritional intake, the mouth care, and the quality of life. Thus, management of mucositis 
pain is a primary component of any mucositis management strategy. Many centers use 
saline mouth rinses, ice chips, and topical mouth rinses containing an anesthetic, such as 2% 
viscous lidocaine, which may be mixed with equal volumes of diphenhydramine and a 
soothing covering agent in equal volumes. Such topical anesthetic agents may provide 
short-term relief. Sucralfate is the most commonly used and widely studied, even though 
there is no significant decrease in the pain control.[14,15] In addition to the use of topical 
agents, most patients with severe mucositis require systemic analgesics, often including 
opioids, for satisfactory pain relief. Though, the so called ‘magic mouthwash’ (lidocaine, 
diphenhydramine, magnesium aluminum hydroxide) has been observed to be beneficial, 
morphine mouth washes are preferable.[16,17] It was significantly better at reducing intensity 
and duration of pain and functional impairment, with fewer adverse effects. 
4.1.1 Sucralfate 
Sucralfate also has been tested in patients receiving radiation therapy. One study compared 
21 patients who received standard oral care to the head and neck with 24 patients who 
received sucralfate suspension four times daily. Results revealed a significant difference in 
mucosal edema, pain, dysphagia, and weight loss in patients receiving sucralfate [18]. In a 
pilot study done by Pfeiffer et al. [19], sequential patients who received radiation therapy to 
the head and neck received sucralfate at the onset of mucositis. Most patients had a decrease 
in pain following the use of sucralfate. A double-blind, placebo-controlled study with 





stastitically significant differences in mucositis; however, the sucralfate group reported less 
oral pain, and other topical and systemic analgesics were started later in the course of 
radiation [20]. A prospective double-blind study compared the effectiveness of sucralfate 
suspension versus diphenhydramine syrup plus kaolin-pectin on radiotherapy-induced 
mucositis. Data were collected daily, including perceived pain, helpfulness of mouth rinses, 
weekly mucositis grade, weight change, and interruption of therapy. Analysis of the two 
groups revealed no statistically significant differences between the two groups. In a 
retrospective review, 15 patients who had not used daily oral rinses were compared with the 
two groups, and the results suggested that the use of a daily oral rinse with a mouth-coating 
agent may result in less pain, reduce weight loss, and help prevent interruption of radiation 
because of severe mucositis[21]. 
 
 
Fig. 2. Oral mucositis in a patient. 
 
Pain Management – Current Issues and Opinions 
 
474 
4.1.2 Morphine in pain control 
In a study to compare the effect of locally applied morphine mouthwash(MO) with Magic 
mouth wash (MG) on mucositis-related oral pain and on the maintenance of oral intake in 
patients with tumors of the head and neck area treated with a chemoradiotherapy 
regimen51. Additional objectives were to evaluate the safety of MO by determining the 
frequency of treatment-emergent drug-related adverse events (local and systemic) or 
hematologic and biochemical abnormalities, the intensity of chemoradiotherapy 
administered, tumor response, weight loss, need of a nasogastric tube, and mucositis-related 
hospitalizations. The duration of severe pain was 3.5 days less in the Morphine group 
compared with the Magic mouth wash group (P _ 0.032). The intensity of oral pain was also 
significantly lower in the MO group compared with the MG group .More patients in the MG 
group needed supplementary (oral or parenteral) analgesia compared with the MO group  
(P _ 0.019). Nevertheless, the time elapsed before the first supplemental analgesic and the 
total amount of analgesics taken was similar for both groups. Of 12 patients in the MG 
group, 3 (25%) and none in the MO group required third-step opiates for alleviation of 
mouth pain. However, the differences in the maximum WHO step needed for control of 
pain were not statistically significant. There was a significant difference in duration of 
severe functional impairment. Nevertheless, the body weight change was similar for both 
groups. There were no significant differences in documented or highly suspected infections, 
change in performance status, tumor response rate, and intensity of the chemoradiotherapy 
delivered between the two treatment groups. No patients required hospitalization due to 
mucositis during the study. Patients in the MG group reported more local side effects [51]. 
4.2 Nutritional support 
A soft diet or liquid diet was more easily tolerated than a normal diet, when oral mucositis 
is present; gastrostomy tube is more beneficial, when there is severe mucositis. 
4.3 Selective oral decontamination 
It has been hypothesized that microbial colonization of oral mucositis lesions exacerbates 
the severity of oral mucositis and, therefore, decontamination may help to reduce mucositis. 
Due to the fact that the oral cavity contains a high amount of Gram-negative bacilli and 
considering its etiological role in mucositis, the concept of ‘Selective Decontamination’ has 
been developed. In this regard, lozenges composed of polymyxin E, tobramycin, and 
amphotericin B have been studied in patients receiving radiation for cancers of head and 
neck in a randomized trial that compared lozenges with placebo or chlorhexidine rinses, the 
antimicrobial lozenges provided more effective mucositis prevention in patients receiving 
head and neck irradiation. Addition of ciprofloxacin or ampicillin with clotrimazole to 
Sucralfate has shown reduction in mucositis.[22] 
4.4 Oral hygiene 
Significant reduction in oral mucositis can be attained by proper oral hygiene measures.[23] It 
was noted that proper oral care also reduced oral toxicity of radiation therapy. Indeed, 
multiple studies have demonstrated that maintenance of good oral hygiene can reduce the 
severity of oral mucositis. Furthermore, oral decontamination can reduce infection of the 
oral cavity by opportunistic pathogens.[24] Therefore, a second function of oral 
decontamination can be to reduce the risk of systemic sepsis from resident oral and/or 
opportunistic pathogens. Intensive oral care protocol decreased risk of oral mucositis, but 





The RTOG and MASCC/ISOO (Mucositis study group of the multinational association for 
supportive care in cancer and the International society of oral oncology) guidelines 
recommend use of a standardized oral care protocol, including brushing with a soft 
toothbrush, flossing, and the use of nonmedicated rinses (for example, saline or sodium 
bicarbonate rinses). Patients and caregivers should be educated regarding the importance of 
effective oral hygiene [26, 52, 53]. 
4.5 Palliation of dry mouth 
In cancer therapy, patients often develop transient or permanent xerostomia and 
hyposalivation. Hyposalivation can further aggravate inflamed tissues, increase risk for 
local infection, and make mastication difficult. Many patients also complain of a thickening 
of salivary secretions, because of a decrease in the serous component of saliva. The 
following measures can be taken for palliation of a dry mouth: 
 Sip water as needed to alleviate mouth dryness; several supportive products including 
artificial saliva are available. 
 Rinse with a solution of half a teaspoon of baking soda half in one cup warm water 
several times a day to clean and lubricate the oral tissues and to buffer the oral 
environment. 
 Chew sugarless gum to stimulate salivary flow. 
 Use cholinergic agents as necessary. 
4.6 Kaolin pectin 
Kaolin pectin, combined with diphenhydramine, which is a H1-histamine antagonist and 
local anesthetic, was found to reduce oral pain without reducing the degree of mucositis in a 
double blind randomized and controlled study.[27] 
5. Growth factors 
One of the problem faced by the therapy is the loss of proliferation of the oral epithelial cells, it 
has seen that various growth factors that can increase epithelial cell proliferation have been 
studied for the management of oral mucositis. Recent evidence shows that intravenous 
recombinant human keratinocyte growth factor-1, Palifermin, significantly reduced incidence 
of WHO grades 3 and 4 oral mucositis in patients with hematologic malignancies (for example, 
lymphoma and multiple myeloma) receiving high-dose chemotherapy and total body 
irradiation before autologous hematopoietic cell transplantation.[28]  
Human keratinocyte growth factor-2, Repifermin, was found to be ineffective in reducing 
the percentage of subjects who experienced severe mucositis.[29] Intravenous human 
fibroblast growth factor-20, Velafermin, is currently in clinical development for reduction of 
mucositis secondary to high-dose chemotherapy in autologous hematopoietic cell transplant 
patients.[30] The safety of this class of growth factors has not been established in patients 
with nonhematologic malignancies. There is a theoretical concern that these growth factors 
may promote growth of tumor cells, which may have receptors for the respective growth 
factor. However, one recent study found no significant difference in survival between 
subjects with colorectal cancer receiving Palifermin or placebo at a median follow-up 
duration of 14.5 months.[31] Further studies are ongoing to confirm the safety of epithelial 
growth factors in the solid tumor setting, including patients receiving radiation therapy for 
head and neck cancer. 
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Source Grade 0 Grade 1 Grade 2 Grade 3 Grade 4 
 WHO No change Soreness/erythema Erythema,ulcers, can eat solids 




RTOG No change over baseline 
May experience mild 
pain not requiring 
analgesic 
Patchy mucositis may 
have a serosanguinous 
discharge. May 
experience pain 
requiring analgesics.         
< 1.5 cm, 
noncontiguous   
Confluent fibrinous 
mucositis/may include 
severe pain requiring 





± bleeding . 
NCI CTC None 
Painless ulcers, 




ulcers, but can eat. 
 painful erythema, 
edema or ulcers  can not 
eat. 
Requires Parenteral or 
enteral support  
Van der 
schueren et al  None Slight erythema Pronounced erythema Spotted mucositis 
Confluent mucositis 
patches >0.5cm. 
Byfield et al  --- 
Minimal dysphasia, 
thinning but no overt 
break in mucosal 
integrity. 
Significant dysphasia, 
semi soft foods only, 
focal mucosal vesicles or 
denuded patches. 
Fluids only tolerated, 
obviously large 
confluent patches of 
mucosal denudation  
Parenteral fluids only, 
severe confluent mucosal 
denudation with 
bleeding. 
Seto et al  ----- Localized erythema with no pain 
Generalized erythema 
without pain or 
localized erythema or 
ulcers with mild pain. 
Multiple ulcers or 
generalized erythema 
with moderate pain 
Generalized erythema or 
ulcers with moderate to 
severe pain. 
Eilers et al   ----- Pink and moist Reddened or white film without ulcerations 
Ulceration with or 
without bleeding  ------- 






ulcers, but can eat 
Painful 
erythema,oedema,or 
ulcers, but can not eat 
Mucosal necrosis and/or 
requires Parenteral or 
enteral 
support,dehydration. 
Spijkervet et al  None  White discoloration  Erythema Pseudomembrane ulceration 




Type : severe 
erythematous area: 25-
50% 




Hickey et al  No stomatitis 
Whitish gingival or 
slight  burning 
sensation or 
discomfort. 
Moderate erythema and 
ulcerations or white 
patches.pain, but can 
eat, drink and swallow. 
severe erythema and 
ulcerations or white 
patches. Severe Pain and 
can not  eat, drink or 
swallow. 
------- 
Table 1. Comparison of commonly used mucositis scoring system 
6. Anti-inflammatory agents 
6.1 Benzydamine hydrochloride  
It is a nonsteroidal antiinflammatory drug that inhibits proinflammatory cytokines 
including TNF-a. In a Phase III trial, Benzydamine hydrochloride mouthrinse reduced the 
severity of mucositis in patients with head and neck cancer undergoing radiation therapy of 
cumulative doses up to 50-Gy radiation therapy.[32] Based on this and previous studies, the 
MASCC/ISOO guidelines recommends use of this agent in patients receiving moderate-
dose radiation therapy.[33] 
6.2 Saforis 
It is a proprietary oral suspension of L-glutamine that enhances the uptake of this amino acid into 
epithelial cells. Glutamine may reduce mucosal injury by reducing the production of 





increasing fibroblast and collagen synthesis.[36] In a Phase III study, this topical agent reduced the 
incidence of clinically significant chemotherapy-induced oral mucositis compared to placebo.[37] 
By comparison, the MASCC/ISOO guidelines recommend that systemically administered 
glutamine not be used for the prevention of GI mucositis because of lack of efficacy.[38] 
6.3 Amifostine 
It (phosphothiorate, radiation protection agent) is thought to act as a scavenger for harmful 
reactive oxygen species that are known to potentiate mucositis.[39] However, because of 
insufficient evidence of benefit, various guidelines could not be established regarding the 
use of this agent in oral mucositis in chemotherapy or radiation therapy patients. The use of 
amifostine has been recommended for the prevention of esophagitis in patients receiving 
chemoradiation for nonsmall-cell lung cancer.[40]  
6.4 RK- 0202 (RxKinetix)  
It consists of the antioxidant, N-acetylcysteine, in a proprietary matrix for topical application 
in the oral cavity. In a placebo-controlled phase II trial in patients with head and neck 
cancer, this agent significantly reduced the incidence of severe oral mucositis up to doses of 
50-Gy radiation therapy.[41] 
6.5 Beta carotene 
Beta carotene, a vitamin A derivative, is a scavenger of singlet oxygen. Based on the findings 
of different randomized controlled study, it is of the view that supplemental dietary beta-
carotene lead to a mild decrease in the severity of chemotherapy and radiotherapy-induced 
oral mucositis.[42] 
7. Immunomodulatory drugs 
7.1 Pentoxifylline 
Oral pentoxiphylline reduced the frequency and severity of all major complications after 
BMT, including reduction of oral mucositis.[43] Contradictory to this, other workers reported 
a significant aggravation of symptoms when they studied the effect of IV Pentoxiphylline in 
92 patients.[44] However, no difference in symptoms was noted in patients who undergone 
chemo radio therapy.  
7.2 Indomethacin 
Indomethacin, a nonsteroidal antiinflammatory drug inhibiting prostaglandin synthesis is 
noted to delay the onset of mucositis. 
7.3 Immunoglobulin 
Treatment with low-dose intra muscular immunoglobulin is said to decrease the severity 
and duration of radio therapy-induced oral mucositis. Immunoglobulin has also been tried 
as a therapeutic agent in radiation-induced mucositis in various clinical trials and the 
observations were promising.[45] 
7.4 Cytokines 
Preclinical models have been used to demonstrate that the cytokines interleukin-1, 
interleukin-2, epidermal growth factor, interleukin-11, and transforming growth factor-beta 
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Oral pentoxiphylline reduced the frequency and severity of all major complications after 
BMT, including reduction of oral mucositis.[43] Contradictory to this, other workers reported 
a significant aggravation of symptoms when they studied the effect of IV Pentoxiphylline in 
92 patients.[44] However, no difference in symptoms was noted in patients who undergone 
chemo radio therapy.  
7.2 Indomethacin 
Indomethacin, a nonsteroidal antiinflammatory drug inhibiting prostaglandin synthesis is 
noted to delay the onset of mucositis. 
7.3 Immunoglobulin 
Treatment with low-dose intra muscular immunoglobulin is said to decrease the severity 
and duration of radio therapy-induced oral mucositis. Immunoglobulin has also been tried 
as a therapeutic agent in radiation-induced mucositis in various clinical trials and the 
observations were promising.[45] 
7.4 Cytokines 
Preclinical models have been used to demonstrate that the cytokines interleukin-1, 
interleukin-2, epidermal growth factor, interleukin-11, and transforming growth factor-beta 
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have direct effect on intestinal or oral mucosa. Interleukin-1 increases thymidine labeling, 
and protects oral and intestinal mucosa, when given to mice before radiation. Interleukin-11 
can decrease mucositis, when given to hamster models. 
7.5 G-CSF, GM-CSF 
The mucosal protection effects of granulocyte colony stimulating factor G-CSF were 
observed in patients treated with various chemotherapy regimens by many authors.[46] But 
controversies to this exist in other clinical trials. In a recent preliminary report of a pilot 
study found significant reduction in oral mucositis.[47] The study was to evaluate the effect 
of GM-CSF in reduction of radiotherapy induced oral mucositis. At about second week of 
radiotherapy, when oral pain was experienced 400 g of GM-CSF was administered locally 
once a day, until completion of radiotherapy. The patients were evaluated weekly for 
mucosal reaction and functional impairment. The result of the study was prompting with 
reduction and almost healing of oral mucositis in 14 out of 17 patients with completion of 
radiotherapy within the preplanned schedule. Moreover patients did not show a significant 
weight loss or functional impairment. 
8. Anti-viral drugs 
8.1 Acyclovir 
Although acyclovir prophylaxis is effective in preventing oropharyngeal shedding of the 
virus in herpes simplex virus seropositive patients receiving intensive chemotherapy or 
BMT, it did not influence chemotherapy, radiotherapy and BMT-related oral toxicity. 
9. Role of safe radiotherapy 
Normal tissue reactions can be reduced in a substantial number of patients with head and neck 
cancer by the use of computed tomography (CT)-based target delineation, Intensity-
Modulated Radiation Therapy (IMRT), and simple, custom-made, intraoral devices that are 
designed to exclude uninvolved tissues from the treatment portals or to provide shielding of 
tissues within the treatment area.[43] Stents can be useful in excluding the palate mucosa during 
treatment of the tongue or floor of the mouth. These shielding stents can decrease the amount 
of radiation that is delivered to the contra-lateral mucosa. More frequent use of electron-beam 
and/or sophisticated three-dimensional conformal, multibeam, wedged-pair, or oblique 
treatment plans will also help to exclude or minimize the radiation dose to uninvolved 
mucosa. Packing gauze between metallic dental restorations and mucosa of the lateral tongue 
and buccal area appears to be very beneficial in minimizing the dose from scattered radiation. 
9.1 Antifungal therapy 
The mucosa of patients undergoing radiation therapy to the oral cavity should be examined 
at least once a week, and antibiotic or antifungal medications should be prescribed when 
infections are documented. Clotrimazole troches, dissolved in the mouth five times a day for 
14 days, generally works well for oral candidiasis. However, if significant mucositis, altered 
taste, or xerostomia has developed, the troches might not be tolerated. In this situation, 
nystatin oral suspension or Fluconazole in tablet or liquid form is often effective. 
Fluconazole is more effective than nystatin and might need to be given at a higher dose 
and/or for an extended period of time in patients who are receiving combined 





9.2 Low-level laser therapy 
The mechanism of low-level laser therapy is not understood, but many studies have proved 
the efficacy of the same in reducing the symptoms related to oral mucositis. Low-level laser 
therapy may reduce levels of reactive oxygen species and/or proinflammatory cytokines 
that contribute to the pathogenesis of mucositis.[49] The various guidelines suggest the use of 
low-level laser therapy for reducing the severity of chemotherapy and radiotherapy-
induced oral mucositis.[50]  
9.3 AMP-18 (Antral mucosal protein) 18 
A study on AMP18 (AMP-18 is a protein constitutively expressed in epithelial cells of the 
gastric antrum that is cell protective, mitogenic and motogenic in cell culture and in vivo) 
shows, AMP peptide, by activating CCKBR (cholecystokinin-B/gastrin receptor), targets 
TJs(Tight Junctions) to maintain mucosal integrity, and sets in motion protective and cell 
regenerative mechanisms for the prevention and treatment of OM. Treatment with AMP 
peptide protected the surface epithelium of the mouse oral mucosa. AMP-18 peptide 
stimulates growth of diverse types of epithelial cells including HaCaT cells [54]. 
10. Summary  
Mucositis is an inevitable side effect of radiation. The severity of the mucositis depends on 
the type of ionizing radiation, the volume of irradiated tissue, the daily dose, and the 
cumulative dose. As the mucositis becomes more severe, pseudomembranes and ulcerations 
develop. Poor nutritional status further interferes with mucosal regeneration by decreasing 
cellular migration and renewal. Radiation-induced oral mucositis affects the quality of life of 
the patients and the family concerned. The present day management of oral mucositis is 
mostly palliative and or supportive care. Management includes good oral hygiene, avoiding 
irritating or abrasive substances, use of bland rinses, topical anesthetic agents, and systemic 
analgesics. Though, the newer guidelines are suggesting Palifermin, which is the first active 
mucositis drug as well as Amifostine, for radiation protection and cryotherapy for 
symptoms related to high-dose melphalan; the role of safe radiotherapy remains the 
ultimate goal in reducing the symptoms of radiation-induced oral mucositis. Future 
research for the newer drugs in the field of radiation-induced oral mucositis is a must, and 
the current management should focus more on palliative measures, such as pain 
management, nutritional support, and maintenance, of good oral hygiene. 
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1. Introduction 
Pain is an unpleasant feeling and emotional experience that is related to real or potential 
tissue damage or a damage that is defined similarly. Pain is mostly subjective (Merskey, 
Bogduk 1986). From many points of view, the pain is a common symptom intended for 
seeking aid (Dickens et al. 2002). International Association for the Study of Pain (IASP) 
defines the pain as “an unpleasant emotional situation which is originating from a certain 
area, which is dependant or non-dependant on tissue damage and which is related to the 
past experience of the person in question” (Merskey, IASP 1986).  
Although there is an increase of knowledge and developments in technological resources 
regarding the pain, many patients still experience pain (Nash et al. 1999). This situation 
causes for reduction in living quality and functional situation of the patients, increase in the 
fatigue levels (Kim et al. 2004) and impairments in daily life activities in working capacity 
and social interactions (McMillan et al., 2000; Allard et al., 2001). Also this situation will 
cause loss of workforce and will affect not only the patients but also his/her family 
members in economical terms thus causing undesired problems in psychological and social 
well being status (Uçan and Ovayolu 2007). All of these elements have directed both the 
patients and caregivers to seek for different searches in pain management (Evans and 
Rosner, 2005). For this reason in addition to the pharmacological treatment options for pain 
management, today, non-pharmacological treatment options and complementary medical 
attempts have started to be used (Kwekkeboom et al., 2003; Menefee and Monti, 2005). It is 
stated that such kind of therapies can be useful in pain management (Uçan and Ovayolu 
2007). In a study conducted with the participation of 31.044 adults in United States, Barnes 
et al. (2004) determined that the usage rate of the complementary methods for the last year 
has been 36% and back pain and lumbago come first with 16.8% and neck pain comes third 
with 6.6% in terms of usage reasons of the complementary methods . Sherman et al. (2004) 
have stated that 24% of the patients with chronic lumbago used massage therapy. 
2. Non-pharmacological therapies in pain management 
It is considered that these therapies help the standard pharmacological treatment in pain 
management. While medical drugs are being used for treating the somatic (physiological 
and emotional) dimension of the pain non-pharmacological therapies aim to treat the 
affective, cognitive, behavioral and socio-cultural dimensions of the pain (Yavuz 2006). 
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These therapies can treat the pain as adjuvant or complementary at middle level and severe 
pain experiences as an adjuvant or complementary treatment. (Delaune & Ladner 2002). 
Non-pharmacological methods,  
 Increase the individual control feeling. 
 Decrease the feeling of weakness. 
 Improves the activity level and functional capacity.  
 Reduces stress and anxiety.  
 Reduces the pain behavior and focused pain level.  
 Reduces the needed dosage of analgesic drugs thus decreasing the side effects of the 
treatment (Yldrm 2006).  
Non-pharmacological methods used in pain management can be classified in different ways. 
In general; they are stated as physical, cognitive, behavioral and other complementary 
methods or as invasive or -non-invasive methods. Meditation, progressive relaxation, 
dreaming, rhythmic respiration, biofeedback, therapeutic touching, transcutaneous electrical 
nerve stimulation (TENS), hypnosis, musical therapy, acupressure and cold-hot 
treatments are non-invasive methods (Black & Matassarin Jacobs, 1997). The most famous 
and common method among the invasive methods is acupuncture (Menifee and Monti, 
2005). It is considered that these methods control the gates that are vehicles for pain to be 
transmitted to the brain and affect pain transmission or the release of natural opioids of 
the body such as endorphin (Black & Matassarin Jacobs, 1997; Menefee & Monti, 2005; 
Uçan & Ovayolu 2007). 
Non-pharmacological methods used in pain management have been examined below in 
three groups such as peripheral therapies (physical agents/skin stimulation methods), 
cognitive-behavioral therapies and other therapies. Some of these methods require special 
training (Turan et al. 2010). 
2.1 Peripheral therapies (physical agents/skin stimulation) 
Skin stimulation that provides analgesia is defined as stimulating the patient’s skin in a 
harmless manner to treat the pain (Yldrm 2006). Skin stimulation attempts (physical 
therapies) can be classified as hot-cold treatments, exercise, positioning, movement 
restriction-resting, acupuncture, hydrotherapy, TENS, massage and therapeutic touch. If 
used in an appropriate manner these methods are effective on secondary pathologies such 
as inflammation, edema, progressive tissue damage, muscle spasm and function loss which 
takes part in acute pain. (Yldrm 2006).  
2.1.1 TENS (Transcutaneous Electrical Nerve Stimulation) 
TENS has been defined by the American Physical Therapy Association as applying electrical 
stimulation to the skin to manage the pain (Sluka & Walsh 2003). Usually, it may be used in 
addition or instead of pharmacological agents to manage acute, chronic and post-operative 
pain. It is an electro-analgesia method (Mucuk and Başer, 2009). That is to say, thick and rapid 
transmitting nerve fibers are stimulated artificially with TENS and the pain transmission is 
tried to be stopped or reduced. TENS, which functions in that way, has an effect to reduce the 
narcotic drugs usage and pain level (Arslan & Çelebioğlu; Chen et al. 1998). TENS has various 
mechanisms of action regarding pain. Gate Control Theory is a theory used to define how 
TENS affects the pain perception which also has a part in improving TENS. Gate control 
theory regarding pain management is very commonly used by TENS in defining the process to  
 








Fig. 1. b) http://www.ib3health.com/products/TensandEMS/Literature/ApplicationChart.shtml 
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prevent the pain (Sluka & Walsh 2003; Johnson 2002). In a study that has been conducted, it 
has been determined that the placebo group experienced 2-4 times less pain when TENS is 
used with pharmacological methods in post-operative pain management (Rakel & Frantz 
2003), and in another study it has been determined that TENS usage in post-operative pain 
management has helped reducing the pain level and dosage of using analgesics (Bjordal et al. 
2003). In addition to that, in some other studies it has been determined that first phase of labor 
in TENS group has been shorter and TENS treatment has been effective in relieving the pain 
(Kaplan et al. 1998; Simkin and Bolding 2004). 
Points to Take into Consideration While Using Tens: 
 TENS device should be used under the control of a health personnel. 
 TENS devices should be used with caution in the areas where the pain could not be 
defined exactly.  
 Device should be turned off while placing the materials.  
 Electrical stimulation should not be used in front parts of the neck.  
 You should use the device after controlling machine or motor vehicle producing TENS. 
 This device should not be used on metal prostheses or monitors.  
 TENS should be kept at places where the children cannot reach.  
 People who are using cardiac pacemaker should consult to their doctors about whether 
TENS usage will be harmful for them or not.  
 Electronic materials such as ECG monitors and ECG alarms may not work in full 
capacity while using TENS. 
 It can cause damages on skin. That can be prevented by changing the type of gel and 
electrodes that are used. 




Dewit, S.C., (2009), Fundamental concepts and skills for nursing, 3rd Edition, W.B. Saunders Comp. 
Philadelphia, p.603-614. 
Fig. 2. TENS Usage  
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2.1.2 Hot-cold treatment  
Hot treatment moves the reflex arcs that inhibit the pain by means of heat receptors and 
reduces pain by vasodilatation effect. It is cheap and easy to use and it has a minimum 
amount of side effects when used regularly. It can be applied deeply or on surfaces. 
Application to the surface includes hot compresses, warm baths and paraphine usage. Deep 
applications such as ultrasound may increase the temperature of the tissues which are three 
to five centimeter deep (Arslan & Çelebioğlu, 2004). 
On the other hand, cold treatment consists of applying a cooling material or device on any 
part of the body. Cold treatment which is a simple and cheap treatment method has an 
important place in non-drug therapies for pain management(Yavuz, 2006). Cold gel 
packages and ice packages commonly used in the application should be used by placing a 
tin towel/gauze between the skin and the package for being able to withstand extreme cold 
feeling during the first contact of the package, for having a homogenous cooling and 
providing hygiene. Cold treatment may be done for 15-30 minutes averagely until the 
anesthesia is felt on the area of application. The cold ice packs should be applied for at least 
20 minutes. As a matter of fact, the affect of cold treatment on the human skin reveals itself 
in 4 stages. The patient will feel the cold within 1 to 3 minutes after the application, then feel 
a burning and pain sensation within 2 to 7 minutes and the pain and lethargy will decrease 
within 5 to 12 minutes, a breaking occurs for the pain-spasm vicious-circle and transmission 
of the nerve fibers in the area will decrease. An increase will occur for the metabolism 
within 12 to 15 minutes after cold treatment and a reflex vasodilatation occurs on the deep 
tissue. Thus, the edema and the pain will reduce and the tissue will be nourished with 
vasodilatation that will develop 15 minutes later (Karagözlüoğlu, 2001). Results of the 
studies made in the area have shown that the cold treatment has increased the pain 
threshold (Koç et al. 2006; Raynor et al. 2005; Sarifakioğlu & Sarifakioğlu 2004). So, the cold 
treatments that are applied locally are used to reduce the edema and treat the pain by taking 
the inflammation process under control (Saeki 2002; Sarifakioğlu & Sarifakioğlu 2004; Van 
der Westhuijzen et al. 2005).  
It has been stated that cold treatment over the area where surgical sutures are found after 
lumbar disc surgery reduces both the pain during first 24 hours and the need for morphine 
(Brandner et al. 1996). Also, it has been shown that fluoromethane spray applications are a 
cheap method that are rapidly effective in managing the injection pain due to vaccination 
(Mawhorter et al. 2004) and cold package and ice applications have reduced the pain due to 
heparin injections (Kuzu ve Uçar 2001; Ross and Soltes 1995). In the study that they 
conducted, Demir and Khorshid (2010) have stated that cold treatment that is applied to the 
skin around the chest tube reduced the severity of the pain that is felt due to exclusion of 
chest tube and it has extended the time between exclusion of chest tube and taking an 
analgesic. It is stated that cold treatment is contraindicated for the situations such as 
urticaria/hypersensitivity, hypertension, Reynaud's phenomenon and sickle cell anemia 
which are related to cold (Mucuk & Başer, 2009). 
2.1.3 Acupuncture and acupressure 
Acupuncture which is one of the important components of traditional Chinese medicine has 
become a largely complementary in the West together with the conventional medicine. 
Acupuncture is accepted as a scientific treatment method that provides the body to restore 
its balance by means of stimulating some special points on the body with needles (Taşç & 
Sevil 2007). Mechanism of action for the acupuncture could not be completely understood 
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until now. Effect of the acupunctures is tried to be explained by Gate Control Theory. 
According to this theory, effect of a sensory stimulant (for example lumbago) can be 
suppressed with another stimulant (picking a needle) within a neural system. Another 
theory that explains the effect of acupuncture is Raising Pain Threshold Theory. That is a 
theory in which inhibitor effect of acupuncture is defined. In this theory, it is predicted to 
stimulate the analgesia mechanisms of the body by causing various pains on the area where 
an individual is feeling the pain to be treated. In addition to these, it has also been evidence 
that the acupuncture stimulates the production of endorphin, serotonin and acetyl choline 
within the central nerve system (Van Tulder et al. 2005). It has been shown in the studies 
that have been conducted that the acupuncture had positive effects on post-traumatic 
somatic pain, patella-femoral pain, rheumatoid arthritis and idiopathic head pain. (Snyder & 
Wieland 2003). It is sated in the literature that the acupuncture is especially useful in 
treating the lumbago but it is underlined that the patients should be informed in terms of 
increasing or carrying on the activities (Öztekin, 2005). Although there are some strong 
evidences showing the benefit of acupuncture in acute pain, the evidence regarding the 
cancer pain is limited (Black & Matassarin Jacobs, 1997; Filshie & Thompson 2004; Menefee 
& Monti, 2005). In spite of that, Alimi et al. (2003) stated that the acupuncture applied to 
cancer patient has decreased the pain level.  
 
 
Fig. 3. http://suphecimelek.wordpress.com/2010/10/31/akupunktur June/2011 
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Acupressure is one of the traditional Chinese medicine approaches used for pain relief, 
diseases and injuries. Acupressure is a therapy that is conducted by applying physical 
pressure on various points on body surface  by means of energy circulation and balance in 
cases of pain symptoms. This therapy is similar to the acupuncture and it is conducted by 
applying pressure on selected points of the body by fingers, hands, palms, wrists and knees 
in order to provide internal flow of energy. Acupressure technique is a noninvasive, safe 
and effective application (Hakverdioğlu, & Türk, 2006). It is suggested that acupressure 
reduces back, head, osteoarthritis, musculoskeletal and neck pains, pre-operative and post-
operative pains, nausea-vomiting and sleeping problems (Tsay, Rong and Lin 2003; Tsay & 
Chen 2003; Hakverdioğlu, & Türk 2006). 
2.1.4 Exercise 
Exercise includes active-passive movements, bed movements and ambulation. Exercise 
increases the movement and provides continuity thus increasing the blood flow, preventing 
spasm and contractures of the muscles and relieving the pain (Musclow et al., 2002).  
2.1.5 Positioning 
It is applied to help or support the patient. This application can be supported by pillows, 
special beds and weight lifting. Position changes, which prevent the subsequent 
development of pain and reducing the acute pain, also increase the blood flow and prevent 
muscle contraction and spasms (Akdağ & Ovayolu, 2008). Positioning has been determined 
as the most common post-operative non-pharmacological method (Carroll 1999). 
2.1.6 Restriction of movement /resting 
These are applied for the patients who need certain bed rest and which are in traction. 
However, it should not be used alone for pain management. It can be used for fractures and 
back surgeries. Restriction of movement can also decrease edema development (Arslan & 
Çelebioğlu, 2004). 
2.1.7 Massage 
Massage is a manipulation applied on the soft tissue with various techniques (such as 
friction, percussion, vibration and tapotement) for recovery and supporting health. It is 
thought that the massage relieve the mind and muscles and increase the pain threshold 
(Karagöz 2006). Peripheral receptors on the body are stimulated with massage and 
stimulants reach the brain by means of spinal cord. In addition to pleasant feeling, a general 
relief is provided here (Turan et al. 2010). It is underlined that especially therapeutic 
massage is effective on chronic lumbago and that effect is stated to be a short term effect 
(Hsieh et al. 2004). Melancon and Miller (2005) draw attention to the fact that pain 
management in patient groups with lumbago that are treated with massage and 
pharmacological therapies are similar and they recommend the sue of massage as an 
alternative treatment option for the patients with lumbago within the framework of a 
integrated care. Nixon et al (1997) has stated that massage played a role in reducing the 
pain. In addition to that it is determined in some randomized controlled studies that 
massage made during labor decreases pain and anxiety; it also improves the general well 
being and progression of birth process and less reaction is given to the pain (Caton et.al 
2002; Simkin & O’Hora 2002). 
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2.1.8 Hydrotherapy (Balneotherapy) 
Using water for treatment by means of thermal springs, potable water resources and other 
methods is defined as "hydrotherapy" while using the water for therapy by means of 
temperature effect is defined as "hydrothermal treatment". Effect of hydrotherapy is related 
to its mechanical or thermal effect. Hot application stimulates the immune system, provides 
hormones that are suppressing the stress to be released, stimulates the circulation and 
digestion systems, increases the blood flow and provides muscle relaxation thus reducing 
the sensitivity developed against the pain (Karagöz, 2006). It is stated in the literature that 
hydrotherapy is effective while treating back and chronic lumbago (Balogh et al. 2005; 
Hartel & Volger 2004). 
2.2 Cognitive-behavioral therapies  
Cognitive-behavioral therapies are a part of multimodal approach in pain management. 
These attempts affect not only the pain level but also helps the patients to establish a 
management feeling of theirselves while dealing with pain and develop management 
behaviors and improved self-esteem. Cognitive-behavioral therapies can generally be 
applied by all members of the pain team. Most of the special techniques can be learned and 
applied by doctors, nurses, social service specialists and psychologists (Yldrm 2006). These 
therapies should be thought and applied as early as possible before the patient experiences 
pain (Delaune & Ladner 2002). 
2.2.1 Relaxation - respiration techniques and dreaming  
Relaxation techniques cause an increase in slow brain waves in EEG by decreasing oxygen 
consumption, blood pressure, respiration amount and the number of pulse. Therefore, it is 
stated that the sensitivity developed against the pain should be prevented by means of these 
techniques (Karagöz, 2006).  
Techniques used in providing the spiritual and physical relaxation are summarized below: 
- Respiration providing the relaxation: It is provided to focus on the respiration and avoid 
disturbing thoughts by taking a deep breath slowly through the nose and giving it back 
in a long time through the mouth. These techniques can be applied for 5-10 minutes per 
day (Nordin 2002). 
- Advanced muscle relaxation treatment: It is aimed to relax the unwanted contractions by 
determining them through making the patient contract and relax certain muscle groups 
on his body (Nordin 2002). 
- Dreaming: After relaxation is provided, the patient is made to focus on a stimulant that 
makes the patient happy (light, color, sound, pattern etc.) in order to get the patient far 
away from his pain for a short period of time (Karagöz 2006). In a study made by 
Lewandowski et al (2005) it has been stated that an effective pain management can be 
obtained by directing the patients to dreaming for more than 4 days. 
2.2.2 Distraction  
Getting the attention away from the pain reduces its severity. The aim in using that 
technique is to increases the tolerance for pain and decrease the sensitivity for pain. This 
method includes listening to music, watching television, reading books and dreaming 
(Arslan & Çelebioğlu, 2004). There are some sources which supports that distraction is a 
method used in decreasing the pain (Seers & Carroll 1998; Petry 2002). 
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2.2.3 Praying  
Most of the individuals with chronic pains use the praying method. It is indicated that 
praying has positive results for decreasing the body pain in old people and relieving their 
physical functional disorders and it is suggested to use the praying method in order to 
reduce the depression and anxiety that is caused by chronic pain (Meisenhelder & Chandler, 
2000; Karagöz, 2006).  
2.2.4 Meditation 
In the traditional meaning, meditation is generally focusing on the moment. Meditation; can 
also be defined as focusing on the present. This act is realized with an individual focusing 
on his own respiration, a word or picture. Duration of the meditation can last from a few 
minutes to 30 minutes or take more (Snyder & Wieland, 2003; Gray, 2004). Considering the 
fact that meditation helps relaxation, it is thought to be effective in relieving the pain (Gray, 
2004). Carson et al (2005) have stated that an 8-week meditation is useful for relieving the 
pain for patients with chronic lumbago. 
2.2.5 Yoga 
Yoga is providing relaxation by using respiration exercises and meditation with slow 
movements. It is considered that it can be useful against musculoskeletal pain in terms of 
using physical stretching moves and increasing strength (Dillard & Knapp, 2005). 
Individuals that use yoga have stated that they believe in the benefit of this method and it is 
a cost-effective method. It is stated in a study that applying yoga for 16 weeks has cured the 
chronic lumbago (Williams et al. 2005). Also, in a study conducted by Williams et al (2005) it 
has been stated that functional insufficiency experienced with chronic lumbago and use of 
pain killers have been reduced by means of yoga. 
2.2.6 Hypnosis 
Hypnosis; it is the state of conscious change similar to sleep. Hypnosis requires the body to 
relax and the patient to focus on an object, a stimulant or memory. Hypnosis is “the deep 
physical relaxation state during which subconscious can be reached and important abilities are 
suspended”. In this state, ability of people to be dominated increases (Taşç & Sevil, 2007). 
Besides mechanism of action of hypnosis over the pain is not known exactly and it is 
mentioned that the pain is reduced with some physiological changes that occur as a result of 
hypnosis. Hypnosis has been used in a positive manner in terms of cancer pain, pains in head-
neck region and phantom pain which is the sensations felt by amputees (Black & Matassarin 
Jacobs, 1997). Jensens and Patterson (2006) has stated that hypnotherapy/hypnosis is used for 
analgesia in various types of chronic pains and it has been stated that hypnosis has been 
effective for neck pain. Also Liossi et al (2006) has made a study with pediatric cancer patients 
in which it has been determined that hypnosis application has decreased pain and anxiety 
level in patients (Liossi et al. 2006). 
2.2.7 Bio-feedback  
Biological feedback is based informing the patient in order to help relaxation or control a 
physiological function. For example, in cases of tension type headache, it is provided for the 
electrical activity received by means of head muscles and facial muscles to be perceived as 
colors or sounds by the patient. Thus, observing the color changes or decreases in the sound, 
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the patient understands whether the relaxation occurred or not (Uçan & Ovayolu 2007). Bio-
feedback is used for treatment in the cases of pain, migraine pain, spinal cord injuries and 
movement disorders. It is aimed to control of physiological reactions such as muscle tension, 
body temperature, heart rate, brain wave activity and other vital parameters. Efficiency of 
the treatment depends on the desire that a patient shows for learning of how controlling of 
these functions and participation of patient in the process. Biofeedback appliers train the 
patient in terms of mental and physical exercises, visualization and deep breaths ( Eidelson, 
2005). In many types of chronic pain the bio-feedback has been shown to be effective 
(Moseikin 2003; Teyhen et al. 2005). 
2.2.8 Behavioral therapy  
Aim of this therapy is to increase the functional level of the patient decrease the maladaptive 
behaviors and firstly reduce and then completely stop painkiller usage. The family is trained 
by the treatment team; description of pain (grimacing, moaning, and remaining motionless) 
is avoided and well-adaptive behaviors such as physical activities are reinforced (Brietbart 
et al. 2004). 
2.3 Other non-pharmacological therapies 
2.3.1 Reflexology 
Reflexology is a technique that is based on the principle that suggests there are reflex points 
on our feet corresponding to all parts of our bodies , all organs and systems and these points 
are the mirrors of the body anatomy. Pressure applied to these reflex points by special hand 
and finger techniques provides the stress to be relieved and cause physiological changes and 
a reduction in pain perception (Yldrm, Fadloğlu and Uyar, 2006). There are totally five 
pressurizing techniques to make massage on reflex areas: Thumb move, finger move, 
rubbing move, patting move and compressing move. These moves are applied to ears, 
hands and feet similarly. The important thing here is to know how this technique will be 
applied to whom. Physical structure of an individual, age and current health status are 
taken into consideration. Treatment consists of applying pressure with the side of a thumb 
or other fingers and turning it clockwise. This pressure is generally deep but it does not 
have to be painful. A good reflexologist prefers repetition of short and painless seances to a 
single but painful seances for the whole disease. Intensity of the pressure can be low at the 
beginning and increased as the treatment progresses. Each seance takes from 10 minutes to 
30 minutes and it is decided according to the situation of the person how many seance will 
be necessary (Stephenson et al. 2000; Bolsoy 2008). 
It is stated in the literature that  reflexology is used especially for reducing migraine pain, 
back pain, muscle pain, end stage cancer pain and side effects of chemotherapy and to 
increase living quality (Long et al. 2001; McNeill et al. 2006; Mollart 2003; Quattrin et al.2006; 
Wringht et al.2002) In spite of that, it is stated that it is unfavorable to use reflexology in 
acute infections and fever situation, deep venous thrombosis, surgical situations and in 
cases of open scars, malign melanoma and during first trimester of the pregnancy or with 
the patients that has miscarriage or premature birth risks (Long et al. 2001; Lett 2002). 
2.3.2 Herbal treatments  
Herbal medicine is using the chemical materials obtained from inside, root, leave, seed and 
flower parts of the herbs for treatment (Karagöz 2006). Today, most individuals use herbal 
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products in addition to their medical treatments with drugs without consulting to any 
professional (Turan et al. 2010 ; Deng et al. 2005). It is stated in the literature that herbal 
medicine has been commonly used to treat lumbago and back pains (Gray, 2004; Gagnier et 
al. 2006; Hartel & Volger 2004). 
2.3.3 Aromatherapy 
Aromatherapy is using the essential oils that are obtained from flowers, herbs and trees to 
improve health and well being. These oils are applied by being respired through oily gauze 
that is placed under the nostrils of the patient or as massage oils being applied on skin. It 
has been evidenced that the aroma oils reached the lymph system by means of blood 
circulation and provided recovery by means of intercellular fluids (Turan et al. 2010). It is 
thought that aromatherapy may be able to help reducing stress, treating cold, sniffles, skin 
and menstruation problems and relieving pain (Karagöz, 2006; Jennings, 2004; Yldrm et al. 
2006; Deng et al. 2005). It is known that lavender oil is used in treating migraine pain, 
osteoarthritis, rheumatoid arthritis and lumbago. It is also known that eucalyptus, black 
pepper, ginger, daisy, licorice, rosemary and myrrh oils are used in relieving pain. But it is 
stated that lavender oil can cause hypersomnia and using licorice for long time can cause 
hypertension (Delaune & Ladner 2002). Although the usage of aromatherapy within health 
system increases day by day it is seen that the researches in this meaning is quite 
insufficient. Data regarding the efficiency of essential oils depend only on individual 
experiences. For this reason, it is necessary to conduct studies with large samples and high 
level of evidence to determine the efficiency of essential oils in pain management (Snyder & 
Wieland 2003; Tseng 2005) 
2.3.4 Chiropractics  
Chiropractics is the neck-pulling movement used in treatment of the disorders in connective 
tissues and musculoskeletal system which consists of muscles, joints, bones, tendon, 
cartilage and ligaments. The main principle of this approach is the fact that to relieve the 
pain and to improve health with the applications made on spine and joints which have had 
a positive effect on neural system and natural defense mechanisms (Gray, 2004). 
Chiropractics have focused on the connection between body structure and the functions of 
the neural system and manipulation of bones and joints to regain the health. It is known that 
the application that is taken, decreases the amount of burden on the neck and relives the 
pain. However, the individuals who have serious disorders such as severe cervical disc 
hernia, complaints due to rheumatoid arthritis , tumors and infection have to avoid from 
these applications (Turan et al. 2010; Karagöz 2006; Deng et al. 2005). 
2.3.5 Musical therapy  
Many studies that have been conducted have sown that the music had positive effects on 
pain and anxiety and increased the living quality of the patient or healthy individuals. 
Music reduces heart rate, blood pressure, body temperature and respiration rate and it 
distraction the attention of the patient to another point thus reducing the pain perception 
and reducing especially the nausea due to chemotherapy so that increasing living quality of 
patients in terminal period of cancer (Chase, 2003; Hilliard, 2003; Deng et al. 2005; Stefano et 
al. 2004, Uçan & Ovayolu 2007). In a study that states listening to music stimulates the alpha 
waves of brain which have been determined as a stimulator for the release of endorphin and 
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and finger techniques provides the stress to be relieved and cause physiological changes and 
a reduction in pain perception (Yldrm, Fadloğlu and Uyar, 2006). There are totally five 
pressurizing techniques to make massage on reflex areas: Thumb move, finger move, 
rubbing move, patting move and compressing move. These moves are applied to ears, 
hands and feet similarly. The important thing here is to know how this technique will be 
applied to whom. Physical structure of an individual, age and current health status are 
taken into consideration. Treatment consists of applying pressure with the side of a thumb 
or other fingers and turning it clockwise. This pressure is generally deep but it does not 
have to be painful. A good reflexologist prefers repetition of short and painless seances to a 
single but painful seances for the whole disease. Intensity of the pressure can be low at the 
beginning and increased as the treatment progresses. Each seance takes from 10 minutes to 
30 minutes and it is decided according to the situation of the person how many seance will 
be necessary (Stephenson et al. 2000; Bolsoy 2008). 
It is stated in the literature that  reflexology is used especially for reducing migraine pain, 
back pain, muscle pain, end stage cancer pain and side effects of chemotherapy and to 
increase living quality (Long et al. 2001; McNeill et al. 2006; Mollart 2003; Quattrin et al.2006; 
Wringht et al.2002) In spite of that, it is stated that it is unfavorable to use reflexology in 
acute infections and fever situation, deep venous thrombosis, surgical situations and in 
cases of open scars, malign melanoma and during first trimester of the pregnancy or with 
the patients that has miscarriage or premature birth risks (Long et al. 2001; Lett 2002). 
2.3.2 Herbal treatments  
Herbal medicine is using the chemical materials obtained from inside, root, leave, seed and 
flower parts of the herbs for treatment (Karagöz 2006). Today, most individuals use herbal 
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products in addition to their medical treatments with drugs without consulting to any 
professional (Turan et al. 2010 ; Deng et al. 2005). It is stated in the literature that herbal 
medicine has been commonly used to treat lumbago and back pains (Gray, 2004; Gagnier et 
al. 2006; Hartel & Volger 2004). 
2.3.3 Aromatherapy 
Aromatherapy is using the essential oils that are obtained from flowers, herbs and trees to 
improve health and well being. These oils are applied by being respired through oily gauze 
that is placed under the nostrils of the patient or as massage oils being applied on skin. It 
has been evidenced that the aroma oils reached the lymph system by means of blood 
circulation and provided recovery by means of intercellular fluids (Turan et al. 2010). It is 
thought that aromatherapy may be able to help reducing stress, treating cold, sniffles, skin 
and menstruation problems and relieving pain (Karagöz, 2006; Jennings, 2004; Yldrm et al. 
2006; Deng et al. 2005). It is known that lavender oil is used in treating migraine pain, 
osteoarthritis, rheumatoid arthritis and lumbago. It is also known that eucalyptus, black 
pepper, ginger, daisy, licorice, rosemary and myrrh oils are used in relieving pain. But it is 
stated that lavender oil can cause hypersomnia and using licorice for long time can cause 
hypertension (Delaune & Ladner 2002). Although the usage of aromatherapy within health 
system increases day by day it is seen that the researches in this meaning is quite 
insufficient. Data regarding the efficiency of essential oils depend only on individual 
experiences. For this reason, it is necessary to conduct studies with large samples and high 
level of evidence to determine the efficiency of essential oils in pain management (Snyder & 
Wieland 2003; Tseng 2005) 
2.3.4 Chiropractics  
Chiropractics is the neck-pulling movement used in treatment of the disorders in connective 
tissues and musculoskeletal system which consists of muscles, joints, bones, tendon, 
cartilage and ligaments. The main principle of this approach is the fact that to relieve the 
pain and to improve health with the applications made on spine and joints which have had 
a positive effect on neural system and natural defense mechanisms (Gray, 2004). 
Chiropractics have focused on the connection between body structure and the functions of 
the neural system and manipulation of bones and joints to regain the health. It is known that 
the application that is taken, decreases the amount of burden on the neck and relives the 
pain. However, the individuals who have serious disorders such as severe cervical disc 
hernia, complaints due to rheumatoid arthritis , tumors and infection have to avoid from 
these applications (Turan et al. 2010; Karagöz 2006; Deng et al. 2005). 
2.3.5 Musical therapy  
Many studies that have been conducted have sown that the music had positive effects on 
pain and anxiety and increased the living quality of the patient or healthy individuals. 
Music reduces heart rate, blood pressure, body temperature and respiration rate and it 
distraction the attention of the patient to another point thus reducing the pain perception 
and reducing especially the nausea due to chemotherapy so that increasing living quality of 
patients in terminal period of cancer (Chase, 2003; Hilliard, 2003; Deng et al. 2005; Stefano et 
al. 2004, Uçan & Ovayolu 2007). In a study that states listening to music stimulates the alpha 
waves of brain which have been determined as a stimulator for the release of endorphin and 
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creates a relaxation state and therefore music has played a role not only in relieving the pain 
but also decreasing blood pressure, heartbeat rate and other physiological responses (Henry, 
1995). A point to be taken into consideration here is to let the music type to be prefered by 
the patient (Delaune & Ladner, 2002). New studies show that slow music creates a relaxing 
effect. According to the literature musical therapy should not be used continuously to be an 
effective method. Applying musical therapy form 25 to 90 minutes per day will provide 
sufficient treatment period. 
 




 It may reduce the pain and anxiety 
without having drug-related side effects. 
 It can be used more likely as an adjuvant 
therapy together with other methods. 
It may increase the management feeling of 
the patient. 
 Most of them are not expensive, they do 
not require special equipment and they are 
easily applicable. 
 The patients should be 
aware of using the 
management strategies by 
theirselves. 
 An appropriate time zone 




 It may reduce the pain and anxiety of the 
patients who have pains that are relatively 
difficult to manage.  
 It may increase the number of methods 
that the patient uses to manage. 








 It may reduce muscle spasms, 
inflammation and pain. 
 It can be used more likely as an adjuvant 
therapy together with other methods. 
 It may increase the controlling ability of 
pain feeling of the patient. 
 It is so easy to use. 
 It may be applied by the patients or 
families. 
 It is a cheap method. 
 Hot application can 
increase the bleeding or 
edema after acute injuries. 
 Cold application is 
contraindicate for the 
situations such as 
uritcaria/hypersensitivity, 
hypertension, Reynaud's 
phenomenon and sickle 
cell anemia which are 
related to cold. 
Transcutaneous 
Electrical Nerve 
Stimulation (TENS)  
 It reduces the pain without having any 
drug-related side effects. 
 It can be used more likely as an adjuvant 
therapy together with other methods. 
 It gives the feeling of pain management to 
the patient. 
 It requires an experienced 
therapist. 
 There is a risk for bleeding 
and infection.  
 There are no reliable 
results for use in cases of 
pregnant women. 
Aromatherapy   It has an analgesic effect. 
 It has a sedative and relaxing effect. 
 It may cause hypersomnia. 
 Some herbs should not be 
used with other anti-
depressants and alcohol. 
Acupuncture 
 It may provide pain reduction without any 
side effects. 
 It can be used more likely as an adjuvant 
therapy together with other methods. 
 It requires an experienced 
therapist. 
Table 1. Advantages and Disadvantages of Some Non-pharmacological Methods  
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In a study they conducted, Nilsson et al (2003) have stated that listening to music for one hour 
in earl post-operative period may reduce post-operative pain and morphine consumption of 
the patients. In a study conducted by Sahler and Hunter (2003) with the patients who had bone 
marrow transplantation, the patients were made to listen music which has a relaxing effect, at 
least twice a week for 45 minutes and it has been determined that the group which was not 
included to music therapy has a higher pain score when compared to the one that has received 
musical therapy. It has been stated that the musical also has positive effects during labor 
period. In a study that is conducted by Browning (2000) related to the mother's pain and 
anxiety levels to evaluate the effect of musical therapy applied to primipar mothers before 
delivery, the mothers have stated that the musical therapy relives their pain and it made them 
feel themselves more comfortable and calm.  
Advantages and disadvantages of some non-pharmacological methods used in pain 
management have been specified below (Table 1). 
3. Conclusion 
As a result, the pain can be managed in a more effective manner with the combination of 
pharmacological and non-pharmacological therapies. Developments in pain management 
may provide different opportunities to the patients and their families thus providing the 
patients to carry on a more comfortable and productive life. Both health personnel and 
caregivers need to have important responsibilities while following these developments. For 
an effective care to be provided to patients, developments regarding pain management and 
updated pharmacological and non-pharmacological approaches regarding pain 
management and pain should be followed. Also these techniques may help reducing pain 
and it must be encouraged as a part of the comprehensive pain management efforts. For this 
reason, abilities and preferences of the patient regarding the use of non-pharmacological 
methods should be taken into consideration; it should be underlined for the patients that 
these are used together with medical and pharmacological treatments and the use of non-
pharmacological methods should be included to the care plan when patient is appropriate 
and willing. From this point of view, it is recommended to use various non-pharmacological 
methods for pain management but we need more study results that support the efficiency of 
these methods. For this reason, it will provide the evidence-based results to be put forward 
if randomized controlled experimental studies, which examine the efficiency of these 
methods in taking the pain under control, are conducted.  
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creates a relaxation state and therefore music has played a role not only in relieving the pain 
but also decreasing blood pressure, heartbeat rate and other physiological responses (Henry, 
1995). A point to be taken into consideration here is to let the music type to be prefered by 
the patient (Delaune & Ladner, 2002). New studies show that slow music creates a relaxing 
effect. According to the literature musical therapy should not be used continuously to be an 
effective method. Applying musical therapy form 25 to 90 minutes per day will provide 
sufficient treatment period. 
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In a study they conducted, Nilsson et al (2003) have stated that listening to music for one hour 
in earl post-operative period may reduce post-operative pain and morphine consumption of 
the patients. In a study conducted by Sahler and Hunter (2003) with the patients who had bone 
marrow transplantation, the patients were made to listen music which has a relaxing effect, at 
least twice a week for 45 minutes and it has been determined that the group which was not 
included to music therapy has a higher pain score when compared to the one that has received 
musical therapy. It has been stated that the musical also has positive effects during labor 
period. In a study that is conducted by Browning (2000) related to the mother's pain and 
anxiety levels to evaluate the effect of musical therapy applied to primipar mothers before 
delivery, the mothers have stated that the musical therapy relives their pain and it made them 
feel themselves more comfortable and calm.  
Advantages and disadvantages of some non-pharmacological methods used in pain 
management have been specified below (Table 1). 
3. Conclusion 
As a result, the pain can be managed in a more effective manner with the combination of 
pharmacological and non-pharmacological therapies. Developments in pain management 
may provide different opportunities to the patients and their families thus providing the 
patients to carry on a more comfortable and productive life. Both health personnel and 
caregivers need to have important responsibilities while following these developments. For 
an effective care to be provided to patients, developments regarding pain management and 
updated pharmacological and non-pharmacological approaches regarding pain 
management and pain should be followed. Also these techniques may help reducing pain 
and it must be encouraged as a part of the comprehensive pain management efforts. For this 
reason, abilities and preferences of the patient regarding the use of non-pharmacological 
methods should be taken into consideration; it should be underlined for the patients that 
these are used together with medical and pharmacological treatments and the use of non-
pharmacological methods should be included to the care plan when patient is appropriate 
and willing. From this point of view, it is recommended to use various non-pharmacological 
methods for pain management but we need more study results that support the efficiency of 
these methods. For this reason, it will provide the evidence-based results to be put forward 
if randomized controlled experimental studies, which examine the efficiency of these 
methods in taking the pain under control, are conducted.  
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1. Introduction  
The Western approach to pain management is focused on the use of pharmacotherapy, 
physical therapy, nerve blocks, nerve ablations, implantable devices. Even though 
increasing of understanding of the mechanisms of pain for the treatments; some pains 
remain intractable (Hariharan et al, 2007; Wagner et al, 2007; Laxmaiah et al, 2009). In 
contrast, traditional Chinese medicine (TCM) centres primarily on the energy relationship 
among the environment and the body and organs, without a clear understanding of 
pathophysiology or the mechanisms of diseases and its effects are varied and inconsistent. 
The collateral meridian therapy (CMT), offers an alternative treatment for different types of 
pain by taking a systematic approach to a variant of traditional Chinese acupuncture (TCA). 
Here, we highlight the recent development of CMT by describing the main theory, 
discussing the differences between CMT and TCA, defining abbreviations associated with 
CMT, explaining acupoint localization principles, and providing clinical reports for 
application in pain management.  
2. The theory behind CMT 
To achieve an understanding of CMT, it is necessary to revisit the modality on which it is 
based. In TCA, it is believed that the manipulation of certain points on the skin can affect the 
movement of energy, or “Qi”, throughout the body. It is assumed that “Qi” flows in channels, 
or meridians, along the body, and that good health is maintained through balancing the 
circulation of Qi along these channels. In TCA, there are 12 established meridians. On these 12 
meridians, a total 361 acupoints are located through which the flow of Qi can be manipulated. 
The selection of points for treatment, following the “one-needle effect”, where therapeutic 
effect is obtained from manipulation of one strong acupoint, is based on the nature of the 
disease treated as defined by the five-element theory of TCM, and by a number of personal 
factors. As a result, the treatment for disease is changed on a case-by-case basis. There has no 
standard method; the effectiveness of TCA varies from patient to patient.  
 
Pain Management – Current Issues and Opinions 
 
502 
Simkin, P.P.& O’Hara, M. (2002). Nonpharmacologic relief of pain during labor: systematic 
reviews of five methods, American Journal of Obstetrics and Gynecology, 186 (5 Suppl 
Nature):S131-159; May 2002. 
Sluka, K.A. & Walsh, D. (2003). Transcutaneous Electrical Nevre Stimulation: Basic Science 
Mechanism and Clinical Effectiveness. The Journal of Pain, 4(3): 109-121. Apr 2003. 
Snyder, M. & Wieland, J. (2003). Complementary and alternative therapies: What is their place 
in the management of chronic pain? Nurs Clin North Am. 38(3): 495-508; Sep 2003. 
Stefano, G.B.; Zhu, W.; Cadet, P.; Salamon, E. & Mantione, K.J. (2004). Music alters 
constitutively expressed opiate and cytokine processes in Listeners. Medical Science 
Monitor, 10(6):18-27. 
Stephenson, N.L.N.; Weinrich, S.P. & Tavakoli, A.S. (2000). The Effects of Foot Reflexology 
on Anxiety and Pain in Patients with Breast and Lung Cancer. Oncol Nurs Forum, 
27( 1):67-72. 
Taşç, E. & Sevil, Ü. (2007). Doğum ağrsna yönelik farmakolojik olmayan yaklaşmlar. 
Genel Tp Dergisi, 17(3): 181-186. 
Teyhen, D.S.; Miltenberger, C.E.; Deiters, H.M.; Del Toro, Y.M.; Pulliam, J.N. & Childs, J.D. 
(2005). The use of ultrasound imaging of the abdominal drawing-in maneuver in 
subjects with low back pain. J Orthop Sports Phys Ther, 35(6): 346-355;Jun 2005. 
Tsay, S.L. & Chen, M.L.(2003). Acupressure and quality of sleep in patients with end- stage 
renal disease-a randomized controlled trial. International Journal of Nursing Studies; 
40(1): 1-7; Jan 2003. 
Tsay, S.L. ; Rong, J.R. & Lin, P.F.(2003). Acupoints massage in improving the quality of sleep 
and quality of life in patients with end-stage renal disease. Journal of Advanced 
Nursing; 42 (2): 134-142; April 2003. 
Tseng, Y.H. (2005). Aromatherapy in nursing practice. Hu Li Za Zhi, 52(4):11-5;PMID 
16088776. 
Turan, N.; Öztürk, A. & Kaya, N.(2010).Hemsirelikte Yeni Bir Sorumluluk Alan: Tamamlayc 
Terapi. Maltepe Üniversitesi Hemsirelik Bilim ve Sanat Dergisi, 3(1):.93-98. 
Uçan, Ö. &  Ovayolu, N. (2007).  Kanser ağrsnn kontrolünde kullanlan nonfarmakolojik 
yöntemler. Frat Sağlk Hizmetleri Dergisi, Vol.2 , No:4 , pp.123-131. 
Van der Westhuijzen, A. J.; Becker, P.J.; Morkel, J. &  Roelse, J.A. (2005). A Randomized 
Observer Blind Comparison of Bilateral Facial Ice Pack Therapy with No Ice Therapy 
Following Third Molar Surgery. Int J Oral Maxillofac Surg, 34(3): 281-286; May 2005. 
Van Tulder, M.W.; Furlan A.D. & Gagnier J.J. (2005). Complementary and alternative 
therapies for low back pain. Best Pract Res Clin Rheumatol, 19(4): 639-654; Aug 2005. 
Williams, K.A.; Petronis, J.; Smith, D.; Goodrich, D.; Wu J.; Ravi, N.; Doyle, E.J.; Juckett, G.; 
Kolar, M.M.; Gross, R. & Steinberg, L. (2005).Effect of Iyengar yoga therapy for 
chronic low back pain. Pain;115(1-2):107–17; May 2005 
Wringht, S.; Courtney, U.; Donnelly, C.; Kenny, T.; Lavin, C. (2002). Clients’perceptions of 
the benefits of reflexology on their quality of life. Complementary Therapy in Nursing 
& Midwifery, 8(2): 69-76; May 2002. 
Yavuz, M.(2006). Ağrda Kullanlan Nonfarmakolojik Yöntemler, In: Ağr Doğas ve Kontrolü, 
1st edition ,  F.E.  Aslan (Editor), , Vol.42, pp.135-147., Avrupa Tp Kitapçlk Ltd. 
Şti. Bilim Yaynlar, ISBN: 975-6257-17-2. 
Yldrm, Y.K. (2006).Kanser Ağrsnn Nonfarmakolojik Yöntemlerle Kontrolü, In: Kanser ve 
Palyatif Bakm, In M. Uyar, R. Uslu, YK. Yldrm, (Eds), pp.97-126; Meta Press 
Matbaaclk, İzmir. 
Yldrm, Y.K.; Fadloğlu, Ç.& Uyar, M. (2006). Palyatif Kanser Bakmnda Tamamlayc 
Tedaviler. Ağr, 18(1), 26–32. 
24 
Overview of Collateral  
Meridian Therapy in Pain Management:  
A Modified Formulated Chinese Acupuncture 
Chih-Shung Wong1, Chun-Chang Yeh2 and Shan-Chi Ko3  
1Department of Anaesthesiology, Cathay General Hospital, Taipei,  
2Department of Anaesthesiology, Tri-Service General Hospital, Taipei, 
3Painless Hospital, Ginza, Tokyo, 
1,2Taiwan 
3Japan  
1. Introduction  
The Western approach to pain management is focused on the use of pharmacotherapy, 
physical therapy, nerve blocks, nerve ablations, implantable devices. Even though 
increasing of understanding of the mechanisms of pain for the treatments; some pains 
remain intractable (Hariharan et al, 2007; Wagner et al, 2007; Laxmaiah et al, 2009). In 
contrast, traditional Chinese medicine (TCM) centres primarily on the energy relationship 
among the environment and the body and organs, without a clear understanding of 
pathophysiology or the mechanisms of diseases and its effects are varied and inconsistent. 
The collateral meridian therapy (CMT), offers an alternative treatment for different types of 
pain by taking a systematic approach to a variant of traditional Chinese acupuncture (TCA). 
Here, we highlight the recent development of CMT by describing the main theory, 
discussing the differences between CMT and TCA, defining abbreviations associated with 
CMT, explaining acupoint localization principles, and providing clinical reports for 
application in pain management.  
2. The theory behind CMT 
To achieve an understanding of CMT, it is necessary to revisit the modality on which it is 
based. In TCA, it is believed that the manipulation of certain points on the skin can affect the 
movement of energy, or “Qi”, throughout the body. It is assumed that “Qi” flows in channels, 
or meridians, along the body, and that good health is maintained through balancing the 
circulation of Qi along these channels. In TCA, there are 12 established meridians. On these 12 
meridians, a total 361 acupoints are located through which the flow of Qi can be manipulated. 
The selection of points for treatment, following the “one-needle effect”, where therapeutic 
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In CMT, however, two acuponts are manipulated, instead of one. The meridian lines are the 
same as in TCA, but each meridian has only nice standard acuponits (a total of 108). Two 
acupoints are used for redirection the flow of Qi from one meridian to another. As such, in 
CMT, the points selected for treatment are commonly on non-diseased meridians. CMT also 
follows the use of a standardized set of protocol for treatment, instead of the individual 
varied treatments given in TCA. The two points manipulated are known as control C-point 
and functional F-point. These points are specific to each meridian and allow the flow of Qi 
to be linked from the diseased meridian to a healthy one.  
2.1 Two-point theory: C-point and F-point 
The C-point is used to connect the diseased meridian and the healthy meridian. In 
treatment, practitioners manipulate the healthy meridian to relieve the pain or symptoms. 
Obstructed energy Qi is allowed to flow from the lesion site to the unobstructed healthy 
meridian, through which the disease will be discharged. Each meridian has its own C-point. 
For the location of C-points, please see figures 1 and 2. For the abbreviations and anatomical 
definition of C-points, please see table 1. The C-point is for linking the diseased meridian to 
the treatment meridian, and the F-point is for the treatment of the disease symptom or 
painful location. The F-points in the different regions of the body are shown in figure 3. 
Each region of pain or disease in the body is represented by its own F-point. For instance, if 
the patient had pain in the neck of shoulder, the practitioner should select “a” as an F-point 
for treatment (Fig. 3). If a patient has an acute lumbar strain, the F-point over the lumbar  
L4-5 region would be “4”; the F-point over the lumbar L3-4 region would be “5” (Fig. 3). 
 
 
Fig. 1. The numbers 6, 5, 4, 3, 2, 1 and letters a, b, c are the treatment function points of six 
yin meridians. The blue points indicated control-point of each yin meridian (1, 2, and 1 for 
TxI, TxII, TxIII; b, 2 and a for AxI, AxII, AxIII).  
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Fig. 2. The numbers 6, 5, 4, 3, 2, 1 and letters a, b, c are the treatment function points of six 
yin meridians. The blue points indicated control-point of each yang meridian (3, 2, and 3 for 
both TyI, TyII, TyIII and AyI, AyII, AyIII).  
2.2 Abbreviations in CMT 
The abbreviations used in CMT are defined as follows: “T” represents the upper extremity 
(Te is the pronunciation of “arm” in Japanese); “A” represents the lower extremity (Ashi is 
the pronunciation of “leg” in Japanese); the roman numerals, I, II and III represent the 
meridians on the radial, median and unlar side of the upper extremities, and the meridians 
on the anterior, medial (or lateral), and posterior aspect on the lower extremities, 
respectively. The use of “x” symbolizes the yin aspect, and use of “y” denotes the yang 
aspect of the extremities. Each extremity had nine acupoints in which point a, b and c are 
located on the hand or foot, and point 1 to 6 are located on the arm or leg (Figs. 1 and 2). The 
letters “r” and “l” represent the right and left side of the limb, respectively. For example, 
“lTyI” describes a meridian on the dorsal aspect (y) of the radial side (I) of the left (l) upper 
extremity (T) (see Fig. 8a).  
2.3 How CMT identifies the diseased meridian and formulates a treatment protocol 
For the purpose of simplicity, the symbols “/”, “()” and “.” are used to describe diseased or 
treatment meridians. For example, if the diseased region is over the right wrist 
(corresponding to “a”, Fir. 3) of the TyI meridian, it is represented by rTyI/a. If the 
treatment meridian selected is lTxI/1:a, then constant pressure is applied on the C-point “1’ 
of the lTxI meridian (Fig. 1), while a “remove” manoeuvre at the corresponding “a” point is 
simultaneously performed on the lTxI meridian. The letter “1” before “:” signifies the C-
point of the lTxI meridian, while the letter “a” after “:” expresses the F-point “a”. T denote a 
supplement or enhancement manoeuvre, place “()” around “a” to make the treatment 
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formula lTxI/1:a); otherwise, “a” without “()” represents a removal manoeuvre on point 
“a”. When there is no need to use the C-point, the symbol “0” is used for the treatment 
meridian. Examples of cases where no C-point is used included yin to yin or yang to yang 
meridians for namesake (T-A) links, or for the original meridian manipulation. Therefore, 
the colon symbol “:” is used to differentiate the diseased from the treatment meridian 
because only the presence of an F-point on the diseased meridian is necessary.  
 
 
Fig. 3. This figure indicates specific body regions corresponding to F-points. The unique “d” 
system, different form the ordinary 9-point (6, 5, 4, 3, 2, 1, a, b, c) system on the treatment 
meridians, corresponds to intracranial, perineum and digits. al: the most painful point 
between point-a and point-1 on the treatment meridian, ac: the most painful point between 
point-c and point-b on the treatment meridian. 
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2.4 How CMT links to channel Qi and diverts the body flow in the meridians 
The C-point ensures the link to channel Qi from the diseased meridian to the healthy one. 
Four different types of links are available to channel Qi: 1) Zang-Fu (TA-xy). 2) Exterior-
Interior (x-y), 3) Namesake (T-A), and 4) Original meridian links (Fig. 4). The selection of 
treatment from the diseased meridian is shown in Figure 4. Zang-Fu (TA-xy) is the most 
common link for treatment. For example, if the diseased meridian is AxI, the treatment 
meridian is TyIII (TA-xy link) and vice versa. The determination of the treatment meridian, 
whether ipsilateral or contralateral, is based on the location of the lesion, as shown in Figure 
5. For example, if the diseased meridian is rAyI, the treatment meridian is TxII (according to 
the TA-xy link in Fig. 4). Figure 5 shows that the treatment side for the TxII meridian is 
contralateral side to the diseased meridian; thus the left side is selected as the treatment 
side. Figure 6 illustrates the usage of the C-point to link the diseased meridian (rAyI) to the 
lTxII meridian by the TA-xy link (visceral Znag-Fu link) for treatment, acting as an area of 
energy discharge. By simultaneously manipulating the C-point and the F-point that 
corresponds to the painful site, the pain in rAyI will flow to lTxII, and the pain will be 
removed or reduced by manipulating the functional F-point pressed against the body flow 
direction (yin meridian). Similarly for the lAyIII or rAyIII problem in post-regional 
anesthesia/analgesia backache, the treatment meridian will be chosen as rTxI or lTxI (Yeh et 
al, 2009). Most acupoints are located along the edge of the bony shaft or on the 
tendinomuscular grooves. The accurate localization of the acupoint can be achieved through 
patient reports of soreness or painful sensation when the area is pressed deeply. For detailed 
anatomical localization of acupoints, please refer to 10b, and book by Ko and Chao (2007).  
 
 
Fig. 4. The four types of links used to choose the treatment meridian.  
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Fig. 5. Determination to choose contralateral or ipsilateral side or ipsilateral side of 
treatment meridian. For yin meridians used as the treatment ones to divert the obstructed 
flow, all of them must choose the opposite side to the diseased meridian, except for TxIII. 
On the other hand, for yang meridians used, all must choose the same side as the diseased 
meridian, except for TyI.  
 
 
Fig. 6. Illustratin of the proposed mechanism of pain reduction. 
2.5 Clinical reports for application in pain management  
Case studies have shown the effectiveness of CMT on the treatment of intractable pain 
(Wong et al, 2006). Patients suffering from intricate chronic pain, such as post-herpetic 
neuralgia and complex regional pain syndrome, are responded dramatically to the CMT 
treatment (Wong et al, 2007). Moreover, CMT is also observed effectively on local 
musculoskeletal pain that resulted from such injuries as sprains or strains and demonstrated 
positive effect on shoulder pain relief after laparcoscopic surgery (Yeh et al, 2008). CMT is 
also an effect technique to reduce painful dysmenorrhea (Lin et al, 2010). Moreover, CMT is 
also highly effective in the treatment of post-neuraxial block backache in patients who were 
failed to treated by the conventional treatment (Yeh et al, 2009). Over the post few years, Dr. 
Ko and his team have repeatedly demonstrated positive results of this therapy through 
workshops, courses and pain clinics throughout Japan., Taiwan, Singapore and the United 
States (Hoka et al, 2008). A mini-symposium on CMT was also offered in the 13th World 
Society of Pain Clinicians Congress for the World Institute of Pain Meeting in 2008.  
(x) (y) 
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TCA C-Point Actual anatomical location 
TxI Lung 1 
On the junction of the metaphysis and diaphysis 
over the distal radius. The pressure should be 
applied on the radial side of the flexor carbi 
radialis directly on the bone; pressure to the 
radial artery should be avoided (Fig. 7a). 
TxII Pericardia 2 Approximately three finger breadths proximal to the TxI/a (Fig. 7b). 
TxIII Heart 1 
On the radial depression of the flexor carbi 
ulnaris at the junction of the metaphysis and 
diaphysis over the distal ulna (Fig. 7a). 
AxI Spleen b 
On the tangent line to the plantar-medial 
depression at the junction of the metaphysis and 
diaphysis over the proximal end of first 
metatarsal bone (Fig. 9a, b). 
AxII Liver 2 Approximately 1 cm posterior to the AxI/2 at the same horizontal level as AxI/2 (Fig. 9a). 
AxIII Kidney a On the tangent line to the posterior border of the medial malleolus (Fig. 9a). 
TyI Large Intestine 3 
On the tangent line to the ulnar side of the radius 
at the musculotendinous junction (Fig. 8a). 
TyII Triple Energizer 2 
Between the distal ulna and radius about one-
sixth of the distance above TyII/a toward the 
olecranon (approximately three finger breadths 
proximal to TyII/a) (Fig. 8b). 
TyIII Small Intestine 3 
On the tangent line to the radial border of the 
dorsal ulna at the musculotendinous junction 
(Fig. 8a). 
AyI Stomach 3 
At the same horizontal level as AyIII/3, 
approximately one finger breadth posterior to 
the anterior crest of the tibia (Fig. 10a). 
AyII Gall Bladder 2 
On the tangent line to the anterior border of the 
fibula at the same horizontal level as AyIII/3 
(Fig. 10a). 
AyIII Bladder 3 
First identify the Chinese traditional acupoint 
BL57 (Chengshan), which is in the depression 
below the belly of the gastrocnemius when the 
leg is stretched or the heel is lifted. After 
pressing BL57, find two lines running from it 
lateroinferiorly and medioinferiorly; AyIII/3 
point is at the lateroinferior end on the tangent 
line to the posterior surface of the fibula (Fig. 
10a, b). 
CMT: Collateral Meridian Therapy; TCA: Traditional Chinese Acupuncture 
Table 1. Anatomical location of C-points. 
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Fig. 7. (a) Volar view of upper extremity for localization of acupoints on TxI and TxIII. 
(b) Volar view of upper extremity for localization of acupoints on TxII.  
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Fig. 8. (a) Dorsal view of upper extremity for localization of acupoints on TyI and TyIII. 
(b) Dorsal view of upper extremity for localization of acupoints on TyII.  
 




Fig. 7. (a) Volar view of upper extremity for localization of acupoints on TxI and TxIII. 
(b) Volar view of upper extremity for localization of acupoints on TxII.  
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Fig. 8. (a) Dorsal view of upper extremity for localization of acupoints on TyI and TyIII. 
(b) Dorsal view of upper extremity for localization of acupoints on TyII.  
 




Fig. 9. (a) Medial view of lower extremity for localization of acupoints on AxI and most of 
AxII and AxIII (except for AxII/b AxII/c and AxIII/c). (b) Anterior view of lower extremity 
for localization of on AxI and AxII. The dotted line is extended along the curve of the lower 
border of the medial gastrocnemius belly.  
Overview of Collateral Meridian Therapy in Pain  




Fig. 10. (a) Lateral view of lower extremity for localization of acupoints on AyI, AyII and 
AyIII. (b) Posterior view of lower extremity for localization of acupoints on AyII and AyIII.  
 




Fig. 9. (a) Medial view of lower extremity for localization of acupoints on AxI and most of 
AxII and AxIII (except for AxII/b AxII/c and AxIII/c). (b) Anterior view of lower extremity 
for localization of on AxI and AxII. The dotted line is extended along the curve of the lower 
border of the medial gastrocnemius belly.  
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Fig. 10. (a) Lateral view of lower extremity for localization of acupoints on AyI, AyII and 
AyIII. (b) Posterior view of lower extremity for localization of acupoints on AyII and AyIII.  
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The National Institute of Health consensus, published in 1998, states that acupuncture shows 
effectiveness in the treatment of postoperative and chemotherapy induced nausea and 
vomiting and postoperative dental pain. The statement concludes that acupuncture may be 
useful in other conditions, including myofascial pain, osteoarthritis, low back pain, menstrual 
cramps and so on. In addition, we conducted a MEDLINE search and found that acupuncture 
therapy is also effective for low back pain (LBP) and myofascial pain. From prospective 
randomized controlled trials published in the peer-reviewed medical literature after 1998, we 
summarize the acupoints/meridians use for TCA and CMT in the management of LBP in  
table 2. According to the rules that we have introduced in this article, we can choose the 
corresponding healthy meridian and formats a set of acupoints for the treatment of LBP, 
whereas in TCA, one usually uses the diseased meridian, with different acupoints chosen in 
different reports (Ezzo et al, 2001; Leibing et al, 2002; Meng et al, 2004; Trinh et al, 2007; Wang 
et al, 2008; Yeh et al; 2009). Based on our literature review, patients with LBP received at lease 
short-term pain relief after TCA treatment; the CMT also provides significant pain relief via 
different approach with a standardized formulated protocol. Table 3 shows as summary of 
published CMT clinical reports for different types of pain (Wong et al, 2006; 2007; Hoka, 2008; 
Yeh et al, 2008; 2009, Lin et al, 2010). Furthermore to date, no clinical reports described the use 
of TCA to treat complex regional pain syndrome which patients may not tolerate the direct 
stimulation/acupuncture to the painful area. In contrast, CMT provides a promising technique 
for treating complex regional pain syndrome that can be used without touching the painful 
sites (Wong et al, 2007; Hoka, 2008).  
 
 
Meridian TCM [ref] CMT [ref] 
Governing vessel meridian (+) Wang et al (2008) Leibing et al (2002)  
Urinary bladder meridian (AyIII) 
(+) Wang et al (2008) 
Leibing et al (2002) 
Meng et al (2004) 
Ezzo et al (2001) 
Trinh et al (2007) 
 
Lung meridian (TxI)  (+) Yeh et al (2008) 
Heart meridian (TxIII)  (+) Yeh et al (2008) 
Spleen meridian (AxI) (+) Wang et al (2008) Carlsson & Sjolund (2001)  
Large intestine meridian (TyI) (+) Wang et al (2008)  
TCM: traditional Chinese medicine; CMT: collateral meridian therapy. (+): treatment meridian. 
Number: reference number. 
Table 2. Acupunture points/meridians used for TCM and CMT in the management of low 
back pain and lumbar myofascial pain syndrome 
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Wong et al (2006)  Acute and chronic intractable pain + + 
Lin et al (2010)  Primary dysmenorrhea + – 
Wong et al (2007)  Complex regional pain syndrome + + 
Hoka et al (2008) Complex regional pain syndrome + + 
Yeh et al (2008) Shoulder-tip pain + + 
Yeh et al (2009)  Post-regional anesthesia/analgesia backache + + 
CMT, collateral meridian therapy. +, Yes; –, Not observed 
Table 3. Clinical reports of CMT for pain management 
3. Conclusion 
CMT provides a different approach for managing intractable pain and various illnesses. It 
may play a role in the field of complementary and alternative medicine. The role of CMT in 
pain management looks promising for both acute and chronic pain, even including 
intractable pains, even though published randomized controlled trials are so far lacking. It is 
our hope that future research can focus on methodologically strong randomized controlled 
trials to validate the efficacy of CMT with high evidence level. The purpose of this article is 
to introduce the theory of CMT to interest physicians to achieve a greater awareness and 
understanding of this technique and theory. 
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When Theoretical Knowledge Is Not Enough: 
Introduction of an Explanatory Model  
on Nurse’s Pain Management 
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1. Introduction  
Relieving the suffering of patients is a paramount responsibility for all health professionals. 
The fact that hospitalised patients still suffer from pain despite increasing technology and a 
wealth of research during recent decades, calls for an audit and new approaches in pain 
management. Nurses are professionally responsible for pain assessment and the 
administration of analgesia and are often considered the key persons in the management of 
pain. However, for many reasons nurses are unable to achieve the desired results of pain relief. 
Our study on nurses’ experiences of caring for patients in pain indicates that previous studies 
in this field have often been limited to isolated aspects of pain management (Blondal & 
Halldorsdottir, 2009). Furthermore, they have been rather negative towards nurses. Our 
position is that many researchers have not appreciated the complexity of the nurse’s 
multifaceted assignment of caring for patients in pain. We suggest that knowledge, in this 
respect, may often have been too narrowly defined. We challenge statements that propose that 
nurses do not believe that pain relief is a priority for nurses (Brockopp et al., 1998) or their 
responsibility (Twycross, 2002). Successful pain relief may provide satisfaction for the nurses 
involved (Blondal & Halldorsdottir, 2009), which is a rarely identified outcome  by means of 
professional achievements. Various research results indicate that nurses’ knowledge is less 
than adequate (Howell et al., 2000; Kuuppelomäki; 2002a; Van Niekerk & Martin, 2002). 
Therefore, the main methods that have previously been employed in order to improve nurses’ 
performance and to achieve better pain control are formal education about pain assessment 
and the use of pain medication. Interestingly, programmes that aim at increasing this 
knowledge, however, often fail to help in diminishing patients’ pain. Some programmes may 
demonstrate changes in practice (e.g. Carr, 2002) where other findings are contradictory 
regarding their effectiveness, indicating that the effect of nurses’ re-education is not 
maintained over time (Howell et al., 2000) and that more theoretical knowledge does not 
necessarily correlate with patients reporting less pain (Watt-Watson et al., 2001). Furthermore, 
Wilson’s (2007) survey on nurses’ knowledge of pain also indicates that nurses may be 
incapable of managing pain, despite their knowledge of the existence of the patients’ pain. It is, 
therefore, important to search for other explanations for inadequate pain management of 
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nurses. Therefore, perhaps other patterns of knowledge are needed in addition to the often 
traditional emphasis on formal education about pain assessment and analgesics.  
1.1 Aim of the theory 
Theory is the acknowledged foundation to practise methodology, professional identity and 
the growth of formalized knowledge. Practice must not only be evidence based but also 
theory based. Hence, pain management must be theory based because theories serve as a 
broad framework for practice and may also articulate the goals of a profession and its core 
values. Our aim was to develop a theory, an explanatory model, which can explain nurses’ 
complex task of pain management. 
2. Methodology 
In our evaluation of the various methods for this theory development we found theory 
synthesis as described by Walker and Avant (2004) a good method for constructing our 
explanatory model. They posit that more theory synthesis is needed to advance practice 
disciplines so we found a perfect fit. In the theory synthesis the theorists combine isolated 
pieces of information that may even be theoretically unconnected. Theory synthesis entails 
constructing a theory from study findings and scholarly writings, which may be numerous. 
It enables the theorist to organise and integrate a large number of findings into a single 
theory which can be presented as a model. The theory put forth in this chapter is based on 
11 study findings, e.g. on our own phenomenological study on nurses’ experience of taking 
care of patients in pain and ten other research findings from various researchers about: 
nursing advocacy; moral obligation; organisational barriers; patient based hindrances; and 
the nurse-doctor relationship (see Table 1). All these different studies helped us to clarify the 
manifold task of a nurse’s pain management. This method can be compared with painting a 
picture where in step one the picture is drawn and step two (the literature in this case) is 
used to compare the “picture” drawn with other similar “pictures” for confirmation and 
clarification. In step three the picture is presented (Figure 1). 
3. Findings 
The theory provides a holistic view of the complicated task of relieving pain. The main tenets 
of this theory are: the role of the nurses as the patient’s advocates, multiple patterns of knowledge and 
the doctor-nurse relationship. The theory is introduced in the form of an exploratory model 
which illustrates the main tenets, how they interact and how other aspects simultaneously 
mould nurses’ actions and reactions while taking care of patients in pain (Figure 1).  
3.1 The explanatory model 
To understand and explain the nurses’ central role of caring for patients in pain and their 
potential for providing adequate pain management, their position may be portrayed as that 
of patients’ advocates (Mallik, 1997) within a goal-directed mission aimed at patients’ pain 
relief. In figure 1, this journey is presented in an explanatory model where its main tenets 
have been arranged into a figure with a definite beginning and an end from top to bottom. 
As may be seen from the four central tenets of the model, acting as patient’s advocate, moral 
obligation, formal and tacit knowledge, knowing persons and the system, initially dominate, 
followed by the concepts of internal and external hindrances, as well as potential outcomes. 
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As may be seen from the four central tenets of the model, acting as patient’s advocate, moral 
obligation, formal and tacit knowledge, knowing persons and the system, initially dominate, 
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Fig. 1. An explanatory model of nurses´ pain management 
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The first two concepts we introduce in our explanatory model are moral obligation (Mallik, 
1997; Oberle and Hughes, 2001) and formal and tacit knowledge (Blondal & Halldorsdottir, 
2009; Mallik, 1997; Nash et al., 1999). We propose that on the nurses’ journey to fulfil their 
mission of relieving patients’ pain these two important drives prevail, as illustrated in figure 
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Fig. 2. Nurses’ moral obligation and formal and tacit knowledge 
The nurses’ moral orientation is displayed in accounts like this one: “If the patients report 
pain, then they’re in pain … and of course you must do something about it” (Blondal & 
Halldorsdottir, 2009, p. 4). Possessing formal or theoretical knowledge about pain assessment, 
pain management and medication is of importance but tacit knowledge is no less important, 
as experience and learning from other colleagues creates a sense of self confidence and 
increased empowerment in following their convictions to be the patient’s advocate (Blondal & 
Halldorsdottir, 2009; Mallik, 1997; Nash et al., 1999). “I suppose I believe advocacy is 
utilizing our own clinical knowledge as well as our own knowledge of the patient and 
putting the two of them together and then doing what you feel is best for the patient.” 
(O'Connor & Kelly, 2005, p. 460). This approach assists nurses to keep on advocating and 
relating with patients and doctors (Blondal & Halldorsdottir, 2009).  
3.3 The nurse as the patient’s advocate  
As may be seen from our model, its central tenet portrays the position of the nurse as the 
patient´s advocate (Figure 3). Here, the mission’s journey begins with the nurse’s assessment 
of the patient’s pain, which leads to further decisions and reactions and where the nurse will 
direct his or her responses; what she or he can solve alone and what problems must be  
referred to physicians (Blondal & Halldorsdottir, 2009).  
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3.3.1 Communicating with doctors at the gate/mutual decision-making 
Since medication is often the major pain treatment, and physicians are required to be 
responsible for all drug prescriptions, a crucial element in this process is the nurses’ 
contribution to mutual decision-making with the doctor, where nurses assume the 
responsibility of advocates (Blondal & Halldorsdottir, 2009). At this point, which may be 
referred to as “the gate”, having a voice is pivotal for nurses (Blondal & Halldorsdottir, 2009; 
Van Niekerk and Martin, 2002) because they represent the patient, and by using their 
influence they try to fulfil their mission (Blondal & Halldorsdottir, 2009; Jenks, 1993; 
O'Connor & Kelly, 2005). As two different nurses put it: “Well, unfortunately the decision-
making is not ours. We are restricted to what's ordered… I mean, if the doctor's ordered it, 
you can't very well make a decision” (Nash et al., 1999, p. 186), and further: “I don’t stand 
by and watch the patients and do nothing if I think they are wild with pain, I keep on 
pushing until something is done.” (Blondal & Halldorsdottir, 2009, pp. 5-6). If the nurse and 
the doctor do not reach reciprocal decision or agreement the nurses may have to keep on 
insisting or else give up -- feeling silenced (Malloy, 2009; Blondal & Halldorsdottir, 2009). 
“We don’t have any nal authority – perhaps that’s what’s most difficult…and we have to 
put up with that, naturally, but it’s very important, of course, that we feel we are listened to, 
that our voice is heard.” (Blondal & Halldorsdottir, 2009, p. 2901). Furthermore, to maintain 
trust between all involved, the nurses sometimes take on the role of a mediator or 
intermediary (Blondal & Halldorsdottir, 2009; O'Connor & Kelly, 2005), but the importance 
of co-operation and holding a mutual vision crystallises in this description: “I just think it´s 
lot of give and take between doctors and nursing staff and patients; you´ve got to work 
together to actively relieve pain.” (Nash et al., 1999, p. 185). 
3.4 Facilitating factors for a successful outcome 
The main drives, moral obligation and formal and tacit knowledge may not be enough for 
successful pain management. There are several facilitating factors which are necessary to 
make use of, together with the main drives, in order to achieve a positive outcome of pain 
management (See Figure 4). 
3.4.1 Knowing the patient  
One of the facilitating factors that are important motivating factors for advocacy (Mallik, 
1997), requires that the nurse knows the patient as a person, that is, as an individual, which 
allows the nurse to interpret information and select individualised interventions (Jenks, 
1993). “I think, knowing the patient’s background and seeing more than just, say, a medical 
condition or a surgical wound, that makes you more able to advocate.” (O'Connor & Kelly, 
2005, p. 459).  
3.4.2 Knowing the doctor 
In the explanatory model we propose that to know the gatekeeper, i.e. the doctor, greatly 
influences the nurse’s success  (Jenks, 1993). “Sometimes I think the nurses are underheard if 
you go and you’re telling the doctor, this patient is in pain. This patient is in pain, ah yeah, 
we’ll change this. The patient is still in pain. Sometimes they don’t actually listen to what 
you’re saying. It depends on how you say it, or who you’re actually saying it to.” (Malloy et 
al., 2009, p. 726). Then on the other hand, “It’s a good feeling when you know that someone 
respects your opinion and respects your assessment of the patient also.” (Jenks, 1993, p. 403). 
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3.4.3 Knowing your own self, having self-confidence and conviction 
It is no less important for nurses to know their own potential and believe in themselves, 
since experience creates a sense of self-confidence and increased empowerment in following 
their own convictions. Therefore, individual factors influence nurses’ decisions on pain 
management; “I’m quite happy to make those decisions, because I’m happy to be 
answerable for them…so I do things that I am comfortable with and I feel that I am doing 
the best for the patient.” (Nash et al., 1999, p. 185) 
3.4.4 Knowing the system and access to specialists 
Organizational knowledge, to know how the system works, together with knowledge of the 
wishes of patients, allows nurses to advocate in an effective way; therefore “[A]n advocate 
to me would be somebody who uses whatever knowledge they have in a situation to do 
the best for the patient.” (O'Connor & Kelly, 2005, p. 460). Then having access to a specialist 
in pain management and pain teams within the organisation is of utmost importance as 
they serve as nurses’ guides and help to turn distress into satisfaction (Blondal & 
Halldorsdottir, 2009). 
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3.5 Hindrances to successful pain management 
This journey is complicated, however, by several obstacles that emerge either as internal or 
external obstacles (see figure 5).  
 
 
Fig. 5. Internal and external obstacles 
3.5.1 Internal obstacles  
Internal obstacles that can complicate this process are the nurses’ inner struggle of moral 
dilemma and doubt, of doing right and trusting one’s own judgement, that appear to be the 
result of tension between doubt and duty. Here a prevailing feature includes the fear of 
giving too much medication and caring for addicts (Blondal & Halldorsdottir, 2009; Nash et 
al., 1999). “I felt it [to give pain medication to an addict] was a strain, really, on human 
nature – are you doing something wrong? Or are you doing right? Or are you just cruel to 
refuse to give it to him? – really, what should you do?”(Blondal & Halldorsdottir, 2009, p. 5).  
3.5.2 External obstacles 
External obstacles are connected to organisational structures (Kuuppelomäki, 2002a) such as 
absence of or an inadequate prescription, lack of access to accountable physicians, and the lack 
of directions and clear rules. Moreover, decisions regarding palliative care are imperative for 
successful pain relief (Blondal & Halldorsdottir, 2009; Kuuppelomäki, 2002a); “Accepting 
death and the transition from acute care to terminal care are a problem.” (Kuuppelomäki, 
2002a, p. 706). External hindrances may also be patient related, such as their unwillingness to 
report pain and to accept analgesics (Blondal & Halldorsdottir, 2009; Kuuppelomäki, 2002a), 
which further complicates the assessment of pain and pain relief. ”He was a difficult man and 
so withdrawn. You just couldn’t get through [to] him and you don’t know why not. Cases like 
that make me feel so uncertain, I start to doubt myself.” (De Schepper et al., 1997, p. 424). 
3.6 Coping mechanisms  
Further action can involve the use of various coping mechanisms in order to share the burden, 
seek better solutions for the patient and/or control their feelings (Blondal & Halldorsdottir, 
2009; Nagy, 1999). (See figure 6.) 
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Fig. 6. Coping mechanisms 
The most important factor is support provided by colleagues (De Schepper et al., 1997; 
Nagy, 1999) and specialists in pain management that serve as their guides (Blondal & 
Halldorsdottir, 2009). "The people that we work with. You can go up and say ‘So-and-so, I 
can’t cope with this any longer! Can you either give me a hand or do it for me?’ And people 
where we are working at the moment will do that. So if we’re getting too fed up someone 
else will either help you out or do it for you so you can go and have a rest. They understand 
what it’s like!” (Nagy, 1999, p. 1433). Furthermore, “I get a lot of support from the team 
here. They give me [the] feedback I need and I can have a good moan.” (De Schepper et al., 
1997, p. 426). Assistance can, therefore, like other coping strategies, transform distress into 
satisfaction (Blondal & Halldorsdottir, 2009) which may keep them satisfied despite 
unfavourable outcomes. Some nurses do sidestep the gate by using independent nursing 
interventions, take control and thread the risky road of bypassing the gate by altering the 
medication on their own initiative or bend existing rules and directions (Blondal & 
Halldorsdottir, 2009). But this also may be the result of the distress mentioned above.  
3.7 Potential outcomes 
As suggested by this model, the nurse’s journey has two potential outcomes, based on the 
degree to which nurses are able to fulfil their commitments (see figure 7).  
Successful pain relief leads to nurses’ satisfaction and empowerment and patients’ satisfaction 
and possibly mutual trust (Blondal & Halldorsdottir, 2009). Conversely, pain management is 
burdensome when the patients’ sufferings are not relieved (Nagy, 1999) or the nurses are 
silenced, with consequent dissatisfaction and distress (De Schepper et al., 1997; Oberle and 
Hughes, 2001), disempowerment and possibly mutual distrust. ”I think, really, it’s one of the 
more difficult things one experiences… I was so upset inside… so angry inside, not being 
able to help and not really knowing where to turn, because the doctors said just that [dose of 
medication], and it didn’t work at all, so I was somehow defenceless about what to do.”  
(Blondal & Halldorsdottir, 2009, p. 6). However, importantly, we want to point out that 
perceived discomfort or dissatisfaction with the outcome can serve as a drive for further 
action (Blondal & Halldorsdottir, 2009; Mallik, 1997).  
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From this overview we conclude that theoretical knowledge is only one aspect of nurses’ 
pain management. They require knowledge from various other sources, ethical, personal, 
and aesthetic, as well as many skills, e.g. communication and negotiation skills, in order 
to fulfil their obligations and role. In our view, lack of recognition of these other kinds of 
knowledge may stem from the fact that many studies focus only on isolated aspects of 
pain management. All too commonly the studies provide only a somewhat fragmented 
analysis of isolated factors of pain management. In contrast, the explanatory model 
presented here provides a more holistic view of the nurses’ complex situation when 
caring for patients in pain and may reveal that neglecting these other facets may have 
contributed to the permanent inadequacy in pain management of patients that is so 
widely described.  
4. Discussion 
This explanatory model clarifies how nurses require various coexisting patterns of 
knowledge, within a favourable organisational environment, to be able to perform in accord 
with their role as key persons in pain management and how their performance may predict 
a positive or negative outcome for the patient and the nurse. This model further explains the 
relationships of nurses with patients and physicians where nurses seek to act as patients’ 
advocates and how having a voice is pivotal for nurses. Furthermore, we depict how 
internal and external barriers can hinder the performance of nurses and how an 
unsuccessful outcome that evokes profound distress may concurrently stimulate further 
actions and turn a negative outcome into a more favourable one. This explanatory model of 
a nurse’s journey therefore denotes nurses’ encounters with, and reactions to, the multiple 
demanding assignments they continually meet on their mission towards pain relief. 
4.1 Nurses´ two main drives: Moral obligation and formal and tacit knowledge 
4.1.1 Knowledge of ethical origins 
According to our explanatory model the role of ethical knowledge in pain management must be 
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and to initiate the process of pain management. Our notion of nurses’ obligation to relieve 
pain is supported by several studies (Oberle and Hughes, 2001; O'Connor & Kelly, 2005; 
Rejeh et al., 2009). However, it may have been underestimated up till now because even if 
nurses possess the relevant theoretical knowledge, they may not necessarily make use of it 
without the requisite motivation.  
We want to emphasize that non-professional and professional moral values that motivate and 
direct individuals’ choices can be inculcated through education or socialisation (Omery, 
1989), and nurses recognise that a sense of responsibility in pain management needs to be 
learned (Rejeh et al., 2009). Taylor et al. (1993) also conclude that nurses’ education about 
pain management must include professional ethical obligations and the suitability of their 
professional values. Importantly, moral values may also be generated by an organisation’s 
philosophy statement or policy (Omery, 1989) and moral values should, therefore, be part of 
nursing education as well as organisational statements.  
4.1.2 Formal and tacit knowledge 
In accordance with our propositions, professional responsibility and moral obligation are 
considered key initiates for advocacy. Twycross (2002) posits that in order to advocate, a 
theoretical knowledge base is needed. Vaartio et al. (2006) and O'Connor & Kelly (2005) add 
to this by stating that theoretical as well as practical knowledge of pain management is a 
necessary antecedent of advocacy. Where sound empirical knowledge about pain 
assessment and various methods for management of pain are vital, it must be kept in mind 
that nurses learn no less through experience, where they learn to utilise their own potential 
and personal knowledge through their own practice and role modelling. This drive for 
taking action by using theoretical or formal knowledge along with experience and self-
confidence is congruent with Mallik’s (1997) statement that ‘intervening conditions’ 
facilitate advocacy. These factors have also been found important for nurses’ decision-
making (Nash et al., 1999). Where knowledge of theoretical origins may be the type of 
knowledge that is most easily recognised and is emphasised during formal education at 
school and in continuous education, we stress that the role of tacit knowledge gained 
through experience and role modelling has more rarely been pointed out, perhaps because it 
is rather of personal and aesthetic origins. Importantly, as we see it, this knowledge 
supplements formal knowledge, for instance in the early stages of the process where nurses 
assess the patient’s pain. 
4.2 The nurse as patient’s advocate in pain management  
Patients in pain have been recognised as a vulnerable group of patients that are in need of 
nurses to advocate on their behalf (Ware et al., 2011), and nurses see it as their role to 
safeguard their interests (Blondal & Halldorsdottir, 2009; Ware et al., 2011). As portrayed in 
our explanatory model nurses assume a central role in assessing and managing patients’ 
pain. However, since doctors are responsible for prescribing analgesia, nurses’ concerns 
about pain relief are often affected by their relationship with the doctors (Kuuppelomäki, 
2002a; Taylor et al., 1993; Van Niekerk and Martin, 2002).  
4.2.1 Communicating with doctors at “the gate” and mutual decision-making 
On the nurses’ journey the gate, where they enter these relations with the gatekeeper—the 
doctor, is an important turning point (Blondal & Halldorsdottir, 2009). Having a voice at the 
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and to initiate the process of pain management. Our notion of nurses’ obligation to relieve 
pain is supported by several studies (Oberle and Hughes, 2001; O'Connor & Kelly, 2005; 
Rejeh et al., 2009). However, it may have been underestimated up till now because even if 
nurses possess the relevant theoretical knowledge, they may not necessarily make use of it 
without the requisite motivation.  
We want to emphasize that non-professional and professional moral values that motivate and 
direct individuals’ choices can be inculcated through education or socialisation (Omery, 
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learned (Rejeh et al., 2009). Taylor et al. (1993) also conclude that nurses’ education about 
pain management must include professional ethical obligations and the suitability of their 
professional values. Importantly, moral values may also be generated by an organisation’s 
philosophy statement or policy (Omery, 1989) and moral values should, therefore, be part of 
nursing education as well as organisational statements.  
4.1.2 Formal and tacit knowledge 
In accordance with our propositions, professional responsibility and moral obligation are 
considered key initiates for advocacy. Twycross (2002) posits that in order to advocate, a 
theoretical knowledge base is needed. Vaartio et al. (2006) and O'Connor & Kelly (2005) add 
to this by stating that theoretical as well as practical knowledge of pain management is a 
necessary antecedent of advocacy. Where sound empirical knowledge about pain 
assessment and various methods for management of pain are vital, it must be kept in mind 
that nurses learn no less through experience, where they learn to utilise their own potential 
and personal knowledge through their own practice and role modelling. This drive for 
taking action by using theoretical or formal knowledge along with experience and self-
confidence is congruent with Mallik’s (1997) statement that ‘intervening conditions’ 
facilitate advocacy. These factors have also been found important for nurses’ decision-
making (Nash et al., 1999). Where knowledge of theoretical origins may be the type of 
knowledge that is most easily recognised and is emphasised during formal education at 
school and in continuous education, we stress that the role of tacit knowledge gained 
through experience and role modelling has more rarely been pointed out, perhaps because it 
is rather of personal and aesthetic origins. Importantly, as we see it, this knowledge 
supplements formal knowledge, for instance in the early stages of the process where nurses 
assess the patient’s pain. 
4.2 The nurse as patient’s advocate in pain management  
Patients in pain have been recognised as a vulnerable group of patients that are in need of 
nurses to advocate on their behalf (Ware et al., 2011), and nurses see it as their role to 
safeguard their interests (Blondal & Halldorsdottir, 2009; Ware et al., 2011). As portrayed in 
our explanatory model nurses assume a central role in assessing and managing patients’ 
pain. However, since doctors are responsible for prescribing analgesia, nurses’ concerns 
about pain relief are often affected by their relationship with the doctors (Kuuppelomäki, 
2002a; Taylor et al., 1993; Van Niekerk and Martin, 2002).  
4.2.1 Communicating with doctors at “the gate” and mutual decision-making 
On the nurses’ journey the gate, where they enter these relations with the gatekeeper—the 
doctor, is an important turning point (Blondal & Halldorsdottir, 2009). Having a voice at the 
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gate is pivotal, because there the nurses represent the patient, and by using their influence 
try to fulfil their mission. Subsequently, the doctor decides what medication the patient can 
or cannot receive; i.e. whether the nurses pass through the gate (Blondal & Halldorsdottir, 
2009). Within the gate the nurses can also assume the role of ‘conciliator’ or ‘intermediary’. 
Nurses’ accounts of their advocating position have, therefore, also been described as 
‘bridging the gap’ between the patients and the medical profession. This involves the 
translation of information between patients and doctors and in both directions (O'Connor & 
Kelly, 2005). As we envision it, yet another aspect of personal knowledge is revealed here 
where, inevitably, nurses must communicate with doctors to achieve the best outcome for 
patients.  
Many nurses do not find it difficult to communicate with doctors or to confront them and 
are ready to push boundaries to acquire what the patient needs (Blondal & Halldorsdottir, 
2009; Vaartio et al., 2008; Ware et al., 2011). For others, communicational problems are a 
matter of fact and they feel uncomfortable about trespassing on the doctors´ domain (De 
Schepper et al. 1997; Willson, 2000). Nurses in cancer-related home care, for instance, 
complain about physicians’ lack of knowledge and collaboration, and problems with 
contacting them (Ferrell et al., 1993). Nurses then also describe physicians’ fear of 
overmedicating patients with dementia or delirium in medical wards (Coker et al., 2010). 
Communicational problems cause feelings of powerlessness and distress (Blondal & 
Halldorsdottir, 2009; Malloy et al., 2009) and ethical dilemmas and they are sometimes 
punished for their advocating activities (Clabo, 2008; Mallik, 1997; Malloy et al., 2009). 
Mallik (1997) maintains that to achieve their goals, advocates often play the doctor-nurse 
game of recommending actions without appearing to do so (Stein et al., 1990) or assume the 
attitude of a ‘stubborn rebel’ with an over-determined and even hostile behaviour (Stein et 
al., 1990). In our study, however, the nurses emphasise assertiveness, rather than pushiness, 
for success (Blondal & Halldorsdottir, 2009). When nurses are straightforward in their 
requests, this could be explained by their perceptions of being respected and having a voice, 
and therefore in keeping with Van Niekerk and Martin (2002) that nurses who feel 
adequately consulted by physicians are more likely to initiate the consultation process. The 
use of assertiveness further matches the argument of Keenan et al. (1998) that conveying 
ideas in a forceful and confrontational manner increases the likelihood for successful 
collaboration. We claim that when nurses choose to bypass the gate by bending rules 
(Blondal & Halldorsdottir, 2009; Ware et al., 2011) despite the risk of  jeopardising their 
career, this might indicate a lack of self-confidence, negotiating competence or 
communicational competence skills. For nurses, ethical problems may often be related to 
their hierarchical position, where their voices are not heard or they are being silenced in 
spite of their professional knowledge (Blondal & Halldorsdottir, 2009; Malloy et al., 2009; 
Oberle and Hughes, 2001). From this, it might be understood that the views of nurses and 
doctors are incompatible, for instance because of the different orientation of care versus cure 
(Malloy et al., 2009). However, doctors can also experience an inability to exercise moral 
agency and experience powerlessness, because of hierarchical structures, and they are faced 
with the same kinds of ethical dilemmas as nurses. Furthermore, the obligation to respond is 
the same for all and this difference could rather be explained by different roles and 
responsibilities and unawareness of each others’ responses (Oberle and Hughes, 2001). This 
also may reflect the reality that nurses and doctors act independently, without mutually 
agreed principles or practices rather than as a team in managing pain (Kuuppelomäki, 
2002a). Although this statement is made in regard to end-of-life situations, we conclude that 
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this could also apply to other pain management decisions and call for more discussions 
about the ethical aspects of pain management across professions.  
4.3 Facilitating factors for a successful outcome 
As represented in our explanatory model, facilitating factors for successful advocacy and a 
favourable outcome require knowing persons and the system. Jenks’ (1993) exploration of 
nurses’ clinical decision-making, proposing that clinical decisions depend on the quality and 
dynamics of nurses’ interpersonal relationships is in harmony with our interpretation of the 
process from pain assessment to reaction. However, we also want to add the dimension of 
knowing your own self and the organisation that also are essential facilitating factors. These 
important features that enhance nurses’ possibilities for using their knowledge and moral 
motivation are opposed to the factors that hinder them in making use of their potential, and 
may, to some degree, be used to overcome their negative effects. 
4.3.1 Knowing the patient 
As repeatedly has been pointed out, insufficient pain assessment by nurses interferes with 
successful pain relief (Carr, 2002). According to McCaffery (Pasero et al., 1999, as cited in 
McCaffery, 1968) “[P]ain is whatever the experiencing person says it is, existing whenever 
he says it does” (p. 17). However, because individuals express pain very differently, this 
definition creates some problems for nurses. For instance, although the risk of addiction is 
minor (McCaffery et al., 1990), caring for a patient who is, or is suspected of being, an abuser 
can be very stressful (Blondal & Halldorsdottir, 2009; Nash et al., 1999). Moreover, 
McCaffery and Ferrell (1997) assert that nurses must appreciate that “the only scientific tool 
for measuring pain intensity is the patient’s report using a pain rating scale” (p. 183). These 
scales may, however, be difficult to use with patients that are disoriented (Coker et al., 2010) 
or unconscious (Kuuppelomäki, 2002a) and many nurses are hesitant to use them 
(Schafheutle et al., 2001). Then many elderly patients suffer in silence with their pain and 
discomforts and do not seek help and more effort is required if those with pain are to be 
identified, supported and cared for as Gudmannsdottir & Halldorsdottir (2009) suggest. 
Whereas the use of various pain scales for pain assessment build on theoretical knowledge, 
conversely, knowing the patient as a person can greatly assist nurses to assess the patient’s 
pain (Blondal and Halldorsdottir, 2009); this approach is more related to personal and 
aesthetic knowledge. Knowing the patient as a person strongly facilitates the assessment of 
patients’ needs and clinical decision-making (Liaschenko, 1997), and allows nurses to 
interpret information and select individualised interventions (Takman and Severinsson, 
1999). Furthermore, the nurse-patient relationship is a motivating factor for advocacy 
(Mallik, 1997; O'Connor & Kelly, 2005) and analysing the patient and the situation is a 
fundamental element of advocacy (Vaartio et al., 2008). Therefore, we suggest that more 
emphasis is given to this special aspect of pain management. Still, yet another pattern of 
knowledge may also be needed here; unknowing the patient. When nurses admit to 
themselves that they do not know the patient and his or her point of view, it allows them to 
hold their former biases and prejudices in abeyance (Munhall, 1993). We suggest that 
assuming this type of knowledge is of utmost importance as it may prevent nurses from 
making assumptions about patients´ pain intensity that is based on diagnosis and course of 
treatment (Clabo, 2008; Manias, 2003; Schafheutle et al., 2001) that is associated with 
underestimation of pain (Sjöström et al., 2000), and a barrier to effective pain relief 
(Schafheutle et al., 2001). Adopting this stance of unknowing could also avoid the 
 
Pain Management – Current Issues and Opinions 530 
gate is pivotal, because there the nurses represent the patient, and by using their influence 
try to fulfil their mission. Subsequently, the doctor decides what medication the patient can 
or cannot receive; i.e. whether the nurses pass through the gate (Blondal & Halldorsdottir, 
2009). Within the gate the nurses can also assume the role of ‘conciliator’ or ‘intermediary’. 
Nurses’ accounts of their advocating position have, therefore, also been described as 
‘bridging the gap’ between the patients and the medical profession. This involves the 
translation of information between patients and doctors and in both directions (O'Connor & 
Kelly, 2005). As we envision it, yet another aspect of personal knowledge is revealed here 
where, inevitably, nurses must communicate with doctors to achieve the best outcome for 
patients.  
Many nurses do not find it difficult to communicate with doctors or to confront them and 
are ready to push boundaries to acquire what the patient needs (Blondal & Halldorsdottir, 
2009; Vaartio et al., 2008; Ware et al., 2011). For others, communicational problems are a 
matter of fact and they feel uncomfortable about trespassing on the doctors´ domain (De 
Schepper et al. 1997; Willson, 2000). Nurses in cancer-related home care, for instance, 
complain about physicians’ lack of knowledge and collaboration, and problems with 
contacting them (Ferrell et al., 1993). Nurses then also describe physicians’ fear of 
overmedicating patients with dementia or delirium in medical wards (Coker et al., 2010). 
Communicational problems cause feelings of powerlessness and distress (Blondal & 
Halldorsdottir, 2009; Malloy et al., 2009) and ethical dilemmas and they are sometimes 
punished for their advocating activities (Clabo, 2008; Mallik, 1997; Malloy et al., 2009). 
Mallik (1997) maintains that to achieve their goals, advocates often play the doctor-nurse 
game of recommending actions without appearing to do so (Stein et al., 1990) or assume the 
attitude of a ‘stubborn rebel’ with an over-determined and even hostile behaviour (Stein et 
al., 1990). In our study, however, the nurses emphasise assertiveness, rather than pushiness, 
for success (Blondal & Halldorsdottir, 2009). When nurses are straightforward in their 
requests, this could be explained by their perceptions of being respected and having a voice, 
and therefore in keeping with Van Niekerk and Martin (2002) that nurses who feel 
adequately consulted by physicians are more likely to initiate the consultation process. The 
use of assertiveness further matches the argument of Keenan et al. (1998) that conveying 
ideas in a forceful and confrontational manner increases the likelihood for successful 
collaboration. We claim that when nurses choose to bypass the gate by bending rules 
(Blondal & Halldorsdottir, 2009; Ware et al., 2011) despite the risk of  jeopardising their 
career, this might indicate a lack of self-confidence, negotiating competence or 
communicational competence skills. For nurses, ethical problems may often be related to 
their hierarchical position, where their voices are not heard or they are being silenced in 
spite of their professional knowledge (Blondal & Halldorsdottir, 2009; Malloy et al., 2009; 
Oberle and Hughes, 2001). From this, it might be understood that the views of nurses and 
doctors are incompatible, for instance because of the different orientation of care versus cure 
(Malloy et al., 2009). However, doctors can also experience an inability to exercise moral 
agency and experience powerlessness, because of hierarchical structures, and they are faced 
with the same kinds of ethical dilemmas as nurses. Furthermore, the obligation to respond is 
the same for all and this difference could rather be explained by different roles and 
responsibilities and unawareness of each others’ responses (Oberle and Hughes, 2001). This 
also may reflect the reality that nurses and doctors act independently, without mutually 
agreed principles or practices rather than as a team in managing pain (Kuuppelomäki, 
2002a). Although this statement is made in regard to end-of-life situations, we conclude that 
When Theoretical Knowledge Is Not Enough:  
Introduction of an Explanatory Model on Nurse’s Pain Management 531 
this could also apply to other pain management decisions and call for more discussions 
about the ethical aspects of pain management across professions.  
4.3 Facilitating factors for a successful outcome 
As represented in our explanatory model, facilitating factors for successful advocacy and a 
favourable outcome require knowing persons and the system. Jenks’ (1993) exploration of 
nurses’ clinical decision-making, proposing that clinical decisions depend on the quality and 
dynamics of nurses’ interpersonal relationships is in harmony with our interpretation of the 
process from pain assessment to reaction. However, we also want to add the dimension of 
knowing your own self and the organisation that also are essential facilitating factors. These 
important features that enhance nurses’ possibilities for using their knowledge and moral 
motivation are opposed to the factors that hinder them in making use of their potential, and 
may, to some degree, be used to overcome their negative effects. 
4.3.1 Knowing the patient 
As repeatedly has been pointed out, insufficient pain assessment by nurses interferes with 
successful pain relief (Carr, 2002). According to McCaffery (Pasero et al., 1999, as cited in 
McCaffery, 1968) “[P]ain is whatever the experiencing person says it is, existing whenever 
he says it does” (p. 17). However, because individuals express pain very differently, this 
definition creates some problems for nurses. For instance, although the risk of addiction is 
minor (McCaffery et al., 1990), caring for a patient who is, or is suspected of being, an abuser 
can be very stressful (Blondal & Halldorsdottir, 2009; Nash et al., 1999). Moreover, 
McCaffery and Ferrell (1997) assert that nurses must appreciate that “the only scientific tool 
for measuring pain intensity is the patient’s report using a pain rating scale” (p. 183). These 
scales may, however, be difficult to use with patients that are disoriented (Coker et al., 2010) 
or unconscious (Kuuppelomäki, 2002a) and many nurses are hesitant to use them 
(Schafheutle et al., 2001). Then many elderly patients suffer in silence with their pain and 
discomforts and do not seek help and more effort is required if those with pain are to be 
identified, supported and cared for as Gudmannsdottir & Halldorsdottir (2009) suggest. 
Whereas the use of various pain scales for pain assessment build on theoretical knowledge, 
conversely, knowing the patient as a person can greatly assist nurses to assess the patient’s 
pain (Blondal and Halldorsdottir, 2009); this approach is more related to personal and 
aesthetic knowledge. Knowing the patient as a person strongly facilitates the assessment of 
patients’ needs and clinical decision-making (Liaschenko, 1997), and allows nurses to 
interpret information and select individualised interventions (Takman and Severinsson, 
1999). Furthermore, the nurse-patient relationship is a motivating factor for advocacy 
(Mallik, 1997; O'Connor & Kelly, 2005) and analysing the patient and the situation is a 
fundamental element of advocacy (Vaartio et al., 2008). Therefore, we suggest that more 
emphasis is given to this special aspect of pain management. Still, yet another pattern of 
knowledge may also be needed here; unknowing the patient. When nurses admit to 
themselves that they do not know the patient and his or her point of view, it allows them to 
hold their former biases and prejudices in abeyance (Munhall, 1993). We suggest that 
assuming this type of knowledge is of utmost importance as it may prevent nurses from 
making assumptions about patients´ pain intensity that is based on diagnosis and course of 
treatment (Clabo, 2008; Manias, 2003; Schafheutle et al., 2001) that is associated with 
underestimation of pain (Sjöström et al., 2000), and a barrier to effective pain relief 
(Schafheutle et al., 2001). Adopting this stance of unknowing could also avoid the 
 
Pain Management – Current Issues and Opinions 532 
stereotyping of patients, such as those who may be addicts, homeless or prisoners (Rejeh et 
al., 2009) or with a lifestyle that may affect nurses’ pain management behaviours (Wilson, 
2007). Therefore, we advise that strategies nurses use to connect to patients which may be 
based on personal knowledge (Carper, 1978) and unknowing (Munhall, 1993) are 
highlighted along with the current emphasis on using pain rating scales (e.g. Paice and 
Cohen, 1997).  
According to our model, competent communication with patients may be a powerful way to 
overcome internal hindrances in addition to theoretical knowledge about pain assessment, 
addiction, respiratory depression and other possible side effects of pain medication that also 
may stem from the ethical orientation of preventing harm to the patients. When nurses’ 
emphasise individualised pain management, knowing the patient as a person, recognising 
his/her special needs and responding to these needs on the basis of envisioned results, 
portrays the importance of aesthetic knowledge and comprehension of the particularity of 
the situation (Carper, 1978). Empathy is also an important component mode of the aesthetic 
pattern in nursing (Carper, 1978), and apparent in nurses’ accounts of pain management 
(Blondal & Halldorsdottir, 2009; Rejeh et al., 2009) and should be not only acknowledged 
but utilised more often. 
4.3.2 Knowing the doctor 
Since nurses call for equality, mutual decision-making and respect for their judgement 
(Blondal & Halldorsdottir, 2009), knowing the doctor is a factor worth further exploration. 
In accordance with our explanatory model Jenks (1993) maintains that knowing the doctor 
creates mutual trust in each others’ perceptions. Therefore, a good nurse-physician 
relationship, in accordance with our metaphor of nurses passing through the gate, knowing 
the gatekeeper may add to optimal pain relief and consequently affects nurses’ and patients’ 
wellbeing. It is, therefore, imperative that both doctors and nurses be aware of the need for 
good rapport and be knowledgeable about good communication techniques and that both 
groups of professionals make every effort to encourage collaboration and to find ways to get 
to know each other as persons. Again, we propose that personal knowledge and 
communicational skills that nurses must use in relations with patients and doctors is vital 
because, as before, possessing theoretical knowledge and the motivation to use it (moral 
orientation) may become of little use if not employed because of lack of communication or 
negotiating abilities or lack of self-confidence or if nurses cannot react because their voice is 
silenced. Therefore, nurses must be taught to act as the patients’ advocates, represent 
themselves and act like the patients’ representative.  
4.3.3 Knowing oneself, having self-confidence and conviction 
We further want to draw attention to how nurses’ awareness of their feelings such as 
distress and empathy, recognition of their own capabilities, self-confidence and persistence 
may be important facilitating factors. As mentioned before, motivational factors such as 
experience and self-confidence are congruent with Mallik’s (1997) ‘intervening conditions’ 
that facilitate advocacy and are  important for nurses’ decision-making (Nash et al., 1999). 
As further discussed later, emotional responses such as anger and frustration are also potent 
motivators for advocacy (Mallik, 1997). Such knowledge is of both personal and aesthetical 
origins and nurses must learn to identify and accept such feelings and be empowered to use 
them to be capable of following their convictions, both for their own sakes and for the good 
of the patient. According to our model, nurses that hold such knowledge and believe in 
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themselves are more capable of entering into and coping positively with difficult relations 
with others —patients, families and doctors, and are more likely to gain what is needed for a 
positive outcome both for the patients and themselves.  
4.3.4 Knowing the system 
Yet another facet that is worth more consideration is nurses´ knowledge of the organisation. 
Knowing the system and the environment is part of nurses’ advocacy, for instance when 
nurses must mediate between the patient and the system through interpretation of medical 
terminology or advocating for a group of patients (O´Connor et al., 2005). It also seems 
necessary to recognise what options or resources are available within the organisation, for 
instance whom to turn to for assistance. Here, the support of professionals — specialists in 
pain management within organisations, must be present at all times to assist them in dealing 
with difficult cases (Blondal and Halldorsdottir, 2009; Nash et al., 1999). Moreover, nurses 
must recognise the availability of specialists and when they should be contacted and involved.  
4.4 Hindrances for successful pain management 
As the model portrays, some inhibiting factors hinder nurses´ potentials for taking action 
and therefore interfere with their drives, moral obligation, and formal and tacit knowledge. 
It may also be seen that these factors are somewhat in opposition to the facilitating factors. 
The main obstacles are grouped as external — originating in the nurses´ environment, or 
internal — concerned with inner doubts or dilemmas. This gives an example of how these 
model elements are interconnected and should not be taken out of the immediate context. 
4.4.1 Internal hindrances 
As previously mentioned, nurses´ moral motivation is complicated by some dilemmas as the 
nurses encounter variable decisional and ethical conflicts (Taylor et al. 1993) that directly 
affect the pain management process and its outcome. The dilemma of inflicting pain to serve 
other goals of treatment (De Schepper, 1997; Willson, 2000), fear of giving too much pain 
medication because of respiratory depression (Ferrell et al., 1991; Howell et al., 2000; Wilson, 
2007), sedation (Howell et al., 2000), fear of the addictive properties of narcotics (Brockopp 
et al., 1998), and doubt whether the pain is real (Nash, 1999; Rejeh et al., 2009) has repeatedly 
been described. So are the difficulties of distinguishing between physical pain and 
psychological distress (Kuuppellomäki, 2002a), patients’ non-compliance in accepting 
analgesia (Kuuppellomäki, 2002a), patients’ reticence (De Schepper et al 1997; Rejeh et al., 
2009) and nurses’ concerns about giving a dying person the last dose (Brockopp et al., 1998), 
as for some, hastening death through pain relief is morally unacceptable (O’Rourke, 1992). 
Ethical problems may also arise from a lack of permission to be honest with patients (Rejeh 
et al., 2009) or because of the attitudes of family members towards pain medication 
(Kuuppelomäki, 2002a). Nurses also frequently describe how difficult it is for them to care 
for patients that are known abusers or suspected of being addicts, and believing their words 
(Blondal & Halldorsdottir, 2009; Nash et al., 1999; Rejeh et al., 2009). Dilemmas may also be 
caused by preconceived notions about certain groups of patients that negatively interfere 
with nurses’ decision-making (Brockopp et al., 2003). Interestingly, Van Niekerk and Martin 
(2002) point out that nurses with greater knowledge of pain assessment are less likely to 
experience ethical conflicts regarding overmedication, addiction or doubt about the 
existence of pain. Hence, more knowledge could prevent such ethical conflicts. Accounts 
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stereotyping of patients, such as those who may be addicts, homeless or prisoners (Rejeh et 
al., 2009) or with a lifestyle that may affect nurses’ pain management behaviours (Wilson, 
2007). Therefore, we advise that strategies nurses use to connect to patients which may be 
based on personal knowledge (Carper, 1978) and unknowing (Munhall, 1993) are 
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Cohen, 1997).  
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groups of professionals make every effort to encourage collaboration and to find ways to get 
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experience and self-confidence are congruent with Mallik’s (1997) ‘intervening conditions’ 
that facilitate advocacy and are  important for nurses’ decision-making (Nash et al., 1999). 
As further discussed later, emotional responses such as anger and frustration are also potent 
motivators for advocacy (Mallik, 1997). Such knowledge is of both personal and aesthetical 
origins and nurses must learn to identify and accept such feelings and be empowered to use 
them to be capable of following their convictions, both for their own sakes and for the good 
of the patient. According to our model, nurses that hold such knowledge and believe in 
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as for some, hastening death through pain relief is morally unacceptable (O’Rourke, 1992). 
Ethical problems may also arise from a lack of permission to be honest with patients (Rejeh 
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like this further sustain our claims about how the separate parts introduced in our model are 
interconnected and cannot be separated from the complete picture. 
4.4.2 External obstacles 
Organisational barriers have formerly been extensively described, where lack of time, 
workload (Ware et al., 2011; Rejeh et al., 2009) financial restraints and staffing cutbacks 
(Oberle and Hughes, 2001; Rejeh et al., 2009), restraints of routine (Willson, 2000), 
insufficient prescribing of analgesics (Schafheutle et al., 2001; Kuuppelomäki, 2002a) 
based on habits instead of individualised needs (Boer et al, 1997), and unavailability of 
physicians (Kuuppelomäki, 2002a; Rejeh et al., 2009) interfere with pain relief. Other 
related hindrances that are part of the system have also been identified such as 
unavailable non-pharmacological pain relief measures and disorganised systems of care 
(Coker et al., 2010). Rejeh et al. (2009) also point out that defective equipment and 
interruptions can lead to ethical problems in pain management. The importance of a 
decision on palliative care for good pain relief is endorsed by Kuuppelomäki (2002b) who 
reports physicians’ hesitancy about starting terminal care, and delayed decisions of using 
a strong analgesia (Kuuppelomäki, 2002a). The organisation must, therefore, provide an 
optimal organisational environment since organisational barriers such as unclear rules, lack 
of prescriptions or time and resources such as specialised pain services, may hinder 
nurses from acting according to their best knowledge, potential and goals. The presence of 
prescriptions, rules and directives are important to be able to give the patient what she or 
he needs. Inflexible protocols and strict policies or routines, on the other hand, impede 
good pain management (Rajeh et al., 2009; Willson, 2000) resulting in the nurses giving up 
and leaving them feeling silenced and disempowered (Blondal & Halldorsdottir, 2009; 
Malloy et al., 2009). Alternatively, nurses may feel compelled to choose to bypass the gate, 
by bending rules (Blondal & Halldorsdottir, 2009; Ware et al., 2011), to obtain favourable 
results for the patient, as is portrayed in our model. Our emphasis on organisational 
structures is supported by the results of Willson’s (2000) participant observation study on 
factors affecting analgesia administration; Willson suggests that because of the interplay 
between multiple organisational and interpersonal features, more education of the nurses 
will not necessarily improve the administration of analgesics.  
4.5 Coping mechanisms 
How nurses cope with their challenges predicts to some extent how they perceive the 
outcome of pain relief and they seem to use various methods to cope and protect 
themselves. Applying methods such as concentrating on patients’ positive attributes is a 
component of strategies that prevent burnout (Simoni and Paterson, 1997), and sharing 
feelings with colleagues (De Schepper et al., 1997; Nagy, 1999) and having the opportunity 
to stand back from situations (De Schepper et al., 1997; Rejeh et al., 2009) are consistent with 
strategies that reduce powerlessness (De Schepper et al., 1997). Seeking and receiving 
support from pain teams and specialists in pain management is vital, and such assistance 
can transform distress into satisfaction. Ironically, those who accept the responsibility as 
seeing to pain relief run the risk of experiencing ethical problems which may lead to a sense 
of loss of control and subsequently burnout, resulting in decreased quality of care (Schmitz 
et al., 2000). If nurses give up their advocating efforts and instead assume coping methods 
such as avoidance, which indicates unsuccessful coping (Simoni and Paterson, 1997), it may 
desensitise them to patients’ needs (Nagy’s, 1999), which means in turn that they may not be 
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willing or able to attend to patients’ suffering. Such strategies should, therefore, be detected, 
and those nurses helped to adopt more constructive coping strategies.  
4.6 Potential outcomes of pain management and advocacy 
Effective pain relief may provide satisfaction, both by means of professional achievements 
and benefits for the patient and the nurse (Blondal & Halldorsdottir, 2009; De Schepper et al. 
1997; Vaartio et al., 2008). However, such positive outcomes are seldom mentioned. We 
believe that this aspect should receive more attention and nurses should be enabled to reap 
satisfaction from overcoming challenges and learning from them. As successful pain relief 
may enhance autonomy and a sense of empowerment, this is relevant to both quality of pain 
management and job satisfaction. Conversely, much more attention is given to the negative 
aspects: dissatisfaction, distress and frustration (e.g. Nagy, 1998; Söderhamn and Idvall, 
2003) following insufficient or unsuccessful pain management that leads in turn to nurses’ 
suffering and disempowerment (Blondal & Halldorsdottir, 2009; Oberle and Hughes, 2001). 
4.6.1 Dissatisfaction and distress as motivators for a successful outcome 
Since dissatisfaction and nurses´ distress may be the inevitable results of nurses‘ inability to 
ease the patients’ pain, for instance because of silencing or lack of resources, it is important 
to note that nurses’ distress can impel further actions. This is in agreement with Mallik’s 
(1997) argument that emotional responses of anger and frustration can be potent motivators 
for advocacy. It, therefore, seems important that nurses accept and recognise such feelings, 
not least because those who acknowledge and try to deal with feelings of powerlessness are 
more capable of coping (De Schepper et al., 1997). All these responses require, once again, 
both personal and aesthetic knowledge where nurses as individuals must learn to know 
themselves and their reactions and be able to develop and maintain a view of what they 
want to achieve with their actions. Here we come back to earlier discussion about nurses’ 
requirements of knowing their own “selves”, their own feelings and capabilities. 
5. Further development of this theory 
Theory provides a more complete picture of practice than factual knowledge alone, and 
theories formulate, identify, and articulate the science and practice of every discipline 
(Butcher, 2006). Nursing scholars need to identify and articulate the processes and 
components of the art and science of pain management. This theory is an attempt to do so in 
an endeavour to continue the discipline’s development by assisting in the understanding 
and practice of creating further theoretical discourse, processes and products for pain 
management, similar to what Kagan (2006) has described. All theories are reconstructed in 
the light of new data. The theory presented here is, therefore, seen as always being in the 
process of emerging, as is our world view. According to Walker and Avant (2004), the next 
steps in the phases of our theory development are: theory testing involving concept revision, 
statement revision, and theory revision, followed by further theory testing. We encourage 
our colleagues to critique the theory and use it to generate research questions and take part 
in testing the theory as well as in concept, statement and theory revision. 
6. Implications for practice and future research 
From our explanatory model many suggestions can be made about how to contribute to 
changes in the education of nurses, their work environment and future research. 
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structures is supported by the results of Willson’s (2000) participant observation study on 
factors affecting analgesia administration; Willson suggests that because of the interplay 
between multiple organisational and interpersonal features, more education of the nurses 
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feelings with colleagues (De Schepper et al., 1997; Nagy, 1999) and having the opportunity 
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seeing to pain relief run the risk of experiencing ethical problems which may lead to a sense 
of loss of control and subsequently burnout, resulting in decreased quality of care (Schmitz 
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Theory provides a more complete picture of practice than factual knowledge alone, and 
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(Butcher, 2006). Nursing scholars need to identify and articulate the processes and 
components of the art and science of pain management. This theory is an attempt to do so in 
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and practice of creating further theoretical discourse, processes and products for pain 
management, similar to what Kagan (2006) has described. All theories are reconstructed in 
the light of new data. The theory presented here is, therefore, seen as always being in the 
process of emerging, as is our world view. According to Walker and Avant (2004), the next 
steps in the phases of our theory development are: theory testing involving concept revision, 
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our colleagues to critique the theory and use it to generate research questions and take part 
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6. Implications for practice and future research 
From our explanatory model many suggestions can be made about how to contribute to 
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6.1 Nurses’ knowledge and formal education  
Firstly, we propose that alterations should be made within nurses’ basic education at 
school and continuous education at the institutional level. Nurses’ formal education at 
school must include extensive knowledge about pain assessment and pain management 
and it is also necessary that courses are offered regularly within all health care settings on 
pain assessment, analgesia, adverse reactions, and respiratory depression. However, in 
addition to the traditional emphasis on the use of pain scales for the assessment of 
patients’ pain, it is also important to emphasise personal and aesthetic knowledge that 
contains strategies that contribute to knowing and involving the patient, and nurses’ 
availability. Then education about the pain management of dying patients, addiction and 
prejudices must also be increased, both at schools and within organisations. The ethical 
aspects of pain management should be included in all courses along with empirical 
knowledge and should contain discussions about moral responsibility, bioethical 
principles, nurses’ professional code of conduct and the Patients’ Rights Act together with 
religious discussions about pain management. Furthermore, despite differences in 
educational programmes and the cultures of nurses and doctors, these professions must 
reach a mutual understanding to achieve suitable and consistent care for their patients 
(Malloy et al., 2009). One method to bring together their views could, therefore, be to 
organise courses that these professionals attend together. That said, as nurses’ 
socialisation occurs to a great extent during their nursing education (Stein et al., 1990), 
nursing students should be taught to make claims for mutual decision-making, to 
recognise their own potential, and be empowered to make claims for resources and 
improvements. As many nurses may lack the vocabulary for ethical decision-making, thus 
contributing to the silenced voices of nurses (Malloy et al., 2009), advocating competence 
should be taught at school. Moreover, they should be prepared for the need for 
negotiation, assertiveness, and effective communication. It is necessary that nurses are 
encouraged to reflect on their experience both as nurse students and as practicing nurses 
and also to establish positive working relationship with doctors. Moreover, since nurses 
seem to learn strategies such as self-confidence through role modelling we emphasize that 
during their nursing education and as novice nurses they should have access to role 
models for guidance that relate to their use of personal and aesthetic knowledge. During 
courses about pain management nurses’ coping methods should be addressed, and they 
should be taught to recognise destructive methods and adopt more constructive ones. The 
method of structured reflection (Johns, 1995), for instance, could be used to assist nurses in 
learning about their own abilities and responses. However, not only should negative 
aspects of their practice or difficult cases be inspected, but also the positive ones. 
6.2 Organisational environment  
Firstly, it is imperative that pain relief is highlighted within all health care settings and 
organisational nursing policies or visions for nursing, which must reflect this important 
aspect of care. It should be stressed that pain management is a priority and recognised 
that time and adequate resources are important aspects of pain management. Protocols 
that exemplify the responsibility of each member of the health care team should exist, but 
all rules that are created should also be flexible; for instance nurses must be enabled to 
choose an analgesic from a range of individualised prescriptions. It also seems vital that 
clear directives exist for the pain relief of addicts and access to support from specialists in 
the management of this group of patients available at all times. Support from specialists in 
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pain management and psychological support at all times are also fundamental. Moreover, 
the opportunity to discuss difficult cases with philosophers or leaders from different 
faiths and denominations should be provided in every health care setting. Subsequently, 
conversations about nurses’ ethical responsibilities and dilemmas should be offered and 
should be open for both nurses and doctors. As pain assessment is partly dependent on 
positive nurse-patient relationships and knowing the patient as a person, nursing models 
and interventions that encourage such relations should be introduced and supported. 
Another aspect of organisational culture that may enhance successful pain management is 
good collaboration and maintenance of trust between nurses and in the nurse-physician 
relationships. All efforts that strengthen dialogue and a culture that enables nurses to seek 
support and advice from colleagues and encourages open discussions about feelings and 
coping may therefore have positive outcomes in this respect. Lastly, an atmosphere of 
persistence and seeking the best available solution should be supported.  
6.3 Future research 
The explanatory model can be a great source of ideas for future research. Firstly, a 
quantitative study could be conducted, to assess nurses’ level of empirical, aesthetic and 
ethical knowledge along with personal knowledge regarding pain relief; including 
communication, collaboration and coping. Secondly, it would be interesting to explore the 
ethical component of the nursing and medical curricula and further to investigate to what 
extent nurses and doctors are guided by moral values in their pain relief at work. Thirdly, 
studies on how nurses’ moral orientation is balanced with the effectiveness of the pain 
relief they provide could also be conducted. Fourthly, it seems necessary to conduct more 
studies where the communication of nurses and doctors connected with pain 
management is explored, for instance by using an ethnographic approach. Fifthly, it 
seems important to run more field studies within each organization to identify the main 
obstructions for effective pain management. It seems vital to begin with identifying what 
hindrances are most prominent before embarking on a campaign for better pain 
management within organisations. A part of these studies could be to inspect the effects 
of workload, lack of time and constraining directives on nurses’ potentials for providing 
optimal pain relief. 
7. Conclusion  
Our explanatory model is at odds with statements proposing that pain relief is not the 
nurses’ priority (Brockopp et al., 1998) or their responsibility (Twycross, 2002). We assert, 
however, that various reasons inhibit the nurses’ potential for taking action. We conclude 
that nurses are the patients´ advocates in pain management and successful pain 
management is rewarded with a sense of satisfaction, empowerment and fulfilment of 
their duty. They are in a key position to assess and manage pain and their mediatory 
position within the hospital is unique. It is vital that nurses are adequately prepared for 
their role educationally by possessing multidimensional knowledge about pain 
management. We assert that good theoretical knowledge may be inadequate if the nurse 
does not have the right motivation, i.e. the moral inclination to use it in practice. 
Furthermore, personal knowledge that nurses must use in relations with patients and 
doctors is also necessary because theoretical knowledge alone may be of little use if it 
cannot be employed because of lack of communication or negotiation competence or 
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educational programmes and the cultures of nurses and doctors, these professions must 
reach a mutual understanding to achieve suitable and consistent care for their patients 
(Malloy et al., 2009). One method to bring together their views could, therefore, be to 
organise courses that these professionals attend together. That said, as nurses’ 
socialisation occurs to a great extent during their nursing education (Stein et al., 1990), 
nursing students should be taught to make claims for mutual decision-making, to 
recognise their own potential, and be empowered to make claims for resources and 
improvements. As many nurses may lack the vocabulary for ethical decision-making, thus 
contributing to the silenced voices of nurses (Malloy et al., 2009), advocating competence 
should be taught at school. Moreover, they should be prepared for the need for 
negotiation, assertiveness, and effective communication. It is necessary that nurses are 
encouraged to reflect on their experience both as nurse students and as practicing nurses 
and also to establish positive working relationship with doctors. Moreover, since nurses 
seem to learn strategies such as self-confidence through role modelling we emphasize that 
during their nursing education and as novice nurses they should have access to role 
models for guidance that relate to their use of personal and aesthetic knowledge. During 
courses about pain management nurses’ coping methods should be addressed, and they 
should be taught to recognise destructive methods and adopt more constructive ones. The 
method of structured reflection (Johns, 1995), for instance, could be used to assist nurses in 
learning about their own abilities and responses. However, not only should negative 
aspects of their practice or difficult cases be inspected, but also the positive ones. 
6.2 Organisational environment  
Firstly, it is imperative that pain relief is highlighted within all health care settings and 
organisational nursing policies or visions for nursing, which must reflect this important 
aspect of care. It should be stressed that pain management is a priority and recognised 
that time and adequate resources are important aspects of pain management. Protocols 
that exemplify the responsibility of each member of the health care team should exist, but 
all rules that are created should also be flexible; for instance nurses must be enabled to 
choose an analgesic from a range of individualised prescriptions. It also seems vital that 
clear directives exist for the pain relief of addicts and access to support from specialists in 
the management of this group of patients available at all times. Support from specialists in 
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pain management and psychological support at all times are also fundamental. Moreover, 
the opportunity to discuss difficult cases with philosophers or leaders from different 
faiths and denominations should be provided in every health care setting. Subsequently, 
conversations about nurses’ ethical responsibilities and dilemmas should be offered and 
should be open for both nurses and doctors. As pain assessment is partly dependent on 
positive nurse-patient relationships and knowing the patient as a person, nursing models 
and interventions that encourage such relations should be introduced and supported. 
Another aspect of organisational culture that may enhance successful pain management is 
good collaboration and maintenance of trust between nurses and in the nurse-physician 
relationships. All efforts that strengthen dialogue and a culture that enables nurses to seek 
support and advice from colleagues and encourages open discussions about feelings and 
coping may therefore have positive outcomes in this respect. Lastly, an atmosphere of 
persistence and seeking the best available solution should be supported.  
6.3 Future research 
The explanatory model can be a great source of ideas for future research. Firstly, a 
quantitative study could be conducted, to assess nurses’ level of empirical, aesthetic and 
ethical knowledge along with personal knowledge regarding pain relief; including 
communication, collaboration and coping. Secondly, it would be interesting to explore the 
ethical component of the nursing and medical curricula and further to investigate to what 
extent nurses and doctors are guided by moral values in their pain relief at work. Thirdly, 
studies on how nurses’ moral orientation is balanced with the effectiveness of the pain 
relief they provide could also be conducted. Fourthly, it seems necessary to conduct more 
studies where the communication of nurses and doctors connected with pain 
management is explored, for instance by using an ethnographic approach. Fifthly, it 
seems important to run more field studies within each organization to identify the main 
obstructions for effective pain management. It seems vital to begin with identifying what 
hindrances are most prominent before embarking on a campaign for better pain 
management within organisations. A part of these studies could be to inspect the effects 
of workload, lack of time and constraining directives on nurses’ potentials for providing 
optimal pain relief. 
7. Conclusion  
Our explanatory model is at odds with statements proposing that pain relief is not the 
nurses’ priority (Brockopp et al., 1998) or their responsibility (Twycross, 2002). We assert, 
however, that various reasons inhibit the nurses’ potential for taking action. We conclude 
that nurses are the patients´ advocates in pain management and successful pain 
management is rewarded with a sense of satisfaction, empowerment and fulfilment of 
their duty. They are in a key position to assess and manage pain and their mediatory 
position within the hospital is unique. It is vital that nurses are adequately prepared for 
their role educationally by possessing multidimensional knowledge about pain 
management. We assert that good theoretical knowledge may be inadequate if the nurse 
does not have the right motivation, i.e. the moral inclination to use it in practice. 
Furthermore, personal knowledge that nurses must use in relations with patients and 
doctors is also necessary because theoretical knowledge alone may be of little use if it 
cannot be employed because of lack of communication or negotiation competence or 
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because their voice is silenced. They also need personal knowledge for self-knowledge, 
and to reflect on their own strengths and weaknesses in order to make better use of their 
own abilities. Therefore, nurses must be taught to act as the patient’s advocate and the 
patients’ representative. This also requires nurses to use their aesthetic knowledge to 
appreciate the needs of every individual patient. Furthermore, nurses must acknowledge 
how little they know about some patients who could beforehand be labelled as “difficult”. 
These patterns of knowledge in pain management are interrelated and should therefore be 
assessed as a whole if pain management is to be enhanced within an organisation or pain 
management skills in nurses’ primary or continuing education. The organisation in turn 
must provide an optimal environment; a clear statement about pain management and clear 
but flexible rules on pain management, and provide ample time and resources such as 
specialised pain services, that otherwise may hinder nurses from acting according to their 
best knowledge, potentials, and nursing goals. Teamwork and good collaboration 
between health care professionals must also be supported. The structure and prevailing 
culture of organisations must therefore be scrutinised before organising improvements in 
pain management.  
All the factors previously mentioned coexist and are interdependent and cannot be taken 
out of the immediate context, as may be seen from our model. Therefore, developments in 
pain management that focus only on one aspect of pain management may be ineffective, 
as many factors affect this process. We, therefore, propose that knowledge in this respect 
has often been too narrowly defined and we call for a more holistic approach in pain 
management by nurses and other health care personnel where multiple types of 
knowledge and skills as well as the organisational context are included and taken into 
consideration during educational efforts and reform of pain management within 
organisations. 
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and to reflect on their own strengths and weaknesses in order to make better use of their 
own abilities. Therefore, nurses must be taught to act as the patient’s advocate and the 
patients’ representative. This also requires nurses to use their aesthetic knowledge to 
appreciate the needs of every individual patient. Furthermore, nurses must acknowledge 
how little they know about some patients who could beforehand be labelled as “difficult”. 
These patterns of knowledge in pain management are interrelated and should therefore be 
assessed as a whole if pain management is to be enhanced within an organisation or pain 
management skills in nurses’ primary or continuing education. The organisation in turn 
must provide an optimal environment; a clear statement about pain management and clear 
but flexible rules on pain management, and provide ample time and resources such as 
specialised pain services, that otherwise may hinder nurses from acting according to their 
best knowledge, potentials, and nursing goals. Teamwork and good collaboration 
between health care professionals must also be supported. The structure and prevailing 
culture of organisations must therefore be scrutinised before organising improvements in 
pain management.  
All the factors previously mentioned coexist and are interdependent and cannot be taken 
out of the immediate context, as may be seen from our model. Therefore, developments in 
pain management that focus only on one aspect of pain management may be ineffective, 
as many factors affect this process. We, therefore, propose that knowledge in this respect 
has often been too narrowly defined and we call for a more holistic approach in pain 
management by nurses and other health care personnel where multiple types of 
knowledge and skills as well as the organisational context are included and taken into 
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1. Introduction 
Complex regional pain syndromes (CRPS) are pain syndromes characterized by pain out of 
proportion to an inciting injury, swelling, discoloration, stiffness, hyperhidrosis 
(sudomotor), temperature (vasomotor) and trophic changes. Also commonly seen are fine 
tremor and less often spasms involving upper and lower extremities. Dr. Silas Wier Mitchell 
described CRPS II, or causalgia, during the American Civil War. CRPS I was described 
about the end of the 19th century by Sudek (Sudek’s atrophy). Evans described reflex 
sympathetic dystrophy (RSD). Numerous other terms used to describe similar syndromes 
include algodystrophy and shoulder- hand syndrome. Bonica described 3 stages of RSD. 
Roberts described sympathetically maintained pain.  
2. Diagnostic criteria 
Specific inclusion criteria are needed for research studies but from a clinical perspective, 
many patients seem to have a constellation of signs and symptoms of CRPS without meeting 
strict criteria. The diagnosis is made by the process of exclusion. While avoiding over 
diagnosing and over treatment, the patients need to be treated.  
3. Prognosis 
The prognosis for CRPS is highly variable and to a large extent is influenced by the 
treatment. Functional restoration and involving the patient in ongoing range of motion 
and resistive exercises is helpful. Timely pain relief and interventional pain procedures, as 
well as psychological support, are important. Patients need to be followed closely and 
treatments adjusted accordingly. Timely and appropriate referral to experienced pain 
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4. Theories of mechanisms 
Multiple possible mechanisms exist for CRPS including psychological, inflammatory, 
vascular, neurogenic and combinations of several mechanisms. Debate regarding definitions 
of neuropathic pain has led to the notion that CRPS may not be neuropathic pain. 
Psychogenic pain could be construed as being “pain arising as a direct consequence of a 
lesion or disease affecting the somatosensory system” but few would think of it as 
neuropathic pain which should be treated with anticonvulsants. 
CRPS II is generally agreed to be caused by an injury to a peripheral nerve. CRPS 1 is caused 
by a lesion in or injury to a small nerve or multiple small nerves. It is difficult to accept that 
it is not neuropathic pain since it resembles CRPS II so closely. Denial of care based on 
psychological explanations is neither reasonable nor justifiable yet in rare instances pain can 
be of psychological origin. Commonly the onset of CRPS is 1- 3 months after the injury. 
5. History 
The diagnosis is made by process of exclusion following history of pain that is out of 
proportion to an injury or period of immobilization. Swelling, temperature asymmetry, 
stiffness, atrophy, hair, skin nail, bone changes. Tremor or spasms and asymmetry in sweat 
function are all potential signs. It is important to remember that many injuries are associated 
with pain, discoloration and swelling without being CRPS. Infection and other causes of 
inflammation are sometimes mistakenly thought to be CRPS. A number of patients have CRPS 
symptoms following stroke and classifying this as central pain or CRPS is problematic. 
6. Physical exam 
Observation of upper extremity guarding or antalgic gait for lower extremity is important. 
Range of motion of affected joints is particularly important as many patients develop 
permanent stiffness without analgesia for specific range of motion therapy. Discoloration or 
asymmetrical coloration, swelling, atrophy and allodynia are other physical findings. The 
allodynia may be tactile or cold induced. 
7. Diagnostic tests 
Bone scans, sweat tests and sympathetic blocks have been used but the diagnosis is a clinical 
one and can be made without confirmatory tests. Thermography has been used, but more 
commonly, the documentation of temperature differences is adequate. Early on in the 
evolution of the condition there may increased temperature and later reduction with the 
increased sympathetic activity. Three phase bone scan often show corresponding changes. 
Comparing contra lateral x-ray images can show osteopenia in the involved area. EMG 
usually does not change from the CRPS but may show nerve injury. 
8. Differential diagnosis 
While it important to be vigilant in diagnosing CRPS, as is important to avoid misdiagnosis 
and over- diagnosis. Many patients have “pain out of proportion”, swelling and 
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discoloration after injuries and will improve within a month with usual therapeutic 
interventions. 
Infection is always a concern after surgery or other penetrating trauma. Other causes of 
acute inflammation, swelling and discoloration need to be considered such as malignancy, 
deep venous thrombosis as well as peripheral nerve entrapment, peripheral neuropathy and 
other neuropathic pains. 
9. Stages 
3 stages of RSD have been described however it is unclear that staging has much value 
regarding decision making.  
10. Timing 
Much has been made about early sympathetic blocks and failure to diagnose early. There is 
no data to support “emergent” sympathetic blocks and some patients have a favorable 
natural history. 
11. Spreading 
Pain from CRPS can spread, in rare instances, proximally and contra- laterally. (Shah, Racz) 
Lower extremity pain can spread to upper extremities and vice versa. 
12. Bone loss 
Osteopenia and fractures can occur in severe cases and aquatic therapy is useful to 
rehabilitate these patients. 
13. Natural history 
The natural history of CRPS 1 is variable but in an interesting report, approximately 25% of 
patients that had Colles’ fractures developed signs of CRPS. (Atkins) Approximately 40% of 
these patients improved in 6 months. This suggests that mild cases may not require 
extensive treatment. Not treating the patients early can be problematic if the condition 
worsens. Appropriate examination and follow up is important where the disease can take a 
benign course. Patients obtain information on the Internet that is usually about catastrophic 
cases that needs to be dealt with by educating patients in an appropriate and caring manner 
where therapy is timely yet one can avoid catastrophizing based on inaccurate information. 
14. Dogma 
Much of “standard care” is not evidence based, but good outcome based. Additionally, it is 
based on physician experience and the outcome is superior in the hands of better-trained 
physicians. As new information becomes available, dogma can be weeded out and 
treatments based on randomized controlled trails can be incorporated into treatment 
guidelines.  
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One lady had not worn high-heeled shoes for a long time and then wore a pair for  
several hours at an event. She developed classic signs and symptoms of RSD. She 
experienced profound analgesia with sympathetic blockade and the condition resolved 
completely. 
Another case was a woman who had a paper cut on her distal index finger on the job. She 
had classic signs and symptoms of CRPS, which resolved with a series of blocks. Both of 
these cases were challenged by insurance companies since the inciting injury was so 
minor but both patients were legitimate. The point is that physicians caring for these 
patients must be willing to serve as advocates for the patient even in an environment of 
cost containment. We have to be mindful of our “report cards” but not at the expense of a 
patient’s outcome.  
16. Overmedication pain syndrome (OPS) 
Approximately 20 years ago, a movement began to improve the quality of pain care for 
cancer patients worldwide. The WHO analgesic ladder was promoted for cancer pain and 
then it was applied for other types of pain. Many patients are now taking large doses of 
opioid for chronic pain. 
Overmedication pain syndrome is characterized by a chronic treatment program consisting 
of high doses of multiple analgesic medications without associated functional productivity 
and psychological coping ability.  
Opioids are the most important class of drugs in pain management; however, it is clear that 
they are two edged swords and overmedication with opioids and other drugs classes have 
become a problem. Abuse may not be the largest problem. Lack of efficacy, unintended 
overdose, diversion, development of drug dependence, habituation and resistance to 
recovery and other unintended consequences may be more common.  
Opioid induced hyperalgesia is a real clinical phenomenon and may be a subtle barrier to 
analgesia in many patients. Pain that is only incrementally responsive to opioid is also 
common. 
Pseudo-addiction is defined in behavioral terms which are similar to addiction but related to 
pain and not addiction. The problem is that there are not good means to differentiate 
behaviors between the setting of pain and the setting of addiction. 
Some have reported a lack of data to support doses of opioid over 200 mg/day of morphine 
equivalents. Also, there are no long term randomized controlled trials of opioid versus 
placebo. Additionally, fracture rates have been reported to be increased in patients on doses 
above 100 mg/day. (Sullivan) Overdose rates have been reported to increase above 50 
mg/day. (Dunn) Drug interactions with other medications, reported and unreported to the 
treating physician, have been causes of fatalities. 
Urine drug testing, opioid contracts and extensive documentation guidelines fail to help 
answer the clinical question: is the dose just too high? 
Patients who are taking opioids chronically should be considered for an evaluation for a 
lack of meaningful efficacy, fall and fracture risk and overdose risk. An interdisciplinary 
evaluation may be a way to accomplish these objectives. Patients who are clearly doing well 
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may be less likely to accept dose reductions. Patients who are working or similarly 
productive and are without signs of poor coping and physical disability may need to 
continue taking the effective dosages. On the other hand, patients, who have been on stable 
doses for a long time may need age related dose reductions.  
Washington State has new guidelines limiting the dose of opioid to 120 mg/day of 
morphine equivalents. Patients, who require doses above this level, are guided to seek a 
pain management consultation. The purpose and intervention of a medical pain 
management consultation is unclear. The practitioner doing the evaluation needs to have 
additional training and qualification as well as be informed and knowledgeable in treatment 
options in addition to opioid management.  
JCAHO, Press Gainey and other organizations have changed the environment with respect 
to patient rights regarding pain. In the past, if a patient wasn’t happy with their opioid dose, 
their recourse was limited. Now, patient satisfaction is used as a factor to determine 
healthcare provider’s compensation. The implication is that patients can pressure providers 
to prescribe more opioid, which is dangerous for patients and providers.  
Regulators have become more active due to the increased rate of diversion and its 
consequences. However, the accidental overdose rate increase is even more concerning.  
Most drugs have dose limits. For example, antibiotics and drugs for hypertension are 
increased to upper limits but there are limits. Perhaps it is time to limit doses of opioids 
regardless of pain severity for patients with non palliative care pain syndromes and find 
another way to treat the patient. 
Other drugs classes that are problematic include benzodiazepines, muscle relaxers, sleeping 
pills and even anticonvulsants and antidepressants. Benzodiazepines are not prominent in 
the pain literature as analgesics. Baclofen and tizanidine are probably the first line muscle 
relaxers of choice. Hypnotic drugs are used too often for chronic sleep disturbances without 
sleep hygiene treatment or other medications which are better for long term use. 
Anticonvulsant use for chronic pain has exploded as opioids have. Antidepressants, even 
those not associated with analgesia, are prescribed for pain. 
The costs of these drugs are significant and usually of incremental benefit. Most patients 
with chronic pain go without an interdisciplinary evaluation and many who receive an 
evaluation do not complete treatment with cognitive behavioral therapy, education and 
conditioning physical therapy. Treatment goals are frequently not established and some 
patients just go through the motions and are considered as a treatment failure. There is very 
little evidence for the multidisciplinary and physical therapy based treatments specifically 
for CRPS. Reimbursement has suffered for these kinds of therapies. 
The cognitive effects and psychological effects of chronic opioid treatment are not well 
known. 
Testosterone levels in males are known to decrease with chronic opioid administration.  
It is proposed that patients with chronic pain have a short term trial of low dose opioid  
to access functional improvement before a treatment plan is finalized. Blinding patients to 
their drug and dose may be very helpful but has its critics on ethical and regulatory 
grounds. 
Patients who are on doses above 50 mg/ day of morphine equivalents need to have access to 
interdisciplinary pain and addictionology evaluations and treatment if needed. Treatment 
goals should include dose reduction to below 200mg/day of morphine equivalents for those 
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taking more than that. Intermediate term treatment goals for patients taking less than  
200 mg/day should strive for less than 100 mg/day and patients taking less than  
100 mg/day, 50 mg/day.  
There is no data to support this approach but there was no data 20 years ago to support 
using the WHO analgesic ladder for headaches, fibromyalgia, back pain or any other 
condition. Data for limited doses of opioid for arthritis and neuropathic pain exists and 
prescribing for opioid responsive pain should not be overly scrutinized by regulators. Never 
the less, diversion, addiction, opioid induced hyperalgesia and other adverse events 
associated with opioids need to be avoided more effectively before the first prescription is 
written.  
Many patients in drug treatment programs were initially treated with opioid for perfectly 
legitimate pain. The patient and the doctor may not be the biggest problems. The biggest 
problem may be the drug and the dosage. 
17. Treatment guideline history 
In 1994, the International Association for the Study of Pain (IASP) revised the terminology 
from RSD and causalgia to CRPS type I and II. 15 years ago we proposed an analgesic 
ladder for CRPS /RSD which included 3 steps. (Racz) Since then, well-respected groups 
have advanced other guidelines. (Van Eijs) (Stanton-Hicks)  
Our initial proposal was: 
Step 1. TENS, opioids, topicals, Tricyclic antidepressants, supportive psychotherapy, 
vocational rehabilitation, patient education, physical therapy and occupational 
therapy  
Step 2. Regional or sympathetic block, evaluation and treatment of the emotional 
component of pain, IV regional block, peripheral block-infusion, carbamazepine, 
baclofen, clonidine, corticosteroid, NSAID, mexiletine, other drug trials 
Step 3. Sympathectomy/sympatholysis, peripheral nerve decompression, lysis, continuous 
local anesthetic infusion epidural and or regional for five to seven days, Spinal 
Cord Stimulation (SCS), Peripheral Nerve Stimulation (PNS), intrathecal/epidural 
analgesia. 
At that time, little data existed to guide treatment and the initial analgesic ladder was based 
on opinion. Since that time, additional data has been produced leading to modifications to 
the analgesic ladder. This is categorically not intended to estabish a standard of care since 
data to do such is inadequate. Rather, our intention is to share our beliefs in hopes of 
helping patients with this disorder. 
18. New principles and information 
Our current analgesic ladder promotes several concepts: 
1. Interdisciplinary pain treatment is recommended rather than multidisciplinary care 
which tends to be fragmented. Interdisciplinary treatment specifically provides 
coordinated medical care, education, cognitive behavioral therapy for pain, physical 
therapy and outcome documentation by the interdisciplinary team. Patients who 
receive care at different clinics for each component of care by a group of providers who 
do not meet on a weekly basis nor document comprehensive outcomes are not receiving 
interdisciplinary pain management.  
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2. Interdisciplinary care is not isolated from medical pain management. Analgesic 
treatments are necessary to provide pain relief and allow functional restoration.  
3. The course of an individual patient is highly variable and adjustments to the treatment 
plan should be made in a highly flexible manner.  
4. Limiting opioid doses to below 200mg/day morphine equivalents 
5. Numerous randomized controlled trials have been performed since our initial analgesic 
ladder was proposed and these findings are incorporated.  
6. However if there is treatment failure and functional restoration failure the patient needs 
to be referred to centers or individuals with recognized experience to be specialists in 
the field. 
Sympathetic blocks have been recommended early on in the management of the disorder 
but little data exists to support this practice. Only recently has any data from a randomized 
controlled trial been published to demonstrate efficacy of sympathetic blockade. (Meier) 
Spinal cord stimulation has been shown to produce significant analgesia even after 5 years 
of treatment. (Klemer) Cortical stimulation has been shown to have some benefit. (Velasco) 
Deep brain stimulation has been shown to be ineffective. Vitamin C has been studied by 
multiple investigators for the prevention of CRPS and has some effect. (Besse) Intravenous 
magnesium has been reported to be effective in an initial study. (Collins) Clodronate has 
been shown to be partially effective. (Varenna) Mirror therapy has been reported to have 
benefit in stroke patients with CRPS. (Cacchio) Multicenter comparison of spinal cord  
stimualtion and peripheral nerve stimulation showed  that PNS is more effective than SCS 
but the best outcome was where both modalities were utilized. ( Calvillo) 
Intravenous regional anesthesia with the addtion of vasodilators such as phentolamine, 
reserpine and bretylium allow manipulation of hands without post  procedure edema  and 
speed up functional restoration without  the pain associated with physical therapy. 
(Heavner, Calvillo, Racz) 
An evidenced based review endorses bisphosphonates (alendronate, pamidronate, 
clodronate), corticosteroid, gabapentin, physiotherapy and psychotherapy/relaxation 
techniques as treatments. (Baron) Additionally intrathecal baclofen for associated dystonia 
and spinal cord stimulation for refractory caes are recommended. Topical DMSO and 
sympathetic blocks are not strongly recommended. Intravenous regional blocks with 
guanethidine are not recommended as specific treatment (Van Eijs)  
19. Treatments to avoid 
Amputation is less common nowadays because it was rarely effective and usually resulted 
in a phantom pain plus different pain of greater severity  
IV regional with guanethidine has been shown to be ineffective in several studies as sole 
agent. 
Deep brain stimulation has been shown to be ineffective. 
High dose opioid should be avoided if possible due to possible opioid induced 
hyperalgesia, addiction, diversion risk and over-dosage. 
20. Proposed treatment 
Step 1.  
Screening for substance abuse, affective disorders and disability 
Education 
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Opioid doses limited to less than 200mg morphine equivalents per day and below 
50mg/day if possible 
Corticosteroid 
Step 2.  
Interdisciplinary pain evaluation including psychological testing (MMPI-RF) and treatment 
(cognitive behavioral therapy, group psycho educational therapy and psychotropic 
medication management, addictionology, physical and occupational therapy, in a 
coordinated goal directed, outcome documenting rehabilitation program) 
Sympathetic block 
IV Regional block 
Peripheral block 
Other drug trials 
Step 3.  
Spinal cord stimulation 
Sympathectomy/sympatholysis 
Peripheral nerve stimulation 
Peripheral nerve decompression/lysis 
Intrathecal/epidural analgesia 
21. Interdisciplinary care 
Interdisciplinary pain management is a term that is poorly understood. It is best reserved to 
describe a team of healthcare professionals led by a physician and including a psychologist 
and physical therapist at a minimum. A care team of multiple physicians from different 
specialties is not an interdisciplinary team for pain management nor is a psychologically 
based treatment program in isolation from medical pain management. Cognitive behavioral 
therapy, education and functional rehabilitation must be provided in an interdisciplinary 
pain care model in addition to medical pain management therapies. Case management, 
psychiatry, outcome database management, nursing, vocational rehabilitation, occupational 
therapy, medical direction and program direction and administrative support are key 
disciplines to include in a mature pain program. Nutrition, chaplaincy and other medical 
specialties are needed for tertiary programs. 
22. Conclusion 
Complex regional pain syndrome is a challenging pain problem that frequently requires a 
comprehensive interdisciplinary assessment and treatment plan. Until a mechanism is 
discovered and a specific treatment for the syndrome is developed, an interdisciplinary 
approach, including pharmacologic and interventional pain management in a step wise 
fashion, will likely remain as the best route to follow.  
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